<table><thead><th>Form of Carvedilol</th><th>a Receptors (Kg, nmol/L’)</th><th>B Receptors (Kg, nmol/L)</th></thead><tr><td>R(+) enantiomer</td><td>14</td><td>45</td></tr><tr><td>S(—) enantiomer</td><td>16</td><td>0.4</td></tr><tr><td>R,S(+) enantiomers</td><td>11</td><td>0.9</td></tr></table>
======================================
<table><thead><th>Transporter</th><th>Physiologic Function</th><th>Pharmacologic Significance</th></thead><tr><td>NET</td><td>Norepinephrine reuptake from synapse</td><td>Target of cocaine and some tricyclic antidepressants</td></tr><tr><td>SERT</td><td>Serotonin reuptake from synapse</td><td>Target of selective serotonin reuptake inhibitors and some tricyclic antidepressants</td></tr><tr><td>VMAT</td><td>Transport of dopamine and norepinephrine into adrenergic vesicles in nerve endings</td><td>Target of reserpine and tetrabenazine</td></tr><tr><td>MDR1</td><td>Transport of many xenobiotics out of cells</td><td>Increased expression confers resistance to certain anticancer drugs; inhibition increases blood levels of digoxin</td></tr><tr><td>MRP1</td><td>Leukotriene secretion</td><td>Confers resistance to certain anticancer and antifungal drugs</td></tr></table>
======================================
<table><thead><th>Neutral</th><th>Aspirin</th><th>Proton</th></thead><tr><td>aspirin</td><td>anion</td><td></td></tr></table>
======================================
<table><thead><th>rug</th><th></th><th>Drug</th><th></th><th>Drug</th><th></th></thead><tr><td>leak acids</td><td></td><td>Weak bases</td><td></td><td colspan="2">Weak bases (cont'd)</td></tr><tr><td>Acetaminophen</td><td></td><td>Albuterol (salbutamol)</td><td></td><td>Isoproterenol</td><td></td></tr><tr><td>Acetazolamide</td><td></td><td>Allopurinol</td><td></td><td>Lidocaine</td><td></td></tr><tr><td>Ampicillin</td><td></td><td>Alprenolol</td><td></td><td>Metaraminol</td><td></td></tr><tr><td>Aspirin</td><td></td><td>Amiloride</td><td></td><td>Methadone</td><td></td></tr><tr><td>Chlorothiazide</td><td>6.8, 9.47</td><td>Amiodarone</td><td></td><td>Methamphetamine</td><td>10.0</td></tr><tr><td>Chlorpropamide</td><td></td><td>Amphetamine</td><td></td><td>Methyldopa</td><td>10.6</td></tr><tr><td>Ciprofloxacin</td><td>6.1, 8.77</td><td>Atropine</td><td></td><td>Metoprolol</td><td></td></tr><tr><td>Cromolyn</td><td></td><td>Bupivacaine</td><td></td><td>Morphine</td><td></td></tr><tr><td>Ethacrynic acid</td><td></td><td>Chlordiazepoxide</td><td></td><td>Nicotine</td><td>7.9, 3.17</td></tr><tr><td>Furosemide</td><td></td><td>Chloroquine</td><td>10.8, 8.4</td><td>Norepinephrine</td><td></td></tr><tr><td>Ibuprofen</td><td>44, 5.2”</td><td>Chlorpheniramine</td><td></td><td>Pentazocine</td><td></td></tr><tr><td>Levodopa</td><td></td><td>Chlorpromazine</td><td></td><td>Phenylephrine</td><td></td></tr><tr><td>Methotrexate</td><td></td><td>Clonidine</td><td></td><td>Physostigmine</td><td>7.9, 1.8</td></tr><tr><td>Methyldopa</td><td>2.2, 9.27</td><td>Cocaine</td><td></td><td>Pilocarpine</td><td>6.9, 1.47</td></tr><tr><td>Penicillamine</td><td></td><td>Codeine</td><td></td><td>Pindolol</td><td></td></tr><tr><td>Pentobarbital</td><td></td><td>Cyclizine</td><td></td><td>Procainamide</td><td></td></tr><tr><td>Phenobarbital</td><td></td><td>Desipramine</td><td>10.2</td><td>Procaine</td><td></td></tr><tr><td>Phenytoin</td><td></td><td>Diazepam</td><td></td><td>Promethazine</td><td></td></tr><tr><td>Propylthiouracil</td><td></td><td>Diphenhydramine</td><td></td><td>Propranolol</td><td></td></tr><tr><td>Salicylic acid</td><td></td><td>Diphenoxylate</td><td></td><td>Pseudoephedrine</td><td></td></tr><tr><td>Sulfadiazine</td><td></td><td>Ephedrine</td><td></td><td>Pyrimethamine</td><td>7.0-7.3°</td></tr><tr><td>Sulfapyridine</td><td></td><td>Epinephrine</td><td></td><td>Quinidine</td><td>8.5, 4.4</td></tr><tr><td>Theophylline</td><td></td><td>Ergotamine</td><td></td><td>Scopolamine</td><td></td></tr><tr><td>Tolbutamide</td><td></td><td>Fluphenazine</td><td>8.0, 3.97</td><td>Strychnine</td><td>8.0, 2.37</td></tr><tr><td rowspan="2">Warfarin</td><td></td><td>Hydralazine</td><td></td><td>Terbutaline</td><td>10.1</td></tr><tr><td></td><td></td><td>Imipramine</td><td></td><td>Thioridazine</td><td></td></tr></table>
======================================
<table><thead><th>Type of Test</th><th>Approach and Goals</th></thead><tr><td>Acute toxicity</td><td>Usually two species, two routes. Determine the no-effect dose and the maximum tolerated dose. In some cases, determine the acute dose that is lethal in approximately 50% of animals.</td></tr><tr><td>Subacute or subchronic toxicity</td><td>Three doses, two species. Two weeks to 3 months of testing may be required before clinical trials. The longer the duration of expected clinical use, the longer the subacute test. Determine biochemical, physiologic effects.</td></tr><tr><td>Chronic toxicity</td><td>Rodent and at least one nonrodent species for &gt;6 months. Required when drug is intended to be used in humans for prolonged periods. Usually run concurrently with clinical trials. Determine same end points as subacute toxicity tests.</td></tr><tr><td>Effect on reproductive performance</td><td>Two species, usually one rodent and rabbits. Test effects on animal mating behavior, reproduction, parturition, progeny, birth defects, postnatal development.</td></tr><tr><td>Carcinogenic potential</td><td>Two years, two species. Required when drug is intended to be used in humans for prolonged periods. Determine gross and histologic pathology.</td></tr><tr><td>Mutagenic potential</td><td>Test effects on genetic stability and mutations in bacteria (Ames test) or mammalian cells in culture; dominant lethal test and clastogenicity in mice.</td></tr></table>
======================================
<table><tr><td>Pure Food and Drug Act of 1906</td><td>Prohibited mislabeling and adulteration of drugs.</td></tr><tr><td>Opium Exclusion Act of 1909</td><td>Prohibited importation of opium.</td></tr><tr><td>Amendment (1912) to the Pure Food and Drug Act</td><td>Prohibited false or fraudulent advertising claims.</td></tr><tr><td>Harrison Narcotic Act of 1914</td><td>Established regulations for use of opium, opiates, and cocaine (marijuana added in 1937).</td></tr><tr><td>Food, Drug, and Cosmetic Act of 1938</td><td>Required that new drugs be safe as well as pure (but did not require proof of efficacy). Enforcement by FDA.</td></tr><tr><td>Durham-Humphrey Act of 1952</td><td>Vested in the FDA the power to determine which products could be sold without prescription.</td></tr><tr><td>Kefauver-Harris Amendments (1962) to the Food, Drug, and Cosmetic Act</td><td>Required proof of efficacy as well as safety for new drugs and for drugs released since 1938; establishe guidelines for reporting of information about adverse reactions, clinical testing, and advertising of nev drugs.</td></tr><tr><td>Comprehensive Drug Abuse Prevention and Control Act (1970)</td><td>Outlined strict controls in the manufacture, distribution, and prescribing of habit-forming drugs; established drug schedules and programs to prevent and treat drug addiction.</td></tr><tr><td>Orphan Drug Amendment of 1983</td><td>Provided incentives for development of drugs that treat diseases with fewer than 200,000 patients in USA.</td></tr><tr><td>Drug Price Competition and Patent Restoration Act of 1984</td><td>Abbreviated new drug applications for generic drugs. Required bioequivalence data. Patent life extended by amount of time drug delayed by FDA review process. Cannot exceed 5 extra years or extend to more than 14 years post-NDA approval.</td></tr><tr><td>Prescription Drug User Fee Act (1992, reauthorized 2007, 2012)</td><td>Manufacturers pay user fees for certain new drug applications. “Breakthrough” products may receive special category approval after expanded phase 1 trials (2012).</td></tr><tr><td>Dietary Supplement Health and Education Act (1994)</td><td>Established standards with respect to dietary supplements but prohibited full FDA review of supplements and botanicals as drugs. Required the establishment of specific ingredient and nutrition information labeling that defines dietary supplements and classifies them as part of the food supply but allows unregulated advertising.</td></tr><tr><td>Bioterrorism Act of 2002</td><td>Enhanced controls on dangerous biologic agents and toxins. Seeks to protect safety of food, water, ant drug supply.</td></tr><tr><td>Food and Drug Administration Amendments Act of 2007</td><td>Granted FDA greater authority over drug marketing, labeling, and direct-to-consumer advertising; required post-approval studies, established active surveillance systems, made clinical trial operations and results more visible to the public.</td></tr><tr><td>Biologics Price Competition and Innovation Act of 2009</td><td>Authorized the FDA to establish a program of abbreviated pathways for approval of “biosimilar” biologics (generic versions of monoclonal antibodies, etc).</td></tr><tr><td>FDA Safety and Innovation Act of 2012</td><td>Renewed FDA authorization for accelerated approval of urgently needed drugs; established new accelerated process, “breakthrough therapy,’ in addition to “priority review,’“accelerated approval,” and “fast-track” procedures.</td></tr></table>
======================================
<table><thead><th>G Protein</th><th>Receptors for</th><th>Effector/Signaling Pathway</th></thead><tr><td>G,</td><td>B-Adrenergic amines, histamine, serotonin, glucagon, and many other hormones</td><td>T Adenylyl cyclase 37 cAMP</td></tr><tr><td>Gi, Giz, Gis</td><td>@p-Adrenergic amines, acetylcholine (muscarinic), opioids, serotonin, and many others</td><td>Several, including: J Adenylyl cyclase &gt;) cAMP Open cardiac K* channels J heart rate</td></tr><tr><td></td><td>Odorants (olfactory epithelium)</td><td>T Adenylyl cyclase 37 cAMP</td></tr><tr><td></td><td>Neurotransmitters in brain (not yet specifically identified)</td><td>Not yet clear</td></tr><tr><td></td><td>Acetylcholine (muscarinic), bombesin, serotonin (5-HT,), and many others</td><td>7 Phospholipase C —T IP3, diacylglycerol, cytoplasmic Ca”*</td></tr><tr><td></td><td>Photons (rhodopsin and color opsins in retinal rod and cone cells)</td><td>T cGMP phosphodiesterase &gt; cGMP (phototransduction)</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Oral Availability (F) (%)</th><th>Urinary Excretion (%)'</th><th>Bound in Plasma (%)</th><th>Clearance (L/h/70 kg)?</th><th>Volume of Distribution (L/70 kg)</th><th>Half-Life (h)</th><th>Target Concentration</th><th>Toxic _Concentrati</th></thead><tr><td>Acetaminophen</td><td>88</td><td>3</td><td>0</td><td>21</td><td>67</td><td>2</td><td>15 mg/L</td><td>&gt;300 mg/L</td></tr><tr><td>Acyclovir</td><td>23</td><td>75</td><td>15</td><td>19.8</td><td>48</td><td>24</td><td></td><td></td></tr><tr><td>Amikacin</td><td></td><td>98</td><td>4</td><td>5.46</td><td>19</td><td>23</td><td>10 mg/L. co</td><td></td></tr><tr><td>Amoxicillin</td><td>93</td><td>86</td><td>18</td><td>10.8</td><td>15</td><td>1.7</td><td></td><td></td></tr><tr><td>Amphotericin</td><td></td><td>4</td><td>90</td><td>1.92</td><td>53</td><td>18</td><td></td><td></td></tr><tr><td>Ampicillin</td><td>62</td><td>82</td><td>18</td><td>16.2</td><td>20</td><td>1.3</td><td></td><td></td></tr><tr><td>Aspirin</td><td>68</td><td>1</td><td>49</td><td>39</td><td>11</td><td>0.25</td><td></td><td></td></tr><tr><td>Atenolol</td><td>56</td><td>94</td><td>5</td><td>10.2</td><td>67</td><td>6.1</td><td>1 mg/L</td><td></td></tr><tr><td>Atropine</td><td>50</td><td>57</td><td>18</td><td>24.6</td><td>120</td><td>43</td><td></td><td></td></tr><tr><td>Captopril</td><td>65</td><td>38</td><td>30</td><td>50.4</td><td>57</td><td>2.2</td><td>50 ng/mL</td><td></td></tr><tr><td>Carbamazepine Cephalexin</td><td>90</td><td>91</td><td>14</td><td>18</td><td>18</td><td>0.9</td><td></td><td></td></tr><tr><td>Cephalothin</td><td></td><td>52</td><td>71</td><td>28.2</td><td>18</td><td>0.57</td><td></td><td></td></tr><tr><td>Chloramphenicol</td><td>80</td><td>25</td><td>53</td><td>10.2</td><td>66</td><td>27</td><td></td><td></td></tr><tr><td>Chlordiazepoxide</td><td>100</td><td>1</td><td>97</td><td>2.28</td><td>21</td><td>10</td><td>T mg/L</td><td></td></tr><tr><td>Chloroquine</td><td>89</td><td>61</td><td>61</td><td>45</td><td>13,000</td><td>214</td><td>20 ng/mL</td><td>250 ng/mL</td></tr><tr><td>Chlorpropamide</td><td>90</td><td>20</td><td>96</td><td>0.126</td><td>68</td><td>33</td><td></td><td></td></tr><tr><td>Cimetidine</td><td>62</td><td>62</td><td>19</td><td>32.4</td><td>70</td><td>1.9</td><td>0.8 mg/L</td><td></td></tr><tr><td>Ciprofloxacin</td><td>60</td><td>65</td><td>40</td><td>25.2</td><td>130</td><td>41</td><td></td><td></td></tr><tr><td>Cyclosporine</td><td>100</td><td>1</td><td>99</td><td>1.62</td><td>77</td><td>43</td><td>ng/mL 300</td><td>ng/mL</td></tr><tr><td>Diazepam</td><td></td><td></td><td></td><td></td><td></td><td></td><td>ng/mL</td><td></td></tr><tr><td>Digoxin</td><td>70</td><td>67</td><td>25</td><td>9</td><td>500</td><td>39</td><td>1 ng/mL</td><td>&gt;2 ng/mL</td></tr><tr><td></td><td></td><td>4</td><td>78</td><td>50.4</td><td>220</td><td>3.7</td><td></td><td></td></tr><tr><td>Diltiazem</td><td>44 83</td><td>55</td><td>2</td><td>5.04</td><td>41</td><td>6</td><td>3</td><td>&gt;8</td></tr><tr><td>Disopyramide</td><td>95</td><td>90</td><td>55</td><td>9</td><td>40</td><td>3</td><td>mg/mL 0.5</td><td>mg/mL</td></tr><tr><td>Enalapril</td><td>35</td><td>12</td><td>84</td><td>38.4</td><td>55</td><td>1.6</td><td>&gt; ng/mL</td><td></td></tr><tr><td>Erythromycin</td><td>77</td><td>79</td><td>5</td><td>36</td><td>110</td><td>3.1</td><td></td><td>&gt;10</td></tr><tr><td>Ethambutol</td><td>60</td><td>3</td><td>94</td><td>40.2</td><td>2500</td><td>53</td><td></td><td>mg/L</td></tr><tr><td>Fluoxetine Furosemide</td><td>61</td><td>66</td><td>99</td><td>8.4</td><td>77</td><td>15</td><td></td><td>&gt;25</td></tr><tr><td></td><td></td><td>76</td><td>10</td><td>47</td><td>20</td><td>3</td><td>3 mg/L?</td><td>mg/L</td></tr><tr><td>Gentamicin Hydralazine</td><td>40</td><td>10</td><td>87</td><td>234</td><td>105</td><td>1</td><td>100</td><td></td></tr><tr><td></td><td>40</td><td>2</td><td>90</td><td>63</td><td>1600</td><td>18</td><td>ng/mL 200</td><td>&gt;1</td></tr><tr><td>Imi
======================================
pramine</td><td>98</td><td>15</td><td>90</td><td>8.4</td><td>18</td><td>24</td><td>ng/mL T</td><td>mg/L &gt;5</td></tr><tr><td>Indomethacin Labetalol</td><td>18</td><td>5</td><td>50</td><td>105</td><td>660</td><td>49</td><td>mg/L 0.1 mg/L</td><td>mg/L</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Oral Availability (F) (%)</th><th>Urinary Excretion (%)'</th><th>Bound in Plasma (%)</th><th>Clearance (L/h/70 kg)”</th><th>Volume of Distribution (L/70 kg)</th><th>Half-Life (h) |</th><th>Target Concentration</th><th>Toxic Concentratic</th></thead><tr><td>Methotrexate</td><td>70</td><td>48</td><td>34</td><td>9</td><td>39</td><td>72</td><td>750 uM-h*&gt;</td><td>&gt;950 uM-h</td></tr><tr><td>Metoprolol</td><td>38</td><td>10</td><td>11</td><td>63</td><td>290</td><td>3.2</td><td>25 ng/mL</td><td></td></tr><tr><td>Metronidazole</td><td>99</td><td>10</td><td>10</td><td>5.4</td><td>52</td><td>8.5</td><td>4mg/L</td><td></td></tr><tr><td>Midazolam</td><td>44</td><td>56</td><td>95</td><td>276</td><td>77</td><td>1.9</td><td></td><td></td></tr><tr><td>Morphine</td><td>24</td><td>8</td><td>35</td><td>60</td><td>230</td><td>1.9</td><td>15 ng/mL</td><td></td></tr><tr><td>Nifedipine</td><td>50</td><td>0</td><td>96</td><td>29.4</td><td>55</td><td>1.8</td><td>50 ng/mL.</td><td></td></tr><tr><td>Nortriptyline</td><td>51</td><td>2</td><td>92</td><td>30</td><td>1300</td><td>31</td><td>100 ng/mL</td><td>&gt;500 ng/mL</td></tr><tr><td>Phenobarbital</td><td>100</td><td>24</td><td>51</td><td>0.258</td><td>38</td><td>98</td><td>15 mg/L</td><td>&gt;30 mg/L</td></tr><tr><td>Phenytoin</td><td>90</td><td>2</td><td>89</td><td>Conc dependent®</td><td>45</td><td>Conc dependent®</td><td>10 mg/L</td><td>&gt;20 mg/L</td></tr><tr><td>Prazosin</td><td>68</td><td>1</td><td>95</td><td>12.6</td><td>42</td><td>29</td><td></td><td></td></tr><tr><td>Procainamide</td><td>83</td><td>67</td><td>16</td><td>36</td><td>130</td><td>3</td><td>5 mg/L</td><td>&gt;14 mg/L</td></tr><tr><td>Propranolol</td><td>26</td><td>1</td><td>87</td><td>50.4</td><td>270</td><td>3.9</td><td>20 ng/mL</td><td></td></tr><tr><td>Pyridostigmine</td><td>14</td><td>85</td><td></td><td>36</td><td>77</td><td>1.9</td><td>75 ng/mL</td><td></td></tr><tr><td>Quinidine</td><td>80</td><td>18</td><td>87</td><td>19.8</td><td>190</td><td>6.2</td><td>3 mg/L</td><td>&gt;8 mg/L</td></tr><tr><td>Ranitidine</td><td>52</td><td>69</td><td>15</td><td>43.8</td><td>91</td><td>2.1</td><td>100 ng/mL</td><td></td></tr><tr><td>Rifampin</td><td>?</td><td>7</td><td>89</td><td>14.4</td><td>68</td><td>3.5</td><td></td><td></td></tr><tr><td>Salicylic acid</td><td>100</td><td>15</td><td>85</td><td>0.84</td><td>12</td><td>13</td><td>200 mg/L.</td><td>&gt;200 mg/L</td></tr><tr><td>Sulfamethoxazole</td><td>100</td><td>14</td><td>62</td><td>1.32</td><td>15</td><td>10</td><td></td><td></td></tr><tr><td>Tacrolimus</td><td>20</td><td></td><td>98”</td><td>3</td><td>133°</td><td>28</td><td>10 mcg/L</td><td></td></tr><tr><td>Terbutaline</td><td>14</td><td>56</td><td>20</td><td>14.4</td><td>125</td><td>14</td><td>2ng/mL</td><td></td></tr><tr><td>Tetracycline</td><td>77</td><td>58</td><td>65</td><td>FQ,</td><td>105</td><td>11</td><td></td><td></td></tr><tr><td>Theophylline</td><td>96</td><td>18</td><td>56</td><td>2.8</td><td>35</td><td>8.1</td><td>10 mg/L</td><td>&gt;20 mg/L</td></tr><tr><td>Tobramycin</td><td></td><td>90</td><td>10</td><td>4.62</td><td>18</td><td>2.2</td><td></td><td></td></tr><tr><td>Tocainide</td><td>89</td><td>38</td><td>10</td><td>10.8</td><td>210</td><td>14</td><td>10 mg/L</td><td></td></tr><tr><td>Tolbutamide</td><td>93</td><td>0</td><td>96</td><td>1.02</td><td>7</td><td>5.9</td><td>100 mg/L</td><td></td></tr><tr><td>Trimethoprim</td><td>100</td><td>69</td><td>44</td><td>9</td><td>130</td><td>11</td><td></td><td></td></tr><tr><td>Tubocurarine</td><td></td><td>63</td><td>50</td><td>8.1</td><td>27</td><td>2</td><td>0.6 mg/L</td><td></td></tr><tr><td>Valproic acid</td><td>100</td><td>2</td><td>93</td><td>0.462</td><td>9.1</td><td>14</td><td>75 mg/L</td><td>&gt;150 mg/L</td></tr><tr><td>Vancomycin</td><td></td><td>79</td><td>30</td><td>5.88</td><td>27</td><td>5.6</td><td>20 mg/L?</td><td></td></tr><tr><td>Verapamil</td><td>22</td><td>3</td><td>90</td><td>63</td><td>350</td><td>4</td><td></td>
======================================
<td></td></tr><tr><td>Warfarin</td><td>93</td><td>3</td><td>99</td><td>0.192</td><td>9.8</td><td>37</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Compartment and Volume</th><th>Examples of Drugs</th></thead><tr><td colspan="2">Water</td></tr><tr><td>Total body water (0.6 L/kg')</td><td>Small water-soluble molecules: eg, ethanol</td></tr><tr><td>Extracellular water (0.2 L/kg)</td><td>Larger water-soluble molecules: eg, gentamicin</td></tr><tr><td>Plasma (0.04 L/kg)</td><td>Large protein molecules: eg, antibodies</td></tr><tr><td>Fat (0.2-0.35 L/kg)</td><td>Highly lipid-soluble molecules: eg, diazepam</td></tr><tr><td>Bone (0.07 L/kg)</td><td>Certain ions: eg, lead, fluoride</td></tr></table>
======================================
<table><thead><th>Route</th><th>Biovailability (%)</th><th>Characteristics</th></thead><tr><td>Intravenous (IV)</td><td>100 (by definition)</td><td>Most rapid onset</td></tr><tr><td>Intramuscular (IM)</td><td>75 to &lt;100</td><td>Large volumes often feasible; may be painful</td></tr><tr><td>Subcutaneous (SC)</td><td>75 to &lt;100</td><td>Smaller volumes than IM; may be painful</td></tr><tr><td>Oral (PO)</td><td>5 to &lt;100</td><td>Most convenient; first-pass effect may be important</td></tr><tr><td>Rectal (PR)</td><td>30 to &lt;100</td><td>Less first-pass effect than oral</td></tr><tr><td>Inhalation</td><td>5 to &lt;100</td><td>Often very rapid onset</td></tr><tr><td>Transdermal</td><td>80 to &lt;100</td><td>Usually very slow absorption; used for lack of first-pass effect; prolonged duration of action</td></tr></table>
======================================
<table><tr><td>Aliphatic hydroxylations</td><td>RCH,CH3 —&gt; RCH)CH,OH RCH,CH, — RCHCH, | OH</td><td>Amobarbital, pentobarbital, secobarbital, chlorpropamide, ibuprofen, meprobamate, glutethimide, phenylbutazone, digitoxin</td></tr><tr><td>Epoxidation</td><td>H OH /N/ \ RCH=CHR—&gt; R—C—C—R</td><td>Aldrin</td></tr><tr><td colspan="3">Oxidative dealkylation</td></tr><tr><td>N-Dealkylation</td><td>RNHCH, —&gt; RNH, + CH,0</td><td>Morphine, ethylmorphine, benzphetamine, aminopyrine, caffeine, theophylline</td></tr><tr><td>O-Dealkylation</td><td>ROCH, —&gt; ROH + CHO</td><td>Codeine, p-nitroanisole</td></tr><tr><td>S-Dealkylation</td><td>RSCH3 — RSH + CH,0</td><td>6-Methylthiopurine, methitural</td></tr><tr><td colspan="3">N-Oxidation</td></tr><tr><td>Primary amines</td><td>RNH,—&gt; RNHOH</td><td>Aniline, chlorphentermine</td></tr><tr><td>Secondary amines</td><td>Ry Ry</td><td>2-Acetylaminofluorene, acetaminophen</td></tr><tr><td>Tertiary amines</td><td>Rg Rg</td><td>Nicotine, methaqualone</td></tr><tr><td>S-Oxidation</td><td>R, R, \ s— s=o Ro Ro</td><td>Thioridazine, cimetidine, chlorpromazine</td></tr><tr><td>Deamination</td><td>OH | RCHCH, —&gt; R—C— CH,—&gt; R— CCH, + NHg</td><td>Amphetamine, diazepam</td></tr><tr><td>Desulfuration</td><td></td><td>Thiopental</td></tr></table>
======================================
<table><thead><th>Substrates</th><th>Inducers</th><th></th></thead><tr><td>amiodarone, amlodipine, aprepitant, astemizole, atazanavir, atorvastatin, bepridil, bexarotene, bosentan, bromocriptine, budesonide, buspirone, carbamazepine, cisapride, clarithro- mycin, clonazepam, clopidogrel, cocaine, colchicine, conivap- tan, cortisol, cyclosporine, dapsone, darunavir, dasatinib, delavirdine, dexamethasone, diazepam, dihydroergotamine, dihydropyridines, diltiazem, disopyramide, doxorubicin, droperidol, dutasteride, ebastine, efavirenz, eletriptan, eplere- none, ergotamine, erlotinib, erythromycin, estazolam, eszopi- clone, ethinyl estradiol, ethosuximide, etoposide, everolimus, exemestane, felodipine, fentanyl, finasteride, flurazepam, fluticasone, fosamprenavir, galantamine, gefitinib, gestodene, granisetron, halofantrine, ifosfamide, imatinib, indinavir, irinotecan, isradipine, itraconazole, ixabepilone, lapatinib, lidocaine, loperamide, lopinavir, loratadine, lovastatin, mac- rolides, maraviroc, mefloquine, methadone, methylpred- nisolone, miconazole, midazolam, mifepristone, modafinil, nefazodone, nevirapine, nicardipine, nifedipine, nimodipine, nisoldipine, paclitaxel, paricalcitol, pimozide, pioglitazone, praziquantel, prednisolone, prednisone, progesterone, que- tiapine, quinacrine, quinidine, quinine, ranolazine, rapamycin, repaglinide, rifabutin, ritonavir, saquinavir, sibutramine, sildenafil, simvastatin, sirolimus, solifenacin, spironolactone, sufentanil, sulfamethoxazole, sunitinib, tacrolimus, tadalafil, tamoxifen, tamsulosin, teniposide, terfenadine, testoster- one, tetrahydrocannabinol, tiagabine, tinidazole, tipranavir, tolvaptan, topiramate, triazolam, troleandomycin, vardenafil, verapamil, vinblastine, vincristine, ziprasidone, zolpidem, zonisamide, zopiclone</td><td>avasimibe, barbiturates, carbamazepine, efavirenz, glucocorticoids, nevirapine, pioglitazone, phenytoin, primidone, rifampin, rifa- pentine, St. John’s wort</td><td>clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice (furanocoumarins), indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole</td></tr></table>
======================================
<table><thead><th>Type of Conjugation</th><th>Endogenous Reactant</th><th>Transferase (Location)</th><th>Types of Substrates</th><th>Examples</th></thead><tr><td>Glucuronidation</td><td>UDP glucuronic acid (UDPGA)</td><td>UDP glucuronosyl- transferase (microsomes)</td><td>Phenols, alcohols, carboxylic acids, hydroxylamines, sulfonamides</td><td>Nitrophenol, morphine, acetaminophen, diazepam, N-hydroxydapsone, sulfathia- zole, meprobamate, digitoxin, digoxin</td></tr><tr><td>Acetylation</td><td>Acetyl-CoA</td><td>N-Acetyltransferase (cytosol)</td><td>Amines</td><td>Sulfonamides, isoniazid, clonazepam, dapsone, mescaline</td></tr><tr><td>Glutathione conjugation</td><td>Glutathione (GSH)</td><td>GSH-S-transferase (cytosol, microsomes)</td><td>Epoxides, arene oxides, nitro groups, hydroxylamines</td><td>Acetaminophen, ethacrynic acid, bromobenzene</td></tr><tr><td>Glycine conjugation</td><td>Glycine</td><td>Acyl-CoA glycinetrans- ferase (mitochondria)</td><td>Acyl-CoA derivatives of carboxylic acids</td><td>Salicylic acid, benzoic acid, nicotinic acid, cinnamic acid, cholic acid, deoxycholic acid</td></tr><tr><td>Sulfation</td><td>Phosphoadenosyl phosphosulfate (PAPS)</td><td>Sulfotransferase (cytosol)</td><td>Phenols, alcohols, aromatic amines</td><td>Estrone, aniline, phenol, 3- hydroxycoumarin, acetaminophen, methyldopa</td></tr><tr><td>Methylation</td><td>S-Adenosylmethionine (SAM)</td><td>Transmethylases (cytosol)</td><td>Catecholamines, phenols, amines</td><td>Dopamine, epinephrine, pyridine, histamine, thiouracil</td></tr><tr><td rowspan="2">Water conjugation</td><td></td><td>Water</td><td>Epoxide hydrolase (microsomes)</td><td>Arene oxides, cis-disubsti- tuted and monosubstituted oxiranes</td><td>Benzopyrene 7,8-epoxide, styrene 1,2-oxide, carbamazepine epoxide</td></tr><tr><td></td><td>(cytosol)</td><td>Alkene oxides, fatty acid epoxides</td><td>Leukotriene A,</td></tr></table>
======================================
<table><thead><th>Enzyme Involved</th><th>Defect</th><th>Genotype</th><th>Drug and Therape: Use</th><th>Clinical Consequences’</th></thead><tr><td rowspan="2">CYP1A2</td><td>N-Demethylation</td><td>EM</td><td>Caffeine (CNS stimulant)</td><td>Reduced CNS stimulation due to increased gene inducibility and thus increased metabolism/clearance in cigarette smokers and frequent ingesters of omeprazole.</td></tr><tr><td></td><td>N-Demethylation</td><td>PM</td><td>Caffeine (CNS stimulant)</td><td>Enhanced CNS stimulation.</td></tr><tr><td rowspan="4">CYP2A6</td><td>Oxidation</td><td>PM</td><td>Nicotine (cholinoceptorstimulant)</td><td>Nicotine toxicity. Lesser craving for frequent cigarette smoking.</td></tr><tr><td></td><td>Oxidation</td><td>EM</td><td>Nicotine (cholinoceptorstimulant)</td><td>Increased nicotine metabolism. Greater craving for frequent cigarette smoking.</td></tr><tr><td></td><td>Oxidation</td><td>PM</td><td>Coumarin (anticoagulant)</td><td>Increased risk of bleeding.</td></tr><tr><td></td><td>Oxidation</td><td>EM</td><td>Coumarin (anticoagulant)</td><td>Increased clearance. Greater risk of thrombosis.</td></tr><tr><td rowspan="2">CYP2B6</td><td></td><td>Oxidation, N-Dechloroethylation</td><td>PM</td><td>Cyclophosphamide, ifosfamide (anti-cancer)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td>Oxidation</td><td>PM</td><td>Efavirenz, nevirapine (anti-HIV)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td rowspan="4">cyP2c8</td><td>Hydroxylation</td><td>PM</td><td>Repaglinide, rosiglitazone, pioglitazone (antidiabetic)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td></td><td>Hydroxylation</td><td>PM</td><td>Paclitaxel (anti-cancer)</td><td>Reduced clearance. Increased risk of ADRs (myelosuppression).</td></tr><tr><td></td><td>N-Deethylation/ N-Dealkylation</td><td>PM</td><td>Amodiaquine, chloroquine (antimalarial)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td></td><td>N-Deethylation</td><td>PM</td><td>Amiodarone (antiarrhythmic)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td rowspan="4">cyYP2c9</td><td></td><td>Hydroxylation</td><td>PM</td><td>Celecoxib, diclofenac, flurbipro- fen, S-ibuprofen (NSAIDs)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td></td><td>Hydroxylation</td><td>PM</td><td>S-Warfarin, S-acenocoumarol (anticoagulants)</td><td>Enhanced bleeding risk. Clinically highly relevant. Dose adjustment required.</td></tr><tr><td></td><td>Hydroxylation</td><td>PM</td><td>Tolbutamide (antidiabetic)</td><td>Cardiotoxicity.</td></tr><tr><td>Hydroxylation</td><td>PM</td><td>Phenytoin (antiepileptic)</td><td>Nystagmus, diplopia, and ataxia.</td></tr><tr><td rowspan="10">CYP2C19</td><td>N-Demethylation</td><td>PM</td><td>Amitriptyline, clomipramine (antidepressants)</td><td>Reduced clearance. Increased risk of ADRs. Dose adjustment required.</td></tr><tr><td></td><td>Oxidation</td><td>PM</td><td>Moclobemide (MAOI)</td><td></td></tr><tr><td></td><td>N-Demethylation</td><td>PM</td><td>Citalopram (SSRI)</td><td>Increased risk of gastrointestinal side effects.</td></tr><tr><td></td><td>O-Demethylation</td><td>PM</td><td>Omeprazole (PPI)</td><td>Increased therapeutic efficacy.</td></tr><tr><td></td><td>Hydroxylation</td><td>PM</td><td>Mephenytoin (antiepileptic)</td><td>Overdose toxicity.</td></tr><tr><td></td><td>N-Demethylation</td><td>EM</td><td>Escitalopram (antidepressants)</td><td>Increased gene transcription resulting in increased activity and thus reduced therapeutic efficacy.</td></tr><tr><td></td><td>O-Demethylation</td><td>EM</td><td>Omeprazole (PPI)</td><td>Reduced therapeutic efficacy.</td></tr><tr><td></td><td>Hydroxylation</td><td>EM</td><td>Tamoxifen (anti-cancer)</td><td>Increased metabolic activation, increased therapeutic efficacy; reduced risk of relapse. Dose adjustment required.</td></tr><tr><td></td><td>Oxidative cyclization</td><td>EM</td><td>Chlorproguanil (antimalarial)</td><td>I
======================================
ncreased metabolic activation, increased therapeutic efficacy. Dose adjustment required.</td></tr><tr><td></td><td>Oxidation</td><td>EM</td><td>Clopidogrel (antiplatelet)</td><td>Increased metabolic activation, increased</td></tr></table>
======================================
<table><thead><th>Enzyme Involved</th><th>Defect</th><th>Genotype</th><th>Drug and Therapeutic Use</th><th>Clinical Consequences’</th></thead><tr><td></td><td>N-Demethylation</td><td>PM</td><td>Nortriptyline (antidepressant)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td></td><td>Oxidation</td><td>PM</td><td>Sparteine</td><td>Oxytocic symptoms.</td></tr><tr><td></td><td>O-Demethylation</td><td>PM</td><td>Dextromethorphan (antitussive)</td><td>Reduced clearance. Increased risk of ADRs.</td></tr><tr><td></td><td>O-Demethylation</td><td>PM</td><td>Tramadol (analgesic)</td><td>Increased risk of seizures.</td></tr><tr><td></td><td>Hydroxylation</td><td>PM</td><td>Tamoxifen (anti-cancer)</td><td>Reduced metabolic activation to the therapeutically active endoxifen and thus reduced therapeutic efficacy.</td></tr><tr><td></td><td>O-Demethylation</td><td>UM</td><td>Codeine (analgesic)</td><td>Increased metabolic activation to morphine and thus increased risk of respiratory depression.</td></tr><tr><td></td><td>N-Demethylation</td><td>UM</td><td>Nortriptyline (antidepressant)</td><td>Reduced therapeutic efficacy due to increased clearance.</td></tr><tr><td></td><td>O-Demethylation</td><td>UM</td><td>Tramadol (analgesic)</td><td>Reduced therapeutic efficacy due to increased clearance.</td></tr><tr><td>CYP3A4</td><td></td><td>PM?</td><td>All drugs metabolized by this enzyme would be potentially affected</td><td>Reduced clearance. Dose adjustment may be required to avoid drug-drug interactions.</td></tr><tr><td>CYP3A5</td><td></td><td>PM?</td><td>Saquinavir, and other CYP3A substrates</td><td>Usually less catalytically active than CYP3A4. A higher frequency of a functional CYP3A5*1 allele is seen in Africans than in Caucasians; the latter most often carry the defective CYP3A5*3 allele. This may significantly affect therapeutics of CYP3A substrates in CYP3A5*1 or CYP3A5*3 homozygous individuals.</td></tr><tr><td>ALDH</td><td>Aldehyde dehydrogenation</td><td>PM</td><td>Ethanol (recreational drug)</td><td>Facial flushing, hypotension, tachycardia, nausea, vomiting.</td></tr><tr><td rowspan="3">BCHE</td><td>Ester hydrolysis</td><td>PM</td><td>Succinylcholine (muscle relaxant)</td><td>Prolonged apnea.</td></tr><tr><td></td><td></td><td></td><td>Mivacurium (neuromuscular blocker)</td><td>Prolonged muscle paralysis.</td></tr><tr><td></td><td></td><td></td><td>Cocaine (CNS stimulant)</td><td>Increased blood pressure, tachycardia, ventricular arrhythmias. due</td></tr><tr><td>GST</td><td>GSH-conjugation</td><td>PM</td><td>Acetaminophen (analgesic), Busulfan (anti-cancer)</td><td>Impaired GSH conjugation to gene deletion.</td></tr><tr><td rowspan="2">NAT2</td><td>N-Acetylation</td><td>PM</td><td>Hydralazine (antihypertensive)</td><td>Lupus erythematosus-like syndrome.</td></tr><tr><td></td><td>N-Acetylation</td><td>PM</td><td>Isoniazid (antitubercular)</td><td>Peripheral neuropathy.</td></tr><tr><td>TPMT</td><td>S-Methylation</td><td>PM</td><td>6-Thiopurines (anti-cancer)</td><td>Myelotoxicity.</td></tr><tr><td>UGT1A1</td><td>Glucuronidation</td><td>PM</td><td>Bilirubin (heme metabolite)</td><td>Hyperbilirubinemia.</td></tr></table>
======================================
<table><thead><th>Inducer</th><th>Drugs Whose Metabolism Is Enhanced</th></thead><tr><td>Benzo[a]pyrene</td><td>Theophylline</td></tr><tr><td>Carbamazepine</td><td>Carbamazepine, clonazepam, itraconazole</td></tr><tr><td>Chlorcyclizine</td><td>Steroid hormones</td></tr><tr><td>Ethchlorvynol</td><td>Warfarin</td></tr><tr><td>Glutethimide</td><td>Antipyrine, glutethimide, warfarin</td></tr><tr><td>Griseofulvin</td><td>Warfarin</td></tr><tr><td>Phenobarbital and other barbiturates’</td><td>Barbiturates, chloramphenicol, chlorpromazine, cortisol, coumarin anticoagulants, desmethyl imipramine, digitoxin, doxorubicin, estradiol, itraconazole, phenylbutazone, phenytoin, quinine, testosterone</td></tr><tr><td>Phenylbutazone</td><td>Aminopyrine, cortisol, digitoxin</td></tr><tr><td>Phenytoin</td><td>Cortisol, dexamethasone, digitoxin, itraconazole, theophylline</td></tr><tr><td>Rifampin</td><td>Coumarin anticoagulants, digi- toxin, glucocorticoids, itracon- azole, methadone, metoprolol, oral contraceptives, prednisone, propranolol, quinidine, saquinavir</td></tr><tr><td>Ritonavir?</td><td>Midazolam</td></tr><tr><td>St. John’s wort?</td><td>Alprazolam, cyclosporine, digoxin, indinavir, oral contra- ceptives, ritonavir, simvastatin, tacrolimus, warfarin</td></tr></table>
======================================
<table><thead><th>itor’</th><th>Drug Whose Metabolism Is Inhibited</th></thead><tr><td>Allopurinol, chloramphenicol, isoniazid</td><td>Antipyrine, dicumarol, probenecid, tolbutamide</td></tr><tr><td>Chlorpromazine</td><td>Propranolol</td></tr><tr><td>Cimetidine</td><td>Chlordiazepoxide, diazepam, warfarin, others</td></tr><tr><td>Dicumarol</td><td>Phenytoin</td></tr><tr><td>Diethylpentenamide</td><td>Diethylpentenamide</td></tr><tr><td>Disulfiram</td><td>Antipyrine, ethanol, phenytoin, warfarin</td></tr><tr><td>Ethanol</td><td>Chlordiazepoxide (?), diazepam (?), methanol</td></tr><tr><td>Grapefruit juice*</td><td>Alprazolam, atorvastatin, cisapride, cyclosporine, midazolam, triazolam</td></tr><tr><td></td><td>atorvastatin, buspirone, cisapride, cyclosporine, delavirdine, diazepam, digoxin, felodipine,</td></tr><tr><td>Itraconazole</td><td>Alfentanil, alprazolam, astemizole, indinavir, loratadine, lovastatin, midazolam, nisoldipine, pheny- toin, quinidine, ritonavir, saqui-</td></tr><tr><td></td><td>navir, sildenafil, simvastatin, sirolimus, tacrolimus, triazolam, verapamil, warfarin</td></tr><tr><td>Ketoconazole</td><td>Astemizole, cyclosporine, terfenadine</td></tr><tr><td>Nortriptyline</td><td>Antipyrine</td></tr><tr><td>Oral contraceptives</td><td>Antipyrine</td></tr><tr><td>Phenylbutazone</td><td>Phenytoin, tolbutamide</td></tr><tr><td>Ritonavir</td><td>Amiodarone, cisapride, itraconazole, midazolam, triazolam</td></tr><tr><td>Saquinavir</td><td>Cisapride, ergot derivatives, midazolam, triazolam</td></tr><tr><td>Secobarbital</td><td>Secobarbital</td></tr></table>
======================================
<table><thead><th>Alprenolol</th><th>Lidocaine</th></thead><tr><td>Amitriptyline</td><td>Meperidine</td></tr><tr><td>Clomethiazole</td><td>Morphine</td></tr><tr><td>Desipramine</td><td>Pentazocine</td></tr><tr><td>Imipramine</td><td>Propoxyphene</td></tr><tr><td>Isoniazid</td><td>Propranolol</td></tr><tr><td>Labetalol</td><td>Verapamil</td></tr></table>
======================================
<table><thead><th>Term</th><th>Definition</th></thead><tr><td>Allele</td><td>One of two or more alternative forms of a gene that arise by mutation and are found at the same genetic locus. Example: CYP2D6*3 is an important variant allele for a drug-metabolizing enzyme, CYP2D6.</td></tr><tr><td>Allele frequency</td><td>The fraction or percentage of times a specific allele is observed in proportion to the total of all possible alleles that could occur at a specific location on a chromosome.</td></tr><tr><td>Coding single nucleotide polymorphisms (cSNPs)</td><td>A single base-pair substitution that occurs in the coding region.</td></tr><tr><td>Copy number variations (CNVs)</td><td>A segment of DNA in which a variable number of that segment has been found.</td></tr><tr><td>Haplotype</td><td>A series of alleles found in a linked locus on a chromosome.</td></tr><tr><td>Hardy-Weinberg equilibrium</td><td>The principle that allele frequencies will remain constant from generation to generation in the absence of evolutionary influences.</td></tr><tr><td>Insertions/deletion (indel)</td><td>Insertion or deletion of base pairs, which may occur in coding and noncoding regions.</td></tr><tr><td>Linkage disequilibrium</td><td>The nonrandom association of alleles at two or more loci that descend from a single ancestral chromosome.</td></tr><tr><td>Noncoding region polymorphism</td><td>Polymorphisms that occur in the 3’ and 5’ untranslated regions, intronic regions, or intergenic regions.</td></tr><tr><td>Nonsynonymous SNPs (nsSNPs)</td><td>A single base-pair substitution in the coding region that results in an amino acid change.</td></tr><tr><td>Polymorphism or variant</td><td>Any genetic variation in the DNA sequence; the terms can be used interchangeably.</td></tr><tr><td>PM, IM, EM, or UM</td><td>Poor, intermediate, extensive, or ultra-rapid metabolizer phenotype.</td></tr><tr><td>SNPs</td><td>Single nucleotide polymorphisms: base-pair substitutions that occur in the genome.</td></tr></table>
======================================
<table><thead><th></th><th>Allele(s)</th><th>dbSNP' Number</th><th>Amino Acid</th><th>Function</th><th></th><th>Fraction in African Populations</th><th>Fraction in Asian Populations</th><th>Fraction in European Population</th></thead><tr><td colspan="9">P2D6</td></tr><tr><td></td><td>*7</td><td>Reference</td><td></td><td>Normal</td><td></td><td>0.39</td><td>0.34</td><td>0.54</td></tr><tr><td></td><td>*1XN</td><td>Gene duplication or multiplication</td><td>Increased expression</td><td>Increased</td><td></td><td>0.015</td><td>0.0028</td><td>0.0080</td></tr><tr><td></td><td>#2</td><td>1516947, rs1135840</td><td>R296C, S486T</td><td>Normal</td><td></td><td>0.20</td><td>0.13</td><td>0.27</td></tr><tr><td></td><td>*2xN</td><td>Duplication or multiplication</td><td>Increased expression</td><td>Increased</td><td>1.0xN</td><td>0.016</td><td>0.0038</td><td>0.013</td></tr><tr><td></td><td></td><td>135742686</td><td>Frameshift</td><td></td><td>0.0</td><td>0.00030</td><td>0.00</td><td>0.013</td></tr><tr><td></td><td></td><td>1s1065852, rs3892097</td><td>P345S, Splicing defect</td><td></td><td>0.0</td><td>0.034</td><td>0.0042</td><td>0.19</td></tr><tr><td></td><td></td><td></td><td>No enzyme</td><td></td><td>0.0</td><td>0.061</td><td>0.056</td><td>0.027</td></tr><tr><td></td><td></td><td>rs5030655</td><td>Frameshift</td><td></td><td>0.0</td><td>0.031</td><td>0.0002</td><td>0.0095</td></tr><tr><td></td><td></td><td>131065852, rs1135840</td><td>P34S, S486T</td><td>Decreased</td><td>0.5</td><td>0.068</td><td>0.42</td><td>0.032</td></tr><tr><td></td><td>#4]</td><td>rs1135840 1316947, rs1135840,</td><td>R296C, S486T, Splicing defect</td><td>Decreased</td><td>0.5</td><td>0.11</td><td>0.020</td><td>0.086</td></tr><tr><td></td><td></td><td>1828371725</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P2C19</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="9">Reference Normal 0.68 0.60 0.63</td></tr><tr><td></td><td>#2</td><td>1s4244285</td><td>Splicing defect</td><td></td><td></td><td>0.15</td><td>0.29</td><td>0.15</td></tr><tr><td></td><td>43</td><td>1s4986893</td><td>W212X</td><td></td><td></td><td>0.0052</td><td>0.089</td><td>0.0042</td></tr><tr><td rowspan="6">YD</td><td></td><td>1312248560</td><td>Increased expression</td><td>Increased</td><td></td><td>0.16</td><td>0.027</td><td>0.21</td></tr><tr><td></td><td></td><td>Reference</td><td></td><td>Normal</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>rs3918290</td><td>Splicing defect</td><td></td><td></td><td>0.00</td><td>0.0015</td><td>0.0086</td></tr><tr><td></td><td></td><td>rs55886062</td><td>1560S</td><td></td><td></td><td></td><td>0.00</td><td>0.0010</td></tr><tr><td></td><td></td><td>1867376798</td><td>D949V</td><td></td><td></td><td></td><td></td><td>0.011</td></tr><tr><td colspan="9">iT1A1</td><td></td></tr><tr><td></td><td></td><td>Reference</td><td>TAs</td><td>Normal</td><td></td><td>0.50</td><td>0.85</td><td>0.68</td></tr><tr><td></td><td></td><td>188175347</td><td>TA;</td><td>Decreased</td><td></td><td>0.39</td><td>0.15</td><td>0.32</td></tr><tr><td></td><td></td><td>188175347</td><td></td><td>Increased</td><td></td><td>0.066</td><td>0.00</td><td>0.00</td></tr><tr><td></td><td></td><td>188175347</td><td></td><td>Decreased</td><td></td><td>0.036</td><td>0.00</td><td>0.0010</td></tr><tr><td colspan="9">MT</td></tr><tr><td></td><td></td><td>Reference</td><td></td><td>Normal</td><td></td><td>0.94</td><td>0.98</td><td>0.96</td></tr><tr><td></td><td></td><td>rs1800462</td><td>A80P</td><td></td><td></td><td>0.00079</td><td>0.00</td><td>0.0019</td></tr><tr><td></td><td></td><td>rs1800460,</td><td>A154T, Y240C</td><td></td><td></td><td>0.0020</td><td>0.00012</td><td>0.036</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Allele(s) | dbSNP’ Number</th><th>Amino Acid</th><th>Function</th><th>Activity</th><th>Fraction in African Populations</th><th>Fraction in Asian Populations</th><th>Fraction in European Populations</th></thead><tr><td colspan="9">36PD</td></tr><tr><td></td><td colspan="2">Reference B</td><td></td><td>Normal</td><td>IV</td><td></td><td></td><td></td></tr><tr><td></td><td>A</td><td>rs1050829</td><td>N126D</td><td>Normal</td><td>III-IV</td><td>0.31-0.35</td><td>0.00</td><td>0.00-0.060</td></tr><tr><td></td><td colspan="2">A- (rs1050829, rs1050828) A- (rs1050829, rs137852328) A- (rs1050829, rs76723693)</td><td>(N126D, V68M) (N126D, R227L) (N126D, L323P)</td><td>Decreased (5-10%)</td><td>Il</td><td>0.00-0.30</td><td></td><td></td></tr><tr><td></td><td colspan="2">Mediterranean (rs5030868)</td><td>S188P</td><td>Decreased (&lt; 1%)</td><td>Il</td><td>0.00-0.052</td><td>0.00-0.31</td><td>0.00-0.074</td></tr><tr><td></td><td colspan="2">Canton (rs72554665), Kaiping</td><td>R459L/R463H</td><td>Decreased</td><td>Il</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Mahidol</td><td>G163S</td><td>Decreased (5-32%)</td><td>Il</td><td></td><td></td><td></td></tr><tr><td rowspan="6">1LCO1B1</td><td colspan="2">Chinese-5, Gaohe</td><td>L342F H32R</td><td>Decreased</td><td>Il</td><td></td><td></td><td></td></tr><tr><td colspan="9"></td><td></td></tr><tr><td></td><td>*la</td><td>Reference</td><td></td><td>Normal</td><td>=</td><td>0.17</td><td>0.27</td><td>0.50</td></tr><tr><td></td><td>*1b</td><td>182306283</td><td>N130D</td><td>Normal</td><td>=</td><td>0.78</td><td>0.60</td><td>0.22</td></tr><tr><td></td><td>a5</td><td>1s4149056</td><td>V174A</td><td>Decreased</td><td>=</td><td>0.00</td><td>0.00</td><td>0.01</td></tr><tr><td></td><td>#15, #17</td><td>1s4149056, others</td><td>V174A others</td><td>Decreased</td><td>=</td><td>0.03</td><td>0.13</td><td>0.14</td></tr><tr><td></td><td>*57:01</td><td>=</td><td></td><td>positive</td><td>=</td><td>0.010</td><td>0.016</td><td>0.068</td></tr><tr><td colspan="9">FNL3</td></tr><tr><td></td><td>TT/CT</td><td>Reference</td><td></td><td>Unfavorable</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>cc</td><td>1812979860</td><td></td><td>Favorable</td><td>=</td><td>0.39</td><td>0.87</td><td>0.63</td></tr><tr><td colspan="9">-YP2C9</td></tr><tr><td></td><td>*]</td><td>Reference</td><td></td><td>Normal</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">*2 131799853</td><td></td><td>Decreased</td><td>=</td><td>0.03</td><td>0.00</td><td>0.13</td></tr><tr><td></td><td>#3</td><td>rs1057910</td><td></td><td>Decreased</td><td>=</td><td>0.02</td><td>0.04</td><td>0.07</td></tr><tr><td colspan="9">/KORC1</td></tr><tr><td></td><td>-1639G</td><td>Reference</td><td></td><td>Normal</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-1639A</td><td>1s9923231</td><td>Reduced expression</td><td>Decreased</td><td>=</td><td>0.11</td><td>0.91</td><td>0.39</td></tr></table>
======================================
<table><thead><th>Gene</th><th>Drug</th><th>Diplotype’</th><th>Likely Phenotype (Activity Score)</th><th>Dosing Recommendation</th><th>Source of Recommendation</th></thead><tr><td colspan="6">CYP2D6</td><td rowspan="5"></td></tr><tr><td></td><td>Codeine</td><td>*1/* 1XN, *1/*2XN</td><td>IM (&gt; 2.0)</td><td>+ Alternative analgesic, eg, morphine or nonopioid; increased formation of morphine following codeine administration leads to higher risk of toxicity.</td><td>CPIC?</td></tr><tr><td></td><td></td><td>1/1, 1/82, #2/#2, RIAL, #2/85</td><td>M (1.0-2.0)</td><td>Standard starting dose.</td><td></td></tr><tr><td></td><td></td><td>4/10, *5/*A1</td><td>M (0.5)</td><td>Standard starting dose; monitor closely for lack of analgesic response due to reduced morphine formation. Consider alternate analgesic, eg, morphine or nonopioid.</td><td></td></tr><tr><td></td><td></td><td>43/04, 24/4, 4/5, 15/45, *4/%6</td><td>PM (0.0)</td><td>Alternative analgesic, eg, morphine or nonopioid analgesic; greatly reduced morphine formation following codeine administration, leading to insufficient pain relief. Avoid higher doses, as central side effects do not differ in PMs.</td><td></td></tr><tr><td colspan="6">CYP2C19</td><td rowspan="4"></td><td></td></tr><tr><td></td><td>Clopidogrel</td><td>*1/*17, *17/*17 (UM), and *1/*1 (EM)</td><td>UM, EM</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td># 1/82, # 1/3, *2/*17</td><td></td><td>Alternative antiplatelet agent, eg, prasugrel or ticagrelor.</td><td></td></tr><tr><td></td><td></td><td>I/D, 82/83, #3/83</td><td></td><td>Alternative antiplatelet agent, eg, prasugrel or ticagrelor.</td><td></td></tr><tr><td rowspan="4">DPYD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Fluoropy- rimidines</td><td>1/1</td><td>Normal</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*1/#2A, *1/*13, *1/rs67376798A</td><td>Reduced activity</td><td>Reduce initial dose 50% and titrate based on toxicity or on pharmacokinetic test results (if available).</td><td></td></tr><tr><td></td><td></td><td>*2A/*2A, *2A/*13, *13/*13, 1867376798A/ 1867376798A</td><td>Complete deficiency</td><td>Different non-fluoropyrimidine anticancer agent.</td><td></td></tr><tr><td colspan="6">UGT1A1</td><td rowspan="7"></td><td></td></tr><tr><td></td><td>lrinotecan</td><td>1/1, 1/428</td><td>Normal</td><td>Standard starting dose.</td><td></td></tr><tr><td></td><td>*28/*28</td><td>Reduced</td><td>Reduce starting dose by at least one dose level. Or,</td><td>Drug label</td></tr><tr><td></td><td></td><td></td><td></td><td>Dose &gt; 250 mg/m’: Reduce starting dose 30% and increase in response to neutrophil count. Dose = 250 mg/m’: No dose adjustment.</td><td>DPWG?</td></tr><tr><td></td><td>Atazanavir</td><td>*1/*1, *1/*36, *36/*36, 1887829 C/C</td><td>Normal</td><td>No reason to avoid prescribing atazanavir. Inform patient of risks. Based on this genotype, there is a less than 1 in 20 chance of stopping atazanavir for jaundice.</td><td>CPIC</td></tr><tr><td></td><td></td><td>#1/%28, *1/%37, 36 /*28, *36/%37, 15887829 C/T, *1/*6</td><td>Intermediate</td><td>No reason to avoid prescribing atazanavir. Inform patient of risks. Based on this genotype, there is a less than 1 in 20 chance of stopping atazanavir for jaundice.</td><td></td></tr><tr><td></td><td></td><td>*28/*28, *28/*37, *37/*37, 18887829 T/T (*80/*80), *6/*6</td><td>Reduced</td><td>Consider alternative agent. Based on this genotype, there is a high (20-60%) likelihood of developing jaundice that will result in discontinua- of</td><td></td></tr></table>
======================================
<table><thead><th>Gene</th><th>Drug</th><th>Diplotype’</th><th>Likely Phenotype (Activity Score)</th><th>Dosing Recommendation</th><th>Source of Recommendation</th></thead><tr><td colspan="6">CYP2D6</td><td rowspan="5"></td></tr><tr><td></td><td>Codeine</td><td>*1/* 1XN, *1/*2XN</td><td>IM (&gt; 2.0)</td><td>+ Alternative analgesic, eg, morphine or nonopioid; increased formation of morphine following codeine administration leads to higher risk of toxicity.</td><td>CPIC?</td></tr><tr><td></td><td></td><td>1/1, 1/82, #2/#2, RIAL, #2/85</td><td>M (1.0-2.0)</td><td>Standard starting dose.</td><td></td></tr><tr><td></td><td></td><td>4/10, *5/*A1</td><td>M (0.5)</td><td>Standard starting dose; monitor closely for lack of analgesic response due to reduced morphine formation. Consider alternate analgesic, eg, morphine or nonopioid.</td><td></td></tr><tr><td></td><td></td><td>43/04, 24/4, 4/5, 15/45, *4/%6</td><td>PM (0.0)</td><td>Alternative analgesic, eg, morphine or nonopioid analgesic; greatly reduced morphine formation following codeine administration, leading to insufficient pain relief. Avoid higher doses, as central side effects do not differ in PMs.</td><td></td></tr><tr><td colspan="6">CYP2C19</td><td rowspan="4"></td><td></td></tr><tr><td></td><td>Clopidogrel</td><td>*1/*17, *17/*17 (UM), and *1/*1 (EM)</td><td>UM, EM</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td># 1/82, # 1/3, *2/*17</td><td></td><td>Alternative antiplatelet agent, eg, prasugrel or ticagrelor.</td><td></td></tr><tr><td></td><td></td><td>I/D, 82/83, #3/83</td><td></td><td>Alternative antiplatelet agent, eg, prasugrel or ticagrelor.</td><td></td></tr><tr><td rowspan="4">DPYD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Fluoropy- rimidines</td><td>1/1</td><td>Normal</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*1/#2A, *1/*13, *1/rs67376798A</td><td>Reduced activity</td><td>Reduce initial dose 50% and titrate based on toxicity or on pharmacokinetic test results (if available).</td><td></td></tr><tr><td></td><td></td><td>*2A/*2A, *2A/*13, *13/*13, 1867376798A/ 1867376798A</td><td>Complete deficiency</td><td>Different non-fluoropyrimidine anticancer agent.</td><td></td></tr><tr><td colspan="6">UGT1A1</td><td rowspan="7"></td><td></td></tr><tr><td></td><td>lrinotecan</td><td>1/1, 1/428</td><td>Normal</td><td>Standard starting dose.</td><td></td></tr><tr><td></td><td>*28/*28</td><td>Reduced</td><td>Reduce starting dose by at least one dose level. Or,</td><td>Drug label</td></tr><tr><td></td><td></td><td></td><td></td><td>Dose &gt; 250 mg/m’: Reduce starting dose 30% and increase in response to neutrophil count. Dose = 250 mg/m’: No dose adjustment.</td><td>DPWG?</td></tr><tr><td></td><td>Atazanavir</td><td>*1/*1, *1/*36, *36/*36, 1887829 C/C</td><td>Normal</td><td>No reason to avoid prescribing atazanavir. Inform patient of risks. Based on this genotype, there is a less than 1 in 20 chance of stopping atazanavir for jaundice.</td><td>CPIC</td></tr><tr><td></td><td></td><td>#1/%28, *1/%37, 36 /*28, *36/%37, 15887829 C/T, *1/*6</td><td>Intermediate</td><td>No reason to avoid prescribing atazanavir. Inform patient of risks. Based on this genotype, there is a less than 1 in 20 chance of stopping atazanavir for jaundice.</td><td></td></tr><tr><td></td><td></td><td>*28/*28, *28/*37, *37/*37, 18887829 T/T (*80/*80), *6/*6</td><td>Reduced</td><td>Consider alternative agent. Based on this genotype, there is a high (20-60%) likelihood of developing jaundice that will result in discontinua- of</td><td></td></tr></table>
======================================
<table><thead><th></th><th>Rasburicase</th><th>B,A</th><th>Normal</th><th rowspan="2">Standard dose. Alternative agent, eg, allopurinol: Rasburicase is contraindicated in patients with G6PD deficiency.</th><th rowspan="3">Drug label/CPIC</th></thead><tr><td></td><td></td><td>A-, Mediterranean, Canton</td><td>Deficient</td><td></td><td></td></tr><tr><td></td><td></td><td>Variable</td><td>Unknown risk of hemolytic anemia</td><td>Enzyme activity must be measured to determine G6PD status. An alternative is allopurinol.</td><td></td></tr><tr><td colspan="6">SLCO1B1</td><td rowspan="4"></td></tr><tr><td></td><td>Simvastatin 40 mg</td><td>*1a/*1a, *1a/*1b, *1b/*1b</td><td>Normal activity</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*1a/*5, *1a/*15, *1a/*17, *1b/*5, *1b/*15, *1b/*17</td><td>Intermediate activity</td><td>Prescribe a lower dose or consider an alternative statin, eg, pravastatin or rosuvastatin; consider routine CK monitoring.</td><td></td></tr><tr><td></td><td></td><td>#5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/#17</td><td>Low activity</td><td>Prescribe a lower dose or consider an alternative statin, eg, pravastatin or rosuvastatin; consider routine CK monitoring.</td><td></td></tr><tr><td colspan="6">HLA</td></tr><tr><td rowspan="2"></td><td>Abacavir</td><td>*Other/*Other</td><td>Negative</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*Other/*57:01, *57:01/*57:01</td><td>Positive</td><td>Alternative agent: abacavir is contraindicated in HLA-B*57:01-positive patients.</td><td></td></tr><tr><td rowspan="4">IFNL3</td><td colspan="6"></td></tr><tr><td></td><td>PEG-IFN-o:/ RBV</td><td>s12979860/ 1312979860</td><td>Favorable</td><td>PEG-IFN-o/RBV: Consider cure rates before initiating regimen; ~70% chance for SVR* after 48 weeks of therapy. PEG-IFN-o/RBV + protease inhibitor combinations: Regimen recommended; ~90% chance for SVR after 24-48 weeks of therapy, with 80-90% chance for shortened duration of therapy.</td><td>CPIC</td></tr><tr><td></td><td></td><td>Reference/reference or reference/rs12979860</td><td>Unfavorable</td><td>PEG-IFN-o:/RBV: Consider cure rates before initiating regimen; ~30% chance for SVR after 48 weeks of therapy. PEG-IFN-o/RBV + protease inhibitor combinations: Consider cure rates before initiating regimen; ~60% chance for SVR after 24-48 weeks of therapy, with 50% chance for shortened duration of therapy.</td><td></td></tr><tr><td colspan="6">CYP2C9, VKORC1</td><td></td></tr><tr><td></td><td>Warfarin</td><td>#1/#1, #1/*2, *2/*2, #2/#3, # 1/3, *3/*3, 1639GG, 1639GA, 1639AA</td><td>Various</td><td>Apply validated dosing algorithm, eg, www.warfarindosing.org (or Iwec?) for international normalized ratio target 2-3) or FDA-approved dosing table per manufacturer's labeling.</td><td>CPIC</td></tr></table>
======================================
<table><thead><th></th><th>Rasburicase</th><th>B,A</th><th>Normal</th><th rowspan="2">Standard dose. Alternative agent, eg, allopurinol: Rasburicase is contraindicated in patients with G6PD deficiency.</th><th rowspan="3">Drug label/CPIC</th></thead><tr><td></td><td></td><td>A-, Mediterranean, Canton</td><td>Deficient</td><td></td><td></td></tr><tr><td></td><td></td><td>Variable</td><td>Unknown risk of hemolytic anemia</td><td>Enzyme activity must be measured to determine G6PD status. An alternative is allopurinol.</td><td></td></tr><tr><td colspan="6">SLCO1B1</td><td rowspan="4"></td></tr><tr><td></td><td>Simvastatin 40 mg</td><td>*1a/*1a, *1a/*1b, *1b/*1b</td><td>Normal activity</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*1a/*5, *1a/*15, *1a/*17, *1b/*5, *1b/*15, *1b/*17</td><td>Intermediate activity</td><td>Prescribe a lower dose or consider an alternative statin, eg, pravastatin or rosuvastatin; consider routine CK monitoring.</td><td></td></tr><tr><td></td><td></td><td>#5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/#17</td><td>Low activity</td><td>Prescribe a lower dose or consider an alternative statin, eg, pravastatin or rosuvastatin; consider routine CK monitoring.</td><td></td></tr><tr><td colspan="6">HLA</td></tr><tr><td rowspan="2"></td><td>Abacavir</td><td>*Other/*Other</td><td>Negative</td><td>Standard dose.</td><td>CPIC</td></tr><tr><td></td><td></td><td>*Other/*57:01, *57:01/*57:01</td><td>Positive</td><td>Alternative agent: abacavir is contraindicated in HLA-B*57:01-positive patients.</td><td></td></tr><tr><td rowspan="4">IFNL3</td><td colspan="6"></td></tr><tr><td></td><td>PEG-IFN-o:/ RBV</td><td>s12979860/ 1312979860</td><td>Favorable</td><td>PEG-IFN-o/RBV: Consider cure rates before initiating regimen; ~70% chance for SVR* after 48 weeks of therapy. PEG-IFN-o/RBV + protease inhibitor combinations: Regimen recommended; ~90% chance for SVR after 24-48 weeks of therapy, with 80-90% chance for shortened duration of therapy.</td><td>CPIC</td></tr><tr><td></td><td></td><td>Reference/reference or reference/rs12979860</td><td>Unfavorable</td><td>PEG-IFN-o:/RBV: Consider cure rates before initiating regimen; ~30% chance for SVR after 48 weeks of therapy. PEG-IFN-o/RBV + protease inhibitor combinations: Consider cure rates before initiating regimen; ~60% chance for SVR after 24-48 weeks of therapy, with 50% chance for shortened duration of therapy.</td><td></td></tr><tr><td colspan="6">CYP2C9, VKORC1</td><td></td></tr><tr><td></td><td>Warfarin</td><td>#1/#1, #1/*2, *2/*2, #2/#3, # 1/3, *3/*3, 1639GG, 1639GA, 1639AA</td><td>Various</td><td>Apply validated dosing algorithm, eg, www.warfarindosing.org (or Iwec?) for international normalized ratio target 2-3) or FDA-approved dosing table per manufacturer's labeling.</td><td>CPIC</td></tr></table>
======================================
<table><thead><th>World Health Organization Class</th><th>_Level of Deficiency</th><th>Enzyme Activity</th><th>Clinical phenotype</th></thead><tr><td>|</td><td>Severe</td><td>&lt;10%</td><td>Chronic (non- spherocytic) hemolytic anemia</td></tr><tr><td>I</td><td>Severe</td><td>&lt;10%</td><td>Risk of acute hemolytic anemia; intermittent hemolysis</td></tr><tr><td>Il</td><td>Moderate</td><td>10-60%</td><td>Risk of acute hemolytic anemia; hemolysis with stressors</td></tr><tr><td>IV</td><td></td><td>60-150%</td><td>Normal</td></tr><tr><td>Vv</td><td></td><td>&gt;150%</td><td>Enhanced activity</td></tr></table>
======================================
<table><thead><th>Variant of HLA Gene</th><th>Drug and Adverse Effect</th></thead><tr><td>HLA-B*57:01</td><td>Abacavir-induced skin toxicity</td></tr><tr><td>HLA-B*58:01</td><td>Allopurinol-induced skin toxicity</td></tr><tr><td>HLA-DRB1 *15:01, DRBS5 *01:01, DQB1 *06:02 haplotype</td><td>Amoxicillin-clavulanate-induced liver injury</td></tr><tr><td>HLA-B* 15:02</td><td>Carbamazepine-induced skin toxicity</td></tr><tr><td>HLA-B *57:01</td><td>Flucloxacillin-induced liver injury</td></tr><tr><td>HLA-DQB1 *06, *02, HLA-DRB1 *15, *07</td><td>Various drugs, subgroup analysis for cholestatic or other types of liver injury</td></tr><tr><td>HLA-DRB1 *07, HLA-DQA1 *02</td><td>Ximelagatran, increased ALT</td></tr></table>
======================================
<table><tr><td rowspan="2">Substance Acetylcholine (ACh)</td><td>Functions</td></tr><tr><td></td><td>The primary transmitter at ANS ganglia, at the somatic neuromuscular junction, and at parasympathetic postganglionic nerve endings. A primary excitatory transmitter to smooth muscle and secretory cells in the ENS. Probably also the major neuron-to-neuron (“ganglionic”) transmitter in the ENS.</td></tr><tr><td>Adenosine triphosphate (ATP)</td><td>Acts as a transmitter or cotransmitter at many ANS-effector synapses.</td></tr><tr><td>Calcitonin gene-related peptide (CGRP)</td><td>Found with substance P in cardiovascular sensory nerve fibers. Present in some secretomotor ENS neurons and interneurons. A cardiac stimulant.</td></tr><tr><td>Cholecystokinin (CCK)</td><td>May act as a cotransmitter in some excitatory neuromuscular ENS neurons.</td></tr><tr><td>Dopamine</td><td>A modulatory transmitter in some ganglia and the ENS. Possibly a postganglionic sympathetic transmitter in renal blood vessels.</td></tr><tr><td>Enkephalin and related opioid peptides</td><td>Present in some secretomotor and interneurons in the ENS. Appear to inhibit ACh release and thereby inhibit peristalsis. May stimulate secretion.</td></tr><tr><td>Galanin</td><td>Present in secretomotor neurons; may play a role in appetite-satiety mechanisms.</td></tr><tr><td>GABA (y-aminobutyric acid)</td><td>May have presynaptic effects on excitatory ENS nerve terminals. Has some relaxant effect on the gut. Prob- ably not a major transmitter in the ENS.</td></tr><tr><td>Gastrin-releasing peptide (GRP)</td><td>Extremely potent excitatory transmitter to gastrin cells. Also known as mammalian bombesin.</td></tr><tr><td>Neuropeptide Y (NPY)</td><td>Found in many noradrenergic neurons. Present in some secretomotor neurons in the ENS and may inhibit secretion of water and electrolytes by the gut. Causes long-lasting vasoconstriction. It is also a cotransmitter in some parasympathetic postganglionic neurons.</td></tr><tr><td>Nitric oxide (NO)</td><td>A cotransmitter at inhibitory ENS and other neuromuscular junctions; may be especially important at sphinc- ters. Cholinergic nerves innervating blood vessels appear to activate the synthesis of NO by vascular endo- thelium. NO is not stored, it is synthesized on demand by nitric oxide synthase, NOS; see Chapter 19.</td></tr><tr><td>Norepinephrine (NE)</td><td>The primary transmitter at most sympathetic postganglionic nerve endings.</td></tr><tr><td>Serotonin (5-HT)</td><td>An important transmitter or cotransmitter at excitatory neuron-to-neuron junctions in the ENS.</td></tr><tr><td>Substance P, related tachykinins</td><td>Substance P is an important sensory neurotransmitter in the ENS and elsewhere. Tachykinins appear to be excitatory cotransmitters with ACh at ENS neuromuscular junctions. Found with CGRP in cardiovascular sen- sory neurons. Substance P is a vasodilator (probably via release of nitric oxide).</td></tr><tr><td>Vasoactive intestinal peptide (VIP)</td><td>Excitatory secretomotor transmitter in the ENS; may also be an inhibitory ENS neuromuscular cotransmitter. A probable cotransmitter in many cholinergic neurons. A vasodilator (found in many perivascular neurons) and cardiac stimulant.</td></tr></table>
======================================
<table><tr><td>Cholinoceptors</td><td></td><td></td></tr><tr><td>Muscarinic M,</td><td>CNS neurons, sympathetic postganglionic neurons, some presynaptic sites</td><td>Formation of IP; and DAG, increased intracellular calcium</td></tr><tr><td>Muscarinic M,</td><td>Myocardium, smooth muscle, some presynaptic sites; CNS neurons</td><td>Opening of potassium channels, inhibition of adenylyl cyclase</td></tr><tr><td>Muscarinic M;</td><td>Exocrine glands, vessels (smooth muscle and endothelium); CNS neurons</td><td>Like M, receptor-ligand binding</td></tr><tr><td>Muscarinic M,</td><td>CNS neurons; possibly vagal nerve endings</td><td>Like M, receptor-ligand binding</td></tr><tr><td>Muscarinic M,</td><td>Vascular endothelium, especially cerebral vessels; CNS neurons</td><td>Like M, receptor-ligand binding</td></tr><tr><td>Nicotinic Ny</td><td>Postganglionic neurons, some presynaptic cholinergic terminals; pentameric receptors typically contain ot- and B-type subunits only (see Chapter 7)</td><td>Opening of Na’, K* channels, depolarization</td></tr><tr><td>Nicotinic Ny,</td><td>Skeletal muscle neuromuscular end plates; receptors typically contain two @,- and B,-type subunits in addition to y and 6 subunits</td><td>Opening of Na‘, K* channels, depolarization</td></tr><tr><td colspan="3">Adrenoceptors</td></tr><tr><td>Alpha,</td><td>Postsynaptic effector cells, especially smooth muscle</td><td>Formation of IP; and DAG, increased intracellular calcium</td></tr><tr><td>Alpha,</td><td>Presynaptic adrenergic nerve terminals, platelets, lipocytes, smooth muscle</td><td>Inhibition of adenylyl cyclase, decreased cAMP</td></tr><tr><td>Beta,</td><td>Postsynaptic effector cells, especially heart, lipocytes, brain; presynaptic adrenergic and cholinergic nerve terminals, juxtaglomerular apparatus of renal tubules, ciliary body epithelium</td><td>Stimulation of adenylyl cyclase, increased cAMP</td></tr><tr><td>Beta,</td><td>Postsynaptic effector cells, especially smooth muscle and cardiac muscle</td><td>Stimulation of adenylyl cyclase and increased cAMP. Activates cardiac G; under some conditions.</td></tr><tr><td>Beta;</td><td>Postsynaptic effector cells, especially lipocytes; heart</td><td>Stimulation of adenylyl cyclase and increased cAMP!</td></tr><tr><td colspan="3">Dopamine receptors</td></tr><tr><td>D, (DA,), Ds</td><td>Brain; effector tissues, especially smooth muscle of the renal vascular bed</td><td>Stimulation of adenylyl cyclase and increased cAMP</td></tr><tr><td>D, (DA,)</td><td>Brain; effector tissues, especially smooth muscle; presynaptic nerve terminals</td><td>Inhibition of adenylyl cyclase; increased potassium conductance</td></tr><tr><td>D;</td><td>Brain</td><td>Inhibition of adenylyl cyclase</td></tr><tr><td>Dy</td><td>Brain, cardiovascular system</td><td>Inhibition of adenylyl cyclase</td></tr></table>
======================================
<table><thead><th>Organ</th><th>Action"</th><th>Receptor”</th><th>Action</th><th>Receptor’</th></thead><tr><td colspan="5">Eye</td></tr><tr><td>Iris radial muscle</td><td>Contracts</td><td>O,</td><td></td><td></td></tr><tr><td>Iris circular muscle</td><td></td><td></td><td>Contracts</td><td></td></tr><tr><td>Ciliary muscle</td><td>[Relaxes]</td><td></td><td>Contracts</td><td></td></tr><tr><td colspan="5">Heart</td></tr><tr><td>Sinoatrial node</td><td>Accelerates</td><td></td><td>Decelerates</td><td></td></tr><tr><td>Ectopic pacemakers</td><td>Accelerates</td><td></td><td></td><td></td></tr><tr><td>Contractility</td><td>Increases</td><td></td><td>Decreases (atria)</td><td></td></tr><tr><td colspan="5">Blood vessels</td></tr><tr><td>Skin, splanchnic vessels</td><td>Contracts</td><td></td><td></td><td></td></tr><tr><td rowspan="3">Skeletal muscle vessels</td><td>Relaxes</td><td></td><td></td><td></td></tr><tr><td></td><td>[Contracts]</td><td></td><td></td><td></td></tr><tr><td></td><td>Relaxes*</td><td></td><td></td><td></td></tr><tr><td>Endothelium of vessels in heart, brain, viscera</td><td></td><td></td><td>Synthesizes and releases EDRF”</td><td></td></tr><tr><td>Bronchiolar smooth muscle</td><td>Relaxes</td><td></td><td>Contracts</td><td></td></tr><tr><td colspan="5">Gastrointestinal tract</td></tr><tr><td colspan="5">Smooth muscle</td></tr><tr><td>Walls</td><td>Relaxes</td><td></td><td>Contracts’</td><td></td></tr><tr><td>Sphincters</td><td>Contracts</td><td></td><td>Relaxes</td><td></td></tr><tr><td>Secretion</td><td>[Decreases]</td><td></td><td>Increases</td><td></td></tr><tr><td colspan="5">Genitourinary smooth muscle</td></tr><tr><td>Bladder wall</td><td>Relaxes</td><td></td><td>Contracts’</td><td></td></tr><tr><td>Sphincter</td><td>Contracts</td><td></td><td>Relaxes</td><td></td></tr><tr><td rowspan="2">Uterus, pregnant</td><td>Relaxes</td><td></td><td></td><td></td></tr><tr><td></td><td>Contracts</td><td></td><td>Contracts</td><td></td></tr><tr><td>Penis, seminal vesicles</td><td>Ejaculation</td><td></td><td>Erection</td><td></td></tr><tr><td colspan="5">Skin</td></tr><tr><td>Pilomotor smooth muscle</td><td>Contracts</td><td></td><td></td><td></td></tr><tr><td>Sweat glands</td><td></td><td></td><td></td><td></td></tr><tr><td>Eccrine</td><td>Increases</td><td></td><td></td><td></td></tr><tr><td>Apocrine (stress)</td><td>Increases</td><td></td><td></td><td></td></tr><tr><td colspan="5">Metabolic functions</td></tr><tr><td>Liver</td><td>Gluconeogenesis</td><td></td><td></td><td></td></tr><tr><td>Liver</td><td>Glycogenolysis</td><td></td><td></td><td></td></tr><tr><td>Fat cells</td><td>Lipolysis</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Transmitter/Modulator</th><th>Receptor Type</th><th>Neuron Terminals Where Found</th></thead><tr><td colspan="3">Inhibitory effects</td></tr><tr><td>Acetylcholine</td><td>M,, M,</td><td>Adrenergic, enteric nervous system</td></tr><tr><td>Norepinephrine</td><td>Alpha,</td><td>Adrenergic</td></tr><tr><td>Dopamine</td><td>D,; less evidence for D,</td><td>Adrenergic</td></tr><tr><td>Serotonin (5-HT)</td><td>5-HT,, 5-HT,, 5-HT;</td><td>Cholinergic preganglionic</td></tr><tr><td>ATP, ADP</td><td>P2Y</td><td>Adrenergic autonomic and ENS cholinergic neurons</td></tr><tr><td>Adenosine</td><td>A,</td><td>Adrenergic autonomic and ENS cholinergic neurons</td></tr><tr><td>Histamine</td><td>Hs, possibly H,</td><td>H; type identified on CNS adrenergic and serotonergic neurons</td></tr><tr><td>Enkephalin</td><td>Delta (also mu, kappa)</td><td>Adrenergic, ENS cholinergic</td></tr><tr><td>Neuropeptide Y</td><td>Y1, Y2 (NPY)</td><td>Adrenergic, some cholinergic</td></tr><tr><td>Prostaglandin E,, E</td><td>EP;</td><td>Adrenergic</td></tr><tr><td colspan="3">Excitatory effects</td></tr><tr><td>Epinephrine</td><td></td><td>Adrenergic, somatic motor cholinergic</td></tr><tr><td>Acetylcholine</td><td></td><td>Somatic motor cholinergic</td></tr><tr><td>Angiotensin II</td><td></td><td>Adrenergic</td></tr></table>
======================================
<table><thead><th>Process Affected</th><th>Drug Example</th><th>Site</th><th>Action</th></thead><tr><td>Action potential propagation</td><td>Local anesthetics, tetrodotoxin,’ saxitoxin?</td><td>Nerve axons</td><td>Block voltage-gated sodium channels; block conduction</td></tr><tr><td rowspan="2">Transmitter synthesis</td><td>Hemicholiniums</td><td>Cholinergic nerve terminals: membrane</td><td>Block uptake of choline and slow ACh synthesis</td></tr><tr><td></td><td>a-Methyltyrosine (metyrosine)</td><td>Adrenergic nerve terminals and adrenal medulla: cytoplasm</td><td>Inhibits tyrosine hydroxylase and blocks synthesis of catecholamines</td></tr><tr><td rowspan="2">Transmitter storage</td><td>Vesamicol</td><td>Cholinergic terminals: VAT on vesicles</td><td>Prevents storage, depletes</td></tr><tr><td></td><td>Reserpine, tetrabenazine</td><td>Adrenergic terminals: VMAT on vesicles</td><td>Prevents storage, depletes</td></tr><tr><td rowspan="6">Transmitter release</td><td>Many*</td><td>Nerve terminal membrane receptors</td><td>Modulate release</td></tr><tr><td></td><td>w-Conotoxin GVIA*</td><td>Nerve terminal calcium channels</td><td>Reduces transmitter release</td></tr><tr><td></td><td>Domoic acid</td><td>Nerve terminal kainate receptors (primarily CNS; see Chapter 21)</td><td>Modulates transmitter release by altering calcium influx/release</td></tr><tr><td></td><td>Botulinum toxin</td><td>Cholinergic vesicles</td><td>Prevents ACh release</td></tr><tr><td></td><td>a-Latrotoxin®</td><td>Cholinergic and adrenergic vesicles</td><td>Causes explosive transmitter release</td></tr><tr><td></td><td>Tyramine, amphetamine</td><td>Adrenergic nerve terminals</td><td>Promote transmitter release</td></tr><tr><td>Transmitter reuptake after release</td><td>Cocaine, tricyclic antidepressants, SNRI antidepressants°</td><td>Adrenergic nerve terminals, NET</td><td>Inhibit uptake; increase transmitter effect on postsynaptic receptors</td></tr><tr><td rowspan="8">Receptor activation or blockade</td><td></td><td>Norepinephrine</td><td>Receptors at adrenergic junctions</td><td>Binds and activates o receptors; causes contraction</td></tr><tr><td></td><td>Phentolamine</td><td>Receptors at adrenergic junctions</td><td>Binds o receptors; prevents activation</td></tr><tr><td></td><td>Isoproterenol</td><td>Receptors at adrenergic junctions</td><td>Binds B receptors; activates adenylyl cyclase</td></tr><tr><td>Propranolol</td><td>Receptors at adrenergic junctions</td><td>Binds B receptors; prevents activation</td></tr><tr><td></td><td>Nicotine</td><td>Receptors at nicotinic cholinergic junctions (autonomic ganglia, neuromuscular end plates)</td><td>Binds nicotinic receptors; opens ion channel in postsynaptic membrane</td></tr><tr><td></td><td>Tubocurarine</td><td>Neuromuscular end plates</td><td>Prevents activation of nicotinic receptors</td></tr><tr><td></td><td>Bethanechol</td><td>Receptors, parasympathetic effector cells (smooth muscle, glands)</td><td>Binds and activates muscarinic receptors</td></tr><tr><td></td><td>Atropine</td><td>Receptors, parasympathetic effector cells</td><td>Binds muscarinic receptors; prevents activation</td></tr><tr><td>Enzymatic inactivation of transmitter</td><td>Neostigmine</td><td>Cholinergic synapses (acetylcholinesterase)</td><td>Inhibits enzyme; prolongs and intensifies transmitter action after release</td></tr></table>
======================================
<table><thead><th>Receptor Type</th><th>Other Names</th><th>Location</th><th>Structural Features</th><th>Postreceptor Mechanism</th></thead><tr><td>M,</td><td></td><td>Nerves</td><td>Seven transmembrane segments, Gy; protein-linked</td><td>IP;, DAG cascade</td></tr><tr><td>M,</td><td>Cardiac M,</td><td>Heart, nerves, smooth muscle</td><td>Seven transmembrane segments, G,, protein-linked</td><td>Inhibition of cAMP production, activation of K* channels</td></tr><tr><td></td><td></td><td>Glands, smooth muscle, endothelium</td><td>Seven transmembrane segments, Gy protein-linked</td><td>IP;, DAG cascade</td></tr><tr><td></td><td></td><td>CNS</td><td>Seven transmembrane segments, Gj. protein-linked</td><td>Inhibition of cAMP production</td></tr><tr><td></td><td></td><td>CNS</td><td>Seven transmembrane segments, Gy; protein-linked</td><td>IP;, DAG cascade</td></tr><tr><td></td><td>Muscle type, end plate receptor</td><td>Skeletal muscle neuromuscular junction</td><td>Pentamer' [(c:1),B16y)]</td><td>Na’, K* depolarizing ion channel</td></tr><tr><td></td><td>Neuronal type, ganglion receptor</td><td>CNS, postganglionic cell body, dendrites</td><td>Pentamer’ with o: and B subunits only, eg, (04)2(2)3 (CNS) or 01305(82); (eel)</td><td>Na*, K* depolarizing ion channel</td></tr></table>
======================================
<table><thead><th>Choline Ester</th><th>Cholinesterase</th><th>Muscarinic Action</th><th>Nicotinic Action</th></thead><tr><td>Acetylcholine chloride</td><td>t44+</td><td>+4++</td><td>+4++</td></tr><tr><td>Methacholine chloride</td><td>+</td><td>+444</td><td></td></tr><tr><td>Carbachol chloride</td><td>Negligible</td><td>++</td><td>+4++</td></tr><tr><td>Bethanechol chloride</td><td>Negligible</td><td>++</td><td></td></tr></table>
======================================
<table><thead><th>Organ</th><th>Response</th></thead><tr><td colspan="2">Eye</td></tr><tr><td>Sphincter muscle of iris</td><td>Contraction (miosis)</td></tr><tr><td>Ciliary muscle</td><td>Contraction for near vision (accommodation)</td></tr><tr><td>Heart</td><td></td></tr><tr><td>Sinoatrial node</td><td>Decrease in rate (negative chronotropy)</td></tr><tr><td>Atria</td><td>Decrease in contractile strength (negative inotropy). Decrease in refractory period</td></tr><tr><td>Atrioventricular node</td><td>Decrease in conduction velocity (negative dromotropy). Increase in refractory period</td></tr><tr><td>Ventricles</td><td>Small decrease in contractile strength</td></tr><tr><td colspan="2">Blood vessels</td></tr><tr><td>Arteries, veins</td><td>Dilation (via EDRF). Constriction direct effect)</td></tr><tr><td colspan="2">Lung (high-dose</td></tr><tr><td>Bronchial muscle</td><td>Contraction (bronchoconstriction)</td></tr><tr><td>Bronchial glands</td><td>Secretion</td></tr><tr><td colspan="2">Gastrointestinal tract</td></tr><tr><td>Motility</td><td>Increase</td></tr><tr><td>Sphincters</td><td>Relaxation</td></tr><tr><td>Secretion</td><td>Stimulation</td></tr><tr><td colspan="2">Urinary bladder</td></tr><tr><td>Detrusor</td><td>Contraction</td></tr><tr><td>Trigone and sphincter</td><td>Relaxation</td></tr><tr><td colspan="2">Glands</td></tr><tr><td>Sweat, salivary, lacrimal, nasopharyngeal</td><td>Secretion</td></tr></table>
======================================
<table><thead><th>Group, Drug</th><th>Uses</th><th>Approximate Duration of Action</th></thead><tr><td colspan="3">Alcohols</td></tr><tr><td>Edrophonium</td><td>Myasthenia gravis, ileus, arrhythmias</td><td>5-15 minutes</td></tr><tr><td colspan="3">Carbamates and related agents</td></tr><tr><td>Neostigmine</td><td>Myasthenia gravis, ileus</td><td>0.5-4 hours</td></tr><tr><td>Pyridostigmine</td><td>Myasthenia gravis</td><td>4-6 hours</td></tr><tr><td>Physostigmine</td><td>For anticholinergic poisoning</td><td>0.5-2 hours</td></tr><tr><td colspan="3">Organophosphates</td></tr><tr><td>Echothiophate</td><td>Glaucoma</td><td>100 hours</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead></table>
======================================
<table><thead><th></th><th></th><th>smooth muscle relaxes), and changes in heart rate</th><th></th><th>parasympathomimetics</th></thead><tr><td colspan="5">+ Carbachol: Nonselective muscarinic and nicotinic agonist; otherwise similar to bethan echol; used topically almost exclusively for glaucoma</td></tr><tr><td colspan="5">DIRECT-ACTING MUSCARINIC ALKALOIDS OR SYNTHETICS + Pilocarpine Like bethanechol, partial Like bethanechol Glaucoma; Sjogren's</td><td rowspan="2">Oral lozenge and topical + Toxicity &amp; interactions: Like bethanechol</td></tr><tr><td colspan="5">agonist syndrome</td><td></td></tr><tr><td colspan="5">+ Cevimeline: Synthetic M;-selective; similar to pilocarpine</td></tr><tr><td>DIRECT-ACTING + Nicotine</td><td>NICOTINIC AGONISTS Agonist at both Ny and Ny receptors</td><td>Activates autonomic postganglionic neurons (both sympathetic and parasympathetic) and skeletal muscle neuromuscular end plates</td><td>Medical use in smoking cessation » nonmedical use in smoking and in insecticides</td><td>Oral gum, patch for smoking cessation + Toxicity: Acutely increased gastrointestinal (Gl) activity, nausea, vomiting, diarrhea - increased blood pressure « high doses cause seizures « long-term Gland cardiovascular risk factor « Interactions: Additive with CNS stimulants</td></tr><tr><td></td><td></td><td>+ enters CNS and activates Ny receptors</td><td></td><td></td></tr><tr><td colspan="5">+ Varenicline: Selecti ive partial agonist at 0.482 nicotinic receptors; used exclusively for smoking cessation</td></tr><tr><td colspan="5">SHORT-ACTING CHOLINESTERASE INHIBITOR (ALCOHOL)</td></tr><tr><td>+ Edrophonium</td><td>Alcohol, binds briefly to active site of acetylcholinesterase (AChE) and prevents access of acetylcholine (ACh)</td><td>Amplifies all actions of ACh + increases parasympathetic activity and somatic neuromuscular transmission</td><td>Diagnosis and acute treatment of myasthenia gravis</td><td>Parenteral - quaternary amine « does not enter CNS Toxicity: Parasympathomimetic excess + Interactions: Additive with parasympathomimetics</td></tr><tr><td colspan="5">NTERMEDIATE-ACTING CHOLINESTERASE INHIBI TORS (CARBAMATES)</td></tr><tr><td>+ Neostigmine</td><td>Forms covalent bond with AChE, but hydrolyzed and released</td><td>Like edrophonium, but longer-acting</td><td>Myasthenia gravis + postoperative and neurogenic ileus and urinary retention</td><td rowspan="2">Oral and parenteral; quaternary amine, does not enter CNS. Duration 2-4 h + Toxicity &amp; interactions: Like edrophonium</td></tr><tr><td>+ Pyridostigmine: + Physostigmine:</td><td>Like neostigmine, but longer-acting Like neostigmine, but natural alkaloid</td><td>(4-6 h); used in myasthenia tertiary amine; enters CNS</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th>smooth muscle relaxes), and changes in heart rate</th><th></th><th>parasympathomimetics</th></thead><tr><td colspan="5">+ Carbachol: Nonselective muscarinic and nicotinic agonist; otherwise similar to bethan echol; used topically almost exclusively for glaucoma</td></tr><tr><td colspan="5">DIRECT-ACTING MUSCARINIC ALKALOIDS OR SYNTHETICS + Pilocarpine Like bethanechol, partial Like bethanechol Glaucoma; Sjogren's</td><td rowspan="2">Oral lozenge and topical + Toxicity &amp; interactions: Like bethanechol</td></tr><tr><td colspan="5">agonist syndrome</td><td></td></tr><tr><td colspan="5">+ Cevimeline: Synthetic M;-selective; similar to pilocarpine</td></tr><tr><td>DIRECT-ACTING + Nicotine</td><td>NICOTINIC AGONISTS Agonist at both Ny and Ny receptors</td><td>Activates autonomic postganglionic neurons (both sympathetic and parasympathetic) and skeletal muscle neuromuscular end plates</td><td>Medical use in smoking cessation » nonmedical use in smoking and in insecticides</td><td>Oral gum, patch for smoking cessation + Toxicity: Acutely increased gastrointestinal (Gl) activity, nausea, vomiting, diarrhea - increased blood pressure « high doses cause seizures « long-term Gland cardiovascular risk factor « Interactions: Additive with CNS stimulants</td></tr><tr><td></td><td></td><td>+ enters CNS and activates Ny receptors</td><td></td><td></td></tr><tr><td colspan="5">+ Varenicline: Selecti ive partial agonist at 0.482 nicotinic receptors; used exclusively for smoking cessation</td></tr><tr><td colspan="5">SHORT-ACTING CHOLINESTERASE INHIBITOR (ALCOHOL)</td></tr><tr><td>+ Edrophonium</td><td>Alcohol, binds briefly to active site of acetylcholinesterase (AChE) and prevents access of acetylcholine (ACh)</td><td>Amplifies all actions of ACh + increases parasympathetic activity and somatic neuromuscular transmission</td><td>Diagnosis and acute treatment of myasthenia gravis</td><td>Parenteral - quaternary amine « does not enter CNS Toxicity: Parasympathomimetic excess + Interactions: Additive with parasympathomimetics</td></tr><tr><td colspan="5">NTERMEDIATE-ACTING CHOLINESTERASE INHIBI TORS (CARBAMATES)</td></tr><tr><td>+ Neostigmine</td><td>Forms covalent bond with AChE, but hydrolyzed and released</td><td>Like edrophonium, but longer-acting</td><td>Myasthenia gravis + postoperative and neurogenic ileus and urinary retention</td><td rowspan="2">Oral and parenteral; quaternary amine, does not enter CNS. Duration 2-4 h + Toxicity &amp; interactions: Like edrophonium</td></tr><tr><td>+ Pyridostigmine: + Physostigmine:</td><td>Like neostigmine, but longer-acting Like neostigmine, but natural alkaloid</td><td>(4-6 h); used in myasthenia tertiary amine; enters CNS</td><td></td><td></td></tr></table>
======================================
<table><tr><td>Echothiophate</td><td>neostigmine, released more slowly</td><td>neostigmine, longer-acting</td><td>glaucoma</td><td></td><td>Topical vision</td><td>only Toxicity:</td><td></td><td></td></tr></table>
======================================
<table><tr><td colspan="2">DIRECT-ACTING CHOLINOMIMETICS</td></tr><tr><td>Acetylcholine</td><td>Miochol-E</td></tr><tr><td>Bethanechol</td><td>Generic, Urecholine</td></tr><tr><td colspan="2">Carbachol</td></tr><tr><td>Ophthalmic (topical)</td><td>lsopto Carbachol, Carboptic</td></tr><tr><td>Ophthalmic (intraocular)</td><td>Miostat, Carbastat</td></tr><tr><td>Cevimeline</td><td>Generic, Evoxac</td></tr><tr><td colspan="2">Nicotine</td></tr><tr><td>Transdermal</td><td>Generic, Nicoderm CQ, Nicotrol</td></tr><tr><td>Inhalation</td><td>Nicotrol Inhaler, Nicotrol NS</td></tr><tr><td>Gum</td><td>Generic, Commit, Nicorette</td></tr><tr><td colspan="2">Pilocarpine</td></tr><tr><td>Ophthalmic (drops)1, 2, 4, 6</td><td>Generic, lsopto Carpine</td></tr><tr><td>Ophthalmic sustained-release inserts</td><td>Ocusert Pilo-20, Ocusert Pilo-40</td></tr><tr><td>Oral</td><td>Salagen</td></tr><tr><td>Varenicline</td><td>Chantix</td></tr><tr><td>Donepezil</td><td>Generic, Aricept</td></tr><tr><td>Echothiophate</td><td>Phospholine</td></tr><tr><td>Edrophonium</td><td>Generic, Tensilon</td></tr><tr><td>Galantamine</td><td>Generic, Reminyl, Razadyne</td></tr><tr><td>Neostigmine</td><td>Generic, Prostigmin</td></tr><tr><td>Physostigmine</td><td>Generic, Eserine</td></tr><tr><td>Pyridostigmine</td><td>Generic, Mestinon, Regonol</td></tr></table>
======================================
<table><thead><th rowspan="2">Property</th><th colspan="3">Subgroup</th></thead><thead><th></th><th>M,</th><th>M,</th><th>M3</th></thead><tr><td>Primary locations</td><td>Nerves</td><td>Heart, nerves, smooth muscle</td><td>Glands, smooth muscle, endothelium</td></tr><tr><td>Dominant effector system</td><td>TIP;, T DAG</td><td>J cAMP, T K* channel current</td><td>TIP, T DAG</td></tr><tr><td>Antagonists</td><td>Pirenzepine, telenzepine, dicyclomine,' trihexyphenidyl*</td><td>Gallamine,? methoctramine, AF-DX 116"</td><td>4-DAMP? darifenacin, solifenacin, oxybutynin, tolterodine</td></tr><tr><td colspan="4">Approximate dissociation constant?</td></tr><tr><td>Atropine</td><td></td><td></td><td></td></tr><tr><td>Pirenzepine</td><td></td><td></td><td></td></tr><tr><td>AF-DX 116</td><td></td><td></td><td></td></tr><tr><td>Darifenacin</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Drug</th><th>Duration of Effect</th><th>Usual Concentration (%)</th></thead><tr><td>Atropine</td><td>5-6 days</td><td>0.5-1</td></tr><tr><td>Scopolamine</td><td>3-7 days</td><td>0.25</td></tr><tr><td>Homatropine</td><td>12-24 hours</td><td>2-5</td></tr><tr><td>Cyclopentolate</td><td>3-6 hours</td><td>0.5-2</td></tr><tr><td>Tropicamide</td><td>15-60 min</td><td>0.5-1</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Usual Dosage</th></thead><tr><td colspan="2">Quaternary amines</td></tr><tr><td>Anisotropine</td><td>50 mg tid</td></tr><tr><td>Clidinium</td><td>2.5 mg tid-qid</td></tr><tr><td>Mepenzolate</td><td>25-50 mg qid</td></tr><tr><td>Methscopolamine</td><td>2.5 mg qid</td></tr><tr><td>Oxyphenonium</td><td>5-10 mg qid</td></tr><tr><td>Propantheline</td><td>15 mg qid</td></tr><tr><td>Trospium</td><td>20 mg bid</td></tr><tr><td colspan="2">Tertiary amines</td></tr><tr><td>Atropine</td><td>0.4 mg tid-qid</td></tr><tr><td>Darifenacin</td><td>7.5 mg daily</td></tr><tr><td>Dicyclomine</td><td>10-20 mg qid</td></tr><tr><td>Oxybutynin</td><td>5 mg tid</td></tr><tr><td>Scopolamine</td><td>0.4 mg tid</td></tr><tr><td>Solifenacin</td><td>5 mg daily</td></tr><tr><td>Tolterodine</td><td>2 mg bid</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">MOTION SICKNESS DRUGS</td></tr><tr><td>+ Scopolamine</td><td>Unknown mechanism in CNS</td><td>Reduces vertigo, postoperative nausea</td><td>Prevention of motion sickness and postoperative nausea and vomiting</td><td>Transdermal patch used for motion sickness + IM injection for postoperative use + Toxicity: Tachycardia, blurred vision, xerostomia, delirium + Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">GASTROINTESTINAL DISORDERS</td></tr><tr><td>+ Dicyclomine</td><td>Competitive antagonism at M; receptors</td><td>Reduces smooth muscle and secretory activity of gut</td><td>Irritable bowel syndrome, minor diarrhea</td><td>Available in oral and parenteral forms - short ty, but action lasts up to 6 hours + Toxicity: Tachycardia, confusion, urinary retention, increased intraocular pressure « Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Hyoscyamine: Longer duration of action</td></tr><tr><td colspan="5" rowspan="2">OPHTHALMOLOGY + Atropine Competitive antagonism at all M receptors Causes mydriasis and cycloplegia Retinal examination; prevention of synechiae Used as drops + long (5-6 days) action + Toxicity: Increased intraocular pressure in closed-angle</td><td colspan="5" rowspan="2"></td></tr><tr><td colspan="5"></td><td colspan="5"></td></tr><tr><td></td><td></td><td></td><td>after surgery</td><td>glaucoma - Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Homatropine: Shorter duration of action (12-24 h) than atropine</td></tr><tr><td colspan="5">+ Cyclopentolate: Shorter duration of action (3-6 h) + Tropicamide: Shortest duration of action (15-60 min)</td></tr><tr><td>RESPIRATORY (ASTHMA, + Ipratropium</td><td>COPD) Competitive, nonselective antagonist at M receptors</td><td>Reduces or prevents bronchospasm</td><td>Prevention and relief of acute episodes of bronchospasm</td><td>Aerosol canister, up to qid + Toxicity: Xerostomia, cough + Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Tiotropium, acli jum, and umeclidinium: Longer duration of action; used once daily</td></tr><tr><td colspan="5">URINARY</td></tr><tr><td>+ Oxybutynin</td><td>Slightly M3-selective</td><td>Reduces detrusor smooth</td><td>Urge incontinence;</td><td>Oral, IV, patch formulations + Toxicity:</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">MOTION SICKNESS DRUGS</td></tr><tr><td>+ Scopolamine</td><td>Unknown mechanism in CNS</td><td>Reduces vertigo, postoperative nausea</td><td>Prevention of motion sickness and postoperative nausea and vomiting</td><td>Transdermal patch used for motion sickness + IM injection for postoperative use + Toxicity: Tachycardia, blurred vision, xerostomia, delirium + Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">GASTROINTESTINAL DISORDERS</td></tr><tr><td>+ Dicyclomine</td><td>Competitive antagonism at M; receptors</td><td>Reduces smooth muscle and secretory activity of gut</td><td>Irritable bowel syndrome, minor diarrhea</td><td>Available in oral and parenteral forms - short ty, but action lasts up to 6 hours + Toxicity: Tachycardia, confusion, urinary retention, increased intraocular pressure « Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Hyoscyamine: Longer duration of action</td></tr><tr><td colspan="5" rowspan="2">OPHTHALMOLOGY + Atropine Competitive antagonism at all M receptors Causes mydriasis and cycloplegia Retinal examination; prevention of synechiae Used as drops + long (5-6 days) action + Toxicity: Increased intraocular pressure in closed-angle</td><td colspan="5" rowspan="2"></td></tr><tr><td colspan="5"></td><td colspan="5"></td></tr><tr><td></td><td></td><td></td><td>after surgery</td><td>glaucoma - Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Homatropine: Shorter duration of action (12-24 h) than atropine</td></tr><tr><td colspan="5">+ Cyclopentolate: Shorter duration of action (3-6 h) + Tropicamide: Shortest duration of action (15-60 min)</td></tr><tr><td>RESPIRATORY (ASTHMA, + Ipratropium</td><td>COPD) Competitive, nonselective antagonist at M receptors</td><td>Reduces or prevents bronchospasm</td><td>Prevention and relief of acute episodes of bronchospasm</td><td>Aerosol canister, up to qid + Toxicity: Xerostomia, cough + Interactions: With other antimuscarinics</td></tr><tr><td colspan="5">+ Tiotropium, acli jum, and umeclidinium: Longer duration of action; used once daily</td></tr><tr><td colspan="5">URINARY</td></tr><tr><td>+ Oxybutynin</td><td>Slightly M3-selective</td><td>Reduces detrusor smooth</td><td>Urge incontinence;</td><td>Oral, IV, patch formulations + Toxicity:</td></tr></table>
======================================
<table><tr><td colspan="2">ANTIMUSCARINIC ANTICHOLINERGIC DRUGS</td></tr><tr><td>Aclidinium</td><td>Tudorza Pressair</td></tr><tr><td>Atropine</td><td>Generic</td></tr><tr><td>Belladonna alkaloids, extract, or tincture</td><td>Generic</td></tr><tr><td>Botulinum toxin A</td><td>Botox</td></tr><tr><td>Clidinium</td><td>Generic, Quarzan, others</td></tr><tr><td>Cyclopentolate</td><td>Generic, Cyclogyl, others</td></tr><tr><td>Darifenacin</td><td>Generic, Enablex</td></tr><tr><td>Dicyclomine</td><td>Generic, Bentyl, others</td></tr><tr><td>Fesoterodine</td><td>Toviaz</td></tr><tr><td>Flavoxate</td><td>Generic, Urispas</td></tr><tr><td>Glycopyrrolate</td><td>Generic, Robinul (systemic) Seebri Neohaler (oral inhalation)</td></tr><tr><td>Homatropine</td><td>Generic, lsopto Homatropine, others</td></tr><tr><td>Hyoscyamine</td><td>Anaspaz, Cystospaz-M, Levsin, others</td></tr><tr><td>Ipratropium</td><td>Generic, Atrovent</td></tr><tr><td>Mepenzolate</td><td>Cantil</td></tr><tr><td>Methscopolamine</td><td>Generic, Pamine</td></tr><tr><td>Oxybutynin</td><td>Generic, Ditropan, Gelnique, others</td></tr><tr><td>Propantheline</td><td>Generic, Pro-Banthine, others</td></tr><tr><td colspan="2">Scopolamine</td></tr><tr><td>Oral</td><td>Generic</td></tr><tr><td>Ophthalmic</td><td>Isopto Hyoscine</td></tr><tr><td>Transdermal</td><td>Transderm Scop</td></tr><tr><td>Solifenacin</td><td>Vesicare</td></tr><tr><td>Tiotropium</td><td>Spiriva</td></tr><tr><td>Tolterodine</td><td>Generic, Detrol</td></tr><tr><td>Tropicamide</td><td>Generic, Mydriacyl Ophthalmic, others</td></tr><tr><td>Trospium</td><td>Generic, Sanctura</td></tr><tr><td>Umeclidinium</td><td>Incruse Ellipta</td></tr><tr><td colspan="2">GANGLION BLOCKERS</td></tr><tr><td colspan="2">Mecamylamine Vecamyl</td></tr><tr><td colspan="2">CHOLINESTERASE REGENERATOR</td></tr><tr><td>Pralidoxime</td><td>Generic, Protopam</td></tr></table>
======================================
<table><thead><th>Receptor</th><th>Agonist</th><th>Antagonist</th><th>G Protein</th><th>Effects</th><th>Gene on Chromosome</th></thead><tr><td>@, type</td><td>Phenylephrine</td><td>Prazosin</td><td>G,</td><td>7 IP3, DAG common to all</td><td></td></tr><tr><td>Oa</td><td></td><td>Tamsulosin</td><td></td><td></td><td>c8</td></tr><tr><td>Ohg</td><td></td><td></td><td></td><td></td><td>cs</td></tr><tr><td>pd</td><td></td><td></td><td></td><td></td><td>C20</td></tr><tr><td>GQ type</td><td>Clonidine</td><td>Yohimbine</td><td>G;</td><td>J cAMP common to all</td><td></td></tr><tr><td>Oa</td><td>Oxymetazoline</td><td></td><td></td><td></td><td>c10</td></tr><tr><td>8</td><td></td><td>Prazosin</td><td></td><td></td><td>c2</td></tr><tr><td>Qe</td><td></td><td>Prazosin</td><td></td><td></td><td>C4</td></tr><tr><td>Btype</td><td>Isoproterenol</td><td>Propranolol</td><td>G,</td><td>T cAMP common to all</td><td></td></tr><tr><td>B</td><td>Dobutamine</td><td>Betaxolol</td><td></td><td></td><td>c10</td></tr><tr><td>B,</td><td>Albuterol</td><td>Butoxamine</td><td></td><td></td><td>C5</td></tr><tr><td>Bs</td><td>Mirabegron</td><td></td><td></td><td></td><td>c8</td></tr><tr><td>Dopamine type</td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td>D,</td><td>Fenoldopam</td><td></td><td>G,</td><td>T cAMP</td><td>cs</td></tr><tr><td>D,</td><td>Bromocriptine</td><td></td><td>G</td><td>J cAMP</td><td>ci</td></tr><tr><td>D;</td><td></td><td></td><td>G</td><td>J cAMP</td><td>G3</td></tr><tr><td>D,</td><td></td><td>Clozapine</td><td>G</td><td>\ cAMP</td><td>cu</td></tr><tr><td>D.</td><td></td><td></td><td>G.</td><td>T cAMP</td><td>C4</td></tr></table>
======================================
<table><thead><th></th><th>Relative Receptor Affini</th></thead><tr><td colspan="2">Alpha agonists</td></tr><tr><td>Phenylephrine, methoxamine</td><td>Q, &gt; 2 &gt;&gt;&gt;&gt;&gt; 8</td></tr><tr><td>Clonidine, methylnorepinephrine</td><td>Q, &gt; a, &gt;&gt;&gt;&gt;&gt;B</td></tr><tr><td colspan="2">Mixed alpha and beta agonists</td></tr><tr><td>Norepinephrine</td><td>Ot; = 02; By &gt;&gt; Ba</td></tr><tr><td>Epinephrine</td><td>01, = Ot; B; = Bp</td></tr><tr><td colspan="2">Beta agonists</td></tr><tr><td>Dobutamine'</td><td>B, &gt; B. &gt;&gt;&gt;&gt; a</td></tr><tr><td>Isoproterenol</td><td>B, = By &gt;&gt;&gt;&gt; a</td></tr><tr><td>Albuterol, terbutaline, metaproterenol, ritodrine</td><td>B, &gt;&gt; B, &gt;&gt;&gt;&gt; a</td></tr><tr><td colspan="2">Dopamine agonists</td></tr><tr><td>Dopamine</td><td>D,=D,&gt;&gt;B&gt;&gt;a</td></tr><tr><td>Fenoldopam</td><td>D, &gt;&gt; D,</td></tr></table>
======================================
<table><thead><th>Type</th><th>Tissue</th><th>Actions</th></thead><tr><td rowspan="5">Oo</td><td>Most vascular smooth muscle (innervated)</td><td>Contraction</td></tr><tr><td></td><td>Pupillary dilator muscle</td><td>Contraction (dilates pupil)</td></tr><tr><td></td><td>Pilomotor smooth muscle</td><td>Erects hair</td></tr><tr><td></td><td>Prostate</td><td>Contraction</td></tr><tr><td></td><td>Heart</td><td>Increases force of contraction</td></tr><tr><td rowspan="5">Oy</td><td>Postsynaptic CNS neurons</td><td>Probably multiple</td></tr><tr><td></td><td>Platelets</td><td>Aggregation</td></tr><tr><td></td><td>Adrenergic and cholinergic nerve terminals</td><td>Inhibits transmitter release</td></tr><tr><td></td><td>Some vascular smooth muscle</td><td>Contraction</td></tr><tr><td></td><td>Fat cells</td><td>Inhibits lipolysis</td></tr><tr><td>Bi</td><td>Heart, juxtaglomerular cells</td><td>Increases force and rate of contraction; increases renin release</td></tr><tr><td rowspan="3">Ba</td><td>Respiratory, uterine, and vas- cular smooth muscle</td><td>Promotes smooth muscle relaxation</td></tr><tr><td></td><td>Skeletal muscle</td><td>Promotes potassium uptake</td></tr><tr><td></td><td>Human liver</td><td>Activates glycogenolysis</td></tr><tr><td rowspan="2">Bs</td><td></td><td>Bladder</td><td>Relaxes detrusor muscle</td></tr><tr><td>Fat cells</td><td>Activates lipolysis</td></tr><tr><td></td><td>Smooth muscle</td><td>Dilates renal blood vessels</td></tr><tr><td>D,</td><td>Nerve endings</td><td>Modulates transmitter</td></tr></table>
======================================
<table><thead><th></th><th>Phenylephrine</th><th>Epinephrine</th><th>Isoproterenol</th></thead><tr><td colspan="4">Vascular resistance (tone)</td></tr><tr><td>Skin, mucous membranes (c)</td><td></td><td></td><td></td></tr><tr><td>Skeletal muscle (82, 2)</td><td></td><td></td><td></td></tr><tr><td>Renal (a, D,)</td><td></td><td></td><td></td></tr><tr><td>Splanchnic (o, B)</td><td></td><td></td><td></td></tr><tr><td>Total peripheral resistance</td><td></td><td></td><td></td></tr><tr><td>Venous tone (c,, 3)</td><td></td><td></td><td></td></tr><tr><td colspan="4">Cardiac</td></tr><tr><td>Contractility (B,)</td><td>Oort</td><td>TT</td><td></td></tr><tr><td>Heart rate (predominantly B,)</td><td>(vagal reflex)</td><td>or L</td><td></td></tr><tr><td>Stroke volume</td><td>1,7</td><td></td><td></td></tr><tr><td>Cardiac output</td><td></td><td></td><td></td></tr><tr><td colspan="4">Blood pressure</td></tr><tr><td>Mean</td><td></td><td></td><td></td></tr><tr><td>Diastolic</td><td></td><td>or 7"</td><td></td></tr><tr><td>Systolic</td><td></td><td></td><td></td></tr><tr><td>Pulse pressure</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Food</th><th>Tyramine Content of an Average Serving</th></thead><tr><td>Beer</td><td>4-45 mg</td></tr><tr><td>Broad beans, fava beans</td><td>Negligible (but contains dopamine)</td></tr><tr><td>Cheese, natural or aged</td><td>Nil to 130 mg (cheddar, Gruyére, and Stilton especially high)</td></tr><tr><td>Chicken liver</td><td>Nil to 9 mg</td></tr><tr><td>Chocolate</td><td>Negligible (but contains phenylethylamine)</td></tr><tr><td>Sausage, fermented (eg, salami, pepperoni, summer sausage)</td><td>Nil to 74 mg</td></tr><tr><td>Smoked or pickled fish (eg, pickled herring)</td><td>Nil to 198 mg</td></tr><tr><td>Wine (red)</td><td>Nil to 3 mg</td></tr><tr><td>Yeast (eg, dietary brewer's yeast supplements)</td><td>2-68 mg</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">AGONISTS</td></tr><tr><td>a, + Midodrine</td><td>Activates phospholipase C, resulting in increased intracellular calcium and vasoconstriction</td><td>Vascular smooth muscle contraction increasing blood pressure (BP)</td><td>Orthostatic hypotension</td><td>Oral - prodrug converted to active drug with a 1-h peak effect - Toxicity: Supine hypertension, piloerection (goose bumps), and urinary retention</td></tr></table>
======================================
<table><tr><td colspan="5">0, AGONISTS</td></tr><tr><td>+ Clonidine</td><td>Inhibits adenylyl cyclase and interacts with other intracellular pathways</td><td>Vasoconstriction is masked by central sympatholytic effect, which lowers BP</td><td>Hypertension</td><td>Oral + transdermal - peak effect 1-3 h + ty. of oral drug ~12 h + produces dry mouth and sedation</td></tr><tr><td colspan="5">+ a-Methyldopa, guanfacine, and guanabenz: Also used as central sympatholytics</td></tr><tr><td colspan="5">+ Dexmedetomidine: Prominent sedative effects and used in anesthesia</td></tr><tr><td colspan="5">+ Tizanidine: Used as a muscle relaxant</td></tr><tr><td colspan="5">+ Apraclonidine and brimonidine: Used topically in glaucoma to reduce intraocular pressure</td></tr><tr><td>B, AGONISTS + Dobutamine’</td><td>Activates adenylyl cyclase, increasing myocardial contractility</td><td>Positive inotropic effect</td><td>Cardiogenic shock, acute heart failure</td><td>IV - requires dose titration to desired effect</td></tr><tr><td>B, AGONISTS + Albuterol</td><td>Activates adenylyl cyclase</td><td rowspan="3">Bronchial smooth muscle dilation</td><td></td><td rowspan="3">Asthma</td><td></td><td rowspan="3">Inhalation + duration 4-6 h + Toxicity: Tremor, tachycardia</td><td></td></tr><tr><td></td><td></td></tr><tr><td>+ See other B,</td><td>agonists in Chapter 20</td><td></td><td></td><td></td></tr><tr><td colspan="5">B, AGONISTS</td></tr><tr><td>+ Mirabegron</td><td>Activates adenylyl cyclase</td><td>Reduces bladder tone</td><td>Urinary urgency</td><td>Oral - duration 50 h + Toxicity: Possible hypertension</td></tr><tr><td colspan="5">DOPAMINE AGONISTS</td></tr><tr><td colspan="5">D, Agonists</td></tr><tr><td>+ Fenoldopam</td><td>Activates adenylyl cyclase</td><td>Vascular smooth muscle relaxation</td><td>Hypertensive emergency</td><td>Requires dose titration to desired effect</td></tr><tr><td colspan="5">D, Agonists</td><td rowspan="3">Parkinson’s disease, prolactinemia</td><td></td><td rowspan="3">Oral - Toxicity: Nausea, headache, orthostatic hypotension</td><td></td></tr><tr><td>+ Bromocriptine</td><td>Inhibits adenylyl cyclase and interacts with other intracellular pathways</td><td rowspan="2">Mimics dopamine actions in the CNS</td></tr><tr><td>+ See other D,</td><td>agonists in Chapters 28 and 37</td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>Amphetamine, racemic mixture</td><td>Generic</td></tr><tr><td>1:1:1:1 mixtures of amphetamine sulfate, amphetamine aspartate, dextroamphetamine sulfate, and dextroamphetamine saccharate</td><td>Adderall</td></tr><tr><td>Apraclonidine</td><td>lopidine</td></tr><tr><td>Armodafinil</td><td>Nuvigil</td></tr><tr><td>Brimonidine</td><td>Alphagan</td></tr><tr><td>Dexmedetomidine</td><td>Precedex</td></tr><tr><td>Dexmethylphenidate</td><td>Focalin</td></tr><tr><td>Dextroamphetamine</td><td>Generic, Dexedrine</td></tr><tr><td>Dobutamine</td><td>Generic, Dobutrex</td></tr><tr><td>Dopamine</td><td>Generic, Intropin</td></tr><tr><td>Droxidopa</td><td>Northera</td></tr><tr><td>Ephedrine Epinephrine</td><td>Generic Generic, Adrenalin Chloride, Bronkaid</td></tr><tr><td>Fenoldopam</td><td>EpiPen, Auvi-Q Corlopam</td></tr><tr><td>Hydroxyamphetamine</td><td>Paremyd (includes 0.25%</td></tr><tr><td>Isoproterenol</td><td>tropicamide) Generic, Isuprel</td></tr><tr><td>Metaraminol</td><td>Aramine</td></tr><tr><td>Methamphetamine</td><td>Desoxyn</td></tr><tr><td>Methylphenidate</td><td>Generic, Ritalin, Ritalin-SR</td></tr><tr><td>Midodrine</td><td>ProAmatine</td></tr><tr><td>Mirabegron</td><td>Myrbetriq</td></tr><tr><td>Modafinil</td><td>Provigil</td></tr><tr><td>Naphazoline</td><td>Generic, Privine</td></tr><tr><td>Norepinephrine</td><td>Generic, Levophed</td></tr><tr><td>Olodaterol</td><td>Striverdi respimat</td></tr><tr><td>Oxymetazoline</td><td>Generic, Afrin, Neo-Synephrine 12 Hour, Visine LR</td></tr><tr><td>Phenylephrine</td><td>Generic, Neo-Synephrine</td></tr><tr><td>Pseudoephedrine</td><td>Generic, Sudafed</td></tr><tr><td>Tetrahydrozoline</td><td>Generic, Visine</td></tr><tr><td>Tizanidine</td><td>Zanaflex</td></tr><tr><td>Xylometazoline</td><td>Generic, Otrivin</td></tr></table>
======================================
<table><thead><th>Drugs</th><th>Receptor Affinity</th></thead><tr><td colspan="2">Alpha antagonists</td></tr><tr><td>Prazosin, terazosin, doxazosin</td><td>Ol, &gt;&gt;&gt;&gt; 2</td></tr><tr><td>Phenoxybenzamine</td><td>OL, &gt; A</td></tr><tr><td>Phentolamine</td><td>Oh, = Oy</td></tr><tr><td>Yohimbine, tolazoline</td><td>Oy &gt;&gt; O,</td></tr><tr><td colspan="2">Mixed antagonists</td></tr><tr><td>Labetalol, carvedilol</td><td>B, =B, 2 a &gt; a</td></tr><tr><td colspan="2">Beta antagonists</td></tr><tr><td>Metoprolol, acebutolol, alprenolol, atenolol, betaxolol, celiprolol, esmolol, nebivolol</td><td>Bi &gt;&gt;&gt; By</td></tr><tr><td>Propranolol, carteolol, nadolol, penbutolol, pindolol, timolol</td><td>1= By</td></tr><tr><td>Butoxamine</td><td>B, &gt;&gt;&gt; B.</td></tr></table>
======================================
<table><thead><th>Drugs</th><th>Partial Agonist</th><th>Local Anesthetic Action</th><th></th><th>Elimination Half-life</th><th>Approximate Bioavailability</th></thead><tr><td>Acebutolol</td><td></td><td>Yes</td><td>Low</td><td>3-4 hours</td><td>50</td></tr><tr><td>Atenolol</td><td></td><td>No</td><td>Low</td><td>6-9 hours</td><td></td></tr><tr><td>Betaxolol</td><td></td><td>Slight</td><td>Low</td><td>14-22 hours</td><td></td></tr><tr><td>Bisoprolol</td><td></td><td>No</td><td>Low</td><td>9-12 hours</td><td></td></tr><tr><td>Carteolol</td><td></td><td>No</td><td>Low</td><td>6 hours</td><td></td></tr><tr><td>Carvedilol’</td><td></td><td>No</td><td>Moderate</td><td>7-10 hours</td><td></td></tr><tr><td>Celiprolol</td><td></td><td>No</td><td>Low</td><td>4-5 hours</td><td></td></tr><tr><td>Esmolol</td><td></td><td>No</td><td>Low</td><td>10 minutes</td><td></td></tr><tr><td>Labetalol'</td><td></td><td>Yes</td><td>Low</td><td>5 hours</td><td></td></tr><tr><td>Metoprolol</td><td></td><td>Yes</td><td>Moderate</td><td>3-4 hours</td><td></td></tr><tr><td>Nadolol</td><td></td><td>No</td><td>Low</td><td>14-24 hours</td><td></td></tr><tr><td>Nebivolol</td><td></td><td>No</td><td>Low</td><td>11-30 hours</td><td></td></tr><tr><td>Penbutolol</td><td></td><td>No</td><td>High</td><td>5 hours</td><td></td></tr><tr><td>Pindolol</td><td></td><td>Yes</td><td>Moderate</td><td>3-4 hours</td><td></td></tr><tr><td>Propranolol</td><td></td><td>Yes</td><td>High</td><td>3.5-6 hours</td><td></td></tr><tr><td>Sotalol</td><td></td><td>No</td><td>Low</td><td>12 hours</td><td></td></tr><tr><td>Timolol</td><td></td><td>No</td><td>Moderate</td><td>4-5 hours</td><td></td></tr></table>
======================================
<table><thead><th>Drugs</th><th>Mechanism</th><th>Methods of Administration</th></thead><tr><td colspan="3">Cholinomimetics</td></tr><tr><td>Pilocarpine, carbachol, physostigmine, echothiophate, demecarium</td><td>Ciliary muscle contraction, opening of trabecular meshwork; increased outflow</td><td>Topical drops or gel; plastic film slow-release insert</td></tr><tr><td colspan="3">Alpha agonists</td></tr><tr><td>Nonselective</td><td>Increased outflow</td><td>Topical drops</td></tr><tr><td colspan="3">Epinephrine, dipivefrin</td></tr><tr><td>Alpha,-selective</td><td>Decreased aqueous secretion</td><td></td></tr><tr><td>Apraclonidine</td><td></td><td>Topical, postlaser only</td></tr><tr><td>Brimonidine</td><td></td><td>Topical</td></tr><tr><td colspan="3">Beta blockers</td></tr><tr><td>Timolol, betaxolol, carteolol, levobunolol, metipranolol</td><td>Decreased aqueous secretion from the ciliary epithelium</td><td>Topical drops</td></tr><tr><td colspan="3">Carbonic anhydrase inhibitors</td></tr><tr><td>Dorzolamide, brinzolamide</td><td>Decreased aqueous secretion due to lack of HCO;—</td><td>Topical</td></tr><tr><td>Acetazolamide, dichlorphenamide, methazolamide</td><td></td><td>Oral</td></tr><tr><td colspan="3">Prostaglandins</td></tr><tr><td>Latanoprost, bimatoprost, travoprost, unoprostone</td><td>Increased outflow</td><td>Topical</td></tr></table>
======================================
<table><thead><th>ubclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">ALPHA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Phenoxybenzamine</td><td>Irreversibly blocks o, and 0 + indirect baroreflex activation</td><td>Lowers blood pressure (BP) + heart rate (HR) rises due to baroreflex activation</td><td>Pheochromocytoma « high catecholamine states</td><td>Irreversible blocker « duration &gt; 1 day - Toxicity: Orthostatic hypotension - tachycardia + myocardial ischemia</td></tr><tr><td>+ Phentolamine</td><td>Reversibly blocks 0, and 0</td><td>Blocks o-mediated vasoconstriction, lowers BP, increases HR (baroreflex)</td><td>Pheochromocytoma</td><td>Half-life ~45 min after IV injection</td></tr><tr><td>+ Prazosin + Doxazosin + Terazosin</td><td>Block 1, but not o.,</td><td>Lower BP</td><td>Hypertension + benign prostatic hyperplasia</td><td>Larger depressor effect with first dose may cause orthostatic hypotension</td></tr><tr><td></td><td></td><td>1, blockade may relax prostatic smooth muscle more than vascular smooth muscle</td><td></td><td>Orthostatic hypotension may be less common with this subtype</td></tr><tr><td>+ Yohimbine</td><td>Blocks ot) « elicits increased central sympathetic activity + increased norepinephrine release</td><td>Raises BP and HR</td><td>Mal le erectile dysfunction + hypotension</td><td>May cause anxiety + excess pressor effect if norepinephrine transporter is blocked</td></tr><tr><td>+ Labetalol (see carvedilol section below)</td><td>B &gt; a, block</td><td>Lowers BP with limited HR increase</td><td>Hypertension</td><td>Oral, parenteral - Toxicity: Less tachycardia than other ol; agents</td></tr><tr><td colspan="5">BETA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Propranolol + Nadolol + Timolol</td><td>Block B, and B,</td><td>Lower HR and BP + reduce renin</td><td>sant Hypertension - angina pectoris thythmias » migraine + hyperthyroidism + glaucoma (topical timolol)</td><td>Oral, parenteral - Toxicity: Bradycardia « worsened asthma - fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Metoprolol + Atenolol + Betaxolol + Nebivolol</td><td>Block 8, &gt; B.</td><td>Lower HR and BP + reduce renin + may be safer in asthma</td><td>san Angina pectori hypertension thythmias + glaucoma (topical betaxolol)</td><td>Bradycardia - fatigue + vivid dreams « cold hands</td></tr><tr><td></td><td></td><td>Increases peripheral resistance</td><td>No clinical indication</td><td></td></tr><tr><td>+ Pindolol + Acebutolol + Carteolol + Bopindolol' + Oxprenolol! + Celiprolol’ + Penbutolol</td><td>B,, B., with intrinsic sympathomimetic (partial agonist) effect</td><td>Lower BP + modestly lower HR</td><td>“m Hypertension + arrhythmias igraine + may avoid worsening of bradycardia</td><td>Oral - Toxicity: Fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Carvedilol + Medroxalol! + Bucindolol' (see</td><td>B &gt; a, block</td><td></td><td>Heart failure</td><td>Oral, long half-life - Toxicity: Fatigue</td></tr></table>
======================================
<table><thead><th>ubclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">ALPHA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Phenoxybenzamine</td><td>Irreversibly blocks o, and 0 + indirect baroreflex activation</td><td>Lowers blood pressure (BP) + heart rate (HR) rises due to baroreflex activation</td><td>Pheochromocytoma « high catecholamine states</td><td>Irreversible blocker « duration &gt; 1 day - Toxicity: Orthostatic hypotension - tachycardia + myocardial ischemia</td></tr><tr><td>+ Phentolamine</td><td>Reversibly blocks 0, and 0</td><td>Blocks o-mediated vasoconstriction, lowers BP, increases HR (baroreflex)</td><td>Pheochromocytoma</td><td>Half-life ~45 min after IV injection</td></tr><tr><td>+ Prazosin + Doxazosin + Terazosin</td><td>Block 1, but not o.,</td><td>Lower BP</td><td>Hypertension + benign prostatic hyperplasia</td><td>Larger depressor effect with first dose may cause orthostatic hypotension</td></tr><tr><td></td><td></td><td>1, blockade may relax prostatic smooth muscle more than vascular smooth muscle</td><td></td><td>Orthostatic hypotension may be less common with this subtype</td></tr><tr><td>+ Yohimbine</td><td>Blocks ot) « elicits increased central sympathetic activity + increased norepinephrine release</td><td>Raises BP and HR</td><td>Mal le erectile dysfunction + hypotension</td><td>May cause anxiety + excess pressor effect if norepinephrine transporter is blocked</td></tr><tr><td>+ Labetalol (see carvedilol section below)</td><td>B &gt; a, block</td><td>Lowers BP with limited HR increase</td><td>Hypertension</td><td>Oral, parenteral - Toxicity: Less tachycardia than other ol; agents</td></tr><tr><td colspan="5">BETA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Propranolol + Nadolol + Timolol</td><td>Block B, and B,</td><td>Lower HR and BP + reduce renin</td><td>sant Hypertension - angina pectoris thythmias » migraine + hyperthyroidism + glaucoma (topical timolol)</td><td>Oral, parenteral - Toxicity: Bradycardia « worsened asthma - fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Metoprolol + Atenolol + Betaxolol + Nebivolol</td><td>Block 8, &gt; B.</td><td>Lower HR and BP + reduce renin + may be safer in asthma</td><td>san Angina pectori hypertension thythmias + glaucoma (topical betaxolol)</td><td>Bradycardia - fatigue + vivid dreams « cold hands</td></tr><tr><td></td><td></td><td>Increases peripheral resistance</td><td>No clinical indication</td><td></td></tr><tr><td>+ Pindolol + Acebutolol + Carteolol + Bopindolol' + Oxprenolol! + Celiprolol’ + Penbutolol</td><td>B,, B., with intrinsic sympathomimetic (partial agonist) effect</td><td>Lower BP + modestly lower HR</td><td>“m Hypertension + arrhythmias igraine + may avoid worsening of bradycardia</td><td>Oral - Toxicity: Fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Carvedilol + Medroxalol! + Bucindolol' (see</td><td>B &gt; a, block</td><td></td><td>Heart failure</td><td>Oral, long half-life - Toxicity: Fatigue</td></tr></table>
======================================
<table><thead><th>ubclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">ALPHA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Phenoxybenzamine</td><td>Irreversibly blocks o, and 0 + indirect baroreflex activation</td><td>Lowers blood pressure (BP) + heart rate (HR) rises due to baroreflex activation</td><td>Pheochromocytoma « high catecholamine states</td><td>Irreversible blocker « duration &gt; 1 day - Toxicity: Orthostatic hypotension - tachycardia + myocardial ischemia</td></tr><tr><td>+ Phentolamine</td><td>Reversibly blocks 0, and 0</td><td>Blocks o-mediated vasoconstriction, lowers BP, increases HR (baroreflex)</td><td>Pheochromocytoma</td><td>Half-life ~45 min after IV injection</td></tr><tr><td>+ Prazosin + Doxazosin + Terazosin</td><td>Block 1, but not o.,</td><td>Lower BP</td><td>Hypertension + benign prostatic hyperplasia</td><td>Larger depressor effect with first dose may cause orthostatic hypotension</td></tr><tr><td></td><td></td><td>1, blockade may relax prostatic smooth muscle more than vascular smooth muscle</td><td></td><td>Orthostatic hypotension may be less common with this subtype</td></tr><tr><td>+ Yohimbine</td><td>Blocks ot) « elicits increased central sympathetic activity + increased norepinephrine release</td><td>Raises BP and HR</td><td>Mal le erectile dysfunction + hypotension</td><td>May cause anxiety + excess pressor effect if norepinephrine transporter is blocked</td></tr><tr><td>+ Labetalol (see carvedilol section below)</td><td>B &gt; a, block</td><td>Lowers BP with limited HR increase</td><td>Hypertension</td><td>Oral, parenteral - Toxicity: Less tachycardia than other ol; agents</td></tr><tr><td colspan="5">BETA-ADRENOCEPTOR ANTAGONISTS</td></tr><tr><td>+ Propranolol + Nadolol + Timolol</td><td>Block B, and B,</td><td>Lower HR and BP + reduce renin</td><td>sant Hypertension - angina pectoris thythmias » migraine + hyperthyroidism + glaucoma (topical timolol)</td><td>Oral, parenteral - Toxicity: Bradycardia « worsened asthma - fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Metoprolol + Atenolol + Betaxolol + Nebivolol</td><td>Block 8, &gt; B.</td><td>Lower HR and BP + reduce renin + may be safer in asthma</td><td>san Angina pectori hypertension thythmias + glaucoma (topical betaxolol)</td><td>Bradycardia - fatigue + vivid dreams « cold hands</td></tr><tr><td></td><td></td><td>Increases peripheral resistance</td><td>No clinical indication</td><td></td></tr><tr><td>+ Pindolol + Acebutolol + Carteolol + Bopindolol' + Oxprenolol! + Celiprolol’ + Penbutolol</td><td>B,, B., with intrinsic sympathomimetic (partial agonist) effect</td><td>Lower BP + modestly lower HR</td><td>“m Hypertension + arrhythmias igraine + may avoid worsening of bradycardia</td><td>Oral - Toxicity: Fatigue + vivid dreams « cold hands</td></tr><tr><td>+ Carvedilol + Medroxalol! + Bucindolol' (see</td><td>B &gt; a, block</td><td></td><td>Heart failure</td><td>Oral, long half-life - Toxicity: Fatigue</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td>+ Esmolol</td><td>Bi &gt; Bo</td><td>Very brief cardiac B blockade</td><td>Rapid control of BP and arrhythmias, thyrotoxicosis, and myocardial ischemia intraoperatively</td><td>Parenteral only « half-life ~10 min - Toxicity: Bradycardia + hypotension</td></tr><tr><td colspan="5">TYROSINE HYDROXYLASE INHIBITOR</td></tr><tr><td>+ Metyrosine</td><td>Blocks tyrosine hydroxylase + reduces synthesis of dopamine, norepinephrine, and epinephrine</td><td>Lowers BP + may elicit extrapyramidal effects (due to low dopamine in CNS)</td><td>Pheochromocytoma</td><td>Toxicity: Extrapyramidal symptoms « orthostatic hypotension - crystalluria</td></tr></table>
======================================
<table><tr><td colspan="3">ALPHA BLOCKERS</td></tr><tr><td>Alfuzosin</td><td></td><td>Uroxatral</td></tr><tr><td>Doxazosin</td><td></td><td>Generic, Cardura</td></tr><tr><td>Phenoxybenzamine</td><td></td><td>Dibenzyline</td></tr><tr><td>Phentolamine</td><td></td><td>Generic</td></tr><tr><td>Prazosin</td><td></td><td>Generic, Minipress</td></tr><tr><td>Silodosin</td><td></td><td>Rapaflo</td></tr><tr><td>Tamsulosin</td><td></td><td>Flomax</td></tr><tr><td>Terazosin</td><td></td><td>Generic, Hytrin</td></tr><tr><td>Tolazoline</td><td></td><td>Priscoline</td></tr><tr><td></td><td>BETA</td><td>BLOCKERS</td></tr><tr><td>Acebutolol</td><td></td><td>Generic, Sectral</td></tr><tr><td>Atenolol</td><td></td><td>Generic, Tenormin</td></tr><tr><td colspan="3">Betaxolol</td></tr><tr><td>Oral</td><td></td><td>Kerlone</td></tr><tr><td>Ophthalmic</td><td></td><td>Generic, Betoptic</td></tr><tr><td>Bisoprolol</td><td></td><td>Generic, Zebeta</td></tr><tr><td colspan="3">Carteolol</td></tr><tr><td>Oral</td><td></td><td>Cartrol</td></tr><tr><td>Ophthalmic</td><td></td><td>Generic, Ocupress</td></tr></table>
======================================
<table><tr><td>Carvedilol</td><td>Coreg</td></tr><tr><td>Esmolol</td><td>Brevibloc</td></tr><tr><td>Labetalol</td><td>Generic, Normodyne, Trandate</td></tr><tr><td>Levobunolol</td><td>Betagan Liquifilm, others</td></tr><tr><td>Metipranolol</td><td>OptiPranolol</td></tr><tr><td>Metoprolol</td><td>Generic, Lopressor, Toprol</td></tr><tr><td>Nadolol</td><td>Generic, Corgard</td></tr><tr><td>Nebivolol</td><td>Bystolic</td></tr><tr><td>Penbutolol</td><td>Levatol</td></tr><tr><td>Pindolol</td><td>Generic, Visken</td></tr><tr><td>Propranolol</td><td>Generic, Inderal</td></tr><tr><td>Sotalol</td><td>Generic, Betapace</td></tr><tr><td colspan="2">Timolol</td></tr><tr><td>Oral</td><td>Generic, Blocadren</td></tr><tr><td>Ophthalmic</td><td>Generic, Timoptic</td></tr><tr><td>TYROSINE</td><td>HYDROXYLASE INHIBITOR</td></tr></table>
======================================
<table><thead><th>iastolic Pressure</th><th>Category</th></thead><tr><td>&lt; 120/80</td><td>Normal</td></tr><tr><td>120-139/80-89</td><td>Prehypertension</td></tr><tr><td>2 140/90</td><td>Hypertension</td></tr><tr><td>140-159/90-99</td><td>Stage 1</td></tr><tr><td>= 160/100</td><td>Stage 2</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Half-life (h)</th><th>Bioavailability (percent)</th><th>Suggested Initial Dose</th><th>Usual Maintenance Dose Range</th><th>Reduction of Dosage Required in Moderate Renal Insufficiency’</th></thead><tr><td>Amlodipine</td><td></td><td>65</td><td>2.5 mg/d</td><td>5-10 mg/d</td><td>No</td></tr><tr><td>Atenolol</td><td></td><td>60</td><td>50 mg/d</td><td>50-100 mg/d</td><td>Yes</td></tr><tr><td>Benazepril</td><td></td><td>35</td><td>5-10 mg/d</td><td>20-40 mg/d</td><td>Yes</td></tr><tr><td>Captopril</td><td></td><td>65</td><td>50-75 mg/d</td><td>75-150 mg/d</td><td>Yes</td></tr><tr><td>Chlorthalidone</td><td></td><td>65</td><td>25 mg/d</td><td>25-50 mg/d</td><td>No</td></tr><tr><td>Clonidine</td><td></td><td>95</td><td>0.2 mg/d</td><td>0.2-1.2 mg/d</td><td>Yes</td></tr><tr><td>Diltiazem</td><td></td><td>40</td><td>120-140 mg/d</td><td>240-360 mg/d</td><td>No</td></tr><tr><td>Hydralazine</td><td></td><td>25</td><td>40 mg/d</td><td>40-200 mg/d</td><td>No</td></tr><tr><td>Hydrochlorothiazide</td><td></td><td>70</td><td>25 mg/d</td><td>25-50 mg/d</td><td>No</td></tr><tr><td>Lisinopril</td><td></td><td>25</td><td>10 mg/d</td><td>10-80 mg/d</td><td>Yes</td></tr><tr><td>Losartan</td><td></td><td>36</td><td>50 mg/d</td><td>25-100 mg/d</td><td>No</td></tr><tr><td>Methyldopa</td><td></td><td>25</td><td>1g/d</td><td>1-2 g/d</td><td>No</td></tr><tr><td>Metoprolol</td><td></td><td>40</td><td>50-100 mg/d</td><td>200-400 mg/d</td><td>No</td></tr><tr><td>Minoxidil</td><td></td><td>90</td><td>5-10 mg/d</td><td>40 mg/d</td><td>No</td></tr><tr><td>Nebivolol</td><td></td><td>Nd*</td><td>5 mg/d</td><td>10-40 mg/d</td><td>No</td></tr><tr><td>Nifedipine</td><td></td><td></td><td>30 mg/d</td><td>30-60 mg/d</td><td>No</td></tr><tr><td>Prazosin</td><td></td><td></td><td>3 mg/d</td><td>10-30 mg/d</td><td>No</td></tr><tr><td>Propranolol</td><td></td><td></td><td>80 mg/d</td><td>80-480 mg/d</td><td>No</td></tr><tr><td>Reserpine</td><td></td><td></td><td>0.25 mg/d</td><td>0.25 mg/d</td><td>No</td></tr><tr><td>Verapamil</td><td></td><td></td><td>180 mg/d</td><td>240-480 mg/d</td><td>No</td></tr></table>
======================================
<table><thead><th>Mechanism</th><th>Examples</th></thead><tr><td>Release of nitric oxide from drug or endothelium</td><td>Nitroprusside, hydralazine, nitrates,’ histamine, acetylcholine</td></tr><tr><td>Reduction of calcium influx</td><td>Verapamil, diltiazem, nifedipine’</td></tr><tr><td>Hyperpolarization of cell</td><td>Minoxidil, diazoxide</td></tr><tr><td>Activation of dopamine receptors</td><td>Fenoldopam</td></tr></table>
======================================
<table><thead><th></th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">DIURETICS</td><td rowspan="4">See Chapter 15</td></tr><tr><td>+ Thiazides: Hydrochlorothiazide, chlorthalidone</td><td>Block Na/CI transporter in renal distal convoluted tubule</td><td>Reduce blood volume and poorly understood vascular effects</td><td>Hypertension, mild heart failure</td><td></td></tr><tr><td>+ Loop diuretics: Furosemide</td><td>Block Na/K/2CI transporter in renal loop of Henle</td><td>Like thiazides + greater efficacy</td><td>Severe hypertension, heart failure</td><td></td></tr><tr><td>+ Spironolactone, eplerenone</td><td>Block aldosterone receptor in renal collecting tubule</td><td>Increase Na and decrease K excretion + poorly understood reduction in heart failure mortality</td><td>Aldosteronism, heart failure, hypertension</td><td></td></tr><tr><td colspan="5">SYMPATHOPLEGICS, CENTRALLY ACTING</td></tr><tr><td>+ Clonidine, methyldopa</td><td>Activate a, adrenoceptors</td><td>Reduce central sympathetic outflow « reduce norepinephrine release from noradrenergic nerve endings</td><td>Hypertension - clonidine also used in withdrawal from abused drugs</td><td>Oral - clonidine also as patch + Toxicity: sedation « methyldopa hemolytic anemia</td></tr><tr><td colspan="5">SYMPATHETIC NERVE TERMINAL BLOCKERS</td></tr><tr><td>+ Reserpine</td><td>Blocks vesicular amine transporter in noradrenergic nerves and depletes transmitter stores</td><td>Reduces all sympathetic effects, especially cardiovascular, and reduce blood pressure</td><td>Hypertension but rarely used</td><td>Oral « long duration (days) « Toxicity: psychiatric depression, gastrointestinal disturbances</td></tr><tr><td>+ Guanethidine, guanadrel</td><td>Interferes with amine release and replaces norepinephrine in vesicles</td><td>Same as reserpine</td><td>Same as reserpine</td><td>Severe orthostatic hypotension + sexual dysfunction « availability limited</td></tr><tr><td colspan="5">o BLOCKERS</td></tr><tr><td>+ Prazosin + Terazosin + Doxazosin</td><td>Selectively block ot, adrenoceptors</td><td>Prevent sympathetic vasoconstriction + reduce prostatic smooth muscle tone</td><td>Hypertension + benign prostatic hyperplasia</td><td>Oral « Toxicity: Orthostatic hypotension</td></tr><tr><td colspan="5">B BLOCKERS</td></tr><tr><td>+ Metoprolol, others + Carvedilol + Nebivolol</td><td>Block 8, receptors; carvedilol also blocks o receptors; nebivolol also releases nitric oxide</td><td>Prevent sympathetic cardiac stimulation + reduce renin secretion</td><td>Hypertension - heart failure + coronary disease</td><td>| See Chapter 10</td></tr><tr><td colspan="5">+ Propranolol: Nonselective prototype B blocker</td></tr><tr><td colspan="5">+ Metoprolol and atenolol: Very widely used B,-selective blockers</td></tr></table>
======================================
<table><thead><th></th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">DIURETICS</td><td rowspan="4">See Chapter 15</td></tr><tr><td>+ Thiazides: Hydrochlorothiazide, chlorthalidone</td><td>Block Na/CI transporter in renal distal convoluted tubule</td><td>Reduce blood volume and poorly understood vascular effects</td><td>Hypertension, mild heart failure</td><td></td></tr><tr><td>+ Loop diuretics: Furosemide</td><td>Block Na/K/2CI transporter in renal loop of Henle</td><td>Like thiazides + greater efficacy</td><td>Severe hypertension, heart failure</td><td></td></tr><tr><td>+ Spironolactone, eplerenone</td><td>Block aldosterone receptor in renal collecting tubule</td><td>Increase Na and decrease K excretion + poorly understood reduction in heart failure mortality</td><td>Aldosteronism, heart failure, hypertension</td><td></td></tr><tr><td colspan="5">SYMPATHOPLEGICS, CENTRALLY ACTING</td></tr><tr><td>+ Clonidine, methyldopa</td><td>Activate a, adrenoceptors</td><td>Reduce central sympathetic outflow « reduce norepinephrine release from noradrenergic nerve endings</td><td>Hypertension - clonidine also used in withdrawal from abused drugs</td><td>Oral - clonidine also as patch + Toxicity: sedation « methyldopa hemolytic anemia</td></tr><tr><td colspan="5">SYMPATHETIC NERVE TERMINAL BLOCKERS</td></tr><tr><td>+ Reserpine</td><td>Blocks vesicular amine transporter in noradrenergic nerves and depletes transmitter stores</td><td>Reduces all sympathetic effects, especially cardiovascular, and reduce blood pressure</td><td>Hypertension but rarely used</td><td>Oral « long duration (days) « Toxicity: psychiatric depression, gastrointestinal disturbances</td></tr><tr><td>+ Guanethidine, guanadrel</td><td>Interferes with amine release and replaces norepinephrine in vesicles</td><td>Same as reserpine</td><td>Same as reserpine</td><td>Severe orthostatic hypotension + sexual dysfunction « availability limited</td></tr><tr><td colspan="5">o BLOCKERS</td></tr><tr><td>+ Prazosin + Terazosin + Doxazosin</td><td>Selectively block ot, adrenoceptors</td><td>Prevent sympathetic vasoconstriction + reduce prostatic smooth muscle tone</td><td>Hypertension + benign prostatic hyperplasia</td><td>Oral « Toxicity: Orthostatic hypotension</td></tr><tr><td colspan="5">B BLOCKERS</td></tr><tr><td>+ Metoprolol, others + Carvedilol + Nebivolol</td><td>Block 8, receptors; carvedilol also blocks o receptors; nebivolol also releases nitric oxide</td><td>Prevent sympathetic cardiac stimulation + reduce renin secretion</td><td>Hypertension - heart failure + coronary disease</td><td>| See Chapter 10</td></tr><tr><td colspan="5">+ Propranolol: Nonselective prototype B blocker</td></tr><tr><td colspan="5">+ Metoprolol and atenolol: Very widely used B,-selective blockers</td></tr></table>
======================================
<table><tr><td>+ Verapamil + Diltiazem</td><td>Nonselective block of L-type calcium channels</td><td>Reduce cardiac rate and output + reduce vascular resistance</td><td>Hypertension, angina, arrhythmias</td><td>See Chapter 12</td></tr><tr><td>+ Nifedipine, amlodipine, other dihydropyridines</td><td>Block vascular calcium channels &gt; cardiac calcium channels</td><td>Reduce vascular resistance</td><td>Hypertension, angina</td><td>See Chapter 12</td></tr><tr><td>+ Hydralazine + Minoxidil</td><td>Causes nitric oxide release Metabolite opens K channels in vascular smooth muscle</td><td>Vasodilation + reduces vascular resistance + arterioles more sensitive than veins « reflex tachycardia</td><td>Hypertension +» minoxidil also used to treat hair loss</td><td>Oral + Toxicity: Angina, tachycardia + Hydralazine: Lupus-like syndrome + Minoxidil: Hypertrichosis</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th></th><th></th><th></th><th></th></thead><tr><td>PARENTERAL AGENTS + Nitroprusside + Fenoldopam + Diazoxide + Labetalol</td><td>Releases nitric oxide Activates D, receptors Opens K channels a, blocker</td><td>Powerful vasodilation</td><td>Hypertensive emergencies + diazoxide now used only in hypoglycemia</td><td>Parenteral - short duration + Toxicity: Excessive hypotension, shock</td></tr><tr><td></td><td>B</td><td></td><td></td><td></td></tr><tr><td>ANGIOTENSIN-CONVERTING + Captopril, many others</td><td>ENZYME (ACE) INHIBITORS Inhibit angiotensin-converting enzyme</td><td>Reduce angiotensin II levels + reduce vasoconstriction and aldosterone secretion + increase bradykinin</td><td>Hypertension - heart failure, diabetes</td><td>Oral + Toxicity: Cough, angioedema - hyperkalemia +renal impairment - teratogenic</td></tr><tr><td>ANGIOTENSIN RECEPTOR</td><td>BLOCKERS (ARBS)</td><td></td><td></td><td></td></tr><tr><td>+ Losartan, many others</td><td>Block AT, angiotensin receptors</td><td>Same as ACE inhibitors but no increase in bradykinin</td><td>Hypertension - heart failure</td><td>Oral - Toxicity: Same as ACE inhibitors but less cough</td></tr><tr><td>RENIN INHIBITOR + Aliskiren</td><td>Inhibits enzyme activity of renin</td><td>Reduces angiotensin | and II and aldosterone</td><td>Hypertension</td><td>Oral - Toxicity: Hyperkalemia, renal impairment « potential teratogen</td></tr></table>
======================================
<table><tr><td>Acebutolol</td><td>Generic, Sectral</td></tr><tr><td>Atenolol</td><td>Generic, Tenormin</td></tr><tr><td>Betaxolol</td><td>Generic, Kerlone</td></tr><tr><td>Bisoprolol</td><td>Generic, Zebeta</td></tr><tr><td>Carvedilol</td><td>Generic, Coreg</td></tr><tr><td>Esmolol</td><td>Generic, Brevibloc</td></tr><tr><td>Labetalol</td><td>Generic, Normodyne, Trandate</td></tr><tr><td>Metoprolol</td><td>Generic, Lopressor, Toprol-XL</td></tr><tr><td>Nadolol</td><td>Generic, Corgard</td></tr><tr><td>Nebivolol</td><td>Bystolic</td></tr><tr><td>Penbutolol</td><td>Levatol</td></tr><tr><td>Pindolol</td><td>Generic, Visken</td></tr><tr><td>Propranolol</td><td>Generic, Inderal,</td></tr><tr><td>Timolol</td><td>Inderal LA Blocadren</td></tr><tr><td colspan="2">Generic, CENTRALLY ACTING SYMPATHOPLEGIC DRUGS</td></tr><tr><td>Clonidine</td><td>Generic, Catapres, Catapres-TTS</td></tr><tr><td>Guanabenz</td><td>Generic, Wytensin</td></tr><tr><td>Guanfacine</td><td>Generic, Tenex</td></tr><tr><td>Methyldopa</td><td>Generic, Methyldopate HCl</td></tr><tr><td>SYMPATHETIC</td><td>POSTGANGLIONIC NERVE TERMINAL BLOCKERS</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td colspan="2">ALPHA,-SELECTIVE ADRENOCEPTOR BLOCKERS</td></tr><tr><td>Doxazosin</td><td>Generic, Cardura</td></tr><tr><td>Prazosin</td><td>Generic, Minipress</td></tr><tr><td>Terazosin</td><td>Generic, Hytrin</td></tr><tr><td colspan="2">GANGLION-BLOCKING AGENTS</td></tr><tr><td>Mecamylamine</td><td>Generic (orphan drug for Tourette's syndrome) VASODILATORS USED</td></tr><tr><td>IN Diazoxide</td><td>HYPERTENSION Hyperstat IV, Proglycem (oral for insulinoma)</td></tr><tr><td>Fenoldopam</td><td>Corlopam</td></tr><tr><td>Hydralazine</td><td>Generic, Apresoline</td></tr><tr><td>Minoxidil</td><td>Generic, Loniten</td></tr><tr><td>Topical</td><td>Rogaine</td></tr><tr><td>Nitroprusside</td><td>Generic, Nitropress</td></tr><tr><td>CALCIUM</td><td>CHANNEL BLOCKERS</td></tr><tr><td>Amlodipine</td><td>Generic, Norvasc</td></tr><tr><td>Clevidipine</td><td>Cleviprex</td></tr><tr><td>Diltiazem</td><td>Generic, Cardizem, Cardizem CD, Cardizem SR, Dilacor XL</td></tr><tr><td>Felodipine</td><td>Generic, Plendil</td></tr><tr><td>Isradipine</td><td>Generic, DynaCirc, Dynacirc CR</td></tr><tr><td>Nicardipine</td><td>Generic, Cardene, Cardene SR, Cardene IV)</td></tr></table>
======================================
<table><tr><td>Captopril</td><td>Generic, Capoten</td></tr><tr><td>Enalapril</td><td>Generic, Vasotec, Enalaprilat (parenteral)</td></tr><tr><td>Fosinopril</td><td>Generic, Monopril</td></tr><tr><td>Lisinopril</td><td>Generic, Prinivil, Zestril</td></tr><tr><td>Moexipril</td><td>Generic, Univasc</td></tr><tr><td>Perindopril</td><td>Generic, Aceon</td></tr><tr><td>Quinapril</td><td>Generic, Accupril</td></tr><tr><td>Ramipril</td><td>Generic, Altace</td></tr><tr><td>Trandolapril</td><td>Generic, Mavik</td></tr><tr><td>Azilsartan</td><td>Edarbi</td></tr><tr><td>Candesartan</td><td>Generic, Atacand</td></tr></table>
======================================
<table><thead><th>Wall stress</th></thead><tr><td>Intraventricular pressure</td></tr><tr><td>Ventricular radius (volume)</td></tr><tr><td>Wall thickness</td></tr><tr><td>Heart rate</td></tr><tr><td>Contractility</td></tr></table>
======================================
<table><thead><th>Effect</th><th>Mechanism and Result</th></thead><tr><td colspan="2">Potential beneficial effects</td></tr><tr><td>Decreased ventricular volume</td><td>Decreased work and myocardial</td></tr><tr><td>Decreased arterial pressure</td><td>oxygen requirement</td></tr><tr><td colspan="2">Decreased ejection time</td></tr><tr><td>Vasodilation of epicardial coronary arteries</td><td>Relief of coronary artery spasm</td></tr><tr><td>Increased collateral flow</td><td>Improved perfusion of ischemic myocardium</td></tr><tr><td>Decreased left ventricular diastolic pressure</td><td>Improved subendocardial perfusion</td></tr><tr><td colspan="2">Potential deleterious effects</td></tr><tr><td>Reflex tachycardia</td><td>Increased myocardial oxygen requirement; decreased diastolic perfusion time and coronary perfusion</td></tr><tr><td>Reflex increase in contractility</td><td>Increased myocardial oxygen requirement</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Dose</th><th>Duration of Action</th></thead><tr><td colspan="3">Short-acting</td></tr><tr><td>Nitroglycerin, sublingual</td><td>0.15-1.2 mg</td><td>10-30 minutes</td></tr><tr><td>Isosorbide dinitrate, sublingual</td><td>2.5-5 mg</td><td>10-60 minutes</td></tr><tr><td>AmyI nitrite, inhalant (obsolete)</td><td>0.18-0.3 mL.</td><td>3-5 minutes</td></tr><tr><td colspan="3">Long-acting</td></tr><tr><td>Nitroglycerin, oral sustained-action</td><td>6.5-13 mg per 6-8 hours</td><td>6-8 hours</td></tr><tr><td>Nitroglycerin, 2% ointment, transdermal</td><td>1-1.5 inches per 4 hours</td><td>3-6 hours</td></tr><tr><td>Nitroglycerin, slow-release, buccal</td><td>1-2 mg per 4 hours</td><td>3-6 hours</td></tr><tr><td>Nitroglycerin, slow-release patch, transdermal</td><td>10-25 mg per 24 hours (one patch per day)</td><td>8-10 hours</td></tr><tr><td>Isosorbide dinitrate, sublingual</td><td>2.5-10 mg per 2 hours</td><td>1.5-2 hours</td></tr><tr><td>Isosorbide dinitrate, oral</td><td>10-60 mg per 4-6 hours</td><td>4-6 hours</td></tr><tr><td>Isosorbide dinitrate, chewable oral</td><td>5-10 mg per 2-4 hours</td><td>2-3 hours</td></tr><tr><td>Isosorbide mononitrate, oral</td><td>20 mg per 12 hours</td><td>6-10 hours</td></tr><tr><td>Pentaerythritol tetranitrate (PETN)</td><td>50 mg per 12 hours</td><td>10-12 hours</td></tr></table>
======================================
<table><thead><th>Type</th><th>Channel Name</th><th>Where Found</th><th>Properties of the Calcium Current</th><th>Blocked By</th></thead><tr><td>L</td><td>Cay1.1-Cay1.4</td><td>Cardiac, skeletal, smooth muscle, neurons (Cay1.4 is found in retina), endocrine cells, bone</td><td>Long, large, high threshold</td><td>Verapamil, DHPs, Cd**, @-aga-II|A</td></tr><tr><td>T</td><td>Cay3.1-Cay3.3</td><td>Heart, neurons</td><td>Short, small, low threshold</td><td>sFTX, flunarizine, Ni?* (Cay3.2 only), mibefradil'</td></tr><tr><td>N</td><td>Cay2.2</td><td>Neurons, sperm?</td><td>Short, high threshold</td><td>Ziconotide,; gabapentin, @-CTXGVIA, w-aga-lllA, Cd**</td></tr><tr><td>P/Q</td><td>Cay2.1</td><td>Neurons</td><td>Long, high threshold</td><td>@-CTX-MVIIC, @-aga-IVA</td></tr><tr><td>R</td><td>Cay2.3</td><td>Neurons, sperm?</td><td>Pacemaking</td><td>SNX-482, w-aga-lllA</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Oral Bioavailability (%)</th><th>Half-Life (hours)</th><th>Indication</th><th>Dosage</th></thead><tr><td colspan="5">Dihydropyridines</td></tr><tr><td>Amlodipine</td><td>65-90</td><td>30-50</td><td>Angina, hypertension</td><td>5-10 mg orally once daily</td></tr><tr><td>Felodipine</td><td>15-20</td><td>11-16</td><td>Hypertension, Raynaud’s phenomenon</td><td>5-10 mg orally once daily</td></tr><tr><td>Isradipine</td><td>15-25</td><td>8</td><td>Hypertension</td><td>2.5-10 mg orally twice daily</td></tr><tr><td>Nicardipine</td><td>35</td><td>2-4</td><td>Angina, hypertension</td><td>20-40 mg orally every 8 hours</td></tr><tr><td>Nifedipine</td><td>45-70</td><td>4</td><td>Angina, hypertension, Raynaud's phenomenon</td><td>3-10 mcg/kg IV; 20-40 mg orally every 8 hours</td></tr><tr><td>Nisoldipine</td><td>&lt;10</td><td>6-12</td><td>Hypertension</td><td>20-40 mg orally once daily</td></tr><tr><td>Nitrendipine</td><td>10-30</td><td>5-12</td><td>Investigational</td><td>20 mg orally once or twice daily</td></tr><tr><td colspan="5">Miscellaneous</td></tr><tr><td>Diltiazem</td><td>40-65</td><td>3-4</td><td>Angina, hypertension, Raynaud's phenomenon</td><td>75-150 mcg/kg IV; 30-80 mg orally every 6 hours</td></tr><tr><td>Verapamil</td><td>20-35</td><td>6</td><td>Angina, hypertension, arrhythmias, migraine</td><td>75-150 mcg/kg IV; 80-160 mg orally every 8 hours</td></tr></table>
======================================
<table><thead><th>Drugs</th></thead><tr><td>Amiloride</td></tr><tr><td>Capsaicin</td></tr><tr><td>Direct bradycardic agents, eg, ivabradine</td></tr><tr><td>Inhibitors of slowly inactivating sodium current, eg, ranolazine</td></tr><tr><td>Metabolic modulators, eg, trimetazidine</td></tr><tr><td>Nitric oxide donors, eg, L-arginine</td></tr><tr><td>Potassium channel activators, eg, nicorandil</td></tr><tr><td>Protein kinase G facilitators, eg, detanonoate</td></tr><tr><td>Rho-kinase inhibitors, eg, fasudil</td></tr><tr><td>Sulfonylureas, eg, glibenclamide</td></tr><tr><td>Thiazolidinediones</td></tr><tr><td>Vasopeptidase inhibitors</td></tr><tr><td>Xanthine oxidase inhibitors, eg, allopurinol</td></tr></table>
======================================
<table><thead><th></th><th>Nitrates Alone</th><th>Beta Blockers or Calcium Channel Blockers</th><th>or Calcium Channel Blockers Combined Nitrates with Beta Blockers</th></thead><tr><td>Heart rate</td><td>Reflex’ increase</td><td>Decrease</td><td>Decrease</td></tr><tr><td>Arterial pressure</td><td>Decrease</td><td>Decrease</td><td>Decrease</td></tr><tr><td>End-diastolic volume</td><td>Decrease</td><td>Increase</td><td>or decrease</td></tr><tr><td>Contractility</td><td>Reflex' increase</td><td>Decrease</td><td></td></tr><tr><td>Ejection time</td><td>Decrease’</td><td>Increase</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">BETA BLOCKERS</td></tr><tr><td>+ Propranolol</td><td>Nonselective competitive antagonist at 8 adrenoceptors</td><td>Decreased heart rate, cardiac output, and blood pressure + decreases myocardial oxygen demand</td><td>Prophylaxis of angina + for other applications, see Chapters 10, 11, and 13</td><td>Oral and parenteral, 4-6 h duration of action + Toxicity: Asthma, atrioventricular block, acute heart failure, sedation + Interactions: Additive with all cardiac depressants</td></tr><tr><td colspan="5">+ Atenolol, metoprolol, others: B ,-selective blockers, less risk of bronchospasm, but still significant + See Chapters 10 and 11 for other B blockers and their applications</td></tr><tr><td>CALCIUM CHANNEL + Verapamil, diltiazem</td><td>BLOCKERS Nonselective block of L-type calcium channels in vessels and heart</td><td>Reduced vascular resistance, cardiac rate, and cardiac force results in decreased oxygen demand</td><td>Prophylaxis of angina, hypertension, others</td><td>Oral, IV, duration 4-8 h + Toxicity: Atrioventricular block, acute heart failure; constipation, edema - Interactions: Additive with other cardiac depressants and hypotensive drugs</td></tr><tr><td>+ Nifedipine (a dihydropyridine)</td><td>Block of vascular L-type calcium channels &gt; cardiac channels</td><td>Like verapamil and diltiazem; less cardiac effect</td><td>Prophylaxis of angina and treatment of hypertension but prompt release nifedipine is contraindicated</td><td>Oral, duration 4-6 h + Toxicity: Excessive hypotension, baroreceptor reflex tachycardia + Interactions: Additive with other vasodilators</td></tr></table>
======================================
<table><thead><th colspan="2">CALCIUM CHANNEL BLOCKERS</th></thead><thead><th>Amlodipine</th><th>Generic, Norvasc, AmVaz</th></thead><tr><td>Clevidipine (approved only for use in hypertensive emergencies)</td><td>Cleviprex</td></tr><tr><td>Diltiazem (oral, oral sustained release, parenteral)</td><td>Generic, Cardizem</td></tr><tr><td>Felodipine</td><td>Generic, Plendil</td></tr><tr><td>Isradipine (oral, oral controlled release)</td><td>DynaCirc</td></tr><tr><td>Nicardipine (oral, oral sustained release, parenteral)</td><td>Cardene, others</td></tr><tr><td>Nifedipine (oral, oral extended release)</td><td>Adalat, Procardia, others</td></tr><tr><td>Nisoldipine</td><td>Sular</td></tr><tr><td>Verapamil (oral, oral sustained release, parenteral)</td><td>Generic, Calan, Isoptin</td></tr><tr><td colspan="2">BETA BLOCKERS</td></tr><tr><td></td><td>See Chapter 10</td></tr><tr><td colspan="2">SODIUM CHANNEL BLOCKERS</td></tr><tr><td>Ranolazine</td><td>Ranexa</td></tr><tr><td colspan="2">DRUGS FOR ERECTILE DYSFUNCTION</td></tr><tr><td>Avanafil</td><td>Stendra</td></tr><tr><td>Sildenafil</td><td>Viagra, Revatio</td></tr></table>
======================================
<table><thead><th>Chronic Systolic Heart Failure</th><th>Acute Heart Failure</th></thead><tr><td>Diuretics</td><td>Diuretics</td></tr><tr><td>Aldosterone receptor antagonists</td><td>Vasodilators</td></tr><tr><td>Angiotensin-converting enzyme inhibitors</td><td>Beta agonists</td></tr><tr><td>Angiotensin receptor blockers</td><td>Bipyridines</td></tr><tr><td>Beta blockers</td><td>Natriuretic peptide</td></tr><tr><td>Cardiac glycosides</td><td>Left ventricular assist device</td></tr><tr><td colspan="2">Vasodilators, neprilysin inhibitor</td></tr><tr><td colspan="2">Resynchronization and cardioverter therapy</td></tr></table>
======================================
<table><thead><th>Tissue or Variable</th><th>Effects at Therapeutic Dosage</th><th>Effects at Toxic Dosage</th></thead><tr><td>Sinus node</td><td>J Rate</td><td>J Rate</td></tr><tr><td>Atrial muscle</td><td>J Refractory period</td><td>J Refractory period, arrhythmias</td></tr><tr><td>Atrioventricular node</td><td>J Conduction velocity, T refractory period</td><td>J Refractory period, arrhythmias</td></tr><tr><td>Purkinje system, ventricular muscle</td><td>Slight J refractory period</td><td>Extrasystoles, tachycardia, fibrillation</td></tr><tr><td>Electrocardiogram</td><td>7 PR interval, J QT interval</td><td>Tachycardia, fibrillation, arrest at extremely high dosage</td></tr></table>
======================================
<table><thead><th>ACC/AHA Stage’</th><th>NYHA Class”</th><th>Description</th><th>Management</th></thead><tr><td>A</td><td>Prefailure</td><td>No symptoms but risk factors present?</td><td>Treat obesity, hypertension, diabetes, hyperlipidemia, etc</td></tr><tr><td>B</td><td>|</td><td>Symptoms with severe exercise</td><td>ACEI/ARB, B blocker, diuretic</td></tr><tr><td>c</td><td>I/II</td><td>Symptoms with marked (class II) or mild (class Ill) exercise</td><td>Add aldosterone antagonist, digoxin; CRT, ARNI, hydralazine/ nitrate*</td></tr><tr><td></td><td>IV</td><td>Severe symptoms at rest</td><td>Transplant, LVAD</td></tr></table>
======================================
<table><thead><th>Variable or Therapy</th><th>Systolic Heart Failure</th><th>Diastolic Heart Failure</th></thead><tr><td>Cardiac output</td><td>Decreased</td><td>Decreased</td></tr><tr><td>Ejection fraction</td><td>Decreased</td><td>Normal</td></tr><tr><td>Diuretics</td><td>bb Symptoms; first-line therapy if edema present</td><td>Use with caution’</td></tr><tr><td>ACEls</td><td>J Mortality in chronic HF</td><td>May help to J LVH</td></tr><tr><td>ARBs</td><td>J Mortality in chronic HF</td><td>May be beneficial</td></tr><tr><td>ARNI</td><td>J Symptoms and NT-proBNP.</td><td>J Symptoms and NT-proBNP.</td></tr><tr><td>Aldosterone inhibitors</td><td>J Mortality in chronic HF</td><td>May be useful</td></tr><tr><td>Beta blockers”, ivabradine</td><td>Beta blocker |. mortality in chronic HF, ivabradine reduces hospitalizations</td><td>Useful to J HR, 4 BP</td></tr><tr><td>Calcium channel blockers</td><td>No or small benefit®</td><td>Useful to J HR, 4 BP</td></tr><tr><td>Digoxin</td><td>May reduce symptoms</td><td>Little or no role</td></tr><tr><td>Nitrates</td><td>May be useful in acute HF*</td><td>Use with caution!</td></tr><tr><td>PDE inhibitors</td><td>May be useful in acute HF</td><td>Very small study in chronic HF was positive</td></tr><tr><td>Positive inotropes</td><td>bb Symptoms, hospitalizations</td><td>Not recommended</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th>al Applications</th><th>Pharmacokin S, Toxi s, Interactions</th></thead><tr><td colspan="5">DIURETICS</td></tr><tr><td>+ Furosemide</td><td>Loop diuretic: Decreases NaCl and KCl reabsorption in thick ascending limb of the loop of Henle in the nephron (see Chapter 15)</td><td>Increased excretion of salt and water + reduces cardiac preload and afterload + reduces pulmonary and peripheral edema</td><td>Acute and chronic heart failure + severe hypertension + edematous conditions</td><td>Oral and IV - duration 2-4 h + Toxicity: Hypovolemia, hypokalemia, orthostatic hypotension, ototoxicity, sulfonamide allergy</td></tr><tr><td>+ Hydrochlorothiazide</td><td>Decreases NaCl reabsorption in the distal convoluted tubule</td><td>Same as furosemide, but much less efficacious</td><td>Mild chronic failure « mild- moderate hypertension + hypercalciuria « has not been shown to reduce mortality</td><td>Oral only + duration 10-12 h + Toxicity: Hyponatremia, hypokalemia, hyperglycemia, hyperuricemia, hyperlipidemia, sulfonamide allergy</td></tr></table>
======================================
<table><tr><td>Angiotensin-converting enzyme (ACE) inhibitors:</td><td>Inhibits ACE + reduces All formation by inhibiting</td><td>Arteriolar and venous dilation - reduces</td><td>Chronic heart failure + hypertension - diabetic</td><td>Oral - half-life 2-4 h but given in large doses so duration</td></tr><tr><td>+ Captopril</td><td>conversion of Al to All</td><td>aldosterone secretion + reduces cardiac remodeling</td><td>renal disease + has been shown to reduce mortality</td><td>12-24 h + Toxicity: Cough, hyperkalemia, angioneurotic edema : Interactions: Additive with other angiotensin antagonists</td></tr><tr><td>Angiotensin receptor blockers (ARBs): + Losartan</td><td>Antagonize All effects at AT, receptors</td><td>Like ACE inhibitors</td><td>Like ACE inhibitors + used in patients intolerant to ACE inhibitors - has been shown to reduce mortality</td><td>Oral - duration 6-8 h - Toxicity: Hyperkalemia; angioneurotic edema : Interactions: Additive with other angiotensin antagonists</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th></th><th>Clinical Applications</th><th>acokinetics, ies, Interactions</th></thead><tr><td>BETA BLOCKERS + Carvedilol</td><td>Competitively blocks B; receptors (see Chapter 10)</td><td>Slows heart rate + reduces blood pressure + poorly understood other effects</td><td>Chronic heart failure: To slow progression + reduce mortality in moderate and severe heart failure » many other indications in Chapter 10</td><td>Oral « duration 10-12 h + Toxicity: | Bronchospasm, bradycardia, atrioventricular block, acute cardiac decompensation + see Chapter 10 for other toxicities and interactions</td></tr></table>
======================================
<table><thead><th>+ Digoxin (other glycosides are used outside the USA)</th><th>Na*/K’-ATPase inhibition results in reduced Ca”* expulsion and increased Ca” stored in sarcoplasmic reticulum</th><th>Increases cardiac contractility + cardiac parasympathomimetic effect (slowed sinus heart rate, slowed atrioventricular conduction)</th><th>Chronic symptomatic heart failure + rapid ventricular rate in atrial fibrillation + has not been shown to reduce mortality but does reduce rehospitalization</th><th>Oral, parenteral - duration 36-40 h - Toxicity: Nausea, vomiting, diarrhea + cardiac arrhythmias</th></thead><tr><td colspan="5">VASODILATORS</td></tr><tr><td colspan="5">Venodilators: Releases nitric oxide (NO) Venodilation + reduces and ventricular Acute and chronic heart failure Oral - duration 4-6 h - Toxicity: Postural</td></tr><tr><td colspan="5">+ Isosorbide dinitrate «activates guanylyl cyclase (see Chapter 12) preload stretch angina hypotension, tachycardia, headache + Interactions: Additive with other vasodilators and synergistic with phosphodiesterase type 5 inhibitors</td></tr><tr><td>Arteriolar dilators: + Hydralazine</td><td>Probably increases NO synthesis in endothelium</td><td>Reduces blood pressure and afterload + results in</td><td>Hydralazine plus nitrates may reduce mortality in African-</td><td>Oral - duration 8-12 h + Toxicity: Tachycardia, fluid retention,</td></tr><tr><td>Combined arteriolar</td><td>(see Chapter 11) Releases NO spontaneously</td><td>increased cardiac output Marked vasodilation</td><td>Americans Acute cardiac</td><td>lupus-like syndrome IV only - duration 1-2 min</td></tr><tr><td>and venodilator: + Nitroprusside</td><td>«activates guanylyl cyclase</td><td>+ reduces preload and afterload</td><td>decompensation + hypertensive emergencies (malignant hypertension)</td><td>+ Toxicity: Excessive hypotension, thiocyanate and cyanide toxicity + Interactions: Additive with other vasodilators</td></tr><tr><td>BETA-ADRENOCEPTOR + Dobutamine</td><td>AGONISTS Beta,-selective agonist + increases cAMP synthesis</td><td>Increases cardiac contractility, output</td><td>Acute decompensated heart failure</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with other sympathomimetics</td></tr><tr><td>+ Dopamine</td><td>Dopamine receptor agonist + higher doses activate B and ot adrenoceptors</td><td>Increases renal blood flow + higher doses increase cardiac force and blood pressure</td><td>Acute decompensated heart failure + shock</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with sympathomimetics</td></tr><tr><td colspan="5">BIPYRIDINES</td></tr><tr><td>+ Milrinone</td><td>Phosphodiesterase type 3 inhibitor - decreases CAMP breakdown</td><td>Vasodilator; lower peripheral vascular resistance + also increases cardiac contractility</td><td>Acute decompensated heart failure + increases mortality in chronic failure</td><td>IV only - duration 3-6 h + Toxicity: Arrhythmias + Interactions: Additive with other arrhythmogenic agents</td></tr><tr><td>NATRIURETIC PEPTIDE + Nesiritide</td><td>Activates BNP receptors, increases cGMP</td><td>Vasodilation - diuresis</td><td>Acute decompensated failure + has not been shown to reduce mortality</td><td>IV only - duration 18 min + Toxicity: Renal damage, hypotension, may increase mortality</td></tr><tr><td colspan="5">NEPRILYSIN INHIBITOR</td></tr><tr><td>+ Sacubitril (used only in combination with valsartan [ARNI])</td><td>Inhibits neprilysin, thus reducing breakdown of ANP and BNP; valsartan inhibits action of angiotensin on its receptors</td><td>Vasodilator</td><td>Chronic failure + combination reduces mortality and rehospitalizations</td><td>Oral - duration 12 h + used only in combination with ARB + Toxicity: Hypotension, angioedema</td></tr></table>
======================================
<table><thead><th>+ Digoxin (other glycosides are used outside the USA)</th><th>Na*/K’-ATPase inhibition results in reduced Ca”* expulsion and increased Ca” stored in sarcoplasmic reticulum</th><th>Increases cardiac contractility + cardiac parasympathomimetic effect (slowed sinus heart rate, slowed atrioventricular conduction)</th><th>Chronic symptomatic heart failure + rapid ventricular rate in atrial fibrillation + has not been shown to reduce mortality but does reduce rehospitalization</th><th>Oral, parenteral - duration 36-40 h - Toxicity: Nausea, vomiting, diarrhea + cardiac arrhythmias</th></thead><tr><td colspan="5">VASODILATORS</td></tr><tr><td colspan="5">Venodilators: Releases nitric oxide (NO) Venodilation + reduces and ventricular Acute and chronic heart failure Oral - duration 4-6 h - Toxicity: Postural</td></tr><tr><td colspan="5">+ Isosorbide dinitrate «activates guanylyl cyclase (see Chapter 12) preload stretch angina hypotension, tachycardia, headache + Interactions: Additive with other vasodilators and synergistic with phosphodiesterase type 5 inhibitors</td></tr><tr><td>Arteriolar dilators: + Hydralazine</td><td>Probably increases NO synthesis in endothelium</td><td>Reduces blood pressure and afterload + results in</td><td>Hydralazine plus nitrates may reduce mortality in African-</td><td>Oral - duration 8-12 h + Toxicity: Tachycardia, fluid retention,</td></tr><tr><td>Combined arteriolar</td><td>(see Chapter 11) Releases NO spontaneously</td><td>increased cardiac output Marked vasodilation</td><td>Americans Acute cardiac</td><td>lupus-like syndrome IV only - duration 1-2 min</td></tr><tr><td>and venodilator: + Nitroprusside</td><td>«activates guanylyl cyclase</td><td>+ reduces preload and afterload</td><td>decompensation + hypertensive emergencies (malignant hypertension)</td><td>+ Toxicity: Excessive hypotension, thiocyanate and cyanide toxicity + Interactions: Additive with other vasodilators</td></tr><tr><td>BETA-ADRENOCEPTOR + Dobutamine</td><td>AGONISTS Beta,-selective agonist + increases cAMP synthesis</td><td>Increases cardiac contractility, output</td><td>Acute decompensated heart failure</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with other sympathomimetics</td></tr><tr><td>+ Dopamine</td><td>Dopamine receptor agonist + higher doses activate B and ot adrenoceptors</td><td>Increases renal blood flow + higher doses increase cardiac force and blood pressure</td><td>Acute decompensated heart failure + shock</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with sympathomimetics</td></tr><tr><td colspan="5">BIPYRIDINES</td></tr><tr><td>+ Milrinone</td><td>Phosphodiesterase type 3 inhibitor - decreases CAMP breakdown</td><td>Vasodilator; lower peripheral vascular resistance + also increases cardiac contractility</td><td>Acute decompensated heart failure + increases mortality in chronic failure</td><td>IV only - duration 3-6 h + Toxicity: Arrhythmias + Interactions: Additive with other arrhythmogenic agents</td></tr><tr><td>NATRIURETIC PEPTIDE + Nesiritide</td><td>Activates BNP receptors, increases cGMP</td><td>Vasodilation - diuresis</td><td>Acute decompensated failure + has not been shown to reduce mortality</td><td>IV only - duration 18 min + Toxicity: Renal damage, hypotension, may increase mortality</td></tr><tr><td colspan="5">NEPRILYSIN INHIBITOR</td></tr><tr><td>+ Sacubitril (used only in combination with valsartan [ARNI])</td><td>Inhibits neprilysin, thus reducing breakdown of ANP and BNP; valsartan inhibits action of angiotensin on its receptors</td><td>Vasodilator</td><td>Chronic failure + combination reduces mortality and rehospitalizations</td><td>Oral - duration 12 h + used only in combination with ARB + Toxicity: Hypotension, angioedema</td></tr></table>
======================================
<table><thead><th>+ Digoxin (other glycosides are used outside the USA)</th><th>Na*/K’-ATPase inhibition results in reduced Ca”* expulsion and increased Ca” stored in sarcoplasmic reticulum</th><th>Increases cardiac contractility + cardiac parasympathomimetic effect (slowed sinus heart rate, slowed atrioventricular conduction)</th><th>Chronic symptomatic heart failure + rapid ventricular rate in atrial fibrillation + has not been shown to reduce mortality but does reduce rehospitalization</th><th>Oral, parenteral - duration 36-40 h - Toxicity: Nausea, vomiting, diarrhea + cardiac arrhythmias</th></thead><tr><td colspan="5">VASODILATORS</td></tr><tr><td colspan="5">Venodilators: Releases nitric oxide (NO) Venodilation + reduces and ventricular Acute and chronic heart failure Oral - duration 4-6 h - Toxicity: Postural</td></tr><tr><td colspan="5">+ Isosorbide dinitrate «activates guanylyl cyclase (see Chapter 12) preload stretch angina hypotension, tachycardia, headache + Interactions: Additive with other vasodilators and synergistic with phosphodiesterase type 5 inhibitors</td></tr><tr><td>Arteriolar dilators: + Hydralazine</td><td>Probably increases NO synthesis in endothelium</td><td>Reduces blood pressure and afterload + results in</td><td>Hydralazine plus nitrates may reduce mortality in African-</td><td>Oral - duration 8-12 h + Toxicity: Tachycardia, fluid retention,</td></tr><tr><td>Combined arteriolar</td><td>(see Chapter 11) Releases NO spontaneously</td><td>increased cardiac output Marked vasodilation</td><td>Americans Acute cardiac</td><td>lupus-like syndrome IV only - duration 1-2 min</td></tr><tr><td>and venodilator: + Nitroprusside</td><td>«activates guanylyl cyclase</td><td>+ reduces preload and afterload</td><td>decompensation + hypertensive emergencies (malignant hypertension)</td><td>+ Toxicity: Excessive hypotension, thiocyanate and cyanide toxicity + Interactions: Additive with other vasodilators</td></tr><tr><td>BETA-ADRENOCEPTOR + Dobutamine</td><td>AGONISTS Beta,-selective agonist + increases cAMP synthesis</td><td>Increases cardiac contractility, output</td><td>Acute decompensated heart failure</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with other sympathomimetics</td></tr><tr><td>+ Dopamine</td><td>Dopamine receptor agonist + higher doses activate B and ot adrenoceptors</td><td>Increases renal blood flow + higher doses increase cardiac force and blood pressure</td><td>Acute decompensated heart failure + shock</td><td>IV only - duration a few minutes + Toxicity: Arrhythmias + Interactions: Additive with sympathomimetics</td></tr><tr><td colspan="5">BIPYRIDINES</td></tr><tr><td>+ Milrinone</td><td>Phosphodiesterase type 3 inhibitor - decreases CAMP breakdown</td><td>Vasodilator; lower peripheral vascular resistance + also increases cardiac contractility</td><td>Acute decompensated heart failure + increases mortality in chronic failure</td><td>IV only - duration 3-6 h + Toxicity: Arrhythmias + Interactions: Additive with other arrhythmogenic agents</td></tr><tr><td>NATRIURETIC PEPTIDE + Nesiritide</td><td>Activates BNP receptors, increases cGMP</td><td>Vasodilation - diuresis</td><td>Acute decompensated failure + has not been shown to reduce mortality</td><td>IV only - duration 18 min + Toxicity: Renal damage, hypotension, may increase mortality</td></tr><tr><td colspan="5">NEPRILYSIN INHIBITOR</td></tr><tr><td>+ Sacubitril (used only in combination with valsartan [ARNI])</td><td>Inhibits neprilysin, thus reducing breakdown of ANP and BNP; valsartan inhibits action of angiotensin on its receptors</td><td>Vasodilator</td><td>Chronic failure + combination reduces mortality and rehospitalizations</td><td>Oral - duration 12 h + used only in combination with ARB + Toxicity: Hypotension, angioedema</td></tr></table>
======================================
<table><thead><th>Dopamine</th><th>Generic, Intropin</th></thead><tr><td colspan="2">ANGIOTENSIN-CONVERTING ENZYME INHIBITORS</td></tr><tr><td>Benazepril</td><td>Generic, Lotensin</td></tr><tr><td>Captopril</td><td>Generic, Capoten</td></tr><tr><td>Enalapril</td><td>Generic, Vasotec, Vasotec I.V.</td></tr><tr><td>Fosinopril</td><td>Generic, Monopril</td></tr><tr><td>Lisinopril</td><td>Generic, Prinivil, Zestril</td></tr><tr><td>Moexipril</td><td>Univasc</td></tr><tr><td>Perindopril</td><td>Aceon</td></tr><tr><td>Quinapril</td><td>Generic, Accupril</td></tr><tr><td>Ramipril</td><td>Generic, Altace</td></tr><tr><td>Trandolapril</td><td>Generic, Mavik</td></tr><tr><td>Candesartan</td><td>Atacand</td></tr><tr><td>Eprosartan</td><td>Generic, Teveten</td></tr><tr><td>Irbesartan</td><td>Generic, Avapro</td></tr><tr><td>Losartan</td><td>Generic, Cozaar</td></tr><tr><td>Olmesartan</td><td>Benicar</td></tr><tr><td>Telmisartan</td><td>Generic, Micardis</td></tr><tr><td>Valsartan</td><td>Diovan</td></tr><tr><td>Bisoprolol</td><td>Generic, Zebeta</td></tr><tr><td>Carvedilol</td><td>Generic, Coreg</td></tr><tr><td>Metoprolol</td><td>Generic, Lopressor, Toprol XL</td></tr><tr><td>Nebivolol</td><td>Bystolic</td></tr><tr><td>Eplerenone</td><td>Generic, Inspra</td></tr><tr><td>Spironolactone</td><td>Generic, Aldactone</td></tr><tr><td>Bosentan</td><td>Tracleer</td></tr><tr><td>Hydralazine</td><td>Generic</td></tr><tr><td>Hydralazine plus isosorbide dinitrate</td><td>BiDil</td></tr><tr><td>Isosorbide dinitrate</td><td>Generic, lsordil</td></tr></table>
======================================
<table><thead><th>Type</th><th>Chromosome Involved</th><th>Defective Gene</th><th>lon Channel or Proteins Affected</th><th>Result</th></thead><tr><td>LOT-1</td><td>11</td><td>KCNQ1</td><td></td><td>LF</td></tr><tr><td>LOT-2</td><td>7</td><td>KCNH2 (HERG)</td><td></td><td>LF</td></tr><tr><td>LOT-3</td><td></td><td>SCNS5SA</td><td></td><td>GF</td></tr><tr><td>LOT-4</td><td></td><td>Ankyrin-B'</td><td></td><td>LF</td></tr><tr><td>LOT-5</td><td></td><td>KCNE1 (mink)</td><td></td><td>LF</td></tr><tr><td>LOT-6</td><td></td><td>KCNE2 (MiRP1)</td><td></td><td>LF</td></tr><tr><td>LOT-7?</td><td></td><td>KCNJ2</td><td></td><td>LF</td></tr><tr><td>LOT-8°</td><td></td><td>CACNAIc</td><td></td><td>GF</td></tr><tr><td>SQT-1</td><td></td><td>KCNH2</td><td></td><td>GF</td></tr><tr><td>SQT-2</td><td></td><td>KCNQ1</td><td></td><td>GF</td></tr><tr><td>SQT-3</td><td></td><td>KCNJ2</td><td>Iie</td><td>GF</td></tr><tr><td>cpvT-1"</td><td></td><td>hRyR2</td><td>Ryanodine receptor</td><td>GF</td></tr><tr><td>CPVT-2</td><td></td><td>CASQ2</td><td>Calsequestrin</td><td>LF</td></tr><tr><td>Sick sinus syndrome</td><td></td><td>HCN4 or SCNSA”</td><td></td><td>LF</td></tr><tr><td>Brugada syndrome</td><td></td><td>SCNS5SA</td><td></td><td>LF</td></tr><tr><td>PCCD</td><td></td><td>SCNSA</td><td></td><td>LF</td></tr><tr><td>Familial atrial fibrillation</td><td></td><td>KCNQ1</td><td></td><td>GF</td></tr></table>
======================================
<table><thead><th rowspan="2">Drug</th><th colspan="2">Block of Sodium Channels</th><th colspan="2">Refractory Period ———SOC(—Calcium</th><th rowspan="2">Channel Blockade</th><th rowspan="2">Effect on Pacemaker Activity</th><th rowspan="2">Sympatholytic Action</th></thead><thead><th></th><th>Normal Cells</th><th>Depolarized Cells</th><th>Normal Cells</th><th>Depolarized Cells</th><th></th><th></th><th></th></thead><tr><td>Adenosine</td><td>(0)</td><td>(0)</td><td>0</td><td>0</td><td>+</td><td>0</td><td></td></tr><tr><td>Amiodarone</td><td>+</td><td>+++</td><td>TT</td><td>TT</td><td>+</td><td></td><td></td></tr><tr><td>Diltiazem</td><td>0</td><td>0</td><td>0</td><td>)</td><td>HH</td><td></td><td></td></tr><tr><td>Disopyramide</td><td>+</td><td>++</td><td></td><td>TT</td><td>+</td><td>L</td><td></td></tr><tr><td>Dofetilide</td><td>0</td><td>0</td><td></td><td>?</td><td>0</td><td></td><td></td></tr><tr><td>Dronedarone</td><td>+</td><td>+</td><td>na</td><td>na</td><td>+</td><td>na</td><td></td></tr><tr><td>Esmolol</td><td>0</td><td>+</td><td>0</td><td>na</td><td>0</td><td></td><td></td></tr><tr><td>Flecainide</td><td>+</td><td>+4</td><td>0</td><td></td><td>0</td><td></td><td></td></tr><tr><td>Ibutilide</td><td>0</td><td>0</td><td></td><td>?</td><td>0</td><td>0</td><td></td></tr><tr><td>Lidocaine</td><td>0</td><td></td><td></td><td>tT</td><td>()</td><td></td><td></td></tr><tr><td>Mexiletine</td><td>0</td><td></td><td>0</td><td>TT</td><td>0</td><td></td><td></td></tr><tr><td>Procainamide</td><td>+</td><td></td><td></td><td>TIT</td><td>()</td><td>L</td><td></td></tr><tr><td>Propafenone</td><td>+</td><td></td><td></td><td>TT</td><td>+</td><td></td><td></td></tr><tr><td>Propranolol</td><td>0</td><td></td><td></td><td>TT</td><td>()</td><td></td><td></td></tr><tr><td>Quinidine</td><td>+</td><td></td><td></td><td>Tt</td><td>0</td><td></td><td></td></tr><tr><td>Sotalol</td><td>0</td><td></td><td>TT</td><td>TMT</td><td>0</td><td></td><td></td></tr><tr><td>Verapamil</td><td>0</td><td></td><td>0</td><td></td><td>H+</td><td></td><td></td></tr><tr><td>Vernakalant'</td><td>+</td><td></td><td>+</td><td>+</td><td>na</td><td>0</td><td></td></tr></table>
======================================
<table><thead><th rowspan="2">Drug</th><th rowspan="2">EffectonSA Nodal Rate</th><th rowspan="2">Effect on AV Nodal Refractory Period</th><th rowspan="2">PR Interval</th><th rowspan="2">QRS Duration</th><th rowspan="2">QT Interval</th><th colspan="3">Usefulness in Arrhythmias</th></thead><thead><th></th><th></th><th></th><th></th><th></th><th></th><th>Supra- ventricular</th><th>Ventricular</th><th>Half-Life</th></thead><tr><td>Adenosine</td><td>i</td><td>tT</td><td>TT</td><td>0</td><td>)</td><td>ttt</td><td>?</td><td>&lt;10s</td></tr><tr><td>Amiodarone</td><td>Ml!</td><td>T</td><td>Variable</td><td></td><td>TT</td><td>Ht</td><td>t4+</td><td>(weeks)</td></tr><tr><td>Diltiazem</td><td>JL</td><td></td><td></td><td>0</td><td>0</td><td>e+</td><td>-</td><td>4-8h</td></tr><tr><td>Disopyramide</td><td>Jie</td><td>i?</td><td>Ll?</td><td></td><td></td><td>+</td><td>++</td><td>7-8h</td></tr><tr><td>Dofetilide</td><td>(?)</td><td>0</td><td>0</td><td>0</td><td></td><td>++</td><td></td><td>7h</td></tr><tr><td>Dronedarone</td><td></td><td></td><td></td><td></td><td></td><td>+H</td><td>-</td><td>24h</td></tr><tr><td>Esmolol</td><td>Lt</td><td>T</td><td>T</td><td>(0)</td><td>(0)</td><td>+</td><td>+</td><td>10 min</td></tr><tr><td>Flecainide</td><td>None,</td><td></td><td></td><td>t</td><td>()</td><td>+</td><td>HHH</td><td>20h</td></tr><tr><td>Ibutilide</td><td>(?)</td><td>0</td><td>0</td><td>0</td><td></td><td>+</td><td>?</td><td>6h</td></tr><tr><td>Lidocaine</td><td>None’</td><td></td><td>0</td><td>0</td><td>0</td><td>None*</td><td>++</td><td>1-2h</td></tr><tr><td>Mexiletine</td><td>None’</td><td></td><td>0</td><td>0</td><td>(0)</td><td></td><td>+H</td><td>8-20h</td></tr><tr><td>Procainamide</td><td>}</td><td>i?</td><td>Ll?</td><td></td><td></td><td>+</td><td>+++</td><td>3-4h</td></tr><tr><td>Propafenone</td><td>0,t</td><td></td><td></td><td>T</td><td>0</td><td>+</td><td>H+</td><td>5-7h</td></tr><tr><td>Propranolol</td><td>d</td><td>T</td><td>+</td><td>0</td><td>0</td><td>+</td><td>+</td><td>5h</td></tr><tr><td>Quinidine</td><td>ee</td><td>a</td><td>i?</td><td></td><td></td><td>+</td><td>+H</td><td>6h</td></tr><tr><td>Sotalol</td><td>4</td><td>tT</td><td>T</td><td>0</td><td>T</td><td>Het</td><td>+++</td><td>7-12h</td></tr><tr><td>Verapamil</td><td>L</td><td>T</td><td>t</td><td>0</td><td>0</td><td>H+</td><td>-</td><td>7h</td></tr><tr><td>Vernakalant</td><td></td><td></td><td></td><td></td><td></td><td>+H</td><td>=</td><td>2h</td></tr></table>
======================================
<table><thead><th>a Subclass, Drug</th><th>| M lechanism _ of Action</th><th>| Effects</th><th>| | Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead></table>
======================================
<table><tr><td colspan="4">LASS 1B</td></tr><tr><td>+ Lidocaine</td><td>Sodium channel (Iy,) blockade</td><td>Blocks activated and inactivated channels with fast kinetics - does not prolong and may shorten action potential</td><td>Terminates tachycardié ventricular cardioversi</td></tr></table>
======================================
<table><thead><th>Subclass, Dr</th><th></th><th></th><th></th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td>CLASS 1€ + Flecainide</td><td>Sodium channel (ly) blockade</td><td>Dissociates from channel with slow kinetics - no change in action potential duration</td><td>Supraventricular arrhythmias | in patients with normal heart | + do not use in ischemic conditions (post-myocardial infarction)</td><td>Oral + hepatic and kidney metabolism half life ~20 h + Toxicity: Proarrhythmic</td></tr></table>
======================================
<table><thead><th>+ Verapamil + Diltiazem: Equivalent</th><th>Calcium channel (Ica type) blockade to verapamil</th><th>Slows SA node automaticity and AV nodal conduction velocity + decreases cardiac contractility - reduces blood pressure</th><th>Supraventricular tachycardias, hypertension, angina</th><th>Oral, IV - hepatic metabolism + caution in patients with hepatic dysfunction + Toxicity &amp; Interactions: See Chapter 12</th></thead><tr><td colspan="5">MISCELLANEOUS</td></tr><tr><td>+ Adenosine</td><td>Activates inward rectifier |x * blocks Ic,</td><td>Very brief, usually complete AV blockade</td><td>Paroxysmal supraventricular tachycardias</td><td>IV only « duration 10-15 s + Toxicity: Flushing, chest tightness, dizziness + Interactions: Minimal</td></tr><tr><td>+ Magnesium</td><td>Poorly understood + interacts with Na*/K’- ATPase, K*, and Ca** channels</td><td>Normalizes or increases plasma Mg™*</td><td>Torsades de pointes - digitalis- induced arrhythmias</td><td>IV - duration dependent on dosage + Toxicity: Muscle weakness in overdose</td></tr><tr><td>+ Potassium</td><td>Increases K* permeability, K* currents</td><td>Slows ectopic pacemakers + slows conduction velocity in heart</td><td>Digitalis-induced arrhythmias + arrhythmias associated with hypokalemia</td><td>Oral, IV - Toxicity: Reentrant arrhythmias, fibrillation or arrest in overdose</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td>Amiodarone</td><td>Generic, Cordarone</td></tr><tr><td>Dofetilide</td><td>Tikosyn</td></tr><tr><td>Dronedarone</td><td>Multaq</td></tr><tr><td>Ibutilide</td><td>Generic, Corvert</td></tr><tr><td>Sotalol</td><td>Generic, Betapace</td></tr><tr><td>Diltiazem</td><td>Generic, Cardizem</td></tr><tr><td>Verapamil</td><td>Generic, Calan, lsoptin</td></tr><tr><td>Adenosine</td><td>Generic, Adenocard</td></tr><tr><td>Magnesium sulfate</td><td>Generic</td></tr><tr><td>lvacaftor (labeled for use in cystic fibrosis)</td><td>Kalydeco</td></tr><tr><td>Crofelemer (labeled for use in diarrhea induced by anti-HIV drugs)</td><td>Fulyzaq</td></tr></table>
======================================
<table><tr><td>Disopyramide</td><td>Generic, Norpace, Norpace CR</td></tr><tr><td>Flecainide</td><td>Generic, Tambocor</td></tr><tr><td>Lidocaine</td><td>Generic, Xylocaine</td></tr><tr><td>Mexiletine</td><td>Generic, Mexitil</td></tr><tr><td>Procainamide</td><td>Generic, Pronestyl, Procan-SR</td></tr><tr><td>Propafenone</td><td>Generic, Rythmol</td></tr><tr><td>Quinidine sulfate (83% quinidine base)</td><td>Generic</td></tr><tr><td>Quinidine gluconate (62% quinidine base)</td><td>Generic</td></tr><tr><td>Quinidine polygalacturonate (60% quinidine base)</td><td>Cardioquin</td></tr><tr><td>Acebutolol</td><td>Generic, Sectral</td></tr><tr><td>Esmolol</td><td>Generic, Brevibloc</td></tr><tr><td>Propranolol</td><td>Generic, Inderal</td></tr></table>
======================================
<table><thead><th>Segment</th><th>Functions</th><th></th><th>Primary Transporters and Drug Targets at Apical Membrane</th><th>Diuretic with Major Action</th></thead><tr><td>Glomerulus</td><td>Formation of glomerular filtrate</td><td>Extremely high</td><td></td><td></td></tr><tr><td>Proximal convoluted tubule (PCT)</td><td>Reabsorption of 65% of filtered Na‘/K*/ CA**, and Mg”*; 85% of NaHCO,, and nearly 100% of glucose and amino acids. Isosmotic reabsorption of water.</td><td>Very high</td><td>Na/H' (NHE3), carbonic anhydrase; Na/glucose cotransporter 2 (SGLT2)</td><td>Carbonic anhydrase inhibi-tors, Adenosine antagonists (under investigation)</td></tr><tr><td>Proximal tubule, straight segments</td><td>Secretion and reabsorption of organic acids and bases, including uric acid and most diuretics</td><td>Very high</td><td>Acid (eg, uric acid) and base transporters</td><td></td></tr><tr><td>Thin descending limb of Henle’s loop</td><td>Passive reabsorption of water</td><td>High</td><td>Aquaporins</td><td></td></tr><tr><td>Thick ascending limb of Henle’s loop (TAL)</td><td>Active reabsorption of 15-25% of filtered Na‘/K*/CI’; secondary reabsorption of CA** and Mg**</td><td>Very low</td><td>Na/K/2CI (NKCC2)</td><td>Loop diuretics</td></tr><tr><td>Distal convoluted tubule (DCT)</td><td>Active reabsorption of 4-8% of filtered Na* and Cl’; CA** reabsorption under parathy-roid hormone control</td><td>Very low</td><td>Na/Cl (NCC)</td><td>Thiazides</td></tr><tr><td>Cortical collecting tubule (CCT)</td><td>Na’ reabsorption (2-5%) coupled to K* and H' secretion</td><td>Variable?</td><td>Na channels (ENaC), K channels,’ H* trans- porter,’ aquaporins</td><td>K*-sparing diuretics Adenosine antagonists (under investigation)</td></tr><tr><td>Medullary collecting duct</td><td>Water reabsorption under vasopressin control</td><td>Variable?</td><td>Aquaporins</td><td>Vasopressin antagonists</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Usual Oral Dosage</th></thead><tr><td>Dichlorphenamide</td><td>50 mg 1-3 times daily</td></tr><tr><td>Methazolamide</td><td>50-100 mg 2-3 times daily</td></tr></table>
======================================
<table><thead><th rowspan="2">Group</th><th colspan="3">Urinary Electrolytes</th><th rowspan="2">Body pH</th></thead><thead><th></th><th>Nacl</th><th>NaHCO,</th><th>Kt</th><th></th></thead><tr><td>Carbonic anhydrase inhibitors</td><td></td><td>+++</td><td>+</td><td></td></tr><tr><td>Loop agents</td><td></td><td></td><td></td><td></td></tr><tr><td>Thiazides</td><td></td><td></td><td></td><td></td></tr><tr><td>Loop agents plus thiazides</td><td></td><td></td><td>++</td><td></td></tr><tr><td>K*-sparing agents</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Drug</th><th>Total Daily Oral Dose’</th></thead><tr><td>Bumetanide</td><td>0.5-2 mg</td></tr><tr><td>Ethacrynic acid</td><td>50-200 mg</td></tr><tr><td>Furosemide</td><td>20-80 mg</td></tr><tr><td>Torsemide</td><td>5-20 mg</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Equivalent Dose’</th></thead><tr><td>Furosemide</td><td>20mg</td></tr><tr><td>Torsemide</td><td>10mg</td></tr><tr><td>Bumetanide</td><td>0.5 mg</td></tr><tr><td>Ethacrynic acid</td><td>~50 mg</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Total Daily Oral Dose</th><th>Frequency of Daily Administration</th></thead><tr><td>Bendroflumethiazide</td><td>2.5-10 mg</td><td>Single dose</td></tr><tr><td>Chlorothiazide</td><td>0.5-2g</td><td>Two divided doses</td></tr><tr><td>Chlorthalidone'</td><td>25-50 mg</td><td>Single dose</td></tr><tr><td>Hydrochlorothiazide</td><td>25-100 mg</td><td>Single dose</td></tr><tr><td>Hydroflumethiazide</td><td>12.5-50 mg</td><td>Two divided doses</td></tr><tr><td>Indapamide'</td><td>2.5-10 mg</td><td>Single dose</td></tr><tr><td>Methyclothiazide</td><td>2.5-10 mg</td><td>Single dose</td></tr><tr><td>Metolazone'</td><td>2.5-10 mg</td><td>Single dose</td></tr><tr><td>Polythiazide</td><td>1-4 mg</td><td>Single dose</td></tr><tr><td>Quinethazone'</td><td>25-100 mg</td><td>Single dose</td></tr><tr><td>Trichlormethiazide</td><td>1-4 mg</td><td>Single dose</td></tr></table>
======================================
<table><thead><th>Trade Name</th><th>Potassium-Sparing Agent</th><th>Hydrochlorothiazide</th></thead><tr><td>Aldactazide</td><td>Spironolactone 25 mg</td><td>50 mg</td></tr><tr><td>Aldactone</td><td>Spironolactone 25, 50, or 100 mg</td><td></td></tr><tr><td>Dyazide</td><td>Triamterene 37.5 mg</td><td>25mg</td></tr><tr><td>Dyrenium</td><td>Triamterene 50 or 100 mg</td><td></td></tr><tr><td>Inspra’</td><td>Eplerenone 25, 50, or 100 mg</td><td></td></tr><tr><td>Maxzide</td><td>Triamterene 75 mg</td><td></td></tr><tr><td>Maxzide-25 mg</td><td>Triamterene 37.5 mg</td><td></td></tr><tr><td>Midamor</td><td>Amiloride 5 mg</td><td></td></tr><tr><td>Moduretic</td><td>Amiloride 5 mg</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th></th></thead><tr><td colspan="5">CARBONIC ANHYDRASE INHIBITORS</td></tr><tr><td>+ Acetazolamide, others Brinzolamide,</td><td>Inhibition of the enzyme prevents dehydration of H,CO; and hydration of CO, in the proximal convoluted tubule dorzolamide: Topical for glaucoma</td><td>Reduce reabsorption of HCO;, causing self-limited diuresis + hyperchloremic metabolic acidosis + reduce body pH, + reduce intraocular pressure</td><td>Glaucoma, mountain sickness, edema with alkalosis</td><td>Oral and topical preparations available - duration of action ~8-12 h + Toxicity: Metabolic acidosis, renal stones, hyperammonemia in cirrhotics</td></tr><tr><td>SGLT2 INHIBITORS + Canagliflozin</td><td>Inhibition of sodium/glucose cotransporter (SGLT2) in the PCT results in decreased Na* and glucose reabsorption</td><td>Inhibition of glucose reabsorption lowers serum glucose concentration, and reduced Na’ reabsorption causes mild diuresis</td><td>Diabetes mellitus; approved for the treatment of hyperglycemia, not as a diuretic</td><td>Available orally. Half-life 10-12 h + not recommended in severe renal or liver disease</td></tr></table>
======================================
<table><thead><th>Subclass, Dr</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, ies, Interactions</th></thead><tr><td>LOOP DIURETICS + Furosemide</td><td>Inhibition of the Na/K/2Cl transporter in the ascending limb of Henle’s loop</td><td>Marked increase in NaCl excretion, some K | wasting, hypokalemic metabolic alkalosis, increased urine Ca and Mg</td><td>Pulmonary edema, peripheral edema, heart failure, hypertension, acute hypercalcemia, anion overdose</td><td>Oral and parenteral preparations + duration of action 2-4 h « Toxicity: Ototoxicity, hypovolemia, K wasting, hyperuricemia, hypomagnesemia</td></tr></table>
======================================
<table><tr><td>+ Spironolactone</td><td>Pharmacologic antagonist of aldosterone in collecting tubules - weak antagonism of androgen receptors</td><td>Reduces Na retention and K wasting in kidney + poorly understood antagonism of aldosterone in heart and vessels</td><td>Aldosteronism from any cause + hypokalemia due to other diuretics + postmyocardial infarction</td><td>Slow onset and offset of effect » duration 24-48 h + Toxicity: Hyperkalemia, gynecomastia (spironolactone, not eplerenone) « additive interaction with other K-retaining drugs</td></tr><tr><td>+ Amiloride</td><td>Blocks epithelial sodium channels in collecting tubules</td><td>Reduces Na retention and K wasting + increases lithium clearance</td><td>Hypokalemia from other diuretics + reduces lithium- induced polyuria + Liddle’s syndrome</td><td>Orally active + duration 24 h + Toxicity: Hyperkalemic metabolic acidosis</td></tr><tr><td colspan="5">+ Eplerenone: Like spironolactone, more selective for aldosterone receptor + Triamterene: Mechanism like amiloride, much less potent, m jore toxic</td></tr><tr><td>OSMOTIC DIURETICS + Mannitol</td><td>Physical osmotic effect on tissue water distribution because it is retained in the vascular compartment</td><td>Marked increase in urine flow, reduced brain volume, decreased intraocular pressure, initial hyponatremia, then hypernatremia</td><td>Renal failure due to increased solute load (rhabdomyolysis, chemotherapy), increased intracranial pressure, glaucoma</td><td>IV administration + Toxicity: Nausea, vomiting, headache</td></tr><tr><td colspan="5">VASOPRESSIN (ADH) ANTAGONISTS</td></tr><tr><td>+ Conivaptan</td><td>Antagonist at V,, and V, ADH receptors</td><td>Reduces water reabsorption, increases plasma Na concentration, vasodilation</td><td>Hyponatremia, congestive heart failure</td><td>IV only, usually continuous + Toxicity: Infusion site reactions, thirst, polyuria, hypernatremia</td></tr><tr><td>+ Tolvaptan</td><td>Selective antagonist at V, ADH receptors</td><td>Reduces water reabsorption, increases plasma Na concentration</td><td>Hyponatremia, SIADH</td><td>Oral + duration 12-24 h + Toxicity: Polyuria (frequency),</td></tr></table>
======================================
<table><tr><td>+ Spironolactone</td><td>Pharmacologic antagonist of aldosterone in collecting tubules - weak antagonism of androgen receptors</td><td>Reduces Na retention and K wasting in kidney + poorly understood antagonism of aldosterone in heart and vessels</td><td>Aldosteronism from any cause + hypokalemia due to other diuretics + postmyocardial infarction</td><td>Slow onset and offset of effect » duration 24-48 h + Toxicity: Hyperkalemia, gynecomastia (spironolactone, not eplerenone) « additive interaction with other K-retaining drugs</td></tr><tr><td>+ Amiloride</td><td>Blocks epithelial sodium channels in collecting tubules</td><td>Reduces Na retention and K wasting + increases lithium clearance</td><td>Hypokalemia from other diuretics + reduces lithium- induced polyuria + Liddle’s syndrome</td><td>Orally active + duration 24 h + Toxicity: Hyperkalemic metabolic acidosis</td></tr><tr><td colspan="5">+ Eplerenone: Like spironolactone, more selective for aldosterone receptor + Triamterene: Mechanism like amiloride, much less potent, m jore toxic</td></tr><tr><td>OSMOTIC DIURETICS + Mannitol</td><td>Physical osmotic effect on tissue water distribution because it is retained in the vascular compartment</td><td>Marked increase in urine flow, reduced brain volume, decreased intraocular pressure, initial hyponatremia, then hypernatremia</td><td>Renal failure due to increased solute load (rhabdomyolysis, chemotherapy), increased intracranial pressure, glaucoma</td><td>IV administration + Toxicity: Nausea, vomiting, headache</td></tr><tr><td colspan="5">VASOPRESSIN (ADH) ANTAGONISTS</td></tr><tr><td>+ Conivaptan</td><td>Antagonist at V,, and V, ADH receptors</td><td>Reduces water reabsorption, increases plasma Na concentration, vasodilation</td><td>Hyponatremia, congestive heart failure</td><td>IV only, usually continuous + Toxicity: Infusion site reactions, thirst, polyuria, hypernatremia</td></tr><tr><td>+ Tolvaptan</td><td>Selective antagonist at V, ADH receptors</td><td>Reduces water reabsorption, increases plasma Na concentration</td><td>Hyponatremia, SIADH</td><td>Oral + duration 12-24 h + Toxicity: Polyuria (frequency),</td></tr></table>
======================================
<table><tr><td>Hydrochlorothiazide</td><td>Generic, Esidrix, Hydro-DIURIL, combination drugs”</td></tr><tr><td>Hydroflumethiazide</td><td>Generic, Saluron</td></tr><tr><td>Indapamide</td><td>Generic, Lozol</td></tr><tr><td>Mannitol</td><td>Generic, Osmitrol</td></tr><tr><td>Methazolamide (for ocular conditions)</td><td>Generic, Neptazane</td></tr><tr><td>Methyclothiazide</td><td>Generic, Aquatensen, Enduron</td></tr><tr><td>Metolazone</td><td>Generic, Mykrox, Zaroxolyn (Note: Bioavailability of Mykrox is greater than that of Zaroxolyn)</td></tr><tr><td>Nesiritide</td><td>Natrecor</td></tr><tr><td>Polythiazide</td><td>Renese, combination drugs”</td></tr><tr><td>Quinethazone</td><td>Hydromox</td></tr><tr><td>Spironolactone</td><td>Generic, Aldactone, combination drugs”</td></tr><tr><td>Tolvaptan</td><td>Samsca</td></tr><tr><td>Torsemide</td><td>Generic, Demadex</td></tr><tr><td>Triamterene</td><td>Dyrenium</td></tr><tr><td>Trichlormethiazide</td><td>Generic, Diurese, Naqua, others</td></tr></table>
======================================
<table><tr><td>Acetazolamide</td><td>Generic, Diamox</td></tr><tr><td>Amiloride</td><td>Generic, Midamor, combination drugs”</td></tr><tr><td>Bendroflumethiazide</td><td>Naturetin, combination drugs”</td></tr><tr><td>Brinzolamide (for ocular conditions)</td><td>Azopt</td></tr><tr><td>Bumetanide</td><td>Generic, Bumex</td></tr><tr><td>Canagliflozin</td><td>Invokana</td></tr><tr><td>Dapagliflozin</td><td>Farxiga</td></tr><tr><td>Chlorothiazide</td><td>Generic, Diuril</td></tr><tr><td>Chlorthalidone</td><td>Generic, Hygroton, Thalitone, combination drugs”</td></tr><tr><td>Conivaptan</td><td>Vaprisol</td></tr><tr><td>Demeclocycline</td><td>Generic, Declomycin</td></tr><tr><td>Dichlorphenamide</td><td>Diclofenamide</td></tr><tr><td>Dorzolamide (for ocular conditions)</td><td>Generic, Trusopt</td></tr><tr><td>Eplerenone</td><td>Inspra</td></tr><tr><td>Ethacrynic acid</td><td>Edecrin</td></tr><tr><td>Furosemide</td><td>Generic, Lasix, others</td></tr></table>
======================================
<table><thead><th>Receptor Subtype</th><th>Distribution</th><th>Postreceptor Mechanism</th><th>Partially Selective Agonists</th><th>Partially Selective Antagonists or Inverse Agonists</th></thead><tr><td>Hy</td><td>Smooth muscle, endothelium, brain</td><td>G,, TIP; DAG</td><td>Histaprodifen</td><td>Mepyramine,' triprolidine, cetirizine</td></tr><tr><td>H,</td><td>Gastric mucosa, cardiac muscle, mast cells, brain</td><td>G,, cAMP</td><td>Amthamine</td><td>Cimetidine,’ ranitidine, ' tiotidine</td></tr><tr><td>Hs</td><td>Presynaptic autoreceptors and heteroreceptors: brain, myenteric plexus, other neurons</td><td>G, | cAMP</td><td>R-a-Methylhistamine, imetit, immepip</td><td>Thioperamide,’ iodophenpropit, clobenpropit,' tiprolisant,' proxyfan</td></tr><tr><td>Ha</td><td>Eosinophils, neutrophils, CD4 T cells</td><td>G, | cAMP</td><td>Clobenpropit, imetit, clozapine</td><td>Thioperamide'</td></tr></table>
======================================
<table><thead><th>Drugs</th><th>Usual Adult Dose</th><th>Anticholinergic Activity |</th><th>Comments</th></thead><tr><td colspan="4">FIRST-GENERATION ANTIHISTAMINES</td></tr><tr><td colspan="4">Ethanolamines</td></tr><tr><td>Carbinoxamine (Clistin)</td><td>4-8 mg</td><td>+++</td><td>Slight to moderate sedation</td></tr><tr><td>Dimenhydrinate (salt of diphenhydramine) (Dramamine)</td><td>50 mg</td><td>+4+</td><td>Marked sedation; anti-motion sickness activity</td></tr><tr><td>Diphenhydramine (Benadryl, etc)</td><td>25-50 mg</td><td>+4+</td><td>Marked sedation; anti-motion sickness activity</td></tr><tr><td colspan="4">Piperazine derivatives</td></tr><tr><td>Hydroxyzine (Atarax, etc)</td><td>15-100 mg</td><td>nd</td><td>Marked sedation</td></tr><tr><td>Cyclizine (Marezine)</td><td>25-50 mg</td><td>_—</td><td>Slight sedation; anti-motion sickness activity</td></tr><tr><td>Meclizine (Bonine, etc)</td><td>25-50 mg</td><td>—</td><td>Slight sedation; anti-motion sickness activity</td></tr><tr><td colspan="4">Alkylamines</td></tr><tr><td>Brompheniramine (Dimetane, etc)</td><td>4-8 mg</td><td>+</td><td>Slight sedation</td></tr><tr><td>Chlorpheniramine (Chlor-Trimeton, etc)</td><td>| 4-8 mg</td><td>+</td><td>Slight sedation; common component of OTC “cold” medication</td></tr><tr><td colspan="4">Phenothiazine derivative</td></tr><tr><td>Promethazine (Phenergan, etc)</td><td>10-25 mg</td><td>+44</td><td>Marked sedation; antiemetic; o-block</td></tr><tr><td colspan="4">Miscellaneous</td></tr><tr><td>Cyproheptadine (Periactin, etc)</td><td>4mg</td><td>+</td><td>Moderate sedation; significant antiserotonin activity;</td></tr></table>
======================================
<table><thead><th>Fexofenadine (Allegra, etc)</th><th>60 mg</th><th></th></thead><tr><td colspan="3">Miscellaneous</td></tr><tr><td>Loratadine (Claritin, etc), desloratadine (Clarinex)</td><td>10 mg (desloratadine, 5 mg)</td><td>Longer action; used at 5 mg dosage</td></tr><tr><td>Cetirizine (Zyrtec, etc)</td><td>5-10 mg</td><td></td></tr></table>
======================================
<table><thead><th>Receptor Subtype</th><th>Distribution</th><th>Postreceptor Mechanism</th><th>Partially Selective Agonists</th><th>Partially Selective Antagonists</th></thead><tr><td>S-HTy,</td><td>Raphe nuclei, hippocampus</td><td>G, J cAMP</td><td>8-OH-DPAT,' repinotan</td><td>WAY 1006351</td></tr><tr><td>5-HTig</td><td>Substantia nigra, globus pallidus, basal ganglia</td><td>G, J cAMP</td><td>Sumatriptan, L694247'</td><td></td></tr><tr><td>5-HTip</td><td>Brain</td><td>G, J cAMP</td><td>Sumatriptan, eletriptan</td><td></td></tr><tr><td>5S-HTi¢</td><td>Cortex, putamen</td><td>G, J cAMP</td><td></td><td></td></tr><tr><td>5-HTip</td><td>Cortex, hippocampus</td><td>G, | cAMP</td><td>Ly3344864'</td><td></td></tr><tr><td>5-HTip</td><td>Enteric nervous system</td><td>G,, slow EPSP</td><td>5-Hydroxyindalpine</td><td>Renzapride</td></tr><tr><td>S-HT 54</td><td>Platelets, smooth muscle, cerebral cortex</td><td>G,, TIP</td><td>a-Methyl-5-HT, DOI"</td><td>Ketanserin</td></tr><tr><td>5-HT5 5</td><td>Stomach fundus</td><td>G,, T IP3</td><td>a-Methyl-5-HT, DOI"</td><td>RS127445'</td></tr><tr><td>5-HT3¢</td><td>Choroid, hippocampus, substantia nigra</td><td>iq, | IP</td><td>a-Methyl-5-HT, DOI," lorcaserin</td><td>Mesulergine</td></tr><tr><td>5-HT;,</td><td>Area postrema, sensory and enteric nerves</td><td>Receptor is an Na‘/ K* ion channel</td><td>2-MethyI-5-HT, m-chlorophenylbiguanide</td><td>Granisetron, ondansetron, others</td></tr><tr><td>5-HT,</td><td>CNS and myenteric neurons, smooth muscle</td><td>G, T cAMP</td><td>BIMUs,' renzapride, metoclopramide</td><td>GR113808'</td></tr><tr><td>S-HTsa5</td><td>Brain</td><td>J cAMP</td><td></td><td></td></tr><tr><td>5-HT,¢7</td><td>Brain</td><td>cAMP Is.</td><td></td><td>Clozapine (5-HT,)</td></tr></table>
======================================
<table><thead><th>Syndrome</th><th>Precipitating Drugs</th><th>‘al Presentation</th><th>Therapy’</th></thead><tr><td>Serotonin syndrome</td><td>SSRIs, second-generation antidepressants, MAOIs, linezolid, tramadol, meperidine, fentanyl, ondansetron, sumatriptan, MDMA, LSD, St. John’s wort, ginseng</td><td>Hypertension, hyperreflexia, tremor, clonus, hyperthermia, hyperactive bowel sounds, diarrhea, mydriasis, agitation, coma; onset within hours</td><td>Sedation (benzodiazepines), paralysis, intubation, and ventilation; consider 5-HT, block with cyproheptadine or chlorpromazine</td></tr><tr><td>Neuroleptic malignant syndrome</td><td>D,-blocking antipsychotics</td><td>Acute severe parkinsonism; hypertension, hyperthermia, normal or reduced bowel sounds; onset over 1-3 days</td><td>Diphenhydramine (parenteral), cooling if temperature is very high, sedation with benzodiazepines</td></tr><tr><td>Malignant hyperthermia</td><td>Volatile anesthetics, succinylcholine</td><td>Hyperthermia, muscle rigidity, hyperten- sion, tachycardia; onset within minutes</td><td>Dantrolene, cooling</td></tr></table>
======================================
<table><thead><th>Drug or Drug Combination</th><th>Drug Group</th><th>Possible Mechanism of Action</th><th></th><th>To: ity</th></thead><tr><td>Orlistat</td><td>Gl lipase inhibitor</td><td>Reduces lipid absorption</td><td>60-120 mg TID PO</td><td>Decreased absorption of fat-soluble vitamins, flatulence, fecal incontinence</td></tr><tr><td>Liraglutide</td><td>GLP-1 agonist</td><td>Decreases appetite</td><td>3 mg/d SC</td><td>Nausea, vomiting, pancreatitis</td></tr><tr><td>Lorcaserin</td><td>5-HT&gt;, agonist</td><td>Decreases appetite</td><td>10 mg PO BID</td><td>Headache, nausea, dry mouth, dizziness, constipation</td></tr><tr><td>Naltrexone/ bupropion</td><td>Opioid antagonist + antidepressant</td><td>Unknown</td><td>32 mg/ 360 mg POTID</td><td>Headache, nausea, dizziness, constipation</td></tr><tr><td>Phentermine</td><td>Sympathomimetic</td><td>Norepinephrine release in CNS</td><td>30-37.5 mg/d PO</td><td>Increased BP, HR; arrhythmias, insomnia, anxiety</td></tr><tr><td>Phentermine/ topiramate</td><td>Sympathomimetic + antiseizure agent</td><td>Norepinephrine release plus unknown mechanism</td><td>3.75-15 mg/ 23-92 mg PO</td><td>Insomnia, dizziness, nausea, paresthesia, dysgeusia</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Routes</th><th>Time to Onset (h)</th><th>Single Dose (mg)</th><th>Maximum Dose per Day (mg)</th><th>Half-Life (h)</th></thead><tr><td>Almotriptan</td><td>Oral</td><td>2.6</td><td>6.25-12.5</td><td>25</td><td>3.3</td></tr><tr><td>Eletriptan</td><td>Oral</td><td>2</td><td>20-40</td><td></td><td></td></tr><tr><td>Frovatriptan</td><td>Oral</td><td>3</td><td>25</td><td></td><td></td></tr><tr><td>Naratriptan</td><td>Oral</td><td>2</td><td>1-2.5</td><td></td><td></td></tr><tr><td>Rizatriptan</td><td>Oral</td><td>1-2.5</td><td>5-10</td><td></td><td></td></tr><tr><td>Sumatriptan</td><td>Oral, nasal, subcutaneous, rectal</td><td>1.5 (0.2 for subcutaneous)</td><td>25-100 (PO), 20 nasal, 6 subcutaneous, 25 rectal</td><td></td><td></td></tr><tr><td>Zolmitriptan</td><td>Oral, nasal</td><td>15-33</td><td>2S-5</td><td></td><td>2.8</td></tr></table>
======================================
<table><thead><th>Ergot Alkaloid</th><th>a Adrenoceptor</th><th>Dopamine Receptor</th><th>Serotonin Receptor (5-HT,)</th><th>Uterine Smooth Muscle Stimulation</th></thead><tr><td>Bromocriptine</td><td></td><td></td><td></td><td>0</td></tr><tr><td>Ergonovine</td><td></td><td></td><td>+++</td><td>++</td></tr><tr><td>Ergotamine</td><td></td><td></td><td>+(PA)</td><td></td></tr><tr><td>Lysergic acid diethylamide (LSD)</td><td></td><td></td><td>=~ (++ in CNS)</td><td></td></tr><tr><td>Methysergide</td><td></td><td></td><td>—-~ (PA)</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th></th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">H, ANTIHISTAMINES First generation: + Diphenhydramine Competitive Reduces or prevents histamine IgE immediate Oral and parenteral + duration 4-6 h + Toxicity:</td></tr><tr><td colspan="5">Second generation:</td></tr><tr><td>+ Cetirizine</td><td>Competitive antagonism/inverse agonism at H, receptors</td><td>Reduces or prevents histamine effects on smooth muscle, immune cells</td><td>IgE immediate allergies; especially hay fever, urticaria</td><td>Oral - duration 12-24 h + Toxicity: Sedation and arrhythmias in overdose + Interactions: Minimal</td></tr></table>
======================================
<table><tr><td>+ Cimetidine, others</td><td>(see Chapter 62)</td><td></td><td></td><td></td></tr><tr><td>EROTONIN AGONISTS</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">“HT gp</td></tr><tr><td>+ Sumatriptan</td><td>Partial agonist at 5-HTj51p receptors</td><td>Effects not fully understood + may reduce release of calcitonin gene-related peptide and perivascular edema in cerebral circulation</td><td>Migraine and cluster headache</td><td>| Oral, nasal, parenteral « duration 2 h - Toxicity: Paresthesias, dizziness, coronary vasoconstriction + Interactions: Additive with other vasoconstrictors</td></tr></table>
======================================
<table><thead><th>Lorcaserin</th><th>Agonist at 5-HToc</th><th>Appears to reduce appetite</th><th>Obesity</th><th>Oral - duration 11 h - Toxicity: Dizziness,</th></thead><tr><td></td><td>receptors</td><td></td><td></td><td>headache, constipation</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Applications</th><th>Pharmacokinetics, Toxi Interactions</th></thead><tr><td colspan="5">SEROTONIN BLOCKERS</td></tr><tr><td colspan="5">5-HT,:</td></tr><tr><td>+ Ketanserin (not available in USA)</td><td>Competitive blockade at 5-HT, receptors</td><td>Prevents vasoconstriction and bronchospasm of carcinoid syndrome</td><td>Hypertension «carcinoid syndrome associated with carcinoid tumor</td><td>Oral - duration 12-24 h + Toxicity: Hypotension</td></tr><tr><td colspan="5">5-HT;:</td></tr><tr><td colspan="5">+ Ondansetron, others (see Chapter 62)</td></tr><tr><td colspan="5">ERGOT ALKALOIDS</td></tr><tr><td colspan="5">Vasoselective:</td></tr><tr><td>+ Ergotamine</td><td>Mixed partial agonist effects at 5-HT, and a adrenoceptors</td><td>Causes marked smooth muscle contraction but blocks a-agonist vasoconstriction</td><td>Migraine and cluster headache</td><td>Oral, parenteral - duration 12-24 h + Toxicity: Prolonged vasospasm causing angina, gangrene; uterine spasm</td></tr><tr><td colspan="5">Uteroselective:</td></tr><tr><td>+ Ergonovine</td><td>Mixed partial agonist effects at 5-HT, and a adrenoceptors</td><td>Same as ergotamine + some selectivity for uterine smooth muscle</td><td>Postpartum bleeding + migraine headache</td><td>Oral, parenteral (methylergonovine) + duration 2-4 h « Toxicity: Same as ergotamine</td></tr><tr><td>diethylamide</td><td>Central nervous system 5-HT, and dopamine agonist + 5-HT, antagonist in periphery</td><td>Hallucinations + psychotomimetic</td><td>- widely abused</td><td>Oral - duration several hours + Toxicity: Prolonged psychotic state, flashbacks</td></tr></table>
======================================
<table><tr><td>Fexofenadine</td><td>Generic, Allegra</td></tr><tr><td>Hydroxyzine</td><td>Generic, Vistaril</td></tr><tr><td>Ketotifen</td><td>Generic, Zaditor</td></tr><tr><td>Levocabastine</td><td>Livostin</td></tr><tr><td>Levocetirizine</td><td>Generic, Xyzal</td></tr><tr><td>Loratadine</td><td>Generic, Claritin</td></tr><tr><td>Meclizine</td><td>Generic, Antivert, Bonine</td></tr><tr><td>Olopatadine</td><td>Patanol, Pataday</td></tr><tr><td>Phenindamine</td><td>Nolahist</td></tr><tr><td>Promethazine</td><td>Generic, Phenergan</td></tr><tr><td>Triprolidine</td><td>Generic, Zymine, Tripohist</td></tr><tr><td colspan="2">See Chapter 62.</td></tr><tr><td>Almotriptan</td><td>Axert</td></tr><tr><td>Eletriptan</td><td>Relpax</td></tr></table>
======================================
<table><tr><td colspan="2">ANTIHISTAMINES (H, BLOCKERS)</td></tr><tr><td>Azelastine</td><td>Generic, Astelin (nasal), Optivar (ophthalmic)</td></tr><tr><td>Brompheniramine</td><td>Brovex, Dimetapp, others</td></tr><tr><td>Buclizine</td><td>Bucladin-S Softabs</td></tr><tr><td>Carbinoxamine</td><td>Generic, Histex</td></tr><tr><td>Cetirizine</td><td>Generic, Zyrtec</td></tr><tr><td>Chlorpheniramine</td><td>Generic, Chlor-Trimeton</td></tr><tr><td>Clemastine</td><td>Generic, Tavist</td></tr><tr><td>Cyclizine</td><td>Generic, Marezine</td></tr><tr><td>Cyproheptadine</td><td>Generic, Periactin</td></tr><tr><td>Desloratadine</td><td>Generic, Clarinex</td></tr><tr><td>Dimenhydrinate*</td><td>Generic, Dramamine</td></tr><tr><td>Diphenhydramine</td><td>Generic, Benadryl</td></tr><tr><td>Doxylamine</td><td>Diclegis (combination with pyridoxine), Unisom Sleep Tabs</td></tr><tr><td>Epinastine</td><td>Generic, Elestat</td></tr></table>
======================================
<table><tr><td>Ergonovine</td><td>Generic, Ergotrate</td></tr><tr><td>Ergotamine mixtures (include caffeine)</td><td>Generic, Cafergot</td></tr><tr><td>Ergotamine tartra</td><td>Generic, Ergomar</td></tr><tr><td>Methylergonovine</td><td>Generic, Methergine</td></tr><tr><td>Liraglutide</td><td>Saxenda, Victoza</td></tr><tr><td>Lorcaserin</td><td>Belviq</td></tr><tr><td>Naltrexone/bupropion</td><td>Contrave</td></tr><tr><td>Orlistat</td><td>Alli, Xenical</td></tr><tr><td>Phentermine</td><td>Generic, Adipex-P, Lomaira</td></tr><tr><td>Phentermine/topiramate</td><td>Qsymia</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th></thead><tr><td colspan="4">ANGIOTENSIN RECEPTOR ANTAGONISTS</td></tr><tr><td>+ Valsartan</td><td>Selective competitive antagonist of angiotensin AT, receptors</td><td>Arteriolar dilation - decreased aldosterone secretion + increased sodium and water excretion</td><td>Hypertension</td></tr><tr><td colspan="4">+ Eprosartan, irbesartan, candesartan, olmesartan, telmisartan: Similar to valsartan</td></tr><tr><td colspan="4">ANGIOTENSIN RECEPTOR AGONISTS</td></tr><tr><td>+ Compound 21</td><td>AT, receptor agonist</td><td>Beneficial cardiovascular effects</td><td>Potential for treatment of cardiovascular disease</td></tr><tr><td colspan="4">CONVERTING ENZYME INH IBITORS</td></tr><tr><td>+ Enalapril</td><td>Inhibits conversion of angiotensin | to angiotensin II</td><td>Arteriolar dilation - decreased aldosterone secretion + increased sodium and water excretion</td><td>Hypertension + heart failure</td></tr><tr><td colspan="4">+ Captopril and many others: Similar to enalapril</td></tr><tr><td colspan="4">RENIN INHIBITOR</td></tr><tr><td>+ Aliskiren</td><td>Inhibits catalytic activity of renin</td><td>Arteriolar dilation - decreased aldosterone secretion + increased sodium and water excretion</td><td>Hypertension</td></tr></table>
======================================
<table><thead><th colspan="4">VASOPRESSIN ANTAGONISTS</th><th rowspan="3">Vasodilation</th><th rowspan="3">Potential use in hypertension and heart failure + hyponatremia</th></thead><thead><th>+ Conivaptan</th><th>Antagonist of vasopressin V, and V, receptors</th><th></th><th></th></thead><thead><th colspan="4">+ Relcovaptan, SRX251: Increased selectivity for V; receptor + Tolvaptan: Increased selectivity for V, receptor</th><th></th><th></th></thead><tr><td colspan="4">NATRIURETIC PEPTIDES</td></tr><tr><td>+ Nesiritide, Carperitide</td><td>Agonists of natriuretic peptide receptors</td><td>Increased sodium and water excretion + vasodilation</td><td>Heart failure</td></tr><tr><td colspan="4">+ Ularitide: Synthetic form of urodilatin</td></tr><tr><td colspan="4">COMBINED ANGIOTENSIN-CONVERTING ENZYME/NEPRILYSIN INHIBITORS (VASOPEPTIDASE INHIBITORS)</td></tr><tr><td>+ Omapatrilat</td><td>Decreases metabolism of natriuretic peptides and formation of angiotensin II</td><td>Vasodilation « increased sodium and water excretion</td><td>Hypertension + heart failure’</td></tr><tr><td colspan="4">+ Sampatrilat, fasidotrilat: Similar to omapatrilat</td></tr><tr><td>COMBINED ANGIOTENSIN</td><td>RECEPTOR ANTAGONIST/NEPRILYSIN INHIBITORS</td><td>(ARNI)</td><td></td></tr><tr><td>+ LCX696 (sacubitril/ valsartan)</td><td>Decreases breakdown of natriuretic peptides and blocks angiotensin II receptors</td><td>Vasodilation + increased sodium and water excretion</td><td>Heart failure + hypertension’</td></tr><tr><td colspan="4">ENDOTHELIN ANTAGONISTS</td><td rowspan="3">Pulmonary arterial hypertension</td></tr><tr><td>+ Bosentan, macitentan</td><td>Nonselective antagonists of endothelin ET, and ET, receptors</td><td>Vasodilation</td><td></td></tr><tr><td>+ Sitaxsentan, ambrisentan:</td><td>Selective antagonists for ET, receptors</td><td></td><td></td></tr><tr><td>COMBINED ENDOTHELIN-CONVERTING</td><td>ENZYME/NEPRILYSIN INHIBITORS</td><td></td><td></td></tr><tr><td>+ SLV306, daglutril</td><td>Blocks formation of endothelins and breakdown of natriuretic peptides</td><td>Vasodilation + increased sodium and water excretion</td><td>Heart failure + hypertension’</td></tr><tr><td>VASOACTIVE INTESTINAL + PB1046, Vasomera</td><td>PEPTIDE AGONISTS Selective agonist of VPAC2 receptors</td><td>Vasodilation « multiple metabolic, endocrine, and other effects</td><td>Hypertension’</td></tr><tr><td colspan="4">SUBSTANCE P ANTAGONISTS</td></tr><tr><td>+ Aprepitant</td><td>Selective antagonist of tachykinin NK, receptors</td><td>Blocks several central nervous system effects of substance P</td><td>Prevention of chemotherapy- induced nausea and vomiting</td></tr><tr><td colspan="4">+ Fosaprepitant: Prodrug that is converted to aprepitant</td></tr><tr><td colspan="4">NEUROTENSIN AGONISTS</td></tr><tr><td>+ PD149163, NT69L, NT79</td><td>Agonists of central neurotensin receptors</td><td>Interact with central dopamine systems</td><td>Potential for treatment of schizophrenia and Parkinson's disease</td></tr></table>
======================================
<table><thead><th colspan="4">VASOPRESSIN ANTAGONISTS</th><th rowspan="3">Vasodilation</th><th rowspan="3">Potential use in hypertension and heart failure + hyponatremia</th></thead><thead><th>+ Conivaptan</th><th>Antagonist of vasopressin V, and V, receptors</th><th></th><th></th></thead><thead><th colspan="4">+ Relcovaptan, SRX251: Increased selectivity for V; receptor + Tolvaptan: Increased selectivity for V, receptor</th><th></th><th></th></thead><tr><td colspan="4">NATRIURETIC PEPTIDES</td></tr><tr><td>+ Nesiritide, Carperitide</td><td>Agonists of natriuretic peptide receptors</td><td>Increased sodium and water excretion + vasodilation</td><td>Heart failure</td></tr><tr><td colspan="4">+ Ularitide: Synthetic form of urodilatin</td></tr><tr><td colspan="4">COMBINED ANGIOTENSIN-CONVERTING ENZYME/NEPRILYSIN INHIBITORS (VASOPEPTIDASE INHIBITORS)</td></tr><tr><td>+ Omapatrilat</td><td>Decreases metabolism of natriuretic peptides and formation of angiotensin II</td><td>Vasodilation « increased sodium and water excretion</td><td>Hypertension + heart failure’</td></tr><tr><td colspan="4">+ Sampatrilat, fasidotrilat: Similar to omapatrilat</td></tr><tr><td>COMBINED ANGIOTENSIN</td><td>RECEPTOR ANTAGONIST/NEPRILYSIN INHIBITORS</td><td>(ARNI)</td><td></td></tr><tr><td>+ LCX696 (sacubitril/ valsartan)</td><td>Decreases breakdown of natriuretic peptides and blocks angiotensin II receptors</td><td>Vasodilation + increased sodium and water excretion</td><td>Heart failure + hypertension’</td></tr><tr><td colspan="4">ENDOTHELIN ANTAGONISTS</td><td rowspan="3">Pulmonary arterial hypertension</td></tr><tr><td>+ Bosentan, macitentan</td><td>Nonselective antagonists of endothelin ET, and ET, receptors</td><td>Vasodilation</td><td></td></tr><tr><td>+ Sitaxsentan, ambrisentan:</td><td>Selective antagonists for ET, receptors</td><td></td><td></td></tr><tr><td>COMBINED ENDOTHELIN-CONVERTING</td><td>ENZYME/NEPRILYSIN INHIBITORS</td><td></td><td></td></tr><tr><td>+ SLV306, daglutril</td><td>Blocks formation of endothelins and breakdown of natriuretic peptides</td><td>Vasodilation + increased sodium and water excretion</td><td>Heart failure + hypertension’</td></tr><tr><td>VASOACTIVE INTESTINAL + PB1046, Vasomera</td><td>PEPTIDE AGONISTS Selective agonist of VPAC2 receptors</td><td>Vasodilation « multiple metabolic, endocrine, and other effects</td><td>Hypertension’</td></tr><tr><td colspan="4">SUBSTANCE P ANTAGONISTS</td></tr><tr><td>+ Aprepitant</td><td>Selective antagonist of tachykinin NK, receptors</td><td>Blocks several central nervous system effects of substance P</td><td>Prevention of chemotherapy- induced nausea and vomiting</td></tr><tr><td colspan="4">+ Fosaprepitant: Prodrug that is converted to aprepitant</td></tr><tr><td colspan="4">NEUROTENSIN AGONISTS</td></tr><tr><td>+ PD149163, NT69L, NT79</td><td>Agonists of central neurotensin receptors</td><td>Interact with central dopamine systems</td><td>Potential for treatment of schizophrenia and Parkinson's disease</td></tr></table>
======================================
<table><thead><th>bclass, Dru</th><th></th><th>Effects</th><th>Applications</th></thead><tr><td colspan="4">NEUROTENSIN ANTAGONISTS</td></tr><tr><td>+ Meclinertant</td><td>Antagonist of central and peripheral neurotensin receptors</td><td>Blocks some central and peripheral (vasodilator) actions of neurotensin</td><td>identified</td></tr><tr><td colspan="4">CALCITONIN GENE-RELATED PEPTIDE ANTAGONISTS</td></tr><tr><td>+ Telcagepant, olcegepant</td><td>Antagonists of the calcitonin gene-related peptide (CGRP) receptor</td><td>Blocks some central and peripheral (vasodilator) actions of CGRP</td><td>Migraine’</td></tr><tr><td colspan="4">NEUROPEPTIDE Y ANTAGONISTS</td></tr><tr><td>+ BIBP3226</td><td>Selective antagonist of neuropeptide Y, receptors</td><td>Blocks vasoconstrictor response to neurotensin</td><td>Potential antiobesity agent</td></tr><tr><td colspan="4">+ BIIEO246: Selective for Y, receptor + MK-0557: Selective for Y; receptor</td></tr><tr><td>UROTENSIN ANTAGONISTS + Palosuran + GSK1440115: More potent than palosuran</td><td>Antagonist of urotensin receptors</td><td>Blocks vasoconstrictor action of urotensin</td><td>Potential for treatment of diabetic renal failure and asthma!</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td colspan="2">ANGIOTENSIN-CONVERTING ENZYME INHIBITORS</td></tr><tr><td colspan="2">(SEE CHAPTER 11)</td></tr><tr><td>ANGIOTENSIN</td><td>RECEPTOR BLOCKERS</td></tr><tr><td colspan="2">(SEE CHAPTER 11)</td></tr><tr><td>RENIN</td><td>INHIBITOR</td></tr><tr><td>Aliskiren</td><td>Tekturna</td></tr><tr><td>Icatibant</td><td>Firazyr</td></tr><tr><td>C1 esterase inhibitor, human</td><td>Cinryze, Berinert</td></tr><tr><td>Ecallantide</td><td>Kalbitor</td></tr><tr><td>Conivaptan</td><td>Vaprisol</td></tr><tr><td>Tolvaptan</td><td>Samsca</td></tr><tr><td>Aprepitant</td><td>Emend</td></tr><tr><td>Nesiritide</td><td>Natrecor</td></tr><tr><td>Ambrisentan</td><td>Letairis</td></tr><tr><td>Bosentan</td><td>Tracleer</td></tr><tr><td>Epoprostenol</td><td>Flolan, Veletri</td></tr><tr><td>lloprost</td><td>Ventavis</td></tr><tr><td>Macitentan</td><td>Opsumit</td></tr><tr><td>Riociguat</td><td>Adempas</td></tr><tr><td>Selexipag</td><td>Uptravi</td></tr></table>
======================================
<table><tr><td>AA</td><td>Arachidonic acid</td></tr><tr><td>cox</td><td>Cyclooxygenase</td></tr><tr><td>DHET</td><td>Dihydroxyeicosatrienoic acid</td></tr><tr><td>EET</td><td>Epoxyeicosatrienoic acid</td></tr><tr><td>HETE</td><td>Hydroxyeicosatetraenoic acid</td></tr><tr><td>HPETE</td><td>Hydroxyperoxyeicosatetraenoic acid</td></tr><tr><td>LTB, LTC</td><td>Leukotriene B, C, etc</td></tr><tr><td>LOX</td><td>Lipoxygenase</td></tr><tr><td>LXA, LXB</td><td>Lipoxin A, B</td></tr><tr><td>NSAID</td><td>Nonsteroidal anti-inflammatory drug</td></tr><tr><td>PGE, PGF</td><td>Prostaglandin E, F, etc</td></tr><tr><td>PLA, PLC</td><td>Phospholipase A, C</td></tr><tr><td>TXA, TXB</td><td>Thromboxane A, B</td></tr></table>
======================================
<table><thead><th>Receptor (Human)</th><th>Endogenous Ligand</th><th>Secondary Ligands</th><th>G Protein; Second Messenger</th><th>Major Phenotype(s) in Knockout Mice</th></thead><tr><td rowspan="2">DP,</td><td rowspan="2">PGD,</td><td></td><td rowspan="2">G. TcAMP</td><td>Allergic asthma</td></tr><tr><td></td><td></td><td></td><td></td><td>Inflammatory cardiovascular disease, hypertension, thrombosis</td></tr><tr><td rowspan="2">DP,</td><td rowspan="2">PGD,</td><td>15d-PGJ,</td><td rowspan="2">G; TCa**,, LcAMP</td><td>Allergic airway inflammation</td></tr><tr><td></td><td></td><td></td><td></td><td>‘Cutaneous inflammation</td></tr><tr><td>EP,</td><td>PGE,</td><td>PGI,</td><td>Gy Tea’;</td><td>Colon carcinogenesis</td></tr><tr><td rowspan="3">EP,</td><td></td><td>PGE,</td><td></td><td rowspan="3">3; TCAMP</td><td></td><td>Impaired fertilization</td></tr><tr><td></td><td></td><td></td><td></td><td>Salt-sensitive hypertension</td></tr><tr><td></td><td></td><td>Tumorgenesis</td></tr><tr><td>EP3 1,1, 1V,V,VLef</td><td rowspan="4">PGE,</td><td></td><td>G; JcAMP, TCa**,</td><td>Resistance to pyrogens</td></tr><tr><td></td><td></td><td></td><td>G. TcAMP</td><td>Acute cutaneous inflammation</td></tr><tr><td></td><td></td><td></td><td>G,; TPLC, TCa’*,</td><td>Allergic airway inflammation</td></tr><tr><td></td><td></td><td></td><td>Gy 9/13; Rho activation</td><td>Obesity</td></tr><tr><td rowspan="4">EP,</td><td></td><td rowspan="4">PGE,</td><td></td><td></td><td>G, TcAMP</td><td>Myocardial infarction severity</td></tr><tr><td></td><td></td><td></td><td></td><td>Intestinal inflammatory/immune response</td></tr><tr><td></td><td></td><td></td><td></td><td>Colon carcinogenesis</td></tr><tr><td></td><td></td><td>Patent ductus arteriosus</td></tr><tr><td rowspan="3">FPag</td><td rowspan="3">PGF 29,</td><td>isoPs</td><td>PLC, TCa”*,</td><td>Parturition failure</td></tr><tr><td></td><td></td><td></td><td>Gy2/13; Rho activation</td><td>Basal blood pressure; TVasopressor response</td></tr><tr><td></td><td></td><td></td><td></td><td>Atherosclerosis</td></tr><tr><td rowspan="4"></td><td rowspan="4">PGI,</td><td>PGE,</td><td>Gs; !cAMP.</td><td>Thrombotic response</td></tr><tr><td></td><td></td><td></td><td></td><td>Response to vascular injury</td></tr><tr><td></td><td></td><td></td><td></td><td>Cardiac fibrosis</td></tr><tr><td></td><td></td><td></td><td></td><td>Salt-sensitive hypertension</td></tr><tr><td rowspan="4">TP op</td><td rowspan="4">TXA,</td><td>isoPs</td><td>GyGranaGigi TPLC, TCa**,, Rho activation</td><td>Bleeding time</td></tr><tr><td></td><td></td><td rowspan="4"></td><td rowspan="3"></td><td>Response to vascular injury</td></tr><tr><td></td><td></td><td></td><td></td><td>Atherosclerosis</td></tr><tr><td></td><td></td><td></td><td></td><td>Survival after cardiac allograft</td></tr><tr><td rowspan="2">BLT,</td><td>LTB,</td><td></td><td>Gy6,Gi; TCa**,, LcAMP</td><td>Inflammatory responses</td></tr><tr><td></td><td rowspan="2">LTB,</td><td></td><td></td><td>insulin resistance in obesity</td></tr><tr><td rowspan="2">BLT,</td><td></td><td>12(S)-HETE</td><td rowspan="2">G,-like, G-like, G,,-like, Ta";</td><td>inflammatory arthritis</td></tr><tr><td></td><td></td><td>12(R)-HETE</td><td></td><td>Experimental colitis</td></tr><tr><td>CysLT,</td><td>LTD,</td><td>LTC, /LTE,</td><td>G,; TPLC, PCa”;</td><td>‘Innate and adaptive immune vascular permeability response</td></tr></table>
======================================
<table><tr><td>Penile injection, mini-suppository</td><td>Caverject, Edex, Muse</td></tr><tr><td>Parenteral</td><td>Generic, Prostin VR Pediatric</td></tr><tr><td>Bimatoprost</td><td>Lumigan, Latisse</td></tr><tr><td>Carboprost tromethamine</td><td>Hemabate</td></tr><tr><td>Dinoprostone [prostaglandin E,]</td><td>Prostin E2, Prepidil, Cervidil</td></tr><tr><td>Epoprostenol [prostacyclin]</td><td>Generic, Flolan, Veletri</td></tr><tr><td>lloprost</td><td>Ventavis</td></tr><tr><td>Latanoprost</td><td>Generic, Xalatan</td></tr><tr><td>Misoprostol</td><td>Generic, Cytotec</td></tr><tr><td>Montelukast</td><td>Generic, Singulair</td></tr><tr><td>Selexipag</td><td>Uptravi</td></tr><tr><td>Travoprost</td><td>Generic, Travatan, Travatan-Z</td></tr><tr><td>Treprostinil</td><td>Remodulin, Tyvaso, Orenitram</td></tr><tr><td>Zafirlukast</td><td>Generic, Accolate</td></tr><tr><td>Zileuton</td><td>Zyflo, Zyflo CR</td></tr></table>
======================================
<table><thead><th rowspan="2">Property</th><th colspan="3">Isoform Names</th></thead><thead><th></th><th>NOS-1</th><th>NOS-2</th><th>NOS-3</th></thead><tr><td>Other names</td><td>nNOS (neuronal NOS)</td><td>iNOS (inducible NOS)</td><td>eNOS (endothelial NOS)</td></tr><tr><td>Tissue</td><td>Neurons, skeletal muscle</td><td>Macrophages, smooth muscle cells</td><td>Endothelial cells, neurons</td></tr><tr><td>Expression</td><td>Constitutive</td><td>Transcriptional induction</td><td>Constitutive</td></tr><tr><td>Calcium regulation</td><td>Yes</td><td>No</td><td>Yes</td></tr></table>
======================================
<table><thead><th>Name</th><th>Structure</th><th>Known Function</th></thead><tr><td>Nitric oxide (NO)</td><td>N=0°</td><td>Vasodilator, platelet inhibitor, immune regulator, neurotransmitter</td></tr><tr><td>Peroxynitrite (NO, ")</td><td>O=N-O-O-</td><td>Oxidant and nitrating agent</td></tr><tr><td rowspan="2">Nitroxyl anion (NO-)</td><td rowspan="2">N=O</td><td>Can form from nonspecific donation of an electron from metals to NO</td></tr><tr><td></td><td></td><td>Exhibits NO-like effects, possibly by first being oxidized to NO</td></tr><tr><td>Nitrous oxide (NO)</td><td></td><td>Anesthetic</td></tr><tr><td>Dinitrogen trioxide (N,O,)</td><td></td><td>Auto-oxidation product of NO that can nitrosylate protein thiols</td></tr><tr><td rowspan="2">Nitrite (NO)</td><td></td><td></td><td>Stable oxidation product of NO</td></tr><tr><td></td><td>Slowly metabolized to nitrosothiols, and decomposes to NO at acidic pH</td></tr><tr><td>Nitrate (NO, )</td><td></td><td>Stable oxidation product of NO</td></tr></table>
======================================
<table><thead><th>Inhibitor</th><th>Mechanism</th><th>Comment</th></thead><tr><td>N°-Monomethyl- L-arginine (L-NMMA)</td><td>Competitive inhibitor, binds arginine-binding site in NOS</td><td>Nonselective NOS inhibitor</td></tr><tr><td>N°-Nitro- L-arginine methyl ester (L-NAME)</td><td>Competitive inhibitor, binds arginine-binding site in NOS</td><td>Nonselective NOS inhibitor</td></tr><tr><td>7-Nitroindazole</td><td>Competitive inhibitor, binds both tetrahydro- biopterin and arginine- binding sites in NOS</td><td>Partially selective for NOS-1 in vivo</td></tr><tr><td>BBS-2</td><td>Inhibits iNOS dimerization</td><td>Also weakly inhibits nNOS and eNOS</td></tr><tr><td>Hemoglobin</td><td>NO scavenger</td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Antibody Name</th><th>Isotype</th><th>Target</th></thead><tr><td>Omalizumab</td><td>Humanized IgG1</td><td>IgE</td></tr><tr><td>Mepolizumab</td><td>Humanized IgG1</td><td>IL-5</td></tr><tr><td>Benralizumab</td><td>Humanized IgG1</td><td>IL-5 receptor</td></tr><tr><td>Reslizumab</td><td>Humanized IgG4</td><td>IL-5</td></tr><tr><td>Lebrikizumab</td><td>Humanized IgG4</td><td>IL-13 (IL-4 receptor- binding epitope)</td></tr><tr><td>GSK679586</td><td>Humanized IgG1</td><td>IL-13 receptors 0.1, 02</td></tr><tr><td>Tralokinumab</td><td>Humanized IgG4</td><td>IL-13 receptors 011, a2</td></tr><tr><td>Dupilumab</td><td>Humanized IgG4</td><td>IL-4 receptor</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, Toxicities</th></thead><tr><td colspan="5">BETA AGONISTS</td></tr><tr><td>+ Albuterol</td><td>Selective B, agonist</td><td>Prompt, efficacious bronchodilation</td><td>Asthma, chronic obstructive pulmonary disease (COPD) + drug of choice in acute asthmatic bronchospasm</td><td>Aerosol inhalation + duration several hours « also available for nebulizer and parenteral use + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td>+ Salmeterol</td><td>Selective B, agonist</td><td>Slow onset, primarily preventive action; potentiates corticosteroid effects</td><td>Bronchodilation, prevention of asthma exacerbations</td><td>Aerosol inhalation + duration 12-24 h + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td colspan="5">+ Metaproterenol, terbutaline: Similar to albuterol; terbutaline available as an oral drug + Formoterol, vilanterol: Similar to salmeterol</td></tr><tr><td>+ Epinephrine</td><td>Nonselective o and B agonist and</td><td>Bronchodilation plus all other sympathomimetic effects on cardiovascular and other organ systems (see Chapter 9) Bronchodilation</td><td>Anaphylaxis, asthma, others. (see Chapter 9) « rarely used for asthma (8,~selective agents preferred) but</td><td>Aerosol, nebulizer, or parenteral + see Chapter 9 Aerosol, nebulizer,</td></tr><tr><td>+ Isoproterenol</td><td>| B, 8, agonist</td><td>plus powerful cardiovascular effects</td><td>Asthma, B,-selective agents preferred</td><td>or parenteral + see Chapter 9</td></tr><tr><td colspan="5">CORTICOSTEROIDS, INHALED + Fluticasone Alters gene Reduces mediators of inflammation Asthma + adjunct in COPD Aerosol + duration hours + Toxicity:</td></tr><tr><td>+ Beclomethasone,</td><td>expression budesonide, flunisolide,</td><td>+ powerful prophylaxis of exacerbations others: Similar to fluticasone</td><td>+ hay fever (nasal)</td><td>Limited by aerosol application - candidal infection, vocal cord changes</td></tr><tr><td>CORTICOSTEROIDS, + Prednisone</td><td>SYSTEMIC Like fluticasone</td><td>Like fluticasone</td><td rowspan="2">Asthma + adjunct in COPD</td><td>Oral + duration 12-24 h « Toxicity: Multiple + see Chapter 39</td></tr><tr><td>+ Methylprednisolone:</td><td>Parenteral agent like</td><td>prednisone</td><td></td><td></td></tr><tr><td colspan="5">STABILIZERS OF MAST AND OTHER CELLS</td></tr><tr><td>+ Cromolyn, nedocromil (no longer available in the USA)</td><td>Alter function of delayed chloride channels « inhibit inflammatory cell activation</td><td>Prevention of bronchospastic response to allergen inhalation</td><td>Asthma (other routes used for ocular, nasal, and gastrointestinal allergy)</td><td>Aerosol + duration 6-8 h - Toxicity: Cough «not absorbed so other toxicities are minimal</td></tr><tr><td colspan="5">METHYLXANTHINES</td></tr><tr><td>+ Theophylline</td><td>Uncertain: + phosphodiesterase inhibition adenosine receptor antagonist</td><td>Bronchodilation, cardiac stimulation, increased skeletal muscle strength (diaphragm)</td><td>Asthma, COPD</td><td rowspan="2">Oral - duration 8-12 h but extended- release preparations often used + Toxicity: Multiple (see text)</td></tr><tr><td colspan="5">+ Roflumilast: Similar to theophylline, but with better therapeutic ratio</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, Toxicities</th></thead><tr><td colspan="5">BETA AGONISTS</td></tr><tr><td>+ Albuterol</td><td>Selective B, agonist</td><td>Prompt, efficacious bronchodilation</td><td>Asthma, chronic obstructive pulmonary disease (COPD) + drug of choice in acute asthmatic bronchospasm</td><td>Aerosol inhalation + duration several hours « also available for nebulizer and parenteral use + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td>+ Salmeterol</td><td>Selective B, agonist</td><td>Slow onset, primarily preventive action; potentiates corticosteroid effects</td><td>Bronchodilation, prevention of asthma exacerbations</td><td>Aerosol inhalation + duration 12-24 h + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td colspan="5">+ Metaproterenol, terbutaline: Similar to albuterol; terbutaline available as an oral drug + Formoterol, vilanterol: Similar to salmeterol</td></tr><tr><td>+ Epinephrine</td><td>Nonselective o and B agonist and</td><td>Bronchodilation plus all other sympathomimetic effects on cardiovascular and other organ systems (see Chapter 9) Bronchodilation</td><td>Anaphylaxis, asthma, others. (see Chapter 9) « rarely used for asthma (8,~selective agents preferred) but</td><td>Aerosol, nebulizer, or parenteral + see Chapter 9 Aerosol, nebulizer,</td></tr><tr><td>+ Isoproterenol</td><td>| B, 8, agonist</td><td>plus powerful cardiovascular effects</td><td>Asthma, B,-selective agents preferred</td><td>or parenteral + see Chapter 9</td></tr><tr><td colspan="5">CORTICOSTEROIDS, INHALED + Fluticasone Alters gene Reduces mediators of inflammation Asthma + adjunct in COPD Aerosol + duration hours + Toxicity:</td></tr><tr><td>+ Beclomethasone,</td><td>expression budesonide, flunisolide,</td><td>+ powerful prophylaxis of exacerbations others: Similar to fluticasone</td><td>+ hay fever (nasal)</td><td>Limited by aerosol application - candidal infection, vocal cord changes</td></tr><tr><td>CORTICOSTEROIDS, + Prednisone</td><td>SYSTEMIC Like fluticasone</td><td>Like fluticasone</td><td rowspan="2">Asthma + adjunct in COPD</td><td>Oral + duration 12-24 h « Toxicity: Multiple + see Chapter 39</td></tr><tr><td>+ Methylprednisolone:</td><td>Parenteral agent like</td><td>prednisone</td><td></td><td></td></tr><tr><td colspan="5">STABILIZERS OF MAST AND OTHER CELLS</td></tr><tr><td>+ Cromolyn, nedocromil (no longer available in the USA)</td><td>Alter function of delayed chloride channels « inhibit inflammatory cell activation</td><td>Prevention of bronchospastic response to allergen inhalation</td><td>Asthma (other routes used for ocular, nasal, and gastrointestinal allergy)</td><td>Aerosol + duration 6-8 h - Toxicity: Cough «not absorbed so other toxicities are minimal</td></tr><tr><td colspan="5">METHYLXANTHINES</td></tr><tr><td>+ Theophylline</td><td>Uncertain: + phosphodiesterase inhibition adenosine receptor antagonist</td><td>Bronchodilation, cardiac stimulation, increased skeletal muscle strength (diaphragm)</td><td>Asthma, COPD</td><td rowspan="2">Oral - duration 8-12 h but extended- release preparations often used + Toxicity: Multiple (see text)</td></tr><tr><td colspan="5">+ Roflumilast: Similar to theophylline, but with better therapeutic ratio</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, Toxicities</th></thead><tr><td colspan="5">BETA AGONISTS</td></tr><tr><td>+ Albuterol</td><td>Selective B, agonist</td><td>Prompt, efficacious bronchodilation</td><td>Asthma, chronic obstructive pulmonary disease (COPD) + drug of choice in acute asthmatic bronchospasm</td><td>Aerosol inhalation + duration several hours « also available for nebulizer and parenteral use + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td>+ Salmeterol</td><td>Selective B, agonist</td><td>Slow onset, primarily preventive action; potentiates corticosteroid effects</td><td>Bronchodilation, prevention of asthma exacerbations</td><td>Aerosol inhalation + duration 12-24 h + Toxicity: Tremor, tachycardia + Overdose: arrhythmias</td></tr><tr><td colspan="5">+ Metaproterenol, terbutaline: Similar to albuterol; terbutaline available as an oral drug + Formoterol, vilanterol: Similar to salmeterol</td></tr><tr><td>+ Epinephrine</td><td>Nonselective o and B agonist and</td><td>Bronchodilation plus all other sympathomimetic effects on cardiovascular and other organ systems (see Chapter 9) Bronchodilation</td><td>Anaphylaxis, asthma, others. (see Chapter 9) « rarely used for asthma (8,~selective agents preferred) but</td><td>Aerosol, nebulizer, or parenteral + see Chapter 9 Aerosol, nebulizer,</td></tr><tr><td>+ Isoproterenol</td><td>| B, 8, agonist</td><td>plus powerful cardiovascular effects</td><td>Asthma, B,-selective agents preferred</td><td>or parenteral + see Chapter 9</td></tr><tr><td colspan="5">CORTICOSTEROIDS, INHALED + Fluticasone Alters gene Reduces mediators of inflammation Asthma + adjunct in COPD Aerosol + duration hours + Toxicity:</td></tr><tr><td>+ Beclomethasone,</td><td>expression budesonide, flunisolide,</td><td>+ powerful prophylaxis of exacerbations others: Similar to fluticasone</td><td>+ hay fever (nasal)</td><td>Limited by aerosol application - candidal infection, vocal cord changes</td></tr><tr><td>CORTICOSTEROIDS, + Prednisone</td><td>SYSTEMIC Like fluticasone</td><td>Like fluticasone</td><td rowspan="2">Asthma + adjunct in COPD</td><td>Oral + duration 12-24 h « Toxicity: Multiple + see Chapter 39</td></tr><tr><td>+ Methylprednisolone:</td><td>Parenteral agent like</td><td>prednisone</td><td></td><td></td></tr><tr><td colspan="5">STABILIZERS OF MAST AND OTHER CELLS</td></tr><tr><td>+ Cromolyn, nedocromil (no longer available in the USA)</td><td>Alter function of delayed chloride channels « inhibit inflammatory cell activation</td><td>Prevention of bronchospastic response to allergen inhalation</td><td>Asthma (other routes used for ocular, nasal, and gastrointestinal allergy)</td><td>Aerosol + duration 6-8 h - Toxicity: Cough «not absorbed so other toxicities are minimal</td></tr><tr><td colspan="5">METHYLXANTHINES</td></tr><tr><td>+ Theophylline</td><td>Uncertain: + phosphodiesterase inhibition adenosine receptor antagonist</td><td>Bronchodilation, cardiac stimulation, increased skeletal muscle strength (diaphragm)</td><td>Asthma, COPD</td><td rowspan="2">Oral - duration 8-12 h but extended- release preparations often used + Toxicity: Multiple (see text)</td></tr><tr><td colspan="5">+ Roflumilast: Similar to theophylline, but with better therapeutic ratio</td><td></td></tr></table>
======================================
<table><thead><th>Omalizumab</th><th>Humanized IgE antibody reduces circulating IgE</th><th>Reduces frequency of asthma exacerbations</th><th>Severe asthma inadequately controlled by above agents</th><th>Parenteral duration 2-4 weeks « Toxicity: Injection site reactions (anaphylaxis extremely rare)</th></thead></table>
======================================
<table><thead><th></th><th>anism of n</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">ANTI-INTERLEUKIN-5 PATHWAY ANTIBODIES AND OTHER ANTIBODIES</td></tr><tr><td>+ Mepolizumab |</td><td>Humanized anti-IL-5 | antibody; reduces circulating and tissue eosinophils</td><td>Reduces frequency of asthma exacerbations</td><td>Severe asthma inadequately controlled by above agents, with associated eosinophilia</td><td>Parenteral + duration 2-4 wk + Toxicity: Injection site reactions (anaphylaxis extremely rare)</td></tr><tr><td>+ Dupilumab</td><td>Humanized antibody against IL-4o1 receptor for IL-4 and IL-13</td><td>Reduces frequency of asthma exacerbations; improves pulmonary function</td><td>Severe asthma inadequately controlled by ICS/LABA therapy</td><td>Parenteral injection every 2-4 wk</td></tr><tr><td colspan="5">Reslizumab and benralizumab: Similar to mepolizumab</td></tr></table>
======================================
<table><thead><th>—GENERICNAME</th><th>—AVAILABLEAS</th></thead><tr><td>Budesonide</td><td>Pulmicort</td></tr><tr><td>Ciclesonide</td><td>Alvesco</td></tr><tr><td>Mometasone</td><td>Asmanex</td></tr><tr><td>Flunisolide</td><td>AeroBid, Aerospan</td></tr><tr><td>Fluticasone</td><td>Flovent</td></tr><tr><td>Triamcinolone</td><td>Azmacort</td></tr><tr><td>Formoterol/budesonide</td><td>Symbicort</td></tr><tr><td>Formoterol/mometasone</td><td>Dulera</td></tr><tr><td>Salmeterol/fluticasone</td><td>Advair</td></tr><tr><td>Vilanterol/fluticasone</td><td>Breo</td></tr><tr><td>Vilanterol/umeclidinium</td><td>Anoro</td></tr><tr><td>Montelukast</td><td>Generic, Singulair</td></tr><tr><td>Zafirlukast</td><td>Accolate</td></tr><tr><td>Zileuton</td><td>Zyflo</td></tr><tr><td>Dyphylline</td><td>Dilor, Dylix, Lufyllin</td></tr><tr><td>Roflumilast</td><td>Daliresp</td></tr><tr><td>Theophylline</td><td>Generic, Elixophyllin, Slo-Phyllin, Uniphyl, Theo-Dur, Theo-24</td></tr><tr><td colspan="2">MONOCLONAL ANTIBODIES</td></tr><tr><td>Omalizumab</td><td>Xolair</td></tr><tr><td>Benralizumab</td><td>(To be determined)</td></tr><tr><td>Mepolizumab</td><td>Nucala</td></tr><tr><td>Reslizumab</td><td>Cingair</td></tr></table>
======================================
<table><tr><td colspan="2">SHORT-ACTING BETA-AGONIST BRONCHODILATORS</td></tr><tr><td>Albuterol</td><td>Generic, Proventil, ProAir, Ventolin</td></tr><tr><td>Bitolterol</td><td>Tornalate</td></tr><tr><td>Ephedrine</td><td>Generic</td></tr><tr><td>Epinephrine</td><td>Generic, Adrenaline</td></tr><tr><td>Levalbuterol</td><td>Xenopex</td></tr><tr><td>Metaproterenol</td><td>Generic, Alupent</td></tr><tr><td>Pirbuterol</td><td>Maxair</td></tr><tr><td>Terbutaline</td><td>Breathaire, Brethine</td></tr><tr><td colspan="2">SHORT-ACTING ANTIMUSCARINIC BRONCHODILATOR</td></tr><tr><td>Ipratropium</td><td>Generic, Atrovent</td></tr><tr><td>Albuterol/ipratropium</td><td>Combivent</td></tr><tr><td colspan="2">LONG-ACTING BETA-ADRENERGIC BRONCHODILATORS</td></tr><tr><td>Formoterol</td><td>Foradil</td></tr><tr><td>Indacaterol</td><td>Arcapta</td></tr><tr><td>Olodaterol</td><td>Striverdi</td></tr><tr><td>Salmeterol</td><td>Serevent</td></tr><tr><td>Aclidinium</td><td>Tudorza</td></tr><tr><td>Tiotropium</td><td>Spiriva</td></tr><tr><td>Umeclidinium</td><td>Incruse</td></tr><tr><td></td><td>See also Chapter 39</td></tr><tr><td>Beclomethasone</td><td>QVAR, Beclovent, Vanceril</td></tr></table>
======================================
<table><thead><th>Channel Types</th><th>Mode of Toxin Action</th><th>Source</th></thead><tr><td colspan="3">Voltage-gated</td></tr><tr><td colspan="3">Sodium channels</td></tr><tr><td>Tetrodotoxin (TTX)</td><td>Blocks channel from outside</td><td>Puffer fish</td></tr><tr><td>Batrachotoxin (BTX)</td><td>Slows inactivation, shifts activation</td><td>Colombian frog</td></tr><tr><td colspan="3">Potassium channels</td></tr><tr><td>Apamin</td><td>Blocks “small Ca-activated” K channel</td><td>Honeybee</td></tr><tr><td>Charybdotoxin</td><td>Blocks “big Ca-activated” K channel</td><td>Scorpion</td></tr><tr><td colspan="3">Calcium channels</td></tr><tr><td>Omega conotoxin (w-CTX-GVIA)</td><td>Blocks N-type channel</td><td>Pacific cone snail</td></tr><tr><td>Agatoxin (w-AGAIVA)</td><td>Blocks P-type channel</td><td>Funnel web spider</td></tr><tr><td colspan="3">Ligand-gated</td></tr><tr><td colspan="3">Nicotinic ACh receptor</td></tr><tr><td>a-Bungarotoxin</td><td>Irreversible antagonist</td><td>Marine snake</td></tr><tr><td colspan="3">GABA,g receptor</td></tr><tr><td>Picrotoxin</td><td>Blocks channel</td><td>South Pacific plant</td></tr><tr><td colspan="3">Glycine receptor</td></tr><tr><td>Strychnine</td><td>Competitive antagonist</td><td>Indian plant</td></tr><tr><td>AMPA receptor Philanthotoxin</td><td>Blocks channel</td><td>Wasp</td></tr></table>
======================================
<table><thead><th>Transmitter</th><th>Anatomy</th><th>Receptor Subtypes and Preferred Agonists</th><th>Receptor Antagonists</th><th>Mechanisms</th></thead><tr><td rowspan="3">Acetylcholine</td><td rowspan="2">Cell bodies at all levels; long and short connections</td><td>Muscarinic (M,): muscarine</td><td>Pirenzepine, atropine</td><td>Excitatory: Lin k* conductance; TIP;, DAG</td></tr><tr><td></td><td></td><td>Muscarinic (M;): muscarine, bethanechol</td><td>Atropine, methoctramine</td><td>Inhibitory: T K* conductance; cAMP</td></tr><tr><td></td><td>Motoneuron-Renshaw cell synapse</td><td>Nicotinic: nicotine</td><td>Dihydro-B-erythroidine, a-bungarotoxin</td><td>Excitatory: T cation conductance</td></tr><tr><td rowspan="2">Dopamine</td><td rowspan="2">Cell bodies at all levels; short, medium, and long connections</td><td>D,: dihydrexidine</td><td>Phenothiazines</td><td>Inhibitory (2): T cAMP</td></tr><tr><td></td><td></td><td>D): bromocriptine</td><td>Phenothiazines, butyrophenones</td><td>Inhibitory (presynaptic): | Ca”*; Inhibitory (postsynaptic): T in K” conductance, / cAMP</td></tr><tr><td rowspan="2">GABA</td><td rowspan="2">Supraspinal and spinal interneurons involved in pre- and postsynaptic inhibition</td><td>GABAg;: muscimol</td><td>Bicuculline, picrotoxin</td><td>Inhibitory: T Cl conductance</td></tr><tr><td></td><td></td><td>GABAsg: baclofen</td><td>2-OH saclofen</td><td>Inhibitory (presynaptic): J Ca** conductance; Inhibitory (postsynaptic): T K* conductance</td></tr><tr><td rowspan="4">Glutamate</td><td rowspan="4">Relay neurons at all levels and some interneurons</td><td>N-Methyl-p-aspartate (NMDA): NMDA</td><td>2-Amino-5- phosphonovalerate, dizocilpine</td><td>Excitatory: T cation conductance, particularly Ca**</td></tr><tr><td></td><td></td><td>AMPA: AMPA</td><td>NBQX</td><td>Excitatory: T cation conductance</td></tr><tr><td></td><td></td><td>Kainate: kainic acid, domoic acid</td><td>ACET</td><td>Excitatory: T cation conductance</td></tr><tr><td></td><td></td><td>Metabotropic: ACPD, quisqualate</td><td>MCPG</td><td>Inhibitory (presynaptic): | Ca** conductance, L cAMP; Excitatory: K* conductance, T IP3, DAG</td></tr><tr><td>Glycine</td><td>Spinal interneurons and some brain stem interneurons</td><td>Taurine, B-alanine</td><td>Strychnine</td><td>Inhibitory: T Cl conductance</td></tr><tr><td rowspan="4">5-Hydroxytryptamine (serotonin)</td><td></td><td rowspan="4">Cell bodies in mid-brain and pons project to all levels</td><td></td><td>5-HT,,: eptapirone</td><td>Metergoline, spiperone</td><td>Inhibitory: K* conductance, cAMP</td></tr><tr><td></td><td></td><td>5-HT2 4: LSD</td><td>Ketanserin</td><td>Excitatory: Kt conductance, IP;, DAG</td></tr><tr><td></td><td></td><td>5-HT3: 2-methyl-5-HT</td><td>Ondansetron</td><td>Excitatory: T cation conductance</td></tr><tr><td>5-HT,: cisapride</td><td>Piboserod</td><td>Excitatory: | K* conductance</td></tr><tr><td rowspan="4">Norepinephrine</td><td rowspan="4">Cell bodies in pons and brain stem project to all levels</td><td>@,: phenylephrine</td><td>Prazosin</td><td>Excitatory: K* conductance, IP;, DAG</td></tr><tr><td></td><td></td><td>2: clonidine</td><td>Yohimbine</td><td>Inhibitory (presynaptic): J Ca’* conductance; Inhibitory: TK conductance, / cAMP</td></tr><tr><td></td><td></td><td>B,: isoproterenol, dobutamine</td><td>Atenolol, practolol</td><td>Excitatory: LK conductance, T cAMP</td></tr><tr><td></td><td></td><td>B.: albuterol</td><td>Butoxamine</td><td>Inhibitory: may involve 7 in elec- T</td></tr></table>
======================================
<table><thead><th>Transmitter</th><th>Anatomy</th><th>Receptor Subtypes and Preferred Agonists</th><th>Receptor Antagonists</th><th>Mechanisms</th></thead><tr><td rowspan="3">Opioid peptides</td><td rowspan="3">Cell bodies at all levels; long and short connections</td><td>Mu: bendorphin</td><td>Naloxone</td><td>Inhibitory (presynaptic): J Ca** conductance, / cAMP</td></tr><tr><td></td><td></td><td>Delta: enkephalin</td><td>Naloxone</td><td>Inhibitory (postsynaptic): TK conductance, / cAMP</td></tr><tr><td></td><td></td><td>Kappa: dynorphin, salvinorin A</td><td>Naloxone</td><td>Inhibitory (postsynaptic): TK conductance, / cAMP</td></tr><tr><td rowspan="2">Orexins</td><td rowspan="2">Cell bodies in hypothala- mus; project widely</td><td>OX,: orexin A</td><td>Suvorexant</td><td rowspan="2">Excitatory, glutamate co-release</td></tr><tr><td></td><td></td><td>OX;,: orexins A and B</td><td>Suvorexant</td><td></td></tr><tr><td rowspan="3">Tachykinins</td><td></td><td rowspan="3">Primary sensory neurons, cell bodies at all levels; long and short connections</td><td></td><td>NK1: substance P methylester</td><td>Aprepitant</td><td>Excitatory: LK conductance, TIP;, DAG</td></tr><tr><td></td><td></td><td>NK2: neurokinin A</td><td>Saredutant</td><td>Excitatory: LK conductance, TIP;, DAG</td></tr><tr><td>NK3: neurokinin B</td><td>Osanetant</td><td>Excitatory: LK conductance, TIP;, DAG</td></tr><tr><td>Endocannabinoids</td><td>Widely distributed</td><td>CB1: anandamide, 2-arachidonyglycerol</td><td>Rimonabant</td><td>Inhibitory (presynaptic): | Ca** conductance, cAMP</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Tmax (hours)'</th><th>ty (hours)?</th><th>Comments</th></thead><tr><td>Alprazolam</td><td>1-2</td><td>12-15</td><td>Rapid oral absorption</td></tr><tr><td>Chlordiazepoxide</td><td>2-4</td><td>15-40</td><td>Active metabolites; erratic bioavailability from IM injection</td></tr><tr><td>Clorazepate</td><td>1-2 (nordiazepam)</td><td>50-100</td><td>Prodrug; hydrolyzed to active form in stomach</td></tr><tr><td>Diazepam</td><td>1-2</td><td>20-80</td><td>Active metabolites; erratic bioavailability from IM injection</td></tr><tr><td>Eszopiclone</td><td></td><td></td><td>Minor active metabolites</td></tr><tr><td>Flurazepam</td><td></td><td></td><td>Active metabolites with long half-lives</td></tr><tr><td>Lorazepam</td><td></td><td></td><td>No active metabolites</td></tr><tr><td>Oxazepam</td><td></td><td></td><td>No active metabolites</td></tr><tr><td>Temazepam</td><td></td><td></td><td>Slow oral absorption</td></tr><tr><td>Triazolam</td><td></td><td></td><td>Rapid onset; short duration of action</td></tr><tr><td>Zaleplon</td><td></td><td></td><td>Metabolized via aldehyde dehydrogenase</td></tr><tr><td>Zolpidem</td><td></td><td></td><td>No active metabolites</td></tr></table>
======================================
<table><thead><th colspan="2">Sedation</th><th colspan="2">Hypnosis</th></thead><thead><th>Drug</th><th>Dosage</th><th>Drug</th><th>Dosage (at Bedtime)</th></thead><tr><td>Alprazolam</td><td>0.25-0.5 mg 2-3 times daily</td><td>Chloral hydrate</td><td>500-1000 mg</td></tr><tr><td>Buspirone</td><td>5-10 mg 2-3 times daily</td><td>Estazolam</td><td>0.5-2 mg</td></tr><tr><td rowspan="2">Chlordiazepoxide</td><td>10-20 mg</td><td>Eszopiclone</td><td>1-3 mg</td></tr><tr><td></td><td>2-3 times daily</td><td>Lorazepam</td><td>2-4 mg</td></tr><tr><td>Clorazepate</td><td>5-7.5 mg twice daily</td><td>Quazepam</td><td>7.5-15 mg</td></tr><tr><td>Diazepam</td><td>5 mg twice daily</td><td>Secobarbital</td><td>| 100-200 mg</td></tr><tr><td rowspan="2">Halazepam</td><td>20-40 mg</td><td>Suvorexant</td><td>10 mg</td></tr><tr><td></td><td>3-4 times daily</td><td>Tasimelteon</td><td>10mg</td></tr><tr><td>Lorazepam</td><td>1-2 mg once or twice daily</td><td>Temazepam</td><td>7.5-30 mg</td></tr><tr><td rowspan="2">Oxazepam</td><td>15-30 mg</td><td>Triazolam</td><td>0.125-0.5 mg</td></tr><tr><td></td><td>3-4 times daily</td><td>Zaleplon</td><td>5-20 mg</td></tr><tr><td>Phenobarbital</td><td>15-30 mg 2-3 times daily</td><td>Zolpidem</td><td>2.5-10 mg</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, s, Interactions</th></thead><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Alprazolam + Chlordiazepoxide + Clonazepam + Clorazepate + Diazepam + Estazolam + Flurazepam + Lorazepam + Midazolam + Oxazepam + Quazepam + Temazepam + Triazolam</td><td>Bind to specific GABA, receptor subunits at central nervous system (CNS) neuronal synapses facilitating GABA-mediated chloride ion channel opening frequency + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia « coma + and respiratory depression</td><td>Acute anxiety states + panic attacks - generalized anxiety disorder - insomnia and other sleep disorders + relaxation of skeletal muscle « anesthesia (adjunctive) + seizure disorders</td><td>Half-lives from 2-40 h (clorazepate longer) + oral activity - hepatic metabolism—some active metabolites + Toxicity: Extensions of CNS depressant effects - dependence liability + Interactions: Additive CNS depression with ethanol and many other drugs</td></tr><tr><td colspan="5">BENZODIAZEPINE ANTAGONIST</td></tr><tr><td>+ Flumazenil</td><td>Antagonist at benzodiazepine- binding sites on the GABA, receptor</td><td>Blocks actions of benzodiazepines and zolpidem but not other sedative-hypnotic drugs</td><td>Management of benzodiazepine overdose</td><td>IV, short half-life - Toxicity: Agitation, confusion - possible withdrawal symptoms in benzodiazepine dependence</td></tr><tr><td>BARBITURATES + Amobarbital + Butabarbital + Mephobarbital + Pentobarbital + Phenobarbital + Secobarbital</td><td>Bind to specific GABA, receptor subunits at CNS neuronal synapses facilitating GABA-mediated chloride ion channel opening duration + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia - coma and respiratory depression + steeper dose-response relationship than benzodiazepines</td><td>Anesthesia (thiopental) + insomnia (secobarbital) + seizure disorders (phenobarbital)</td><td>Half-lives from 4-60 h (phenobarbital longer) « oral activity « hepatic metabolism— phenobarbital 20% renal elimination + Toxicity: Extensions of CNS depressant effects » dependence liability &gt; benzodiazepines - Interactions: Additive CNS depression with ethanol and many other drugs + induction of hepatic drug- metabolizing enzymes</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, s, Interactions</th></thead><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Alprazolam + Chlordiazepoxide + Clonazepam + Clorazepate + Diazepam + Estazolam + Flurazepam + Lorazepam + Midazolam + Oxazepam + Quazepam + Temazepam + Triazolam</td><td>Bind to specific GABA, receptor subunits at central nervous system (CNS) neuronal synapses facilitating GABA-mediated chloride ion channel opening frequency + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia « coma + and respiratory depression</td><td>Acute anxiety states + panic attacks - generalized anxiety disorder - insomnia and other sleep disorders + relaxation of skeletal muscle « anesthesia (adjunctive) + seizure disorders</td><td>Half-lives from 2-40 h (clorazepate longer) + oral activity - hepatic metabolism—some active metabolites + Toxicity: Extensions of CNS depressant effects - dependence liability + Interactions: Additive CNS depression with ethanol and many other drugs</td></tr><tr><td colspan="5">BENZODIAZEPINE ANTAGONIST</td></tr><tr><td>+ Flumazenil</td><td>Antagonist at benzodiazepine- binding sites on the GABA, receptor</td><td>Blocks actions of benzodiazepines and zolpidem but not other sedative-hypnotic drugs</td><td>Management of benzodiazepine overdose</td><td>IV, short half-life - Toxicity: Agitation, confusion - possible withdrawal symptoms in benzodiazepine dependence</td></tr><tr><td>BARBITURATES + Amobarbital + Butabarbital + Mephobarbital + Pentobarbital + Phenobarbital + Secobarbital</td><td>Bind to specific GABA, receptor subunits at CNS neuronal synapses facilitating GABA-mediated chloride ion channel opening duration + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia - coma and respiratory depression + steeper dose-response relationship than benzodiazepines</td><td>Anesthesia (thiopental) + insomnia (secobarbital) + seizure disorders (phenobarbital)</td><td>Half-lives from 4-60 h (phenobarbital longer) « oral activity « hepatic metabolism— phenobarbital 20% renal elimination + Toxicity: Extensions of CNS depressant effects » dependence liability &gt; benzodiazepines - Interactions: Additive CNS depression with ethanol and many other drugs + induction of hepatic drug- metabolizing enzymes</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, s, Interactions</th></thead><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Alprazolam + Chlordiazepoxide + Clonazepam + Clorazepate + Diazepam + Estazolam + Flurazepam + Lorazepam + Midazolam + Oxazepam + Quazepam + Temazepam + Triazolam</td><td>Bind to specific GABA, receptor subunits at central nervous system (CNS) neuronal synapses facilitating GABA-mediated chloride ion channel opening frequency + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia « coma + and respiratory depression</td><td>Acute anxiety states + panic attacks - generalized anxiety disorder - insomnia and other sleep disorders + relaxation of skeletal muscle « anesthesia (adjunctive) + seizure disorders</td><td>Half-lives from 2-40 h (clorazepate longer) + oral activity - hepatic metabolism—some active metabolites + Toxicity: Extensions of CNS depressant effects - dependence liability + Interactions: Additive CNS depression with ethanol and many other drugs</td></tr><tr><td colspan="5">BENZODIAZEPINE ANTAGONIST</td></tr><tr><td>+ Flumazenil</td><td>Antagonist at benzodiazepine- binding sites on the GABA, receptor</td><td>Blocks actions of benzodiazepines and zolpidem but not other sedative-hypnotic drugs</td><td>Management of benzodiazepine overdose</td><td>IV, short half-life - Toxicity: Agitation, confusion - possible withdrawal symptoms in benzodiazepine dependence</td></tr><tr><td>BARBITURATES + Amobarbital + Butabarbital + Mephobarbital + Pentobarbital + Phenobarbital + Secobarbital</td><td>Bind to specific GABA, receptor subunits at CNS neuronal synapses facilitating GABA-mediated chloride ion channel opening duration + enhance membrane hyperpolarization</td><td>Dose-dependent depressant effects on the CNS including sedation and relief of anxiety + amnesia + hypnosis + anesthesia - coma and respiratory depression + steeper dose-response relationship than benzodiazepines</td><td>Anesthesia (thiopental) + insomnia (secobarbital) + seizure disorders (phenobarbital)</td><td>Half-lives from 4-60 h (phenobarbital longer) « oral activity « hepatic metabolism— phenobarbital 20% renal elimination + Toxicity: Extensions of CNS depressant effects » dependence liability &gt; benzodiazepines - Interactions: Additive CNS depression with ethanol and many other drugs + induction of hepatic drug- metabolizing enzymes</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">NEWER HYPNOTICS</td></tr><tr><td>+ Eszopiclone + Zaleplon + Zolpidem</td><td>Bind selectively to a subgroup of GABA, receptors, acting like benzodiazepines to enhance membrane hyperpolarization</td><td>Rapid onset of hypnosis with few amnestic effects or day- after psychomotor depression or somnolence</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep</td><td>Oral activity » short half-lives - CYP substrates + Toxicity: Extensions of CNS depressant effects « dependence liability + Interactions: Additive CNS depression with ethanol and many other drugs</td></tr><tr><td colspan="5">MELATONIN RECEPTOR AGONISTS</td></tr><tr><td>+ Ramelteon</td><td>Activates MT, and MT), receptors in suprachiasmatic nuclei in the CNS</td><td>Rapid onset of sleep with minimal rebound insomnia or withdrawal symptoms</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep + not a controlled substance</td><td>Oral activity - forms active metabolite via CYP1A2 - Toxicity: Dizziness + fatigue + endocrine changes « Interactions: Fluvoxamine inhibits metabolism</td></tr><tr><td colspan="5">+ Tasimelteon: Orally active MT, and MT, agonist, recently approved for non-24-ho ur sleep disorder</td></tr><tr><td>OREXIN ANTAGONIST + Suvorexant</td><td>Blocks binding of orexins, neuropeptides that promote wakefulness</td><td>Promotes sleep onset and duration</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep</td><td>CYP450 metabolism is inhibited by fluconazole, verapamil, and grapefruit juice + next-day somnolence and driving impairment</td></tr><tr><td colspan="5">5-HT-RECEPTOR AGONIST</td></tr><tr><td>+ Buspirone</td><td>Mechanism uncertain: Partial agonist at 5-HT receptors but affinity for D, receptors also possible</td><td>Slow onset (1-2 weeks) of anxiolytic effects « minimal psychomotor impairment— no additive CNS depression with sedative-hypnotic drugs</td><td>Generalized anxiety states</td><td>Oral activity - forms active metabolite + short half-life « Toxicity: Tachycardia + paresthesias + gastrointestinal distress + Interactions: CYP3A4 inducers and inhibitors</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">NEWER HYPNOTICS</td></tr><tr><td>+ Eszopiclone + Zaleplon + Zolpidem</td><td>Bind selectively to a subgroup of GABA, receptors, acting like benzodiazepines to enhance membrane hyperpolarization</td><td>Rapid onset of hypnosis with few amnestic effects or day- after psychomotor depression or somnolence</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep</td><td>Oral activity » short half-lives - CYP substrates + Toxicity: Extensions of CNS depressant effects « dependence liability + Interactions: Additive CNS depression with ethanol and many other drugs</td></tr><tr><td colspan="5">MELATONIN RECEPTOR AGONISTS</td></tr><tr><td>+ Ramelteon</td><td>Activates MT, and MT), receptors in suprachiasmatic nuclei in the CNS</td><td>Rapid onset of sleep with minimal rebound insomnia or withdrawal symptoms</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep + not a controlled substance</td><td>Oral activity - forms active metabolite via CYP1A2 - Toxicity: Dizziness + fatigue + endocrine changes « Interactions: Fluvoxamine inhibits metabolism</td></tr><tr><td colspan="5">+ Tasimelteon: Orally active MT, and MT, agonist, recently approved for non-24-ho ur sleep disorder</td></tr><tr><td>OREXIN ANTAGONIST + Suvorexant</td><td>Blocks binding of orexins, neuropeptides that promote wakefulness</td><td>Promotes sleep onset and duration</td><td>Sleep disorders, especially those characterized by difficulty in falling asleep</td><td>CYP450 metabolism is inhibited by fluconazole, verapamil, and grapefruit juice + next-day somnolence and driving impairment</td></tr><tr><td colspan="5">5-HT-RECEPTOR AGONIST</td></tr><tr><td>+ Buspirone</td><td>Mechanism uncertain: Partial agonist at 5-HT receptors but affinity for D, receptors also possible</td><td>Slow onset (1-2 weeks) of anxiolytic effects « minimal psychomotor impairment— no additive CNS depression with sedative-hypnotic drugs</td><td>Generalized anxiety states</td><td>Oral activity - forms active metabolite + short half-life « Toxicity: Tachycardia + paresthesias + gastrointestinal distress + Interactions: CYP3A4 inducers and inhibitors</td></tr></table>
======================================
<table><thead><th>|_GENERICNAME</th><th>—AVAILABLEAS</th></thead><tr><td>Pentobarbital</td><td>Generic, Nembutal Sodium</td></tr><tr><td>Phenobarbital</td><td>Generic, Luminal Sodium</td></tr><tr><td>Secobarbital</td><td>Generic, Seconal</td></tr><tr><td></td><td>DRUGS</td></tr><tr><td>Buspirone</td><td>Generic, BuSpar</td></tr><tr><td>Chloral hydrate</td><td>Generic, Aquachloral Supprettes</td></tr><tr><td>Eszopiclone</td><td>Lunesta</td></tr><tr><td>Hydroxyzine</td><td>Generic, Atarax, Vistaril</td></tr><tr><td>Meprobamate</td><td>Generic, Equanil, Miltown</td></tr><tr><td>Paraldehyde</td><td>Generic</td></tr><tr><td>Ramelteon</td><td>Rozerem</td></tr><tr><td>Suvorexant</td><td>Belsomra</td></tr><tr><td>Tasimelteon</td><td>Hetlioz</td></tr><tr><td>Zaleplon</td><td>Sonata</td></tr><tr><td>Zolpidem</td><td>Generic, Ambien, Ambien-CR</td></tr></table>
======================================
<table><tr><td></td><td>BENZODIAZEPINES</td></tr><tr><td>Alprazolam</td><td>Generic, Xanax</td></tr><tr><td>Chlordiazepoxide</td><td>Generic, Librium</td></tr><tr><td>Clonazepam</td><td>Generic, Tranxene</td></tr><tr><td>Clorazepate</td><td>Generic, Klonopin</td></tr><tr><td>Diazepam</td><td>Generic, Valium</td></tr><tr><td>Estazolam</td><td>Generic, ProSom</td></tr><tr><td>Flurazepam</td><td>Generic, Dalmane</td></tr><tr><td>Lorazepam</td><td>Generic, Ativan</td></tr><tr><td>Midazolam</td><td>Generic, Versed</td></tr><tr><td>Oxazepam</td><td>Generic, Serax</td></tr><tr><td>Quazepam</td><td>Generic, Doral</td></tr><tr><td>Temazepam</td><td>Generic, Restoril</td></tr><tr><td>Triazolam</td><td>Generic, Halcion</td></tr><tr><td>Flumazenil</td><td>Generic, Romazicon</td></tr><tr><td>Amobarbital</td><td>Amytal</td></tr><tr><td>Mephobarbital</td><td>Mebaral (withdrawn)</td></tr></table>
======================================
<table><thead><th>BAC(mg/dL)'</th><th>_ Clinical Effect</th></thead><tr><td>50-100</td><td>Sedation, subjective “high,’ slower reaction times</td></tr><tr><td>100-200</td><td>Impaired motor function, slurred speech, ataxia</td></tr><tr><td>200-300</td><td>Emesis, stupor</td></tr><tr><td>300-400</td><td>Coma</td></tr><tr><td>&gt;400</td><td>Respiratory depression, death</td></tr></table>
======================================
<table><thead><th>Subclass, D:</th><th>Mechanism of Action, Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="4">ALCOHOLS</td></tr><tr><td>+ Ethanol</td><td>Multiple effects on neurotransmitter receptors, ion channels, and signaling pathways</td><td>Antidote in methanol and ethylene glycol poisoning; topical antiseptic</td><td>Zero-order metabolism + duration depends on dose - Toxicity: Acutely, central nervous system depression and respiratory failure + chronically, damage to many systems, including liver, pancreas, gastrointestinal tract, and central and peripheral nervous systems « Interactions: Induces CYP2E1 increased conversion of acetaminophen to toxic metabolite</td></tr></table>
======================================
<table><tr><td colspan="4">DRUGS USED IN ACUTE ETHANOL WITHDRAWAL</td></tr><tr><td>+ Benzodiazepines (eg, chlordiazepoxide, diazepam, {eieciapei))</td><td>BDZ receptor agonists that facilitate GABA- mediated activation of GABA, receptors</td><td>Prevention and treatment of acute ethanol withdrawal syndrome</td><td>See Chapter 22</td></tr><tr><td>+ Thiamine (vitamin B,)</td><td>Essential vitamin required for synthesis of the coenzyme thiamine pyrophosphate</td><td>Administered to patients suspected of having alcoholism (those exhibiting acute alcohol intoxication or alcohol withdrawal syndrome) to prevent Wernicke-Korsakoff syndrome</td><td>(einintsere parenterally + Toxicity: « Interactions:</td></tr><tr><td colspan="4">DRUGS USED IN CHRONIC ALCOHOLISM</td></tr><tr><td>+ Naltrexone</td><td>Nonselective competitive antagonist of opioid receptors</td><td>Reduced risk of relapse in individuals with alcoholism</td><td>Available as an oral or long-acting parenteral formulation + Toxicity: Gl effects and liver toxicity; will precipitate a withdrawal reaction in individuals physically dependent on lle and will prevent the analgesic effect of opioids</td></tr><tr><td></td><td>Poorly understood NMDA receptor antagonist and hE ragonisy effects</td><td>Reduced risk of relapse in indi with alcoholism</td><td></td></tr><tr><td>+ Disulfiram</td><td>Inhibits aldehyde dehydrogenase, resulting in aldehyde accumulation during ethanol ingestion</td><td>Deterrent to drinking in individuals with alcohol dependence; rarely used</td><td>Toxicity: Li Little effect alone but severe and potentially dangerous flushing, headache, nausea, vomiting, and hypotension when combined with ethanol</td></tr><tr><td colspan="4">DRUGS USED IN ACUTE MI ETHANOL OR ETHYLENE GLYCOL TOXICITY</td></tr><tr><td>+ Fomepizole</td><td>Inhibits alcohol dehydrogenase, prevents conversion of methanol and ethylene glycol to toxic metabolites</td><td>Methanol and ethylene glycol poisoning</td><td>Orphan drug + Toxicity: Headache, nausea, dizziness, rare allergic reactions</td></tr></table>
======================================
<table><tr><td>Chlordiazepoxide HCI</td><td>Generic, Librium</td></tr><tr><td>Diazepam</td><td>Generic, Valium</td></tr><tr><td>Lorazepam</td><td>Generic, Ativan</td></tr><tr><td>Oxazepam</td><td>Generic, Serax</td></tr><tr><td>Thiamine HCI</td><td>Generic</td></tr></table>
======================================
<table><tr><td colspan="2">Voltage-gated ion channels</td></tr><tr><td>Voltage-gated sodium channels (Na,)</td><td>Phenytoin, fosphenytoin’, carbamazepine, oxcarbazepine’, eslicarbazepine acetate’, lamotrigine, lacosamide; possibly topiramate, zonisamide, rufinamide</td></tr><tr><td>Voltage-gated calcium channels (T-type)</td><td>Ethosuximide</td></tr><tr><td>Voltage-gated potassium channels (K,7)</td><td>Retigabine (ezogabine)</td></tr><tr><td colspan="2">GABA inhibition</td></tr><tr><td>GABAy receptors</td><td>Phenobarbital, primidone, benzodiazepines including diazepam, lorazepam, and clonazepam; possibly topiramate, felbamate, ezogabine</td></tr><tr><td>GAT-1 GABA transporter</td><td>Tiagabine</td></tr><tr><td>GABA transaminase</td><td>Vigabatrin</td></tr><tr><td colspan="2">Synaptic release machinery</td></tr><tr><td>SV2A</td><td>Levetiracetam, brivaracetam</td></tr><tr><td>0126</td><td>Gabapentin, gabapentin enacarbil*, pregabalin</td></tr><tr><td colspan="2">lonotropic glutamate receptors</td></tr><tr><td>AMPA receptor</td><td>Perampanel</td></tr><tr><td>Mixed/unknown”</td><td>Valproate, felbamate, topiramate, zonisamide, rufinamide, adrenocorticotropin</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Reference Range’</th></thead><tr><td>Carbamazepine</td><td>15-45</td><td>4-12</td></tr><tr><td>Clobazam</td><td>0.1-1.0</td><td>0.03-0.30</td></tr><tr><td>Clonazepam</td><td>60-220 nmol/L</td><td>19-70 ng/mL</td></tr><tr><td>Ethosuximide</td><td>300-600</td><td>40-100</td></tr><tr><td>Phenytoin</td><td>40-80</td><td>10-20</td></tr><tr><td>Phenobarbital</td><td>65-172</td><td>15-40</td></tr><tr><td rowspan="2">Primidone</td><td></td><td>Primidone: 37-55</td><td>Primidone: 8-12</td></tr><tr><td>Phenobarbital: 65-129</td><td>— Phenobarbital: 15-30</td></tr><tr><td>Valproate</td><td>300-600</td><td>40-100</td></tr><tr><td>Eslicarbazepine acetate”</td><td>20-140</td><td>5-35</td></tr><tr><td>Retigabine</td><td>No data</td><td></td></tr><tr><td>(Ezogabine) Felbamate</td><td>125-250</td><td>30-60</td></tr><tr><td>Gabapentin</td><td>70-120</td><td>12-21</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Lacosamide Lamotrigine</td><td>40-80 10-60</td><td>10-20 3-15</td></tr><tr><td>Levetiracetam</td><td>70-270</td><td>12-46</td></tr><tr><td>Oxcarbazepine*</td><td>20-140</td><td>5-35</td></tr><tr><td>Perampanel</td><td>0.14-1.14</td><td>0.05-0.4</td></tr><tr><td>Pregabalin®</td><td>18-52</td><td>2.8-8.2</td></tr><tr><td>Rufinamide*</td><td>37-168</td><td>9-40</td></tr><tr><td>Stiripentol*</td><td>34-51</td><td>8-12</td></tr><tr><td>Tiagabine</td><td>0.05-0.53</td><td>0.02-0.2</td></tr><tr><td>Topiramate</td><td>15-60</td><td>5-20</td></tr><tr><td>Vigabatrin</td><td>6-279</td><td>0.8-36</td></tr><tr><td>Zonisamide</td><td>47-188</td><td>10-40</td></tr><tr><td colspan="3">‘These data are provided only as a general guideline. Many patients will respond better at different levels, and some patients may have drug-related adverse events within the listed reference ranges.</td></tr></table>
======================================
<table><thead><th></th><th></th><th>Pharmacokinetics</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">SODIUM CHANNEL BLOCKERS</td></tr><tr><td>+ Carbamazepine</td><td>Sodium channel blocker</td><td>Rapidly absorbed orally, with bioavailability 75-85% + peak levels in 4-5 h- plasma protein binding 75% + extensively metabolized in liver, in part to active carbamazepine-10, 11-epoxide - t,,. of parent in adults initially 25-65 h, decreasing to 12-17 h with autoinduction</td><td>Focal and focal-to-bilateral tonic-clonic seizures; trigeminal neuralgia</td><td>Toxicity: Nausea, diplopia, ataxia, hyponatremia, headache - Interactions: Phenytoin, valproate, fluoxetine, verapamil, macrolide antibiotics, isoniazid, propoxyphene, danazol, phenobarbital, primidone, many others</td></tr></table>
======================================
<table><thead><th>+ Lamotrigine</th><th>Sodium channel blocker</th><th>Nearly complete (~90%) absorption + peak levels in 1-3 h- protein binding 55% + extensively metabolized; no active metabolites « t,,.8-35 h</th><th>Focal seizures, generalized tonic-clonic seizures, absence seizures, other generalized seizures; bipolar depression</th><th>Toxicity: Dizziness, headache, diplopia, rash + Interactions: Valproate, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, succinimides, sertraline, topiramate</th></thead><tr><td></td><td>Sodium channel blocker, slow blocking kinetics</td><td>Complete absorption « peak levels in 1-2 h- protein binding &lt;30% « no active metabolites ty. 12-14h</td><td></td><td>Toxicity: Dizziness, headache, nausea + small increase in PR interval + Interactions: Minimal</td></tr><tr><td>+ Phenytoin, fosphenytoin</td><td>Sodium channel blocker</td><td>Absorption is formulation dependent + highly bound to plasma proteins no active metabolites + dose-dependent elimination, t,. 12-36 h + fosphenytoin is for IV, IM routes</td><td>Focal seizures, tonic-clonic seizures</td><td>Toxicity: Diplopia, ataxia, gingival hyperplasia, hirsutism, neuropathy + Interactions: Phenobarbital, carbamazepine, isoniazid, felbamate, oxcarbazepine, topiramate, fluoxetine, fluconazole, digoxin, quinidine, cyclosporine, steroids, oral contraceptives, others</td></tr></table>
======================================
<table><thead><th>+ Lamotrigine</th><th>Sodium channel blocker</th><th>Nearly complete (~90%) absorption + peak levels in 1-3 h- protein binding 55% + extensively metabolized; no active metabolites « t,,.8-35 h</th><th>Focal seizures, generalized tonic-clonic seizures, absence seizures, other generalized seizures; bipolar depression</th><th>Toxicity: Dizziness, headache, diplopia, rash + Interactions: Valproate, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, succinimides, sertraline, topiramate</th></thead><tr><td></td><td>Sodium channel blocker, slow blocking kinetics</td><td>Complete absorption « peak levels in 1-2 h- protein binding &lt;30% « no active metabolites ty. 12-14h</td><td></td><td>Toxicity: Dizziness, headache, nausea + small increase in PR interval + Interactions: Minimal</td></tr><tr><td>+ Phenytoin, fosphenytoin</td><td>Sodium channel blocker</td><td>Absorption is formulation dependent + highly bound to plasma proteins no active metabolites + dose-dependent elimination, t,. 12-36 h + fosphenytoin is for IV, IM routes</td><td>Focal seizures, tonic-clonic seizures</td><td>Toxicity: Diplopia, ataxia, gingival hyperplasia, hirsutism, neuropathy + Interactions: Phenobarbital, carbamazepine, isoniazid, felbamate, oxcarbazepine, topiramate, fluoxetine, fluconazole, digoxin, quinidine, cyclosporine, steroids, oral contraceptives, others</td></tr></table>
======================================
<table><thead><th>Type, Drug</th><th>of Action</th><th>Pharmacokinetics</th><th>Clinical Applications</th><th>Toxicities, Interactions</th></thead><tr><td colspan="5">BROAD SPECTRUM</td></tr><tr><td>+ Valproate</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak levels formulation dependent + highly (90%) bound to plasma proteins + extensively metabolized in liver *typ5-16h</td><td>Generalized tonic-clonic seizures, partial seizures, absence seizures, myoclonic seizures, other generalized seizure; migraine prophylaxis</td><td>Toxicity: Nausea, tremor, weight gain, hair loss, teratogenic, hepatotoxic + Interactions: Phenobarbital, phenytoin, carbamazepine, lamotrigine, felbamate, rifampin, ethosuximide, primidone</td></tr><tr><td>+ Levetiracetam</td><td>SV2A ligand</td><td>Nearly complete (~95%) absorption + peak levels in 1-2 h+ not bound to plasma proteins + minimal metabolism in blood to inactive metabolite; ~66% excreted unchanged in urine *typ6-11h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Nervousness, dizziness, depression, seizures + Interactions: Rare</td></tr><tr><td>Brivaracetam: Similar + Topiramate</td><td>to levetiracetam but in Multiple actions</td><td>teraction with carbamazepine Bioavailability ~80% + peak levels in</td><td>Focal seizures, primary</td><td>Toxicity: Somnolence, cognitive slowing,</td></tr><tr><td></td><td></td><td>2-4 h+ minimal (15%) plasma protein binding - variable metabolism; no active metabolites; 20-70% excreted unchanged in the urine + f;/. 20-30 h, but decreases with concomitant drugs</td><td>generalized seizures, Lennox- Gastaut syndrome; migraine prophylaxis</td><td>confusion, paresthesias « Interactions: Phenytoin, carbamazepine, oral contraceptives, lamotrigine, lithium?</td></tr><tr><td>+ Zonisamide</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak concentrations in 2-6 h » modest (40-60%) plasma protein binding + moderate (&gt; 50%) metabolism in liver; 30% excreted unchanged in urine + t/250-70 h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Drowsiness, cognitive impairment, confusion, skin rashes « Interactions: Minimal</td></tr><tr><td>+ Rufinamide</td><td>Sodium channel blocker and other mechanisms</td><td>Well absorbed orally peak concentrations in 4-6 h + low (35%) plasma protein binding « t, 6-10 h +no active metabolites + mostly excreted in urine</td><td>Lennox-Gastaut syndrome; focal seizures</td><td>Toxicity: Somnolence, vomiting, pyrexia, diarrhea + Interactions: Not metabolized via P450 enzymes, but antiseizure drug interactions may be present</td></tr><tr><td>GABAPENTINOIDS + Gabapentin</td><td>128 ligand (Ca”* channel and possibly other sites)</td><td>Bioavailability 50%, decreasing with increasing doses + peak concentrations in 2-3 h+ not bound to plasma proteins + not metabolized; 100% excreted unchanged in urine + ty25-9h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr><tr><td>+ Pregabalin BARBITURATES</td><td>28 ligand (Ca** channel and possibly other sites)</td><td>Nearly complete (~90%) absorption + peak concentrations in 1-2 h + not bound to plasma proteins « not metabolized; 98% excreted unchanged in urine + t,,.4.5-7 h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; fibromyalgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr></table>
======================================
<table><thead><th>Type, Drug</th><th>of Action</th><th>Pharmacokinetics</th><th>Clinical Applications</th><th>Toxicities, Interactions</th></thead><tr><td colspan="5">BROAD SPECTRUM</td></tr><tr><td>+ Valproate</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak levels formulation dependent + highly (90%) bound to plasma proteins + extensively metabolized in liver *typ5-16h</td><td>Generalized tonic-clonic seizures, partial seizures, absence seizures, myoclonic seizures, other generalized seizure; migraine prophylaxis</td><td>Toxicity: Nausea, tremor, weight gain, hair loss, teratogenic, hepatotoxic + Interactions: Phenobarbital, phenytoin, carbamazepine, lamotrigine, felbamate, rifampin, ethosuximide, primidone</td></tr><tr><td>+ Levetiracetam</td><td>SV2A ligand</td><td>Nearly complete (~95%) absorption + peak levels in 1-2 h+ not bound to plasma proteins + minimal metabolism in blood to inactive metabolite; ~66% excreted unchanged in urine *typ6-11h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Nervousness, dizziness, depression, seizures + Interactions: Rare</td></tr><tr><td>Brivaracetam: Similar + Topiramate</td><td>to levetiracetam but in Multiple actions</td><td>teraction with carbamazepine Bioavailability ~80% + peak levels in</td><td>Focal seizures, primary</td><td>Toxicity: Somnolence, cognitive slowing,</td></tr><tr><td></td><td></td><td>2-4 h+ minimal (15%) plasma protein binding - variable metabolism; no active metabolites; 20-70% excreted unchanged in the urine + f;/. 20-30 h, but decreases with concomitant drugs</td><td>generalized seizures, Lennox- Gastaut syndrome; migraine prophylaxis</td><td>confusion, paresthesias « Interactions: Phenytoin, carbamazepine, oral contraceptives, lamotrigine, lithium?</td></tr><tr><td>+ Zonisamide</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak concentrations in 2-6 h » modest (40-60%) plasma protein binding + moderate (&gt; 50%) metabolism in liver; 30% excreted unchanged in urine + t/250-70 h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Drowsiness, cognitive impairment, confusion, skin rashes « Interactions: Minimal</td></tr><tr><td>+ Rufinamide</td><td>Sodium channel blocker and other mechanisms</td><td>Well absorbed orally peak concentrations in 4-6 h + low (35%) plasma protein binding « t, 6-10 h +no active metabolites + mostly excreted in urine</td><td>Lennox-Gastaut syndrome; focal seizures</td><td>Toxicity: Somnolence, vomiting, pyrexia, diarrhea + Interactions: Not metabolized via P450 enzymes, but antiseizure drug interactions may be present</td></tr><tr><td>GABAPENTINOIDS + Gabapentin</td><td>128 ligand (Ca”* channel and possibly other sites)</td><td>Bioavailability 50%, decreasing with increasing doses + peak concentrations in 2-3 h+ not bound to plasma proteins + not metabolized; 100% excreted unchanged in urine + ty25-9h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr><tr><td>+ Pregabalin BARBITURATES</td><td>28 ligand (Ca** channel and possibly other sites)</td><td>Nearly complete (~90%) absorption + peak concentrations in 1-2 h + not bound to plasma proteins « not metabolized; 98% excreted unchanged in urine + t,,.4.5-7 h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; fibromyalgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr></table>
======================================
<table><thead><th>Type, Drug</th><th>of Action</th><th>Pharmacokinetics</th><th>Clinical Applications</th><th>Toxicities, Interactions</th></thead><tr><td colspan="5">BROAD SPECTRUM</td></tr><tr><td>+ Valproate</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak levels formulation dependent + highly (90%) bound to plasma proteins + extensively metabolized in liver *typ5-16h</td><td>Generalized tonic-clonic seizures, partial seizures, absence seizures, myoclonic seizures, other generalized seizure; migraine prophylaxis</td><td>Toxicity: Nausea, tremor, weight gain, hair loss, teratogenic, hepatotoxic + Interactions: Phenobarbital, phenytoin, carbamazepine, lamotrigine, felbamate, rifampin, ethosuximide, primidone</td></tr><tr><td>+ Levetiracetam</td><td>SV2A ligand</td><td>Nearly complete (~95%) absorption + peak levels in 1-2 h+ not bound to plasma proteins + minimal metabolism in blood to inactive metabolite; ~66% excreted unchanged in urine *typ6-11h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Nervousness, dizziness, depression, seizures + Interactions: Rare</td></tr><tr><td>Brivaracetam: Similar + Topiramate</td><td>to levetiracetam but in Multiple actions</td><td>teraction with carbamazepine Bioavailability ~80% + peak levels in</td><td>Focal seizures, primary</td><td>Toxicity: Somnolence, cognitive slowing,</td></tr><tr><td></td><td></td><td>2-4 h+ minimal (15%) plasma protein binding - variable metabolism; no active metabolites; 20-70% excreted unchanged in the urine + f;/. 20-30 h, but decreases with concomitant drugs</td><td>generalized seizures, Lennox- Gastaut syndrome; migraine prophylaxis</td><td>confusion, paresthesias « Interactions: Phenytoin, carbamazepine, oral contraceptives, lamotrigine, lithium?</td></tr><tr><td>+ Zonisamide</td><td>Unknown</td><td>Nearly complete (&gt;90%) absorption + peak concentrations in 2-6 h » modest (40-60%) plasma protein binding + moderate (&gt; 50%) metabolism in liver; 30% excreted unchanged in urine + t/250-70 h</td><td>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures</td><td>Toxicity: Drowsiness, cognitive impairment, confusion, skin rashes « Interactions: Minimal</td></tr><tr><td>+ Rufinamide</td><td>Sodium channel blocker and other mechanisms</td><td>Well absorbed orally peak concentrations in 4-6 h + low (35%) plasma protein binding « t, 6-10 h +no active metabolites + mostly excreted in urine</td><td>Lennox-Gastaut syndrome; focal seizures</td><td>Toxicity: Somnolence, vomiting, pyrexia, diarrhea + Interactions: Not metabolized via P450 enzymes, but antiseizure drug interactions may be present</td></tr><tr><td>GABAPENTINOIDS + Gabapentin</td><td>128 ligand (Ca”* channel and possibly other sites)</td><td>Bioavailability 50%, decreasing with increasing doses + peak concentrations in 2-3 h+ not bound to plasma proteins + not metabolized; 100% excreted unchanged in urine + ty25-9h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr><tr><td>+ Pregabalin BARBITURATES</td><td>28 ligand (Ca** channel and possibly other sites)</td><td>Nearly complete (~90%) absorption + peak concentrations in 1-2 h + not bound to plasma proteins « not metabolized; 98% excreted unchanged in urine + t,,.4.5-7 h</td><td>Focal seizures; neuropathic pain; postherpetic neuralgia; fibromyalgia; anxiety</td><td>Toxicity: Somnolence, dizziness, ataxia + Interactions: Minimal</td></tr></table>
======================================
<table><thead><th>+ Phenobarbital</th><th>Positive allosteric modulator of GABA, receptors + reduces excitatory synaptic responses</th><th>Nearly complete (&gt;90%) absorption + peak concentrations in 0.5-4h + modest (55%) plasma protein binding + extensively metabolized in liver; no active metabolites; 20-25% excreted unchanged in urine « ty) 75-140 h</th><th>Focal seizures, generalized tonic-clonic seizures, myoclonic seizures, neonatal seizures; sedation</th><th>Toxicity: Sedation, cognitive issues, ataxia, hyperactivity + Interactions: Valproate, carbamazepine, felbamate, phenytoin, cyclosporine, felodipine, lamotrigine, nifedipine, nimodipine, steroids, theophylline, verapamil, others</th></thead><tr><td>+ Primidone</td><td>Sodium channel blocker-like but converted to phenobarbital</td><td>Nearly complete (&gt;90%) absorption + minimal (10%) plasma protein binding + peak concentrations in 2-6 h + extensively metabolized in liver; 2 active metabolites (phenobarbital and phenylethylmalonamide); 65% excreted unchanged in urine « t,,. 10-25 h</td><td>Generalized tonic-clonic seizures, partial seizures</td><td>Toxicity: Sedation, cognitive issues, ataxia, hyperactivity + Interactions: Similar to phenobarbital</td></tr></table>
======================================
<table><thead><th></th><th></th><th>Pharmacokinetics</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">ABSENCE SEIZURE-SPECIFIC</td></tr><tr><td>+ Ethosuximide</td><td>Inhibit low- threshold calcium channels (Ttype)</td><td>Nearly complete (&gt;90%) absorption + peak concentrations in 3-7 h+ not bound to plasma proteins - extensively metabolized in liver; no active metabolites; 20% excreted unchanged in urine « ty) 20-60 h</td><td>Absence seizures</td><td>Toxicity: Nausea, headache, dizziness, lethargy - Interactions: Valproate, phenobarbital, phenytoin, carbamazepine, rifampicin</td></tr><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Diazepam</td><td>Positive allosteric modulator of GABA, receptors</td><td>Nearly complete (&gt;90%) oral or rectal absorption + peak concentrations in 1-1.5 h- IV for status epilepticus + highly (95-98%) bound to plasma proteins + extensively metabolized to several active metabolites « t,,. of active metabolite N-desmethyldiazepam up to 100h</td><td>Status epilepticus, seizure clusters; sedation, anxiety, muscle relaxation (muscle spasms, spasticity), acute alcohol withdrawal</td><td>Toxicity: Sedation + Interactions: Additive with sedative-hypnotics</td></tr><tr><td>+ Clonazepam</td><td>Positive allosteric modulator of GABA, receptors</td><td>Bioavailability &gt;80% + peak concentrations in 1-4 h « highly (86%) bound to plasma proteins - extensively metabolized in liver; no active metabolites + t),. 12-56h</td><td>Absence seizures, myoclonic seizures, infantile spasms</td><td>Toxicity: Similar to diazepam « Interactions: Additive with sedative-hypnotics</td></tr></table>
======================================
<table><thead><th></th><th></th><th>Pharmacokinetics</th><th></th><th>ies, Interactions</th></thead><tr><td colspan="5">ABSENCE SEIZURE-SPECIFIC</td></tr><tr><td>+ Ethosuximide</td><td>Inhibit low- threshold calcium channels (Ttype)</td><td>Nearly complete (&gt;90%) absorption + peak concentrations in 3-7 h+ not bound to plasma proteins - extensively metabolized in liver; no active metabolites; 20% excreted unchanged in urine « ty) 20-60 h</td><td>Absence seizures</td><td>Toxicity: Nausea, headache, dizziness, lethargy - Interactions: Valproate, phenobarbital, phenytoin, carbamazepine, rifampicin</td></tr><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Diazepam</td><td>Positive allosteric modulator of GABA, receptors</td><td>Nearly complete (&gt;90%) oral or rectal absorption + peak concentrations in 1-1.5 h- IV for status epilepticus + highly (95-98%) bound to plasma proteins + extensively metabolized to several active metabolites « t,,. of active metabolite N-desmethyldiazepam up to 100h</td><td>Status epilepticus, seizure clusters; sedation, anxiety, muscle relaxation (muscle spasms, spasticity), acute alcohol withdrawal</td><td>Toxicity: Sedation + Interactions: Additive with sedative-hypnotics</td></tr><tr><td>+ Clonazepam</td><td>Positive allosteric modulator of GABA, receptors</td><td>Bioavailability &gt;80% + peak concentrations in 1-4 h « highly (86%) bound to plasma proteins - extensively metabolized in liver; no active metabolites + t),. 12-56h</td><td>Absence seizures, myoclonic seizures, infantile spasms</td><td>Toxicity: Similar to diazepam « Interactions: Additive with sedative-hypnotics</td></tr></table>
======================================
<table><thead><th>Tiagabine</th><th>transporter inhibitor</th><th>Nearly complete (~90%) absorption + peak concentrations in 0.5-2 h- highly (96%) bound to plasma proteins + extensively metabolized in liver; no active metabolites; &lt;2% excreted unchanged in urine t,,. 2-9_h</th><th></th><th>Toxicity: Nervousness, dizziness, depression, seizures + Interactions: Phenobarbital, phenytoin, carbamazepine, primidone</th></thead><tr><td>+ Vigabatrin</td><td>Irreversible inhibitor of GABA transaminase</td><td>Complete absorption + peak concentrations in 1h + not bound to plasma proteins + not metabolized; eliminated unchanged in urine * ty25-8 h (not relevant because of irreversible action)</td><td>Focal seizures, infantile spasms</td><td>Toxicity: Drowsiness, dizziness, psychosis, visual field loss « Interactions: Minimal</td></tr></table>
======================================
<table><tr><td>Retigabine (ezogabine)</td><td>Opens KCNQ potassium channels</td><td>Bioavailability ~60% + peak concentrations in 0.5-2 h « moderately (~80%) bound to plasma proteins + extensively metabolized in liver; 36% excreted unchanged in urine *ty7-11h</td><td>Focal seizures</td><td>Toxicity: Dizziness, somnolence, confusion, blurred vision « Interactions: minimal</td></tr></table>
======================================
<table><tr><td>Methsuximide</td><td>Celontin</td></tr><tr><td>Oxcarbazepine</td><td>Generic, Trileptal, Oxtellar XR</td></tr><tr><td>Pentobarbital sodium</td><td>Generic, Nembutal Sodium</td></tr><tr><td>Perampanel</td><td>Fycompa</td></tr><tr><td>Phenobarbital</td><td>Generic, Luminal Sodium, others</td></tr><tr><td>Phenytoin</td><td>Phenytoin, Dilantin, others</td></tr><tr><td>Pregabalin</td><td>Lyrica</td></tr><tr><td>Primidone</td><td>Generic, Mysoline</td></tr><tr><td>Retigabine (ezogabine)</td><td>Potiga, Trobalt</td></tr><tr><td>Rufinamide</td><td>Banzel</td></tr><tr><td>Stiripentol</td><td>Diacomit</td></tr><tr><td>Tiagabine</td><td>Generic, Gabitril</td></tr><tr><td colspan="2">Topiramate forms</td></tr><tr><td>Topiramate</td><td>Generic, Topamax</td></tr><tr><td>Topiramate extended release</td><td>Trokendi XR, Qudexy XR</td></tr><tr><td>Trimethadione</td><td>Tridione</td></tr><tr><td colspan="2">Valproate/valproic acid forms</td></tr><tr><td>Valproic acid</td><td>Generic, Depakene</td></tr><tr><td>Divalproex sodium delayed release</td><td>Generic, Depakote</td></tr><tr><td>Divalproex sodium extended release</td><td>Depakote ER</td></tr><tr><td>Valproate sodium injection</td><td>Generic, Depacon</td></tr><tr><td>Vigabatrin</td><td>Sabril</td></tr></table>
======================================
<table><tr><td colspan="2">Carbamazepine forms</td></tr><tr><td>Carbamazepine</td><td>Generic, Tegretol</td></tr><tr><td>Carbamazepine injection</td><td>Carnexiv</td></tr><tr><td>Clobazam</td><td>Onfi</td></tr><tr><td>Clonazepam</td><td>Generic, Klonopin</td></tr><tr><td>Clorazepate dipotassium</td><td>Generic, Tranxene</td></tr><tr><td colspan="2">Diazepam forms</td></tr><tr><td>Diazepam</td><td>Generic, Valium, others</td></tr><tr><td>Diazepam rectal gel</td><td>Diastat Acudial</td></tr><tr><td>Eslicarbazepine acetate</td><td>Aptiom, Stedesa</td></tr><tr><td>Ethosuximide</td><td>Generic, Zarontin</td></tr><tr><td>Ethotoin</td><td>Peganone</td></tr><tr><td>Felbamate</td><td>Generic, Felbatol</td></tr><tr><td>Fosphenytoin</td><td>Generic, Cerebyx</td></tr><tr><td>Gabapentin</td><td>Generic, Neurontin, Gralise</td></tr><tr><td>Gabapentin enacarbil</td><td>Horizant</td></tr><tr><td colspan="2">Lacosamide forms</td></tr><tr><td>Lacosamide</td><td>Vimpat</td></tr><tr><td>Lacosamide injection</td><td>Vimpat injection</td></tr><tr><td colspan="2">Lamotrigine forms</td></tr><tr><td>Lamotrigine</td><td>Generic, Lamictal</td></tr><tr><td>Lamotrigine extended release</td><td>Generic, Lamictal XR</td></tr><tr><td>Levetiracetam</td><td>Generic, Keppra, Spritam</td></tr><tr><td>Lorazepam</td><td>Generic, Ativan</td></tr><tr><td>Mephenytoin</td><td>Mesantoin (discontinued in</td></tr></table>
======================================
<table><thead><th>Anesthetic</th><th>Blood:Gas Partition Coefficient’</th><th>Brain:Blood Partition Coefficient’</th><th>Minimal Alveolar Concentration (MAC) (%)?</th><th>Metabolism</th><th>Comments</th></thead><tr><td>Nitrous oxide</td><td>0.47</td><td>ilcil</td><td>&gt;100</td><td></td><td>Incomplete anesthetic; rapid onset and recovery</td></tr><tr><td>Desflurane</td><td>0.42</td><td>1.3</td><td>6-7</td><td>&lt;0.05%</td><td>Low volatility; poor induction agent (pungent); rapid recovery</td></tr><tr><td>Sevoflurane</td><td>0.69</td><td>eZ</td><td>2.0</td><td>2-5% (fluoride)</td><td>Rapid onset and recovery; unstable in soda-lime</td></tr><tr><td>Isoflurane</td><td>1.40</td><td>2.6</td><td>1.40</td><td>&lt;2%</td><td>Medium rate of onset and recovery</td></tr><tr><td>Enflurane</td><td>1.80</td><td>1.4</td><td>17</td><td>8%</td><td>Medium rate of onset and recovery</td></tr><tr><td>Halothane</td><td>2.30</td><td>2.9</td><td>0.75</td><td>&gt;40%</td><td>Medium rate of onset and recovery</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Induction Dose (mg/kg IV)</th><th>Duration of Action (min)</th><th>Vass (L/kg)</th><th>t,, Distribution (min)</th><th>Protein Binding (%)</th><th>CL (mL/kg/ min)</th><th>t,, Elimination (h)</th></thead><tr><td>Dexmedetomidine</td><td></td><td></td><td>2-3</td><td></td><td>94</td><td>10-30</td><td>23</td></tr><tr><td>Diazepam</td><td></td><td>15-30</td><td>0.7-1.7</td><td></td><td>98</td><td>0.2-0.5</td><td>20-50</td></tr><tr><td>Etomidate</td><td></td><td>3-8</td><td>2.5-4.5</td><td></td><td>77</td><td>18-25</td><td>2.9-5.3</td></tr><tr><td>Ketamine</td><td></td><td>5-10</td><td>3.1</td><td></td><td>12</td><td>12-17</td><td></td></tr><tr><td>Lorazepam</td><td></td><td>60-120</td><td>0.8-1.3</td><td></td><td>98</td><td>0.8-1.8</td><td></td></tr><tr><td>Methohexital</td><td></td><td>47</td><td>2.2</td><td></td><td>73</td><td></td><td></td></tr><tr><td>Midazolam</td><td></td><td>15-20</td><td>1.1-1.7</td><td></td><td>94</td><td></td><td></td></tr><tr><td>Propofol</td><td></td><td>3-8</td><td>2-10</td><td></td><td>97</td><td></td><td></td></tr><tr><td>Thiopental</td><td></td><td>5-10</td><td>2.5</td><td></td><td>83</td><td></td><td></td></tr></table>
======================================
<table><tr><td>Desflurane</td><td>Suprane</td></tr><tr><td>Dexmedetomidine</td><td>Precedex</td></tr><tr><td>Diazepam</td><td>Generic, Valium</td></tr><tr><td>Droperidol</td><td>Generic, Inapsine</td></tr><tr><td>Enflurane</td><td>Enflurane, Ethrane</td></tr><tr><td>Etomidate</td><td>Generic, Amidate</td></tr><tr><td>Fospropofol</td><td>Lusedra</td></tr><tr><td>Halothane</td><td>Generic, Fluothane</td></tr><tr><td>Isoflurane</td><td>Generic, Forane, Terrell</td></tr></table>
======================================
<table><thead><th>Agent</th><th>ty 2 Distribution (min)</th><th>ty 2 Elimination (h)</th><th>Vass (L)</th><th>CL (L/min)</th></thead><tr><td>Bupivacaine</td><td>28</td><td>3.5</td><td>72</td><td>0.47</td></tr><tr><td>Lidocaine</td><td>10</td><td>1.6</td><td>91</td><td>0.95</td></tr><tr><td>Mepivacaine</td><td>7</td><td>1.9</td><td>84</td><td>0.78</td></tr><tr><td>Prilocaine</td><td>5</td><td>15</td><td>261</td><td>2.84</td></tr><tr><td>Ropivacaine</td><td>23</td><td>42</td><td>47</td><td>0.44</td></tr></table>
======================================
<table><thead><th>Fiber Type</th><th>Function</th><th>Diameter (11m)</th><th>Myelination</th><th>Conduction Velocity (m/s)</th><th></th></thead><tr><td colspan="6">TypeA</td></tr><tr><td>Alpha</td><td>Proprioception, motor</td><td></td><td>Heavy</td><td>70-120</td><td></td></tr><tr><td>Beta</td><td>Touch, pressure</td><td></td><td>Heavy</td><td>30-70</td><td></td></tr><tr><td>Gamma</td><td>Muscle spindles</td><td></td><td>Heavy</td><td>15-30</td><td></td></tr><tr><td>Delta</td><td>Pain, temperature</td><td></td><td>Heavy</td><td>5-25</td><td></td></tr><tr><td>TypeB</td><td>Preganglionic autonomic</td><td></td><td>Light</td><td>3-15</td><td></td></tr><tr><td colspan="6">Type C</td></tr><tr><td>Dorsal root</td><td>Pain</td><td></td><td></td><td>0.5-2.3</td><td>F444</td></tr><tr><td>Sympathetic</td><td>Postganglionic</td><td></td><td></td><td>0.7-2.3</td><td>444+</td></tr></table>
======================================
<table><thead><th></th><th>Mechanism of Action</th><th></th><th></th><th></th></thead><tr><td>AMIDES + Lidocaine</td><td>Blockade of sodium channels</td><td>Slows, then blocks, action potential propagation</td><td>Short-duration procedures + topical (mucosal), intravenous, infiltration, spinal, epidural, minor | and major peripheral blocks</td><td>Parenteral (eg, peripheral block, but varies significantly based on specific site) duration 1-2 h + 2-4 h with epinephrine - Toxicity: Central nervous system (CNS) excitation (high-volume blocks) and local neurotoxicity</td></tr><tr><td>+ Bupivacaine</td><td>Same as lidocaine</td><td>Same as lidocaine</td><td>Longer-duration procedures (but not used topically or intravenously)</td><td>Parenteral + duration 3-6 h + Toxicity: CNS excitation + cardiovascular collapse (high-volume blocks)</td></tr></table>
======================================
<table><thead><th>+ Chloroprocaine</th><th>Like lidocaine</th><th>Like lidocaine</th><th>Very short procedures (not generally used topically or intravenously)</th><th>Parenteral » duration 30-60 min + 60-90 min with epinephrine - Toxicity: Like lidocaine</th></thead><tr><td>+ Cocaine</td><td>Same as above also has sympathomimetic effects</td><td>Same as above</td><td>Procedures requiring high surface activity and vasoconstriction</td><td>Topical or parenteral « duration 1-2 h + Toxicity: CNS excitation, convulsions, cardiac arrhythmias, hypertension, stroke</td></tr></table>
======================================
<table><tr><td>Articaine</td><td>Septocaine</td></tr><tr><td>Benzocaine (topical)</td><td>Generic</td></tr><tr><td>Bupivacaine</td><td>Generic, Marcaine, Sensorcaine</td></tr><tr><td>Chloroprocaine</td><td>Generic, Nesacaine</td></tr><tr><td>Cocaine (topical)</td><td>Generic</td></tr><tr><td>Dibucaine (topical)</td><td>Generic, Nupercainal</td></tr><tr><td>Dyclonine (topical lozenge)</td><td>Sepacol, Sucrets, Dyclone</td></tr><tr><td>Intravenous lipid emulsion for overdose</td><td>Intralipid</td></tr><tr><td>Levobupivacaine</td><td>Chirocaine, others</td></tr><tr><td>Lidocaine</td><td>Generic, Xylocaine</td></tr><tr><td>Lidocaine and hydrocortisone (patch)</td><td>Generic</td></tr><tr><td>Lidocaine and bupivacaine mixture</td><td>Duocaine</td></tr><tr><td>Lidocaine and prilocaine eutectic mixture (topical)</td><td>EMLA cream</td></tr><tr><td>Mepivacaine</td><td>Generic, Carbocaine</td></tr><tr><td>Pramoxine (topical)</td><td>Generic, Tronothane</td></tr><tr><td>Prilocaine</td><td>Citanest</td></tr><tr><td>Procaine</td><td>Generic, Novocain</td></tr><tr><td>Proparacaine (ophthalmic)</td><td>Generic, Alcaine, others</td></tr><tr><td>Ropivacaine</td><td>Generic, Naropin</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Elimination</th><th>Clearance (mL/kg/min)</th><th>Approximate Duration of Action (minutes)</th><th>Approximate Potency Relative to Tubocurarine</th></thead><tr><td colspan="5">Isoquinoline derivatives</td></tr><tr><td>Atracurium</td><td>Spontaneous’</td><td>6.6</td><td>20-35</td><td>15</td></tr><tr><td>Cisatracurium</td><td>Mostly spontaneous</td><td>5-6</td><td>25-44</td><td>1.5</td></tr><tr><td>Tubocurarine</td><td>Kidney (40%)</td><td>2.3-2.4</td><td>&gt;50</td><td>1</td></tr><tr><td colspan="5">Steroid derivatives</td></tr><tr><td>Pancuronium</td><td>Kidney (80%)</td><td>1.7-1.8</td><td>&gt;35</td><td>6</td></tr><tr><td>Rocuronium</td><td>Liver (75-90%) and kidney</td><td>2.9</td><td>20-35</td><td>0.8</td></tr><tr><td>Vecuronium</td><td>Liver (75-90%) and kidney</td><td>3-5.3</td><td>20-35</td><td>6</td></tr><tr><td colspan="5">Depolarizing agent</td></tr><tr><td>Succinylcholine</td><td>Plasma ChE” (100%)</td><td>&gt;100</td><td>&lt;8</td><td>0.4</td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">Rocuronium</th><th colspan="2">Succinylcholine</th></thead><thead><th></th><th></th><th>Phase!</th><th>Phase II</th></thead><tr><td>Administration of tubocurarine</td><td>Additive</td><td>Antagonistic</td><td>Augmented!</td></tr><tr><td>Administration of succinylcholine</td><td>Antagonistic</td><td>Additive</td><td>Augmented!</td></tr><tr><td>Effect of neostigmine</td><td>Antagonistic</td><td>Augmented!</td><td>Antagonistic</td></tr><tr><td>Initial excitatory effect on skeletal muscle</td><td></td><td>Fasciculations</td><td></td></tr><tr><td>Response to a tetanic stimulus</td><td>Unsustained (fade)</td><td>Sustained? (no fade)</td><td>Unsustained (fade)</td></tr><tr><td>Posttetanic facilitation</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Rate of recovery</td><td>30-60 min®</td><td>4-8 min</td><td>&gt;20 min*</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Effect on Autonomic Ganglia</th><th>Effect on Cardiac Muscarinic Receptors</th><th>Tendency to Cause Histamine Release</th></thead><tr><td colspan="4">Isoquinoline derivatives</td></tr><tr><td>Atracurium</td><td></td><td></td><td>Slight</td></tr><tr><td>Cisatracurium</td><td></td><td></td><td></td></tr><tr><td>Tubocurarine</td><td>Weak block</td><td></td><td>Moderate</td></tr><tr><td colspan="4">Steroid derivatives</td></tr><tr><td>Pancuronium</td><td></td><td>Moderate block</td><td></td></tr><tr><td>Rocuronium'</td><td></td><td>Slight</td><td></td></tr><tr><td>Vecuronium</td><td></td><td></td><td></td></tr><tr><td colspan="4">Other agents</td></tr><tr><td>Gallamine</td><td></td><td>Strong block</td><td></td></tr><tr><td>Succinylcholine</td><td>Stimulation</td><td>Stimulation</td><td>Slight</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Pharmacokinetics, s, Interactions</th></thead></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th></th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS</td></tr><tr><td>+ d-Tubocurarine</td><td>Competitive antagonist at nACh receptors, especially at neuromuscular junctions</td><td>Prevents depolarization by ACh, causes flaccid paralysis + can cause histamine release with hypotension + weak block of cardiac muscarinic ACh receptors</td><td>Prolonged relaxation for surgical procedures + superseded by newer nondepolarizing agents</td><td>Renal excretion + duration, ~40-60 min - Toxicities: Histamine release - hypotension + prolonged apnea</td></tr><tr><td>+ Cisatracurium</td><td>Similar to tubocurarine</td><td>Like tubocurarine but lacks histamine release and antimuscarinic effects</td><td>Prolonged relaxation for surgical procedures - relaxation of respiratory muscles to facilitate mechanical ventilation in intensive care unit</td><td>Not dependent on renal or hepatic function + duration ~25-45 min - Toxicities: Prolonged apnea but less toxic than atracurium</td></tr><tr><td>+ Rocuronium</td><td>Similar to cisatracurium</td><td>Like cisatracurium but slight antimuscarinic effect</td><td>Like cisatracurium + useful in patients with renal impairment</td><td>Hepatic metabolism + duration ~20-35 min + Toxicities: Like cisatracurium</td></tr></table>
======================================
<table><thead><th>+ Baclofen</th><th>GABA, agonist, facilitates spinal inhibition of motor neurons</th><th>Pre- and postsynaptic inhibition of motor output</th><th>Severe spasticity due to cerebral palsy, multiple sclerosis, stroke</th><th>Oral, intrathecal - Toxicities: Sedation, weakness; rebound spasticity upon abrupt withdrawal</th></thead><tr><td></td><td>Facilitates GABAergic transmission in central nervous system (see Chapter 22)</td><td>Increases interneuron inhibition of primary motor afferents in spinal cord + central sedation</td><td>Chronic spasm due to cerebral palsy, stroke, spinal cord injury + acute spasm due to muscle injury</td><td>Hepatic metabolism + duration ~12-24 h « Toxicities: See Chapter 22</td></tr><tr><td>+ Tizanidine</td><td>a,-Adrenoceptor agonist in the spinal cord</td><td>Presynaptic and postsynaptic inhibition of reflex motor output</td><td>Spasm due to multiple sclerosis, stroke, amyotrophic lateral sclerosis</td><td>Oral + renal and hepatic elimination + duration 3-6 h + Toxicities: Weakness, sedation, hypotension, hepatotoxicity (rare), rebound hypertension upon abrupt withdrawal</td></tr></table>
======================================
<table><tr><td>+ Dantrolene</td><td>Blocks RyR1 Ca’*-release channels in the sarcoplasmic reticulum of skeletal muscle</td><td>Reduces actin-myosin interaction + weakens skeletal muscle contraction</td><td>IV: Malignant hyperthermia + Oral: Spasm due to cerebral palsy, spinal cord injury, multiple sclerosis</td><td>IV, oral + duration 4-6 h + Toxicities: Muscle weakness « Black box warning: hepatotoxicity</td></tr><tr><td>+ Botulinum toxi in</td><td>Inhibits synaptic exocytosis through clipping of vesicle fusion proteins in presynaptic nerve terminal</td><td>Flaccid paralysis</td><td>Upper and lower limb spasm due to cerebral palsy, multiple sclerosis; cervical dystonia, overactive bladder, migraine, hyperhidrosis</td><td>Direct injection into muscle + duration 2-3 months + Toxicities: muscle weakness, falls</td></tr></table>
======================================
<table><tr><td>NEUROMUSCULAR</td><td>BLOCKING DRUGS</td></tr><tr><td>Atracurium</td><td>Generic</td></tr><tr><td>Cisatracurium</td><td>Generic, Nimbex</td></tr><tr><td>Pancuronium</td><td>Generic</td></tr><tr><td>Rocuronium</td><td>Generic, Zemuron</td></tr><tr><td>Succinylcholine</td><td>Generic, Anectine, Quelicin</td></tr><tr><td>Tubocurarine</td><td>Generic</td></tr><tr><td>Vecuronium</td><td>Generic, Norcuron</td></tr><tr><td>Neostigmine</td><td>Generic</td></tr><tr><td>Edrophonium</td><td>Generic</td></tr><tr><td>Sugammadex</td><td>Bridion</td></tr><tr><td>Baclofen</td><td>Generic, Lioresal, Gablofen</td></tr><tr><td>Botulinum toxin type A</td><td>Botox, Dysport, Xeomin</td></tr><tr><td>Botulinum toxin type B</td><td>Myobloc</td></tr><tr><td>Carisoprodol</td><td>Generic, Soma, Vanadom</td></tr><tr><td>Chlorzoxazone</td><td>Generic</td></tr><tr><td>Cyclobenzaprine</td><td>Generic, Amrix, Fexmid, Flexeril</td></tr><tr><td>Dantrolene</td><td>Generic, Dantrium, Revonto</td></tr><tr><td>Diazepam</td><td>Generic, Valium, Diastat</td></tr><tr><td>Gabapentin</td><td>Generic, Neurontin, Gabarone</td></tr><tr><td colspan="2">Note: This drug is labeled for use only in epilepsy and postherpetic neuralgia.</td></tr><tr><td>Metaxalone</td><td>Generic, Skelaxin</td></tr><tr><td>Methocarbamol</td><td>Generic, Robaxin</td></tr><tr><td>Orphenadrine</td><td>Generic, Norflex, others</td></tr><tr><td>Riluzole</td><td>Generic, Rilutek</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Usual Daily Dose (mg)</th></thead><tr><td>Benztropine mesylate</td><td>1-6</td></tr><tr><td>Biperiden</td><td>2-12</td></tr><tr><td>Orphenadrine</td><td>150-400</td></tr><tr><td>Procyclidine</td><td>7.5-30</td></tr><tr><td>Trihexyphenidyl</td><td>6-20</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead></table>
======================================
<table><tr><td>Amantadine</td><td>Generic, Symmetrel</td></tr><tr><td>Apomorphine</td><td>Apokyn</td></tr><tr><td>Benztropine</td><td>Generic, Cogentin</td></tr><tr><td>Biperiden</td><td>Akineton</td></tr><tr><td>Bromocriptine</td><td>Generic, Parlodel</td></tr><tr><td>Carbidopa</td><td>Lodosyn</td></tr><tr><td>Carbidopa/levodopa</td><td>Generic, Sinemet, Parcopa, Rytary</td></tr><tr><td>Carbidopa/levodopa/entacapone</td><td>Generic, Stalevo</td></tr><tr><td>Entacapone</td><td>Generic, Comtan</td></tr><tr><td>Levodopa</td><td>Dopar, others</td></tr><tr><td>Orphenadrine</td><td>Generic, various</td></tr><tr><td>Penicillamine</td><td>Cuprimine, Depen</td></tr><tr><td>Pergolide”</td><td>Permax, other</td></tr><tr><td>Pramipexole</td><td>Generic, Mirapex</td></tr><tr><td>Procyclidine</td><td>Kemadrin</td></tr><tr><td>Rasagiline</td><td>Azilect</td></tr><tr><td>Ropinirole</td><td>Generic, Requip, Requip XL</td></tr><tr><td>Safinamide</td><td>Xadago</td></tr><tr><td>Selegiline (deprenyl)</td><td>Emsam</td></tr><tr><td>Tetrabenazine</td><td>Xenazine</td></tr><tr><td>Tolcapone</td><td>Tasmar</td></tr><tr><td>Trientine</td><td>Syprine</td></tr><tr><td>Trihexyphenidyl</td><td>Generic, Artane, others</td></tr></table>
======================================
<table><thead><th>Chemical Class</th><th>Drug</th><th>D,/5-HT 2, Ratio"</th><th>Clinical Potency</th><th>Extrapyramidal Toxicity</th><th>Sedative Action</th><th>Hypotensive Actions</th></thead><tr><td colspan="7">Phenothiazines</td></tr><tr><td>Aliphatic</td><td>Chlorpromazine</td><td>High</td><td>Low</td><td>Medium</td><td>High</td><td>High</td></tr><tr><td>Piperazine</td><td>Fluphenazine</td><td>High</td><td>High</td><td>High</td><td>Low</td><td>Very low</td></tr><tr><td>Thioxanthene</td><td>Thiothixene</td><td>Very high</td><td>High</td><td>Medium</td><td>Medium</td><td>Medium</td></tr><tr><td>Butyrophenone</td><td>Haloperidol</td><td>Medium</td><td>High</td><td>Very high</td><td>Low</td><td>Very low</td></tr><tr><td>Dibenzodiazepine</td><td>Clozapine</td><td>Very low</td><td>Medium</td><td>Very low</td><td>Low</td><td>Medium</td></tr><tr><td>Benzisoxazole</td><td>Risperidone</td><td>Very low</td><td>High</td><td>Low?</td><td>Low</td><td>Low</td></tr><tr><td>Thienobenzodiazepine</td><td>Olanzapine</td><td>Low</td><td>High</td><td>Very low</td><td>Medium</td><td>Low</td></tr><tr><td>Dibenzothiazepine</td><td>Quetiapine</td><td>Low</td><td>Low</td><td>Very low</td><td>Medium</td><td>Low to medium</td></tr><tr><td>Dihydroindolone</td><td>Ziprasidone</td><td>Low</td><td>Medium</td><td>Very low</td><td>Low</td><td>Very low</td></tr><tr><td>Dihydrocarbostyril</td><td>Aripiprazole</td><td>Medium</td><td>High</td><td>Very low</td><td>Very low</td><td>Low</td></tr></table>
======================================
<table><thead><th>Type</th><th>Manifestations</th><th>Mechanism</th></thead><tr><td rowspan="2">Autonomic nervous system</td><td>Loss of accommodation, dry mouth, difficulty urinating, constipation</td><td>Muscarinic cholinoceptor blockade</td></tr><tr><td></td><td>Orthostatic hypoten- sion, impotence, failure to ejaculate</td><td>a-Adrenoceptor blockade</td></tr><tr><td rowspan="3">Central nervous system</td><td>Parkinson's syndrome, akathisia, dystonias</td><td>Dopamine-receptor blockade</td></tr><tr><td></td><td>Tardive dyskinesia</td><td>Supersensitivity of dopamine receptors</td></tr><tr><td></td><td>Toxic-confusional state</td><td>Muscarinic blockade</td></tr><tr><td>Endocrine system</td><td>Amenorrhea- galactorrhea, infertility, impotence</td><td>Dopamine-receptor blockade resulting in hyperprolactinemia</td></tr><tr><td>Other</td><td>Weight gain</td><td>Possibly combined H, and 5-HT, blockade</td></tr></table>
======================================
<table><thead><th>Drug Class</th><th>Drug</th><th>Advantages</th><th>Disadvantages</th></thead><tr><td colspan="4">Phenothiazines</td></tr><tr><td>Aliphatic</td><td>Chlorpromazine’</td><td>Generic, inexpensive</td><td>Many adverse effects, especially autonomic</td></tr><tr><td>Piperidine</td><td>Thioridazine?</td><td>Slight extrapyramidal syndrome; generic</td><td>800 mg/d limit; no parenteral form; cardiotoxicity</td></tr><tr><td>Piperazine</td><td>Fluphenazine®</td><td>Depot form also available (enanthate, decanoate)</td><td>Possible increased tardive dyskinesia</td></tr><tr><td>Thioxanthene</td><td>Thiothixene</td><td>Parenteral form also available; possible decreased tardive dyskinesia</td><td>Uncertain</td></tr><tr><td>Butyrophenone</td><td>Haloperidol</td><td>Parenteral form also available; generic</td><td>Severe extrapyramidal syndrome</td></tr><tr><td>Dibenzoxazepine</td><td>Loxapine</td><td>Possible no weight gain</td><td>Uncertain</td></tr><tr><td>Dibenzodiazepine</td><td>Clozapine</td><td>May benefit treatment-resistant patients; little extrapyramidal toxicity</td><td>May cause agranulocytosis in up to 2% of patients; dose-related lowering of seizure threshold</td></tr><tr><td>Benzisoxazole</td><td>Risperidone</td><td>Broad efficacy; little or no extrapyramidal system dysfunction at low doses</td><td>Extrapyramidal system dysfunction and hypotension with higher doses</td></tr><tr><td>Thienobenzodiazepine</td><td>Olanzapine</td><td>Effective against negative as well as positive symptoms; little or no extrapyramidal system dysfunction</td><td>Weight gain; dose-related lowering of seizure threshold</td></tr><tr><td>Dibenzothiazepine</td><td>Quetiapine</td><td>Similar to olanzapine; perhaps less weight gain</td><td>May require high doses if there is associated hypotension; short ty, and twice-daily dosing</td></tr><tr><td>Dihydroindolone</td><td>Ziprasidone</td><td>Perhaps less weight gain than clozapine, paren- teral form available</td><td>QT. prolongation</td></tr><tr><td>Dihydrocarbostyril</td><td>Aripiprazole</td><td>Lower weight gain liability, long half-life, novel mechanism potential</td><td>Uncertain, novel toxicities possible</td></tr></table>
======================================
<table><thead><th></th><th>Minimum Effective Therapeutic Dose (mg)</th><th>Usual Range of Daily Doses (mg)</th></thead><tr><td>Chlorpromazine</td><td>100</td><td>100-1000</td></tr><tr><td>Thioridazine</td><td>100</td><td>100-800</td></tr><tr><td>Trifluoperazine</td><td>5</td><td>5-60</td></tr><tr><td>Perphenazine</td><td>10</td><td>8-64</td></tr><tr><td>Fluphenazine</td><td>2</td><td>2-60</td></tr><tr><td>Thiothixene</td><td>2</td><td>2-120</td></tr><tr><td>Haloperidol</td><td>2</td><td>2-60</td></tr><tr><td>Loxapine</td><td>10</td><td>20-160</td></tr><tr><td>Molindone</td><td>10</td><td>20-200</td></tr><tr><td>Clozapine</td><td>50</td><td>300-600</td></tr><tr><td>Olanzapine</td><td>5</td><td>10-30</td></tr><tr><td>Quetiapine</td><td>150</td><td>150-800</td></tr><tr><td>Risperidone</td><td>4</td><td>4-16</td></tr><tr><td>Ziprasidone</td><td>40</td><td>80-160</td></tr><tr><td>Aripiprazole</td><td>10</td><td>10-30</td></tr></table>
======================================
<table><thead><th>Absorption</th><th>Virtually complete within 6-8 hours; peak plasma levels in 30 minutes to 2 hours</th></thead><tr><td>Distribution</td><td>In total body water; slow entry into intracellular compartment. Initial volume of distribution is 0.5 L/kg, rising to 0.7—0.9 L/kg; some sequestration in bone. No protein binding.</td></tr><tr><td>Metabolism</td><td></td></tr><tr><td>Excretion</td><td>Virtually entirely in urine. Lithium clearance about 20% of creatinine. Plasma half-life about 20 hours.</td></tr><tr><td>Target plasma</td><td>0.6-1.4 mEq/L.</td></tr><tr><td>Dosage</td><td>0.5 mEq/kg/d in divided doses</td></tr></table>
======================================
<table><thead><th>Enzyme</th><th>Enzyme Function; Action of Li</th></thead><tr><td>Inositol monophosphatase</td><td>The rate-limiting enzyme in inositol recycling; inhibited by lithium, resulting in depletion of substrate for IP; production (Figure 29-4)</td></tr><tr><td>Inositol polyphos- phate 1-phosphatase</td><td>Another enzyme in inositol recycling; inhibited by lithium, resulting in depletion of substrate for IP; production (Figure 29-4)</td></tr><tr><td>Bisphosphate nucleotidase</td><td>Involved in AMP production; inhibited by lithium; may be target that results in lithium-induced nephrogenic diabetes</td></tr><tr><td>Fructose</td><td>insipidus Involved in gluconeogenesis; inhibition by</td></tr><tr><td>1,6-biphosphatase Phosphoglucomutase</td><td>lithium of unknown relevance Involved in glycogenolysis; inhibition by</td></tr><tr><td></td><td>lithium of unknown relevance active that</td></tr><tr><td>Glycogen synthase kinase-3</td><td>Constitutively enzyme appears to limit neurotrophic and neuroprotective processes; lithium inhibits</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, To: ies, Interactions</th></thead><tr><td>PHENOTHIAZINES + Chlorpromazine + Fluphenazine + Thioridazine THIOXANTHENE + Thiothixene</td><td>Blockade of D, receptors &gt;&gt; 5-HT,, receptors</td><td>o-Receptor blockade (fluphenazine least) + muscarinic (M)-receptor blockade (especially chlorpromazine and thioridazine) + H,-receptor blockade (chlorpromazine, thiothixene) « central nervous system (CNS) depression (sedation) + decreased seizure threshold - QT prolongation (thioridazine)</td><td>Psychiatric: schizophrenia (alleviate positive symptoms), bipolar disorder (manic phase) + nonpsychiatric: antiemesis, preoperative sedation (promethazine) * pruritus</td><td>Oral and parenteral forms, long half-lives with metabolism-dependent elimination + Toxicity: Extensions of effects on o. and M receptors + blockade of dopamine receptors may result in akathisia, dystonia, parkinsonian symptoms, tardive dyskinesia, and hyperprolactinemia</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th></th><th>Effects</th><th>al Applications</th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td>BUTYROPHENONE + Haloperidol</td><td>Blockade of D, receptors &gt;&gt; 5-HT,, receptors</td><td>Some o blockade, but minimal M-receptor blockade and much less sedation than the phenothiazines</td><td>Schizophrenia (alleviates positive symptoms), bipolar disorder (manic phase), Huntington's chorea, Tourette syndrome</td><td>Oral and parenteral forms with metabolism-dependent elimination + Toxicity: Extrapyramidal dysfunction is major adverse effect</td></tr><tr><td colspan="5">SECOND-GENERATION ANTIPSYCHOTICS</td></tr><tr><td>+ Aripiprazole + Brexpiprazole + Cariprazine + Clozapine + Lurasidone + Olanzapine + Quetiapine + Risperidone + Ziprasidone</td><td>Blockade of 5-HT,, receptors &gt; blockade of D, receptors</td><td>Some o. blockade (clozapine, risperidone, ziprasidone) and M-receptor blockade (clozapine, olanzapine) + variable H,-receptor blockade (all)</td><td>Schizophrenia—improve both positive and negative symptoms « bipolar disorder (olanzapine or risperidone adjunctive with lithium) + agitation in Alzheimer's and Parkinson’s patients (low doses) « major depression (aripiprazole)</td><td>Toxicity: Agranulocytosis (clozapine), diabetes (clozapine, olanzapine), hypercholesterolemia (clozapine, olanzapine), hyperprolactinemia (risperidone), QT prolongation (ziprasidone), weight gain (clozapine, olanzapine)</td></tr><tr><td>LITHIUM</td><td>Mechanism of action uncertain + suppresses inositol signaling and inhibits glycogen synthase kinase-3 (GSK-3), a multifunctional protein kinase</td><td>No significant antagoni: actions on autonomic nervous system receptors or specific CNS receptors «no sedative effects</td><td>Bipolar affective disorder— prophylactic use can prevent mood swings between mania and depression</td><td>Oral absorption, renal elimination + half-life 20 h - narrow therapeutic window (monitor blood levels) + Toxicity: Tremor, edema, hypothyroidism, renal dysfunction, dysrhythmias + pregnancy category D + Interactions: Clearance decreased by thiazides and some NSAIDs</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th></th><th>Effects</th><th>al Applications</th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td>BUTYROPHENONE + Haloperidol</td><td>Blockade of D, receptors &gt;&gt; 5-HT,, receptors</td><td>Some o blockade, but minimal M-receptor blockade and much less sedation than the phenothiazines</td><td>Schizophrenia (alleviates positive symptoms), bipolar disorder (manic phase), Huntington's chorea, Tourette syndrome</td><td>Oral and parenteral forms with metabolism-dependent elimination + Toxicity: Extrapyramidal dysfunction is major adverse effect</td></tr><tr><td colspan="5">SECOND-GENERATION ANTIPSYCHOTICS</td></tr><tr><td>+ Aripiprazole + Brexpiprazole + Cariprazine + Clozapine + Lurasidone + Olanzapine + Quetiapine + Risperidone + Ziprasidone</td><td>Blockade of 5-HT,, receptors &gt; blockade of D, receptors</td><td>Some o. blockade (clozapine, risperidone, ziprasidone) and M-receptor blockade (clozapine, olanzapine) + variable H,-receptor blockade (all)</td><td>Schizophrenia—improve both positive and negative symptoms « bipolar disorder (olanzapine or risperidone adjunctive with lithium) + agitation in Alzheimer's and Parkinson’s patients (low doses) « major depression (aripiprazole)</td><td>Toxicity: Agranulocytosis (clozapine), diabetes (clozapine, olanzapine), hypercholesterolemia (clozapine, olanzapine), hyperprolactinemia (risperidone), QT prolongation (ziprasidone), weight gain (clozapine, olanzapine)</td></tr><tr><td>LITHIUM</td><td>Mechanism of action uncertain + suppresses inositol signaling and inhibits glycogen synthase kinase-3 (GSK-3), a multifunctional protein kinase</td><td>No significant antagoni: actions on autonomic nervous system receptors or specific CNS receptors «no sedative effects</td><td>Bipolar affective disorder— prophylactic use can prevent mood swings between mania and depression</td><td>Oral absorption, renal elimination + half-life 20 h - narrow therapeutic window (monitor blood levels) + Toxicity: Tremor, edema, hypothyroidism, renal dysfunction, dysrhythmias + pregnancy category D + Interactions: Clearance decreased by thiazides and some NSAIDs</td></tr></table>
======================================
<table><tr><td>Perphenazine</td><td>Generic, Trilafon</td></tr><tr><td>Pimavanserin</td><td>Nuplazid</td></tr><tr><td>Pimozide</td><td>Orap</td></tr><tr><td>Prochlorperazine</td><td>Generic, Compazine</td></tr><tr><td>Quetiapine</td><td>Generic, Seroquel</td></tr><tr><td>Risperidone</td><td>Generic, Risperdal</td></tr><tr><td>Thioridazine</td><td>Generic, Mellaril</td></tr><tr><td>Thiothixene</td><td>Generic, Navane</td></tr><tr><td>Trifluoperazine</td><td>Generic, Stelazine</td></tr><tr><td>Ziprasidone</td><td>Generic, Geodon</td></tr><tr><td colspan="2">MOOD STABILIZERS</td></tr><tr><td>Carbamazepine</td><td>Generic, Tegretol</td></tr><tr><td>Divalproex</td><td>Generic, Depakote</td></tr><tr><td>Lamotrigine</td><td>Generic, Lamictal</td></tr><tr><td>Lithium carbonate</td><td>Generic, Eskalith</td></tr><tr><td>Topiramate</td><td>Generic, Topamax</td></tr><tr><td>Valproic acid</td><td>Generic, Depakene</td></tr></table>
======================================
<table><tr><td colspan="2">ANTIPSYCHOTIC AGENTS</td></tr><tr><td>Aripiprazole</td><td>Abilify</td></tr><tr><td>Asenapine</td><td>Saphris</td></tr><tr><td>Brexpiprazole</td><td>Rexulti</td></tr><tr><td>Cariprazine</td><td>Vraylar</td></tr><tr><td>Chlorpromazine</td><td>Generic, Thorazine</td></tr><tr><td>Clozapine</td><td>Generic, Clozaril, others</td></tr><tr><td>Fluphenazine</td><td>Generic</td></tr><tr><td>Fluphenazine decanoate</td><td>Generic, Prolixin Decanoate</td></tr><tr><td>Haloperidol</td><td>Generic, Haldol</td></tr><tr><td>Haloperidol ester</td><td>Haldol Decanoate</td></tr><tr><td>lloperidone</td><td>Fanapt</td></tr><tr><td>Loxapine</td><td>Adasuve</td></tr><tr><td>Lurasidone</td><td>Latuda</td></tr><tr><td>Molindone</td><td>Moban</td></tr><tr><td>Olanzapine</td><td>Generic, Zyprexa</td></tr><tr><td>Paliperidone</td><td>Invega</td></tr></table>
======================================
<table><thead><th>Class, Drug</th><th>Bioavailability (%)</th><th>Plasma t,,2 (hours)</th><th>Active Metabolite ty/2 (hours)</th><th>Volume of Distribution (L/kg)</th><th>Protein Binding (%)</th></thead><tr><td colspan="6">SSRIs</td></tr><tr><td>Citalopram</td><td>80</td><td>33-38</td><td>ND</td><td>15</td><td>80</td></tr><tr><td>Escitalopram</td><td>80</td><td>27-32</td><td>ND</td><td>12-15</td><td>80</td></tr><tr><td>Fluoxetine</td><td>70</td><td>48-72</td><td>180</td><td>12-97</td><td>95</td></tr><tr><td>Fluvoxamine</td><td>90</td><td>14-18</td><td>14-16</td><td>25</td><td>80</td></tr><tr><td>Paroxetine</td><td>50</td><td>20-23</td><td>ND</td><td>28-31</td><td>94</td></tr><tr><td>Sertraline</td><td>45</td><td>22-27</td><td>62-104</td><td>20</td><td>98</td></tr><tr><td colspan="6">SNRIs</td></tr><tr><td>Duloxetine</td><td>50</td><td>12-15</td><td>ND</td><td>10-14</td><td>97</td></tr><tr><td>Milnacipran</td><td>85-90</td><td>6-8</td><td>ND</td><td>5-6</td><td>13</td></tr><tr><td>Venlafaxine"</td><td>45</td><td>8-11</td><td>9-13</td><td>4-10</td><td>27</td></tr><tr><td colspan="6">Tricyclics</td></tr><tr><td>Amitriptyline</td><td>45</td><td>31-46</td><td>20-92</td><td>5-10</td><td>90</td></tr><tr><td>Clomipramine</td><td>50</td><td>19-37</td><td>54-77</td><td>7-20</td><td>97</td></tr><tr><td>Imipramine</td><td>40</td><td>9-24</td><td>14-62</td><td>15-30</td><td>84</td></tr><tr><td colspan="6">5-HT modulators</td></tr><tr><td>Nefazodone</td><td>20</td><td>2-4</td><td>ND</td><td>0.5-1</td><td>99</td></tr><tr><td>Trazodone</td><td>95</td><td>3-6</td><td>ND</td><td>IFS</td><td>96</td></tr><tr><td colspan="6" rowspan="2">Vortioxetine 75 66 ND ND 98 Tetracyclics and unicyclic</td></tr><tr><td colspan="6"></td></tr><tr><td>Amoxapine</td><td>ND</td><td>7-12</td><td>5-30</td><td>0.9-1.2</td><td>85</td></tr><tr><td>Bupropion</td><td>70</td><td>11-14</td><td>15-25</td><td>20-30</td><td>85</td></tr><tr><td>Maprotiline</td><td>70</td><td>43-45</td><td>ND</td><td>23-27</td><td>88</td></tr><tr><td>Mirtazapine</td><td>50</td><td>20-40</td><td>20-40</td><td>3-7</td><td>85</td></tr><tr><td>Vilazodone</td><td>72</td><td>25</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td colspan="6">MAOIs</td></tr><tr><td>Phenelzine</td><td>ND</td><td>11</td><td>ND</td><td>ND</td><td>ND</td></tr></table>
======================================
<table><thead><th>Antidepressant</th><th></th><th>SERT</th></thead><tr><td>Amitriptyline</td><td></td><td></td></tr><tr><td>Amoxapine</td><td></td><td></td></tr><tr><td>Bupropion</td><td></td><td></td></tr><tr><td>Citalopram, escitalopram</td><td></td><td></td></tr><tr><td>Clomipramine</td><td></td><td></td></tr><tr><td>Desipramine</td><td></td><td></td></tr><tr><td>Doxepin</td><td></td><td></td></tr><tr><td>Fluoxetine</td><td></td><td></td></tr><tr><td>Fluvoxamine</td><td>OCD</td><td></td></tr><tr><td>Imipramine</td><td>+</td><td></td></tr><tr><td>Maprotiline</td><td></td><td></td></tr><tr><td>Mirtazapine</td><td>O+F</td><td></td></tr><tr><td>Nefazodone</td><td>+</td><td></td></tr><tr><td>Nortriptyline</td><td></td><td></td></tr><tr><td>Paroxetine</td><td>Or</td><td></td></tr><tr><td>Protriptyline</td><td></td><td></td></tr><tr><td>Sertraline</td><td>or</td><td></td></tr><tr><td>Trazodone</td><td></td><td></td></tr><tr><td>Trimipramine</td><td>++</td><td></td></tr><tr><td>Venlafaxine</td><td></td><td></td></tr><tr><td>Vortioxetine’</td><td>ND</td><td>+44</td></tr></table>
======================================
<table><tr><td colspan="2">SSRIs</td></tr><tr><td>Citalopram</td><td>20-60</td></tr><tr><td>Escitalopram</td><td>10-30</td></tr><tr><td>Fluoxetine</td><td>20-60</td></tr><tr><td>Fluvoxamine</td><td>100-300</td></tr><tr><td>Paroxetine</td><td>20-60</td></tr><tr><td>Sertraline</td><td>50-200</td></tr><tr><td colspan="2">SNRIs</td></tr><tr><td>Venlafaxine</td><td>75-375</td></tr><tr><td>Desvenlafaxine</td><td>50-200</td></tr><tr><td>Duloxetine</td><td>40-120</td></tr><tr><td>Milnacipran</td><td>100-200</td></tr><tr><td colspan="2">Tricyclics</td></tr><tr><td>Amitriptyline</td><td>150-300</td></tr><tr><td>Clomipramine</td><td>100-250</td></tr><tr><td>Desipramine</td><td>150-300</td></tr><tr><td>Doxepin</td><td>150-300</td></tr><tr><td>Imipramine</td><td>150-300</td></tr><tr><td>Nortriptyline</td><td>50-150</td></tr><tr><td>Protriptyline</td><td>15-60</td></tr><tr><td>Trimipramine maleate</td><td>150-300</td></tr><tr><td colspan="2">5-HT, antagonists</td></tr><tr><td>Nefazodone</td><td>300-500</td></tr><tr><td>Trazodone</td><td>150-300</td></tr><tr><td colspan="2">Tetracyclics and unicyclics</td></tr><tr><td>Amoxapine</td><td>150-400</td></tr><tr><td>Bupropion</td><td>200-450</td></tr><tr><td>Maprotiline</td><td>150-225</td></tr><tr><td>Mirtazapine</td><td>15-45</td></tr><tr><td colspan="2">MAOIs</td></tr><tr><td>Isocarboxazid</td><td>30-60</td></tr><tr><td>Phenelzine</td><td>45-90</td></tr><tr><td>Selegiline</td><td>20-50</td></tr><tr><td>Tranylcypromine</td><td>30-60</td></tr></table>
======================================
<table><thead><th>Enzyme</th><th>Substrates</th><th>Inhibitors</th><th>Inducers</th></thead><tr><td>1A2</td><td>Tertiary amine tricyclic antidepressants (TCAs), dulox- etine, theophylline, phenacetin, TCAs (demethylation), clozapine, diazepam, caffeine</td><td>Fluvoxamine, fluoxetine, moclobemide, ramelteon</td><td>Tobacco, omeprazole</td></tr><tr><td>2C19</td><td>TCAs, citalopram (partly), warfarin, tolbutamide, phenytoin, diazepam</td><td>Fluoxetine, fluvoxamine, sertraline, imipramine, ketoconozole, omeprazole</td><td>Rifampin</td></tr><tr><td>2D6</td><td>TCAs, benztropine, perphenazine, clozapine, halo- peridol, codeine/oxycodone, risperidone, class Ic antiarrhythmics, B blockers, trazodone, paroxetine, maprotiline, amoxapine, duloxetine, mirtazapine (partly), venlafaxine, bupropion</td><td>Fluoxetine, paroxetine, duloxetine, hydroxybupropion, methadone, cimetidine, haloperidol, quinidine, ritonavir</td><td>Phenobarbital, rifampin</td></tr><tr><td>3A4</td><td>Citalopram, escitalopram, TCAs, glucocorticoids, androgens/estrogens, carbamazepine, erythromycin, Ca?* channel blockers, levomilnacipran, protease inhibitors, sildenafil, alprazolam, triazolam, vincristine/ vinblastine, tamoxifen, zolpidem</td><td>Fluvoxamine, nefazodone, sertraline, fluoxetine, cimetidine, fluconazole, erythromycin, protease inhibitors, ketoconazole, verapamil</td><td>Barbiturates, glucocorti- coids, rifampin, modafinil, carbamazepine</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th></thead></table>
======================================
<table><thead><th>+ Duloxetine + Venlafaxine + Levomilnacipran</th><th>Moderately selective blockade of NET and SERT</th><th>Acute increase in serotonergic and adrenergic synaptic activity » otherwise like SSRIs</th><th>Major depression, chronic pain disorders « fibromyalgia, perimenopausal symptoms</th><th>Toxicity: Anticholinergic, sedation, hypertension (venlafaxine) « Interactions: Some CYP2D6 inhibition (duloxetine, desvenlafaxine) - CYP3A4 interactions with levomilnacipran</th></thead><thead><th colspan="5">+ Desvenlafaxine: Desmethyl metabolite of venlafaxine, metabolism is by phase Il rather than CYP phase | + Milnacipran: Approved only for fibromyalgia in the USA; significantly more selective for NET than SERT,; little effect on DAT</th></thead><tr><td>TRICYCLIC + Imipramine + Many others.</td><td>ANTIDEPRESSANTS (TCAs) Mixed and variable blockade of NET and SERT</td><td>Like SNRIs plus significant blockade of autonomic nervous system and histamine receptors</td><td>Major depression not responsive to other drugs + chronic pain disorders + incontinence + obsessive- compulsive disorder (clomipramine)</td><td>Long half-lives » CYP substrates + active metabolites + Toxicity: Anticholinergic, a-blocking effects, sedation, weight gain, arrhythmias, and seizures in overdose + Interactions: CYP inducers and inhibitors</td></tr><tr><td colspan="5">5-HT RECEPTOR MODULATORS</td></tr><tr><td>+ Nefazodone + Trazodone</td><td>Inhibition of 5-HT., receptor + nefazodone also blocks SERT weakly</td><td>Trazodone forms a metabolite (m-cpp) that blocks 5-HT&gt;,¢ receptors</td><td>Major depression + sedation and hypnosis (trazodone)</td><td>Relatively short half-lives « active metabolites + Toxicity: Modest o- and H,-receptor blockade (trazodone) + Interactions: Nefazodone inhibits CYP3A4</td></tr><tr><td>+ Vortioxetine</td><td>Antagonist at 5-HT;, 5-HT;, 5-HT,p receptors; partial agonist at 5-HT,, receptor, agonist at SHT,, receptor; inhibits SERT</td><td>Complex modulation of serotonergic systems</td><td>Major depression</td><td>Extensively metabolized via CYP2D6 and glucuronic acid conjugation + Toxicity: Gl disturbances, sexual dysfunction + Interactions: Additive with serotonergic agents</td></tr></table>
======================================
<table><thead><th>+ Duloxetine + Venlafaxine + Levomilnacipran</th><th>Moderately selective blockade of NET and SERT</th><th>Acute increase in serotonergic and adrenergic synaptic activity » otherwise like SSRIs</th><th>Major depression, chronic pain disorders « fibromyalgia, perimenopausal symptoms</th><th>Toxicity: Anticholinergic, sedation, hypertension (venlafaxine) « Interactions: Some CYP2D6 inhibition (duloxetine, desvenlafaxine) - CYP3A4 interactions with levomilnacipran</th></thead><thead><th colspan="5">+ Desvenlafaxine: Desmethyl metabolite of venlafaxine, metabolism is by phase Il rather than CYP phase | + Milnacipran: Approved only for fibromyalgia in the USA; significantly more selective for NET than SERT,; little effect on DAT</th></thead><tr><td>TRICYCLIC + Imipramine + Many others.</td><td>ANTIDEPRESSANTS (TCAs) Mixed and variable blockade of NET and SERT</td><td>Like SNRIs plus significant blockade of autonomic nervous system and histamine receptors</td><td>Major depression not responsive to other drugs + chronic pain disorders + incontinence + obsessive- compulsive disorder (clomipramine)</td><td>Long half-lives » CYP substrates + active metabolites + Toxicity: Anticholinergic, a-blocking effects, sedation, weight gain, arrhythmias, and seizures in overdose + Interactions: CYP inducers and inhibitors</td></tr><tr><td colspan="5">5-HT RECEPTOR MODULATORS</td></tr><tr><td>+ Nefazodone + Trazodone</td><td>Inhibition of 5-HT., receptor + nefazodone also blocks SERT weakly</td><td>Trazodone forms a metabolite (m-cpp) that blocks 5-HT&gt;,¢ receptors</td><td>Major depression + sedation and hypnosis (trazodone)</td><td>Relatively short half-lives « active metabolites + Toxicity: Modest o- and H,-receptor blockade (trazodone) + Interactions: Nefazodone inhibits CYP3A4</td></tr><tr><td>+ Vortioxetine</td><td>Antagonist at 5-HT;, 5-HT;, 5-HT,p receptors; partial agonist at 5-HT,, receptor, agonist at SHT,, receptor; inhibits SERT</td><td>Complex modulation of serotonergic systems</td><td>Major depression</td><td>Extensively metabolized via CYP2D6 and glucuronic acid conjugation + Toxicity: Gl disturbances, sexual dysfunction + Interactions: Additive with serotonergic agents</td></tr></table>
======================================
<table><tr><td>Bupropion Amoxapine</td><td>Increased norepinephrine and dopamine activity</td><td>Presynaptic release of catecholamines but no effect</td><td>Major depression + smoking cessation (bupropion)</td><td>Extensive metabolism in liver + Toxicity: Lowers seizure threshold (amoxapine,</td></tr><tr><td>Maprotiline</td><td>(bupropion) + NET &gt; SERT</td><td>on 5-HT (bupropion)</td><td>+ sedation (mirtazapine)</td><td>bupropion); sedation and weight gain</td></tr><tr><td>Mirtazapine</td><td>inhibition (amoxapine, maprotiline) + increased release of norepinephrine, 5-HT (mirtazapine)</td><td>+ amoxapine and maprotiline resemble TCAs</td><td>* amoxapine and maprotiline rarely used</td><td>(mirtazapine) + Interactions: CYP2D6 inhibitor (bupropion)</td></tr></table>
======================================
<table><tr><td colspan="2">SELECTIVE SEROTONIN REUPTAKE INHIBITORS</td></tr><tr><td>Citalopram</td><td>Generic, Celexa</td></tr><tr><td>Escitalopram</td><td>Generic, Lexapro</td></tr><tr><td>Fluoxetine</td><td>Generic, Prozac, Prozac Weekly</td></tr><tr><td>Fluvoxamine*</td><td>Generic</td></tr><tr><td>Paroxetine</td><td>Generic, Paxil</td></tr><tr><td>Sertraline</td><td>Generic, Zoloft</td></tr><tr><td>Desvenlafaxine</td><td>Pristiq</td></tr><tr><td>Duloxetine</td><td>Generic, Cymbalta</td></tr><tr><td>Levomilnacipran</td><td>Fetzima</td></tr><tr><td>Milnacipran*</td><td>Savella</td></tr><tr><td>Venlafaxine</td><td>Generic, Effexor</td></tr><tr><td colspan="2">5-HT RECEPTOR MODULATORS</td></tr><tr><td>Nefazodone</td><td>Generic</td></tr><tr><td>Trazodone</td><td>Generic, Desyrel</td></tr><tr><td colspan="2">Vortioxetine Trintellix</td></tr><tr><td>Amitriptyline</td><td>Generic, Elavil</td></tr><tr><td>Amoxapine</td><td>Generic</td></tr><tr><td>Clomipramine®</td><td>Generic, Anafranil</td></tr><tr><td>Desipramine</td><td>Generic, Norpramin</td></tr><tr><td>Doxepin</td><td>Generic, Sinequan</td></tr><tr><td>Imipramine Nortriptyline</td><td>Generic, Pamelor</td></tr><tr><td>Protriptyline</td><td>Generic, Vivactil</td></tr><tr><td>Trimipramine</td><td>Surmontil</td></tr><tr><td>Amoxapine</td><td>Generic</td></tr><tr><td>Bupropion</td><td>Generic, Wellbutrin</td></tr><tr><td>Maprotiline</td><td>Generic</td></tr><tr><td>Mirtazapine</td><td>Generic, Remeron</td></tr><tr><td>Vilazodone</td><td>Viibryd</td></tr><tr><td>Isocarboxazid</td><td>Marplan</td></tr><tr><td>Phenelzine</td><td>Generic, Nardil</td></tr><tr><td>Selegiline</td><td>Generic, Eldepryl</td></tr><tr><td>Tranylcypromine</td><td>Generic, Parnate</td></tr></table>
======================================
<table><thead><th>Receptor Subtype</th><th>Functions</th><th>Endogenous Opioid Peptide Affinity</th></thead><tr><td>bt (mu)</td><td>Supraspinal and spinal anal- gesia; sedation; inhibition of respiration; slowed gastroin- testinal transit; modulation of hormone and neurotransmit- ter release</td><td>Endorphins &gt; enkephalins &gt; dynorphins</td></tr><tr><td>6 (delta)</td><td>Supraspinal and spinal anal- gesia; modulation of hormone and neurotransmitter release</td><td>Enkephalins &gt; endorphins and dynorphins</td></tr><tr><td>i (kappa)</td><td>Supraspinal and spinal analge- sia; psychotomimetic effects; slowed gastrointestinal transit</td><td>Dynorphins &gt; &gt; endorphins and enkephalins</td></tr></table>
======================================
<table><thead><th rowspan="2">Generic Name</th><th colspan="3">Receptor Effects’</th><th rowspan="2">Approximately Equivalent Dose (mg)</th><th rowspan="2">Oral: Parenteral Potency Ratio</th><th rowspan="2">Duration of Analgesia (hours)</th><th rowspan="2">Maximum Efficacy</th></thead><thead><th></th><th></th><th>5</th><th>K</th><th></th><th></th><th></th><th></th></thead><tr><td>Morphine”</td><td></td><td></td><td>+</td><td>10</td><td>Low</td><td>4-5</td><td>High</td></tr><tr><td>Hydromorphone</td><td></td><td></td><td></td><td>1.5</td><td>Low</td><td>4-5</td><td>High</td></tr><tr><td>Oxymorphone</td><td></td><td></td><td></td><td>1.5</td><td>Low</td><td>3-4</td><td>High</td></tr><tr><td>Methadone</td><td></td><td></td><td></td><td>10°</td><td>High</td><td>46</td><td>High</td></tr><tr><td>Meperidine</td><td></td><td></td><td></td><td>60-100</td><td>Medium</td><td>2-4</td><td>High</td></tr><tr><td>Fentanyl</td><td></td><td></td><td></td><td>0.1</td><td>Low</td><td>1-1.5</td><td>High</td></tr><tr><td>Sufentanil</td><td></td><td></td><td></td><td>0.02</td><td>Parenteral only</td><td>1-1.5</td><td>High</td></tr><tr><td>Alfentanil</td><td></td><td></td><td></td><td>Titrated</td><td>Parenteral only</td><td>0.25-0.75</td><td>High</td></tr><tr><td>Remifentanil</td><td></td><td></td><td></td><td>Titrated*</td><td>Parenteral only</td><td>0.05°</td><td>High</td></tr><tr><td>Levorphanol</td><td></td><td></td><td></td><td>2-33</td><td>High</td><td>45</td><td>High</td></tr><tr><td>Codeine</td><td></td><td></td><td></td><td>30-60</td><td>High</td><td>3-4</td><td>Low</td></tr><tr><td>Hydrocodone®</td><td></td><td></td><td></td><td>5-10</td><td>Medium</td><td>4-6</td><td>Moderate</td></tr><tr><td>Oxycodone*”</td><td></td><td></td><td></td><td>45</td><td>Medium</td><td>3-4</td><td>Mod-High</td></tr><tr><td>Pentazocine</td><td></td><td></td><td></td><td>30-50</td><td>Medium</td><td>3-4</td><td>Moderate</td></tr><tr><td>Nalbuphine</td><td></td><td></td><td></td><td></td><td>Parenteral only</td><td>3-6</td><td>High</td></tr><tr><td>Buprenorphine</td><td>ae</td><td></td><td></td><td></td><td>Low</td><td>4-8</td><td>High</td></tr><tr><td>Butorphanol</td><td>ae</td><td></td><td>+++</td><td></td><td>Parenteral only</td><td>3-4</td><td>High</td></tr></table>
======================================
<table><thead><th>High</th><th>Moderate</th><th>Minimal or</th></thead><tr><td>Analgesia</td><td>Bradycardia</td><td>Miosis</td></tr><tr><td>Euphoria, dysphoria</td><td></td><td>Constipation</td></tr><tr><td>Mental clouding</td><td></td><td>Convulsions</td></tr><tr><td colspan="3">Sedation</td></tr><tr><td colspan="3">Respiratory depression</td></tr><tr><td colspan="3">Antidiuresis</td></tr><tr><td colspan="3">Nausea and vomiting</td></tr><tr><td>Cough suppression</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Adverse Effects with Acute Use</th><th>Adverse Effects with Chronic Use</th></thead><tr><td>Respiratory depression</td><td>Hypogonadism</td></tr><tr><td>Nausea / vomiting</td><td>Immunosuppression</td></tr><tr><td>Pruritus</td><td>Increased feeding</td></tr><tr><td>Urticaria</td><td>Increased growth hormone secretion</td></tr><tr><td>Constipation</td><td>Withdrawal effects</td></tr><tr><td>Urinary retention</td><td>Tolerance, dependence</td></tr><tr><td>Delirium</td><td>Abuse, addiction</td></tr><tr><td>Sedation</td><td>Hyperalgesia</td></tr><tr><td>Myoclonus</td><td>Impairment while driving</td></tr><tr><td>Seizures</td><td></td></tr></table>
======================================
<table><thead><th>Drug Group</th><th>Interaction with Opioids</th></thead><tr><td>Antipsychotic</td><td>Increased sedation. Variable effects on respira-</td></tr><tr><td>agents</td><td>tory depression. Accentuation of cardiovascular effects (antimuscarinic and o-blocking actions).</td></tr><tr><td>Monoamine</td><td>Relative contraindication to all opioid analgesics</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th>Applications</th><th>Pharmacokinetics,</th></thead><tr><td colspan="5">OPIOID AGONISTS</td></tr><tr><td>+ Morphine + Methadone + Fentanyl</td><td>Strong ul-receptor agonists + variable affinity for 5 and K receptors</td><td>Analgesia - relief of anxiety + sedation + slowed gastrointestinal transit</td><td>Severe pain + adjunct in anesthesia (fentanyl, morphine) + pulmonary edema (morphine only) « maintenance in rehabilitation programs (methadone only)</td><td>First-pass effect « duration 1-4h except methadone, 4-6 h + Toxicity: Respiratory depression + severe constipation + addiction liability « convulsions</td></tr><tr><td colspan="5">+ Hydromorphone, oxymorphone: Like morphine in efficacy, but higher potency + Meperidine: Strong agonist with anticholinergic effects + Oxycodone: Dose-dependent analgesia remifentanil: Like fentanyl but shorter durations of action + Sufentanil, alfentanil,</td></tr><tr><td>+ Codeine + Hydrocodone</td><td>Less efficacious than morphine + can antagonize strong agonists</td><td>Like strong agonists + weaker effects</td><td>Mild-moderate pain + cough (codeine)</td><td>Like strong agonists, toxicity dependent on genetic variation of metabolism</td></tr><tr><td colspan="5">MIXED OPIOID AGONIST-ANTAGONISTS + Buprenorphine Partial tt agonist Like strong agonists but can Moderate pain + some Long duration of action 4-8 h</td></tr><tr><td>+ Nalbuphine</td><td>K antagonist « Agonist - u antagonist</td><td>antagonize their effects + also reduces craving for alcohol Similar to buprenorphine</td><td>maintenance rehabilitation programs Moderate pain</td><td>may precipitate abstinence syndrome Like buprenorphine</td></tr><tr><td>ANTITUSSIVES + Dextromethorphan</td><td>Poorly understood but strong and partial | agonists are also effective antitussives</td><td>Reduces cough reflex + Dextromethorphan, levopropoxyphene not analgesic</td><td>Acute debilitating cough</td><td>Duration 30-60 min - Toxicity: Minimal when taken as directed</td></tr><tr><td colspan="5">+ Codeine, levopropoxyphene: Similar to dextromethorphan</td></tr><tr><td colspan="5">OPIOID ANTAGONISTS</td></tr><tr><td>+ Naloxone</td><td>Antagonist at 1, 5, and K receptors</td><td>Rapidly antagonizes all opioid effects</td><td>Opioid overdose</td><td>Duration 1-2 h (may have to be repeated when treating</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th>Applications</th><th>Pharmacokinetics,</th></thead><tr><td colspan="5">OPIOID AGONISTS</td></tr><tr><td>+ Morphine + Methadone + Fentanyl</td><td>Strong ul-receptor agonists + variable affinity for 5 and K receptors</td><td>Analgesia - relief of anxiety + sedation + slowed gastrointestinal transit</td><td>Severe pain + adjunct in anesthesia (fentanyl, morphine) + pulmonary edema (morphine only) « maintenance in rehabilitation programs (methadone only)</td><td>First-pass effect « duration 1-4h except methadone, 4-6 h + Toxicity: Respiratory depression + severe constipation + addiction liability « convulsions</td></tr><tr><td colspan="5">+ Hydromorphone, oxymorphone: Like morphine in efficacy, but higher potency + Meperidine: Strong agonist with anticholinergic effects + Oxycodone: Dose-dependent analgesia remifentanil: Like fentanyl but shorter durations of action + Sufentanil, alfentanil,</td></tr><tr><td>+ Codeine + Hydrocodone</td><td>Less efficacious than morphine + can antagonize strong agonists</td><td>Like strong agonists + weaker effects</td><td>Mild-moderate pain + cough (codeine)</td><td>Like strong agonists, toxicity dependent on genetic variation of metabolism</td></tr><tr><td colspan="5">MIXED OPIOID AGONIST-ANTAGONISTS + Buprenorphine Partial tt agonist Like strong agonists but can Moderate pain + some Long duration of action 4-8 h</td></tr><tr><td>+ Nalbuphine</td><td>K antagonist « Agonist - u antagonist</td><td>antagonize their effects + also reduces craving for alcohol Similar to buprenorphine</td><td>maintenance rehabilitation programs Moderate pain</td><td>may precipitate abstinence syndrome Like buprenorphine</td></tr><tr><td>ANTITUSSIVES + Dextromethorphan</td><td>Poorly understood but strong and partial | agonists are also effective antitussives</td><td>Reduces cough reflex + Dextromethorphan, levopropoxyphene not analgesic</td><td>Acute debilitating cough</td><td>Duration 30-60 min - Toxicity: Minimal when taken as directed</td></tr><tr><td colspan="5">+ Codeine, levopropoxyphene: Similar to dextromethorphan</td></tr><tr><td colspan="5">OPIOID ANTAGONISTS</td></tr><tr><td>+ Naloxone</td><td>Antagonist at 1, 5, and K receptors</td><td>Rapidly antagonizes all opioid effects</td><td>Opioid overdose</td><td>Duration 1-2 h (may have to be repeated when treating</td></tr></table>
======================================
<table><tr><td>+ Tapentadol</td><td>Moderate i agonist, strong NET inhibitor</td><td>Analgesia</td><td>Moderate pain</td><td>Duration 4-6 h - Toxicity: Headache; nausea and vomiting; possible dependence</td></tr><tr><td>+ Tramadol</td><td>Mixed effects: weak agonist, moderate SERT inhibitor, weak NET inhibitor</td><td>Analgesia</td><td>Moderate pain + adjunct to opioids in chronic pain syndromes</td><td>Duration 4-6 h = Toxicity: Seizures + risk of serotonin syndrome</td></tr></table>
======================================
<table><thead><th></th><th>OTHER ANALGESICS</th></thead><tr><td>Tapentadol</td><td>Nucynta</td></tr><tr><td>Tramadol</td><td>Generic, Ultram, others</td></tr><tr><td>Ziconotide</td><td>Prialt</td></tr><tr><td>Codeine/acetaminophen</td><td>Generic, Tylenol with Codeine, others</td></tr><tr><td>Codeine/aspirin</td><td>Generic, Empirin Compound, others</td></tr><tr><td>Hydrocodone/ acetaminophen</td><td>Generic, Norco, Vicodin, Lortab, others</td></tr><tr><td>Hydrocodone/ibuprofen</td><td>Vicoprofen</td></tr><tr><td>Oxycodone/ acetaminophen</td><td>Generic, Percocet, Tylox, others</td></tr><tr><td>Oxycodone/aspirin</td><td>Generic, Percodan</td></tr><tr><td>Alvimopan</td><td>Entereg</td></tr><tr><td>Methylnaltrexone</td><td>Relistor</td></tr><tr><td>Nalmefene</td><td>Revex</td></tr><tr><td>Naloxone</td><td>Generic, Narcan</td></tr><tr><td>Naltrexone</td><td>Generic, ReVia, Depade, Vivitrol</td></tr><tr><td></td><td>ANTITUSSIVES</td></tr><tr><td>Codeine</td><td>Generic</td></tr><tr><td>Dextromethorphan</td><td>Generic, Benylin DM, Delsym, others</td></tr></table>
======================================
<table><tr><td></td><td>ANALGESIC OPIOIDS</td></tr><tr><td>Alfentanil</td><td>Generic, Alfenta</td></tr><tr><td>Buprenorphine</td><td>Buprenex, others, Butrans (transdermal)</td></tr><tr><td>Butorphanol</td><td>Generic, Stadol, Stadol NS (nasal)</td></tr><tr><td>Codeine (sulfate or phosphate)</td><td>Generic</td></tr><tr><td>Fentanyl</td><td>Generic, Duragesic (transdermal). Fentanyl Buccal, Fentanyl Actiq (lozenge)</td></tr><tr><td>Hydromorphone</td><td>Generic, Dilaudid, others</td></tr><tr><td>Levomethadyl acetate’</td><td>Orlaam</td></tr><tr><td colspan="2">Morphine sulfate</td></tr><tr><td>Oral, rectal, parenteral</td><td>Generic</td></tr><tr><td>Oral sustained-release capsules</td><td>Avinza, Kadian</td></tr><tr><td>Oral extended-release capsules (morphine sulfate/naltrexone HCl)</td><td>Embeda</td></tr><tr><td>Nalbuphine</td><td>Generic, Nubain</td></tr><tr><td>Oxycodone</td><td>Generic, OxyContin (sustained release)</td></tr><tr><td>Oxymorphone</td><td>Generic, Numorphan, others</td></tr><tr><td>Pentazocine</td><td>Talwin</td></tr><tr><td>Remifentanil</td><td>Generic, Ultiva</td></tr><tr><td>Sufentanil</td><td>Generic, Sufenta</td></tr></table>
======================================
<table><thead><th>Name</th><th>Main Molecular Target</th><th>Pharmacology</th><th>Effect on Dopamine (DA) Neurons</th></thead><tr><td colspan="4">Drugs That Activate G Protein-Coupled Receptors</td></tr><tr><td>Opioids</td><td>u-OR (G,,)</td><td>Agonist</td><td>Disinhibition</td></tr><tr><td>Cannabinoids</td><td>CB,R (G,.)</td><td>Agonist</td><td>Disinhibition</td></tr><tr><td>-Hydroxybutyric acid (GHB)</td><td>GABA,R (G,,)</td><td>Weak agonist</td><td>Disinhibition</td></tr><tr><td>LSD, mescaline, psilocybin</td><td>5-HT2aR (Gq)</td><td>Partial agonist</td><td></td></tr><tr><td colspan="4">Drugs That Bind to lonotropic Receptors and Ion Channels</td></tr><tr><td>Nicotine</td><td>nAChR (0482)</td><td>Agonist</td><td>Excitation</td></tr><tr><td>Alcohol</td><td>GABA,R, 5-HT3R, nAChR, NMDAR, Kir3 channels</td><td></td><td>Excitation, disinhibition (?)</td></tr><tr><td>Benzodiazepines</td><td>GABA,R</td><td>Positive modulator</td><td>Disinhibition</td></tr><tr><td>Phencyclidine, ketamine</td><td>NMDAR</td><td>Antagonist</td><td></td></tr><tr><td colspan="4">Drugs That Bind to Transporters of Biogenic Amines</td></tr><tr><td>Cocaine</td><td>DAT, SERT, NET</td><td>Inhibitor</td><td>Blocks DA uptake</td></tr><tr><td>Amphetamine</td><td>DAT, NET, SERT, VMAT</td><td>Reverses transport</td><td>Blocks DA uptake, synaptic depletion</td></tr><tr><td>Ecstasy</td><td>SERT &gt; DAT, NET</td><td>Reverses transport</td><td>Blocks DA uptake, synaptic depletion</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokine' Interactions</th></thead><tr><td colspan="5">OPIOID RECEPTOR ANTAGONIST</td></tr><tr><td>+ Naloxone</td><td>Nonselective antagonist of opioid receptors</td><td>Reverses the acute effects of opioids; can precipitate severe abstinence syndrome</td><td>Opioid overdose</td><td>Effect much shorter than morphine (1-2 h); therefore several injections required</td></tr><tr><td>+ Naltrexone</td><td>Antagonist of opioid receptors</td><td>Blocks effects of illicit opioids</td><td>Treatment of alcoholism, opioid addiction</td><td>Half-life 10 h (oral); 5-10 days (depot injection)</td></tr><tr><td colspan="5">SYNTHETIC OPIOID</td></tr><tr><td>+ Methadone</td><td>Slow-acting agonist of L-opioid receptor</td><td>Acute effects similar to morphine (see text)</td><td>Substitution therapy for opioid addicts</td><td>High oral bioavailability « half-life highly variable among individuals (range 4-130 h) « Toxicity: Respiratory depression, constipation, miosis, tolerance, dependence, arrhythmia, and withdrawal symptoms</td></tr><tr><td>+ Levomethadone</td><td>“Enantiopure” methadone containing only the left- enantiomer of the molecule</td><td>Similar to morphine and methadone, but at half the dose of the latter</td><td>Substitution therapy</td><td>Less toxic compared to racemic methadone, particularly related to cardiac adverse effects (long QT interval)</td></tr><tr><td>+ Morphine sulphate</td><td>Asalt containing morphine sulfate pentahydrate</td><td>Slow-release version with a longer action than morphine</td><td>Substitution therapy</td><td></td></tr><tr><td colspan="5">PARTIAL -OPIOID RECEPTOR AGONIST</td></tr><tr><td>+ Buprenorphine</td><td>Partial agonist at 1-opioid receptors</td><td>Attenuates acute effects of morphine</td><td>Oral substitution therapy for opioid addicts</td><td>Long half-life (40 h) « formulated together with naloxone to avoid illicit IV injections</td></tr><tr><td colspan="5">NICOTINIC RECEPTOR PARTIAL AGONIST</td></tr><tr><td>+ Varenicline</td><td>Partial agonist of nicotinic acetylcholine receptor of the o.4B2-type</td><td>Occludes “rewarding” effects of smoking « heightened awareness of colors</td><td>Smoking cessation</td><td>Toxicity: Nausea and vomiting, seizures, psychiatric changes</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th></th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">BENZODIAZEPINES</td></tr><tr><td>+ Oxazepam, others + Lorazepam: Alternate</td><td>Positive modulators of the GABA, receptors, increase frequency of channel opening to oxazepam with similar properties</td><td>Enhances GABAergic synaptic transmission; attenuates withdrawal symptoms (tremor, hallucinations, anxiety) in alcoholics + prevents withdrawal seizures</td><td>Delirium tremens</td><td>Half-life 4-15 h « pharmacokinetics not affected by decreased liver function</td></tr><tr><td colspan="5">N-METHYL-b-ASPARTATE (NMDA) ANTAGONIST</td></tr><tr><td>+ Acamprosate</td><td>Antagonist of NMDA glutamate receptors</td><td>May interfere with forms of synaptic plasticity that depend on NMDA receptors</td><td>Treatment of alcoholism + effective only in combination with counseling</td><td>Allergic reactions, arrhythmia, and low or high blood pressure, headaches, insomnia, and impotence +</td></tr><tr><td colspan="5">patients</td></tr><tr><td>CANNABINOID + Rimonabant</td><td>RECEPTOR INVERSE AGONIST CB, receptor inverse agonist</td><td>Decreases neurotransmitter release at GABAergic and glutamatergic synapses</td><td>Approved in Europe from 2006 to 2008 to treat obesity, then withdrawn because of major side effects + smoking cessation has never been approved, but remains an off-label indication</td><td>Major depression, including increased risk of suicide</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Iron Content (mg)</th></thead><thead><th></th><th></th><th>Women</th></thead><tr><td>Hemoglobin</td><td></td><td>1700</td></tr><tr><td>Myoglobin</td><td></td><td>300</td></tr><tr><td>Enzymes</td><td></td><td></td></tr><tr><td>Transport (transferrin)</td><td></td><td></td></tr><tr><td>Storage (ferritin and other forms)</td><td></td><td></td></tr><tr><td>Total</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Nutritional Deficiency</th><th>Type of Anemia</th><th>Laboratory Abnormalities</th></thead><tr><td>Iron</td><td>Microcytic, hypochromic with MCV &lt; 80 fl and MCHC &lt; 30%</td><td>Low SI &lt; 30 mcg/dL with increased TIBC, resulting in a % transferrin saturation (SI/TIBC) of &lt;10%; low serum ferritin level (&lt;20 mcg/L)</td></tr><tr><td>Folic acid</td><td>Macrocytic, nor- mochromic with MCV &gt;100 fL and normal or elevated MCHC</td><td>Low serum folic acid (&lt;4 ng/mL)</td></tr><tr><td rowspan="2">Vitamin B,,</td><td>Same as folic acid deficiency</td><td>Low serum cobalamin (&lt;100 pmol/L) accompanied by increased serum homocysteine</td></tr><tr><td></td><td></td><td>serum (&gt;0.4 mol/L) and urine (&gt;3.6 mol/mol creatinine) methylmalonic acid</td></tr></table>
======================================
<table><thead><th>Preparation</th><th>Tablet Size</th><th>Elemental Iron per Tablet</th><th>Usual Adult Dosage for Treatment of Iron Deficiency (Tablets per Day)</th></thead><tr><td>Ferrous sulfate, hydrated</td><td>325 mg</td><td>65 mg</td><td>2-4</td></tr><tr><td>Ferrous sulfate, desiccated</td><td>200 mg</td><td>65 mg</td><td>2-4</td></tr><tr><td>Ferrous gluconate</td><td>325 mg</td><td>36 mg</td><td>3-4</td></tr><tr><td>Ferrous fumarate</td><td>325 mg</td><td>106 mg</td><td>2-3</td></tr></table>
======================================
<table><thead><th>Hematopoietic Growth Factor</th><th>Clinical Condition Being Treated or Prevented</th><th></th></thead><tr><td rowspan="4">Erythropoietin, darbepoetin alfa</td><td rowspan="4">Anemia</td><td>Patients with chronic renal failure</td></tr><tr><td></td><td></td><td>HIV-infected patients treated with zidovudine</td></tr><tr><td></td><td></td><td>Cancer patients treated with myelosuppressive cancer chemotherapy</td></tr><tr><td></td><td></td><td>Patients scheduled to undergo elective, noncardiac, nonvascular surgery</td></tr><tr><td rowspan="5">Granulocyte colony-stimulating factor (G-CSF; filgrastim) and granulocyte-macrophage colony- stimulating factor (GM-CSF; sargramostim)</td><td rowspan="3">Neutropenia</td><td>Cancer patients treated with myelosuppressive cancer chemotherapy</td></tr><tr><td></td><td></td><td>Patients with severe chronic neutropenia</td></tr><tr><td></td><td></td><td>Patients recovering from bone marrow transplantation</td></tr><tr><td></td><td>Stem cell or bone marrow transplantation</td><td>Patients with nonmyeloid malignancies or other conditions being treated with stem cell or bone marrow transplantation</td></tr><tr><td></td><td>Mobilization of peripheral blood progenitor cells (PBPCs)</td><td>Donors of stem cells for allogeneic or autologous transplantation</td></tr><tr><td>Interleukin-11 (IL-11, oprelvekin)</td><td>Thrombocytopenia</td><td>Patients with nonmyeloid malignancies who receive myelosuppressive cancer chemotherapy</td></tr><tr><td>Romiplostim, eltrombopag</td><td>Thrombocytopenia</td><td>Patients with idiopathic thrombocytopenic purpura</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxi Interactions</th></thead><tr><td colspan="5">IRON</td></tr><tr><td>+ Ferrous sulfate</td><td>Required for biosynthesis of heme and heme-containing proteins, including hemoglobin and myoglobin</td><td>Adequate supplies required for normal heme synthesis + deficiency results in inadequate heme production</td><td>Iron deficiency, which manifests as microcytic anemia « oral preparation</td><td>Complicated endogenous system for absorbing, storing, and transporting iron + Toxicity: Acute overdose results in necrotizing gastroenteritis, abdominal pain, bloody diarrhea, shock, lethargy, and dyspnea - chronic iron overload results in hemochromatosis, with damage to the heart, liver, pancreas, and other organs + organ failure and death can ensue</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead></table>
======================================
<table><tr><td>vekin</td><td>Recombinant form of</td><td>Stimulates growth of</td><td>Secondary p</td></tr></table>
======================================
<table><tr><td>Darbepoetin alfa</td><td>Aranesp</td></tr><tr><td>Deferasirox</td><td>Exjade</td></tr><tr><td>Deferoxamine</td><td>Generic, Desferal</td></tr><tr><td>Eltrombopag</td><td>Promacta</td></tr><tr><td>Epoetin alfa</td><td>Erythropoietin (EPO), Epogen, Procrit</td></tr><tr><td>Epoetin beta (Methoxy polyethylene glycol-epoetin beta)</td><td>Mircera</td></tr><tr><td>Filgrastim (G-CSF)</td><td>Neupogen, Granix</td></tr><tr><td>Folic acid (folacin, pteroylglutamic acid)</td><td>Generic</td></tr><tr><td colspan="2">Iron</td></tr><tr><td colspan="2">Oral: See Table 33-3.</td></tr><tr><td>Iron dextran (parenteral)</td><td>INFeD, Dexferrum</td></tr><tr><td>Sodium ferric gluconate complex (parenteral)</td><td>Ferrlecit</td></tr><tr><td>Iron sucrose (parenteral)</td><td>Venofer</td></tr><tr><td>Ferric carboxymaltose (parenteral)</td><td>Injectafer</td></tr><tr><td>Ferumoxytol (parenteral)</td><td>Feraheme</td></tr><tr><td>Oprelvekin (IL-11)</td><td>Neumega</td></tr><tr><td>Pegfilgrastim</td><td>Neulasta</td></tr><tr><td>Plerixafor</td><td>Mozobil</td></tr><tr><td>Romiplostim</td><td>Nplate</td></tr><tr><td>Sargramostim (GM-CSF)</td><td>Leukine</td></tr><tr><td colspan="2">Vitamin B,&gt;</td></tr><tr><td>Oral, parenteral</td><td>Generic cyanocobalamin or hydroxocobalamin</td></tr><tr><td>Nasal</td><td>Nascobal, CaloMist</td></tr></table>
======================================
<table><thead><th>Component or Factor</th><th>Common Synonym</th><th>Target for the Action of:</th></thead><tr><td></td><td>Fibrinogen</td><td></td></tr><tr><td></td><td>Prothrombin</td><td>Heparin, dabigatran (Ila); warfarin (synthesis)</td></tr><tr><td></td><td>Tissue thromboplastin</td><td></td></tr><tr><td></td><td>Calcium</td><td></td></tr><tr><td></td><td>Proaccelerin</td><td></td></tr><tr><td></td><td>Proconvertin</td><td>Warfarin (synthesis)</td></tr><tr><td></td><td>Antihemophilic factor (AHF)</td><td></td></tr><tr><td></td><td>Christmas factor, plasma thromboplas- tin component (PTC)</td><td>Warfarin (synthesis)</td></tr><tr><td></td><td>Stuart-Prower factor</td><td>Heparin, rivaroxiban, apixaban, edoxaban (Xa); warfarin (synthesis)</td></tr><tr><td>Xl</td><td>Plasma thromboplas- tin antecedent (PTA)</td><td></td></tr><tr><td>XII</td><td>Hageman factor</td><td></td></tr><tr><td>XII</td><td>Fibrin-stabilizing factor</td><td></td></tr><tr><td>Proteins C and $</td><td></td><td>Warfarin (synthesis)</td></tr><tr><td>Plasminogen</td><td></td><td>Thrombolytic enzymes, aminocaproic acid</td></tr></table>
======================================
<table><thead><th>Increased Prothrombin Time</th><th>Decreased Prothrombin Time</th></thead><tr><td>Pharmacokinetic</td><td>Pharmacokinetic</td></tr><tr><td>Amiodarone</td><td>Barbiturates</td></tr><tr><td>Cimetidine</td><td>Cholestyramine</td></tr><tr><td>Disulfiram</td><td>Rifampin</td></tr><tr><td colspan="2">Fluconazole"</td></tr><tr><td colspan="2">Metronidazole’</td></tr><tr><td colspan="2">Phenylbutazone’</td></tr><tr><td colspan="2">Sulfinpyrazone’</td></tr><tr><td colspan="2">Trimethoprim-sulfamethoxazole</td></tr><tr><td>Pharmacodynamic</td><td>Pharmacodynamic</td></tr><tr><td>Drugs</td><td>Drugs</td></tr><tr><td>Aspirin (high doses)</td><td>Diuretics</td></tr><tr><td>Cephalosporins, third-generation</td><td>Vitamin K</td></tr><tr><td colspan="2">Heparin, argatroban, dabigatran, rivaroxaban, apixaban</td></tr><tr><td>Body factors</td><td>Body factors</td></tr><tr><td>Hepatic disease</td><td>Hereditary resistance</td></tr><tr><td>Hyperthyroidism</td><td>Hypothyroidism</td></tr></table>
======================================
<table><thead><th>Factor</th><th>Deficiency State</th><th>Hemostatic Levels</th><th>Half-Life of Infused Factor</th><th>Replacement Source</th></thead><tr><td></td><td>Hypofibrinogenemia</td><td>1 g/dL</td><td>4 days</td><td>Cryoprecipitate, FFP</td></tr><tr><td></td><td>Prothrombin deficiency</td><td>30-40%</td><td>3 days</td><td>Prothrombin complex concentrates (intermediate purity factor IX concentrates)</td></tr><tr><td></td><td>Factor V deficiency</td><td>20%</td><td>1 day</td><td>FFP</td></tr><tr><td></td><td>Factor VII deficiency</td><td>30%</td><td>4-6 hours</td><td>FFP Prothrombin complex concentrates (intermediate purity factor IX concentrates) Recombinant factor Vlla</td></tr><tr><td rowspan="2">VIII</td><td rowspan="2">Hemophilia A</td><td>30-50% 100% for major or trauma</td><td>12 hours</td><td>Recombinant factor VIII products Plasma-derived high purity concentrates</td></tr><tr><td></td><td></td><td>bleeding</td><td></td><td>Cryoprecipitate” Some patients with mild deficiency will respond to DDAVP</td></tr><tr><td></td><td>Christmas disease</td><td>100% for major bleeding or trauma</td><td></td><td>Plasma-derived high purity concentrates</td></tr><tr><td rowspan="2"></td><td>Stuart-Prower defect</td><td>25%</td><td>36 hours</td><td>FFP</td></tr><tr><td></td><td></td><td></td><td></td><td>Prothrombin complex concentrates</td></tr><tr><td>XI</td><td>Hemophilia C</td><td>30-50%</td><td>3 days</td><td>FFP</td></tr><tr><td>XII</td><td>Hageman defect</td><td>Not required</td><td></td><td>Treatment not necessary</td></tr><tr><td rowspan="3">von Willebrand</td><td rowspan="3">von Willebrand disease</td><td>30%</td><td>Approximately 10 hours</td><td>Intermediate purity factor Vill concentrates that contain von Willebrand factor</td></tr><tr><td></td><td></td><td></td><td></td><td>Type | patients respond to DDAVP</td></tr><tr><td></td><td></td><td></td><td></td><td>Cryoprecipitate*</td></tr><tr><td rowspan="2">XIll</td><td></td><td rowspan="2">Factor XIII deficiency</td><td></td><td>5%</td><td>6 days</td><td>FFP</td></tr><tr><td></td><td></td><td>Cryoprecipitate</td></tr></table>
======================================
<table><thead><th>| GENERICNAME</th><th>—AVAILABLEAS</th></thead><tr><td colspan="2">Eptifibatide Integrilin</td></tr><tr><td colspan="2">Factor Vlla: see Coagulation factor Vila recombinant</td></tr><tr><td colspan="2">Factor VIII: see Antihemophilic factor</td></tr><tr><td>Factor IX complex, human</td><td>AlphaNine SD, Bebulin VH, BeneFix, Konyne 80, Mononine, Profilnine SD, Proplex T, Proplex SX-T</td></tr><tr><td>AF PCC</td><td>Kcentra</td></tr><tr><td>Fondaparinux</td><td>Generic, Arixtra</td></tr><tr><td>Heparin sodium</td><td>Generic, Liquaemin</td></tr><tr><td>Prasugrel</td><td>Effient</td></tr><tr><td>Protamine</td><td>Generic</td></tr><tr><td>Reteplase</td><td>Retavase</td></tr><tr><td>Rivaroxaban</td><td>Xarelto</td></tr><tr><td>Streptokinase</td><td>Streptase</td></tr><tr><td>Tenecteplase</td><td>TNKase</td></tr><tr><td>Ticlopidine</td><td>Generic, Ticlid</td></tr><tr><td>Tinzaparin</td><td>Innohep</td></tr><tr><td>Tirofiban</td><td>Aggrastat</td></tr><tr><td>Tranexamic acid</td><td>Generic, Cyklokapron, Lysteda</td></tr><tr><td>Urokinase</td><td>Abbokinase, Kinlytic</td></tr><tr><td>Vitamin K</td><td>Generic, various</td></tr><tr><td>Warfarin</td><td>Generic, Coumadin</td></tr></table>
======================================
<table><tr><td>Abciximab</td><td>ReoPro</td></tr><tr><td>Alteplase recombinant [t-PA]</td><td>Activase</td></tr><tr><td>Aminocaproic acid</td><td>Generic, Amicar</td></tr><tr><td>Anisindione</td><td>Miradon (outside the USA)</td></tr><tr><td>Antihemophilic factor [factor VIII], AHF]</td><td>Alphanate, Bioclate, Helixate, Hemofil M, Koate-HP, Kogenate, Monoclate, Recombinate, others</td></tr><tr><td>Anti-inhibitor coagulant complex</td><td>Autoplex T, Feiba VH Immuno</td></tr><tr><td>Antithrombin Ill</td><td>Thrombate Ill, ATryn</td></tr><tr><td>Apixaban</td><td>Eliquis</td></tr><tr><td>Argatroban</td><td>Generic</td></tr><tr><td>Bivalirudin</td><td>Generic, Angiomax</td></tr><tr><td>Cilostazol</td><td>Generic, Pletal</td></tr><tr><td>Clopidogrel</td><td>Generic, Plavix</td></tr><tr><td>Coagulation factor Vila recombinant</td><td>NovoSeven</td></tr><tr><td>Dabigatran</td><td>Pradaxa</td></tr><tr><td>Dalteparin</td><td>Fragmin</td></tr><tr><td>Danaparoid</td><td>Orgaran</td></tr><tr><td>Desirudin</td><td>Iprivask</td></tr><tr><td>Dipyridamole</td><td>Generic, Persantine</td></tr><tr><td>Enoxaparin (low-molecular- weight heparin)</td><td>Generic, Lovenox</td></tr></table>
======================================
<table><tr><td>Apo</td><td>Apolipoprotein</td></tr><tr><td>CETP</td><td>Cholesteryl ester transfer protein</td></tr><tr><td>cK</td><td>Creatine kinase</td></tr><tr><td>HDL</td><td>High-density lipoproteins</td></tr><tr><td>HMG-CoA</td><td>3-Hydroxy-3-methylglutaryl-coenzyme A</td></tr><tr><td>IDL</td><td>Intermediate-density lipoproteins</td></tr><tr><td>LCAT</td><td>Lecithin:cholesterol acyltransferase</td></tr><tr><td>LDL</td><td>Low-density lipoproteins</td></tr><tr><td>Lp(a)</td><td>Lipoprotein(a)</td></tr><tr><td>LPL</td><td>Lipoprotein lipase</td></tr><tr><td>PCSK9</td><td>Proprotein convertase subtilisin/kexin type 9</td></tr><tr><td>PPAR</td><td>Peroxisome proliferator-activated receptor</td></tr><tr><td>VLDL</td><td>Very-low-density lipoproteins</td></tr></table>
======================================
<table><thead><th>Disorder</th><th>Manifestations</th><th>Diet + Single Drug’</th><th>Drug Combination</th></thead><tr><td>Primary chylomicronemia (familial lipoprotein lipase, cofactor deficiency; others)</td><td>Chylomicrons, VLDL increased</td><td>Dietary management; Omega-3 fatty acids, fibrate, or niacin (Apo C-Ill antisense)</td><td>Fibrate plus niacin</td></tr><tr><td>Familial hypertriglyceridemia</td><td>VLDL increased; chylomicrons may be increased</td><td>Dietary management; Omega-3 fatty acids, fibrate, or niacin</td><td>Fibrate plus niacin</td></tr><tr><td rowspan="3">Familial combined hyperlipoproteinemia</td><td>VLDL predominantly increased</td><td>Reductase inhibitor, Omega-3 fatty acids, fibrate, niacin</td><td>Two or three of the single agents”</td></tr><tr><td></td><td>LDL predominantly increased</td><td>Reductase inhibitor, ezetimibe, or niacin</td><td>Two or three of the single agents</td></tr><tr><td></td><td>VLDL, LDL increased</td><td>Reductase inhibitor, Omega-3 fatty acids, or niacin</td><td>Niacin or fibrate plus reductase inhibitor”</td></tr><tr><td>Familial dysbetalipoproteinemia</td><td>VLDL remnants, chylomicron remnants increased</td><td>Fibrate, reductase inhibitor, niacin, Omega 3 fatty acids</td><td>Reductase inhibitor plus fibrate or niacin</td></tr><tr><td colspan="4">Familial hypercholesterolemia</td></tr><tr><td>Heterozygous</td><td>LDL increased</td><td>Reductase inhibitor, resin, niacin, or ezetimibe</td><td>Two or three of the individual drugs</td></tr><tr><td>Homozygous</td><td>LDL increased</td><td>Atorvastatin, rosuvastatin, ezetimibe, mipomersen, lomitapide or PCSK9 MAB</td><td>Combinations of some of the single agents</td></tr><tr><td>Familial ligand-defective apo B-100</td><td>LDL increased</td><td>Reductase inhibitor, niacin, or ezetimibe</td><td>Two or three of the single agents</td></tr><tr><td>Lp(a) hyperlipoproteinemia</td><td>Lp(a) increased</td><td>Niacin</td><td></td></tr></table>
======================================
<table><thead><th>Hypertriglyceridemia</th><th>Hypercholesterolemia</th></thead><tr><td>Diabetes mellitus</td><td>Hypothyroidism</td></tr><tr><td>Alcohol ingestion</td><td>Early nephrosis</td></tr><tr><td>Severe nephrosis</td><td>Resolving lipemia</td></tr><tr><td>Estrogens</td><td>Immunoglobulin-lipoprotein complex disorders</td></tr><tr><td>Uremia</td><td>Anorexia nervosa</td></tr><tr><td>HIV infection</td><td>Cholestasis</td></tr><tr><td>Myxedema</td><td>Hypopituitarism</td></tr><tr><td>Glycogen storage disease</td><td>Corticosteroid excess</td></tr><tr><td>Hypopituitarism</td><td>Androgen overdose</td></tr><tr><td colspan="2">Acromegaly</td></tr><tr><td colspan="2">Immunoglobulin-lipoprotein complex disorders</td></tr><tr><td colspan="2">Lipodystrophy</td></tr><tr><td>Protease inhibitors, tacrolimus, sirolimus, other drugs</td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td colspan="5">STATINS</td></tr><tr><td>+ Atorvastatin, simvastatin, rosuvastatin, pitavastatin</td><td>Inhibit HMG-CoA reductase</td><td>Reduce cholesterol synthesis and upregulate low-density lipoprotein (LDL) receptors on hepatocytes - modest reduction in triglycerides</td><td>Atherosclerotic vascular disease (primary and secondary prevention) + acute coronary syndromes</td><td>Oral - duration 12-24 h + Toxicity: Myopathy, hepatic dysfunction + Interactions: CyP-dependent metabolism (3A4, 2C9) interacts with CYP inhibitors/competitors</td></tr><tr><td colspan="5">+ Fluvastatin, pravastatin, lovastatin: Similar but somewhat less efficacious</td></tr><tr><td>FIBRATES + Fenofibrate, gemfibrozil</td><td>Peroxisome proliferator- activated receptor-alpha (PPAR-a) agonists</td><td>Decrease secretion of very-low-density lipoproteins (VLDL) + increase lipoprotein lipase activity + increase high-density lipoproteins (HDL)</td><td>Hypertriglyceridemia, low HDL</td><td>Oral - duration 3-24 h - Toxicity: Myopathy, hepatic dysfunction</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">BILE ACID SEQUESTRANTS</td></tr><tr><td>+ Colestipol</td><td>Binds bile acids in gut + prevents reabsorption + increases cholesterol catabolism + upregulates LDL receptors</td><td>Decreases LDL</td><td>Elevated LDL, digitalis toxicity, pruritus</td><td>Oral - taken with meals « not absorbed + Toxicity: Constipation, bloating « interferes with absorption of some drugs and vitamins</td></tr><tr><td colspan="5">+ Cholestyramine, colesevelam: Similar to colestipol</td></tr><tr><td colspan="5">STEROL ABSORPTION INHIBITOR Ezetimibe Blocks sterol Inhibits reabsorption of Elevated LDL, Oral duration 24 h + Low incidence</td></tr><tr><td></td><td>transporter NPC1L1 in intestine brush border</td><td>cholesterol excreted in bile + decreases LDL and phytosterols</td><td>phytosterolemia</td><td>Toxicity: of hepatic dysfunction, myositis</td></tr><tr><td>NIACIN</td><td>Decreases catabolism of apo Al - reduces VLDL secretion from liver</td><td>Increases HDL + decreases lipoprotein(a) [Lp(a)], LDL</td><td>Low HDL - elevated VLDL, Lp(a); elevated LDL in statin-unresponsive or intolerant patients</td><td>Oral - large doses « Toxicity: Gastric irritation, flushing, low incidence of hepatic toxicity + may reduce glucose tolerance</td></tr><tr><td colspan="5">+ Extended-release niacin: Similar to regular niacin + Sustained-release niacin (not the same as extended-release product): Should be avoided</td></tr><tr><td colspan="5">PCSK9 HUMANIZED MONOCLONAL ANTIBODI ES</td></tr><tr><td>Evolocumab</td><td>Complexes PCSK9</td><td>Inhibits catabolism of LDL receptor</td><td rowspan="2">Familial hypercholesterolemia not responsive to oral therapy</td><td rowspan="2">Parenteral » Cost ~ $14,000/year + Toxicity: injection site reactions, nasopharyngitis, flu-like symptoms, rarely myalgia, neurocognitive and ophthalmologic events</td></tr><tr><td>+ Alirocumab</td><td>Similar to evolucumab</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">BILE ACID SEQUESTRANTS</td></tr><tr><td>+ Colestipol</td><td>Binds bile acids in gut + prevents reabsorption + increases cholesterol catabolism + upregulates LDL receptors</td><td>Decreases LDL</td><td>Elevated LDL, digitalis toxicity, pruritus</td><td>Oral - taken with meals « not absorbed + Toxicity: Constipation, bloating « interferes with absorption of some drugs and vitamins</td></tr><tr><td colspan="5">+ Cholestyramine, colesevelam: Similar to colestipol</td></tr><tr><td colspan="5">STEROL ABSORPTION INHIBITOR Ezetimibe Blocks sterol Inhibits reabsorption of Elevated LDL, Oral duration 24 h + Low incidence</td></tr><tr><td></td><td>transporter NPC1L1 in intestine brush border</td><td>cholesterol excreted in bile + decreases LDL and phytosterols</td><td>phytosterolemia</td><td>Toxicity: of hepatic dysfunction, myositis</td></tr><tr><td>NIACIN</td><td>Decreases catabolism of apo Al - reduces VLDL secretion from liver</td><td>Increases HDL + decreases lipoprotein(a) [Lp(a)], LDL</td><td>Low HDL - elevated VLDL, Lp(a); elevated LDL in statin-unresponsive or intolerant patients</td><td>Oral - large doses « Toxicity: Gastric irritation, flushing, low incidence of hepatic toxicity + may reduce glucose tolerance</td></tr><tr><td colspan="5">+ Extended-release niacin: Similar to regular niacin + Sustained-release niacin (not the same as extended-release product): Should be avoided</td></tr><tr><td colspan="5">PCSK9 HUMANIZED MONOCLONAL ANTIBODI ES</td></tr><tr><td>Evolocumab</td><td>Complexes PCSK9</td><td>Inhibits catabolism of LDL receptor</td><td rowspan="2">Familial hypercholesterolemia not responsive to oral therapy</td><td rowspan="2">Parenteral » Cost ~ $14,000/year + Toxicity: injection site reactions, nasopharyngitis, flu-like symptoms, rarely myalgia, neurocognitive and ophthalmologic events</td></tr><tr><td>+ Alirocumab</td><td>Similar to evolucumab</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>_GENERICNAME</th><th>—TRADENAMES</th></thead><tr><td>Alirocumab</td><td>Praluent</td></tr><tr><td>Atorvastatin</td><td>Generic, Lipitor</td></tr><tr><td>Cholestyramine</td><td>Generic, Questran, Prevalite</td></tr><tr><td>Colesevelam</td><td>Welchol</td></tr><tr><td>Colestipol</td><td>Generic, Colestid</td></tr><tr><td>Evolocumab</td><td>Repatha</td></tr><tr><td>Ezetimibe</td><td>Generic, Zetia</td></tr><tr><td>Fenofibrate</td><td>Generic, Tricor, Antara, Lofibra</td></tr><tr><td>Fluvastatin</td><td>Generic, Lescol, Lescol XL</td></tr><tr><td>Gemfibrozil</td><td>Generic, Lopid</td></tr><tr><td>Lomitapide</td><td>Juxtapid</td></tr><tr><td>Mipomersen</td><td>Kynamro</td></tr><tr><td>Lovastatin</td><td>Generic, Mevacor, Altoprev</td></tr><tr><td>Niacin, nicotinic acid, vitamin B;</td><td>Generic only</td></tr><tr><td>Omega-3 fatty acids-marine</td><td>Lovaza</td></tr><tr><td>Pitavastatin</td><td>Livalo</td></tr><tr><td>Pravastatin</td><td>Generic, Pravachol</td></tr><tr><td>Rosuvastatin</td><td>Generic, Crestor</td></tr><tr><td>Simvastatin</td><td>Generic, Zocor</td></tr><tr><td colspan="2">COMBINATION TABLETS</td></tr><tr><td>Ezetimibe/simvastatin</td><td>Vytorin</td></tr><tr><td>Niacin/lovastatin extended-release</td><td>Advicor</td></tr><tr><td>Niacin/simvastatin extended-release</td><td>Simcor</td></tr></table>
======================================
<table><tr><td>AS</td><td>Ankylosing spondylitis</td><td>PsA</td><td>Psoriatic arthritis</td></tr><tr><td>COX</td><td>Cyclooxygenase</td><td>PJIA</td><td>Polyarticular juvenile idiopathic arthritis</td></tr><tr><td>DMARD</td><td>Disease-modifying antirheumatic drug</td><td>RA</td><td>Rheumatoid arthritis</td></tr><tr><td>IL.</td><td>Interleukin</td><td>SJIA</td><td>Systemic juvenile idiopathic arthritis</td></tr><tr><td>IA</td><td>Juvenile idiopathic arthritis</td><td>SLE</td><td>Systemic lupus erythematosus</td></tr><tr><td>NSAID</td><td>Nonsteroidal anti-inflammatory drug</td><td>TNF</td><td>Tumor necrosis factor</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Half-Life (hours)</th><th>Urinary Excretion of Unchanged Drug</th><th>Recommended Anti-inflammatory Dosage</th></thead><tr><td>Aspirin</td><td>0.25</td><td>&lt;2%</td><td>1200-1500 mg tid</td></tr><tr><td>Salicylate’</td><td>2-19</td><td>2-30%</td><td>See footnote”</td></tr><tr><td>Celecoxib</td><td>11</td><td>27%*</td><td>100-200 mg bid</td></tr><tr><td>Diclofenac</td><td>1.1</td><td>&lt;1%</td><td>50-75 mg qid</td></tr><tr><td>Diflunisal</td><td>13</td><td>3-9%</td><td>500 mg bid</td></tr><tr><td>Etodolac</td><td></td><td>&lt;1%</td><td>200-300 mg qid</td></tr><tr><td>Fenoprofen</td><td></td><td>30%</td><td>600 mg qid</td></tr><tr><td>Flurbiprofen</td><td></td><td>&lt;1%</td><td>300 mg tid</td></tr><tr><td>Ibuprofen</td><td></td><td>&lt;1%</td><td>600 mg qid</td></tr><tr><td>Indomethacin</td><td></td><td>16%</td><td>50-70 mg tid</td></tr><tr><td>Ketoprofen</td><td></td><td>&lt;1%</td><td>70 mg tid</td></tr><tr><td>Meloxicam</td><td></td><td>&lt;1%</td><td>7.5-15 mg qd</td></tr><tr><td>Nabumetone*</td><td></td><td>1%</td><td>1000-2000 mg qd”</td></tr><tr><td>Naproxen</td><td></td><td>&lt;1%</td><td>375 mg bid</td></tr><tr><td>Oxaprozin</td><td></td><td>1-4%</td><td>1200-1800 mg qd”</td></tr><tr><td>Piroxicam</td><td></td><td>4-10%</td><td>20mg qd”</td></tr><tr><td>Sulindac</td><td></td><td>™%</td><td>200 mg bid</td></tr><tr><td>Tolmetin</td><td></td><td>™%</td><td>400 mg qid</td></tr></table>
======================================
<table><tr><td>Anakinra</td><td>Kineret</td></tr><tr><td>Auranofin</td><td>Ridaura</td></tr><tr><td>Aurothioglucose</td><td>Solganal</td></tr><tr><td>Belimumab</td><td>Benlysta</td></tr><tr><td>Canakinumab</td><td>Haris</td></tr><tr><td>Certolizumab</td><td>Cimzia</td></tr><tr><td>Cyclophosphamide</td><td>Generic, Cytoxan</td></tr><tr><td>Cyclosporine</td><td>Generic, Sandimmune</td></tr><tr><td>Etanercept</td><td>Enbrel</td></tr><tr><td>Gold sodium thiomalate</td><td>Generic, Aurolate</td></tr><tr><td>Golimumab</td><td>Simponi</td></tr><tr><td>Infliximab</td><td>Remicade</td></tr><tr><td>Leflunomide</td><td>Generic, Arava</td></tr><tr><td>Methotrexate</td><td>Generic, Rheumatrex</td></tr><tr><td>Mycophenolate mofetil</td><td>Generic, Cellcept</td></tr><tr><td>Penicillamine</td><td>Cuprimine, Depen</td></tr><tr><td>Rilonacept</td><td>Arcalyst</td></tr><tr><td>Rituximab</td><td>Rituxan</td></tr><tr><td>Sulfasalazine</td><td>Generic, Azulfidine</td></tr><tr><td>Tocilizumab Tofacitinib</td><td>Actemra</td></tr><tr><td>ACETAMINOPHEN</td><td>AND OTHER ANALGESICS Xeljanz</td></tr><tr><td>Acetaminophen</td><td>Generic, Tylenol, Tempra, Panadol,</td></tr><tr><td>Ketorolac tromethamine</td><td>Acephen, others Generic, Toradol</td></tr><tr><td>Tramadol</td><td>Ultram</td></tr><tr><td>DRUGS</td><td>USED IN GOUT</td></tr><tr><td>Allopurinol</td><td>Generic, Zyloprim</td></tr><tr><td>Colchicine</td><td>Generic’,</td></tr><tr><td></td><td>Colchrys</td></tr><tr><td>Febuxostat</td><td>Uloric</td></tr><tr><td>Pegloticase</td><td>Krystexxa</td></tr></table>
======================================
<table><tr><td colspan="2">NONSTEROIDAL ANTI-INFLAMMATORY</td></tr><tr><td>Aspirin, acetylsalicylic acid</td><td>Generic, Easprin, others</td></tr><tr><td>Bromfenac</td><td>Prolensa, Bromday</td></tr><tr><td>Celecoxib</td><td>Celebrex</td></tr><tr><td>Choline salicylate</td><td>Various</td></tr><tr><td>Diclofenac</td><td>Generic, Cataflam, Voltaren</td></tr><tr><td>Diflunisal</td><td>Generic, Dolobid</td></tr><tr><td>Etodolac</td><td>Generic, Lodine</td></tr><tr><td>Fenoprofen</td><td>Generic, Nalfon</td></tr><tr><td>Flurbiprofen</td><td>Generic, Ansaid, Ocufen (ophthalmic)</td></tr><tr><td>Ibuprofen</td><td>Generic, Motrin, Rufen, Advil (OTC), Nuprin (OTC), others</td></tr><tr><td>Indomethacin</td><td>Generic, Indocin</td></tr><tr><td>Ketoprofen</td><td>Generic, Orudis</td></tr><tr><td>Magnesium salicylate</td><td>Doan’s Pills, Magan, Mobidin</td></tr><tr><td>Meclofenamate sodium</td><td>Generic</td></tr><tr><td>Mefenamic acid</td><td>Generic, Ponstel</td></tr><tr><td>Meloxicam</td><td>Generic, Mobic</td></tr><tr><td>Nabumetone</td><td>Generic</td></tr><tr><td>Naproxen</td><td>Generic (OTC), Naprosyn, Anaprox, Aleve (OTC)</td></tr><tr><td>Oxaprozin</td><td>Generic, Daypro</td></tr><tr><td>Piroxicam</td><td>Generic, Feldene</td></tr><tr><td>Salsalate, salicylsalicylic acid</td><td>Generic, Disalcid</td></tr><tr><td>Sodium salicylate</td><td>Generic</td></tr><tr><td>Sodium thiosalicylate</td><td>Generic, Rexolate</td></tr><tr><td>Sulindac</td><td>Generic, Clinoril</td></tr><tr><td>Suprofen</td><td>Profenal (Ophthalmic)</td></tr><tr><td>Tolmetin</td><td>Generic, Tolectin</td></tr><tr><td colspan="2">DISEASE-MODIFYING ANTIRHEUMATI</td></tr><tr><td>Abatacept</td><td>Orencia</td></tr></table>
======================================
<table><tr><td>Adrenocorticotropic hormone (corticotropin)</td></tr><tr><td>Corticotropin-releasing hormone</td></tr><tr><td>Follicle-stimulating hormone</td></tr><tr><td>Growth hormone</td></tr><tr><td>Growth hormone-releasing hormone</td></tr><tr><td>Gonadotropin-releasing hormone</td></tr><tr><td>Human chorionic gonadotropin</td></tr><tr><td>Human menopausal gonadotropin</td></tr><tr><td>Insulin-like growth factor</td></tr><tr><td>Luteinizing hormone</td></tr><tr><td>Prolactin</td></tr><tr><td>Recombinant human growth hormone</td></tr><tr><td>Somatostatin</td></tr><tr><td>Thyrotropin-releasing hormone</td></tr></table>
======================================
<table><thead><th>Anterior Pituitary Hormone</th><th>Hypothalamic Hormone</th><th>Target Organ</th><th>Primary Target Organ Hormone or Mediator</th></thead><tr><td>Growth hormone (GH, somatotropin)</td><td>Growth hormone-releasing hormone (GHRH) (+), Somatostatin (—)</td><td>Liver, bone, muscle, kidney, and others</td><td>Insulin-like growth factor-I (IGF-I)</td></tr><tr><td>Thyroid-stimulating hormone (TSH)</td><td>Thyrotropin-releasing hormone (TRH) (+)</td><td>Thyroid</td><td>Thyroxine, triiodothyronine</td></tr><tr><td>Adrenocorticotropin (ACTH)</td><td>Corticotropin-releasing hormone (CRH) (+)</td><td>Adrenal cortex</td><td>Cortisol</td></tr><tr><td>Follicle-stimulating hormone (FSH) Luteinizing hormone (LH)</td><td>Gonadotropin-releasing hormone (GnRH) (+)</td><td>Gonads</td><td>Estrogen, progesterone, testosterone</td></tr><tr><td>Prolactin (PRL)</td><td>Dopamine (—)</td><td>Breast</td><td></td></tr></table>
======================================
<table><thead><th>Hypothalamic Hormone</th><th>Clinical Uses</th></thead><tr><td>Growth hormone- releasing hormone (GHRH)</td><td>Used rarely as a diagnostic test for GH and GHRH sufficiency</td></tr><tr><td>Thyrotropin- releasing- hormone (TRH, protirelin)</td><td>May be used to diagnose TRH or TSH deficiencies; not currently available for clinical use in United States</td></tr><tr><td>Corticotropin-releasing hormone (CRH)</td><td>Used rarely to distinguish Cushing's disease from ectopic ACTH secretion</td></tr><tr><td>Gonadotropin- releasing hormone (GnRH)</td><td>May be used in a single dose to assess initiation of puberty (pubertal gonadotropin response)</td></tr><tr><td></td><td>May be used in pulses to treat infertility caused by GnRH deficiency Analogs used in long-acting formulations to inhibit gonadal function in children with precocious puberty, in some transgender/ gender variant early pubertal adolescents (to block endogenous puberty), in men with prostate cancer and women under- going assisted reproductive technology (ART) or women who require ovarian suppression for a gynecologic disorder</td></tr><tr><td>Dopamine</td><td>Dopamine agonists (eg, bromocriptine, cabergoline) used for treatment of hyperprolactinemia</td></tr></table>
======================================
<table><thead><th>Hormone</th><th>Diagnostic Use</th></thead><tr><td>Thyroid-stimulating- hormone (TSH; thyrotropin)</td><td>In patients who have been treated surgically for thyroid carcinoma, to test for cancer recur- rence by assessing TSH-stimulated radioac-</td></tr><tr><td></td><td>particular in suspected cases of congenital adrenal hyperplasia. (See Figure 39-1 and Chapter 39.)</td></tr></table>
======================================
<table><thead><th>Primary Therapeutic Objective</th><th>Clinical Condition</th></thead><tr><td rowspan="9">Growth</td><td>Growth failure in pediatric patients associated with:</td></tr><tr><td></td><td>Growth hormone deficiency</td></tr><tr><td></td><td>Chronic renal insufficiency pre-transplant</td></tr><tr><td></td><td>Noonan syndrome</td></tr><tr><td></td><td>Prader-Willi syndrome</td></tr><tr><td></td><td>Short stature homeobox-containing gene (SHOX) deficiency</td></tr><tr><td></td><td>Turner syndrome</td></tr><tr><td></td><td>Small-for-gestational-age with failure to catch up by age 2 years</td></tr><tr><td></td><td>Idiopathic short stature</td></tr><tr><td>Improved metabolic state, increased lean body mass, sense of well-being</td><td>Growth hormone deficiency in adults</td></tr><tr><td>Increased lean body mass, weight, and physical endurance</td><td>Wasting in patients with HIV infection</td></tr><tr><td>Improved gastrointes- tinal function</td><td>Short bowel syndrome in patients who are also receiving specialized nutritional support</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">GROWTH HORMONE (GH)</td></tr><tr><td>+ Somatropin</td><td>Recombinant form of human GH - acts through GH receptors to increase production of IGF-I</td><td>Restores normal growth and metabolic GH effects in GH-deficient individuals + increases final adult height in some children with short stature not due to GH deficiency</td><td>Replacement in GH deficiency + increased final adult height in children with certain conditions associated with short stature (see Table 37-4) + wasting in HIV infection « short bowel syndrome</td><td>SC injection + Toxicity: Pseudotumor cerebri, slipped capital femoral epiphysis, edema, hyperglycemia, progression of scoliosis, risk of asphyxia in severely obese patients with Prader-Willi syndrome and upper airway obstruction or sleep apnea</td></tr><tr><td>IGF-I AGONIST + Mecasermin</td><td>Recombinant form of IGF-I that stimulates IGF-I receptors</td><td>Improves growth and metabolic IGF-I effects in individuals with IGF-| deficiency due to severe GH resistance</td><td>Replacement in IGF-I deficiency that is not responsive to exogenous GH</td><td>SC injection + Toxicity: Hypoglycemia, intracranial hypertension, increased liver enzymes</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">SOMATOSTATIN ANALOGS</td></tr><tr><td>+ Octreotide</td><td>Agonist at somatostatin receptors</td><td>Inhibits production of GH and, to a lesser extent, of TSH, glucagon, insulin, and gastrin</td><td>Acromegaly and several other hormone-secreting tumors + acute control of bleeding from esophageal varices</td><td>SC or IV injection + long-acting formulation injected IM monthly + Toxicity: Gastrointestinal disturbances, gallstones, bradycardia, cardiac conduction problems</td></tr></table>
======================================
<table><thead><th>+ Lanreotide: Similar</th><th>to octreotide; available as a</th><th>long-acting formulation for acromegaly</th><th></th><th>alsturbances, gallstones, bradycardia, cardiac conduction problems</th></thead><thead><th colspan="5">jH RECEPTOR ANTAGONIST</th></thead><thead><th>+ Pegvisomant</th><th>Blocks GH receptors</th><th>Ameliorates effects of excess GH production</th><th>Acromegaly</th><th>SC injection + Toxicity: Increased liver enzymes</th></thead><tr><td colspan="5">jONADOTROPINS: FOLLICLE-STIMULATING HORMONE (FSH) ANALOGS</td></tr><tr><td colspan="5">+ Follitropin alfa Activates FSH receptors Mimics effects of endogenous FSH Controlled ovarian stimulation + infertility due to hypogonadotropic hypogonadism in men SC injection + Toxicity: Ovarian hyperstimulation syndrome and multiple pregnancies in women + gynecomastia in men + headache, depression, edema in both sexes + Follitropin beta: A recombinant product with the same peptide sequence as follitropin alfa but differs in its carbohydrate side chains Urofollitropin: Human FSH purified from the urine of postmenopausal</td></tr><tr><td colspan="5">+ Menotropins (hMG): Extract of the urine of postmenopausal women; contains both FSH and LH activity jONADOTROPINS: LUTEINIZING HORMONE (LH) ANALOGS</td></tr><tr><td>+ Human chorionic</td><td>| Agonist at LH</td><td>| Mimics effects of</td><td>| Initiation of final oocyte maturation</td><td>| IM or SC injection + Toxicity: Ovarian</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th></th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">DOPAMINE AGONISTS</td></tr><tr><td>+ Bromocriptine + Cabergoline: Another</td><td>Activates dopamine D, receptors ergot derivative with similar</td><td>Suppresses pituitary secretion of prolactin and, less effectively, GH + dopaminergic effects on CNS motor control and behavior effects</td><td>Treatment of hyperprolactinemia + acromegaly « Parkinson's disease (see Chapter 28)</td><td>Administered orally or, for hyperprolactinemia, vaginally + Toxicity: Gastrointestinal disturbances, orthostatic hypotension, headache, psychiatric disturbances, vasospasm and pulmonary infiltrates in high doses</td></tr><tr><td>OXYTOCIN</td><td>Activates oxytocin receptors</td><td>Increased uterine contractions</td><td>Induction and augmentation of labor + control of uterine hemorrhage after delivery</td><td>IV infusion or IM injection + Toxicity: Fetal distress, placental abruption, uterine rupture, fluid retention,</td></tr><tr><td colspan="5">hypotension OXYTOCIN RECEPTOR ANTAGONIST</td></tr><tr><td>+ Atosiban</td><td>Blocks oxytocin receptors</td><td>Decreased uterine contractions</td><td>Tocolysis for preterm labor (not available in the USA)</td><td>IV infusion - Toxicity: Concern about increased rates of infant death; not FDA approved</td></tr><tr><td colspan="5">VASOPRESSIN RECEPTOR AGONISTS</td></tr><tr><td>+ Desmopressin</td><td>Relatively selective vasopressin V, receptor | agonist</td><td>Acts in the kidney collecting duct cells to decrease the excretion of water + acts on extrarenal V, receptors to increase factor VIII and von Willebrand factor</td><td>Pituitary diabetes insipidus + pediatric primary nocturnal enuresis » hemophilia A and von Willebrand disease</td><td>Oral, IV, SC, or intranasal « Toxicity: Gastrointestinal disturbances, headache, hyponatremia, allergic reactions</td></tr><tr><td colspan="5">+ Vasopressin: Available for treatment of diabetes insipidus and sometimes used to control bleeding from esophageal varices</td></tr></table>
======================================
<table></table>
======================================
<table><tr><td>Leuprolide acetate</td><td>Generic, Eligard, Lupron</td></tr><tr><td>Lutropin alfa (rLH)</td><td>Luveris”</td></tr><tr><td>Menotropins (hMG)</td><td>Menopur, Repronex</td></tr><tr><td>Nafarelin acetate</td><td>Synarel</td></tr><tr><td>Triptorelin pamoate</td><td>Trelstar, Trelstar LA, Trelstar Depot</td></tr><tr><td>Urofollitropin</td><td>Bravelle’, Fertinex”</td></tr><tr><td>Bromocriptine mesylate</td><td>Generic, Parlodel, Cycloset</td></tr><tr><td>Cabergoline</td><td>Generic, Dostinex</td></tr><tr><td>Oxytocin</td><td>Generic, Pitocin</td></tr><tr><td>Conivaptan HCl</td><td>Vaprisol</td></tr><tr><td>Desmopressin acetate (DDAVP)</td><td>Generic, Minirin, Stimate</td></tr><tr><td>Tolvaptan</td><td>Samsca</td></tr><tr><td>Vasopressin</td><td>Generic, Pitressin</td></tr><tr><td>Corticorelin ovine triflutate</td><td>Acthrel</td></tr><tr><td>Corticotropin</td><td>H.P. Acthar Gel</td></tr><tr><td>Cosyntropin</td><td>Generic, Cortrosyn, Cosyntropin</td></tr></table>
======================================
<table><tr><td>GROWTH FACTOR</td><td>AGONISTS &amp; ANTAGONISTS</td></tr><tr><td>Lanreotide acetate</td><td>Somatuline Depot</td></tr><tr><td>Mecasermin</td><td>Increlex</td></tr><tr><td>Octreotide acetate</td><td>Generic, Sandostatin, Sandostatin LAR Depot</td></tr><tr><td>Pegvisomant</td><td>Somavert</td></tr><tr><td>Somatropin</td><td>Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, Tev-tropin, Zorbtive</td></tr><tr><td>GONADOTROPIN</td><td>AGONISTS &amp; ANTAGONISTS</td></tr><tr><td>Abarelix</td><td>Plenaxis*</td></tr><tr><td>Cetrorelix acetate</td><td>Cetrotide</td></tr><tr><td>Choriogonadotropin alfa (rhCG)</td><td>Ovidrel</td></tr><tr><td>Chorionic gonadotropin (hCG)</td><td>Generic, Profasi, Pregnyl</td></tr><tr><td>Degarelix</td><td>Firmagon</td></tr><tr><td>Follitropin alfa (rFSH)</td><td>Gonal-f</td></tr><tr><td>Follitropin beta (rFSH)</td><td>Follistim</td></tr><tr><td>Ganirelix acetate</td><td>Antagon</td></tr><tr><td>Gonadorelin hydrochloride (GnRH)</td><td>Factrel</td></tr><tr><td>Goserelin acetate</td><td>Zoladex</td></tr></table>
======================================
<table><thead><th>Variable</th><th></th><th>T;</th></thead><tr><td>Volume of distribution</td><td></td><td>40L</td></tr><tr><td>Extrathyroidal pool</td><td></td><td>54 mcg</td></tr><tr><td>Daily production</td><td></td><td>25 mcg</td></tr><tr><td>Fractional turnover per day</td><td></td><td>60%</td></tr><tr><td>Metabolic clearance per day</td><td></td><td>24L</td></tr><tr><td>Half-life (biologic)</td><td>7 days</td><td>1 day</td></tr><tr><td colspan="3">Serum levels</td></tr><tr><td rowspan="2">Total</td><td>4.8-10.4 mcg/dL</td><td>60-181 ng/dL</td></tr><tr><td></td><td>(62-134 nmol/L)</td><td>(0.92-2.79 nmol/L)</td></tr><tr><td rowspan="2">Free</td><td>0.8-2.7 ng/dL</td><td>230-420 pg/dL</td></tr><tr><td></td><td>(10.3-34.7 pmol/L)</td><td>(3.5-6.47 pmol/L)</td></tr><tr><td>Amount bound</td><td>99.96%</td><td>99.6%</td></tr><tr><td>Biologic potency</td><td>1</td><td>4</td></tr><tr><td>Oral absorption</td><td>70%</td><td>95%</td></tr></table>
======================================
<table><thead><th>Name of Test</th><th>Normal Value’</th><th>Results in Hypothy</th><th>Results in Hyperthyroidism</th></thead><tr><td>Total thyroxine (T,)</td><td>4.8-10.4 mcg/dL (62-134 nmol/L)</td><td>Low</td><td>High</td></tr><tr><td>Total triiodothyronine (T3)</td><td>59-156 ng/dL. (0.9-2.4 nmol/L)</td><td>Normal or low</td><td>High</td></tr><tr><td>Free T, (FT4)</td><td>0.8-1.4 ng/dL (10-18 pmol/L)</td><td>Low</td><td>High</td></tr><tr><td>Free T; (FT3)</td><td>169-371 ng/dL (2.6-5.7 pmol/L)</td><td>Low</td><td>High</td></tr><tr><td>Thyrotropic hormone (TSH)</td><td>0.45-4.12 wlU/mL (0.45-4.12 mlU/L)</td><td>High?</td><td>Low</td></tr><tr><td>3) uptake at 24 hours</td><td>5-35%</td><td>Low</td><td>High</td></tr><tr><td>Antithyroglobulin antibodies (Tg-Ab)</td><td>&lt;200 IU/mL</td><td>Often present</td><td>Usually present</td></tr><tr><td>Thyroperoxidase antibodies (ATPO)</td><td>&lt;100 WHO units</td><td>Often present</td><td>Usually present</td></tr><tr><td>Isotope scan with I or °"TCO,</td><td>Normal pattern</td><td>Test not indicated</td><td>Diffusely enlarged gland</td></tr><tr><td>Fine-needle aspiration (FNA) biopsy</td><td>Normal pattern</td><td>Test not indicated</td><td>Test not indicated</td></tr><tr><td>Serum thyroglobulin</td><td>Women: 1.5-38.5 mcg/L Men: 1.4-29.2 mcg/L</td><td>Test not indicated</td><td>Test not indicated</td></tr><tr><td>TSH receptor-stimulating antibody or thyroid-stimulating immunoglobulin (TS!)</td><td>Negative &lt;140% of baseline</td><td>Test not indicated</td><td>Elevated in Graves’ disease</td></tr></table>
======================================
<table><tr><td colspan="2">Change in thyroid hormone synthesis</td></tr><tr><td>Inhibition of TRH or TSH secretion without induction of hypothyroidism or hyperthyroidism</td><td>Bexarotene, dopamine, bromocriptine, cabergoline, levodopa, corticosteroids, somatostatin, octreotide, metformin, interleukin-6, heroin</td></tr><tr><td>Inhibition of thyroid hormone synthesis or release with the induction of hypothyroidism (or occasionally hyperthyroidism)</td><td>lodides (including amiodarone), lithium, aminoglutethimide, thioamides, ethionamide, tyrosine kinase inhibitors (eg, sunitinib, sorafenib, imatinib), HIV protease inhibitors</td></tr><tr><td colspan="2">Alteration of thyroid hormone transport and serum total T; and T, levels, but usually no modification of FT, or TSH</td></tr><tr><td>Increased TBG</td><td>Estrogens, tamoxifen, raloxifene, heroin, methadone, mitotane, 5-fluorouracil, perphenazine</td></tr><tr><td>Decreased TBG</td><td>Androgens, anabolic steroids, glucocorticoids, danazol, t-asparaginase, nicotinic acid</td></tr><tr><td>Displacement of T; and T, from TBG with transient hyperthyroxinemia</td><td>Salicylates, fenclofenac, mefenamic acid, intravenous furosemide, heparin</td></tr><tr><td colspan="2">Alteration of T, and T, metabolism with modified serum T; and T, levels but not TSH levels (unless receiving thyroxine replacement therapy)</td></tr><tr><td>Increased hepatic metabolism, enhanced degradation of thyroid hormone</td><td>Nicardipine, phenytoin, carbamazepine, primidone, phenobarbital, rifampin, rifabutin, tyrosine kinase inhibitors (eg, sunitinib, sorafenib, imatinib), sertraline, quetiapine</td></tr><tr><td>Inhibition of 5’-deiodinase with decreased T3, increased rT;</td><td>lopanoic acid, ipodate, amiodarone, B blockers, corticosteroids, propylthiouracil, flavonoids, interleukin-6</td></tr><tr><td>Other interactions</td><td></td></tr><tr><td>Interference with T, absorption from the gut</td><td>Oral bisphosphonates, cholestyramine, colesevelam, colestipol, chromium picolinate, charcoal, ciprofloxacin, proton pump inhibitors, sucralfate, Kayexalate, raloxifene, sevelamer hydrochloride, aluminum hydroxide, ferrous sulfate, calcium carbonate, bran/fiber, soy, coffee, orlistat</td></tr><tr><td>Induction of autoimmune thyroid disease with hypothyroidism or hyperthyroidism</td><td>Interferon-a, interleukin-2, interferon-f, lithium, amiodarone, tyrosine kinase inhibitors (eg, sunitinib, sorafenib, imatinib)</td></tr><tr><td colspan="2">Effect of thyroid function on drug effects</td></tr><tr><td>Anticoagulation</td><td>Lower doses of warfarin required in hyperthyroidism, higher doses in hypothyroidism</td></tr><tr><td>Glucose control</td><td>Increased hepatic glucose production and glucose intolerance in hyperthyroidism; impaired insulin action and glucose disposal in hypothyroidism</td></tr><tr><td>Cardiac drugs</td><td>Higher doses of digoxin required in hyperthyroidism; lower doses in hypothyroidism</td></tr><tr><td>Sedatives; analgesics</td><td>Increased sedative and respiratory depressant effects from sedatives and opioids in</td></tr></table>
======================================
<table><thead><th>System</th><th></th><th>Hypothyroidism</th></thead><tr><td>Skin and appendages</td><td>Warm, moist skin; sweating; heat intolerance; fine, thin hair; Plummer’s nails; pretibial dermopathy (Graves’ disease)</td><td>Pale, cool, puffy, yellowish skin, face, and hands; dry and brittle hair; brittle nails</td></tr><tr><td>Eyes, face</td><td>Retraction of upper lid with wide stare; periorbital edema; exophthalmos; diplopia (Graves’ disease)</td><td>Drooping of eyelids; periorbital edema; loss of temporal aspects of eyebrows; puffy, nonpitting facies; large tongue, hoarseness</td></tr><tr><td>Cardiovascular system</td><td>Decreased peripheral vascular resistance; increased heart rate, stroke volume, cardiac output, pulse pres- sure; high-output heart failure; increased inotropic and chronotropic effects; arrhythmias; angina</td><td>Increased peripheral vascular resistance; decreased heart rate, stroke volume, cardiac output, pulse pressure; low- output heart failure; ECG: bradycardia, prolonged PR interval, flat T wave, low voltage; pericardial effusion</td></tr><tr><td>Respiratory system</td><td>Dyspnea; hypoventilation; decreased vital capacity</td><td>Pleural effusions; hypoventilation and CO, retention; sleep apnea</td></tr><tr><td>Gastrointestinal system</td><td>Increased appetite; increased frequency of bowel movements; hypoproteinemia</td><td>Decreased appetite; decreased frequency of bowel movements, constipation; ascites</td></tr><tr><td>Central nervous system</td><td>Nervousness; hyperkinesia; emotional lability, agitation</td><td>Lethargy/fatigue; general slowing of mental processes; neuropathies; weakness and muscle cramps</td></tr><tr><td>Musculoskeletal system</td><td>Weakness and muscle fatigue; increased deep tendon reflexes; tremors; hypercalcemia; osteoporosis</td><td>Stiffness and muscle fatigue; carpal tunnel syndrome; decreased deep tendon reflexes; increased alkaline phosphatase, LDH, AST</td></tr><tr><td>Renal system</td><td>Mild polyuria; increased renal blood flow; increased glomerular filtration rate</td><td>Impaired water excretion; decreased renal blood flow; decreased glomerular filtration rate</td></tr><tr><td>Hematopoietic system</td><td>Increased erythropoiesis; anemia’</td><td>Decreased erythropoiesis; anemia’</td></tr><tr><td>Reproductive system</td><td>Menstrual irregularities; amenorrhea; infertility; increased gonadal steroid metabolism</td><td>Menorrhagia; infertility; decreased libido; impotence; oligospermia; decreased gonadal steroid metabolism</td></tr><tr><td>Metabolic system</td><td>Increased basal metabolic rate; negative nitrogen balance; hyperglycemia; increased free fatty acids; decreased total cholesterol and triglycerides; increased hormone degradation; increased require- ments for fat- and water-soluble vitamins; increased drug metabolism; decreased warfarin requirement</td><td>Decreased basal metabolic rate; slight positive nitrogen balance; delayed degradation of insulin with increased sensitivity; increased total cholesterol and triglycerides; hyponatremia; decreased hormone degradation; decreased requirements for fat- and water-soluble vitamins; decreased drug metabolism; increased warfarin requirement</td></tr></table>
======================================
<table><thead><th>Cause</th><th>Pathogenesis</th><th>Goiter</th><th>Degree of Hypothyroidism</th></thead><tr><td>Hashimoto's thyroiditis</td><td>Autoimmune destruction of thyroid</td><td>Present early, absent later</td><td>Mild to severe</td></tr><tr><td>Drug-induced"</td><td>Blocked hormone formation?</td><td>Present</td><td>Mild to moderate</td></tr><tr><td>Dyshormonogenesis</td><td>Impaired synthesis of T, due to enzyme deficiency</td><td>Present</td><td>Mild to severe</td></tr><tr><td>Radiation, my X-ray, thyroidectomy</td><td>Destruction or removal of gland</td><td>Absent</td><td>Severe</td></tr><tr><td>Congenital (cretinism)</td><td>Athyreosis or ectopic thyroid, iodine defi- ciency; TSH receptor-blocking antibodies</td><td>Absent or present</td><td>Severe</td></tr><tr><td>Secondary (TSH deficit)</td><td>Pituitary or hypothalamic disease</td><td>Absent</td><td>Mild</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of A: and Effects</th><th></th><th></th></thead><tr><td>THYROID PREPARATIONS + Levothyroxine (T,) + Liothyronine (T;)</td><td>Activation of nuclear receptors results in gene expression with RNA formation and protein synthesis</td><td>Hypothyroidism</td><td>See Table 38-1 + maximum effect seen after 6-8 weeks of therapy + Toxicity: See Table 38-4 for symptoms of thyroid excess</td></tr><tr><td>ANTITHYROID AGENTS THIOAMIDES + Methimazole + Propylthiouracil (PTU)</td><td>Inhibit thyroid peroxidase reactions + block iodine organification + inhibit peripheral deiodination of T, and T; (primarily PTU)</td><td>Hyperthyroidism</td><td>Oral + duration of action: 24 h (methimazole), 6-8 h (PTU) + delayed onset of action + Toxicity: Nausea, gastrointestinal distress, rash, agranulocytosis, hepatitis</td></tr><tr><td>IODIDES + Lugol's solution + Potassium iodide</td><td>Inhibit organification and hormone release + reduce the size and vascularity of the gland</td><td>Preparation for surgical thyroidectomy</td><td>Oral - acute onset within 2-7 days + Toxicity: Rare (see text)</td></tr><tr><td>BETA BLOCKERS + Propranolol, other B blockers lacking partial agonist activity</td><td>Inhibition of 8 adrenoreceptors + inhibit T, to T; conversion (only</td><td>Hyperthyroidism, especially thyroid storm + adjunct to control tachycardia,</td><td>Onset within hours « duration of 4-6 h (oral propranolol) « Toxicity: Asthma, AV</td></tr><tr><td>RADIOACTIVE IODINE '*"I (RAI)</td><td>Radiation destruction of thyroid parenchyma</td><td>Hyperthyroidism + patients should be euthyroid or on B blockers before RAI - avoid in pregnancy and in nursing mothers</td><td>Oral - half-life 5 days - onset in 6-12 weeks «maximum effect in 3-6 months - Toxicity: Sore throat, sialitis, hypothyroidism</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of A: and Effects</th><th></th><th></th></thead><tr><td>THYROID PREPARATIONS + Levothyroxine (T,) + Liothyronine (T;)</td><td>Activation of nuclear receptors results in gene expression with RNA formation and protein synthesis</td><td>Hypothyroidism</td><td>See Table 38-1 + maximum effect seen after 6-8 weeks of therapy + Toxicity: See Table 38-4 for symptoms of thyroid excess</td></tr><tr><td>ANTITHYROID AGENTS THIOAMIDES + Methimazole + Propylthiouracil (PTU)</td><td>Inhibit thyroid peroxidase reactions + block iodine organification + inhibit peripheral deiodination of T, and T; (primarily PTU)</td><td>Hyperthyroidism</td><td>Oral + duration of action: 24 h (methimazole), 6-8 h (PTU) + delayed onset of action + Toxicity: Nausea, gastrointestinal distress, rash, agranulocytosis, hepatitis</td></tr><tr><td>IODIDES + Lugol's solution + Potassium iodide</td><td>Inhibit organification and hormone release + reduce the size and vascularity of the gland</td><td>Preparation for surgical thyroidectomy</td><td>Oral - acute onset within 2-7 days + Toxicity: Rare (see text)</td></tr><tr><td>BETA BLOCKERS + Propranolol, other B blockers lacking partial agonist activity</td><td>Inhibition of 8 adrenoreceptors + inhibit T, to T; conversion (only</td><td>Hyperthyroidism, especially thyroid storm + adjunct to control tachycardia,</td><td>Onset within hours « duration of 4-6 h (oral propranolol) « Toxicity: Asthma, AV</td></tr><tr><td>RADIOACTIVE IODINE '*"I (RAI)</td><td>Radiation destruction of thyroid parenchyma</td><td>Hyperthyroidism + patients should be euthyroid or on B blockers before RAI - avoid in pregnancy and in nursing mothers</td><td>Oral - half-life 5 days - onset in 6-12 weeks «maximum effect in 3-6 months - Toxicity: Sore throat, sialitis, hypothyroidism</td></tr></table>
======================================
<table><tr><td>THYROID</td><td>AGENTS</td></tr><tr><td>Levothyroxine (T,)</td><td>Generic, Levoxyl, Levo-T, Levothroid, Levolet*, Novothyrox, Synthroid, Tirosint (capsule), Unithroid</td></tr><tr><td>Liothyronine (Ts)</td><td>Generic, Cytomel, Triostat (IV)</td></tr><tr><td>Liotrix (a 4:1 ratio of T,:T3)</td><td>Thyrolar</td></tr><tr><td>Thyroid desiccated (USP)</td><td>Generic, Armour, Nature- Throid, Westhroid</td></tr><tr><td>ANTITHYROID</td><td>AGENTS</td></tr><tr><td>131 Radioactive iodine (~~ 1) sodium</td><td>lodotope, Sodium lodide 1131 Therapeutic</td></tr><tr><td>Methimazole</td><td>Generic, Tapazole</td></tr><tr><td colspan="2">Potassium iodide</td></tr><tr><td>Oral solution (SSKI)</td><td>ThyroShield</td></tr><tr><td>Oral solution (Lugol's solution)</td><td>Lugol's solution</td></tr><tr><td>Oral potassium iodide tablets</td><td>IOSAT, Thyro-Block, Thyro-Safe</td></tr><tr><td>Propylthiouracil [PTU]</td><td>Generic</td></tr><tr><td colspan="2">DIAGNOSTIC AGENT</td></tr><tr><td>Thyrotropin; recombinant human TSH</td><td>— Thyrogen</td></tr></table>
======================================
<table><thead><th rowspan="2">Agent</th><th colspan="3">Activity’</th><th>Oral</th><th rowspan="2">Forms Available</th></thead><thead><th></th><th>Anti-Inflammatory</th><th>Topical</th><th>Salt-Retaining</th><th>Equivalent Dose (mg)</th><th></th></thead><tr><td colspan="6">Short- to medium-acting glucocorticoids</td></tr><tr><td>Hydrocortisone (cortisol)</td><td>1</td><td>1</td><td></td><td></td><td>Oral, injectable, topical</td></tr><tr><td>Cortisone</td><td>0.8</td><td>0</td><td></td><td></td><td>Oral</td></tr><tr><td>Prednisone</td><td>4</td><td>(0)</td><td></td><td></td><td>Oral</td></tr><tr><td>Prednisolone</td><td>5</td><td>4</td><td></td><td>UY</td><td>Oral, injectable</td></tr><tr><td>Methylprednisolone</td><td>5</td><td>5</td><td></td><td></td><td>Oral, injectable</td></tr><tr><td>Meprednisone*</td><td>5</td><td></td><td></td><td>RR</td><td>Oral, injectable</td></tr><tr><td colspan="6">Intermediate-acting glucocorticoids</td></tr><tr><td>Triamcinolone</td><td>5</td><td>5</td><td></td><td></td><td>Oral, injectable, topical</td></tr><tr><td>Paramethasone”</td><td>10</td><td></td><td></td><td></td><td>Oral, injectable</td></tr><tr><td>Fluprednisolone*</td><td>15</td><td>7</td><td></td><td></td><td>Oral</td></tr><tr><td colspan="6">Long-acting glucocorticoids</td></tr><tr><td>Betamethasone</td><td>25-40</td><td>10</td><td></td><td></td><td>Oral, injectable, topical</td></tr><tr><td>Dexamethasone</td><td>30</td><td>10</td><td></td><td>0.75</td><td>Oral, injectable, topical</td></tr><tr><td colspan="6">Mineralocorticoids</td></tr><tr><td>Fludrocortisone</td><td>10</td><td>(0)</td><td>250</td><td></td><td>Oral</td></tr><tr><td>Desoxycorticosterone acetate”</td><td>0</td><td>0</td><td></td><td></td><td>Injectable, pellets</td></tr></table>
======================================
<table><thead><th>Disorder</th><th>Examples</th></thead><tr><td>Allergic reactions</td><td>Angioneurotic edema, asthma, bee stings, contact dermatitis, drug reactions, allergic rhinitis, serum sickness, urticaria</td></tr><tr><td>Collagen-vascular disorders</td><td>Giant cell arteritis, lupus erythematosus, mixed connective tissue syndromes, polymyositis, polymyalgia rheumatica, rheumatoid arthritis, temporal arteritis</td></tr><tr><td>Eye diseases</td><td>Acute uveitis, allergic conjunctivitis, choroiditis, optic neuritis</td></tr><tr><td>Gastrointestinal diseases</td><td>Inflammatory bowel disease, nontropical sprue, subacute hepatic necrosis</td></tr><tr><td>Hematologic disorders</td><td>Acquired hemolytic anemia, acute allergic purpura, leukemia, lymphoma, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, multiple myeloma</td></tr><tr><td>Systemic inflammation</td><td>Acute respiratory distress syndrome (sustained therapy with moderate dosage accelerates recovery and decreases mortality)</td></tr><tr><td>Infections Inflammatory conditions</td><td>Acute respiratory distress syndrome, sepsis Arthritis, bursitis, tenosynovitis</td></tr><tr><td>of bones and joints Nausea and</td><td>dose of dexamethasone reduces emetic effects of and anesthesia</td></tr><tr><td>vomiting Neurologic disorders</td><td>A large chemotherapy general Cerebral edema (large doses of dexamethasone are given to patients following brain surgery to minimize cerebral</td></tr><tr><td>Organ transplants</td><td>edema in the postoperative period), multiple sclerosis Prevention and treatment of rejection (immunosuppression)</td></tr><tr><td>Pulmonary diseases</td><td>Aspiration pneumonia, bronchial asthma, prenatal prevention of infant respiratory distress syndrome, sarcoidosis</td></tr><tr><td>Renal disorders</td><td>Nephrotic syndrome</td></tr><tr><td>Skin diseases</td><td>Atopic dermatitis, dermatoses, lichen simplex chronicus (localized neurodermatitis), mycosis fungoides, pemphigus,</td></tr><tr><td>Thyroid diseases</td><td>psoriasis, seborrheic dermatitis, xerosis Malignant exophthalmos, subacute thyroiditis</td></tr></table>
======================================
<table><tr><td colspan="2">GLUCOCORTICOIDS FOR ORAL &amp; PARENTERAL US|</td></tr><tr><td>Betamethasone</td><td>Celestone</td></tr><tr><td>Betamethasone sodium phosphate</td><td>Generic, Celestone Phosphate</td></tr><tr><td>Budesonide</td><td>Generic, Entocort EC</td></tr><tr><td>Cortisone</td><td>Generic</td></tr><tr><td>Dexamethasone</td><td>Generic, Decadron</td></tr><tr><td>Dexamethasone sodium phosphate</td><td>Generic</td></tr><tr><td>Hydrocortisone (cortisol)</td><td>Generic, Cortef</td></tr><tr><td>Hydrocortisone acetate</td><td>Generic</td></tr><tr><td>Hydrocortisone sodium phosphate</td><td>Hydrocortone</td></tr><tr><td>Hydrocortisone sodium succinate</td><td>Generic, Solu-Cortef, others</td></tr><tr><td>Methylprednisolone</td><td>Generic, Medrol</td></tr><tr><td>Methylprednisolone acetate</td><td>Generic, Depo-Medrol</td></tr><tr><td>Methylprednisolone sodium succinate</td><td>Generic, Solu-Medrol, others</td></tr><tr><td>Prednisolone</td><td>Generic, Prelone, others</td></tr><tr><td>Prednisolone acetate</td><td>Generic, Flo-Pred</td></tr><tr><td>Prednisolone sodium phosphate</td><td>Generic, Hydeltrasol</td></tr><tr><td>Prednisone</td><td>Generic, Deltasone, Prednicot</td></tr><tr><td>Triamcinolone acetonide</td><td>Generic, Kenalog, Azmacort</td></tr><tr><td>Triamcinolone hexacetonide</td><td>Aristospan</td></tr><tr><td colspan="2">MINERALOCORTICOIDS</td></tr><tr><td>Fludrocortisone acetate</td><td>Generic, Florinef Acetate, Cortineff Acetate</td></tr><tr><td colspan="2">ADRENAL STEROID INHIBITORS</td></tr><tr><td>Abiraterone</td><td>Zytiga</td></tr><tr><td>Ketoconazole</td><td>Generic, Nizoral</td></tr><tr><td>Etomidate</td><td>Amidate</td></tr></table>
======================================
<table><tr><td>CBG</td><td>Corticosteroid-binding globulin (transcortin)</td></tr><tr><td>DHEA</td><td>Dehydroepiandrosterone</td></tr><tr><td>DHEAS</td><td>Dehydroepiandrosterone sulfate</td></tr><tr><td>ERE</td><td>Estrogen response element</td></tr><tr><td>FSH</td><td>Follicle-stimulating hormone</td></tr><tr><td>GnRH</td><td>Gonadotropin-releasing hormone</td></tr><tr><td>HDL</td><td>High-density lipoprotein</td></tr><tr><td>HRT</td><td>Hormone replacement therapy (also called HT)</td></tr><tr><td>LDL</td><td>Low-density lipoprotein</td></tr><tr><td>LH</td><td>Luteinizing hormone</td></tr><tr><td>PRE</td><td>Progesterone response element</td></tr><tr><td>SERM</td><td>Selective estrogen receptor modulator</td></tr><tr><td>SHBG</td><td>Sex hormone-binding globulin</td></tr></table>
======================================
<table><thead><th>Preparation</th><th>Average Replacement Dosage</th></thead><tr><td>Ethinyl estradiol</td><td>0.005-0.02 mg/d</td></tr><tr><td>Micronized estradiol</td><td>1-2 mg/d</td></tr><tr><td>Estradiol cypionate</td><td>2-5 mg every 3-4 weeks</td></tr><tr><td>Estradiol valerate</td><td>2-20 mg every other week</td></tr><tr><td>Estropipate</td><td>1.25-2.5 mg/d</td></tr><tr><td colspan="2">Conjugated, esterified, or mixed estrogenic substances:</td></tr><tr><td>Oral</td><td>0.3-1.25 mg/d</td></tr><tr><td>Injectable</td><td>0.2-2 mg/d</td></tr><tr><td>Transdermal</td><td>Patch</td></tr><tr><td>Quinestrol</td><td>0.1-0.2 mg/week</td></tr><tr><td>Chlorotrianisene</td><td>12-25 mg/d</td></tr><tr><td>Methallenestril</td><td>3-9 mg/d</td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">Route</th><th rowspan="2">Duration of Action</th><th colspan="5">Activities</th></thead><thead><th></th><th></th><th></th><th>Estrogenic</th><th>Androgenic</th><th>Antiestrogenic</th><th>Antiandrogenic</th><th>Anabolic</th></thead><tr><td colspan="8">Progesterone and derivatives</td></tr><tr><td>Progesterone</td><td>IM</td><td>1 day</td><td>-</td><td>-</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Hydroxyprogesterone caproate</td><td>IM</td><td>8-14 days</td><td>sl</td><td>sl</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Medroxyprogesterone acetate</td><td>IM,PO</td><td>Tabs: 1-3 days; injection: 4-12 weeks</td><td>-</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Megestrol acetate</td><td>PO</td><td>1-3 days</td><td>-</td><td>+</td><td>-</td><td>+</td><td>-</td></tr><tr><td colspan="8">17-Ethinyl testosterone derivatives</td></tr><tr><td>Dimethisterone</td><td>PO</td><td>1-3 days</td><td>-</td><td>-</td><td>sl</td><td>-</td><td>-</td></tr><tr><td colspan="8">19-Nortestosterone derivatives</td></tr><tr><td>Desogestrel</td><td>PO</td><td>1-3 days</td><td>-</td><td>-</td><td>-</td><td>=</td><td>=</td></tr><tr><td>Norethynodrel</td><td>PO</td><td>1-3 days</td><td>+</td><td>-</td><td>-</td><td>=</td><td>=</td></tr><tr><td>Lynestrenol*</td><td>PO</td><td>1-3 days</td><td>+</td><td>+</td><td>-</td><td>=</td><td>+</td></tr><tr><td>Norethindrone</td><td>PO</td><td>1-3 days</td><td>sl</td><td>+</td><td>+</td><td>-</td><td>+</td></tr><tr><td>Norethindrone acetate</td><td>PO</td><td>1-3 days</td><td>sl</td><td>+</td><td>+</td><td>-</td><td>+</td></tr><tr><td>Ethynodiol diacetate</td><td>PO</td><td>1-3 days</td><td>sl</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>t-Norgestrel”</td><td>PO</td><td>1-3 days</td><td>-</td><td>+</td><td>+</td><td>-</td><td>a</td></tr></table>
======================================
<table><tr><td>Monophasic Combination Tablets</td><td></td><td></td><td></td><td></td></tr><tr><td>Aviane, Falmina, Lessina, Lutera, Orsythia, Sronyx</td><td>Ethinyl estradiol</td><td>0.02</td><td>L-Norgestrel</td><td>0.1</td></tr><tr><td>Beyaz, Gianvi, Loryna, Yaz, Vestura</td><td>Ethinyl estradiol</td><td>0.02</td><td>Drospirone</td><td></td></tr><tr><td>Gildess 1/20, Junel, Loestrin, Microgestin, Minastrin</td><td>Ethinyl estradiol</td><td>0.02</td><td>Norethindrone</td><td></td></tr><tr><td>Apri, Desogen, Ortho-Cept, Reclipsen, Solia</td><td>Ethinyl estradiol</td><td>0.03</td><td>Desonorgestrel</td><td></td></tr><tr><td>Altavera, Chateal, Introvate, Jolessa, Kurvelo, Levora, Marlissa, Portia</td><td>Ethinyl estradiol</td><td>0.03</td><td>L-Norgestrel</td><td></td></tr><tr><td>Cryselle, Elinest, Low-Ogestrel</td><td>Ethinyl estradiol</td><td>0.03</td><td>Norgestrel</td><td></td></tr><tr><td>Ocella, Safyral, Syeda, Yasmin, Zarah</td><td>Ethinyl estradiol</td><td>0.03</td><td>Drospirenone</td><td></td></tr><tr><td>Gildess, Junel, Loestrin, Microgestin</td><td>Ethinyl estradiol</td><td>0.03</td><td>Norethindrone</td><td></td></tr><tr><td>Cyclafem 1/35, Necon 1/35, Norinyl 1/35</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td></td></tr><tr><td>Estarylla, MonoNessa, Ortho-Cyclen, Previfem, Sprintec</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norgestimate</td><td></td></tr><tr><td>Alyacen 1/35; Cyclafem 1/35, Dasetta 1/35, Necon 1/35, Norinyl 1+35, Nortrel 1/35, Ortho-Novum 1/35, Pirmella 1/35</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td></td></tr><tr><td>Brevicon, Modicon, Necon 0.5/35, Nortrel 0.5/35, Wera</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td></td></tr><tr><td>Ovcon-35, Femcon Fe, Balziva, Briellyn, Gildagia, others</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>0.4</td></tr><tr><td>Ogestrel 0.5/50</td><td>Ethinyl estradiol</td><td>0.05</td><td>D,L-Norgestrel</td><td>0.5</td></tr><tr><td>Norinyl 1+50, Necon 1/50</td><td>Mestranol</td><td>0.05</td><td>Norethindrone</td><td></td></tr><tr><td colspan="5">Biphasic Combination Tablets</td></tr><tr><td colspan="5">Azurette, Kariva, Mircette, Viorele</td></tr><tr><td>Days 1-21</td><td>Ethinyl estradiol</td><td>0.02</td><td>Desogestrel</td><td>0.15</td></tr><tr><td>Days 22-27</td><td>Ethinyl estradiol</td><td>0.01</td><td></td><td></td></tr><tr><td colspan="5">Necon 10/11</td></tr><tr><td>Days 1-10</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>0.5</td></tr><tr><td>Days 11-21</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>1.0</td></tr><tr><td colspan="5">lriphasic Combination Tablets</td></tr><tr><td colspan="5">Enpresse, Levonest, Myzilra, Triphasil, Tri-Levlen, Trivora</td></tr><tr><td>Days 1-6</td><td>Ethinyl estradiol</td><td>0.03</td><td>L-Norgestrel</td><td>0.05</td></tr><tr><td>Days 7-11</td><td>Ethinyl estradiol</td><td>0.04</td><td>L-Norgestrel</td><td>0.075</td></tr><tr><td>Days 12-21</td><td>Ethinyl estradiol</td><td>0.03</td><td>L-Norgestrel</td><td>0.125</td></tr><tr><td colspan="5">Casiant, Cyclessa, Cesia, Velivet</td></tr><tr><td>Days 1-6</td><td>Ethinyl estradiol</td><td>0.025</td><td>Desogestrel</td><td>0.1</td></tr><tr><td>Days 7-14</td><td>Ethinyl estradiol</td><td>0.025</td><td>Desogestrel</td><td>0.125</td></tr><tr><td>Days 15-21</td><td>Ethinyl estradiol</td><td>0.025</td><td>Desogestrel</td><td>0.15</td></tr><tr><td colspan="5">Alyacen 7/7/7, Cyclafem 7/7/7, Dasetta 7/7/7, Ortho-Novum 7/7/7, Necon 7/7/7, Nortrel 7/7/7, Pirmella 7/7/7</td></tr><tr><td>Days 1-7</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>0.5</td></tr><tr><td>Days 8-14</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>0.75</td></tr><tr><td>Days 15-21</td><td>Ethinyl estradiol</td><td>0.035</td><td>Norethindrone</td><td>1.0</td></tr><tr><td colspan="5">Ortho-Tri-Cyclen</td></tr><tr><td>Days 1-7</td><td>Et
======================================
hinyl estradiol</td><td>0.035</td><td>Norgestimate</td><td>0.18</td></tr></table>
======================================
<table><thead><th rowspan="2">4-Phasic Combination Tablet</th><th colspan="2">Estrogen (mg)</th><th colspan="2">Progestin (mg)</th></thead><thead><th></th><th></th><th></th><th></th><th></th></thead><tr><td colspan="5">Natazia</td></tr><tr><td>Days 1-2</td><td>Estradiol valerate</td><td>3</td><td></td><td>=</td></tr><tr><td>Days 3-8</td><td>Estradiol valerate</td><td>2</td><td>Dienogest</td><td>2</td></tr><tr><td>Days 9-25</td><td>Estradiol valerate</td><td>2</td><td>Dienogest</td><td>3</td></tr><tr><td>Day 26-27</td><td>Estradiol valerate</td><td>1</td><td></td><td>=</td></tr><tr><td colspan="5">Daily Progestin Tablets</td></tr><tr><td>Camila, Errin, Heather, Jencycla, Jolivette, Lyza, Nora-BE, Nor-QD, Ortho Micronor</td><td></td><td>_—</td><td>Norethindrone</td><td>0.35</td></tr><tr><td colspan="5">Contraceptive Transdermal Patch (Apply 1 Patch per Week)</td></tr><tr><td>Ortho Evra</td><td>Ethinyl estradiol</td><td>0.02/24h</td><td>—Norgestromin</td><td>0.150/24h</td></tr><tr><td colspan="5">Implantable Progestin Preparation</td></tr><tr><td>Implanon, Nexplanon</td><td></td><td></td><td>Etonogestrel (one</td><td>tube of 68 mg</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Androgenic:Anabolic Activity</th></thead><tr><td>Testosterone</td><td></td></tr><tr><td>Testosterone cypionate</td><td></td></tr><tr><td>Testosterone enanthate</td><td></td></tr><tr><td>Methyltestosterone</td><td></td></tr><tr><td>Fluoxymesterone</td><td></td></tr><tr><td>Oxymetholone</td><td></td></tr><tr><td>Oxandrolone</td><td></td></tr><tr><td>Nandrolone decanoate</td><td></td></tr></table>
======================================
<table><thead><th>Drug</th><th>Route of Administration</th><th>Dosage</th></thead><tr><td rowspan="2">Methyltestosterone</td><td>Oral</td><td>25-50 mg/d</td></tr><tr><td></td><td>Sublingual (buccal)</td><td>5-10 mg/d</td></tr><tr><td>Testosterone enanthate</td><td>Intramuscular</td><td>See text</td></tr><tr><td>Testosterone cypionate</td><td>Intramuscular</td><td>See text</td></tr><tr><td rowspan="2">Testosterone</td><td>Transdermal</td><td>2.5-10 mg/d</td></tr><tr><td></td><td>Topical gel (1%)</td><td>5-10 g/d</td></tr></table>
======================================
<table><tr><td colspan="2">—GENERICNAME __—=—_AVAILABLEAS ESTROGENS</td></tr><tr><td>Conjugated estrogens (equine)</td><td>Premarin</td></tr><tr><td>Diethylstilbestrol"</td><td>Generic, DES, Stilphostrol</td></tr><tr><td>Esterified estrogens</td><td>Cenestin, Enjuvia, Menest</td></tr><tr><td>Estradiol Estradiol in oil</td><td>Generic, Estrace, others others</td></tr><tr><td>cypionate Estradiol transdermal</td><td>Depo-Estradiol, Generic, Estraderm, Estrasorb,</td></tr><tr><td>Estradiol valerate in oil</td><td>Estrogel, others Generic,</td></tr><tr><td></td><td>Delestrogen</td></tr></table>
======================================
<table><thead><th>Levonorgestrel</th><th>Generic, Plan B, others</th></thead><tr><td>Medroxyprogesterone acetate</td><td>Generic, Provera</td></tr><tr><td>Megestrol acetate</td><td>Generic, Megace</td></tr><tr><td>Norethindrone acetate</td><td>Generic, Aygestin</td></tr><tr><td>Progesterone</td><td>Generic, Prometrium, others</td></tr></table>
======================================
<table><tr><td>rFluoxymesterone Methyltestosterone</td><td>Anaroxy Android, others</td></tr><tr><td>Nandrolone decanoate</td><td>Generic, Deca Durabolin, others</td></tr><tr><td>Oxandrolone</td><td>Generic, Oxandrin</td></tr><tr><td>Oxymetholone</td><td>Androl-50</td></tr><tr><td>Testosterone</td><td>Generic</td></tr><tr><td>Testosterone cypionate in oil</td><td>Generic, Depo-testosterone</td></tr><tr><td>Testosterone enanthate in oil</td><td>Generic, Delatestryl</td></tr><tr><td>Testosterone transdermal system</td><td>Androderm, AndroGel</td></tr><tr><td>Testosterone pellets</td><td>Testopel</td></tr></table>
======================================
<table><tr><td>Abiraterone</td><td>Zytiga</td></tr><tr><td>Anastrozole</td><td>Generic, Arimidex</td></tr><tr><td>Bazedoxifene (in combination with conjugated equine estrogens)</td><td>Duavee</td></tr><tr><td>Bicalutamide</td><td>Generic, Casodex</td></tr><tr><td>Clomiphene</td><td>Generic, Clomid, Serophene, Milophene</td></tr><tr><td>Danazol</td><td>Generic, Danocrine</td></tr><tr><td>Dutasteride</td><td>Avodart</td></tr><tr><td>Enzalutamide</td><td>Xtandi</td></tr><tr><td>Exemestane</td><td>Generic, Aromasin</td></tr><tr><td>Finasteride</td><td>Generic, Propecia, Proscar</td></tr><tr><td>Flutamide</td><td>Generic, Eulexin</td></tr><tr><td>Fulvestrant</td><td>Faslodex</td></tr><tr><td>Letrozole</td><td>Generic, Femara</td></tr><tr><td>Mifepristone</td><td>Mifeprex, Korlym</td></tr><tr><td>Nilutamide</td><td>Nilandron</td></tr><tr><td>Raloxifene</td><td>Evista</td></tr><tr><td>Tamoxifen</td><td>Generic, Nolvadex</td></tr><tr><td>Toremifene</td><td>Fareston</td></tr></table>
======================================
<table><thead><th>Cell Types’</th><th>Approximate Percent of Islet Mass</th><th>Secretory Products</th></thead><tr><td>Alpha (A) cell</td><td>20</td><td>Glucagon, proglucagon</td></tr><tr><td>Beta (B) cell</td><td>75</td><td>Insulin, C-peptide, proinsulin, amylin</td></tr><tr><td>Delta (D) cell</td><td>Bao</td><td>Somatostatin</td></tr><tr><td>Epsilon cell</td><td>&lt;1</td><td>Ghrelin</td></tr></table>
======================================
<table><thead><th>Transporter</th><th>Tissues</th><th>Glucose K,, (mmol/L)</th><th>Function</th></thead><tr><td>GLUT 1</td><td>All tissues, especially red cells, brain</td><td>1-2</td><td>Basal uptake of glucose; transport across the blood-brain barrier</td></tr><tr><td>GLUT 2</td><td>Beta cells of pancreas; liver, kidney; gut</td><td>15-20</td><td>Regulation of insulin release, other aspects of glucose homeostasis</td></tr><tr><td>GLUT 3</td><td>Brain, placenta</td><td>&lt;1</td><td>Uptake into neurons, other tissues</td></tr><tr><td>GLUT 4</td><td>Muscle, adipose</td><td>Ss</td><td>Insulin-mediated uptake of glucose</td></tr><tr><td>GLUT 5</td><td>Gut, kidney</td><td>1-2</td><td>Absorption of fructose</td></tr></table>
======================================
<table><thead><th></th><th>Normal Glucose Tolerance, mg/dL (mMol/L)</th><th>Prediabetes</th><th>Diabetes Mellitus”</th></thead><tr><td>Fasting plasma glucose mg/dL (mmol/L)</td><td>&lt;100 (5.6)</td><td>100-125 (5.6-6.9)</td><td>2126</td></tr><tr><td rowspan="2">Two hours after glucose load' mg/dL (mmol/L)</td><td>&lt;140 (7.8)</td><td>2140-199</td><td>2200</td></tr><tr><td></td><td></td><td>(7.8-11.0) (impaired glucose tolerance)</td><td>(11.1)</td></tr><tr><td>HbA, (%) (ADA criteria)</td><td>&lt;5.7</td><td>5.7-6.4</td><td></td></tr></table>
======================================
<table><thead><th>Insulin Preparations</th><th>Onset of Action</th><th>Peak Action</th><th>Effective Duration</th></thead><tr><td>Insulins lispro, aspart, glulisine</td><td>5-15 min</td><td>1-1.5h</td><td>3-4h</td></tr><tr><td>Human regular</td><td>30-60 min</td><td>2h</td><td>6-8h</td></tr><tr><td>Technosphere inhaled insulin</td><td>5-15 min</td><td>Th</td><td>3h</td></tr><tr><td>Human NPH</td><td>2-4h</td><td>6-7h</td><td>10-20 h</td></tr><tr><td>Insulin glargine</td><td>0.5-1h</td><td>Flat</td><td>~24h</td></tr><tr><td>Insulin detemir</td><td>0.5-1h</td><td>Flat</td><td>17h</td></tr><tr><td>Insulin degludec</td><td>0.5-1.5h</td><td>Flat</td><td>&gt;42h</td></tr></table>
======================================
<table><thead><th>Preparation</th><th>Species Source</th><th>Concentration</th></thead><tr><td colspan="3">Short-acting insulins</td></tr><tr><td>Insulin lispro (Humalog, Lilly)</td><td>Human analog</td><td>U100, U200</td></tr><tr><td>Insulin aspart (Novolog, Novo Nordisk)</td><td>Human analog</td><td>U100</td></tr><tr><td>Insulin glulisine (Apidra, Sanofi Aventis)</td><td>Human analog</td><td>U100</td></tr><tr><td>Regular insulin (Humulin R, Lilly; Novolin R, Novo Nordisk)</td><td>Human</td><td>U100, US00</td></tr><tr><td>Regular insulin inhaled (MannKind)</td><td>Human</td><td></td></tr><tr><td colspan="3">Long-acting insulins</td></tr><tr><td>NPH insulin (Humulin N, Lilly, Novolin N, Novo Nordisk)</td><td>Human</td><td>U100</td></tr><tr><td>Insulin glargine (Lantus, Toujeo, Sanofi Aventis, Basaglar, Lilly)</td><td>Human analog</td><td>U100, U300</td></tr><tr><td>Insulin detemir (Levemir, Novo Nordisk)</td><td>Human analog</td><td>U100</td></tr><tr><td>Insulin degludec (Tresiba, Novo Nordisk)</td><td>Human analog</td><td>U100, U200</td></tr><tr><td colspan="3">Premixed insulins</td></tr><tr><td>70 NPH/30 regular (Novolin, Novo Nordisk; Humulin, Lilly)</td><td>Human</td><td>U100</td></tr><tr><td>75/25 NPL, Lispro (Humalog mix 75/25, Lilly)</td><td>Human analog</td><td>U100</td></tr><tr><td>50/50 NPL, Lispro (Humalog mix 50/50, Lilly)</td><td>Human analog</td><td>U100</td></tr><tr><td>70/30 NPA, Aspart (Novolog mix 70/30, Novo Nordisk)</td><td>Human analog</td><td>U100</td></tr><tr><td>70/30 Degludec/Aspart (Ryzodeg, Novo Nordisk)</td><td>Human analog</td><td>U100</td></tr></table>
======================================
<table><thead><th></th><th>Prebreakfast</th><th>Prelunch</th><th>Predinner</th><th>Bedtime</th></thead><tr><td>Rapid-acting insulin analog</td><td>5U</td><td>4U</td><td>6U</td><td></td></tr><tr><td>NPH insulin</td><td>3U</td><td>3U</td><td>2U</td><td>8-9U</td></tr><tr><td colspan="5">or</td></tr><tr><td>Rapid-acting insulin analog</td><td>5U</td><td>4U</td><td>6U</td><td></td></tr><tr><td>Insulin glargine or degludec</td><td></td><td></td><td></td><td></td></tr><tr><td>Insulin detemir</td><td>6-7 U</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Subclass, Dr</th><th></th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">INSULINS</td></tr><tr><td>+ Rapid-acting: Lispro, aspart, glulisine, inhaled regular + Short-acting: Regular + Intermediate-acting: NPH + Long-acting: Detemir, glargine, degludec</td><td>Activate insulin receptor</td><td>Reduce circulating glucose</td><td>Type 1 and type 2 diabetes</td><td>Parenteral (SC or IV) « duration varies (see text) + Toxicity: Hypoglycemia, weight gain, lipodystrophy (rare)</td></tr><tr><td>SULFONYLUREAS + Glipizide + Glyburide + Glimepiride * Gliclazide’</td><td>Insulin secretagogues: Close K* channels in beta cells increase insulin release</td><td>Reduce circulating glucose in patients with functioning beta cells</td><td>Type 2 diabetes</td><td>Orally active « duration 10-24 h + Toxicity: Hypoglycemia, weight gain</td></tr><tr><td>+ Tolazamide, tolbutamide, chlorpropamide,</td><td>acetohexamide: Older</td><td>sulfonylureas, lower potency, greater</td><td>toxicity; rarely used</td><td></td></tr><tr><td>MEGLITINIDE ANALOGS; p-PHENYL. + Repaglinide, nateglinide + Mitiglinide!</td><td>ANALINE DERIVATIVE Insulin secretagogue: Similar to sulfonylureas with some overlap in binding sites</td><td>In patients with functioning beta cells, reduce circulating glucose</td><td>Type 2 diabetes</td><td>Oral - very fast onset of action + duration 5-8 h, nateglinide «4h + Toxicity: Hypoglycemia</td></tr><tr><td>BIGUANIDES + Metformin</td><td>Activates AMP kinase + reduces hepatic and renal gluconeogenesis</td><td>Decreases circulating glucose</td><td>Type 2 diabetes</td><td>Oral - maximal plasma concentration in 2-3 h + Toxicity: Gastrointestinal symptoms, lactic acidosis (rare) « cannot use if impaired renal/hepatic function + congestive heart failure (CHF), hypoxic/acidotic states, alcoholism</td></tr></table>
======================================
<table><thead><th>Subclass, Dr</th><th></th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">INSULINS</td></tr><tr><td>+ Rapid-acting: Lispro, aspart, glulisine, inhaled regular + Short-acting: Regular + Intermediate-acting: NPH + Long-acting: Detemir, glargine, degludec</td><td>Activate insulin receptor</td><td>Reduce circulating glucose</td><td>Type 1 and type 2 diabetes</td><td>Parenteral (SC or IV) « duration varies (see text) + Toxicity: Hypoglycemia, weight gain, lipodystrophy (rare)</td></tr><tr><td>SULFONYLUREAS + Glipizide + Glyburide + Glimepiride * Gliclazide’</td><td>Insulin secretagogues: Close K* channels in beta cells increase insulin release</td><td>Reduce circulating glucose in patients with functioning beta cells</td><td>Type 2 diabetes</td><td>Orally active « duration 10-24 h + Toxicity: Hypoglycemia, weight gain</td></tr><tr><td>+ Tolazamide, tolbutamide, chlorpropamide,</td><td>acetohexamide: Older</td><td>sulfonylureas, lower potency, greater</td><td>toxicity; rarely used</td><td></td></tr><tr><td>MEGLITINIDE ANALOGS; p-PHENYL. + Repaglinide, nateglinide + Mitiglinide!</td><td>ANALINE DERIVATIVE Insulin secretagogue: Similar to sulfonylureas with some overlap in binding sites</td><td>In patients with functioning beta cells, reduce circulating glucose</td><td>Type 2 diabetes</td><td>Oral - very fast onset of action + duration 5-8 h, nateglinide «4h + Toxicity: Hypoglycemia</td></tr><tr><td>BIGUANIDES + Metformin</td><td>Activates AMP kinase + reduces hepatic and renal gluconeogenesis</td><td>Decreases circulating glucose</td><td>Type 2 diabetes</td><td>Oral - maximal plasma concentration in 2-3 h + Toxicity: Gastrointestinal symptoms, lactic acidosis (rare) « cannot use if impaired renal/hepatic function + congestive heart failure (CHF), hypoxic/acidotic states, alcoholism</td></tr></table>
======================================
<table><thead><th>+ Acarbose, miglitol + Voglibose’</th><th>Inhibit intestinal a-glucosidases</th><th>Reduce conversion of starch and disaccharides to monosaccharides + reduce postprandial hyperglycemia</th><th>Type 2 diabetes</th><th>Oral - rapid onset + Toxicity: Gastrointestinal symptoms + cannot use if impaired renal/hepatic function, intestinal disorders</th></thead><tr><td>THIAZOLIDINEDIONES + Pioglitazone, rosiglitazone</td><td>Regulate gene expression by binding to PPAR-y and PPAR-c.</td><td>Reduce insulin resistance</td><td>Type 2 diabetes</td><td>Oral - long-acting (&gt;24 h) « Toxicity: Fluid retention, edema, anemia, weight gain, macular edema, bone fractures in women « cannot use if CHE. hepatic disease</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, ies, Interactions</th></thead><tr><td colspan="5">GLUCAGON-LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS</td></tr><tr><td>+ Exenatide, liraglutide, albiglutide, dulaglutide</td><td>Analogs of GLP-1: Bind to GLP-1 receptors</td><td>Reduce post-meal glucose excursions: Increase glucose- mediated insulin release, lower glucagon levels, slow gastric emptying, decrease appetite</td><td>Type 2 diabetes, liraglutide only: obesity</td><td>Parenteral (SC) - Toxicity: Nausea, headache, vomiting, anorexia, mild weight loss, pancreatitis, C-cell tumors in rodents</td></tr><tr><td colspan="5">DIPEPTIDYL PEPTIDASE-4 (DPP-4) I INHIBITORS</td></tr><tr><td>+ Sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin’</td><td>Block degradation of GLP-1, raise circulating GLP-1 levels</td><td>Reduces post-meal glucose excursions: Increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite</td><td>Type 2 diabetes</td><td>Oral « half-life ~12 h + 24-h duration of action + Toxicity: Rhinitis, upper respiratory infections, headaches, pancreatitis, rare allergic reactions</td></tr><tr><td>SODIUM-GLUCOSE CO-TRANSPORTER + Canagliflozin, dapagliflozin, empagliflozin</td><td>2 (SGLT2) INHIBITORS Block renal glucose resorption</td><td>Increase glucosuria, lower plasma glucose levels</td><td>Type 2 diabetes</td><td>Oral - half-life ~10-14 h + Toxicity: Genital and urinary tract infections, polyuria, pruritus, thirst, osmotic diuresis, constipation</td></tr><tr><td colspan="5">ISLET AMYLOID POLYPEPETIDE ANALOG</td></tr><tr><td>+ Pramlintide</td><td>Analog of amylin: Binds to amylin receptors</td><td>Reduces post-meal glucose excursions: Lowers glucagon levels, slows gastric emptying, decreases appetite</td><td>Type 1 and type 2 diabetes</td><td>Parenteral (SC) - rapid onset + half-life ~48 min + Toxicity: Nausea, anorexia, hypoglycemia, headache</td></tr><tr><td colspan="5">BILE ACID SEQUESTRANT</td></tr><tr><td colspan="5">+ Colesevelam hydrochloride Bile acid binder: Lowers glucose through unknown mechanisms Reduces glucose levels Type 2 diabetes Oral + 24-h duration of action + Toxicity: Constipation, indigestion, flatulence</td></tr><tr><td>DOPAMINE AGONIST + Bromocriptine</td><td>D, receptor agonist: Lowers glucose through unknown mechanism</td><td>Reduces glucose levels</td><td>Type 2 diabetes</td><td>Oral « 24-h action + Toxicity: Nausea, vomiting, dizziness, headache</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, ies, Interactions</th></thead><tr><td colspan="5">GLUCAGON-LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS</td></tr><tr><td>+ Exenatide, liraglutide, albiglutide, dulaglutide</td><td>Analogs of GLP-1: Bind to GLP-1 receptors</td><td>Reduce post-meal glucose excursions: Increase glucose- mediated insulin release, lower glucagon levels, slow gastric emptying, decrease appetite</td><td>Type 2 diabetes, liraglutide only: obesity</td><td>Parenteral (SC) - Toxicity: Nausea, headache, vomiting, anorexia, mild weight loss, pancreatitis, C-cell tumors in rodents</td></tr><tr><td colspan="5">DIPEPTIDYL PEPTIDASE-4 (DPP-4) I INHIBITORS</td></tr><tr><td>+ Sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin’</td><td>Block degradation of GLP-1, raise circulating GLP-1 levels</td><td>Reduces post-meal glucose excursions: Increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite</td><td>Type 2 diabetes</td><td>Oral « half-life ~12 h + 24-h duration of action + Toxicity: Rhinitis, upper respiratory infections, headaches, pancreatitis, rare allergic reactions</td></tr><tr><td>SODIUM-GLUCOSE CO-TRANSPORTER + Canagliflozin, dapagliflozin, empagliflozin</td><td>2 (SGLT2) INHIBITORS Block renal glucose resorption</td><td>Increase glucosuria, lower plasma glucose levels</td><td>Type 2 diabetes</td><td>Oral - half-life ~10-14 h + Toxicity: Genital and urinary tract infections, polyuria, pruritus, thirst, osmotic diuresis, constipation</td></tr><tr><td colspan="5">ISLET AMYLOID POLYPEPETIDE ANALOG</td></tr><tr><td>+ Pramlintide</td><td>Analog of amylin: Binds to amylin receptors</td><td>Reduces post-meal glucose excursions: Lowers glucagon levels, slows gastric emptying, decreases appetite</td><td>Type 1 and type 2 diabetes</td><td>Parenteral (SC) - rapid onset + half-life ~48 min + Toxicity: Nausea, anorexia, hypoglycemia, headache</td></tr><tr><td colspan="5">BILE ACID SEQUESTRANT</td></tr><tr><td colspan="5">+ Colesevelam hydrochloride Bile acid binder: Lowers glucose through unknown mechanisms Reduces glucose levels Type 2 diabetes Oral + 24-h duration of action + Toxicity: Constipation, indigestion, flatulence</td></tr><tr><td>DOPAMINE AGONIST + Bromocriptine</td><td>D, receptor agonist: Lowers glucose through unknown mechanism</td><td>Reduces glucose levels</td><td>Type 2 diabetes</td><td>Oral « 24-h action + Toxicity: Nausea, vomiting, dizziness, headache</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td>Pioglitazone plus glimepiride</td><td>Duetact</td></tr><tr><td>Alogliptin plus pioglitazone</td><td>Oseni</td></tr><tr><td>Rosiglitazone plus glimepiride</td><td>Avandaryl</td></tr><tr><td>Acarbose</td><td>Generic, Precose</td></tr><tr><td>Miglitol</td><td>Glyset</td></tr><tr><td colspan="2">Voglibose*</td></tr><tr><td>GLUCAGON-LIKE POLYPEPTIDE-1</td><td>RECEPTOR AGONISTS</td></tr><tr><td>Exenatide</td><td>Byetta</td></tr><tr><td>Liraglutide</td><td>Victoza</td></tr><tr><td>Albiglutide</td><td>Tanzeum, Eperzan</td></tr><tr><td>Dulaglutide</td><td>Trulicity</td></tr><tr><td>Linagliptin</td><td>Tradjenta</td></tr><tr><td>Saxagliptin</td><td>Onglyza</td></tr><tr><td>Sitagliptin</td><td>Januvia</td></tr><tr><td>Alogliptin</td><td>Nesina</td></tr><tr><td colspan="2">Vildagliptin*</td></tr><tr><td>SODIUM GLUCOSE</td><td>CO-TRANSPORTER 2 INHIBITORS</td></tr><tr><td>Canagliflozin</td><td>Invokana</td></tr><tr><td>Dapagliflozin</td><td>Farxiga</td></tr><tr><td>Empagliflozin</td><td>Jardiance</td></tr><tr><td colspan="2">SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS COMBINATION</td></tr><tr><td>Empagliflozin plus linagliptin</td><td>Glyxambi</td></tr><tr><td colspan="2">ISMISCELLANEOUS DRUGSLET AMYLOID POLYPEPTIDE ANALOG</td></tr><tr><td colspan="2">Pramlintide Symlin</td></tr><tr><td colspan="2">BILE ACID SEQUESTRANT</td></tr><tr><td colspan="2">Colesevelam hydrochloride Welchol</td></tr><tr><td colspan="2">DOPAMINE RECEPTOR AGONIST</td></tr><tr><td colspan="2">Bromocriptine Generic, Parlodel, Cycloset</td></tr><tr><td colspan="2">GLUCAGON</td></tr><tr><td>Glucagon</td><td>Generic</td></tr></table>
======================================
<table><thead><th colspan="2">SULFONYLUREAS</th></thead><tr><td>Acetohexamide*</td><td>Generic, Dymelor</td></tr><tr><td>Chlorpropamide</td><td>Generic, Diabinese</td></tr><tr><td>Gliclazide*</td><td>Generic, Diamicron</td></tr><tr><td>Glimepiride</td><td>Generic, Amaryl</td></tr><tr><td>Glipizide</td><td>Generic, Glucotrol, Glucotrol XL</td></tr><tr><td>Glyburide</td><td>Generic, DiaBeta, Micronase, Glynase PresTab</td></tr><tr><td>Tolazamide</td><td>Generic, Tolinase</td></tr><tr><td>Tolbutamide</td><td>Generic, Orinase</td></tr><tr><td></td><td>MEGLITINIDES</td></tr><tr><td colspan="2">Repaglinide Generic, Prandin</td></tr><tr><td colspan="2">Mitiglinide*</td></tr><tr><td>bD-PHENYL</td><td>NINE DERIVATIVE</td></tr><tr><td>Nateglinide</td><td>Generic, Starlix</td></tr><tr><td></td><td>BIGUANIDE</td></tr><tr><td>Metformin</td><td>Generic, Glucophage, Glucophage XR</td></tr><tr><td>METFORMIN</td><td>COMBINATIONS*</td></tr><tr><td>Glipizide plus metformin</td><td>Generic, Metaglip</td></tr><tr><td>Glyburide plus metformin</td><td>Generic, Glucovance</td></tr><tr><td>Pioglitazone plus metformin</td><td>ACTOplus Met</td></tr><tr><td>Repaglinide plus metformin</td><td>Prandi-Met</td></tr><tr><td>Rosiglitazone plus metformin</td><td>Avandamet</td></tr><tr><td>Saxagliptin plus metformin</td><td>Kombiglyze</td></tr><tr><td>Sitagliptin plus metformin</td><td>Janumet</td></tr><tr><td>Linagliptin plus metformin</td><td>Jentadueto</td></tr><tr><td>Alogliptin plus metformin</td><td>Kazano</td></tr><tr><td>Dapagliflozin plus metformin</td><td>Xigduo</td></tr><tr><td>Canagliflozin plus metformin</td><td>Invokamet</td></tr><tr><td>Empagliflozin plus metformin</td><td>Synjardy</td></tr><tr><td>THIAZOLIDINEDIONE</td><td>DERIVATIVES</td></tr></table>
======================================
<table><thead><th>Chemical and Generic Names</th><th>Abbreviation</th></thead><tr><td>Vitamin D3; cholecalciferol</td><td>D;</td></tr><tr><td>Vitamin D,; ergocalciferol</td><td>D,</td></tr><tr><td>25-Hydroxyvitamin D,; calcifediol</td><td>25(OH)D;</td></tr><tr><td>1,25-Dihydroxyvitamin D,; calcitriol</td><td>1,25(OH),D3</td></tr><tr><td>24,25-Dihydroxyvitamin D,; secalciferol</td><td>24,25(OH),D;</td></tr><tr><td>Dihydrotachysterol</td><td>DHT</td></tr><tr><td>Calcipotriene (calcipotriol)</td><td></td></tr><tr><td>1a-Hydroxyvitamin D.; doxercalciferol</td><td>10(OH)D,</td></tr><tr><td>19-nor-1,25-Dihydroxyvitamin D.; paricalcitol</td><td>19-nor-1,25(OH)D,</td></tr></table>
======================================
<table><thead><th></th><th>PTH</th><th>Vitamin D</th><th>FGF23</th></thead><tr><td>Intestine</td><td>Increased calcium and phosphate absorption (by increased 1,25[OH],D production)</td><td>Increased calcium and phosphate absorption by 1,25(OH),D</td><td>Decreased calcium and phosphate absorption by decreased 1,25(OH), production</td></tr><tr><td>Kidney</td><td>Decreased calcium excretion, increased phosphate excretion, stimulation of 1,25(OH),D production</td><td>Calcium and phosphate excretion may be decreased by 25(OH)D and 1,25(OH),D'</td><td>Increased phosphate excretion, decreased 1,25(OH),D production</td></tr><tr><td>Bone</td><td>Calcium and phosphate resorption increased by high doses. Low doses increase bone formation.</td><td>Increased calcium and phosphate resorption by 1,25(OH),D; bone formation may be increased by 1,25(OH),D</td><td>Decreased mineralization due to hypophosphatemia and low 1,25(OH),D levels.</td></tr><tr><td>Net effect on serum levels</td><td>Serum calcium increased, serum phosphate decreased</td><td>Serum calcium and phosphate both increased</td><td>Decreased serum phosphate</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th>Mechanism of Ac</th><th></th><th>Applications</th><th></th></thead><tr><td colspan="5">VITAMIN D, METABOLITES, ANALOGS</td></tr><tr><td>+ Cholecalciferol (D;) + Ergocalciferol (D2) + Calcitriol + Calcifediol + Doxercalciferol + Paricalcitol + Calcipotriene BISPHOSPHONATES</td><td>| Regulate gene transcription via the vitamin D receptor</td><td>Stimulate intestinal calcium absorption, bone resorption, renal calcium and phosphate reabsorption + decrease parathyroid hormone (PTH) « promote innate immunity + inhibit adaptive immunity</td><td>Osteoporosis, osteomalacia, renal failure, malabsorption, psoriasis</td><td>Hypercalcemia, hypercalciuria + the vitamin D preparations have much longer half-lives than the metabolites and analogs</td></tr></table>
======================================
<table><thead><th>Subclass, Dr</th><th>Mechanism of Action</th><th></th><th></th><th></th></thead><tr><td>HORMONES + Teriparatide + Abaloparatide + Calcitonin + rhPTH1-84</td><td>These hormones act via their cognate G protein-coupled receptors Recombinant full-length PTH; acts on the same receptors as teriparatide</td><td>Teriparatide stimulates bone turnover + calcitonin suppresses bone resorption rhPTH1-84 increases RANKL, decreases sclerostin, enhances calcium reabsorption from the kidney</td><td>Both are used in osteoporosis « calcitonin is used for hypercalcemia Hypoparathyroidism</td><td>Teriparatide may cause hypercalcemia and hypercalciuria Hypercalcemia, hypercalciuria</td></tr><tr><td>SELECTIVE ESTROGEN + Raloxifene</td><td>RECEPTOR MODULATORS (SERMs) Interacts selectively with estrogen receptors</td><td>Inhibits bone resorption without stimulating breast or endometrial hyperplasia</td><td>Osteoporosis</td><td>Does not prevent hot flashes + increased risk of venous thromboembolism</td></tr><tr><td>RANK LIGAND (RANKL) + Denosumab</td><td>INHIBITOR Monoclonal antibody + binds to RANKL and prevents it from stimulating osteoclast</td><td>Blocks bone resorption</td><td>Osteoporosis</td><td>May increase risk of infections</td></tr><tr><td></td><td>differentiation and function</td><td></td><td></td><td></td></tr><tr><td>CALCIUM RECEPTOR + Cinacalcet</td><td>AGONIST Activates the calcium-</td><td>Inhibits PTH secretion</td><td>Hyperparathyroidism</td><td>Nausea</td></tr><tr><td colspan="5">sensing receptor</td></tr><tr><td>MINERALS + Calcium, phosphate + Strontium</td><td>Multiple physiologic actions through regulation of multiple enzymatic pathways</td><td>Strontium suppresses bone resorption and increases bone formation + calcium and phosphate required for bone mineralization</td><td>Osteoporosis + osteomalacia + deficiencies in calcium or phosphate</td><td>Ectopic calcification</td></tr></table>
======================================
<table><tr><td>[e} ATE AND</td><td>PHOSPHATE BINDER</td></tr><tr><td colspan="2">Phosphate</td></tr><tr><td>Oral: solution</td><td>Fleet Phospho-soda, K-Phos- Neutral, Neutra-Phos, Neutra- Phos-K</td></tr><tr><td>Sevelamer carbonate or HCI</td><td>Renagel, Renvela</td></tr><tr><td>Lanthanum carbonate</td><td>Fosrenol</td></tr><tr><td>Alendronate sodium</td><td>Generic, Fosamax</td></tr><tr><td>Etidronate disodium</td><td>Generic, Didronel</td></tr><tr><td>Ibandronate sodium</td><td>Generic, Boniva</td></tr><tr><td>Pamidronate disodium</td><td>Generic, Aredia</td></tr><tr><td>Risedronate sodium</td><td>Actonel, Atelvia</td></tr><tr><td>Tiludronate disodium</td><td>Skelid</td></tr><tr><td>Zoledronic acid</td><td>Zometa</td></tr><tr><td>Calcitonin-salmon</td><td>Miacalcin, Calcimar, Salmonine</td></tr><tr><td>Cinacalcet</td><td>Sensipar</td></tr><tr><td>Denosumab</td><td>Prolia, Xgeva</td></tr><tr><td>Gallium nitrate</td><td>Ganite</td></tr><tr><td>Sodium fluoride</td><td>Generic</td></tr><tr><td>Teriparatide (1-34 active segment of PTH)</td><td>_ Forteo</td></tr><tr><td>Recombinant human PTH 1-84</td><td>Natpara</td></tr></table>
======================================
<table><thead><th>VITAMIN D,</th><th>METABOLITES, AND ANALOGS</th></thead><tr><td colspan="2">Calcifediol (25(0H)D3) Rayaldee</td></tr><tr><td colspan="2">Calcitriol</td></tr><tr><td>Oral</td><td>Generic, Rocaltrol</td></tr><tr><td>Parenteral</td><td>Calcijex</td></tr><tr><td>Cholecalciferol (D3) (vitamin Ds)</td><td>Generic, Delta-D</td></tr><tr><td>Doxercalciferol</td><td>Generic, Hectorol</td></tr><tr><td>Ergocalciferol (D.) (vitamin D,, calciferol)</td><td>Generic, Drisdol, others</td></tr><tr><td>Paricalcitol</td><td>Generic, Zemplar</td></tr><tr><td colspan="2">CALCIUM</td></tr><tr><td>Calcium acetate (25% calcium)</td><td>Generic, PhosLo</td></tr><tr><td>Calcium carbonate (40% calcium)</td><td>Generic, Tums, Cal-Sup, Os-Cal 500</td></tr><tr><td>Calcium chloride (27% calcium)</td><td>Generic</td></tr><tr><td>Calcium citrate (21% calcium)</td><td>Generic, Cal-C-Caps, Cal-Cee</td></tr><tr><td>Calcium glubionate (6.5% calcium)</td><td>Neo-Calglucon, Calcionate, Calciquid</td></tr><tr><td>Calcium gluceptate (8% calcium)</td><td>Generic</td></tr><tr><td>Calcium gluconate (9% calcium)</td><td>Generic</td></tr><tr><td>Calcium lactate (13% calcium)</td><td>Generic</td></tr></table>
======================================
<table><thead><th rowspan="2">Antibiotic (Route of Administration)</th><th rowspan="2">Adult Dose</th><th rowspan="2">Pediatric Dose’</th><th rowspan="2">Neonatal Dose”</th><th colspan="2">Adjusted Dose as a Percentage of Normal Dose for Renal Failure Based on Creatinine Clearance (Cl.,)</th></thead><thead><th></th><th></th><th></th><th></th><th>Clcr Approx 50 mL/min</th><th>Clcr Approx 10 mL/min</th></thead><tr><td colspan="6">Pen ins</td></tr><tr><td>Penicillin G (IV)</td><td>1-4 x 10° units q4-6h</td><td>25,000-400,000 units/kg/d in 4-6 doses</td><td>— 75,000-150,000 units/ kg/d in 2 or 3 doses</td><td>50-75%</td><td>25%</td></tr><tr><td>Penicillin V (PO)</td><td>0.25-0.5 g qid</td><td>25-75 mg/kg/d in 4 doses</td><td></td><td></td><td></td></tr><tr><td colspan="6">Antistaphylococcal penicillins</td></tr><tr><td>Cloxacillin, dicloxacillin (PO)</td><td>0.25-0.5 g qid</td><td>15-25 mg/kg/d in 4 doses</td><td></td><td>100%</td><td>100%</td></tr><tr><td>Nafcillin (IV)</td><td>1-2 g q4-6h</td><td>100-200 mg/kg/d in 4-6 doses</td><td>50-75 mg/kg/d in 2 or 3 doses</td><td>100%</td><td>100%</td></tr><tr><td>Oxacillin (IV)</td><td>1-2 g q4-6h</td><td>50-100 mg/kg/d in 4-6 doses</td><td>50-75 mg/kg/d in 2 or 3 doses</td><td>100%</td><td>100%</td></tr><tr><td colspan="6">Extended-spectrum penicillins</td></tr><tr><td>Amoxicillin (PO)</td><td>0.25-0.5 g tid</td><td>20-40 mg/kg/d in 3 doses</td><td></td><td>66%</td><td>33%</td></tr><tr><td>Amoxicillin/potassium clavulanate (PO)</td><td>— 500/125 mg tid- 875/125 mg bid</td><td>20-40 mg/kg/d in 3 doses</td><td></td><td>66%</td><td>33%</td></tr><tr><td>Piperacillin/ tazobactam (IV)</td><td>3.375-4.5 g q4-6h</td><td>300 mg/kg/d in 4-6 doses’</td><td>150 mg/kg/d in 2 doses*</td><td>50-75%</td><td>25-33%</td></tr></table>
======================================
<table><thead><th rowspan="2">Antibiotic (Route of</th><th rowspan="2">Adult Dose</th><th colspan="2" rowspan="2">Pediatric Dose’</th><th rowspan="2">Neonatal Dose”</th><th colspan="2">of Normal Dose for Renal Failure Based on Creatinine Clearance</th></thead><thead><th></th><th></th><th colspan="2"></th><th></th><th>Cl,, Approx 50 mL/min</th><th>Cl, Approx 10 mL/min</th></thead><tr><td colspan="7">First-generation cephalosporins</td></tr><tr><td>Cephalexin (PO)</td><td>0.25-0.5 g qid</td><td>25-50 mg/kg/d in 4 doses</td><td></td><td></td><td>50%</td><td>25%</td></tr><tr><td>Cefazolin (IV)</td><td>0.5-2 g q8h</td><td>25-100 mg/kg/d in 3 or 4 doses</td><td></td><td></td><td>50%</td><td>25%</td></tr><tr><td colspan="7">Second-generation cephalosporins</td></tr><tr><td>Cefoxitin (IV)</td><td>1-2 g q6-8h</td><td>75-150 mg/kg/d in 3 or 4 doses</td><td></td><td></td><td>50-75%</td><td>25%</td></tr><tr><td>Cefotetan (IV)</td><td>1-29 q12h</td><td></td><td></td><td></td><td>50%</td><td>25%</td></tr><tr><td>Cefuroxime (IV)</td><td>0.75-1.5 g q8h</td><td>50-100 mg/kg/d in 3 or 4 doses</td><td></td><td></td><td>66%</td><td>25-33%</td></tr><tr><td>Third- and fourth-generation</td><td>cephalosporins</td><td>including ceftaroline fosamil</td><td></td><td></td><td></td><td></td></tr><tr><td>Cefotaxime (IV)</td><td>1-2 g q6-12h</td><td>50-200 mg/kg/d in 4-6 doses</td><td></td><td>100 mg/kg/din2doses</td><td>50%</td><td>25%</td></tr><tr><td>Ceftazidime (IV)</td><td>1-2 g q8-12h</td><td>75-150 mg/kg/d in 3 doses</td><td></td><td>100-150 mg/kg/d in 2 or 3 doses</td><td>50%</td><td>25%</td></tr><tr><td>Ceftriaxone (IV)</td><td>1-4g q24h</td><td>50-100 mg/kg/d in 1 or 2 doses</td><td></td><td>50 mg/kg/d qd</td><td></td><td></td></tr><tr><td>Cefepime (IV)</td><td>0.5-2 g qi2h</td><td>75-120 mg/kg/d in 2 or 3 divided doses</td><td></td><td></td><td>50%</td><td>25%</td></tr><tr><td>Ceftaroline fosamil (IV)</td><td>600 mg qi2h</td><td></td><td></td><td></td><td>50-66%</td><td>33%</td></tr><tr><td colspan="7">Cephalosporin-B-lactamase inhibitor combinations</td></tr><tr><td>Ceftazidime- avibactam (IV)</td><td>2.59 q8h</td><td></td><td></td><td></td><td>25-50%</td><td>6.25-12.5%</td></tr><tr><td>Ceftolozane- tazobactam (IV)</td><td>1.59 q8h</td><td></td><td></td><td></td><td>25-50%</td><td>Not studied</td></tr><tr><td colspan="7">Carbapenems</td></tr><tr><td>Ertapenem (IM or IV)</td><td>1gq24h</td><td></td><td></td><td></td><td>100%?</td><td>50%</td></tr><tr><td>Doripenem</td><td>500 mg q8h</td><td></td><td></td><td></td><td>50%</td><td>33%</td></tr><tr><td>Imipenem (IV)</td><td>0.25-0.5 g q6-8h</td><td></td><td></td><td></td><td>75%</td><td>50%</td></tr><tr><td>Meropenem (IV)</td><td>1g q8h (2g q8h for meningitis)</td><td>60-120 mg/kg/d in 3 doses (maximum of 2 g q8h)</td><td></td><td></td><td>66%</td><td>50%</td></tr><tr><td colspan="7">Glycopeptides</td></tr><tr><td>Vancomycin (IV)</td><td>30-60 mg/kg/d in 2-3 doses</td><td>40 mg/kg/d in 3 or 4 doses</td><td></td><td>15 mg/kg load, then 20 mg/kg/d in 2 doses</td><td>40%</td><td>10%</td></tr><tr><td>Telavancin (IV)</td><td>10 mg/kg daily</td><td></td><td></td><td></td><td>75%</td><td>50%</td></tr><tr><td>Dalbavancin (IV)</td><td>1000 mg on day 1, 500 mg day 8 Alternative: 1500 mg x 1</td><td></td><td></td><td></td><td>&gt;30 mL/min</td><td>75%</td></tr><tr><td>Oritavancin (IV)</td><td>1200 mg x 1</td><td></td><td></td><td></td><td>&gt;30 mL/min</td><td>Not studied</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th></th><th></th></thead><tr><td colspan="5">PENICILLINS</td></tr><tr><td>+ PenicillinG |</td><td>Prevents bacterial cell wall synthesis by binding to and inhibiting cell wall transpeptidases</td><td>Rapid bactericidal activity against susceptible bacteria |</td><td>Streptococcal infections, meningococcal infections, neurosyphilis</td><td>IV administration + rapid renal clearance (half-life 30 min, so requires dosing every 4 h) + Toxicity: Immediate hypersensitivity, rash, seizures</td></tr></table>
======================================
<table><tr><td>EPHALOSPORINS</td><td></td><td></td><td></td><td></td></tr><tr><td>+ Cefazolin</td><td>Prevents bacterial cell wall synthesis by binding to and inhibiting cell wall transpeptidases</td><td>Rapid bactericidal activity against susceptible bacteria |</td><td>Skin and soft tissue infections, urinary tract infections, surgical prophylaxis</td><td>IV administration « renal clearance (half-life 1.5 h) + given every 8h - poor penetration into the central nervous system (CNS) « Toxicity: Rash, drug fever</td></tr></table>
======================================
<table><thead><th colspan="5">MONOBACTAMS</th></thead><thead><th>+ Aztreonam</th><th>Prevents bacterial cell wall synthesis by binding to and inhibiting cell wall transpeptidases</th><th>Rapid bactericidal activity against susceptible bacteria</th><th>Infections caused by aerobic, Gram-negative bacteria in patients with immediate hypersensitivity to penicillins</th><th>IV administration « renal clearance half-life 1.5 h + dosed every 8 h - Toxicity: No cross-allergenicity with penicillins</th></thead><tr><td colspan="5">GLYCOPEPTIDE</td></tr><tr><td>+ Vancomycin</td><td>Inhibits cell wall synthesis by binding to the p-Ala-p- Ala terminus of nascent peptidoglycan</td><td>Bactericidal activity against susceptible bacteria, slower kill than B-lactam antibiotics</td><td>Infections caused by Gram-positive bacteria including sepsis, endocarditis, and meningitis « C difficile colitis (oral formulation)</td><td>Oral, IV administration - renal clearance (half-life 6h) « starting dose of 30 mg/kg/d in two or three divided doses in patients with normal renal function + trough concentrations of 10-15 mcg/mL sufficient for most infections + Toxicity: Red man” syndrome + nephrotoxicity</td></tr><tr><td colspan="5">+ Teicoplanin: Intravenous, similar to vancomycin except that long half-life (45-70 h) permits once-daily dosing + Dalbavancin: Intravenous, very long half-life (&gt;10 days) permits once-weekly dosing + Oritavancin: Intravenous, very long half-life (&gt;10 days) permits once-weekly dosing + Telavancin: Intravenous, once-daily dosing</td></tr><tr><td colspan="5">LIPOPEPTIDE</td></tr><tr><td>+ Daptomycin</td><td>Binds to cell membrane, causing depolarization and rapid cell death</td><td>Bactericidal activity against susceptible bacteria » more rapidly bactericidal than vancomycin</td><td>Infections caused by Gram- positive bacteria including sepsis and endocarditis</td><td>IV administration « renal clearance (half-life 8 h) + dosed once daily « inactivated by pulmonary surfactant so cannot be used to treat pneumonia + Toxicity: Myopathy + monitoring of weekly creatine phosphokinase levels recommended</td></tr></table>
======================================
<table><thead><th colspan="5">MONOBACTAMS</th></thead><thead><th>+ Aztreonam</th><th>Prevents bacterial cell wall synthesis by binding to and inhibiting cell wall transpeptidases</th><th>Rapid bactericidal activity against susceptible bacteria</th><th>Infections caused by aerobic, Gram-negative bacteria in patients with immediate hypersensitivity to penicillins</th><th>IV administration « renal clearance half-life 1.5 h + dosed every 8 h - Toxicity: No cross-allergenicity with penicillins</th></thead><tr><td colspan="5">GLYCOPEPTIDE</td></tr><tr><td>+ Vancomycin</td><td>Inhibits cell wall synthesis by binding to the p-Ala-p- Ala terminus of nascent peptidoglycan</td><td>Bactericidal activity against susceptible bacteria, slower kill than B-lactam antibiotics</td><td>Infections caused by Gram-positive bacteria including sepsis, endocarditis, and meningitis « C difficile colitis (oral formulation)</td><td>Oral, IV administration - renal clearance (half-life 6h) « starting dose of 30 mg/kg/d in two or three divided doses in patients with normal renal function + trough concentrations of 10-15 mcg/mL sufficient for most infections + Toxicity: Red man” syndrome + nephrotoxicity</td></tr><tr><td colspan="5">+ Teicoplanin: Intravenous, similar to vancomycin except that long half-life (45-70 h) permits once-daily dosing + Dalbavancin: Intravenous, very long half-life (&gt;10 days) permits once-weekly dosing + Oritavancin: Intravenous, very long half-life (&gt;10 days) permits once-weekly dosing + Telavancin: Intravenous, once-daily dosing</td></tr><tr><td colspan="5">LIPOPEPTIDE</td></tr><tr><td>+ Daptomycin</td><td>Binds to cell membrane, causing depolarization and rapid cell death</td><td>Bactericidal activity against susceptible bacteria » more rapidly bactericidal than vancomycin</td><td>Infections caused by Gram- positive bacteria including sepsis and endocarditis</td><td>IV administration « renal clearance (half-life 8 h) + dosed once daily « inactivated by pulmonary surfactant so cannot be used to treat pneumonia + Toxicity: Myopathy + monitoring of weekly creatine phosphokinase levels recommended</td></tr></table>
======================================
<table><tr><td colspan="2">Broad-spectrum (third- &amp; fourth-generation) cephalosporins</td></tr><tr><td>Cefdinir</td><td>Generic</td></tr><tr><td>Cefditoren pivoxil</td><td>Spectracef</td></tr><tr><td>Cefepime</td><td>Generic, Maxipime</td></tr><tr><td>Cefixime</td><td>Suprax</td></tr><tr><td>Cefotaxime</td><td>Generic, Claforan</td></tr><tr><td>Cefpodoxime proxetil</td><td>Generic</td></tr><tr><td>Ceftaroline fosamil</td><td>Teflaro</td></tr><tr><td>Ceftazidime</td><td>Generic, Fortaz, Tazicef</td></tr><tr><td>Ceftazidime/avibactam®</td><td>Avycaz</td></tr><tr><td>Ceftibuten</td><td>Generic, Cedax</td></tr><tr><td>Ceftolozane/tazobactam</td><td>Zerbaxa</td></tr><tr><td>Ceftriaxone</td><td>Generic, Rocephin</td></tr><tr><td colspan="2">Monobactam &amp; Carbapenems</td></tr><tr><td>Aztreonam</td><td>Generic, Azactam, Cayston</td></tr><tr><td>Doripenem</td><td>Doribax</td></tr><tr><td>Ertapenem</td><td>Invanz</td></tr><tr><td>Imipenem/cilastatin</td><td>Generic, Primaxin IM, Primaxin IV.</td></tr><tr><td>Meropenem</td><td>Generic, Merrem IV</td></tr><tr><td colspan="2">OTHER DRUGS DISCUSSED IN THIS CHAPTER</td></tr><tr><td>Cycloserine</td><td>Generic</td></tr><tr><td>Dalbavancin</td><td>Dalvance</td></tr><tr><td>Daptomycin</td><td>Cubicin</td></tr><tr><td>Fosfomycin</td><td>Monurol</td></tr></table>
======================================
<table><tr><td></td><td>PENICILLINS</td></tr><tr><td>Amoxicillin</td><td>Generic, Amoxil, others</td></tr><tr><td>Amoxicillin/potassium clavulanate”</td><td>Generic, Augmentin</td></tr><tr><td>Ampicillin</td><td>Generic</td></tr><tr><td>Ampicillin/sulbactam sodium’</td><td>Generic, Unasyn</td></tr><tr><td>Dicloxacillin</td><td>Generic, Dynapen</td></tr><tr><td>Nafcillin</td><td>Generic, Nallpen</td></tr><tr><td>Oxacillin</td><td>Generic, Bactocill</td></tr><tr><td>Penicillin G</td><td>Generic, Pfizerpen</td></tr><tr><td>Penicillin G benzathine</td><td>Permapen, Bicillin L-A</td></tr><tr><td>Penicillin G procaine</td><td>Generic</td></tr><tr><td>Penicillin V</td><td>Generic, V-Cillin, Pen-Vee K, others</td></tr></table>
======================================
<table><thead><th>Cefadroxil</th><th>Generic</th></thead><tr><td>Cefazolin</td><td>Generic, Ancef, Kefzol</td></tr><tr><td>Cephalexin</td><td>Generic, Keflex, others</td></tr></table>
======================================
<table><tr><td>MACROLIDES</td><td></td><td></td><td></td><td></td></tr><tr><td>+ Erythromycin</td><td>Prevents bacterial protein synthesis by binding to the 50S ribosomal subunit</td><td>Bacteriostatic activity | against susceptible bacteria</td><td>Community-acquired pneumonia pertussis + corynebacterial and chlamydial infections</td><td>Oral, IV - hepatic clearance (half-life 1.5 h) + dosed every 6 h + cytochrome P450 inhibitor + Toxicity: Gastrointestinal upset, hepatotoxicity, QT. prolongation</td></tr></table>
======================================
<table><thead><th>LINCOSAMIDE + Clindamycin</th><th>Prevents bacterial protein synthesis by binding to the 505 ribosomal subunit</th><th>Bacteriostatic activity against susceptible bacteria</th><th>Skin and soft tissue infections «anaerobic infections</th><th>Oral, IV - hepatic clearance (half-life 2.5 h) + dosed every 6-8 hours + Toxicity: Gastrointestinal upset, C difficile colitis</th></thead><tr><td colspan="5">STREPTOGRAMINS</td></tr><tr><td>+ Quinupristin- dalfopristin</td><td>Prevents bacterial protein synthesis by binding to the 50S ribosomal subunit</td><td>Rapid bactericidal activity against most susceptible bacteria</td><td>Infections caused by staphylococci or vancomycin- resistant strains of E faecium</td><td>IV - hepatic clearance - dosed every 8-12 h + cytochrome P450 inhibitor « Toxicity: Severe infusion-related myalgias and arthralgias</td></tr><tr><td colspan="5">CHLORAMPHENICOL</td></tr><tr><td colspan="5">OXAZOLIDINONES aplastic gray baby syndrome</td></tr><tr><td>+ Linezolid</td><td>Prevents bacterial protein synthesis by binding to the 235 ribosomal RNA of 50S subunit</td><td>Bacteriostatic activity against susceptible bacteria</td><td>Infections caused by methicillin-resistant staphylococci and vancomycin- resistant enterococci</td><td>Oral, IV - hepatic clearance (half-life 6 h) « dosed twice-daily + Toxicity: Duration-dependent bone marrow suppression, neuropathy, and optic neuritis + serotonin syndrome may occur when co-administered with other serotonergic drugs (eg, selective serotonin reuptake inhibitors)</td></tr></table>
======================================
<table><thead><th>LINCOSAMIDE + Clindamycin</th><th>Prevents bacterial protein synthesis by binding to the 505 ribosomal subunit</th><th>Bacteriostatic activity against susceptible bacteria</th><th>Skin and soft tissue infections «anaerobic infections</th><th>Oral, IV - hepatic clearance (half-life 2.5 h) + dosed every 6-8 hours + Toxicity: Gastrointestinal upset, C difficile colitis</th></thead><tr><td colspan="5">STREPTOGRAMINS</td></tr><tr><td>+ Quinupristin- dalfopristin</td><td>Prevents bacterial protein synthesis by binding to the 50S ribosomal subunit</td><td>Rapid bactericidal activity against most susceptible bacteria</td><td>Infections caused by staphylococci or vancomycin- resistant strains of E faecium</td><td>IV - hepatic clearance - dosed every 8-12 h + cytochrome P450 inhibitor « Toxicity: Severe infusion-related myalgias and arthralgias</td></tr><tr><td colspan="5">CHLORAMPHENICOL</td></tr><tr><td colspan="5">OXAZOLIDINONES aplastic gray baby syndrome</td></tr><tr><td>+ Linezolid</td><td>Prevents bacterial protein synthesis by binding to the 235 ribosomal RNA of 50S subunit</td><td>Bacteriostatic activity against susceptible bacteria</td><td>Infections caused by methicillin-resistant staphylococci and vancomycin- resistant enterococci</td><td>Oral, IV - hepatic clearance (half-life 6 h) « dosed twice-daily + Toxicity: Duration-dependent bone marrow suppression, neuropathy, and optic neuritis + serotonin syndrome may occur when co-administered with other serotonergic drugs (eg, selective serotonin reuptake inhibitors)</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td>Chloramphenicol</td><td>Generic, Chloromycetin</td></tr><tr><td>Demeclocycline</td><td>Generic, Declomycin</td></tr><tr><td>Doxycycline</td><td>Generic, Vibramycin, others</td></tr><tr><td>Minocycline</td><td>Generic, Minocin, others</td></tr><tr><td>Tetracycline</td><td>Generic, others</td></tr><tr><td>Tigecycline</td><td>Tygacil</td></tr><tr><td>Azithromycin</td><td>Generic, Zithromax</td></tr><tr><td>Clarithromycin</td><td>Generic, Biaxin</td></tr><tr><td>Erythromycin</td><td>Generic, others</td></tr><tr><td></td><td>KETOLIDES</td></tr><tr><td>Telithromycin</td><td>Ketek</td></tr><tr><td></td><td>LINCOMYCIN</td></tr><tr><td>Clindamycin</td><td>Generic, Cleocin</td></tr><tr><td colspan="2">STREPTOGRAMINS</td></tr><tr><td colspan="2">Quinupristin and dalfopristin Synercid</td></tr><tr><td colspan="2">OXAZOLIDINONE</td></tr><tr><td>Linezolid</td><td>Generic, Zyvox</td></tr><tr><td>Tedizolid</td><td>Sivextro</td></tr></table>
======================================
<table><tr><td>Subclass, Drug</td><td>Interactions</td></tr></table>
======================================
<table><tr><td>Amikacin</td><td>Generic, Amikin</td></tr><tr><td>Gentamicin</td><td>Generic</td></tr><tr><td>Kanamycin Neomycin</td><td>Generic, Generic, Mycifradin</td></tr><tr><td>Paromomycin</td><td>Generic, Humatin</td></tr><tr><td>Streptomycin</td><td>Generic</td></tr><tr><td>Tobramycin</td><td>Generic, Nebcin</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Half-Life (h)</th><th></th><th>Peak Serum Concentration (mcg/mL)</th><th>Oral Dose (mg)</th><th>Primary Route of Excretion</th></thead><tr><td>Ciprofloxacin</td><td>3-5</td><td></td><td>24</td><td>500 twice daily</td><td>Renal</td></tr><tr><td>Gemifloxacin</td><td></td><td></td><td>1.6</td><td>320 once daily</td><td>Renal and nonrenal</td></tr><tr><td>Levofloxacin</td><td></td><td></td><td>5.7</td><td>500 once daily</td><td>Renal</td></tr><tr><td>Moxifloxacin</td><td></td><td>&gt;85</td><td>3.1</td><td>400 once daily</td><td>Nonrenal</td></tr><tr><td>Norfloxacin</td><td></td><td></td><td>1.5</td><td>400 twice daily</td><td>Renal</td></tr><tr><td>Ofloxacin</td><td></td><td></td><td>2.9</td><td>400 twice daily</td><td>Renal</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th></th><th></th><th></th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td colspan="5">FOLATE ANTAGONISTS</td></tr><tr><td>+ Trimethoprim- sulfamethoxazole</td><td>Synergistic combination of folate antagonists blocks purine production and nucleic acid synthesis</td><td>Bactericidal activity against susceptible bacteria</td><td>Urinary tract infections + soft tissue infections + bone and joint infections + P jiroveci pneumonia « toxoplasmosis +nocardiosis</td><td>Oral, IV « renal clearance (half-life 8 h) + dosed every 8-12 h + formulated in a 5:1 ratio of sulfamethoxazole to trimethoprim + Toxicity: Rash, fever, bone marrow suppression, hyperkalemia, nephrotoxicity</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>AVAILABLE AS</th></thead><tr><td>GENERAL-PURPOSE</td><td>SULFONAMIDES</td></tr><tr><td colspan="2">Sulfadiazine Generic</td></tr><tr><td>Mafenide</td><td>Generic, Sulfamylon</td></tr><tr><td>Silver sulfadiazine</td><td>Generic, Silvadene</td></tr><tr><td>Sulfacetamide sodium (ophthalmic)</td><td>Generic</td></tr><tr><td>Trimethoprim</td><td>Generic, Proloprim, Trimpex</td></tr><tr><td>Trimethoprim-sulfamethoxazole (co-trimoxazole, TMP-SMZ)</td><td>Generic, Bactrim, Septra, others</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Typical Adult Dosage’</th></thead><tr><td colspan="2">First-line agents</td></tr><tr><td>Isoniazid</td><td>300 mg/d</td></tr><tr><td>Rifampin</td><td>600 mg/d</td></tr><tr><td>Pyrazinamide</td><td>25 mg/kg/d</td></tr><tr><td>Ethambutol</td><td>15-25 mg/kg/d</td></tr><tr><td colspan="2">Second-line agents</td></tr><tr><td>Amikacin</td><td>15 mg/kg/d</td></tr><tr><td>Aminosalicylic acid</td><td>8-12 g/d</td></tr><tr><td>Bedaquiline</td><td>400 mg/d</td></tr><tr><td>Capreomycin</td><td>15 mg/kg/d</td></tr><tr><td>Clofazimine</td><td>200 mg/d</td></tr><tr><td>Cycloserine</td><td>500-1000 mg/d, divided</td></tr><tr><td>Ethionamide</td><td>500-750 mg/d</td></tr><tr><td>Levofloxacin</td><td>500-750 mg/d</td></tr><tr><td>Linezolid</td><td>600 mg/d</td></tr><tr><td>Moxifloxacin</td><td>400 mg/d</td></tr><tr><td>Rifabutin?</td><td>300 mg/d</td></tr><tr><td>Rifapentine®</td><td>600 mg once weekly</td></tr><tr><td>Streptomycin</td><td>15 mg/kg/d</td></tr></table>
======================================
<table><thead><th rowspan="2">Regimen (in order of preference)</th><th colspan="2">Intensive Phase (min duration = 8 weeks)</th><th colspan="2">Continuation Phase (min duration = 18 weeks)’</th><th rowspan="2">Comments</th></thead><thead><th></th><th>Drugs</th><th>Dosing Interval</th><th>Drugs</th><th>Dosing Interval</th><th></th></thead><tr><td rowspan="4">1</td><td>INH</td><td rowspan="4">7 days per week”</td><td>INH</td><td rowspan="4">7 days per week?</td><td rowspan="4">Preferred regimen.</td></tr><tr><td></td><td>RIF</td><td></td><td rowspan="3">RIF</td><td></td><td></td></tr><tr><td></td><td>PZA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>EMB</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4"></td><td></td><td>INH</td><td>7 days per week?</td><td rowspan="4">INH RIF</td><td></td><td rowspan="4">3 days per week</td><td></td><td rowspan="4">Preferred alternative if less frequent DOT is needed.</td><td></td></tr><tr><td></td><td>RIF</td><td></td><td></td><td></td><td></td></tr><tr><td>PZA</td><td></td></tr><tr><td></td><td>EMB</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4"></td><td>INH</td><td rowspan="4">3 days per week</td><td>INH</td><td rowspan="4">3 days per week</td><td rowspan="4">Caution in patients with HIV and/or cavitary disease due to concerns for treatment failure, relapse, drug resistance.</td></tr><tr><td></td><td>RIF</td><td></td><td>RIF</td><td></td><td></td></tr><tr><td></td><td>PZA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>EMB</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4"></td><td></td><td>INH</td><td>7 days per week x</td><td>INH</td><td rowspan="4">2 days per week</td><td></td><td rowspan="4">Avoid in patients with HIV or those with smear-positive and/ or cavitary disease.</td><td></td></tr><tr><td></td><td>RIF</td><td>2 weeks, then</td><td>RIF</td><td></td><td></td></tr><tr><td>PZA</td><td>2 days per week x</td><td></td></tr><tr><td></td><td>EMB</td><td>6 weeks</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Species</th><th>Clinical Features</th><th>Treatment Options</th></thead><tr><td>M kansasii</td><td>Resembles tuberculosis</td><td>Amikacin, clarithromycin, ethambutol, isoniazid, moxifloxacin, rifampin, streptomycin, trimethoprim-sulfamethoxazole</td></tr><tr><td>Mmarinum</td><td>Granulomatous cutaneous disease</td><td>Amikacin, clarithromycin, ethambutol, doxycycline, levofloxacin, minocycline, rifampin, trimethoprim-sulfamethoxazole</td></tr><tr><td>M scrofulaceum</td><td>Cervical adenitis in children</td><td>Amikacin, erythromycin (or other macrolide), rifampin, streptomycin (Surgical excision is often curative and the treatment of choice.)</td></tr><tr><td>Mavium complex (MAC)</td><td>Pulmonary disease in patients with chronic lung disease; disseminated infection in AIDS</td><td>Amikacin, azithromycin, clarithromycin, ethambutol, moxifloxacin, rifabutin</td></tr><tr><td>M chelonae</td><td>Abscess, sinus tract, ulcer; bone, joint, tendon infection</td><td>Amikacin, doxycycline, imipenem, linezolid, macrolides, tobramycin</td></tr><tr><td>M fortuitum</td><td>Abscess, sinus tract, ulcer; bone, joint, tendon infection</td><td>Amikacin, cefoxitin, ciprofloxacin, doxycycline, imipenem, minocycline, moxifloxacin, ofloxacin, trimethoprim-sulfamethoxazole</td></tr><tr><td>Mulcerans</td><td>Skin ulcers</td><td>Clarithromycin, isoniazid, streptomycin, rifampin, minocycline, moxifloxacin (Surgical excision may be effective.)</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td>ISONIAZID</td><td>Inhibits synthesis of mycolic acids, an essential component of mycobacterial cell walls</td><td>Bactericidal activity against susceptible strains of M tuberculosis</td><td>First-line agent for tuberculosis + treatment of latent infection less active against nontuberculous mycobacteria</td><td>Oral, IV - hepatic clearance (half-life 1h) + reduces levels of phenytoin + Toxicity: Hepatotoxic, peripheral neuropathy (give pyridoxine to prevent)</td></tr></table>
======================================
<table><thead><th>PYRAZINAMIDE</th><th>Not fully understood + pyrazinamide is converted to the active pyrazinoic acid under acidic conditions in macrophage lysosomes</th><th>Bacteriostatic activity against susceptible strains of M tuberculosis + may be bactericidal against actively dividing organisms</th><th>“Sterilizing” agent used during first 2 months of therapy « allows total duration of therapy to be shortened to 6 months</th><th>Oral - hepatic clearance (half-life 9 h), but metabolites are renally cleared so use 3 doses weekly if creatinine clearance &lt;30 mL/min - Toxicity: Hepatotoxic, hyperuricemia</th></thead><tr><td>ETHAMBUTOL</td><td>Inhibits mycobacterial arabinosyl transferases, which are involved in the polymerization reaction of arabinoglycan, an essential component of the mycobacterial cell wall</td><td>Bacteriostatic activity against susceptible mycobacteria</td><td>Given in four-drug initial combination therapy for tuberculosis until drug sensitivities are known « also used for nontuberculous mycobacterial infections</td><td>Oral + mixed clearance (half-life 4 h) + dose must be reduced in renal failure + Toxicity: Retrobulbar neuritis</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Physical Form</th><th>Dosing (mg/kg/d)</th><th>Cmax</th><th>Clearance</th><th>Nephrotoxicity</th><th>Infusional Toxicity</th><th>Daily Cost ($)</th></thead><tr><td colspan="8">Conventional formulation</td></tr><tr><td>Fungizone</td><td>Micelles</td><td></td><td></td><td></td><td></td><td></td><td>24</td></tr><tr><td colspan="8">Lipid formulations</td></tr><tr><td>AmBisome</td><td>Spheres</td><td></td><td></td><td></td><td></td><td></td><td>1300</td></tr><tr><td>Amphotec</td><td>Disks</td><td></td><td></td><td></td><td></td><td></td><td>660</td></tr><tr><td>Abelcet</td><td>Ribbons</td><td></td><td></td><td></td><td></td><td></td><td>570</td></tr></table>
======================================
<table><thead><th></th><th>Water Solubili</th><th>Absorption</th><th>CSF: Serum Concentration Ratio</th><th>t,, (hours)</th><th>Elimination</th><th>Formulations</th></thead><tr><td>Ketoconazole</td><td>Low</td><td>Variable</td><td>&lt;0.1</td><td>7-10</td><td>Hepatic</td><td>Oral</td></tr><tr><td>Itraconazole</td><td>Low</td><td>Variable</td><td>&lt;0.01</td><td>24-42</td><td>Hepatic</td><td>Oral, IV</td></tr><tr><td>Fluconazole</td><td>High</td><td>High</td><td>&gt;0.7</td><td>22-31</td><td>Renal</td><td>Oral, IV</td></tr><tr><td>Voriconazole</td><td>High</td><td>High</td><td>&gt;0.21</td><td>6</td><td>Hepatic</td><td>Oral, IV</td></tr><tr><td>Posaconazole</td><td>Low</td><td>High</td><td>_—</td><td>25</td><td>Hepatic</td><td>Oral, IV</td></tr><tr><td>Isavuconazole</td><td>High</td><td>High</td><td></td><td>130</td><td>Hepatic</td><td>Oral, IV</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxi Interactions</th></thead><tr><td colspan="5">POLYENE MACROLIDE</td></tr><tr><td>+ Amphotericin B</td><td>Forms pores in fungal membranes (which contain ergosterol) but not in mammalian (cholesterol- containing) membranes</td><td>Loss of intracellular contents through pores is fungicidal + broad spectrum of action</td><td>Localized and systemic candidemia + Cryptococcus + Histoplasma + Blastomyces + Coccidioides + Aspergillus</td><td>Oral form is not absorbed - IV for systemic use « intrathecal for fungal meningitis + topical for ocular and bladder infections + duration, days + Toxicity: Infusion reactions « renal impairment - Interactions: Additive with other renal toxic drugs</td></tr><tr><td colspan="5">+ Lipid formulations: Lower toxicity, higher doses can be used</td></tr><tr><td>PYRIMIDINE ANALOG + Flucytosine</td><td>Interferes with DNA and RNA | synthesis selectively in fungi</td><td>Synergistic with | amphotericin - systemic toxicity in host due to DNA and RNA effects</td><td>Cryptococcus and chromoblastomycosis infections</td><td>Oral - duration, hours « renal excretion + Toxicity: Myelosuppression</td></tr><tr><td colspan="5">AZOLES</td></tr><tr><td>+ Ketoconazole</td><td>Blocks fungal P450 enzymes and interferes with ergosterol synthesis</td><td>Poorly selective + also interferes with mammalian P450 function</td><td>Broad spectrum but toxicity restricts use to topical therapy</td><td>Oral, topical + Toxicity and interactions: Interferes with steroid hormone synthesis and phase | drug metabolism</td></tr><tr><td>+ Itraconazole</td><td>Same as for ketoconazole</td><td>Much more selective than ketoconazole</td><td>Broad spectrum: Candida, Cryptococcus, blastomycosis, coccidioidomycosis, histoplasmosis</td><td>Oral and IV + duration, 1-2 d + poor entry into central nervous system (CNS) + Toxicity and interactions: Low toxicity</td></tr><tr><td colspan="5">+ Fluconazole, voriconazole, posaconazole, isavuconazole: Fluconazole has excellent CNS penetration, used in fungal meningitis</td></tr><tr><td colspan="5">ECHINOCANDINS</td></tr><tr><td>+ Caspofungin</td><td>Blocks B-glucan synthase</td><td>Prevents synthesis of fungal cell wall</td><td>Fungicidal Candida sp - also used in aspergillosis</td><td>IV only + duration, 11-15 h « Toxicity: Minor gastrointestinal effects, flushing + Interactions: Increases cyclosporine</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxi Interactions</th></thead><tr><td colspan="5">POLYENE MACROLIDE</td></tr><tr><td>+ Amphotericin B</td><td>Forms pores in fungal membranes (which contain ergosterol) but not in mammalian (cholesterol- containing) membranes</td><td>Loss of intracellular contents through pores is fungicidal + broad spectrum of action</td><td>Localized and systemic candidemia + Cryptococcus + Histoplasma + Blastomyces + Coccidioides + Aspergillus</td><td>Oral form is not absorbed - IV for systemic use « intrathecal for fungal meningitis + topical for ocular and bladder infections + duration, days + Toxicity: Infusion reactions « renal impairment - Interactions: Additive with other renal toxic drugs</td></tr><tr><td colspan="5">+ Lipid formulations: Lower toxicity, higher doses can be used</td></tr><tr><td>PYRIMIDINE ANALOG + Flucytosine</td><td>Interferes with DNA and RNA | synthesis selectively in fungi</td><td>Synergistic with | amphotericin - systemic toxicity in host due to DNA and RNA effects</td><td>Cryptococcus and chromoblastomycosis infections</td><td>Oral - duration, hours « renal excretion + Toxicity: Myelosuppression</td></tr><tr><td colspan="5">AZOLES</td></tr><tr><td>+ Ketoconazole</td><td>Blocks fungal P450 enzymes and interferes with ergosterol synthesis</td><td>Poorly selective + also interferes with mammalian P450 function</td><td>Broad spectrum but toxicity restricts use to topical therapy</td><td>Oral, topical + Toxicity and interactions: Interferes with steroid hormone synthesis and phase | drug metabolism</td></tr><tr><td>+ Itraconazole</td><td>Same as for ketoconazole</td><td>Much more selective than ketoconazole</td><td>Broad spectrum: Candida, Cryptococcus, blastomycosis, coccidioidomycosis, histoplasmosis</td><td>Oral and IV + duration, 1-2 d + poor entry into central nervous system (CNS) + Toxicity and interactions: Low toxicity</td></tr><tr><td colspan="5">+ Fluconazole, voriconazole, posaconazole, isavuconazole: Fluconazole has excellent CNS penetration, used in fungal meningitis</td></tr><tr><td colspan="5">ECHINOCANDINS</td></tr><tr><td>+ Caspofungin</td><td>Blocks B-glucan synthase</td><td>Prevents synthesis of fungal cell wall</td><td>Fungicidal Candida sp - also used in aspergillosis</td><td>IV only + duration, 11-15 h « Toxicity: Minor gastrointestinal effects, flushing + Interactions: Increases cyclosporine</td></tr></table>
======================================
<table><tr><td colspan="2">Amphotericin B</td></tr><tr><td colspan="2">Parenteral:</td></tr><tr><td>Conventional formulation</td><td>Generic</td></tr><tr><td>Lipid formulations</td><td>Abelcet, AmBisome</td></tr><tr><td>Anidulafungin</td><td>Eraxis</td></tr><tr><td>Butenafine</td><td>Mentax</td></tr><tr><td>Butoconazole</td><td>Gynazole-1</td></tr><tr><td>Caspofungin</td><td>Cancidas</td></tr><tr><td>Clotrimazole</td><td>Generic, Lotrimin, Mycelex, others</td></tr><tr><td>Econazole</td><td>Generic, Ecoza</td></tr><tr><td>Fluconazole</td><td>Generic, Diflucan</td></tr><tr><td>Flucytosine</td><td>Generic, Ancobon</td></tr><tr><td>Griseofulvin</td><td>Grifulvin, Gris-Peg</td></tr><tr><td>Itraconazole</td><td>Generic, Sporanox, Onmel</td></tr><tr><td>Ketoconazole</td><td>Generic, Nizoral, others</td></tr><tr><td>Micafungin</td><td>Mycamine</td></tr><tr><td>Miconazole</td><td>Generic, Oravig, Micatin</td></tr><tr><td>Naftifine</td><td>Naftin</td></tr><tr><td>Natamycin</td><td>Natacyn</td></tr><tr><td>Nystatin</td><td>Generic</td></tr><tr><td>Oxiconazole</td><td>Generic, Oxistat, others</td></tr><tr><td>Posaconazole</td><td>Noxafil</td></tr><tr><td>Sulconazole</td><td>Exelderm</td></tr><tr><td>Terbinafine</td><td>Generic, Lamisil</td></tr><tr><td>Terconazole</td><td>Generic, Terazol 3, Terazol 7</td></tr><tr><td>Tioconazole</td><td>Vagistat-1, Monistat 1</td></tr><tr><td>Tolnaftate</td><td>Generic, Aftate, Tinactin, others</td></tr><tr><td>Voriconazole</td><td>Generic, Vfend</td></tr></table>
======================================
<table><thead><th>Agent</th><th>Treatment of First Episode</th><th>Treatment of Recurrent Episodes</th><th>Suppression</th></thead><tr><td colspan="4">Genital Herpes</td></tr><tr><td>Acyclovir, oral’</td><td>400 mg tid x 7-10 days or 200 mg 5 times daily</td><td>800 mg tid x 2 days or 800 mg bid x 5 days or 400 mg tid x 5 days</td><td>400-800 mg bid-tid*</td></tr><tr><td>Famciclovir, oral’</td><td>250 mg tid x 7-10 days</td><td>1000 mg bid x 1 day or 125 mg bid x 5 days or 500 mg once then 250 mg bid x 2 days’</td><td>250-500 mg bid?</td></tr><tr><td>Valacyclovir, oral’</td><td>1000 mg bid x 10 days</td><td>500 mg bid x 3 days or 1 g qd x 5 days</td><td>500-1000 mg qd-bid?</td></tr><tr><td colspan="4">Orolabial herpes</td></tr><tr><td>Acyclovir, oral’</td><td>400 mg tid x 7-10 days or 200 mg 5 times daily</td><td>200-400 mg 5 times daily x 5 days</td><td>400-800 mg bid-tid?</td></tr><tr><td>aewh 1 Famciclovir, oral</td><td>500 mg tid x 7-10 days</td><td>1500 mg once or 750 mg bid</td><td>500 mg bid</td></tr><tr><td>Valacyclovir, oral’</td><td>1g bid x 7-10 days</td><td>2g bid x 1 day</td><td>500-1000 mg qd</td></tr><tr><td>Acyclovir, topical (5% cream)</td><td></td><td>5 times daily x 4 days</td><td></td></tr><tr><td>Docosanol, topical (10% cream)</td><td></td><td>5 times daily</td><td></td></tr><tr><td>Penciclovir, topical (1% cream)</td><td></td><td>Every 2 h while awake</td><td></td></tr><tr><td colspan="4">Herpes proctitis, treatment</td></tr><tr><td colspan="4">Acyclovir, oral’ 400 mg 5 times daily until healed</td></tr><tr><td colspan="4">Severe HSV infection or HSV infection in the immunocompromised host, treatment</td></tr><tr><td>Acyclovir, IV!</td><td>5-10 mg/kg q8h x 7-14 days</td><td></td><td></td></tr><tr><td colspan="4">Herpes encephalitis, treatment</td></tr><tr><td colspan="4">Acyclovir, IV! 10-15 mg/kg q8h x 21 days</td></tr><tr><td colspan="4">Neonatal HSV infection, treatment</td></tr><tr><td colspan="4">Acyclovir, IV! 10-20 mg/kg q8h x 14-21 days</td></tr><tr><td colspan="4">Herpetic keratoconjunctivitis, treatment</td></tr><tr><td>Ganciclovir, topical (0.15% gel)</td><td>5 times daily</td><td></td><td></td></tr><tr><td>Trifluridine, topical (1% solution)</td><td>Every 2 h while awake</td><td></td><td></td></tr><tr><td colspan="4">Varicella infection, treatment</td></tr><tr><td>Acyclovir, oral!</td><td>20 mg/kg (maximum 800 mg) qid x</td><td>5 days</td><td></td></tr><tr><td>Valacyclovir, oral’</td><td>20 mg/kg (maximum, 1 g) tid x 5</td><td>days</td><td></td></tr><tr><td colspan="4">Zoster infection, treatment</td></tr><tr><td>Acyclovir, oral’</td><td>800 mg 5 times daily x 7-10 days</td><td></td><td></td></tr><tr><td>Famciclovir, oral’</td><td>500 mg tid x 7 days</td><td></td><td></td></tr><tr><td>Valacyclovir, oral!</td><td>1g tid x 7 days</td><td></td><td></td></tr><tr><td colspan="4">Severe VZV infection or VZV infection in the immunocompromised host, treatment</td></tr><tr><td>Acyclovir, IV!</td><td>10-15 mg/kg q8h x &gt;7 days</td><td></td><td></td></tr><tr><td colspan="4">Acyclovir-resistant HSV or VZV infection, treatment</td></tr><tr><td>Foscarnet, IV'</td><td>40-60 mg/kg q8h until healed”</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Agent</th><th>Route of Administration</th><th>Use</th><th>Recommended Adult Dosage</th></thead><tr><td rowspan="3">Valganciclovir'</td><td rowspan="2">Oral</td><td rowspan="2">CMV retinitis treatment</td><td>Induction: 900 mg bid x 21 days</td></tr><tr><td></td><td></td><td></td><td>Maintenance: 900 mg daily</td></tr><tr><td></td><td>Oral</td><td>CMV prophylaxis (transplant patients)</td><td>900 mg daily</td></tr><tr><td rowspan="2">Ganciclovir!</td><td rowspan="2">Intravenous</td><td rowspan="2">CMV retinitis treatment</td><td>Induction: 5 mg/kg q12h x 14-21 days</td></tr><tr><td></td><td></td><td></td><td>Maintenance: 5 mg/kg/d or 6 mg/kg five times per week</td></tr><tr><td rowspan="2">Foscarnet'</td><td rowspan="2">Intravenous</td><td rowspan="2">CMV retinitis treatment</td><td>Induction: 60 mg/kg g8h or 90 mg/kg q12h x 14-21 days</td></tr><tr><td></td><td></td><td></td><td>Maintenance: 90-120 mg/kg/d</td></tr><tr><td rowspan="2">Cidofovir'</td><td rowspan="2">Intravenous</td><td>CMV retinitis treatment</td><td>Induction: 5 mg/kg/wk x 2 weeks</td></tr><tr><td></td><td></td><td></td><td>Maintenance: 5 mg/kg every week</td></tr></table>
======================================
<table><tr><td>syuawu0&gt;</td><td>“yoyoo|e ploay</td><td></td><td>“MAPUDIGWUS OJ ‘DULIAPI}A ‘1}SID1IGOD /4AeBaAIa PlOAY “fy 310U}OOJ Bas</td><td>“aulueje|Auayd sureyuod Japmod je10 ay “ADuald1yNsu! JHeday BAAS U! PlOAY “AJAeUeIdN ‘auidesAaU</td><td>“ABuayje eyjns YIM sjuaijed Ul ploay “«AlAaidauuls pue 3e}s191G0&gt; /A\AesBayiAja PIOAY “fy 9}OUJOO} Bas</td><td>JUBIINIUOD PIOAY “fp 9JOU}OOJ 99S</td><td>*sye1 ul</td><td>‘Ba) sirup 214,edounau jualINdUOD ploAy DJuaGojyesa| “sJAeuadueso}</td><td>ulejUuod $}3/qe}. ajqemay&gt; ‘joulNdo||e 40 ‘ulAeqls ‘(pizeuos! ‘aulqey3]ez ‘Qulpnaeys</td><td>‘auideiiaau ‘aplijayop ‘auidazeweqie&gt; ploAy saujuejejAuayd</td><td>“uloyhuayd ‘jeyqueqouayd</td><td></td><td>“Aas UUIS ‘AU! PU! ‘BULIARIIA “}2]SID1IGOD /lAeABaA|a PIOAY “y 2}0UJOOJ 39S</td><td>“auidesiAou pue ZuasAeja ploay “fp 3}0U00) aas “soqewud ul luaboyesa]</td><td></td><td>2] JUaLINDUOD PIOAY</td></tr><tr><td>sypeayg asdaapy 2sl4a}DeIeYD</td><td>AyanisuassadAy ‘ysey</td><td>uolyD4e4u! jeIPYeDOAW ul aseadul ajqissod feasneu ‘uO!eaL</td><td>‘eimaulgnaljiquadAy yau1pur “elBjeAw ‘yses ‘easnen,</td><td>JeAsaqu! Yq pabuojoid ‘sowAzua Ja Al} | ‘eayuelp</td><td>asejAwe wines | ‘sawAzua Jal] | ‘elwapidijeddy ‘yses ‘easneu ‘aydepeay ‘eayuelg</td><td>~peay ‘sawAzua Jani) | ‘ysey</td><td>eayelp ‘easneu ‘ayre</td><td>-ued ‘Ayjyedonau jesaydieg</td><td>“eayuelp ‘SiIe319</td><td>‘ayrepeay ‘eluwosu|</td><td>12Al| | ‘uonead AyANIsuassad Ay,</td><td>sawAzua</td><td>-peay ‘saw Azua Jal] J ‘used ‘suuojduuAs 3143e142Asdounany</td><td>sawAzua Jaal] | ‘yses ‘eayueiq easneu ‘ayse</td><td></td><td>uonejyuawbiduedfy ‘yses ‘easneu ‘eayielp ‘aysepeay</td></tr><tr><td>epuawwi0s9y uonedjsiulupy</td><td>aduasaid ay} NO ajn 0} Isa]</td><td>‘Adesay} Jo UO!!! 07 Jold ajal@ LOZSE-V1H 24} JO</td><td>“spipeque JueyWo2U0&gt; PIOAY ‘POOJ YIM aye) ysnfpe 4AeuO</td><td>“Y OL= Aq sjuabe Bursnpas -pioe Buisop ajyeredas</td><td>“pooy YIM aye UUM 4AeUOY,</td><td>4O |pp Woy Bulsop ajeiedas</td><td>“y L= sproeque</td><td>“yoewo}s Ajduwa ue uo aye] Aq</td><td></td><td>-DejUe WOY Hulsop ajesedas</td><td>yz suo}}e&gt; JuajeAdjod pue sp! -WWRSO}</td><td>hq 0¢ JO</td><td>“aWIIpag je ‘yoewojs Ajdua ue uo aye]</td><td>“y 7= Aq spineque wou Bul -sop ajeiedas ‘poo yum aye] J1A0JOUaY -121G0&gt;</td><td>pb 6w</td><td></td></tr><tr><td>abesog ynpy papueuworsy</td><td>pb Bw 909 Jo piq Bw ooE</td><td></td><td>Bu QS e3SIDIqGO&gt; Jo pb Hu QOL YUM pb Bw Cog 40 pb bu OV</td><td>ADualdiyNsul Jeday ul asop</td><td>009 :pasuatadxa-juatw}eal | Bw 9¢1 3e3s!91G09 10 pb Bw QoL pb Hw Q0g :aAleu-JUaW}eAL |</td><td>pa 6w oor pig 6w 001 saeuoys</td><td></td><td>6 00z 40 pb Bu oor ‘sia1qeL</td><td>_PIq 6w Osz apmod paiayng 1ybiam Jo} paysn{[pe</td><td>pb Bw os :aaleu-lLSNI</td><td>‘ZUAJIARJ2 YIM Pasa}SIU!LUPe-OD J}</td><td>pig ‘suoNeyNw | LSNI Uleya&gt; J! 40 UldwueyL ‘MAPUOW/ACURIG!} “APUOY!/AIAeUaId</td><td>pb 6 009 6w</td><td>Puke ‘OZ aUIGeIIUJWA ‘QS| BIS pb Bw o¢ | :aAleu-juawyeady</td><td>JoUqi yu! aseajoid e YM |-6w ¢g :pasuavadxe-juawjeal)</td><td>&lt;pb 6w 00z</td></tr></table>
======================================
<table><tr><td>syuawu0&gt;</td><td>“yoyoo|e ploay</td><td></td><td>“MAPUDIGWUS OJ ‘DULIAPI}A ‘1}SID1IGOD /4AeBaAIa PlOAY “fy 310U}OOJ Bas</td><td>“aulueje|Auayd sureyuod Japmod je10 ay “ADuald1yNsu! JHeday BAAS U! PlOAY “AJAeUeIdN ‘auidesAaU</td><td>“ABuayje eyjns YIM sjuaijed Ul ploay “«AlAaidauuls pue 3e}s191G0&gt; /A\AesBayiAja PIOAY “fy 9}OUJOO} Bas</td><td>JUBIINIUOD PIOAY “fp 9JOU}OOJ 99S</td><td>*sye1 ul</td><td>‘Ba) sirup 214,edounau jualINdUOD ploAy DJuaGojyesa| “sJAeuadueso}</td><td>ulejUuod $}3/qe}. ajqemay&gt; ‘joulNdo||e 40 ‘ulAeqls ‘(pizeuos! ‘aulqey3]ez ‘Qulpnaeys</td><td>‘auideiiaau ‘aplijayop ‘auidazeweqie&gt; ploAy saujuejejAuayd</td><td>“uloyhuayd ‘jeyqueqouayd</td><td></td><td>“Aas UUIS ‘AU! PU! ‘BULIARIIA “}2]SID1IGOD /lAeABaA|a PIOAY “y 2}0UJOOJ 39S</td><td>“auidesiAou pue ZuasAeja ploay “fp 3}0U00) aas “soqewud ul luaboyesa]</td><td></td><td>2] JUaLINDUOD PIOAY</td></tr><tr><td>sypeayg asdaapy 2sl4a}DeIeYD</td><td>AyanisuassadAy ‘ysey</td><td>uolyD4e4u! jeIPYeDOAW ul aseadul ajqissod feasneu ‘uO!eaL</td><td>‘eimaulgnaljiquadAy yau1pur “elBjeAw ‘yses ‘easnen,</td><td>JeAsaqu! Yq pabuojoid ‘sowAzua Ja Al} | ‘eayuelp</td><td>asejAwe wines | ‘sawAzua Jal] | ‘elwapidijeddy ‘yses ‘easneu ‘aydepeay ‘eayuelg</td><td>~peay ‘sawAzua Jani) | ‘ysey</td><td>eayelp ‘easneu ‘ayre</td><td>-ued ‘Ayjyedonau jesaydieg</td><td>“eayuelp ‘SiIe319</td><td>‘ayrepeay ‘eluwosu|</td><td>12Al| | ‘uonead AyANIsuassad Ay,</td><td>sawAzua</td><td>-peay ‘saw Azua Jal] J ‘used ‘suuojduuAs 3143e142Asdounany</td><td>sawAzua Jaal] | ‘yses ‘eayueiq easneu ‘ayse</td><td></td><td>uonejyuawbiduedfy ‘yses ‘easneu ‘eayielp ‘aysepeay</td></tr><tr><td>epuawwi0s9y uonedjsiulupy</td><td>aduasaid ay} NO ajn 0} Isa]</td><td>‘Adesay} Jo UO!!! 07 Jold ajal@ LOZSE-V1H 24} JO</td><td>“spipeque JueyWo2U0&gt; PIOAY ‘POOJ YIM aye) ysnfpe 4AeuO</td><td>“Y OL= Aq sjuabe Bursnpas -pioe Buisop ajyeredas</td><td>“pooy YIM aye UUM 4AeUOY,</td><td>4O |pp Woy Bulsop ajeiedas</td><td>“y L= sproeque</td><td>“yoewo}s Ajduwa ue uo aye] Aq</td><td></td><td>-DejUe WOY Hulsop ajesedas</td><td>yz suo}}e&gt; JuajeAdjod pue sp! -WWRSO}</td><td>hq 0¢ JO</td><td>“aWIIpag je ‘yoewojs Ajdua ue uo aye]</td><td>“y 7= Aq spineque wou Bul -sop ajeiedas ‘poo yum aye] J1A0JOUaY -121G0&gt;</td><td>pb 6w</td><td></td></tr><tr><td>abesog ynpy papueuworsy</td><td>pb Bw 909 Jo piq Bw ooE</td><td></td><td>Bu QS e3SIDIqGO&gt; Jo pb Hu QOL YUM pb Bw Cog 40 pb bu OV</td><td>ADualdiyNsul Jeday ul asop</td><td>009 :pasuatadxa-juatw}eal | Bw 9¢1 3e3s!91G09 10 pb Bw QoL pb Hw Q0g :aAleu-JUaW}eAL |</td><td>pa 6w oor pig 6w 001 saeuoys</td><td></td><td>6 00z 40 pb Bu oor ‘sia1qeL</td><td>_PIq 6w Osz apmod paiayng 1ybiam Jo} paysn{[pe</td><td>pb Bw os :aaleu-lLSNI</td><td>‘ZUAJIARJ2 YIM Pasa}SIU!LUPe-OD J}</td><td>pig ‘suoNeyNw | LSNI Uleya&gt; J! 40 UldwueyL ‘MAPUOW/ACURIG!} “APUOY!/AIAeUaId</td><td>pb 6 009 6w</td><td>Puke ‘OZ aUIGeIIUJWA ‘QS| BIS pb Bw o¢ | :aAleu-juawyeady</td><td>JoUqi yu! aseajoid e YM |-6w ¢g :pasuavadxe-juawjeal)</td><td>&lt;pb 6w 00z</td></tr></table>
======================================
<table><thead><th>syuaww0&gt;</th><th></th><th></th><th>‘uAeuesdyy “IAeuIpul 4iaeuaidtuesoy ‘JeysID1GQor/AIAeABayAjO ‘ZUAMIARJ9 “IIACURZE}L PIOAY “y 3}0UJOOJ BBS</th><th>pue ‘uo;n|os jes AAeUOq “9 UWA ‘Q|OZEPIUOAJa WW ‘LURAY /NSIP ‘BUIPIaLUID PIOAY “AdualdyjNsul Jeday asanas 10 Abualje BIjNs YUM sqjualjed ul ploay “auldesAau ‘MAPUO}L/AAUIGO] ‘BUIIARIJ9 ‘JLYSI91GOI /MAeIBAUAa PIOAY “py BJOUJOOJ3aS</th><th>Pue ZuUadIAeja 2}0UJ00} “UOIANIOS Je10 BY} YUM JOYod|e</th><th>“auLIAel a PIOAy “y 3aS</th><th>“auiqeyojez JO auIge}D}WA YYM JaysiuIUpe JOU oq</th><th>PloAy wsAeuesdi “AeUadWeSoO} ‘je}S191GOD AlnesBayaja ‘APUNIP PIOAY “f 2}0U}00j 39S</th><th>“uolnjos [e240 yum ajozepiuosaW pue WeljNsip</th><th>“uon2unys(p jeuad asanas YUM sjualed Ul JaysiuIUpe JOU Og “p BJ0U}00} Bag</th><th>“al ejejAuayd SUIEJUOD JaPMOd [e410 BY] “fy 2}0UJOO} 39S</th><th>“quawuieduu! seday aianas JO B}RJBpOW YUM poyedipulesjUOD VWIAeU -a1duesoy 3e1SID1GOd/AIAeABayAja ‘“41Ae16 -a]NJOP ‘“4WAeUZe}e PIOAY “7 8]0U}OOJ 9a</th><th>sauruejejAuayd UleJUOD sja/qe} a|qemay&gt; ay</th><th>“fy 8}]0U}00} 39S</th></thead><tr><td>speya assaApy 2Sl4a}DeIeYD</td><td>‘aypepeay ‘e!UWOSU! ‘uonoead AyANIsuassad Ay, ‘sUO!DeaJ AUIS UONDafu|</td><td>eluowneud JeW9]eq paseaidu! ajqissod teij1ydoulsoa ‘easneu ‘ssaulzzip</td><td>eaywueip ‘easneu ‘ysey</td><td>sewiAzua Jal] | ‘aye —-peRay ‘easneu ‘eayweIp ‘yseYy</td><td></td><td>Jelpsed0Aw ul aseasdU! 9} -sod ‘eayueip ‘aysepeay ‘era uiqnul|iqiadAy y2au1put ‘easneu ‘S| jouydan</td><td>‘ssaulzzip ‘aysepeay ‘easney, uonr.eju!</td><td>Jani] | ‘e1WapHarh|61y -dadhy ‘easneu ‘eayuelg anbiyey</td><td>uolyD4e4u! jeIPYeDOAW asealdul ajqissod ‘sawiAzua</td><td>uol}D4e4U! jeIPYeDOAW ul aseasdU! ajqissod ‘sawAzua Jaal| | ‘e2ueqinysip daa|s ‘eaYeIp ‘UIed ajasnuu ‘YBno&gt;</td><td>aduainjey ‘easneu ‘eayueig</td><td>aypepeay ‘easneu ‘(Queullujny Ajjeuolsed30) siyeday ‘ysey</td><td>sawAzua Jani] | ‘S|2A2| asejAwe | ‘sayoe apsnu vanbiqey ‘aydepeay ‘easnen</td><td>sawAzua JaAl| | ‘Ysed ‘UOls -saidap ‘eluwosu! ‘ayepeay,</td></tr><tr><td>uopepuawiw0day uonedjsiuupy</td><td></td><td></td><td>“Pooj YM aye]</td><td></td><td>“yoewioys</td><td>“y L= Aq Ipp Op ayeiedas ‘Ajlep ZO Bp ysea] Je YULG Adwia ue uo jsag</td><td></td><td>yu L Aq Ipp woy Bulsop ajeredas</td><td></td><td></td><td>“poo} YIM ayeL</td><td>“skep p| JaA0 Ajlep Bw 00Z Woy aje|e9sa-asoq</td><td></td><td>y Jo sploejue Woy Bulsop aqesedas ‘poo ym ayel</td></tr><tr><td>abesog ynpy papueuworsy</td><td>Ppiq Ajsnoaueynoqns Bw 06</td><td></td><td>pig 6w 00z</td><td>Adua!d1yNsUl 21yeday ul asop ysn{pe ‘pb Bw 00Z-001 4AeUO YUM Ajlep Bw QOL 40 pig Bu OOL JIACUOY! YUM pig Bw 0OZ 10 pig bw OOrL</td><td>YIM pig py</td><td>s!SOyJ4ID UL asop ysnfpe ‘pig Bw 0OZ-00L JIARUO} Bw OOg 40 Bw 00g</td><td>Pb Bw o0E 40 piq Bw OSL</td><td>pb Bw 002/008 40 piq Bw 001/00”</td><td></td><td>sua2npul YEdAD YUM pig Bw 009 ‘S1OUGIYU! YEdAD YUM PIG OSL ‘Pig Bu COE</td><td>Pig Gu 0SZ1 40 py Bu og</td><td>Piq Bw 00z</td><td>piq bw oor</td><td>pb Bw cz</td></tr></table>
======================================
<table><thead><th>syuaww0&gt;</th><th></th><th></th><th>‘uAeuesdyy “IAeuIpul 4iaeuaidtuesoy ‘JeysID1GQor/AIAeABayAjO ‘ZUAMIARJ9 “IIACURZE}L PIOAY “y 3}0UJOOJ BBS</th><th>pue ‘uo;n|os jes AAeUOq “9 UWA ‘Q|OZEPIUOAJa WW ‘LURAY /NSIP ‘BUIPIaLUID PIOAY “AdualdyjNsul Jeday asanas 10 Abualje BIjNs YUM sqjualjed ul ploay “auldesAau ‘MAPUO}L/AAUIGO] ‘BUIIARIJ9 ‘JLYSI91GOI /MAeIBAUAa PIOAY “py BJOUJOOJ3aS</th><th>Pue ZuUadIAeja 2}0UJ00} “UOIANIOS Je10 BY} YUM JOYod|e</th><th>“auLIAel a PIOAy “y 3aS</th><th>“auiqeyojez JO auIge}D}WA YYM JaysiuIUpe JOU oq</th><th>PloAy wsAeuesdi “AeUadWeSoO} ‘je}S191GOD AlnesBayaja ‘APUNIP PIOAY “f 2}0U}00j 39S</th><th>“uolnjos [e240 yum ajozepiuosaW pue WeljNsip</th><th>“uon2unys(p jeuad asanas YUM sjualed Ul JaysiuIUpe JOU Og “p BJ0U}00} Bag</th><th>“al ejejAuayd SUIEJUOD JaPMOd [e410 BY] “fy 2}0UJOO} 39S</th><th>“quawuieduu! seday aianas JO B}RJBpOW YUM poyedipulesjUOD VWIAeU -a1duesoy 3e1SID1GOd/AIAeABayAja ‘“41Ae16 -a]NJOP ‘“4WAeUZe}e PIOAY “7 8]0U}OOJ 9a</th><th>sauruejejAuayd UleJUOD sja/qe} a|qemay&gt; ay</th><th>“fy 8}]0U}00} 39S</th></thead><tr><td>speya assaApy 2Sl4a}DeIeYD</td><td>‘aypepeay ‘e!UWOSU! ‘uonoead AyANIsuassad Ay, ‘sUO!DeaJ AUIS UONDafu|</td><td>eluowneud JeW9]eq paseaidu! ajqissod teij1ydoulsoa ‘easneu ‘ssaulzzip</td><td>eaywueip ‘easneu ‘ysey</td><td>sewiAzua Jal] | ‘aye —-peRay ‘easneu ‘eayweIp ‘yseYy</td><td></td><td>Jelpsed0Aw ul aseasdU! 9} -sod ‘eayueip ‘aysepeay ‘era uiqnul|iqiadAy y2au1put ‘easneu ‘S| jouydan</td><td>‘ssaulzzip ‘aysepeay ‘easney, uonr.eju!</td><td>Jani] | ‘e1WapHarh|61y -dadhy ‘easneu ‘eayuelg anbiyey</td><td>uolyD4e4u! jeIPYeDOAW asealdul ajqissod ‘sawiAzua</td><td>uol}D4e4U! jeIPYeDOAW ul aseasdU! ajqissod ‘sawAzua Jaal| | ‘e2ueqinysip daa|s ‘eaYeIp ‘UIed ajasnuu ‘YBno&gt;</td><td>aduainjey ‘easneu ‘eayueig</td><td>aypepeay ‘easneu ‘(Queullujny Ajjeuolsed30) siyeday ‘ysey</td><td>sawAzua Jani] | ‘S|2A2| asejAwe | ‘sayoe apsnu vanbiqey ‘aydepeay ‘easnen</td><td>sawAzua JaAl| | ‘Ysed ‘UOls -saidap ‘eluwosu! ‘ayepeay,</td></tr><tr><td>uopepuawiw0day uonedjsiuupy</td><td></td><td></td><td>“Pooj YM aye]</td><td></td><td>“yoewioys</td><td>“y L= Aq Ipp Op ayeiedas ‘Ajlep ZO Bp ysea] Je YULG Adwia ue uo jsag</td><td></td><td>yu L Aq Ipp woy Bulsop ajeredas</td><td></td><td></td><td>“poo} YIM ayeL</td><td>“skep p| JaA0 Ajlep Bw 00Z Woy aje|e9sa-asoq</td><td></td><td>y Jo sploejue Woy Bulsop aqesedas ‘poo ym ayel</td></tr><tr><td>abesog ynpy papueuworsy</td><td>Ppiq Ajsnoaueynoqns Bw 06</td><td></td><td>pig 6w 00z</td><td>Adua!d1yNsUl 21yeday ul asop ysn{pe ‘pb Bw 00Z-001 4AeUO YUM Ajlep Bw QOL 40 pig Bu OOL JIACUOY! YUM pig Bw 0OZ 10 pig bw OOrL</td><td>YIM pig py</td><td>s!SOyJ4ID UL asop ysnfpe ‘pig Bw 0OZ-00L JIARUO} Bw OOg 40 Bw 00g</td><td>Pb Bw o0E 40 piq Bw OSL</td><td>pb Bw 002/008 40 piq Bw 001/00”</td><td></td><td>sua2npul YEdAD YUM pig Bw 009 ‘S1OUGIYU! YEdAD YUM PIG OSL ‘Pig Bu COE</td><td>Pig Gu 0SZ1 40 py Bu og</td><td>Piq Bw 00z</td><td>piq bw oor</td><td>pb Bw cz</td></tr></table>
======================================
<table><thead><th>BABS Ul PIOAY “JRAJAIU! 1D BY} aseasdUl yey} s6nup pue sIAeuesd)) ‘sajnsde&gt; a1126 “aeunsep ploAy “fy 230U}00} aa</th><th>s6nip s1yyedounau pue sulpnaopiz ploay “AQualysnsul Ieday</th><th>“(plze!uos! ‘auiqey!&gt;)ez ‘Ipp ‘6a)</th><th>“Adualdiyynsul Jeua aianas ul! plone os|y “(4AeUOI /alneuesdiy ‘WON S,UYOF 3S ‘Jeyqueqouayd ‘uloyAuayd ‘unngeyu ‘uiduuejis) ula}01d024|6-d Jo siaanpul ploay</th><th>*plpauagoid ‘aulsouepip ‘sAeuezeje ploay</th><th>“QUIIARIa ‘12ISID1GOI/AAeIBayAja ‘ACULZ -2]2 ]UBINIUOD PIOAY “y 8}0U}OOJ 395</th><th>Joy su ye ase OYM ‘AdUAIDYJNSU! Jeday aiaAas YM sjualed u! ploay «lAeuinbes /AIACU!CO|</th><th>“UONINIOS }e1O BY} YM J UI “PLA ploay ‘Abualje eyjns YM JO ‘Hulpae|q,</th><th>“(ULIAequ 4IA0|21DUeB ‘Ha) s6nup aaissaiddnsojaAw pue auipnaeys juarindu02 ploy</th><th></th><th>j.5opido)9 ‘apuidesi&gt; ‘auipnawi&gt; ‘ qiuntia&gt; ‘auidazewequed |pozuag ‘auonbenoye ‘ajoz}wayse ‘UL IUeyaUUN|/JaYyawa.e</th><th>-e4}!) sjuabe je6unynue ajozer S3dd “' A ‘SNUUI[0192} ‘140M S,UYOF yeU ‘AURTOUIL ‘BUOPeYya ‘(UIDAWOIY}a} ‘UIDAWOIYWE)) Nd ‘SAAIEALAP plojey|e JOHJa ‘apiweynyjezua ‘auosepauolp</th><th></th></thead><tr><td>6w 001 seo YM Pig BW OOOL</td><td>3461am uo Bulpuadap ‘pig Oy-0¢ €</td><td>bw</td><td>SUIAIG | = oulqeyd1yWe yum pb Bu ¢z ‘3e3s1ID1IGQod/4AesHayIAja snjd auigeyioujWa ym pb bw OL</td><td>Pb Bw ove</td><td>Pig 6w 00z 4Aeuoy, YM pig Bw 00S</td><td></td><td></td><td>&lt;P!q Bui OE 40 pn Bw 00z</td><td>adUe}sISAJ UI|NSU! PUR ‘eILUAadA|HadAy ‘UO!NqI4}SIP|EW } “Juana assanpe |eiuajod e se 0Jea}s Neday yy</td><td>JeUUYD WNID[e&gt; ‘UoIdosdng ‘ue\UAsog ‘1plidaq ‘auazoLe Pinoys Warsks PYEdAD 24} YM PesaU! Jey} SHndp yua</td><td>“1OYe&gt;DeA! ‘UeI3}0U 1a. ‘siouqiyut duind ulayoid ‘suouayedoud ‘suopiuid |2|ap! ‘2uapoysab ‘auosed! ‘aulwesdisap ‘auosdep ‘qiuajesqep ‘aulic</td><td>YN 40 Yul aseydysue} asienad apisoajanuuou “ue eM pue ‘aulpeuassa} ‘(3/02</td></tr></table>
======================================
<table><thead><th>BABS Ul PIOAY “JRAJAIU! 1D BY} aseasdUl yey} s6nup pue sIAeuesd)) ‘sajnsde&gt; a1126 “aeunsep ploAy “fy 230U}00} aa</th><th>s6nip s1yyedounau pue sulpnaopiz ploay “AQualysnsul Ieday</th><th>“(plze!uos! ‘auiqey!&gt;)ez ‘Ipp ‘6a)</th><th>“Adualdiyynsul Jeua aianas ul! plone os|y “(4AeUOI /alneuesdiy ‘WON S,UYOF 3S ‘Jeyqueqouayd ‘uloyAuayd ‘unngeyu ‘uiduuejis) ula}01d024|6-d Jo siaanpul ploay</th><th>*plpauagoid ‘aulsouepip ‘sAeuezeje ploay</th><th>“QUIIARIa ‘12ISID1GOI/AAeIBayAja ‘ACULZ -2]2 ]UBINIUOD PIOAY “y 8}0U}OOJ 395</th><th>Joy su ye ase OYM ‘AdUAIDYJNSU! Jeday aiaAas YM sjualed u! ploay «lAeuinbes /AIACU!CO|</th><th>“UONINIOS }e1O BY} YM J UI “PLA ploay ‘Abualje eyjns YM JO ‘Hulpae|q,</th><th>“(ULIAequ 4IA0|21DUeB ‘Ha) s6nup aaissaiddnsojaAw pue auipnaeys juarindu02 ploy</th><th></th><th>j.5opido)9 ‘apuidesi&gt; ‘auipnawi&gt; ‘ qiuntia&gt; ‘auidazewequed |pozuag ‘auonbenoye ‘ajoz}wayse ‘UL IUeyaUUN|/JaYyawa.e</th><th>-e4}!) sjuabe je6unynue ajozer S3dd “' A ‘SNUUI[0192} ‘140M S,UYOF yeU ‘AURTOUIL ‘BUOPeYya ‘(UIDAWOIY}a} ‘UIDAWOIYWE)) Nd ‘SAAIEALAP plojey|e JOHJa ‘apiweynyjezua ‘auosepauolp</th><th></th></thead><tr><td>6w 001 seo YM Pig BW OOOL</td><td>3461am uo Bulpuadap ‘pig Oy-0¢ €</td><td>bw</td><td>SUIAIG | = oulqeyd1yWe yum pb Bu ¢z ‘3e3s1ID1IGQod/4AesHayIAja snjd auigeyioujWa ym pb bw OL</td><td>Pb Bw ove</td><td>Pig 6w 00z 4Aeuoy, YM pig Bw 00S</td><td></td><td></td><td>&lt;P!q Bui OE 40 pn Bw 00z</td><td>adUe}sISAJ UI|NSU! PUR ‘eILUAadA|HadAy ‘UO!NqI4}SIP|EW } “Juana assanpe |eiuajod e se 0Jea}s Neday yy</td><td>JeUUYD WNID[e&gt; ‘UoIdosdng ‘ue\UAsog ‘1plidaq ‘auazoLe Pinoys Warsks PYEdAD 24} YM PesaU! Jey} SHndp yua</td><td>“1OYe&gt;DeA! ‘UeI3}0U 1a. ‘siouqiyut duind ulayoid ‘suouayedoud ‘suopiuid |2|ap! ‘2uapoysab ‘auosed! ‘aulwesdisap ‘auosdep ‘qiuajesqep ‘aulic</td><td>YN 40 Yul aseydysue} asienad apisoajanuuou “ue eM pue ‘aulpeuassa} ‘(3/02</td></tr></table>
======================================
<table><thead><th>Agent</th><th>Drugs That Increase Its Serum Levels</th><th>Drugs That Decrease Its Serum Levels</th></thead><tr><td>Atazanavir</td><td>Ritonavir</td><td>Didanosine, efavirenz, elvitegravir/cobicistat, etravirine, fosamprenavir, nevirapine, stavudine, tenofovir, tipranavir</td></tr><tr><td>Darunavir</td><td>Indinavir</td><td>Efavirenz, lopinavir/ritonavir, saquinavir</td></tr><tr><td>Delavirdine?</td><td></td><td>Didanosine, fosamprenavir</td></tr><tr><td>Didanosine</td><td>Tenofovir</td><td>Atazanavir, ritonavir</td></tr><tr><td>Dolutegravir</td><td></td><td>Efavirenz, etravirine, nevirapine</td></tr><tr><td>Efavirenz”</td><td>Darunavir</td><td></td></tr><tr><td>Elvitegravir®</td><td>Ritonavir</td><td>Efavirenz, nevirapine</td></tr><tr><td>Etravirine</td><td>Atazanavir, delavirdine, indinavir, lopinavir/ritonavir</td><td>Efavirenz, nevirapine, ritonavir, saquinavir, tipranavir</td></tr><tr><td>Fosamprenavir</td><td>Atazanavir, delavirdine, etravirine, ritonavir</td><td>Didanosine, efavirenz, lopinavir/ritonavir, maraviroc, nevirapine, tipranavir</td></tr><tr><td>Indinavir</td><td>Darunavir, delavirdine, nelfinavir, ritonavir</td><td>Didanosine, efavirenz, etravirine, nevirapine</td></tr><tr><td>Lopinavir/ritonavir</td><td>Darunavir</td><td>Didanosine, efavirenz, fosamprenavir, nelfinavir, nevirapine, tipranavir</td></tr><tr><td>Maraviroc</td><td>Atazanavir, darunavir, lopinavir/ritonavir, nevirapine, saquinavir, ritonavir</td><td>Efavirenz, etravirine, tipranavir</td></tr><tr><td>Nelfinavir</td><td>Delavirdine, indinavir, ritonavir, saquinavir</td><td></td></tr><tr><td>Nevirapine”</td><td>Fosamprenavir</td><td></td></tr><tr><td>Raltegravir</td><td>Atazanavir</td><td>Etravirine, tipranavir</td></tr><tr><td>Rilpivirine?</td><td>Darunavir, lopinavir/ritonavir</td><td></td></tr><tr><td>Saquinavir</td><td>Atazanavir, delavirdine, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir</td><td>Efavirenz, etravirine, nevirapine, tipranavir</td></tr><tr><td>Tenofovir alafenamide</td><td>Ritonavir</td><td>Darunavir</td></tr><tr><td>Tenofovir disoproxil fumarate</td><td>Atazanavir</td><td></td></tr><tr><td>Tipranavir</td><td></td><td>Efavirenz</td></tr></table>
======================================
<table><thead><th>Recommended Agents</th><th>Alternate Agents</th></thead><tr><td colspan="2">Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)</td></tr><tr><td colspan="2">Abacavir, emtricitabine, lamivudine, tenofovir disoproxil fumarate, zidovudine</td></tr><tr><td colspan="2">Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</td></tr><tr><td>Efavirenz</td><td>Rilpivirine</td></tr><tr><td colspan="2">Protease inhibitors (Pls)</td></tr><tr><td>Atazanavir/ritonavir, darunavir/ritonavir</td><td>Lopinavir/ritonavir</td></tr><tr><td>Raltegravir</td><td></td></tr></table>
======================================
<table><thead><th>Agent</th><th>Recommended Adult Dosage</th><th>Potential Adverse Effects</th></thead><tr><td colspan="3">Nucleoside/nucleotide analogs</td></tr><tr><td>a Entecavir</td><td>500 or 1000 mg qd orally</td><td>Headache, fatigue, upper abdominal pain; lactic acidosis</td></tr><tr><td>Tenofovir alafenamide fumarate</td><td>25 mg qd orally</td><td>Nausea, abdominal pain, diarrhea, dizziness, fatigue, nephropathy, lactic acidosis</td></tr><tr><td>Tenofovir disoproxil'</td><td>300 mg qd orally</td><td>Nausea, abdominal pain, diarrhea, dizziness, fatigue, nephropathy, lactic acidosis</td></tr><tr><td>Adefovir dipivoxil'</td><td>10 mg qd orally</td><td>Renal dysfunction, lactic acidosis</td></tr><tr><td>Lamivudine!</td><td>100 mg qd orally</td><td>Headache, nausea, diarrhea, dizziness, myalgia, and malaise, lactic acidosis</td></tr><tr><td>Telbivudine'</td><td>600 mg qd orally</td><td>Fatigue, headache, cough, nausea, diarrhea, myopathy, peripheral neuropathy, lactic acidosis</td></tr><tr><td>Interferon alfa-2b</td><td>5 million IU/d or 10 million IU three times weekly subcutaneously or intramuscularly</td><td>Flu-like symptoms, fatigue, mood disturbances, cytopenias, autoimmune disorders</td></tr><tr><td>Pegylated interferon alfa-2a"</td><td>180 mcg once weekly subcutaneously</td><td>Flu-like symptoms, fatigue, mood disturbances, cytopenias, autoimmune disorders</td></tr></table>
======================================
<table><thead><th>Regimen</th><th>Class of Agent(s)</th><th>HCV Genotype(s)</th></thead><tr><td>Velpatasvir 100 mg /sofosbuvir 400 mg once daily x 12 weeks</td><td>NSSA inhibitor/NSSB polymerase inhibitor</td><td>1,2, 3,4,5,6</td></tr><tr><td>Elbasvir 50 mg/grazoprevir 100 mg once daily x 12 weeks”</td><td>NSSA inhibitor/NS 3/4A protease inhibitor</td><td>la, 1b, 4</td></tr><tr><td>Ledipasvir 90 mg/sofosbuvir 400 mg once daily x 12 weeks</td><td>NSSA inhibitor/NSSB polymerase inhibitor</td><td>1a, 1b, 4, 5,6</td></tr><tr><td>Paritaprevir 150/ritonavir 100/ombitasvir 25 once daily plus dasabuvir 250 mg bid plus weight-based ribavirin x 12 weeks</td><td>NS 3/4A protease inhibitor/ NS5A inhibitor plus NS5B polymerase inhibitor plus guanosine analog</td><td>1a, 1b</td></tr><tr><td>Paritaprevir 150/ritonavir 100/ombitasvir 25 once daily plus weight- based ribavirin x 12 weeks</td><td>NS 3/4A protease inhibitor/ NSSA inhibitor plus guanosine analog</td><td></td></tr><tr><td>Simeprevir 150 mg plus sofosbuvir 400 mg once daily x 12 weeks</td><td>NS3/4A protease inhibitor plus NSSB polymerase inhibitor</td><td>1a, 1b</td></tr><tr><td>Daclatasvir 60 mg® plus sofosbuvir 400 mg once daily x 12 weeks</td><td>NSSA inhibitor plus NS5B polymerase inhibitor</td><td>1a, 1b, 2,3</td></tr><tr><td>Sofosbuvir 400 mg once daily plus weight-based ribavirin x 12 weeks</td><td>NSS5B polymerase inhibitor plus guanosine analog</td><td>2,3)</td></tr></table>
======================================
<table><tr><td>| GENERICNAME Etravirine</td><td>AVAILABLE Intelence</td></tr><tr><td>Famciclovir</td><td>Generic, Famvir</td></tr><tr><td>Fosamprenavir</td><td>Lexiva</td></tr><tr><td>Foscarnet</td><td>Generic, Foscavir</td></tr><tr><td>Ganciclovir</td><td>Generic, Cytovene</td></tr><tr><td>Imiquimod</td><td>Generic, Aldara, others</td></tr><tr><td>Indinavir</td><td>Crixivan</td></tr><tr><td>Interferon alfa-2a</td><td>Roferon-A</td></tr><tr><td>Interferon alfa-2b</td><td>Intron-A</td></tr><tr><td>Interferon alfa-2b/ribavirin</td><td>Rebetron</td></tr><tr><td>Interferon alfa-n3</td><td>Alferon N</td></tr><tr><td>Interferon alfacon-1</td><td>Infergen</td></tr><tr><td>Lamivudine</td><td>Generic, Epivir, Epivir-HBV</td></tr><tr><td>Lamivudine/zidovudine</td><td>Combivir</td></tr><tr><td>Lamivudine/abacavir/zidovudine</td><td>Trizivir</td></tr><tr><td>Lopinavir/ritonavir</td><td>Kaletra</td></tr><tr><td>Maraviroc</td><td>Selzentry</td></tr><tr><td>Nelfinavir</td><td>Viracept</td></tr><tr><td>Nevirapine</td><td>Generic, Viramune</td></tr></table>
======================================
<table><tr><td>Abacavir</td><td>Generic, Ziagen</td></tr><tr><td>Abacavir/lamivudine</td><td>Epzicom</td></tr><tr><td>Abacavir/lamivudine/zidovudine</td><td>Trizivir</td></tr><tr><td>Acyclovir</td><td>Generic, Zovirax</td></tr><tr><td>Adefovir</td><td>Generic, Hepsera</td></tr><tr><td>Amantadine</td><td>Generic, Symmetrel</td></tr><tr><td>Atazanavir</td><td>Reyataz</td></tr><tr><td>Boceprevir</td><td>Victrelis</td></tr><tr><td>Cidofovir</td><td>Generic, Vistide</td></tr><tr><td>Darunavir</td><td>Prezista (must be taken with ritonavir)</td></tr><tr><td>Delavirdine</td><td>Rescriptor</td></tr><tr><td>Didanosine (dideoxyinosine, ddl)</td><td>Generic, Videx, Videx-EC</td></tr><tr><td>Docosanol</td><td>Abreva (over-the-counter)</td></tr><tr><td>Efavirenz</td><td>Sustiva</td></tr><tr><td>Emtricitabine</td><td>Emtriva</td></tr><tr><td>Emtricitabine/tenofovir</td><td>Truvada</td></tr><tr><td>Emtricitabine/tenofovir/efavirenz</td><td>Atripla</td></tr><tr><td>Enfuvirtide</td><td>Fuzeon</td></tr><tr><td>Entecavir</td><td>Baraclude</td></tr></table>
======================================
<table><tr><td>Palivizumab</td><td>Synagis</td></tr><tr><td>Peginterferon alfa-2a (pegylated interferon alfa-2a)</td><td>Pegasys</td></tr><tr><td>Peginterferon alfa-2b (pegylated interferon alfa-2b)</td><td>PEG-Intron</td></tr><tr><td>Penciclovir</td><td>Denavir</td></tr><tr><td>Raltegravir</td><td>Isentress</td></tr><tr><td>Ribavirin</td><td>Generic, Rebetol</td></tr><tr><td>Ribavirin/interferon alfa-2b</td><td>Rebetron</td></tr><tr><td>Ribavirin Aerosol</td><td>Virazole</td></tr><tr><td>Rilpivirine</td><td>Edurant</td></tr><tr><td>Rilpivirine/emtricitabine/-tenofovir</td><td>Complera</td></tr><tr><td>Rimantadine</td><td>Generic, Flumadine</td></tr><tr><td>Ritonavir</td><td>Norvir</td></tr><tr><td>Saquinavir</td><td>Invirase</td></tr></table>
======================================
<table><tr><td>Sofosbuvir</td><td>Sovaldi</td></tr><tr><td>Stavudine</td><td>Generic, Zerit, Zerit XR</td></tr><tr><td>Telaprevir</td><td>Incivek</td></tr><tr><td>Telbivudine</td><td>Tyzeka</td></tr><tr><td>Tenofovir</td><td>Viread</td></tr><tr><td>Tipranavir</td><td>Aptivus</td></tr><tr><td>Trifluridine</td><td>Generic, Viroptic</td></tr><tr><td>Valacyclovir</td><td>Generic, Valtrex</td></tr><tr><td>Valganciclovir</td><td>Valcyte</td></tr><tr><td>Zalcitabine (dideoxycytidine, ddC)</td><td>Hivid (withdrawn)</td></tr><tr><td>Zanamivir</td><td>Relenza</td></tr><tr><td>Zidovudine (azidothymidine, AZT)</td><td>Generic, Retrovir</td></tr><tr><td>Zidovudine/lamivudine</td><td>Combivir</td></tr><tr><td>Zidovudine/lamivudine/abacavir</td><td>Trizivir</td></tr></table>
======================================
<table><thead><th></th><th colspan="3">Bacteria</th><th colspan="3">Viruses</th><th colspan="2"></th></thead><thead><th></th><th>Gram- Positive</th><th>Gram- Negative</th><th>Acid-Fast</th><th>Spores</th><th>Lipophilic</th><th>Hydrophilic</th><th>Fungi</th><th>Prions</th></thead><tr><td>Alcohols (isopropanol, ethanol)</td><td>HS</td><td>HS</td><td>Ss</td><td>R</td><td>Ss</td><td>Vv</td><td></td><td>R</td></tr><tr><td>Aldehydes (glutaraldehyde, formaldehyde)</td><td>HS</td><td>HS</td><td>Ms</td><td>S (slow)</td><td></td><td>Ms</td><td></td><td></td></tr><tr><td>Chlorhexidine gluconate</td><td>HS</td><td>MS</td><td></td><td>R</td><td></td><td>R</td><td></td><td>R</td></tr><tr><td>Sodium hypochlorite, chlorine dioxide</td><td>HS</td><td>HS</td><td>Ms</td><td>S (pH 7.6)</td><td></td><td>S (at high conc)</td><td></td><td>MS (at high conc)</td></tr><tr><td>Hexachlorophene</td><td>S (slow)</td><td></td><td></td><td>R</td><td></td><td>R</td><td></td><td>R</td></tr><tr><td>Povidone, iodine</td><td>HS</td><td>HS</td><td></td><td>S (at high conc)</td><td>nw</td><td>R</td><td></td><td>R</td></tr><tr><td>Phenols, quaternary ammo- nium compounds</td><td>HS</td><td>HS</td><td>MS</td><td>R</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Antisepsis</th><th>Application of an agent to living tissue for the purpose of preventing infection</th></thead><tr><td>Decontamination</td><td>Process that produces marked reduction in number or activity of microorganisms</td></tr><tr><td>Disinfection</td><td>Chemical or physical treatment that destroys most vegetative microbes and viruses, but not spores, in or on inanimate surfaces</td></tr><tr><td>Sanitization</td><td>Reduction of microbial load on an inanimate surface to a level considered acceptable for public health purposes</td></tr><tr><td>Sterilization</td><td>A process intended to kill or remove all types of microorganisms, including spores, and usu- ally including viruses, with an acceptably low probability of their survival</td></tr><tr><td>Pasteurization</td><td>A process that kills nonsporulating microor- ganisms by hot water or steam at 65-100°C</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td>NITROIMIDAZOLE + Metronidazole</td><td>Disruption of electron transport chain</td><td>Bactericidal activity against susceptible anaerobic bacteria and protozoa</td><td>Anaerobic infections + vaginitis + Cdifficile colitis</td><td>Oral or IV - hepatic clearance (t), 8 h) + disulfiram-like reaction when given with alcohol - Toxicity: Gastrointestinal upset + metallic taste - neuropathy « seizures</td></tr></table>
======================================
<table><thead><th>+ Fidaxomicin</th><th>Inhibits bacterial RNA polymerase</th><th>Bactericidal in Gram-positive bacteria</th><th>C difficile colitis</th><th>Oral - blood levels negligible + Toxicity: Nonspecific gastrointestinal upset</th></thead><tr><td>RIFAMYCIN + Rifaximin</td><td>Inhibits bacterial RNA polymerase</td><td>Bactericidal activity in Gram-positive and Gram-negative bacteria</td><td>Travelers’ diarrhea, hepatic encephalopathy, C difficile colitis, irritable bowel syndrome</td><td>Oral - blood levels negligible + Toxicity: Nausea</td></tr><tr><td colspan="5">URINARY ANTISEPTI: ics</td></tr><tr><td>+ Nitrofurantoin</td><td>Not fully understood + disrupts protein synthesis and inhibits multiple bacterial enzyme systems</td><td>Bacteriostatic or bactericidal activity against susceptible bacteria</td><td>Uncomplicated urinary tract infections + long-term prophylaxis</td><td>Oral - rapid renal clearance (ty, 0.5 h) « blood levels are negligible - contraindicated in renal failure + Toxicity: Gastrointestinal upset + neuropathies + hypersensitivity pneumonitis</td></tr></table>
======================================
<table><thead><th>__GENERICNAME</th><th>_______AVAILABLEAS</th></thead><tr><td>MISCELLANEOUS</td><td>ANTIMICROBIAL DRUGS</td></tr><tr><td>Colistimethate sodium</td><td>Generic, Coly-Mycin M</td></tr><tr><td>Fidaxomicin</td><td>Dificid</td></tr><tr><td>Methenamine hippurate</td><td>Generic, Hiprex</td></tr><tr><td>Methenamine mandelate</td><td>Generic, Mandelamine</td></tr><tr><td>Metronidazole</td><td>Generic, Flagyl, Metro</td></tr><tr><td>Mupirocin</td><td>Generic, Bactroban, Centany</td></tr><tr><td>Nitrofurantoin</td><td>Generic, Macrodantin, Macrobid</td></tr></table>
======================================
<table><thead><th>Benzalkonium</th><th>Generic, Zephiran</th></thead><tr><td>Benzoyl peroxide</td><td>Generic</td></tr><tr><td>Chlorhexidine gluconate topical</td><td>Generic, Hibiclens, Betasept, others</td></tr><tr><td>Chlorhexidine gluconate, oral rinse: 0.12%</td><td>Peridex, Periogard</td></tr><tr><td>Glutaraldehyde</td><td>Cidex</td></tr><tr><td>lodine aqueous</td><td>Generic, Lugol’s Solution</td></tr><tr><td>lodine tincture</td><td>Generic</td></tr><tr><td>Nitrofurazone</td><td>Generic, Furacin</td></tr><tr><td>Ortho-phthalaldehyde</td><td>Cidex OPA</td></tr><tr><td>Povidone-iodine</td><td>Generic, Betadine</td></tr><tr><td>Silver nitrate</td><td>Generic</td></tr><tr><td>Thimerosal</td><td>Generic, Mersol</td></tr></table>
======================================
<table><tr><td colspan="3">Gram-negative cocci (aerobic)</td></tr><tr><td>Moraxella (Branhamella) catarrhalis</td><td>TMP-SMZ,' cephalosporin (second- or third-generation)”</td><td>Quinolone,’ macrolide*</td></tr><tr><td>Neisseria gonorrhoeae</td><td>Ceftriaxone, cefixime</td><td>Spectinomycin, azithromycin</td></tr><tr><td>Neisseria meningitidis</td><td>Penicillin G</td><td>Chloramphenicol, ceftriaxone, cefotaxime</td></tr><tr><td colspan="3">Gram-negative rods (aerobic)</td></tr><tr><td>E coli, Klebsiella, Proteus</td><td>Cephalosporin (first- or second- generation),? TMP-SMz'</td><td>Quinolone,’ aminoglycoside®</td></tr><tr><td>Enterobacter, Citrobacter, Serratia</td><td>TMP-SMZ,' quinolone,® carbapenem®</td><td>Antipseudomonal penicillin,’ aminoglycoside,’ cefepime</td></tr><tr><td>Shigella</td><td>Quinolone?</td><td>TMP-SMZ,' ampicillin, azithromycin, ceftriaxone</td></tr><tr><td>Salmonella</td><td>Quinolone? ceftriaxone</td><td>Chloramphenicol, ampicillin, TMP-SMZ'</td></tr><tr><td>Campylobacter jejuni</td><td>Erythromycin or azithromycin</td><td>Tetracycline, quinolone®</td></tr><tr><td>Helicobacter pylori</td><td>Proton pump inhibitor + amoxicillin + clarithromycin</td><td>Bismuth + metronidazole + tetracycline + proton pump inhibitor</td></tr><tr><td>Vibrio species</td><td>Tetracycline</td><td>Quinolone,’ TMP-SMZ!</td></tr><tr><td>Pseudomonas aeruginosa</td><td>Antipseudomonal penicillin + aminoglycoside°</td><td>Antipseudomonal penicillin + quinolone,* cefepime, ceftazidime, antipseudomonal carbapenem,° or aztreonam + aminoglycoside</td></tr><tr><td>Burkholderia cepacia (formerly Pseudomonas</td><td>TMP-SMZ'</td><td>Ceftazidime, chloramphenicol</td></tr><tr><td>cepacia) Stenotrophomonas maltophilia (formerly</td><td>TMP-SMZ'</td><td>Minocycline, ticarcillin-clavulanate, tigecycline, ceftazidime,</td></tr><tr><td>Xanthomonas maltophilia)</td><td></td><td>quinolone®</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Legionella species</td><td>Azithromycin or quinolone®</td><td>Clarithromycin, erythromycin</td></tr><tr><td colspan="3">Gram-positive cocci (aerobic)</td></tr><tr><td>Streptococcus pneumoniae</td><td>Penicillin®</td><td>Doxycycline, ceftriaxone, antipneumococcal quinolone,*</td></tr><tr><td>Streptococcus pyogenes (group A)</td><td>Penicillin, clindamycin</td><td>Erythromycin, cephalosporin (first-generation)</td></tr><tr><td>Streptococcus agalactiae (group B)</td><td>Penicillin + aminoglycoside’)</td><td>Vancomycin</td></tr><tr><td>Viridans streptococci</td><td>Penicillin</td><td>Cephalosporin (first- or third-generation),? vancomycin</td></tr><tr><td colspan="3">Staphylococcus aureus</td></tr><tr><td>B-Lactamase negative</td><td>Penicillin</td><td>Cephalosporin (first-generation), vancomycin</td></tr><tr><td>B-Lactamase positive</td><td>Penicillinase-resistant penicillin</td><td>As above</td></tr><tr><td>Methicillin-resistant</td><td>Vancomycin</td><td>TMP-SMZ,' minocycline, linezolid, daptomycin, tigecycline</td></tr><tr><td>Enterococcus species’</td><td>Penicillin + aminoglycoside”</td><td>Vancomycin + aminoglycoside”</td></tr><tr><td colspan="3">Gram-positive rods (aerobic)</td></tr><tr><td>Bacillus species (non-anthracis)</td><td>Vancomycin</td><td>Imipenem, quinolone,® clindamycin</td></tr><tr><td>Listeria species</td><td>Ampicillin (+ aminoglycoside’)</td><td>TMP-SMZ'</td></tr><tr><td>Nocardia species</td><td>Sulfadiazine, TMP-SMZ'</td><td>Minocycline, imipenem, amikacin, linezolid</td></tr><tr><td>Anaerobic bacteria</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Suspected or Proven Disease or Pathogen</th><th></th><th>Alternative Drugs</th></thead><tr><td colspan="3">Mycobacteria</td></tr><tr><td>Mycobacterium tuberculosis</td><td>Isoniazid + rifampin + ethambutol + pyrazinamide</td><td>Streptomycin, moxifloxacin, amikacin, ethionamide, cycloserine, PAS, linezolid</td></tr><tr><td colspan="3">Mycobacterium leprae</td></tr><tr><td>Multibacillary</td><td>Dapsone + rifampin + clofazimine</td><td></td></tr><tr><td>Paucibacillary</td><td>Dapsone + rifampin</td><td></td></tr><tr><td>Mycoplasma pneumoniae</td><td>Tetracycline, erythromycin</td><td>Azithromycin, clarithromycin, quinolone®</td></tr><tr><td colspan="3">Chlamydia</td></tr><tr><td>C trachomatis</td><td>Tetracycline, azithromycin</td><td>Clindamycin, ofloxacin</td></tr><tr><td>C pneumoniae</td><td>Tetracycline, erythromycin</td><td>Clarithromycin, azithromycin</td></tr><tr><td>C psittaci</td><td>Tetracycline</td><td>Chloramphenicol</td></tr><tr><td colspan="3">Spirochetes</td></tr><tr><td>Borrelia recurrentis</td><td>Doxycycline</td><td>Erythromycin, chloramphenicol, penicillin</td></tr><tr><td colspan="3">Borrelia burgdorferi</td></tr><tr><td>Early</td><td>Doxycycline, amoxicillin</td><td>Cefuroxime axetil, penicillin</td></tr><tr><td>Late</td><td>Ceftriaxone</td><td></td></tr><tr><td>Leptospira species</td><td>Penicillin</td><td>Tetracycline</td></tr><tr><td>Treponema species</td><td>Penicillin</td><td>Tetracycline, azithromycin, ceftriaxone</td></tr><tr><td colspan="3">Fungi</td></tr><tr><td>Aspergillus species</td><td>Voriconazole</td><td>Amphotericin B, itraconazole, caspofungin, isavuconazole</td></tr><tr><td>Blastomyces species</td><td>Amphotericin B</td><td>Itraconazole, fluconazole</td></tr><tr><td>Candida species</td><td>Amphotericin B, echinocandin"</td><td>Fluconazole, itraconazole, voriconazole</td></tr><tr><td>Cryptococcus neoformans</td><td>Amphotericin B + flucytosine (5-FC)</td><td>Fluconazole, voriconazole</td></tr><tr><td>Coccidioides immitis</td><td>Amphotericin B</td><td>Fluconazole, itraconazole, voriconazole, posaconazole</td></tr><tr><td>Histoplasma capsulatum</td><td>Amphotericin B</td><td>Itraconazole</td></tr><tr><td>Mucoraceae (Rhizopus, Absidia)</td><td>Amphotericin B</td><td>Posaconazole, isavuconazole</td></tr><tr><td>Sporothrix schenckii</td><td>Amphotericin B</td><td>Itraconazole</td></tr></table>
======================================
<table><thead><th>Presumed Site of Infection</th><th>Common Pathogens</th><th>Drugs of First Choice</th><th>Alternative Drugs</th></thead><tr><td colspan="4">Bacterial endocarditis</td></tr><tr><td>Acute</td><td>Staphylococcus aureus</td><td>Vancomycin + ceftriaxone</td><td>Penicillinase-resistant penicillin’ + gentamicin</td></tr><tr><td>Subacute</td><td>Viridans streptococci, enterococci</td><td>Penicillin + gentamicin</td><td>Vancomycin + gentamicin</td></tr><tr><td>Child</td><td>Haemophilus influenzae, S aureus, B-hemolytic streptococci</td><td>Vancomycin + ceftriaxone</td><td>Vancomycin + ampicillin-sulbactam or ertapenem</td></tr><tr><td>Adult</td><td>S aureus, Enterobacteriaceae, Neisseria gonorrhoeae</td><td>Vancomycin + ceftriaxone</td><td>Vancomycin + ertapenem, or quinolone</td></tr><tr><td>Acute otitis media, sinusitis</td><td>Hinfluenzae, Streptococcus pneumoniae, Moraxella catarrhalis</td><td>Amoxicillin</td><td>Amoxicillin-clavulanate, cefuroxime axetil, TMP-SMZ</td></tr><tr><td>Cellulitis</td><td>S aureus, group A streptococcus</td><td>Penicillinase-resistant penicillin, cephalosporin (first-generation)</td><td>Vancomycin, clindamycin, linezolid, daptomycin</td></tr><tr><td colspan="4">Meningitis</td></tr><tr><td>Neonate</td><td>Group B streptococcus, Escherichia</td><td>Ampicillin + cephalosporin</td><td>Ampicillin + aminoglycoside,</td></tr><tr><td></td><td>coli, Listeria</td><td>(third-generation)</td><td>chloramphenicol, meropenem</td></tr><tr><td>Child</td><td>Hinfluenzae, pneumococcus, meningococcus</td><td>Ceftriaxone or cefotaxime + vancomycin?</td><td>Chloramphenicol, meropenem</td></tr><tr><td>Adult</td><td>Pneumococcus, meningococcus</td><td>Ceftriaxone, cefotaxime</td><td>Vancomycin + ceftriaxone or cefotaxime®</td></tr><tr><td>Peritonitis due to ruptured viscus</td><td>Coliforms, Bacteroides fragilis</td><td>Metronidazole + cephalosporin (third-generation), piperacillin/ tazobactam</td><td>Carbapenem, tigecycline</td></tr><tr><td colspan="4">Pneumonia</td></tr><tr><td>Neonate</td><td>As in neonatal meningitis</td><td></td><td></td></tr><tr><td>Child</td><td>Pneumococcus, S aureus, Hinfluenzae</td><td>Ceftriaxone, cefuroxime, cefotaxime</td><td>Ampicillin-sulbactam</td></tr><tr><td rowspan="2">Adult (community-acquired)</td><td>Pneumococcus, Mycoplasma, Legionella, H influenzae, S aureus, Chlamydophila pneumonia, coliforms</td><td>Outpatient: Macrolide,* amoxicillin, tetracycline</td><td>Outpatient: Quinolone</td></tr><tr><td></td><td></td><td>Inpatient: Macrolide* + cefotaxime, ceftriaxone, ertapenem, or ampicillin</td><td>Inpatient: Doxycycline + cefotaxime, ceftriaxone, ertapenem, or ampicillin; respiratory quinolone”</td></tr><tr><td>Septicemia®</td><td>Any</td><td colspan="2">Vancomycin + cephalosporin (third-generation) or piperacillin/tazobactam or imipenem or meropenem</td></tr><tr><td>Septicemia with granulocytopenia</td><td>Any</td><td colspan="2">Antipseudomonal penicillin + aminoglycoside; ceftazidime; cefepime; imipenem or meropenem; consider addition of systemic antifungal therapy if fever persists beyond 5 days of empiric therapy</td></tr></table>
======================================
<table><thead><th>Bactericidal Agents</th><th>Bacteriostatic Agents</th></thead><tr><td>Aminoglycosides</td><td>Chloramphenicol</td></tr><tr><td>Bacitracin</td><td>Clindamycin</td></tr><tr><td>B-Lactam antibiotics</td><td>Ethambutol</td></tr><tr><td>Daptomycin</td><td>Macrolides</td></tr><tr><td>Fosfomycin</td><td>Nitrofurantoin</td></tr><tr><td>Glycopeptide antibiotics</td><td>Novobiocin</td></tr><tr><td>Isoniazid</td><td>Oxazolidinones</td></tr><tr><td>Ketolides</td><td>Sulfonamides</td></tr><tr><td>Metronidazole</td><td>Tetracyclines</td></tr><tr><td>Polymyxins</td><td>Tigecycline</td></tr><tr><td>Pyrazinamide</td><td>Trimethoprim</td></tr><tr><td colspan="2">Quinolones</td></tr><tr><td colspan="2">Rifampin</td></tr><tr><td>Streptogramins</td><td></td></tr></table>
======================================
<table><thead><th>Against Gram-Positive Cocci</th><th>Against Gram-Negative Bacilli</th></thead><tr><td>Aminoglycosides</td><td>Aminoglycosides</td></tr><tr><td>Carbapenems</td><td>Carbapenems</td></tr><tr><td>Cephalosporins</td><td>Chloramphenicol</td></tr><tr><td>Chloramphenicol</td><td>Quinolones</td></tr><tr><td>Clindamycin</td><td>Rifampin</td></tr><tr><td>Daptomycin</td><td>Tetracyclines</td></tr><tr><td>Glycopeptide antibiotics</td><td>Tigecycline</td></tr><tr><td colspan="2">Ketolides</td></tr><tr><td colspan="2">Macrolides</td></tr><tr><td colspan="2">Oxazolidinones</td></tr><tr><td colspan="2">Penicillins</td></tr><tr><td colspan="2">Quinolones</td></tr><tr><td colspan="2">Rifampin</td></tr><tr><td colspan="2">Streptogramins</td></tr><tr><td colspan="2">Sulfonamides</td></tr><tr><td colspan="2">Tetracyclines</td></tr><tr><td colspan="2">Tigecycline</td></tr><tr><td>Trimethoprim</td><td></td></tr></table>
======================================
<table><thead><th>Dosage Adjustment Needed in Renal Impairment</th><th>Contraindicated in Renal Impairment</th><th>Dosage Adjustment Needed in Hepatic Impairment</th></thead><tr><td>Acyclovir, amantadine, aminoglycosides, aztreonam, carbapenems, cephalosporins,’ clarithromycin, colistin, cycloserine, dalbavancin, daptomycin, didanosine, emtricitabine, ethambutol, ethionamide, famciclovir, fluconazole, flucytosine, foscarnet, ganciclovir, lamivudine, oseltamivir, penicillins,” peramivir, polymyxin B, pyrazinamide, quinolones, ribavirin, rifabutin, rimantadine, stavudine, telavancin, telbivudine, telithromycin, tenofovir, terbinafine, trimethoprim- sulfamethoxazole, valacyclovir, vancomycin, zidovudine</td><td>Cidofovir, methenamine, nalidixic acid, nitrofurantoin, sulfonamides (long-acting), tetracyclines*</td><td>Abacavir, atazanavir, caspofungin, chloramphenicol, clindamycin, erythromycin, fosamprenavir, indinavir, metronidazole, rimantadine, tigecycline</td></tr></table>
======================================
<table><thead><th>Antimicrobial Agent</th><th>CSF Concentration (Uninflamed Meninges) as % of Serum Concentration</th><th>CSF Concentration (Inflamed Meninges) as % of Serum Concentration</th></thead><tr><td>Ampicillin</td><td>2-3</td><td>2-100</td></tr><tr><td>Aztreonam</td><td></td><td></td></tr><tr><td>Cefepime</td><td></td><td></td></tr><tr><td>Cefotaxime</td><td></td><td></td></tr><tr><td>Ceftazidime</td><td></td><td></td></tr><tr><td>Ceftriaxone</td><td></td><td></td></tr><tr><td>Cefuroxime</td><td></td><td></td></tr><tr><td>Ciprofloxacin</td><td></td><td></td></tr><tr><td>Imipenem</td><td></td><td></td></tr><tr><td>Meropenem</td><td></td><td></td></tr><tr><td>Nafcillin</td><td></td><td></td></tr><tr><td>Penicillin G</td><td></td><td></td></tr><tr><td>Sulfamethoxazole</td><td></td><td></td></tr><tr><td>Trimethoprim</td><td></td><td></td></tr><tr><td>Vancomycin</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Type of Operation</th><th>Common Pathogens</th><th>Drug of Choice</th></thead><tr><td>Cardiac (with median sternotomy)</td><td>Staphylococci, enteric Gram-negative rods</td><td>Cefazolin</td></tr><tr><td>Noncardiac, thoracic</td><td>Staphylococci, streptococci, enteric Gram-negative rods</td><td>Cefazolin</td></tr><tr><td>Vascular (abdominal and lower extremity)</td><td>Staphylococci, enteric Gram-negative rods</td><td>Cefazolin</td></tr><tr><td>Neurosurgical (craniotomy)</td><td>Staphylococci</td><td>Cefazolin</td></tr><tr><td>Orthopedic (with hardware insertion)</td><td>Staphylococci</td><td>Cefazolin</td></tr><tr><td>Head and neck (with entry into the oropharynx)</td><td>Staphylococcus aureus, oral flora</td><td>Cefazolin + metronidazole</td></tr><tr><td>Gastroduodenal</td><td>S aureus, oral flora, enteric Gram-negative rods</td><td>Cefazolin</td></tr><tr><td>Biliary tract</td><td>S aureus, enterococci, enteric Gram-negative rods</td><td>Cefazolin</td></tr><tr><td>Colorectal (elective surgery)</td><td>Enteric Gram-negative rods, anaerobes</td><td>Oral erythromycin + neomycin’</td></tr><tr><td>Colorectal (emergency surgery or obstruction)</td><td>Enteric Gram-negative rods, anaerobes</td><td>Cefoxitin, cefotetan, ertapenem, or cefazolin + metronidazole</td></tr><tr><td>Appendectomy, nonperforated</td><td>Enteric Gram-negative rods, anaerobes</td><td>Cefoxitin, cefotetan, or cefazolin + metronidazole</td></tr><tr><td>Hysterectomy</td><td>Enteric Gram-negative rods, anaerobes, enterococci, group B streptococci</td><td>Cefazolin, cefotetan, or cefoxitin</td></tr><tr><td>Cesarean section</td><td>Enteric Gram-negative rods, anaerobes, enterococci, group B streptococci</td><td>Cefazolin</td></tr></table>
======================================
<table><thead><th>Prevented</th><th>Indication(s)</th><th>Drug of Choice</th><th>Efficacy</th></thead><tr><td>Anthrax</td><td>Suspected exposure</td><td>Ciprofloxacin or doxycycline</td><td>Proposed effective</td></tr><tr><td>Cholera</td><td>Close contacts of a case</td><td>Tetracycline</td><td>Proposed effective</td></tr><tr><td>Diphtheria</td><td>Unimmunized contacts</td><td>Penicillin or erythromycin</td><td>Proposed effective</td></tr><tr><td>Endocarditis</td><td>Dental, oral, or upper respiratory tract procedures’ in at-risk patients</td><td>Amoxicillin or clindamycin</td><td>Proposed effective</td></tr><tr><td>Genital herpes simplex</td><td>Recurrent infection (24 episodes per year)</td><td>Acyclovir</td><td>Excellent</td></tr><tr><td>Perinatal herpes simplex type 2 infection</td><td>Mothers with primary HSV or frequent recurrent genital HSV</td><td>Acyclovir</td><td>Proposed effective</td></tr><tr><td>Group B streptococcal (GBS) infection</td><td>Mothers with cervical or vaginal GBS colonization and their newborns with one or more of the following: (a) onset of labor or membrane rupture before 37 weeks’ ges- tation, (b) prolonged rupture of membranes (&gt;12 hours), (c) maternal intrapartum fever, (d) history of GBS bacteri- uria during pregnancy, (e) mothers who have given birth to infants who had early GBS disease or with a history of streptococcal bacteriuria during pregnancy</td><td>Ampicillin or penicillin</td><td>Excellent</td></tr><tr><td>Haemophilus influenzae type B infection</td><td>Close contacts of a case in incompletely immunized children (&gt;48 months old)</td><td>Rifampin</td><td>Excellent</td></tr><tr><td rowspan="4">HIV infection Influenza A and B</td><td>Health care workers exposed to blood after needle-stick injury</td><td>Tenofovir/emtricitabine and raltegravir</td><td>Good</td></tr><tr><td></td><td>Pregnant HIV-infected women who are at =14 weeks of newborns of HIV-infected women for the first</td><td>HAART?</td><td>Excellent</td></tr><tr><td></td><td>gestation; 6 weeks of life, beginning 8-12 hours after birth Unvaccinated</td><td>Oseltamivir</td><td>Good</td></tr><tr><td></td><td>geriatric patients, imnmunocompromised hosts, and health care workers during outbreaks</td><td></td><td></td></tr><tr><td rowspan="2">Malaria</td><td>Travelers to areas endemic for chloroquine-susceptible disease</td><td>Chloroquine</td><td>Excellent</td></tr><tr><td></td><td>Travelers to areas endemic for chloroquine-resistant disease</td><td>Mefloquine, doxycycline, or atovaquone/proguanil</td><td>Excellent</td></tr><tr><td>Meningococcal infection</td><td>Close contacts of a case</td><td>Rifampin, ciprofloxacin, or ceftriaxone</td><td>Excellent</td></tr><tr><td>Mycobacterium avium complex</td><td>HIV-infected patients with CD4 count &lt;75/uL</td><td>Azithromycin, clarithromycin, or rifabutin</td><td>Excellent</td></tr><tr><td>Otitis media</td><td>Recurrent infection</td><td>Amoxicillin</td><td>Good</td></tr><tr><td>Pertussis</td><td>Close contacts of a case</td><td>Azithromycin</td><td>Excellent</td></tr><tr><td>Plague</td><td>Close contacts of a case</td><td>Tetracycline</td><td>Proposed effective</td></tr><tr><td>Pneumococcemia</td><td>Children with sickle cell disease or asplenia</td><td>Penicillin</td><td>Excellent</td></tr><tr><td>Pneumocystis jiroveci pneumonia (PCP)</td><td>High-risk patients (eg, AIDS, leukemia, transplant)</td><td>Trimethoprim-sulfamethoxa- zole, dapsone, or atovaquone</td><td>Excellent</td></tr><tr><td>Rheumatic fever</td><td>History of rheumatic fever or known rheumatic heart disease</td><td>Benzathine penicillin</td><td>Excellent</td></tr><tr><td>Toxoplasmosis</td><td>HIV-infected patients with IgG antibody to Toxoplasma and CD4 count &lt;100/uL</td><td>Trimethoprim- sulfamethoxazole</td><td>Good</td></tr><tr><td>Tuberculosis</td><td>Persons with positive tuberculin skin tests and one or more of the following: (a) HIV infection, (b) close contacts with newly diagnosed disease, (c) recent s
======================================
kin test conver-</td><td>Isoniazid or rifampin or iso- niazid + rifapentine</td><td>Excellent</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Class</th><th>Use</th></thead><tr><td>Chloroquine</td><td>4-Aminoquinoline</td><td>Treatment and chemoprophylaxis of infection with sensitive parasites</td></tr><tr><td>Amodiaquine'</td><td>4-Aminoquinoline</td><td>Treatment of infection with some chloroquine-resistant P falciparum strains and in fixed combination with artesunate</td></tr><tr><td>Piperaquine’</td><td>Bisquinoline</td><td>Treatment of P falciparum infection in fixed combination with dihydroartemisinin</td></tr><tr><td>Quinine</td><td>Quinoline methanol</td><td>Oral and intravenous’ treatment of P falciparum infections</td></tr><tr><td>Quinidine</td><td>Quinoline methanol</td><td>Intravenous therapy of severe infections with P falciparum</td></tr><tr><td>Mefloquine</td><td>Quinoline methanol</td><td>Chemoprophylaxis and treatment of infections with P falciparum</td></tr><tr><td>Primaquine</td><td>8-Aminoquinoline</td><td>Radical cure and terminal prophylaxis of infections with P vivax and P ovale; alternative chemoprophylaxis for all species</td></tr><tr><td>Sulfadoxine-pyrimethamine (Fansidar)</td><td>Folate antagonist combination</td><td>Treatment of infections with some chloroquine-resistant P falciparum, including combination with artesunate; intermittent preventive therapy in endemic areas</td></tr><tr><td>Atovaquone-proguanil (Malarone)</td><td>Quinone-folate antagonist combination</td><td>Treatment and chemoprophylaxis of P falciparum infection</td></tr><tr><td>Doxycycline</td><td>Tetracycline</td><td>Treatment (with quinine) of infections with P falciparum; chemoprophylaxis</td></tr><tr><td>Halofantrine'</td><td>Phenanthrene methanol</td><td>Treatment of P falciparum infections</td></tr><tr><td>Lumefantrine”</td><td>Amyl alcohol</td><td>Treatment of P falciparum malaria in fixed combination with artemether (Coartem)</td></tr><tr><td>Pyronaridine</td><td>Mannich base acridine</td><td>Treatment of P falciparum malaria in fixed combination with artesunate (Pyramax)</td></tr><tr><td>Artemisinins (artesunate, artemether,” dihydroartemisinin')</td><td>Sesquiterpene lactone endoperoxides</td><td>Treatment of P falciparum infections; oral combination therapies for uncomplicate disease; intravenous artesunate for severe disease</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Use”</th><th>Adult Dosage*</th></thead><tr><td>Chloroquine</td><td>Areas without resistant P falciparum</td><td>500 mg weekly</td></tr><tr><td>Malarone</td><td>Areas with chloroquine-resistant P falciparum</td><td>1 tablet (250 mg atovaquone/100 mg proguanil) daily</td></tr><tr><td>Mefloquine</td><td>Areas with chloroquine-resistant P falciparum</td><td>250 mg weekly</td></tr><tr><td>Doxycycline</td><td>Areas with multidrug-resistant P falciparum</td><td>100 mg daily</td></tr><tr><td>Primaquine*</td><td>Terminal prophylaxis of P vivax and P ovale infections; alternative for primary prevention</td><td>52.6 mg (30 mg base) daily for 14 days after travel; for primary prevention 52.6 mg (30 mg base) daily</td></tr></table>
======================================
<table><tr><td rowspan="2">Chloroquine-sensitive P falciparum and P malariae infections</td><td>Chloroquine phosphate, 1 g, followed by 500 mg at 6, 24, and 48 hours or</td><td></td></tr><tr><td></td><td>Chloroquine phosphate, 1 g at 0 and 24 hours, then 0.5 g at 48 hours</td><td></td></tr><tr><td>P vivax and P ovale infections</td><td>Chloroquine (as above), then (if G6PD normal) primaquine, 52.6 mg (30 mg base) for 14 days</td><td>For infections from Indonesia, Papua New Guinea, and other areas with suspected resistance: therapies listed for uncomplicated chloroquine-resistant P falciparum plus primaquine</td></tr><tr><td rowspan="6">Uncomplicated infections with chloroquine-resistant P falciparum</td><td rowspan="6">Coartem (artemether, 20 mg, plus lumefantrine, 120 mg), four tablets twice daily for 3 days</td><td>Malarone, four tablets (total of 1 g atovaquone, 400 mg proguanil) daily for 3 days</td></tr><tr><td></td><td></td><td>or</td></tr><tr><td></td><td></td><td>Mefloquine, 15 mg/kg once or 750 mg, then 500 mg in 6-8 hours</td></tr><tr><td></td><td></td><td>or Quinine sulfate, 650 mg 3 times daily for 3 days, plus doxycycline, 100 mg twice daily for 7 days, or clindamycin, 600 mg twice daily for 7 days</td></tr><tr><td></td><td></td><td>or</td></tr><tr><td></td><td></td><td>Other artemisinin-based combination regimens (see Table 52-4)</td></tr><tr><td rowspan="3">Severe or complicated infections with P falciparum</td><td>Artesunate,” 2.4 mg/kg IV, every 12 hours for 1 day, then daily for 2 additional days; follow with</td><td>Artemether,’ 3.2 mg/kg IM, then 1.6 mg/kg/d IM; follow with oral therapy as for artesunate</td></tr><tr><td></td><td>7-day oral course of doxycycline or clindamycin or full treatment course of Coartem, Malarone, or mefloquine or Quinidine gluconate,** 10 mg/kg IV over 1-2 hours, then 0.02 mg/kg IV/min or</td><td>or Quinine dihydrochloride,*° 20 mg/kg IV, then 10 mg/kg every 8 hours</td></tr><tr><td></td><td>Quinidine gluconate** 15 mg/kg IV over 4 hours, then 7.5 mg/kg IV over 4 hours every 8 hours</td><td></td></tr></table>
======================================
<table><thead><th>Regimen</th><th>Notes</th></thead><tr><td>Artemether-lumefantrine (Coartem, Riamet)</td><td>Co-formulated; first-line therapy in many countries; approved in the USA</td></tr><tr><td>Artesunate-amodiaquine (ASAQ, Arsucam, Coarsucam)</td><td>Co-formulated; first-line therapy in many African countries</td></tr><tr><td>Artesunate-mefloquine</td><td>Co-formulated; first-line therapy in parts of Southeast Asia and South America</td></tr><tr><td>Dihydroartemisinin-pipera- quine (Artekin, Duocotecxin) Artesunate-sulfadoxine-</td><td>Co-formulated; first-line therapy in some countries in Southeast Asia First-line therapy in countries,</td></tr><tr><td>pyrimethamine</td><td>but efficacy lower than other regimens in most areas</td></tr></table>
======================================
<table><thead><th rowspan="6">Clinical Setting Asymptomatic intestinal infection</th><th>Drugs of Choice</th><th>and Adult Dosage</th><th>Alternative Drugs and Adult Dosage</th></thead><thead><th></th><th colspan="2">Luminal agent: Diloxanide furoate,” 500 mg 3 times daily</th><th></th></thead><thead><th></th><th>for 10 days</th><th>or</th><th></th></thead><thead><th></th><th>650</th><th>3 times for 21</th><th></th></thead><thead><th></th><th>lodoquinol, mg</th><th>daily days or</th><th></th></thead><thead><th></th><th>10</th><th>3 times for 7</th><th></th></thead><tr><td rowspan="6">Mild to moderate intestinal infection</td><td>Paromomycin, Metronidazole, 750</td><td>mg/kg daily days mg 3 times daily (or 500 mg IV every</td><td>Luminal agent (see above)</td></tr><tr><td></td><td colspan="2">6 hours) for 10 days</td><td>plus either</td></tr><tr><td></td><td></td><td>or</td><td>250 3 times for 10</td></tr><tr><td></td><td colspan="2">Tinidazole, 2 g daily for 3 days</td><td>Tetracycline, mg daily days or</td></tr><tr><td></td><td colspan="2" rowspan="2">plus Luminal (see above)</td><td>500 4 times for 10</td></tr><tr><td></td><td colspan="2"></td><td>Erythromycin, mg daily days</td></tr><tr><td>Severe intestinal</td><td>agent Metronidazole, 750</td><td>3 times daily (or 500 IV</td><td>Luminal agent (see above)</td></tr><tr><td rowspan="5">infection</td><td></td><td>6 hours) for 10 days</td><td>mg mg every</td><td>plus either</td></tr><tr><td></td><td>2</td><td>or for 3</td><td>250 3 times for 10</td></tr><tr><td></td><td colspan="2" rowspan="2">Tinidazole, g daily days plus</td><td colspan="2"></td><td>Tetracycline, mg daily days or</td></tr><tr><td>Dehydroemetine’ or emetine,” 1 mg/kg SC or IM for</td></tr><tr><td></td><td>Luminal agent (see</td><td>above)</td><td>3-5 days</td></tr><tr><td>Hepatic abscess, ameboma, and other</td><td>Metronidazole, 750 6 hours) for 10 days</td><td>mg 3 times daily (or 500 mg IV every</td><td>Dehydroemetine” or emetine,’ 1 mg/kg SC or IM for 8-10 days, followed by (liver abscess only) chloroquine,</td></tr><tr><td>extraintestinal disease</td><td></td><td>or</td><td>500 mg twice daily for 2 days, then 500 mg daily for</td></tr><tr><td colspan="4"></td></tr><tr><td></td><td>Tinidazole, 2 g daily</td><td>for 5 days plus</td><td>21 days plus</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Luminal agent (see</td><td>above)</td><td>Luminal agent (see above)</td></tr></table>
======================================
<table><thead><th>Disease</th><th>Stage</th><th>First-Line Drugs</th><th>Alternative Drugs</th></thead><tr><td rowspan="2">West African</td><td>Early</td><td>Pentamidine</td><td>Suramin, eflornithine</td></tr><tr><td></td><td>CNS involvement</td><td>Eflornithine</td><td>Melarsoprol,’ eflornithine-nifurtimox'</td></tr><tr><td rowspan="2">East African</td><td>Early</td><td>Suramin'</td><td>Pentamidine</td></tr><tr><td></td><td>CNS involvement</td><td>Melarsoprol'</td><td></td></tr></table>
======================================
<table><thead><th>Organism or Clinical Setting</th><th>Drugs of Choice”</th><th>Alternative Drugs</th></thead><tr><td rowspan="2">Babesia species</td><td>Clindamycin, 600 mg 3 times daily for 7 days plus</td><td>Atovaquone or azithromycin</td></tr><tr><td></td><td>Quinine, 650 mg for 7 days</td><td></td></tr><tr><td>Balantidium coli</td><td>Tetracycline, 500 mg 4 times daily for 10 days</td><td>Metronidazole, 750 mg 3 times daily for 5 days</td></tr><tr><td>Cryptosporidium species</td><td>Paromomycin, 500-750 mg 3 or 4 times daily for 10 days</td><td>Azithromycin, 500 mg daily for 21 days</td></tr><tr><td>Cyclospora cayetanensis</td><td>Trimethoprim-sulfamethoxazole, one double-strength tablet 4 times daily for 7-14 days</td><td></td></tr><tr><td rowspan="2">Dientamoeba fragilis</td><td>lodoquinol, 650 mg 3 times daily for 20 days</td><td>Tetracycline, 500 mg 4 times daily for 10 days or</td></tr><tr><td></td><td></td><td>Paromomycin, 500 mg 3 times daily for 7 days</td></tr><tr><td>Giardia lamblia</td><td>Metronidazole, 250 mg 3 times daily or 500 mg twice daily for 5 days or</td><td>Furazolidone, 100 mg 4 times daily for 7 days or</td></tr><tr><td></td><td>Tinidazole, 2 g once</td><td>Albendazole, 400 mg daily for 5 days</td></tr><tr><td rowspan="3">Isospora belli</td><td>Trimethoprim-sulfamethoxazole, one double-strength tablet 4 times daily for 10 days, then twice daily for 21 days</td><td>Pyrimethamine, 75 mg daily for 14 days</td></tr><tr><td></td><td></td><td>plus</td></tr><tr><td></td><td></td><td>Folinic acid, 10 mg daily for 14 days</td></tr><tr><td>Microsporidia</td><td>Albendazole, 400 mg twice daily for 20-30 days</td><td></td></tr><tr><td rowspan="9">Leishmaniasis* Visceral (L donovani, L chagasi, L infan- tum) or mucosal (L braziliensis)</td><td></td><td></td></tr><tr><td></td><td>Sodium stibogluconate, 20 mg/kg/d IV or IM for 28 days</td><td>Meglumine antimoniate</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td>or Amphotericin (liposomal preparations preferred (3 mg/kg/d IV on and various other</td><td>or Pentamidine, 2-4 mg/kg IM daily or every other for to 15 doses</td></tr><tr><td></td><td>days 1-5, 14, 21)); dosing regimens, including single dose</td><td>day up or</td></tr><tr><td></td><td>or</td><td>Combinations of listed drugs</td></tr><tr><td></td><td>Miltefosine, 2.5 mg/kg/d for 28 days</td><td></td></tr><tr><td></td><td>or</td><td></td></tr><tr><td></td><td>Paromomycin,15 mg/kg for 21 days</td><td></td></tr><tr><td rowspan="5">Cutaneous (L major, L tropica, L mexicana, L braziliensis)</td><td>Sodium stibogluconate, 20 mg/kg/d IV or IM for 20 days</td><td>Meglumine antimoniate</td></tr><tr><td></td><td></td><td>or</td></tr><tr><td></td><td></td><td>Miltefosine</td></tr><tr><td></td><td></td><td>or</td></tr><tr><td></td><td></td><td>Topical or intralesional therapies</td></tr><tr><td rowspan="3">Pneumocystis jiroveci, P carinii</td><td>Trimethoprim-sulfamethoxazole, 15-20 mg trimethoprim component/kg/d IV, or two double-strength tablets every 8 hours for 21 days</td><td>Pentamidine or</td></tr><tr><td></td><td></td><td>Trimethoprim-dapsone or</td></tr><tr><td></td><td></td><td>Clindamycin plus primaquine</td></tr></table>
======================================
<table><thead><th>Organism or Clinical Setting</th><th></th><th>Alternative Drugs</th></thead><tr><td rowspan="3">Trichomonas vaginalis</td><td>g once or 250 mg 3 times daily for 7 days</td><td></td></tr><tr><td></td><td>or</td><td></td></tr><tr><td></td><td>once</td><td></td></tr><tr><td rowspan="3">Trypanosoma cruzi</td><td></td><td></td></tr><tr><td></td><td>or</td><td></td></tr><tr><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>Artemether/lumefantrine</td><td>Coartem, Riamet</td></tr><tr><td colspan="2">Artesunate”</td></tr><tr><td>Artesunate-pyronaridine</td><td>Pyramax</td></tr><tr><td>Atovaquone</td><td>Generic, Mepron</td></tr><tr><td>Atovaquone-proguanil</td><td>Malarone</td></tr><tr><td colspan="2">Benznidazole”</td></tr><tr><td>Chloroquine</td><td>Generic, Aralen</td></tr><tr><td>Clindamycin</td><td>Generic, Cleocin</td></tr><tr><td>Doxycycline</td><td>Generic, Vibramycin</td></tr><tr><td>Eflornithine</td><td>Vaniqa, Ornidyl</td></tr><tr><td>lodoquinol</td><td>Diquinol, Yodoxin</td></tr><tr><td>Mefloquine</td><td>Generic, Lariam</td></tr><tr><td>Melarsoprol”</td><td>Mel B</td></tr><tr><td>Metronidazole</td><td>Generic, Flagyl</td></tr><tr><td colspan="2">Nifurtimox”</td></tr><tr><td>Nitazoxanide</td><td>Alinia</td></tr><tr><td>Paromomycin</td><td>Generic, Humatin</td></tr><tr><td>Pentamidine</td><td>Pentam 300, Pentacarinat, pentami- dine isethionate, Nebupent (aerosol)</td></tr><tr><td>Primaquine</td><td>Generic</td></tr><tr><td>Pyrimethamine</td><td>Daraprim</td></tr><tr><td>Quinidine gluconate</td><td>Generic</td></tr><tr><td>Quinine</td><td>Generic</td></tr><tr><td colspan="2">Sodium stibogluconate™</td></tr><tr><td>Sulfadoxine-pyrimethamine</td><td>Fansidar</td></tr><tr><td colspan="2">Suramin’</td></tr><tr><td>Tinidazole</td><td>Generic, Tindamax</td></tr></table>
======================================
<table><thead><th>Infecting Orga</th><th>Drug of Choice</th><th>Alternative Drugs</th></thead><tr><td colspan="3">Roundworms (nematodes)</td></tr><tr><td>Ascaris lumbricoides (roundworm)</td><td>Albendazole or pyrantel pamoate or mebendazole</td><td>Ivermectin, piperazine</td></tr><tr><td>Trichuris trichiura (whipworm)</td><td>Mebendazole or albendazole</td><td>Ivermectin, oxantel pamoate, drug combinations</td></tr><tr><td>Necator americanus (hookworm); Ancylostoma duodenale (hookworm)</td><td>Albendazole or mebendazole or pyrantel pamoate</td><td></td></tr><tr><td>Strongyloides stercoralis (threadworm)</td><td>Ivermectin</td><td>Albendazole or thiabendazole</td></tr><tr><td>Enterobius vermicularis (pinworm)</td><td>Mebendazole or pyrantel pamoate</td><td>Albendazole</td></tr><tr><td>Trichinella spiralis (trichinosis)</td><td>Mebendazole or albendazole; add corticosteroids for severe infection</td><td></td></tr><tr><td>Trichostrongylus species</td><td>Pyrantel pamoate or mebendazole</td><td>Albendazole</td></tr><tr><td>Cutaneous larva migrans (creeping eruption)</td><td>Albendazole or ivermectin</td><td>Thiabendazole (topical)</td></tr><tr><td>Visceral larva migrans</td><td>Albendazole</td><td>Mebendazole</td></tr><tr><td>Angiostrongylus cantonensis</td><td>Albendazole or mebendazole</td><td></td></tr><tr><td>Wuchereria bancrofti (filariasis); Brugia malayi (filariasis); tropical eosinophilia; Loa loa (loiasis)</td><td>Diethylcarbamazine</td><td>Ivermectin</td></tr><tr><td>Onchocerca volvulus (onchocerciasis)</td><td>Ivermectin</td><td></td></tr><tr><td>Dracunculus medinensis (guinea worm)</td><td>Metronidazole</td><td>Thiabendazole or mebendazole</td></tr><tr><td>Capillaria philippinensis (intestinal capillariasis)</td><td>Albendazole</td><td>Mebendazole</td></tr><tr><td colspan="3">Flukes (trematodes)</td></tr><tr><td>Schistosoma haematobium (bilharziasis)</td><td>Praziquantel</td><td>Metrifonate</td></tr><tr><td>Schistosoma mansoni</td><td>Praziquantel</td><td>Oxamniquine</td></tr><tr><td>Schistosoma japonicum</td><td>Praziquantel</td><td></td></tr><tr><td>Clonorchis sinensis (liver fluke); Opisthorchis species</td><td>Praziquantel</td><td>Albendazole</td></tr><tr><td>Paragonimus westermani (lung fluke)</td><td>Praziquantel</td><td>Bithionol</td></tr><tr><td>Fasciola hepatica (sheep liver fluke)</td><td>Bithionol or triclabendazole</td><td></td></tr><tr><td>Fasciolopsis buski (large intestinal fluke)</td><td>Praziquantel or niclosamide</td><td></td></tr><tr><td>Heterophyes heterophyes; Metagonimus yokogawai (small intestinal flukes)</td><td>Praziquantel or niclosamide</td><td></td></tr><tr><td colspan="3">Tapeworms (cestodes)</td></tr><tr><td>Taenia saginata (beef tapeworm)</td><td>Praziquantel or niclosamide</td><td>Mebendazole</td></tr><tr><td>Diphyllobothrium latum (fish tapeworm)</td><td>Praziquantel or niclosamide</td><td></td></tr><tr><td>Taenia solium (pork tapeworm)</td><td>Praziquantel or niclosamide</td><td></td></tr><tr><td>Cysticercosis (pork tapeworm larval stage)</td><td>Albendazole</td><td>Praziquantel</td></tr><tr><td>Hymenolepis nana (dwarf tapeworm)</td><td>Praziquantel</td><td>Niclosamide, nitazoxanide</td></tr><tr><td>Echinococcus granulosus (hydatid disease); Echinococcus multilocularis</td><td>Albendazole</td><td></td></tr></table>
======================================
<table><thead><th>| GENERICNAME</th><th>—AVAILABLEAS</th></thead><tr><td>Albendazole</td><td>Albenza</td></tr><tr><td>Bithionol</td><td>Bitin</td></tr><tr><td>Diethylcarbamazine</td><td>Hetrazan</td></tr><tr><td>Ivermectin</td><td>Mectizan, Stromectol</td></tr><tr><td>Mebendazole</td><td>Generic, Vermox</td></tr><tr><td>Metrifonate</td><td>Trichlorfon, Bilarcil</td></tr><tr><td>Niclosamide</td><td>Niclocide</td></tr><tr><td>Oxamniquine</td><td>Vansil, Mansil</td></tr><tr><td>Oxantel pamoate</td><td>Quantrel</td></tr><tr><td>Oxantel/pyrantel pamoate</td><td>Telopar</td></tr><tr><td>Piperazine</td><td>Generic, Vermizine</td></tr><tr><td>Praziquantel</td><td>Biltricide; others outside the USA</td></tr><tr><td>Pyrantel pamoate</td><td>Ascarel, Pamix, Pin Rid, Pin-X</td></tr><tr><td>Thiabendazole</td><td>Mintezol</td></tr></table>
======================================
<table><tr><td>ABVD</td><td>Doxorubicin (Adriamycin, hydroxydaunorubicin), bleomycin, vinblastine, dacarbazine</td></tr><tr><td>BCNU</td><td>Carmustine</td></tr><tr><td>CCNU</td><td>Lomustine</td></tr><tr><td>CHOP</td><td>Cyclophosphamide, doxorubicin (Adriamycin, hydroxy daunorubicin), vincristine (Oncovin), prednisone</td></tr><tr><td>CMF</td><td>Cyclophosphamide, methotrexate, fluorouracil</td></tr><tr><td>COP</td><td>Cyclophosphamide, vincristine (Oncovin), prednisone</td></tr><tr><td>CRC</td><td>Colorectal cancer</td></tr><tr><td>FAC</td><td>5-Fluorouracil, doxorubicin (Adriamycin, hydroxydau- norubicin), cyclophosphamide</td></tr><tr><td>FEC</td><td>5-Fluorouracil, epirubicin, cyclophosphamide</td></tr><tr><td>5-FU</td><td>5-Fluorouracil</td></tr><tr><td>FOLFIRI</td><td>5-Fluorouracil, leucovorin, irinotecan</td></tr><tr><td>FOLFOX</td><td>5-Fluorouracil, leucovorin, oxaliplatin</td></tr><tr><td></td><td>Melphalan, prednisone</td></tr><tr><td></td><td>6-Mercaptopurine</td></tr><tr><td></td><td>Mechlorethamine, vincristine (Oncovin), procarbazine, prednisone</td></tr><tr><td></td><td>Methotrexate</td></tr><tr><td></td><td>Non-small cell lung cancer</td></tr><tr><td></td><td>Procarbazine, lomustine, vincristine</td></tr><tr><td></td><td>Cisplatin (platinum), etoposide, bleomycin</td></tr><tr><td></td><td>6-Thioguanine</td></tr><tr><td></td><td>Vincristine, doxorubicin (Adriamycin, hydroxydaunoru bicin), dexamethasone</td></tr></table>
======================================
<table><thead><th>Antimetabolites (S phase)</th><th>Alkylating agents</th></thead><tr><td>Capecitabine</td><td>Altretamine</td></tr><tr><td>Cladribine</td><td>Bendamustine</td></tr><tr><td>Clofarabine</td><td>Busulfan</td></tr><tr><td>Cytarabine (ara-C)</td><td>Carmustine</td></tr><tr><td>Fludarabine</td><td>Chlorambucil</td></tr><tr><td>5-Fluorouracil (5-FU)</td><td>Cyclophosphamide</td></tr><tr><td>Gemcitabine</td><td>Dacarbazine</td></tr><tr><td>6-Mercaptopurine (6-MP)</td><td>Lomustine</td></tr><tr><td>Methotrexate (MTX)</td><td>Mechlorethamine</td></tr><tr><td>Nelarabine</td><td>Melphalan</td></tr><tr><td>Pralatrexate</td><td>Temozolomide</td></tr><tr><td>6-Thioguanine (6-TG)</td><td>Thiotepa</td></tr><tr><td>Topoisomerase II inhibitor</td><td>Antitumor antibiotic</td></tr><tr><td>(G,-S phase)</td><td>Dactinomycin</td></tr><tr><td>Etoposide</td><td>Mitomycin</td></tr><tr><td>Topoisomerase | inhibitors</td><td>Platinum analogs</td></tr><tr><td>(Camptothecins, G,-M)</td><td>Carboplatin</td></tr><tr><td>lrinotecan</td><td>Cisplatin</td></tr><tr><td>Topotecan</td><td>Oxaliplatin</td></tr><tr><td>Taxanes (M phase)</td><td>Anthracyclines</td></tr><tr><td>Albumin-bound paclitaxel</td><td>Daunorubicin</td></tr><tr><td>Cabazitaxel</td><td>Doxorubicin</td></tr><tr><td>Docetaxel</td><td>Epirubicin</td></tr><tr><td>Paclitaxel</td><td>Idarubicin</td></tr><tr><td>Vinca alkaloids (M phase)</td><td>Mitoxantrone</td></tr><tr><td colspan="2">Vinblastine</td></tr><tr><td colspan="2">Vincristine</td></tr><tr><td>Vinorelbine</td><td></td></tr></table>
======================================
<table><thead><th>Alkylating Agent</th><th>Mechanism of Action</th><th>Clinical Applications</th><th>Acute Toxi</th><th>Delayed Toxi</th></thead><tr><td>Mechlorethamine</td><td>Forms DNA cross- links, resulting in inhibition of DNA synthesis and function</td><td>Hodgkin’s and non-Hodgkin's lymphoma</td><td>Nausea and vomiting</td><td rowspan="7">Moderate depression of peripheral blood count; excessive doses produce severe bone marrow depression with leukopenia, thrombocytopenia, and bleeding; alopecia and hemorrhagic cys- titis occasionally occur with cyclophos- phamide; cystitis can be prevented with adequate hydration; busulfan is associ- ated with skin pigmentation, pulmonary fibrosis, and adrenal insufficiency</td></tr><tr><td>Chlorambucil</td><td>Same as above</td><td>CLL and non-Hodgkin's lymphoma</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Cyclophosphamide</td><td>Same as above</td><td>Breast cancer, ovarian cancer, non-Hodgkin’s lymphoma, CLL, soft tissue sarcoma, neuroblastoma, Wilms’ tumor, rhabdomyosarcoma</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Bendamustine</td><td>Same as above</td><td>CLL and non-Hodgkin's lymphoma</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Melphalan</td><td>Same as above</td><td>Multiple myeloma, breast cancer, ovarian cancer</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Thiotepa</td><td>Same as above</td><td>Breast cancer, ovarian cancer, superficial bladder cancer</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Busulfan</td><td>Same as above</td><td>CML</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Carmustine</td><td>Same as above</td><td>Brain cancer, Hodgkin's and non-Hodgkin's lymphoma</td><td>Nausea and vomiting</td><td>Myelosuppression; rarely interstitial lung disease and interstitial nephritis</td></tr><tr><td>Lomustine</td><td>Same as above</td><td>Brain cancer</td><td>Nausea and vomiting</td><td></td></tr><tr><td>Altretamine</td><td>Same as above</td><td>Ovarian cancer</td><td>Nausea and vomiting</td><td>Myelosuppression, peripheral neuropa- thy, flu-like syndrome</td></tr><tr><td>Temozolomide</td><td>Methylates DNA and inhibits DNA synthesis and function</td><td>Brain cancer, melanoma</td><td>Nausea and vomiting, head- ache and fatigue</td><td>Myelosuppression, mild elevation in liver function tests, photosensitivity</td></tr><tr><td>Procarbazine</td><td>Methylates DNA and inhibits DNA synthesis and function</td><td>Hodgkin’s and non-Hodgkin's lymphoma, brain tumors</td><td>Central nervous system depression</td><td>Myelosuppression, hypersensitivity reactions</td></tr><tr><td>Dacarbazine</td><td>Methylates DNA and inhibits DNA synthesis and function</td><td>Hodgkin's lymphoma, melanoma, soft tissue sarcoma</td><td>Nausea and vomiting</td><td>Myelosuppression, central nervous system toxicity with neuropathy, ataxia, lethargy, and confusion</td></tr><tr><td>Cisplatin</td><td>Forms intrastrand and interstrand DNA cross-links; binding to nuclear and cytoplasmic proteins</td><td>Non-small cell and small cell lung cancer, breast cancer, bladder cancer, cholangio- carcinoma, gastroesophageal cancer, head and neck cancer, ovarian cancer, germ cell cancer</td><td>Nausea and vomiting</td><td>Nephrotoxicity, peripheral sen- sory neuropathy, ototoxicity, nerve dysfunction</td></tr><tr><td>Carboplatin</td><td>Same as cisplatin</td><td>Non-small cell and small cell lung cancer, breast cancer, bladder cancer, head and neck cancer, ovarian cancer</td><td>Nausea and vomiting</td><td>Myelosuppression; rarely peripheral neuropathy, renal toxicity, hepatic dysfunction</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Mechanism of Action</th><th>Clinical Applications</th><th>Toxicity</th></thead><tr><td>Capecitabine</td><td>Inhibits TS; incorporation of FUTP into RNA resulting in alteration in RNA processing; incorporation of FdUTP into DNA resulting in inhibition of DNA synthesis and function</td><td>Breast cancer, colorectal can- cer, gastroesophageal cancer, hepatocellular cancer, pancreatic cancer</td><td>Diarrhea, hand-foot syndrome, myelosuppression, nausea and vomiting</td></tr><tr><td>5-Fluorouracil</td><td>Inhibits TS; incorporation of FUTP into RNA resulting in alteration in RNA processing; incorporation of FAUTP into DNA resulting in inhibition of DNA synthesis and function</td><td>Colorectal cancer, anal cancer, breast cancer, gastroesophageal cancer, head and neck cancer, hepatocellular cancer</td><td>Nausea, mucositis, diarrhea, bone marrow depression, neurotoxicity</td></tr><tr><td>Methotrexate</td><td>Inhibits DHFR; inhibits TS; inhibits de novo purine nucleotide synthesis</td><td>Breast cancer, head and neck cancer, osteogenic sarcoma, primary central nervous system lymphoma, non- Hodgkin's lymphoma, bladder cancer, choriocarcinoma</td><td>Mucositis, diarrhea, myelosup- pression with neutropenia and thrombocytopenia</td></tr><tr><td>Pemetrexed</td><td>Inhibits TS, DHFR, and purine nucleotide synthesis</td><td>Mesothelioma, non-small cell lung cancer</td><td>Myelosuppression, skin rash, mucositis, diarrhea, fatigue, hand-foot syndrome</td></tr><tr><td>Cytarabine</td><td>Inhibits DNA chain elongation, DNA synthesis and repair; inhibits ribonucleotide reductase with reduced formation of dNTPs; incorporation of cytarabine triphosphate into DNA</td><td>AML, ALL, CML in blast crisis</td><td>Nausea and vomiting, myelosuppression with neutro- penia and thrombocytopenia, cerebellar ataxia</td></tr><tr><td>Gemcitabine</td><td>Inhibits DNA synthesis and repair; inhibits ribonucleotide reductase with reduced formation of dNTPs; incorporation of gemcitabine triphosphate into DNA resulting in inhibition of DNA synthesis and function</td><td>Pancreatic cancer, bladder cancer, breast cancer, non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, soft tissue sarcoma</td><td>Nausea, vomiting, diarrhea, myelosuppression</td></tr><tr><td>Fludarabine</td><td>Inhibits DNA synthesis and repair; inhibits ribonucleotide reductase; incorporation of fludarabine triphosphate into DNA; induction of apoptosis</td><td>Non-Hodgkin's lymphoma, CLL</td><td>Myelosuppression, immunosup- pression, nausea and vomiting, fever, myalgias, arthralgias</td></tr><tr><td>Cladribine</td><td>Inhibits DNA synthesis and repair; inhibits ribonucleotide reductase; incorporation of cladribine triphosphate into DNA; induction of apoptosis</td><td>Hairy cell leukemia, CLL, non-Hodgkin's lymphoma</td><td>Myelosuppression, nau- sea and vomiting, and immunosuppression</td></tr><tr><td>6-Mercaptopurine (6-MP)</td><td>Inhibits de novo purine nucleotide synthe- sis; incorporation of triphosphate into RNA; incorporation of triphosphate into DNA</td><td>AML</td><td>Myelosuppression, immunosup- pression, and hepatotoxicity</td></tr><tr><td>6-Thioguanine</td><td>Same as 6-MP</td><td>ALL, AML</td><td>Same as 6-MP.</td></tr></table>
======================================
<table><thead><th>Drug Bleomycin</th><th>Mechanism of Action Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks</th><th>Clinical Applications Hodgkin's and non-Hodgkin's lymphoma, germ cell cancer, head and neck cancer</th><th>Acute Toxicity Allergic reactions, fever, hypotension</th><th>Delayed Toxicity Skin toxicity, pulmo- nary fibrosis, mucositis, alopecia</th></thead><tr><td>Daunorubicin</td><td>Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks; inhibits topoisomerase II; intercalates into DNA</td><td>AML, ALL</td><td>Nausea and vomit- ing, fever, red urine (not hematuria)</td><td>Cardiotoxicity (see text), alopecia, myelosuppression</td></tr><tr><td>Docetaxel</td><td>Inhibits mitosis</td><td>Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer, ovarian cancer, bladder cancer</td><td>Hypersensitivity</td><td>Neurotoxicity, fluid reten- tion, myelosuppression with neutropenia</td></tr><tr><td>Doxorubicin</td><td>Oxygen free radicals bind to DNA causing single- and double- strand DNA breaks; inhibits topoisomerase II; intercalates into DNA</td><td>Breast cancer, Hodgkin's and non-Hodg- kin’s lymphoma, soft tissue sarcoma, ovarian cancer, non-small cell and small cell lung cancer, thyroid cancer, Wilms’ tumor, neuroblastoma</td><td>Nausea, red urine (not hematuria)</td><td>Cardiotoxicity (see text), alopecia, myelosuppres- sion, stomatitis</td></tr><tr><td>Etoposide</td><td>Inhibits topoisomerase II</td><td>Non-small cell and small cell lung can- cer; non-Hodgkin’s lymphoma, gastric cancer</td><td>Nausea, vomiting, hypotension</td><td>Alopecia, myelosuppression</td></tr><tr><td>Idarubicin</td><td>Oxygen free radicals bind to DNA causing single- and double- strand DNA breaks; inhibits topoisomerase II; intercalates into DNA</td><td>AML, ALL, CML in blast crisis</td><td>Nausea and vomiting</td><td>Myelosuppression, muco- sitis, cardiotoxicity</td></tr><tr><td>lrinotecan</td><td>Inhibits topoisomerase |</td><td>Colorectal cancer, gastroesophageal cancer, non-small cell and small cell lung cancer</td><td>Diarrhea, nausea, vomiting</td><td>Diarrhea, myelosuppres- sion, nausea and vomiting</td></tr><tr><td>Mitomycin</td><td>Acts as an alkylating agent and forms cross-links with DNA; for- mation of oxygen free radicals, which target DNA</td><td>Superficial bladder cancer, gastric can- cer, breast cancer, non-small cell lung cancer, head and neck cancer (in combi- nation with radiotherapy)</td><td>Nausea and vomiting</td><td>Myelosuppression, mucositis, anorexia and fatigue, hemolytic-uremic syndrome</td></tr><tr><td>Paclitaxel</td><td>Inhibits mitosis</td><td>Breast cancer, non-small cell and small cell lung cancer, ovarian cancer, gas- troesophageal cancer, prostate cancer, bladder cancer, head and neck cancer</td><td>Nausea, vomit- ing, hypotension, arrhythmias, hypersensitivity</td><td>Myelosuppression, periph- eral sensory neuropathy</td></tr><tr><td>Topotecan</td><td>Inhibits topoisomerase |</td><td>Small cell lung cancer, ovarian cancer</td><td>Nausea and vomiting</td><td>Myelosuppression</td></tr><tr><td>Vinblastine</td><td>Inhibits mitosis</td><td>Hodgkin's and non-Hodgkin's lym- phoma, germ cell cancer, breast cancer, Kaposi's sarcoma</td><td>Nausea and vomiting</td><td>Myelosuppression, muco- sitis, alopecia, syndrome of inappropriate secretion of antidiuretic hormone (SIADH), vascular events</td></tr><tr><td>Vincristine</td><td>Inhibits mitosis</td><td>ALL, Hodgkin's and non-Hodgkin's lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms’ tumor</td><td></td><td>Neurotoxicity with periph- eral neuropathy, paralytic ileus, myelosuppression, alopecia, SIADH</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Mechanism of Action’</th><th>cl al Applications’</th><th>Acute Toxicity</th><th>Delayed Toxicity</th></thead><tr><td>Bortezomib</td><td>Inhibitor of the 26S proteosome; results in down-regulation of the NF-KB signaling pathway</td><td>Multiple myeloma, mantle cell lymphoma</td><td>Nausea and vomiting, fever</td><td>Peripheral sensory neuropathy, diarrhea, orthostatic hypotension, fever, pulmonary toxicity, reversible posterior leukoenceph- alopathy (RPLS), congestive heart failure (CHF), rare cases of QT prolongation</td></tr><tr><td>Carfilzomib</td><td>Inhibitor of the 26S proteosome; results in down-regulation of the NF-KB signaling pathway; maintains activity in bortezomib-resistant tumors</td><td>Multiple myeloma</td><td>Fever</td><td>Fatigue, cardiac toxicity with CHF and myocardial infarction, myelosuppression, pulmonary toxicity, hepatotoxicity, ortho- static hypotension</td></tr><tr><td>Erlotinib</td><td>Inhibits EGFR tyrosine kinase leading to inhibition of EGFR signaling</td><td>Non-small cell lung can- cer, pancreatic cancer</td><td>Diarrhea</td><td>Skin rash, diarrhea, anorexia, interstitial lung disease</td></tr><tr><td>Imatinib</td><td>Inhibits Bcr-Abl tyrosine kinase and other receptor tyrosine kinases, including PDGFR, and c-kit</td><td>CML, gastrointestinal stromal tumor (GIST), Philadelphia chromo- some-positive ALL</td><td>Nausea and vomiting</td><td>Fluid retention with ankle and periorbital edema, diarrhea, myalgias, congestive heart failure</td></tr><tr><td>Bosutinib</td><td>Inhibits Bcr-Abl tyrosine kinase and retains activity in imatinib-resistant Bcr-Abl mutations except for the 73151 and V299L mutations. Inhibits Src family tyrosine kinases.</td><td>CML</td><td>Nausea and vomiting</td><td>Diarrhea, fluid retention, myelosuppres- sion, skin rash hepatotoxicity</td></tr><tr><td>Cetuximab</td><td>Binds to EGFR and inhibits down- stream EGFR signaling; enhances response to chemotherapy and radiotherapy</td><td>Colorectal cancer, head and neck cancer (used in combination with radio- therapy), non-small cell lung cancer</td><td>Infusion reaction</td><td>Skin rash, hypomagnesemia, fatigue, interstitial lung disease</td></tr><tr><td>Panitumumab</td><td>Binds to EGFR and inhibits down- stream EGFR signaling; enhances response to chemotherapy and radiotherapy</td><td>Colorectal cancer</td><td>Infusion reaction (rarely)</td><td>Skin rash, hypomagnesemia, fatigue, interstitial lung disease</td></tr><tr><td>Bevacizumab</td><td>Inhibits binding of VEGF-A to VEGFR leading to inhibition of VEGF signal- ing; inhibits tumor vascular perme- ability; enhances tumor blood flow and drug delivery</td><td>Colorectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, glioblastoma multiformae</td><td>Hyperten- sion, infusion reaction</td><td>Arterial thromboembolic events, gastro- intestinal perforations, wound healing complications, bleeding complications, proteinuria</td></tr><tr><td>Ziv-aflibercept</td><td>Inhibits binding of VEGF-A, VEGF-B, and PIGF to VEGFR leading to inhibi- tion of VEGF signaling; inhibits tumor vascular permeability; enhances tumor blood flow and drug delivery</td><td>Colorectal cancer</td><td>Hypertension</td><td>Arterial thromboembolic events, gastro- intestinal perforations, wound healing complications, bleeding complications, diarrhea, mucositis, proteinuria</td></tr><tr><td>Sorafenib</td><td>Inhibits multiple RTKs, including raf kinase, VEGF-R2, VEGF-R3, and PDGFR-B leading to inhibition of angiogenesis, invasion, and metastasis</td><td>Renal cell cancer, hepa- tocellular cancer</td><td>Nausea, hypertension</td><td>Skin rash, fatigue and asthenia, bleeding complications, hypophosphatemia</td></tr><tr><td>Sunitinib, pazopanib</td><td>Inhibits multiple RTKs, includ- ing VEGF-R1, VEGF-R2, VEGF-R3, PDGFR-o and PDGFR-B leading to</td><td>Renal cell cancer, GIST</td><td>Hypertension</td><td>Skin rash, fatigue and asthenia, bleeding complications, cardiac
======================================
 toxicity leading to congestive heart failure in rare cases</td></tr></table>
======================================
<table><tr><td></td><td>Adenosine deaminase</td></tr><tr><td></td><td>Antibody-drug conjugate</td></tr><tr><td></td><td>Antilymphocyte globulin</td></tr><tr><td></td><td>Antigen-presenting cell</td></tr><tr><td></td><td>Antithymocyte globulin</td></tr><tr><td></td><td>Cluster of differentiation</td></tr><tr><td></td><td>Colony-stimulating factor</td></tr><tr><td></td><td>Cytotoxic T lymphocyte</td></tr><tr><td></td><td>Dendritic cell</td></tr><tr><td></td><td>Delayed-type hypersensitivit</td></tr><tr><td></td><td>Fk-binding protein</td></tr><tr><td></td><td>Graft-versus-host disease</td></tr><tr><td></td><td>Human antimouse antibody</td></tr><tr><td></td><td>Human leukocyte antigen</td></tr><tr><td></td><td>Interferon</td></tr><tr><td></td><td>Immune globulin intravenou</td></tr><tr><td></td><td>Interleukin</td></tr><tr><td></td><td>Leukocyte function-associate</td></tr><tr><td></td><td>Monoclonal antibody</td></tr><tr><td>MHC</td><td>Major histocompatibility con</td></tr><tr><td>NK cell</td><td>Natural killer cell</td></tr><tr><td>SCID</td><td>Severe combined immunode</td></tr><tr><td>TCR</td><td>T-cell receptor</td></tr><tr><td>TGF-B</td><td>Transforming growth factor-</td></tr><tr><td>TH1, TH2</td><td>T helper cell types 1 and 2</td></tr></table>
======================================
<table><tr><td colspan="3">Autoimmune diseases</td></tr><tr><td>Idiopathic thrombocytopenic purpura (ITP)</td><td>Prednisone,’ vincristine, occasionally cyclophosphamide, mercaptopurine, or azathioprine; commonly high-dose gamma globulin, plasma immunoadsorption or plasma exchange</td><td>Usually good</td></tr><tr><td>Autoimmune hemolytic anemia</td><td>Prednisone,’ cyclophosphamide, chlorambucil, mercaptopurine, azathioprine, high-dose gamma globulin</td><td>Usually good</td></tr><tr><td>Acute glomerulonephritis</td><td>Prednisone,’ mercaptopurine, cyclophosphamide</td><td>Usually good</td></tr><tr><td>Acquired factor XIII antibodies</td><td>Cyclophosphamide plus factor XIII</td><td>Usually good</td></tr><tr><td>Autoreactive tissue disorders . 7 2 (autoimmune diseases)</td><td>Prednisone, cyclophosphamide, methotrexate, interferon-a and -B, azathioprine, cyclosporine, infliximab, etanercept, adalimumab</td><td>Often good, variable</td></tr><tr><td colspan="3">Isoimmune disease</td></tr><tr><td>Hemolytic disease of the newborn</td><td>Rh,(D) immune globulin</td><td>Excellent</td></tr><tr><td colspan="3">Organ transplantation</td></tr><tr><td>Renal</td><td>Cyclosporine, azathioprine, prednisone, ALG, OKT3, tacrolimus, basiliximab, daclizumab,?, sirolimus</td><td>Very good</td></tr><tr><td>Heart</td><td>Cyclosporine, azathioprine, prednisone, ALG, OKT3, tacrolimus, basiliximab,* daclizumab,?, sirolimus</td><td>Good</td></tr><tr><td>Liver</td><td>Cyclosporine, prednisone, azathioprine, tacrolimus, sirolimus</td><td>Fair</td></tr><tr><td>Bone marrow</td><td>Cyclosporine, cyclophosphamide, prednisone, methotrexate, ALG</td><td>Good</td></tr><tr><td colspan="3">Prevention of cell proliferation</td></tr><tr><td>Coronary stents</td><td>Sirolimus (impregnated stent)</td><td>Good</td></tr><tr><td>Neovascular macular degeneration</td><td>Ranibizumab (labeled), bevacizumab (off-label)</td><td>Fair</td></tr></table>
======================================
<table><thead><th>Cytokine</th><th>Properties</th></thead><tr><td>Interferon-. (IFN-c.)</td><td>Antiviral, oncostatic, activates NK cells</td></tr><tr><td>Interferon-B (IFN-B)</td><td>Antiviral, oncostatic, activates NK cells</td></tr><tr><td>Interferon-y (IFN-y)</td><td>Antiviral, oncostatic, secreted by and activates or up-regulates TH1 cells, NK cells, CTLs, and macrophages</td></tr><tr><td>Interleukin-1 (IL-1)</td><td>T-cell activation, B-cell proliferation and differentiation</td></tr><tr><td>Interleukin-2 (IL-2)</td><td>T-cell proliferation, TH1, NK, and LAK cell activation</td></tr><tr><td>Interleukin-3 (IL-3)</td><td>Hematopoietic precursor proliferation and differentiation</td></tr><tr><td>Interleukin-4 (IL-4)</td><td>TH2 and CTL activation, B-cell proliferation</td></tr><tr><td>Interleukin-5 (IL-5)</td><td>Eosinophil proliferation, B-cell proliferation and differentiation</td></tr><tr><td>Interleukin-6 (IL-6)</td><td>HCF, TH2, CTL, and B-cell proliferation</td></tr><tr><td>Interleukin- 7 (IL-7)</td><td>CTL, NK, LAK, and B-cell proliferation, thymic precursor stimulation</td></tr><tr><td>Interleukin-8 (IL-8)</td><td>Neutrophil chemotaxis, proinflammatory</td></tr><tr><td>Interleukin-9 (IL-9)</td><td>T-cell proliferation</td></tr><tr><td>Interleukin-10 (IL-10)</td><td>TH1 suppression, CTL activation, B-cell proliferation</td></tr><tr><td>Interleukin-11 (IL-11)</td><td>Megakaryocyte proliferation, B-cell differentiation</td></tr><tr><td>Interleukin-12 (IL-12)</td><td>TH1 and CTL proliferation and activation</td></tr><tr><td>Interleukin-13 (IL-13)</td><td>Macrophage function modulation, B cell proliferation</td></tr><tr><td>Interleukin-14 (IL-14)</td><td>B-cell proliferation and differentiation</td></tr><tr><td>Interleukin-15 (IL-15)</td><td>TH1, CTL, and NK/LAK activation, expansion of T-cell memory pools</td></tr><tr><td>Interleukin-16 (IL-16)</td><td>T-lymphocyte chemotaxis, suppresses HIV replication</td></tr><tr><td>Interleukin-17 (IL-17)</td><td>Stromal cell cytokine production</td></tr><tr><td>Interleukin-18 (IL-18)</td><td>Induces TH1 responses</td></tr><tr><td>Interleukin-19 (IL-19)</td><td>Proinflammatory</td></tr><tr><td>Interleukin-20 (IL-20)</td><td>Promotes skin differentiation</td></tr><tr><td>Interleukin-21 (IL-21)</td><td>Promotes proliferation of activated T cells, maturation of NK cells</td></tr><tr><td>Interleukin-22 (IL-22)</td><td>Regulator of TH2 cells</td></tr><tr><td>Interleukin-23 (IL-23)</td><td>Promotes proliferation of TH1 memory cells</td></tr><tr><td>Interleukin-24 (IL-24)</td><td>Induces tumor apoptosis, induces TH1 responses</td></tr><tr><td>Interleukin-27 (IL-27)</td><td>Stimulates naive CD4 cells to produce IFN-y</td></tr><tr><td>Interleukin-28 and -29 (IL-28, IL-29)</td><td>Antiviral, interferon-like properties</td></tr><tr><td>Interleukin-30 (IL-30)</td><td>p28 subunit of IL-27</td></tr><tr><td>Interleukin-31 (IL-31)</td><td>Contributes to type | hypersensitivities and TH2 responses</td></tr><tr><td>Interleukin-32 (IL-32)</td><td>Involved in inflammation</td></tr><tr><td>Interleukin-34 (IL-34)</td><td>Stimulates monocyte proliferation via the CSF-1 receptor (CSF-1R)</td></tr><tr><td>Interleukin-35 (IL-35)</td><td>Induces regulatory T cells (iT,35)</td></tr><tr><td>Tumor necrosis factor-o (TNF-a)</td><td>Oncostatic, macrophage activation, proinflammatory</td></tr><tr><td>Tumor necrosis factor-B (TNF-B)</td><td>Oncostatic, proinflammatory, chemotactic</td></tr><tr><td>Granulocyte colony-stimulating factor</td><td>Granulocyte production</td></tr></table>
======================================
<table><tr><td>Etanercept</td><td>Enbrel</td></tr><tr><td>Everolimus</td><td>Afinitor, Zortress</td></tr><tr><td>Evolocumab</td><td>Repatha</td></tr><tr><td>Fingolimod hydrochloride</td><td>Gilenya</td></tr><tr><td>Glatiramer acetate</td><td>Copaxone</td></tr><tr><td>Golimumab</td><td>Simponi</td></tr><tr><td>Ibritumomab tiuxetan</td><td>Zevalin</td></tr><tr><td>Immune globulin intravenous [IGIV]</td><td>Various</td></tr><tr><td>Infliximab</td><td>Remicade</td></tr><tr><td>Interferon alfa-2a Interferon alfa-2b</td><td>Roferon Intron-A</td></tr><tr><td>Interferon beta-1a</td><td>Avonex, Rebif</td></tr><tr><td>Interferon beta-1b</td><td>Betaseron, Extavia</td></tr><tr><td>Interferon gamma-1b</td><td>Actimmune</td></tr><tr><td>Ipilimumab</td><td>Yervoy</td></tr><tr><td>Leflunomide</td><td>Arava</td></tr><tr><td>Lenalidomide</td><td>Revlimid</td></tr><tr><td>Lymphocyte immune globulin</td><td>Atgam</td></tr><tr><td>Mepolizumab</td><td>Nucala</td></tr><tr><td>Mycophenolate mofetil</td><td>Generic, CellCept</td></tr><tr><td>Natalizumab</td><td>Tysabri</td></tr><tr><td>Necitumumab</td><td>Portrazza</td></tr><tr><td>Nivolumab</td><td>Opdivo</td></tr><tr><td>Obiltoxaximab</td><td>Anthim</td></tr><tr><td>Ofatumumab</td><td>Arzerra</td></tr><tr><td>Omalizumab</td><td>Xolair</td></tr><tr><td>Palivizumab</td><td>Synagis</td></tr></table>
======================================
<table><tr><td>Abatacept</td><td>Orencia</td></tr><tr><td>Abciximab</td><td>ReoPro</td></tr><tr><td>Adalimumab</td><td>Humira</td></tr><tr><td>Ado-trastuzumab emtansine</td><td>Kadcyla</td></tr><tr><td>Alefacept</td><td>Amevive</td></tr><tr><td>Alemtuzumab</td><td>Campath</td></tr><tr><td>Alirocumab</td><td>Praluent</td></tr><tr><td>Anakinra</td><td>Kineret</td></tr><tr><td>Antithymocyte globulin</td><td>Thymoglobulin</td></tr><tr><td>Arcitumomab</td><td>CEA-Scan</td></tr><tr><td>Atezolizumab</td><td>Tecentriq</td></tr><tr><td>Azathioprine</td><td>Generic, Imuran</td></tr><tr><td>Basiliximab</td><td>Simulect</td></tr><tr><td>Belimumab</td><td>Benlysta</td></tr><tr><td>Bevacizumab</td><td>Avastin</td></tr><tr><td>Brentuximab vedotin</td><td>Adcetris</td></tr><tr><td>Canakinumab</td><td>llaris</td></tr><tr><td>Capromab pendetide</td><td>ProstaScint</td></tr><tr><td>Catumaxomab</td><td>Removab</td></tr><tr><td>Certolizumab</td><td>Cimzia</td></tr><tr><td>Cetuximab</td><td>Erbitux</td></tr><tr><td>Cyclophosphamide</td><td>generic</td></tr><tr><td>Cyclosporine</td><td>Generic, Sandimmune, Restasis</td></tr><tr><td>Daclizumab</td><td>Zenapax</td></tr><tr><td>Daratumumab</td><td>Darzalex</td></tr><tr><td>Denileukin diftitox</td><td>Ontak</td></tr><tr><td>Denosumab</td><td>Prolia</td></tr><tr><td>Dimethyl fumarate</td><td>Tecfidera</td></tr><tr><td>Eculizumab</td><td>Soliris</td></tr></table>
======================================
<table><tr><td>Pegademase bovine (bovine adenosine deaminase)</td><td>Adagen</td></tr><tr><td>Pegaptanib</td><td>Macugen</td></tr><tr><td>Peginterferon alfa-2a</td><td>Pegasys</td></tr><tr><td>Peginterferon alfa-2b</td><td>PEG-Intron</td></tr><tr><td>Pembrolizumab</td><td>Keytruda</td></tr><tr><td>Pertuzumab</td><td>Perjeta</td></tr><tr><td>Pomalidomide</td><td>Pomalyst</td></tr><tr><td>Ramucirumab</td><td>Cyramza</td></tr><tr><td>Ranibizumab</td><td>Lucentis</td></tr><tr><td>Raxibacumab</td><td>ABthrax</td></tr><tr><td>Reslizumab</td><td>Cingair</td></tr><tr><td>Rh,(D) immune globulin micro-dose</td><td>RhoGam, others</td></tr></table>
======================================
<table><tr><td>Rilonacept</td><td>Arcalyst</td></tr><tr><td>Rituximab</td><td>Rituxan</td></tr><tr><td>Scorpion antivenom (equine (Fab)¢2)</td><td>Anascorp</td></tr><tr><td>Siltuximab</td><td>Sylvant</td></tr><tr><td>Sirolimus</td><td>Generic, Rapamune</td></tr><tr><td>Tacrolimus (FK 506)</td><td>Generic, Prograf, others</td></tr><tr><td>Teriflunomide</td><td>Aubagio</td></tr><tr><td>Thalidomide</td><td>Thalomid</td></tr><tr><td>Tocilizumab</td><td>Actemra</td></tr><tr><td>Trastuzumab</td><td>Herceptin</td></tr><tr><td>Ustekinumab</td><td>Stelara</td></tr><tr><td>Vedolizumab</td><td>Entyvio</td></tr></table>
======================================
<table><thead><th>Source</th><th>PCB Concentration (ppm)'</th><th>Concentration Relative to Phytoplankton</th></thead><tr><td>Phytoplankton</td><td>0.0025</td><td></td></tr><tr><td>Zooplankton</td><td>0.123</td><td></td></tr><tr><td>Rainbow smelt</td><td>1.04</td><td></td></tr><tr><td>Lake trout</td><td>4.83</td><td></td></tr><tr><td>Herring gull</td><td>124</td><td></td></tr></table>
======================================
<table><thead><th>Compound</th><th>PEL’ (ppm)</th></thead><tr><td>Benzene</td><td>1.0</td></tr><tr><td>Carbon monoxide</td><td>50</td></tr><tr><td>Carbon tetrachloride</td><td></td></tr><tr><td>Chloroform</td><td></td></tr><tr><td>Nitrogen dioxide</td><td></td></tr><tr><td>Ozone</td><td></td></tr><tr><td>Sulfur dioxide</td><td></td></tr><tr><td>Tetrachloroethylene</td><td></td></tr><tr><td>Toluene</td><td></td></tr><tr><td>1,1,1-Trichloroethane</td><td></td></tr><tr><td>Trichloroethylene</td><td></td></tr></table>
======================================
<table><thead><th>Chemical Class</th><th>Compounds</th><th>Toxicity Rating’</th></thead><tr><td rowspan="3">DDT and analogs</td><td>Dichlorodiphenyltrichloroethane (DDT)</td><td>=~</td></tr><tr><td></td><td>Methoxychlor</td><td>Ww</td></tr><tr><td></td><td>Tetrachlorodiphenylethane (TDE)</td><td>Bw</td></tr><tr><td rowspan="2">Benzene hexachlorides</td><td>Benzene hexachloride (BHC; hexachlorocyclohexane)</td><td>RRU</td></tr><tr><td></td><td>Lindane</td><td>BR</td></tr><tr><td rowspan="4">Cyclodienes</td><td></td><td>Aldrin</td><td>RU</td></tr><tr><td></td><td>Chlordane</td><td></td></tr><tr><td>Dieldrin</td><td></td></tr><tr><td></td><td>Heptachlor</td><td></td></tr><tr><td>Toxaphenes</td><td>Toxaphene (camphechlor)</td><td></td></tr></table>
======================================
<table><thead><th>Compound</th><th>Toxicity Rating</th></thead><tr><td>Azinphos-methyl</td><td>5</td></tr><tr><td>Chlorfenvinphos</td><td></td></tr><tr><td>Diazinon</td><td>4</td></tr><tr><td>Dichlorvos</td><td></td></tr><tr><td>Dimethoate</td><td></td></tr><tr><td>Fenitrothion</td><td></td></tr><tr><td>Malathion</td><td>A</td></tr><tr><td>Parathion</td><td></td></tr><tr><td>Parathion-methyl</td><td>RUA</td></tr><tr><td>Trichlorfon</td><td></td></tr></table>
======================================
<table><thead><th>Compound</th><th>Toxicity Rating’</th></thead><tr><td>Aldicarb</td><td>a</td></tr><tr><td>Aminocarb</td><td></td></tr><tr><td>Carbaryl</td><td>PR</td></tr><tr><td>Carbofuran</td><td>RH</td></tr><tr><td>Dimetan</td><td></td></tr><tr><td>Dimetilan</td><td>He</td></tr><tr><td>Isolan</td><td></td></tr><tr><td>Methomyl</td><td>FU</td></tr><tr><td>Propoxur</td><td></td></tr><tr><td>Pyramat</td><td></td></tr><tr><td>Pyrolan</td><td></td></tr><tr><td>Zectran</td><td>wu</td></tr></table>
======================================
<table><thead><th></th><th>Form Entering Body</th><th>Major Route of Absorption</th><th>Distribution</th><th>Major Clinical Effects</th><th>Key Aspects of Mechanism</th><th>Metabolism and Elimination</th></thead><tr><td>Arsenic</td><td>Inorganic arsenic salts</td><td>Gastrointesti- nal, respiratory (all mucosal surfaces)</td><td>Predominantly soft tissues (highest in liver, kidney). Avidly bound in skin, hair, nails</td><td>Cardiovascular: shock, arrhythmias. CNS: encephalopathy, periph- eral neuropathy. Gastro- enteritis; pancytopenia; cancer (many sites)</td><td>Inhibits enzymes; interferes with oxida- tive phosphorylation; alters cell signaling, gene expression</td><td>Methylation. Renal (major); sweat and feces (minor)</td></tr><tr><td rowspan="2">Lead</td><td>Inorganic lead oxides and salts</td><td>Gastrointesti- nal, respiratory</td><td>Soft tissues; redistributed to skeleton (&gt;90% of adult body burden)</td><td>CNS deficits; peripheral neuropathy; anemia; nephropathy; hyper- tension; reproductive toxicity</td><td>Inhibits enzymes; interferes with essen- tial cations; alters membrane structure</td><td>Renal (major); feces and breast milk (minor)</td></tr><tr><td></td><td>Organic (tetra- ethyl lead)</td><td>Skin, gastro- intestinal, respiratory</td><td>Soft tissues, especially liver, CNS</td><td>Encephalopathy</td><td>Hepatic dealkylation (fast) &gt; trialkyl metabolites (slow) &gt; dissociation to lead</td><td>Urine and feces (major); sweat (minor)</td></tr><tr><td rowspan="3">Mercury</td><td>Elemental mercury</td><td>Respiratory tract</td><td>Soft tissues, especially kidney, CNS</td><td>CNS: tremor, behav- ioral (erethism); gingivo-stomatitis, peripheral neuropathy; acrodynia; pneumonitis (high-dose)</td><td>Inhibits enzymes; alters membranes</td><td>Elemental Hg converted to Hg”. Urine (major); feces (minor)</td></tr><tr><td></td><td>Inorganic: Hg* (less toxic); Hg”* (more toxic)</td><td>Gastrointes- tinal, skin (minor)</td><td>Soft tissues, especially kidney</td><td>Acute renal tubular necrosis; gastroenteritis; CNS effects (rare)</td><td>Inhibits enzymes; alters membranes</td><td>Urine</td></tr><tr><td></td><td>Organic: alkyl, aryl</td><td>Gastrointesti- nal, skin, respi- ratory (minor)</td><td>Soft tissues</td><td>CNS effects, birth defects</td><td>Inhibits enzymes; alters microtubules, neuronal structure</td><td>Deacylation. Fecal (alkyl, major); urine (Hg** after deacyla- tion, minor)</td></tr></table>
======================================
<table><thead><th>Exposure: Sources</th><th>Examples of Preventive Measures</th></thead><tr><td>Home exposure: The US Consumer Product Safety Commission adopted major restrictions on the use of lead in residential house paint in 1977. Prior to then, thousands of tons of lead pigments were applied in millions of homes. The American Healthy Homes Survey (2005-2006) estimated that 35% of homes had some lead-based paint and 22% had one or more lead-based paint hazards.</td><td>The US Environmental Protection Agency's (EPA) Lead Renovation, Repair, and Painting Rule requires that companies performing renovation, repair, and painting projects that disturb lead-based paint in homes, child care facilities, and preschools built before 1978 have their firm certified by EPA (or an EPA-authorized state), use certified renovators who are trained by EPA-approved training providers, and follow lead-safe work practices. [https://www.epa.gov/lead/renovation-repair-and-painting-program]</td></tr><tr><td>and Safety Administration (OSHA) estimates that more than 1.6 million workers are potentially exposed to lead. State and federal OSHA programs have established permissible exposure levels for lead in workplace air, as well as medical surveillance requirements for workers that may mandate peri-</td><td>removal protection date from the late 1970s and no longer offer adequate protection. The Occupational Lead Poisoning Prevention Program of the California Department of Public Health offers up-to-date, health protec- tive guidance. [https://archive.cdph.ca.gov/programs/olppp/Pages/default.aspx]</td></tr><tr><td>odic blood lead monitoring. Water: Lead may enter drinking water when service pipes contain lead, especially when the water has high acidity or low mineral content that corrodes pipes and plumbing fixtures.</td><td>Under EPA's Lead and Copper Rule [https://www.epa.gov/dwreginfo/lead- and-copper-rule], if more than 10% of tap water samples at sites likely to have lead plumbing exceed the lead action level of 15 parts per billion, water systems are required to institute corrosion control and other mea- sures. The Safe Drinking Water Act, amended by the Reduction of Lead in Drinking Water Act of 2011, sets limits on the lead content of new plumb- ing materials for potable water. [ https://www.epa.gov/dwstandardsregulations/ use-lead-free-pipes-fittings-fixtures-solder-and-flux-drinking-water]</td></tr><tr><td>Children: Because of normal mouthing behavior, children are at special risk of exposure to lead present in toys, jewelry, printed material, and other consumer products.</td><td>The US Consumer Product Safety Commission has promulgated rules that limit the amount of lead that can be present in children’s products. [https://www.cpsc.gov/Business--Manufacturing/Business-Education/ Lead/Lead-in-Paint] [https://www.cpsc.gov/Business--Manufacturing/Business-Education/ Lead/Total-Lead-Content]</td></tr></table>
======================================
<table><tr><td>Deferasirox</td><td>Exjade, Jadenu</td></tr><tr><td>Deferiprone</td><td>Ferriprox</td></tr><tr><td>Deferoxamine</td><td>Generic, Desferal</td></tr><tr><td>Dimercaprol</td><td>BAL in Oil</td></tr><tr><td>Edetate calcium [calcium EDTA]</td><td>Calcium Disodium Versenate</td></tr><tr><td>Penicillamine</td><td>Cuprimine, Depen</td></tr><tr><td>Pentetate Calcium Trisodium [calcium DTPA] and Pentetate Zinc Trisodium [zinc DTPA]</td><td>Generic</td></tr><tr><td>Prussian Blue</td><td>Radiogardase</td></tr><tr><td>Succimer</td><td>Chemet, Succicaptal (in Europe)</td></tr><tr><td>Unithiol</td><td>Dimaval</td></tr></table>
======================================
<table><thead><th>Type of Elevation ofthe AnionGap</th><th>Agents</th></thead><tr><td>Organic acid metabolites</td><td>Methanol, ethylene glycol, diethylene glycol,</td></tr><tr><td>Lactic acidosis</td><td>Cyanide, carbon monoxide, ibuprofen, isoniazid, metformin, salicylates, valproic acid; any drug-induced seizures, hypoxia, or hypotension</td></tr></table>
======================================
<table><tr><td>Carbamazepine</td></tr><tr><td>Ethylene glycol</td></tr><tr><td>Lithium</td></tr><tr><td>Methanol</td></tr><tr><td>Metformin</td></tr><tr><td>Phenobarbital</td></tr><tr><td>Salicylate</td></tr><tr><td>Theophylline</td></tr><tr><td>Valproic acid</td></tr><tr><td>Hemodialysis is ineffective or is not useful:</td></tr><tr><td>Amphetamines</td><td></td></tr><tr><td>Antidepressants</td></tr><tr><td>Antipsychotic drugs</td></tr><tr><td>Benzodiazepines</td></tr><tr><td>Calcium channel blockers</td></tr><tr><td>Digoxin</td></tr><tr><td>Metoprolol and propranolol</td></tr><tr><td>Opioids</td></tr></table>
======================================
<table><thead><th>Antidote</th><th>Pe in(s)</th><th>Comments</th></thead><tr><td>Acetylcysteine (Acetadote, Mucomyst)</td><td>Acetaminophen</td><td>Best results if given within 8-10 hours of overdose. Follow liver function tests and acetaminophen blood levels. Acetadote is given intravenously; Mucomyst is given orally.</td></tr><tr><td>Atropine</td><td>Anticholinesterase intoxication: organophosphates, carbamates</td><td>An initial dose of 1-2 mg (for children, 0.05 mg/kg) is given IV, and if there is no response, the dose is doubled every 10-15 minutes, with decreased wheezing and pulmonary secretions as therapeutic end points.</td></tr><tr><td>Atropine</td><td>Rapid-onset mushroom poisoning with predominant muscarinic excess symptoms</td><td>Useful for control of muscarinic symptoms. Note: Of no value in delayed-onset mushroom poisoning.</td></tr><tr><td>Bicarbonate, sodium</td><td>Membrane-depressant cardiotoxic drugs (tricyclic antidepressants, quinidine, etc)</td><td>1-2 mEq/kg IV bolus usually reverses cardiotoxic effects (wide QRS, hypotension). Give cautiously in heart failure (avoid sodium overload).</td></tr><tr><td>Calcium</td><td>Fluoride; calcium channel blockers</td><td>Large doses may be needed in severe calcium channel blocker overdose. Start with 15 mg/kg IV.</td></tr><tr><td>Deferoxamine</td><td>Iron salts</td><td>If poisoning is severe, give 15 mg/kg/h IV. 100 mg of deferoxamine binds 8.5 mg of iron.</td></tr><tr><td>Digoxin antibodies</td><td>Digoxin and related cardiac glycosides</td><td>One vial binds 0.5 mg digoxin; indications include serious arrhythmias, hyperkalemia.</td></tr><tr><td>Esmolol</td><td>Theophylline, caffeine, metaproterenol</td><td>Short-acting B blocker. Infuse 25-50 mcg/kg/min IV.</td></tr><tr><td>Ethanol</td><td>Methanol, ethylene glycol</td><td>A loading dose is calculated so as to give a blood level of at least 100 mg/dL (42 g/70 kg in adults). Fomepizole (see below) is easier to use.</td></tr><tr><td>Flumazenil</td><td>Benzodiazepines</td><td>Adult dose is 0.2 mg IV, repeated as necessary to a maximum of 3 mg. Do not give to patients with seizures, benzodiazepine dependence, or tricyclic overdose.</td></tr><tr><td>Fomepizole</td><td>Methanol, ethylene glycol</td><td>More convenient than ethanol. Give 15 mg/kg; repeat every 12 hours.</td></tr><tr><td>Glucagon</td><td>B blockers</td><td>5-10 mg IV bolus may reverse hypotension and bradycardia.</td></tr><tr><td>Hydroxocobalamin</td><td>Cyanide</td><td>Adult dose is 5 g IV over 15 minutes. Converts cyanide to cyanocobalamin (vitamin B,,).</td></tr><tr><td>Naloxone</td><td>Narcotic drugs, other opioid derivatives</td><td>A specific antagonist of opioids; give 0.4—-2 mg initially by IV, IM, or SC injection. Larger doses may be needed to reverse the effects of overdose with propoxyphene, codeine, or fentanyl derivatives. Duration of action (2-3 hours) may be significantly shorter than that of the opioid being antagonized.</td></tr><tr><td>Oxygen</td><td>Carbon monoxide</td><td>Give 100% by high-flow nonrebreathing mask; use of hyperbaric chamber is controversial but often recommended for severe poisoning.</td></tr><tr><td>Physostigmine</td><td>Suggested for delirium caused by anticholinergic agents</td><td>Adult dose is 0.5-1 mg IV slowly. The effects are transient (30-60 minutes), and the lowest effective dose may be repeated when symptoms return. May cause bradycardia, increased bronchial secretions, seizures. Have atropine ready to reverse excess effects. Do not use for tricyclic antidepressant overdose.</td></tr><tr><td>Pralidoxime (2-PAM)</td><td>Organophosphate (OP) cholinesterase inhibitors</td><td>Adult dose is 1 g IV, which should be repeated every 3-4 hours as needed or preferably as a constant infusion of 250-400 mg/h. Pediatric dose is approximately 250 mg. No proved benefit in carbamate poisoning; uncertain benefit in established OP poisoning.</td></tr></table>
======================================
<table><thead><th>Gas</th><th>Mechanism of Toxicity</th><th>Clinical Features and Treatment</th></thead><tr><td>Irritant gases (eg, chlorine, ammonia, sulfur dioxide, nitrogen oxides)</td><td>Corrosive effect on upper and lower airways</td><td>Cough, stridor, wheezing, pneumonia Treatment: Humidified oxygen, bronchodilators</td></tr><tr><td>Carbon monoxide</td><td>Binds to hemoglobin, reducing oxygen delivery to tissues</td><td>Headache, dizziness, nausea, vomiting, seizures, coma Treatment: 100% oxygen; consider hyperbaric oxygen</td></tr><tr><td>Cyanide</td><td>Binds to cytochrome, blocks cellular oxygen use</td><td>Headache, nausea, vomiting, syncope, seizures, coma Treatment: Conventional antidote kit consists of nitrites to induce methemoglobin- emia (which binds cyanide) and thiosulfate (which hastens conversion of cyanide to less toxic thiocyanate); a newer antidote kit (Cyanokit) consists of concentrated hydroxocobalamin, which directly converts cyanide into cyanocobalamin</td></tr><tr><td>Hydrogen sulfide</td><td>Similar to cyanide</td><td>Similar to cyanide. Smell of rotten eggs Treatment: No specific antidote; some authorities recommend the nitrite portion of the conventional cyanide antidote kit.</td></tr><tr><td rowspan="2">Oxidizing agents (eg, nitrogen oxides)</td><td>Can cause</td><td>Dyspnea, cyanosis (due to brown color of methemoglobin), syncope, seizures, coma</td></tr><tr><td></td><td>methemoglobinemia</td><td>Treatment: Methylene blue (which hastens conversion back to normal hemoglobin)</td></tr></table>
======================================
<table><tr><td>Drug</td><td>Trimester</td><td>Effect</td></tr><tr><td>ACE inhibitors</td><td>All, especially second and third</td><td>Renal damage, hypocalvaria</td></tr><tr><td>Aminopterin</td><td>First</td><td>Multiple gross anomalies</td></tr><tr><td>Amphetamines</td><td>All</td><td>Suspected abnormal developmental patterns, decreased school performance</td></tr><tr><td>Androgens</td><td>Second and third</td><td>Masculinization of female fetus</td></tr><tr><td>Antidepressants, tricyclic</td><td>Third</td><td>Neonatal withdrawal symptoms have been reported in a few cases with clomipramine, desipramine, and imipramine</td></tr><tr><td>Barbiturates</td><td>All</td><td>Chronic use can lead to neonatal dependence.</td></tr><tr><td>Busulfan</td><td>All</td><td>Various congenital malformations; low birth weight</td></tr><tr><td>Carbamazepine</td><td>First</td><td>Neural tube defects</td></tr><tr><td>Chlorpropamide</td><td>All</td><td>Prolonged symptomatic neonatal hypoglycemia</td></tr><tr><td>Clomipramine</td><td>Third</td><td>Neonatal lethargy, hypotonia, cyanosis, hypothermia</td></tr><tr><td>Cocaine</td><td>All</td><td>Increased risk of spontaneous abortion, abruptio placentae, and premature labor; neonatal cerebral infarction, abnormal development, and decreased school performance</td></tr><tr><td>Cyclophosphamide</td><td>First</td><td>Various congenital malformations</td></tr><tr><td>Cytarabine</td><td>First, second</td><td>Various congenital malformations</td></tr><tr><td>Diazepam</td><td>All</td><td>Chronic use may lead to neonatal dependence</td></tr><tr><td>Diethylstilbestrol</td><td>All</td><td>Vaginal adenosis, clear cell vaginal adenocarcinoma</td></tr><tr><td>Ethanol</td><td>All</td><td>Risk of fetal alcohol spectrum disorder</td></tr><tr><td>Etretinate</td><td>All</td><td>High risk of multiple congenital malformations</td></tr><tr><td>Heroin</td><td>All</td><td>Chronic use leads to neonatal abstinence syndrome</td></tr><tr><td>lodide</td><td>All</td><td>Congenital goiter, hypothyroidism</td></tr><tr><td>Isotretinoin</td><td>All</td><td>Extremely high risk of central nervous system (CNS), face, ear, and other malformations</td></tr><tr><td>Lithium</td><td>First, third</td><td>Ebstein’s anomaly, neonatal toxicity after third trimester exposure</td></tr><tr><td>Methadone</td><td>All</td><td>Chronic use may lead to neonatal abstinence syndrome</td></tr><tr><td>Methotrexate</td><td>First</td><td>Multiple congenital malformations</td></tr><tr><td>Methylthiouracil</td><td>All</td><td>Hypothyroidism</td></tr><tr><td>Misoprostol</td><td>First</td><td>Mobius sequence</td></tr><tr><td>Mycophenolate mofetil</td><td>First</td><td>Major malformations of the face, limbs, and other organs</td></tr><tr><td>Organic solvents</td><td>First</td><td>Multiple malformations</td></tr><tr><td>Penicillamine</td><td>First</td><td>Cutis laxa, other congenital malformations</td></tr><tr><td>Phencyclidine</td><td>All</td><td>Abnormal neurologic examination, poor suck reflex and feeding</td></tr><tr><td>Phenytoin</td><td>All</td><td>Fetal hydantoin syndrome</td></tr><tr><td>Propylthiouracil</td><td>All</td><td>Congenital goiter</td></tr><tr><td>Serotonin reuptake inhibitors</td><td>Third</td><td>Neonatal abstinence syndrome, persistent pulmonary hypertension of the newborn</td></tr><tr><td>Smoking (constituents of tobacco smoke)</td><td>All</td><td>Intrauterine growth restriction; prematurity; sudden infant death syndrome; perinatal complications</td></tr><tr><td>Tamoxifen</td><td>All</td><td>Increased risk of spontaneous abortion or fetal damage</td></tr><tr><td>Tetracycline</td><td>All</td><td>Discoloration and defects of teeth and altered bone growth</td></tr><tr><td>Thalidomide</td><td>First</td><td>Phocomelia (shortened or absent long bones of the limbs) and many internal malformations</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Oral Absorption</th></thead><tr><td>Acetaminophen</td><td>Decreased</td></tr><tr><td>Ampicillin</td><td>Increased</td></tr><tr><td>Diazepam</td><td>Normal</td></tr><tr><td>Digoxin</td><td>Normal</td></tr><tr><td>Penicillin G</td><td>Increased</td></tr><tr><td>Phenobarbital</td><td>Decreased</td></tr><tr><td>Phenytoin</td><td>Decreased</td></tr><tr><td>Sulfonamides</td><td>Normal</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Neonatal Age</th><th>Neonates t,, (hours)</th><th>Adults t,, (hours)</th></thead><tr><td>Acetaminophen</td><td></td><td>2.2-5</td><td>0.9-2.2</td></tr><tr><td>Diazepam</td><td></td><td>25-100</td><td>40-50</td></tr><tr><td>Digoxin</td><td></td><td>60-70</td><td>30-60</td></tr><tr><td rowspan="3">Phenobarbital</td><td>0-5 days</td><td>200</td><td>64-140</td></tr><tr><td></td><td>5-15 days</td><td>100</td><td></td></tr><tr><td></td><td>1-30 months</td><td>50</td><td></td></tr><tr><td rowspan="3">Phenytoin</td><td></td><td>0-2 days</td><td>80</td><td>12-18</td></tr><tr><td>3-14 days</td><td>18</td><td></td></tr><tr><td></td><td>14-50 days</td><td>6</td><td></td></tr><tr><td>Salicylate</td><td></td><td>45-11</td><td>10-15</td></tr><tr><td rowspan="2">Theophylline</td><td>Neonate</td><td>13-26</td><td>5-10</td></tr><tr><td></td><td>Child</td><td>3-4</td><td></td></tr></table>
======================================
<table><tr><td>Amiodarone</td><td>Significant</td><td>Large amounts in milk; follow-up of thyroid function in the baby.</td></tr><tr><td>Ampicillin</td><td>Minimal</td><td>No significant adverse effects; possible occurrence of diarrhea or allergic sensitization.</td></tr><tr><td>Aspirin</td><td>Minimal</td><td>Occasional doses are safe.</td></tr><tr><td>Caffeine</td><td>Minimal</td><td>Caffeine intake in moderation is safe; concentration in breast milk is low.</td></tr><tr><td>Chloral hydrate</td><td>Significant</td><td>May cause drowsiness if infant is fed at peak concentration in milk.</td></tr><tr><td>Chloramphenicol</td><td>Significant</td><td>Concentrations too low to cause gray baby syndrome; possibility of bone marrow suppression does exist; recommend not taking chloramphenicol while breast-feeding.</td></tr><tr><td>Chlorothiazide</td><td>Minimal</td><td>No adverse effects reported.</td></tr><tr><td>Chlorpromazine</td><td>Minimal</td><td>Appears insignificant.</td></tr><tr><td>Codeine</td><td>Variable, based on genetic polymorphism</td><td>Safe in most cases. Neonatal toxicity described when the mother is an ultra rapid 2D6 metabolizer, producing substantially more morphine from codeine.</td></tr><tr><td>Dicumarol</td><td>Minimal</td><td>No adverse side effects reported; may wish to follow infant's prothrombin time.</td></tr><tr><td>Digoxin</td><td>Minimal</td><td>Insignificant quantities enter breast milk.</td></tr><tr><td>Ethanol</td><td>Moderate</td><td>Moderate ingestion by mother unlikely to produce effects in infant; large amounts consumed by mother can produce alcohol effects in infant.</td></tr><tr><td>Heroin</td><td>Significant</td><td>Enters breast milk and can prolong neonatal narcotic dependence.</td></tr><tr><td>lodine (radioactive)</td><td>Significant</td><td>Enters milk in quantities sufficient to cause thyroid suppression in infant.</td></tr><tr><td>Isoniazid (INH)</td><td>Minimal</td><td>Milk concentrations equal maternal plasma concentrations. Possibility of pyridoxine deficiency developing in the infant.</td></tr><tr><td>Kanamycin</td><td>Minimal</td><td>No adverse effects reported.</td></tr><tr><td>Lithium</td><td>Variable</td><td>In some cases—but not in others—large amounts enter breast milk.</td></tr><tr><td>Methadone</td><td>Significant</td><td>(See heroin.) Under close physician supervision, breast-feeding can be continued. Signs of opioid withdrawal in the infant may occur if mother stops taking methadone or stops breast-feeding abruptly.</td></tr><tr><td>Oral contraceptives</td><td>Minimal</td><td>May suppress lactation in high doses.</td></tr><tr><td>Penicillin</td><td>Minimal</td><td>Very low concentrations in breast milk.</td></tr><tr><td>Phenobarbital</td><td>Moderate</td><td>Hypnotic doses can cause sedation in the infant.</td></tr><tr><td>Phenytoin</td><td>Moderate</td><td>Amounts entering breast milk are not sufficient to cause adverse effects in infant.</td></tr><tr><td>Prednisone</td><td>Moderate</td><td>Low maternal doses (5 mg/d) probably safe. Doses 2 or more times physiologic amounts (&gt;15 mg/d) should probably be avoided.</td></tr><tr><td>Propranolol</td><td>Minimal</td><td>Very small amounts enter breast milk.</td></tr><tr><td>Propylthiouracil</td><td>Variable</td><td>Rarely may suppress thyroid function in infant.</td></tr><tr><td>Radioactive nuclides</td><td>Will expose baby to radioactivity</td><td>Ensure that mother’s system has cleared the radioactivity.</td></tr><tr><td>Spironolactone</td><td>Minimal</td><td>Very small amounts enter breast milk.</td></tr><tr><td>Tetracycline</td><td>Moderate</td><td>Possibility of permanent staining of developing teeth in the infant. Should be avoided during lactation.</td></tr><tr><td>Theophylline</td><td>Moderate</td><td>Can enter breast milk in moderate quantities but not likely to produce significant effects.</td></tr><tr><td>Thyroxine</td><td>Minimal</td><td>No adverse effects in therapeutic doses.</td></tr><tr><td>Tolbutamide</td><
======================================
td>Minimal</td><td>Low concentrations in breast milk.</td></tr></table>
======================================
<table><thead><th colspan="2">Weight</th><th rowspan="2">Approximate Age</th><th rowspan="2">Surface Area (m?)</th><th rowspan="2">Percent of Adult Dose</th></thead><thead><th>(kg)</th><th>————————___ (Ib)</th><th></th><th></th><th></th></thead><tr><td>3</td><td>6.6</td><td>Newborn</td><td>0.2</td><td>12</td></tr><tr><td>6</td><td>13.2</td><td>3 months</td><td>0.3</td><td>18</td></tr><tr><td>10</td><td>22</td><td>1 year</td><td>0.45</td><td>28</td></tr><tr><td>20</td><td>44</td><td>5.5 years</td><td>0.8</td><td>48</td></tr><tr><td>30</td><td>66</td><td>9 years</td><td>1</td><td>60</td></tr><tr><td>40</td><td>88</td><td>12 years</td><td>1.3</td><td>78</td></tr><tr><td>50</td><td>110</td><td>14 years</td><td>1.5</td><td>90</td></tr><tr><td>60</td><td>132</td><td>Adult</td><td>17</td><td>102</td></tr><tr><td>70</td><td>154</td><td>Adult</td><td>1.76</td><td>103</td></tr></table>
======================================
<table><thead><th>Variable</th><th>Young Adults (20-30 years)</th><th>Older Adults (60-80 years)</th></thead><tr><td>Body water (% of body weight)</td><td>61</td><td>53</td></tr><tr><td>Lean body mass (% of body weight)</td><td>19</td><td>12</td></tr><tr><td rowspan="2">Body fat (% of body weight)</td><td>26-33 (women)</td><td>38-45</td></tr><tr><td></td><td>18-20 (men)</td><td>36-38</td></tr><tr><td>Serum albumin (g/dL)</td><td>47</td><td>3.8</td></tr><tr><td>Kidney weight (% of young adult)</td><td>100</td><td>80</td></tr><tr><td>Hepatic blood flow (% of young adult)</td><td>= 100</td><td>55-60</td></tr></table>
======================================
<table><thead><th>Age-Related Decrease in Hepatic Clearance Found</th><th>No Age-Related Difference Found</th></thead><tr><td>Alprazolam</td><td>Ethanol</td></tr><tr><td>Barbiturates</td><td>Isoniazid</td></tr><tr><td>Carbenoxolone</td><td>Lidocaine</td></tr><tr><td>Chlordiazepoxide</td><td>Lorazepam</td></tr><tr><td>Chlormethiazole</td><td>Nitrazepam</td></tr><tr><td>Clobazam</td><td>Oxazepam</td></tr><tr><td>Desmethyldiazepam</td><td>Prazosin</td></tr><tr><td>Diazepam</td><td>Salicylate</td></tr><tr><td>Flurazepam</td><td>Warfarin</td></tr><tr><td colspan="2">Imipramine</td></tr><tr><td colspan="2">Meperidine</td></tr><tr><td colspan="2">Nortriptyline</td></tr><tr><td colspan="2">Phenylbutazone</td></tr><tr><td colspan="2">Propranolol</td></tr><tr><td colspan="2">Quinidine, quinine</td></tr><tr><td colspan="2">Theophylline</td></tr><tr><td>Tolbutamide</td><td></td></tr></table>
======================================
<table><thead><th>Therapy</th><th>Comment</th></thead><tr><td>Cholinesterase inhibitors</td><td>Increase cholinergic activity; 4 drugs approved</td></tr><tr><td>N-methyl-p-aspartate glutamate antagonists</td><td>Inhibit glutamate excitotoxicity; 1 drug approved</td></tr><tr><td>Modifiers of glucose utilization</td><td>PPAR-y agonists</td></tr><tr><td>Antilipid drugs</td><td>Statins (off-label use)</td></tr><tr><td>Retinoid X receptor</td><td>Bexarotene transiently reduced AB in mice</td></tr><tr><td>NSAIDs</td><td>Disappointing results with cyclooxy- genase (COX)-2 inhibitors but interest continues</td></tr><tr><td>Anti-amyloid vaccines</td><td>In clinical trials</td></tr><tr><td>Anti-amyloid antibodies</td><td>Bapineuzumab and solanezumab failed clinical trials but did modify AB kinetics; should treatment be started before symptoms appear?</td></tr><tr><td>Inhibitors of AB synthesis.</td><td>y-Secretase modulator studies in progress</td></tr><tr><td>Microtubule stabilizers</td><td>Drugs that inhibit disassembly of microtubules reduce accumulation of tau protein tangles in mice</td></tr><tr><td>Anticytokine antibodies</td><td>Anti-IL-12 and -23 antibodies reversed age-related cognitive decline and AB accumulation in mice</td></tr><tr><td>Antioxidants</td><td>Disappointing results</td></tr><tr><td>Nerve growth factor</td><td>One very small trial</td></tr><tr><td>PERK inhibitor GSK2606414</td><td>Preliminary study in mice</td></tr></table>
======================================
<table><thead><th>Reaction Type</th><th>Mechanism</th><th>Comment</th></thead><tr><td>Irritation</td><td>Nonallergic</td><td>Most common local reaction</td></tr><tr><td>Photoirritation</td><td>Nonallergic</td><td>Phototoxicity; usually requires UVA exposure</td></tr><tr><td>Allergic contact dermatitis</td><td>Allergic</td><td>Type IV delayed hypersensitivity</td></tr><tr><td>Photoallergic contact dermatitis</td><td>Allergic</td><td>Type IV delayed hypersensitivity; usually requires UVA exposure</td></tr><tr><td>Immunologic contact urticaria</td><td>Allergic</td><td>IgE-mediated type | immediate hypersensitivity; may result in anaphylaxis</td></tr><tr><td>Nonimmunologic contact urticaria</td><td>Nonallergic</td><td>Most common contact urticaria; occurs without prior sensitization</td></tr></table>
======================================
<table><thead><th>Biologic Agent</th><th>Usual Adult Dosage</th></thead><tr><td>Adalimumab—Humira</td><td>80 mg SC x 1, then 40 mg q2 weeks</td></tr><tr><td>Etanercept—Enbrel</td><td>50 mg SC twice/week x 12 weeks, then once/week</td></tr><tr><td>Infliximab—Remicade</td><td>5 mg/kg IV at 0, 2, and 6 weeks, then q8 weeks</td></tr><tr><td>Ixekizumab—Taltz</td><td>160 mg at 0 weeks and 80 mg at 2, 4, 6, 8, 10, and 12 weeks, then q4 weeks</td></tr><tr><td>Secukinumab—Cosentyx</td><td>300 mg SC at 0, 1, 2, 3, and 4 weeks, then q4 weeks</td></tr><tr><td>Ustekinumab—Stelara</td><td>Either 45 mg or 90 mg SC at 0 and 4 weeks, then q12 weeks (dose for psoriasis is 45 mg for patients weighing &lt;100 kg and 90 mg for those weighing =100 kg)</td></tr></table>
======================================
<table><thead><th rowspan="2">Day 1 AM</th><th colspan="2">Day 2</th><th colspan="2">Day 3</th><th colspan="2">Day 4</th><th colspan="2">Day 5</th><th colspan="2">Day 6 &amp; Thereafter</th></thead><thead><th></th><th>AM</th><th>PM</th><th>AM</th><th>PM</th><th>AM</th><th>PM</th><th>AM</th><th>PM</th><th>AM</th><th>PM</th></thead><tr><td>10mg</td><td>10 mg</td><td>10mg</td><td>10 mg</td><td>20 mg</td><td>20 mg</td><td>20mg</td><td>20mg</td><td>30mg</td><td>30 mg</td><td>30 mg</td></tr></table>
======================================
<table><thead><th>Commonly Used Preparations</th><th>Drug</th><th>Commonly Used Preparations</th><th>Drug</th></thead><tr><td>Lowest efficacy</td><td></td><td colspan="2">Intermediate efficacy (continued)</td></tr><tr><td>0.25-2.5%</td><td>Hydrocortisone</td><td>0.05%</td><td>Fluticasone propionate (Cutivate)</td></tr><tr><td>0.25%</td><td>Methylprednisolone acetate (Medrol)</td><td>0.05%</td><td>Desonide (Desowen)</td></tr><tr><td>0.1%</td><td>Dexamethasone’ (Decaderm)</td><td>0.025%</td><td>Halcinonide' (Halog)</td></tr><tr><td>1.0%</td><td>Methylprednisolone acetate (Medrol)</td><td>0.05%</td><td>Desoximetasone’ (Topicort L.P.)</td></tr><tr><td>0.5%</td><td>Prednisolone (MetiDerm)</td><td>0.05%</td><td>Flurandrenolide' (Cordran)</td></tr><tr><td>0.2%</td><td>Betamethasone’ (Celestone)</td><td>0.1%</td><td>Triamcinolone acetonide’</td></tr><tr><td>Low efficacy</td><td></td><td>0.025%</td><td>Fluocinolone acetonide’</td></tr><tr><td>0.01%</td><td>Fluocinolone acetonide’ (Fluonid, Synalar)</td><td>High efficacy</td><td></td></tr><tr><td>0.01%</td><td>Betamethasone valerate’ (Valisone)</td><td>0.05%</td><td>Fluocinonide' (Lidex)</td></tr><tr><td>0.025%</td><td>Fluorometholone’ (Oxylone)</td><td>0.05%</td><td>Betamethasone dipropionate’ (Diprosone,</td></tr><tr><td></td><td></td><td></td><td>Maxivate)</td></tr><tr><td>0.05% 0.025%</td><td>Alclometasone dipropionate (Aclovate) Triamcinolone acetonide’</td><td>0.1%</td><td>Amcinonide' (Cyclocort)</td></tr><tr><td></td><td>(Aristocort, Kenalog, Triacet)</td><td>0.25%</td><td>Desoximetasone’ (Topicort)</td></tr><tr><td>0.1%</td><td>Clocortolone pivalate’ (Cloderm)</td><td>0.5%</td><td>Triamcinolone acetonide’</td></tr><tr><td>0.03%</td><td>Flumethasone pivalate’ (Locorten)</td><td>0.2%</td><td>Fluocinolone acetonide’ (Synalar-HP)</td></tr><tr><td>Intermediate efficacy</td><td></td><td>0.05%</td><td>Diflorasone diacetate’ (Florone, Maxiflor)</td></tr><tr><td>0.2%</td><td>Hydrocortisone valerate (Westcort)</td><td>0.1%</td><td>Halcinonide' (Halog)</td></tr><tr><td>0.1%</td><td>Mometasone furoate (Elocon)</td><td>Highest efficacy</td><td></td></tr><tr><td>0.1%</td><td>Hydrocortisone butyrate (Locoid)</td><td>0.05%</td><td>Betamethasone dipropionate in optimized</td></tr><tr><td>0.1%</td><td>Hydrocortisone probutate (Pandel)</td><td></td><td>vehicle (Diprolene)'</td></tr><tr><td>0.025%</td><td>Betamethasone benzoate’ (Uticort)</td><td>0.05%</td><td>Diflorasone diacetate’ in optimized vehicle (Psorcon)</td></tr><tr><td>0.025%</td><td>Flurandrenolide' (Cordran)</td><td>0.05%</td><td rowspan="2">Halobetasol propionate’ (Ultravate) Clobetasol propionate’ (Temovate)</td><td></td></tr><tr><td>0.1%</td><td>Betamethasone valerate’ (Valisone)</td><td>0.05%</td></tr></table>
======================================
<table><tr><td>Very responsive</td></tr><tr><td>Atopic dermatitis</td></tr><tr><td>Seborrheic dermatitis</td></tr><tr><td>Lichen simplex chronicus.</td></tr><tr><td>Pruritus ani</td></tr><tr><td>Later phase of allergic contact dermatitis</td></tr><tr><td>Later phase of irritant dermatitis</td></tr><tr><td>Nummular eczematous dermatitis</td></tr><tr><td>Stasis dermatitis</td></tr><tr><td>Psoriasis, especially of genitalia and face</td></tr><tr><td>Less responsive</td><td></td></tr><tr><td>Discoid lupus erythematosus</td></tr><tr><td>Psoriasis of palms and soles</td><td></td></tr><tr><td>Necrobiosis lipoidica diabeticorum</td></tr><tr><td>Sarcoidosis</td><td></td></tr><tr><td>Lichen striatus</td></tr><tr><td>Pemphigus</td></tr><tr><td>Familial benign pemphigus</td><td></td></tr><tr><td>Pemphigoid</td><td></td></tr><tr><td>Vitiligo</td></tr><tr><td>Granuloma annulare</td></tr><tr><td>Least responsive: Intralesional injection required</td></tr><tr><td>Keloids</td></tr><tr><td>Hypertrophic scars</td></tr><tr><td>Hypertrophic lichen planus</td></tr><tr><td>Alopecia areata</td></tr><tr><td>Acne cysts</td></tr></table>
======================================
<table><thead><th>Active Ingredient</th><th>Typical Trade Name</th></thead><tr><td>Betamethasone valerate foam</td><td>Luxiq</td></tr><tr><td>Chloroxine shampoo</td><td>Capitrol</td></tr><tr><td>Coal tar shampoo</td><td>lonil-T, Pentrax, Theraplex-T, T-Gel</td></tr><tr><td>Fluocinolone acetonide shampoo</td><td>FS Shampoo</td></tr><tr><td>Ketoconazole shampoo and gel</td><td>Nizoral, Xolegel</td></tr><tr><td>Selenium sulfide shampoo</td><td>Selsun, Exsel</td></tr><tr><td>Zinc pyrithione shampoo</td><td>DHS-Zinc, Theraplex-Z</td></tr></table>
======================================
<table><thead><th>Drug or Group</th><th>Conditions</th><th>For More Details, See:</th></thead><tr><td>Antihistamines</td><td>Pruritus (any cause), urticarial</td><td>Chapter 16</td></tr><tr><td>Antimalarials</td><td>Lupus erythematosus, photosensitization</td><td>Chapters 36, 52</td></tr><tr><td>Antimetabolites</td><td>Pemphigus, pemphigoid</td><td>Chapter 54</td></tr><tr><td>Becaplermin</td><td>Diabetic neuropathic ulcers</td><td>Chapter 41</td></tr><tr><td>Belimumab</td><td>Systemic lupus erythematosus</td><td>Chapters 36, 54</td></tr><tr><td>Capsaicin</td><td>Postherpetic neuralgia</td><td>Chapter 31</td></tr><tr><td>Corticosteroids</td><td>Pemphigus, pemphigoid, lupus erythematosus, allergic contact dermatoses, and certain other dermatoses</td><td>Chapter 39</td></tr><tr><td>Cyclosporine</td><td>Psoriasis</td><td>Chapter 55</td></tr><tr><td>Dapsone</td><td>Dermatitis herpetiformis, erythema elevatum diutinum, pemphigus, pemphigoid, bullous lupus erythematosus</td><td>Chapter 47</td></tr><tr><td>Denileukin diftitox</td><td>Cutaneous T-cell lymphomas</td><td>Chapters 54, 55</td></tr><tr><td>Drospirenone/ethinyl estradiol</td><td>Moderate female acne</td><td>Chapter 39</td></tr><tr><td>Mechlorethamine gel</td><td>Cutaneous T-cell lymphoma</td><td>Chapter 54</td></tr><tr><td>Methotrexate</td><td>Psoriasis</td><td>Chapter 54</td></tr><tr><td>Mycophenolate mofetil</td><td>Bullous disease</td><td>Chapters 54, 55</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Relative Potency</th><th>Dose to Achieve &gt;50% Acid Inhibition for 10 Hours</th><th>Usual Dose for Acute Duodenal or Gastric Ulcer</th><th>Usual Dose for Gastroesophageal Reflux Disease</th><th>Usual Dose for Prevention of Stress- Related Bleeding</th></thead><tr><td>Cimetidine</td><td></td><td>400-800 mg</td><td>800 mg HS or 400 mg bid</td><td>800 mg bid</td><td>50 mg/h continuous infusion</td></tr><tr><td>Ranitidine</td><td></td><td>150 mg</td><td>300 mg HS or 150 mg bid</td><td>150 mg bid</td><td>6.25 mg/h continuous infusion or 50 mg IV every 6-8 h</td></tr><tr><td>Nizatidine</td><td></td><td>150 mg</td><td>300 mg HS or 150 mg bid</td><td>150 mg bid</td><td>Not available</td></tr><tr><td>Famotidine</td><td></td><td>20 mg</td><td>40 mg HS or 20 mg bid</td><td>20 mg bid</td><td>20 mg IV every 12h</td></tr></table>
======================================
<table><thead><th>Drug</th><th>pK,</th><th>Bioavailability (%)</th><th>typ (h)</th><th>Trax (h)</th><th>Usual Dosage for Peptic Ulcer or GERD</th></thead><tr><td>Omeprazole</td><td></td><td>40-65</td><td>0.5-1.0</td><td>1-3</td><td>20-40 mg qd</td></tr><tr><td>Esomeprazole</td><td></td><td>&gt;80</td><td>1</td><td>1.6</td><td>20-40 mg qd</td></tr><tr><td>Lansoprazole</td><td></td><td>&gt;80</td><td>1.0-2.0</td><td>17</td><td>30 mg qd</td></tr><tr><td>Dexlansoprazole</td><td></td><td></td><td>1.0-2.0</td><td>5.0</td><td>30-60 mg qd</td></tr><tr><td>Pantoprazole</td><td></td><td>77</td><td>1.0-1.9</td><td>2.5-4.0</td><td>40 mg qd</td></tr><tr><td>Rabeprazole</td><td></td><td>52</td><td>0-2.</td><td>b 3.1</td><td>20 mg qd</td></tr></table>
======================================
<table><thead><th>Disease severity</th><th>Therapy</th><th>Responsiveness to therapy</th></thead><tr><td>Severe</td><td>Surgery Natalizumab Cyclosporine TNF antagonists Intravenous corticosteroids</td><td>Refractory</td></tr><tr><td>Moderate</td><td>TNF antagonists Oral corticosteroids Methotrexate Azathioprine / 6-Mercaptopurine</td><td></td></tr><tr><td>Mild</td><td>Budesonide (ileitis) Topical corticosteroids (proctitis) Antibiotics 5-Aminosalicylates</td><td>Responsive</td></tr></table>
======================================
<table><thead><th></th><th>Infliximab</th><th>Adalimumab</th><th>Certolizumab</th><th>Golimumab</th></thead><tr><td>Class</td><td>Monoclonal antibody</td><td>Monoclonal antibody</td><td>Monoclonal antibody</td><td>Monoclonal antibody</td></tr><tr><td>% Human</td><td>75%</td><td>100%</td><td>95%</td><td>100%</td></tr><tr><td>Structure</td><td>IgG,</td><td>IgG,</td><td>Fab fragment attached to PEG (lacks Fc portion)</td><td>IgG,</td></tr><tr><td>Route of administration</td><td>Intravenous</td><td>Subcutaneous</td><td>Subcutaneous</td><td>Subcutaneous</td></tr><tr><td>Half-life</td><td>8-10 days</td><td>10-20 days</td><td>14 days</td><td>14 days</td></tr><tr><td>Neutralizes soluble TNF</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Neutralizes membrane-bound TNF</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Induces apoptosis of cells expressing membrane-bound TNF</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Complement-mediated cytotoxicity of cells expressing membrane- bound TNF</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Induction dose</td><td>5 mg/kg at 0, 2, and 6 weeks</td><td>160 mg, 80 mg, and 40 mg at 0, 2, and 4 weeks</td><td>400 mg at 0, 2, and 4 weeks</td><td>200 mg, 100 mg at 0, 2 weeks</td></tr><tr><td>Maintenance dose</td><td>5 mg/kg every 8 weeks</td><td>40 mg every 2 weeks</td><td>400 mg every 4 weeks</td><td>100 mg every 4 weeks</td></tr></table>
======================================
<table><thead><th>bclass, Drug</th><th></th><th></th><th></th><th>Pharmacokinetics, To: Interactions</th></thead><tr><td colspan="5">DRUGS USED IN ACID-PEPTIC DISEASES</td></tr><tr><td>+ Proton-pump inhibitors (PPIs), eg, omeprazole, lansoprazole</td><td>Irreversible blockade of H'/ K*-ATPase pump in active parietal cells of stomach</td><td>Long-lasting reduction of stimulated and nocturnal acid secretion</td><td>Peptic ulcer, gastroesophageal reflux disease, erosive gastritis</td><td>Half-lives much shorter than duration of action + low toxicity + reduction of stomach acid may reduce absorption of some drugs and increase that of others</td></tr></table>
======================================
<table><thead><th>Subclass, Drug</th><th>Mechanism of Action</th><th>Effects</th><th>Clinical Applications</th><th>Pharmacokinetics, Toxicities, Interactions</th></thead><tr><td colspan="5">ANTIEMETIC DRUGS</td></tr><tr><td>+ Ondansetron, other 5-HT; antagonists</td><td>5-HT; blockade in gut and CNS with shorter duration of binding than alosetron</td><td>Extremely effective in preventing chemotherapy- induced and postoperative nausea and vomiting</td><td>First-line agents in cancer chemotherapy; also useful for postop emesis</td><td>Usually given IV but orally active in prophylaxis + 4-9 h duration of action + very low toxicity but may slow colonic transit</td></tr><tr><td>+ Aprepitant</td><td>NK,-receptor blocker in CNS</td><td>Interferes with vomiting reflex + no effect on 5-HT, dopamine, or steroid receptors</td><td>Effective in reducing both early and delayed emesis in cancer chemotherapy</td><td>Given orally « lV fosaprepitant available + fatigue, dizziness, diarrhea + CYP interactions</td></tr><tr><td>+ Corticosteroids: Mechanism</td><td>not known but useful in antiemetic</td><td>IV cocktails</td><td></td><td></td></tr></table>
======================================
<table><tr><td>5-Aminosalicylates, eg, mesalamine in many formulations Sulfasalazine</td><td>Mechanism uncertain » may be inhibition of eicosanoid inflammatory mediators</td><td>Topical therapeutic action + systemic absorption may cause toxicity</td><td>Mild to moderately severe Crohn's disease and ulcerative colitis</td><td>Sulfasalazine causes sulfonamide toxicity and may cause Gl upset, myalgias, arthralgias, myelosuppression + other aminosalicylates much less toxic</td></tr><tr><td>Purine analogs and antimetabolites, eg, 6-mercaptopurine, methotrexate</td><td>Mechanism uncertain » may promote apoptosis of immune cells » Methotrexate blocks dihydrofolate reductase</td><td>Generalized suppression of immune processes</td><td>Moderately severe to severe Crohn's disease and ulcerative colitis</td><td>Gl upset, mucositis - myelosuppression + purine analogs may cause hepatotoxicity, but rare with methotrexate at the low doses used</td></tr><tr><td>Anti-TNF antibodies, eg, infliximab, others</td><td>Bind tumor necrosis factor and prevent it from binding to its receptors</td><td>Suppression of several aspects of immune function, especially TH1 lymphocytes</td><td>Infliximab: Moderately severe to severe Crohn's disease and ulcerative colitis » others approved in Crohn's disease</td><td>Infusion reactions + reactivation of latent tuberculosis + increased risk of dangerous systemic fungal and bacterial infections</td></tr></table>
======================================
<table><tr><td>5-Aminosalicylates, eg, mesalamine in many formulations Sulfasalazine</td><td>Mechanism uncertain » may be inhibition of eicosanoid inflammatory mediators</td><td>Topical therapeutic action + systemic absorption may cause toxicity</td><td>Mild to moderately severe Crohn's disease and ulcerative colitis</td><td>Sulfasalazine causes sulfonamide toxicity and may cause Gl upset, myalgias, arthralgias, myelosuppression + other aminosalicylates much less toxic</td></tr><tr><td>Purine analogs and antimetabolites, eg, 6-mercaptopurine, methotrexate</td><td>Mechanism uncertain » may promote apoptosis of immune cells » Methotrexate blocks dihydrofolate reductase</td><td>Generalized suppression of immune processes</td><td>Moderately severe to severe Crohn's disease and ulcerative colitis</td><td>Gl upset, mucositis - myelosuppression + purine analogs may cause hepatotoxicity, but rare with methotrexate at the low doses used</td></tr><tr><td>Anti-TNF antibodies, eg, infliximab, others</td><td>Bind tumor necrosis factor and prevent it from binding to its receptors</td><td>Suppression of several aspects of immune function, especially TH1 lymphocytes</td><td>Infliximab: Moderately severe to severe Crohn's disease and ulcerative colitis » others approved in Crohn's disease</td><td>Infusion reactions + reactivation of latent tuberculosis + increased risk of dangerous systemic fungal and bacterial infections</td></tr></table>
======================================
<table><thead><th colspan="5">+ Pancreatin: Similar pancreatic extracts but much lower potency; rarely used</th></thead><thead><th colspan="5">BILE ACID THERAPY FOR GALLSTONES AND PRIMARY BILIARY CIRRHOSIS</th></thead><thead><th>+ Ursodiol</th><th>Reduces cholesterol secretion into bile and concentration of endogenous hepatocyte bile salts</th><th>Dissolves gallstones + reduces hepatic inflammation and fibrosis</th><th>Gallstones in patients refusing or not eligible for surgery + early primary biliary cirrhosis</th><th>May cause diarrhea</th></thead><tr><td>+ Obeticholic acid</td><td>Binds to hepatocyte nuclear farnesoid X receptor</td><td>Reduces hepatic inflammation and fibrosis</td><td>Treatment of primary biliary cirrhosis in patients with inadequate response to ursodiol</td><td>Severe pruritus</td></tr><tr><td colspan="5">DRUGS USED TO TREAT VARICEAL HEMORRHAGE</td><td rowspan="3">Reduced endocrine and exocrine pancreatic activity + other endocrine abnormalities - Gl upset</td></tr><tr><td>+ Octreotide</td><td>Somatostatin analog + mechanism not certain</td><td>May alter portal blood flow and variceal pressures</td><td>Patients with bleeding varices or at high risk of repeat bleeding</td><td></td></tr><tr><td colspan="5">+ Beta blockers: Reduce cardiac output and splanchnic blood flow; see Chapter 10</td><td></td></tr></table>
======================================
<table><tr><td>Aluminum hydroxide gel”</td><td>Generic, AlternaGEL, others</td></tr><tr><td>Calcium carbonate”</td><td>Generic, Tums, others</td></tr><tr><td>Combination aluminum hydroxide and magnesium hydroxide preparations”</td><td>Generic, Maalox, Mylanta, Gaviscon, Gelusil, others</td></tr><tr><td colspan="2">H, HISTAMINE RECEPTOR BLOCKERS</td></tr><tr><td>Cimetidine</td><td>Generic, Tagamet, Tagamet HB™</td></tr><tr><td>Famotidine</td><td>Generic, Pepcid, Pepcid AG, Pepcid Complete®</td></tr><tr><td>Nizatidine</td><td>Generic, Axid, Axid AR"</td></tr><tr><td>Ranitidine</td><td>Generic, Zantac, Zantac 75</td></tr><tr><td>Atropine</td><td>Generic</td></tr><tr><td>Belladonna alkaloids tincture</td><td>Generic</td></tr><tr><td>Dicyclomine</td><td>Generic, Bentyl, others</td></tr><tr><td>Glycopyrrolate</td><td>Generic, Robinul</td></tr><tr><td>Hyoscyamine</td><td>Anaspaz, Levsin, others</td></tr><tr><td colspan="2">Scopolamine Generic, Transderm Scop</td></tr><tr><td colspan="2">Esomeprazole magnesium Nexium*</td></tr><tr><td colspan="2">Esomeprazole strontium Prilosec OTC”</td></tr><tr><td>Omeprazole Omeprazole-sodium bicarbonate</td><td>Generic, Prilosec, —Zegerid</td></tr><tr><td>Lansoprazole</td><td>Generic, Prevacid”</td></tr><tr><td></td><td>Dexilant</td></tr><tr><td>Dexlansoprazole</td><td></td></tr><tr><td>Pantoprazole</td><td>Generic, Protonix</td></tr><tr><td>Rabeprazole</td><td>Generic, Aciphex</td></tr><tr><td>Sucralfate</td><td>Generic, Carafate</td></tr><tr><td>Pancrelipase</td><td>Creon, Pancrease, Zenpep, Pertyze, Ultresa</td></tr><tr><td colspan="2">DRUGS FOR MOTILITY DISORDERS &amp; SELECTED ANTIEMETICS</td></tr><tr><td colspan="2">5-HT;-RECEPTOR ANTAGONISTS</td></tr><tr><td>Alosetron</td><td>Lotronex</td></tr><tr><td>Dolasetron</td><td>Anzemet</td></tr><tr><td>Granisetron</td><td>Generic, Kytril</td></tr><tr><td>Ondansetron</td><td>Generic, Zofran</td></tr><tr><td>Palonosetron</td><td>Aloxi</td></tr></table>
======================================
<table><thead><th>Aprepitant</th><th>Emend</th></thead><tr><td>Dronabinol</td><td>Generic, Marinol</td></tr><tr><td>Fosaprepitant</td><td>Emend, Emend IV</td></tr><tr><td>Metoclopramide</td><td>Generic, Reglan, others</td></tr><tr><td>Nabilone</td><td>Cesamet</td></tr><tr><td>Netupitant/palonosetron</td><td>Akynzeo</td></tr><tr><td>Prochlorperazine</td><td>Generic, Compazine</td></tr><tr><td>Promethazine</td><td>Generic, Phenergan, others</td></tr><tr><td>Rolapitant</td><td>Varubi</td></tr></table>
======================================
<table><tr><td>Adalimumab</td><td>Humira</td></tr><tr><td>Balsalazide</td><td>Colazal</td></tr><tr><td>Budesonide</td><td>Entocort, Uceris</td></tr><tr><td>Certolizumab</td><td>Cimzia</td></tr><tr><td>Golimumab</td><td>Symponi</td></tr><tr><td>Hydrocortisone</td><td>Cortenema, Cortifoam, Proctofoam—HC</td></tr><tr><td>Infliximab</td><td>Remicade</td></tr><tr><td>Mesalamine</td><td>5-ASA</td></tr><tr><td>Oral:</td><td>Asacol</td></tr><tr><td>Rectal:</td><td>Rowasa, Canasa</td></tr><tr><td>Methylprednisolone</td><td>Medrol Enpack</td></tr><tr><td>Olsalazine</td><td>Dipentum</td></tr><tr><td>Sulfasalazine</td><td>Generic, Azulfidine</td></tr><tr><td>Vedolizumab</td><td>Entyvio</td></tr><tr><td>Bismuth subsalicylate”</td><td>Pepto-Bismol, others</td></tr><tr><td>Difenoxin</td><td>Motofen</td></tr><tr><td>Diphenoxylate</td><td>Generic, Lomotil, others</td></tr><tr><td>Eluxadoline</td><td>Viberzi</td></tr><tr><td>Loperamide”</td><td>Generic, Imodium</td></tr><tr><td>Methylcellulose</td><td>Generic, Citrucel</td></tr><tr><td>Psyllium</td><td>Generic, Serutan, Metamucil, others</td></tr><tr><td>Alvimopan</td><td>Entereg</td></tr><tr><td>Bisacodyl"</td><td>Generic, Dulcolax, others</td></tr><tr><td>Cascara sagrada”</td><td>Generic</td></tr></table>
======================================
<table><thead><th>Alvimopan</th><th>Entereg</th></thead><tr><td>Bisacodyl"</td><td>Generic, Dulcolax, others</td></tr><tr><td>Cascara sagrada”</td><td>Generic</td></tr><tr><td>Docusate”</td><td>Generic, Colace, others</td></tr><tr><td>Lactulose</td><td>Generic, Chronulac, Cephulac, others</td></tr><tr><td>Linaclotide</td><td>Linzess</td></tr><tr><td>Lubiprostone</td><td>Amitiza</td></tr><tr><td>Magnesium hydroxide (milk of magnesia, Epsom Salt)”</td><td>Generic</td></tr><tr><td>Methylnaltrexone bromide</td><td>Relistor</td></tr><tr><td>Polycarbophil*</td><td>Equalactin, Mitrolan, FiberCon, Fiber-Lax</td></tr><tr><td>Polyethylene glycol electrolyte solution</td><td>Co-Lyte, GoLYTELY, HalfLytely, Moviprep, others</td></tr><tr><td>Senna’</td><td>Senokot, ExoLax, others</td></tr><tr><td>Sodium Phosphate</td><td>Fleets Phospho-soda, OsmoPrep, Visicol</td></tr><tr><td colspan="2">DRUGS THAT DISSOLVE GALLSTONES</td></tr><tr><td>Obeticholic acid</td><td>Ocaliva</td></tr></table>
======================================
<table><thead><th>Ingredient</th><th>Indication (Pharmacologic Category)</th><th>Year Ingredient First Switched</th><th>Single-Ingredient Product Examples</th></thead><tr><td>Adapalene</td><td>Acne (topical retinoid)</td><td>2016</td><td>Differin Gel</td></tr><tr><td>Budesonide</td><td>Allergic rhinitis (topical glucocorticoid)</td><td>2015</td><td>Rhinocort Allergy Spray</td></tr><tr><td>Cetirizine</td><td>Hay fever/upper respiratory allergies (antihistamine)</td><td>2007</td><td>Zyrtec</td></tr><tr><td>Esomeprazole</td><td>Acid reducer (proton-pump inhibitor)</td><td>2014</td><td>Nexium 24 hour</td></tr><tr><td>Fexofenadine</td><td>Hay fever/upper respiratory allergies (antihistamine)</td><td>2011</td><td>Allegra 12 hour, Allegra 24 hour</td></tr><tr><td>Fluticasone</td><td>Allergic rhinitis (topical glucocorticoid)</td><td>2014</td><td>Flonase Allergy Relief, Flonase Sensimist Allergy-Relief</td></tr><tr><td>Ketotifen</td><td>Itchy eyes (ophthalmic antihistamine)</td><td>2006</td><td>Alaway, Zaditor</td></tr><tr><td>Lansoprazole</td><td>Acid reducer (proton-pump inhibitor)</td><td>2009</td><td>Prevacid 24 hour</td></tr><tr><td>Levocetirizine</td><td>Hay fever/upper respiratory allergies (antihistamine)</td><td>2017</td><td>Xyzal</td></tr><tr><td>Levonorgestrel</td><td>Emergency contraceptive (progestin)</td><td>2006</td><td>Plan B One-Step</td></tr><tr><td>Orlistat</td><td>Weight loss aid (lipase inhibitor)</td><td>2007</td><td>Alli</td></tr><tr><td>Oxybutynin</td><td>Overactive bladder (transdermal anticholinergic)</td><td>2013</td><td>Oxytrol for Women</td></tr><tr><td>Polyethylene glycol</td><td>Constipation (osmotic laxative)</td><td>2006</td><td>MiraLAX</td></tr><tr><td>Triamcinolone</td><td>Allergic rhinitis (topical glucocorticoid)</td><td>2013</td><td>Nasacort Allergy 24 hour</td></tr></table>
======================================
<table><thead><th rowspan="3">Acid reducers (H, antagonists) Acid reducers</th><th rowspan="3">Cimetidine (Tagamet HB) Famotidine (Pepcid AC) Ranitidine (Zantac 75, Zantac 150) Esomeprazole</th><th rowspan="3">Relief and prevention of heartburn asso- ciated with acid indigestion. Treatment of</th><th rowspan="3">Avoid use: in children &lt;12 years of age; if patient has trouble or pain swallowing food, vomiting with blood, or bloody or black stools; with other acid reducers; if symptoms include heartburn with lightheadedness, sweating, dizziness, or chest pain; for treatment durations &gt;14 days. Adverse effects include: nausea, agitation, headache, dizziness, agitation, and gynecomastia (cimetidine; rare). Avoid use: in children &lt;18 years</th><th>To prevent symptoms, take 30-60 minutes before consuming food or beverages that cause heartburn.</th></thead><thead><th></th><th></th><th></th><th></th><th>Cimetidine may increase the serum concentrations of theophylline, warfarin, and phenytoin.</th></thead><thead><th></th><th></th><th></th><th></th><th>Not intended for immediate relief (products</th></thead><tr><td rowspan="2">(proton-pump inhibitors [PPI])</td><td>(Nexium 24 hour) Lansoprazole (Prevacid 24 hour) Omeprazole (Pri- losec OTC)</td><td rowspan="2">frequent heart- burn (occurs 2 or more days a week).</td><td>of age; if patient has trouble or pain swallowing food, vomiting with blood, or bloody or black stools; if symptoms include heartburn with lightheaded- ness, sweating, dizziness, or chest pain; for treatment durations &gt;14 days.</td><td>take 1-4 days for full effect). Take with water before eating in the morning. Patients may repeat a 2-week course of therapy every 4 months. PPI therapy can increase risk of Clostridium difficile-associated diarrhea and risk of</td></tr><tr><td></td><td></td><td></td><td>Adverse effects include: head- ache, abdominal pain, nausea, diarrhea, and flatulence.</td><td>Esomeprazole, lansoprazole, and omeprazole may interact with warfarin, clopidogrel, cilostazol, antifungal medications, diazepam, digoxin, tacrolimus, and HIV antiretrovirals.</td></tr><tr><td rowspan="4">Allergy preparations</td><td></td><td rowspan="4">Chlorpheniramine (Chlor-Trimeton) Clemastine (Tavist Allergy) Cetirizine (Zyrtec) Diphenhydramine (Benadryl Allergy) Fexofenadine (Allegra 12 hour, Allegra 24 hour) Levocetirizine (Xyzal) Loratadine (Alavert, Claritin)</td><td></td><td>Temporary relief of the following</td><td rowspan="3">Avoid use: in children &lt;2 years of age; in combination with other sedatives and alcohol as sedative effects may be potentiated. Use caution when driving or operating machinery. Adverse effects include: drowsi-</td><td>Diphenhydramine is the most sedating antihistamine.</td></tr><tr><td></td><td></td><td>symptoms due to hay fever or upper respiratory</td><td></td><td>Consult product labeling before use in children ages 2-11 years.</td></tr><tr><td></td><td></td><td>allergies: sneezing, runny nose, itchy,</td><td></td><td>First-generation antihistamines (chlorpheni- ramine, clemastine, diphenhydramine) may cause excitability in children.</td></tr><tr><td>watery eyes, itching of nose or throat.</td><td>ness, dizziness, fatigue, nausea, and urinary retention. Antihistamines are contained in many OTC preparations in combination with analgesics, decongestants, and expectorants. See the warnings section for each formulation.</td><td>Second-generation antihistamines (cetirizine, fexofenadine, levocetirizine, loratadine) have minimal anticholinergic effects and are associated with lower chances of sedation.</td></tr></table>
======================================
<table><thead><th>Igesics and</th><th>Acetaminophen</th><th>Temporary</th><th>Acetaminophen</th><th>Acetaminophen</th></thead><tr><td rowspan="4"></td><td>(NSAIDs) Aspirin (Ecotrin)</td><td>aches, pains, and headaches.</td><td>3 or more alcoholic beverages daily due to an increased risk of severe liver damage.</td><td>+ Many products may include acetaminophen, which can lead to unintentional overdose.</td></tr><tr><td></td><td>Ibuprofen (Advil,</td><td></td><td>Adverse effects include:</td><td>Aspirin and other NSAIDs</td></tr><tr><td></td><td>Motrin IB) Naproxen (Aleve)</td><td></td><td>drowsiness, hepatotoxicity (dose related), nephrotoxicity (with chronic overdose), and hypersensitivity reactions (rare).</td><td>+ Use can increase risk of severe gastrointestinal hemorrhage in individu: age 60 or older; with peptic ulcer diseas</td></tr><tr><td></td><td></td><td></td><td>renal insufficiency; hepatic insufficiency; in children or teenagers with chickenpox or flu-like symptoms due to</td><td>Maximum recommended adult daily do: for OTC use: aspirin (3900 mg); ibuprofer (1200 mg); naproxen (660 mg). May reduce the effectiveness of medica-</td></tr></table>
======================================
<table><thead><th colspan="3">Antidiarrheal agents (cont.)</th><th>Adverse effects include: fecal discoloration (black, tarry), tongue discoloration (darkening), and tinnitus (dose- related and more likely when coadministered with aspirin).</th><th></th></thead><thead><th></th><th></th><th></th><th>Loperamide</th><th></th></thead><thead><th></th><th></th><th></th><th>Avoid use in: children &lt;12 years of age; patients with bloody or black stools.</th><th></th></thead><thead><th></th><th></th><th></th><th>Adverse effects include: abdom- inal pain, nausea, constipation, drowsiness, dizziness, and dry mouth.</th><th></th></thead><tr><td rowspan="5">Antifungal preparations (topical)</td><td>Butenafine (Lotrimin Ultra) Clotrimazole</td><td>Relieves itching, burning, scaling, chafing, and</td><td rowspan="4">For external use only. Avoid contact with eyes, nose, mouth, or other mucous membranes. Avoid use: in children &lt;2 years of age (clotrimazole, micon- azole, tolnaftate) or children &lt;12 years of age (butenafine, terbinafine). Adverse effects include: erythema, irritation, itching, and</td><td>+ For treatment of athlete's foot, apply product to spaces between toes and change shoes and socks daily.</td></tr><tr><td></td><td>(Lotrimin Antifungal) Miconazole (Desenex, Lotrimin AF)</td><td>discomfort asso- ciated with tinea pedis (athlete's foot), tinea cruris</td><td></td><td></td></tr><tr><td></td><td>Terbinafine (Lamisil AT)</td><td>(jock itch), tinea corporis (ringworm).</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Tolnaftate (Tinactin)</td><td></td><td>burning.</td><td></td></tr><tr><td rowspan="5">Antifungal preparations (vaginal)</td><td>Clotrimazole (Gyne-Lotrimin) Miconazole (Monistat-1,</td><td rowspan="3">Treatment of vaginal yeast (candidiasis) infections and for the relief of external vulvar itching and irrita- tion associated with vaginal yeast infections.</td><td>For vaginal use only. Avoid use: in children &lt;12 years of age; if patient has lower abdominal, back, or shoulder pain, or fever, chills, nausea, vomiting, or foul-</td><td>+ Topical vaginal antifungals should only be used for treatment of recurrent vulvovaginal candidiasis in healthy, nonpregnant women who were previously diagnosed by a clinician.</td></tr><tr><td></td><td>Monistat-3, Monistat-7, Vagistat-3)</td><td></td><td>smelling vaginal discharge; in combination with tampons, douches, spermicides, or other vaginal products.</td><td>Therapy should be discontinued if symp- toms do not improve within 3 days or if symptoms persist after 7 days of treatment.</td></tr><tr><td></td><td>Tioconazole (Monistat-1 1-Day, Vagistat-1)</td><td></td><td>Adverse effects include: vaginal itching, burning, vaginal</td><td>Vaginal products (7-day therapy preferred) can be used for treatment in pregnant women.</td></tr><tr><td></td><td></td><td></td><td>soreness, and swelling.</td><td>Products with similar brand names may contain different antifungal products; read labels and instructions for use carefully.</td></tr><tr><td></td><td></td><td></td><td></td><td>Condoms and diaphragms may be dam- aged by the products and fail to prevent pregnancy or sexually transmitted disease.</td></tr></table>
======================================
<table><thead><th>OTC Category</th><th>(Brand Example)</th><th>Labeled Use</th><th>Warnings</th><th>Considerations</th></thead><tr><td rowspan="2">Decongestants, topical (intranasal)</td><td>Oxymetazoline (Afrin, Mucinex Full Force, Vicks Sinex)</td><td rowspan="2">Temporary relief of nasal con- gestion due to common cold, hay fever, upper respiratory aller- gies, or sinus congestion and pressure.</td><td rowspan="2">Avoid use for &gt;3 days. Use with caution in patients with: heart disease; high blood pres- sure; thyroid disease; diabetes; trouble urinating due to an enlarged prostate. Adverse effects include: sneezing, burning, stinging, and rhinorrhea.</td><td>Long-acting agents (oxymetazoline- containing products) are generally preferred.</td></tr><tr><td></td><td>Phenylephrine (Neo-Synephrine)</td><td></td><td></td><td>Topical decongestants should not exceed 3 days to prevent rebound nasal congestion (eg, worsening or recurrence of congestion symptoms).</td></tr><tr><td rowspan="3">Decongestants, systemic</td><td rowspan="3">Phenylephrine (Sudafed PE) Pseudoephedrine (Sudafed)</td><td rowspan="3">Temporary relief of sinus conges- tion and pres- sure. Temporarily relieves nasal congestion due to the common cold, hay fever, or other upper respiratory allergies.</td><td>dryness, Avoid use: in patients taking an MAOI or for 2 weeks after stop- ping the MAOI. Use with caution</td><td>May be found in combination with antihistamine, antitussives, expectorants, and analgesic products.</td></tr><tr><td></td><td></td><td></td><td>in patients with heart disease; high blood pressure; diabetes; thyroid disease; trouble urinat-</td><td>Extended-release pseudoephedrine products should not be used in children &lt;12 years of age.</td></tr><tr><td></td><td></td><td></td><td>ing due to an enlarged prostate gland. Adverse effects include: arrhyth- mias, tachycardia, high blood pressure, anxiety, headache, dizziness, tremor, and insomnia.</td><td>Federal regulations established to discour- age the illicit manufacture of metham- phetamine specify that all drug products containing pseudoephedrine must be stored in locked cabinets or behind the pharmacy counter and can only be sold in limited quantities to consumers after they provide photo identification and are entered into a registry.</td></tr><tr><td rowspan="5">Emergency contraceptive</td><td rowspan="5">Levonorgestrel (Plan B One-Step)</td><td>To prevent preg-</td><td>Avoid use in the case of known</td><td>Available only by prescription for women</td></tr><tr><td></td><td></td><td>nancy following</td><td>or suspected pregnancy.</td><td>&lt;17 years of age.</td></tr><tr><td></td><td></td><td>unprotected intercourse or possible contra-</td><td>Adverse effects include: heavier menstrual bleeding, nausea, lower abdominal pain, fatigue,</td><td>Should be taken as soon as possible within 72 hours after unprotected intercourse.</td></tr><tr><td></td><td></td><td>ceptive failure.</td><td>headache, dizziness, and breast tenderness.</td><td>If vomiting occurs within 2 hours of taking the tablet, the dose may need to be repeated.</td></tr><tr><td></td><td></td><td></td><td></td><td>Use backup contraceptive after administra- tion. Patients taking oral contraceptives regularly should also use backup contra- ception, such as condom, until next period cycle starts.</td></tr><tr><td rowspan="4">Expectorants</td><td rowspan="4">Guaifenesin (Mucinex)</td><td rowspan="4">Used to help loosen phlegm (mucus) and thin bronchial secre- tions to make cough more productive.</td><td>Avoid use in children &lt;2 years of age.</td><td>The only OTC expectorant recognized as safe and effective by the FDA.</td></tr><tr><td></td><td></td><td></td><td>Adverse effects include: nausea, vomiting, stomach pain, and dizziness.</td><td>Often used with antihistamines, decon- gestants, and antitussives in combination products.</td></tr><tr><td></td><td></td><td></td><td></td><td>Administer with a large quantity of fluids for best 
======================================
results.</td></tr><tr><td></td><td></td><td></td><td></td><td>When used for self-care, do not use extended-release tablets in children &lt;12 years of age.</td></tr><tr><td rowspan="2">Laxatives</td><td></td><td>Bulk formers</td><td>Temporary relief of occasional</td><td>Bulk formers Avoid in with</td><td>The safest laxatives for chronic use include bulk formers and stool softeners.</td></tr><tr><td>Polycarbophil, psyllium, and methylcellulose preparations</td><td>constipation and irregularity.</td><td>use patients difficulty swallowing. Polyethylene glycol 3350</td><td>The bulk formers in powder formulation must be taken with adequate fluid for optimal effect and to avoid choking.</td></tr></table>
======================================
<table><thead><th>ITC Category</th><th>Generic Name (Brand Example)</th><th>Labeled Use</th><th>Warnings</th><th>Considerations</th></thead><tr><td rowspan="10">.axatives (cont.)</td><td>Hyperosmotics Glycerin (Fleet Glycerin</td><td></td><td>Adverse effects include: nausea, abdominal bloating, cramping, and flatulence.</td><td></td></tr><tr><td></td><td>suppositories)</td><td></td><td>Stool softeners</td><td></td></tr><tr><td></td><td>Polyethylene glycol 3350 (Miralax)</td><td></td><td>Avoid use in patients taking mineral oil.</td><td></td></tr><tr><td></td><td>Stool softeners</td><td></td><td>Stimulants</td><td></td></tr><tr><td></td><td>Docusate sodium (Colace, Dulcolax) Docusate calcium</td><td></td><td>Adverse effects include: stomach discomfort, rectal burning, and mild cramps.</td><td></td></tr><tr><td></td><td>(Surfak)</td><td></td><td>Saline laxatives</td><td></td></tr><tr><td></td><td>Stimulant laxatives Bisacodyl (Dulcolax,</td><td></td><td>Do not use more than one enema in a 24-hour period.</td><td></td></tr><tr><td></td><td>Ex-Lax) Senna (Senokot) Saline laxatives</td><td></td><td>Use with caution in patients ona sodium-restricted diet; in patients with kidney disease.</td><td></td></tr><tr><td></td><td>Sodium phosphate</td><td></td><td>All laxatives</td><td></td></tr><tr><td></td><td>(Fleet enema)</td><td></td><td>Use with caution in patients with a sudden change in bowel habits that persist for 2 weeks; in patients with abdominal pain, nausea, or vomiting.</td><td></td></tr><tr><td rowspan="4">Dveractive sladder reatment</td><td>Oxybutynin transdermal system for</td><td>Treatment of overactive blad- der for women</td><td>Avoid use in: men; women &lt;18 years of age; patients with symptoms of a urinary tract</td><td>Women should consult with their physician about symptoms before using this product.</td></tr><tr><td></td><td>(Oxytrol women)</td><td>with symptoms of urge incon- tinence and urinary urgency and frequency for at least</td><td>infection (pain or burning when urinating, blood in urine, unex- plained lower back pain, urine that is cloudy or foul smelling). Adverse effects include:</td><td>Women who only experience accidental urine loss when coughing, sneezing, or laughing may have stress incontinence; this product is not effective for this condition.</td></tr><tr><td></td><td></td><td>3 months.</td><td>sleepiness, dizziness, confusion, dry mouth, constipation, and blurred vision.</td><td>The OTC patch formulation contains the same dosage as the prescription product.</td></tr><tr><td></td><td></td><td></td><td></td><td>One patch should be applied to abdomen, hips, or buttocks every 4 days; alternating sites.</td></tr></table>
======================================
<table><thead><th>Sleep aids</th><th>Diphenhydramine (Nytol, Sominex) Doxylamine (Unisom)</th><th>Reduces difficulty in falling asleep.</th><th>Avoid use in: children &lt;12 years of age; combination with alcohol, other antihistamines, or sedatives; individuals with angle-closure glaucoma; men with trouble urinating due to an enlarged prostate gland. Use caution when driving or operating machinery. Adverse effects include: dizziness, constipation, and dry</th><th>Insomnia persisting for &gt;2 weeks may be a sign of a serious underlying medical condition.</th></thead><tr><td rowspan="8">Smoking cessation aids</td><td>Nicotine polacrilex gum (Nicorette)</td><td>Reduces with- drawal symp-</td><td>mouth. Avoid use in: children &lt;18 years of age; women who</td><td>Nicotine replacement products in addition to behavioral support approximately</td></tr><tr><td></td><td rowspan="7">Nicotine polacrilex lozenge (Nicorette) Nicotine transdermal patch (Nicoderm CQ)</td><td>toms (including nicotine craving) associated</td><td>are pregnant or breastfeeding; individuals with temporoman- dibular joint disease (gum only);</td><td>double the long-term cessation rates compared with placebo. Nicotine replacement products can be</td></tr><tr><td></td><td></td><td>with quitting smoking.</td><td>individuals with allergies to adhesive tape (patch only). Use patch with caution in patients</td><td>used in combination to improve long-term abstinence rates.</td></tr><tr><td></td><td></td><td></td><td>with a history of dermatologic conditions (eczema, psoriasis, ectopic dermatitis).</td><td rowspan="5">patch may improved (once-daily dosing). Do not use lozenge if allergic to soya (soy beans).</td></tr><tr><td></td><td></td><td></td><td>Gum</td><td></td></tr><tr><td></td><td></td><td></td><td>Adverse effects include: jaw soreness, hiccups, dyspepsia, throat and mouth irritation, nausea, vomiting, lightheadedness.</td><td></td></tr><tr><td></td><td></td><td></td><td>Lozenge Adverse effects include: mouth irritation, nausea, hiccups,</td><td></td></tr><tr><td></td><td></td><td></td><td>cough, heartburn, headache, sore throat, dizziness. Transdermal patch</td><td></td></tr></table>
======================================
<table><thead><th>Hidden Drug or Drug Class</th><th></th><th>Selected Product Examples</th></thead><tr><td rowspan="2">Alcohol (percent ethanol)</td><td>Cough syrups, cold preparations</td><td>Theraflu Nighttime (10%); Vicks NyQuil Cold &amp; Flu Liquid (10%); Vicks NyQuil Cough (10%)</td></tr><tr><td></td><td>Mouthwashes</td><td>Listerine (27%); Cepacol (14%)</td></tr><tr><td rowspan="3">Antihistamines</td><td>Analgesics</td><td>Advil PM; Excedrin PM; Goody's PM Pain Relief Powder; Tylenol PM</td></tr><tr><td></td><td>Menstrual products</td><td>Midol Complete; Pamprin</td></tr><tr><td></td><td>Sleep aids</td><td>Nytol; Simply Sleep; Sominex; Unisom</td></tr><tr><td rowspan="4">Aspirin and other salicylates</td><td></td><td>Antacids</td><td>Alka-Seltzer Original; Alka-Seltzer Extra Strength</td></tr><tr><td></td><td>Antidiarrheals</td><td>Pepto-Bismol (bismuth subsalicylate); Kaopectate (bismuth subsalicylate)</td></tr><tr><td>Menstrual products</td><td>Pamprin Max</td></tr><tr><td></td><td>Cold/allergy preparations</td><td>Alka-Seltzer Plus Formulation: Cold; Cold and Cough; Night Cold</td></tr><tr><td rowspan="3">Caffeine (mg/tablets or as stated)</td><td>Analgesics</td><td>Anacin Advanced Headache (65); Excedrin Extra Strength (65); Excedrin Migraine (65); Goody's Headache Relief Shot (65/60 mL)</td></tr><tr><td></td><td>Menstrual products</td><td>Midol Complete (60); Pamprin Max (65)</td></tr><tr><td></td><td>Stimulants</td><td>NoDoz Maximum Strength (200); Vivarin (200)</td></tr><tr><td rowspan="4">Local anesthetics (usually benzocaine)</td><td></td><td>Antitussives/lozenges</td><td>Cepacol Sore Throat Lozenges; Chloraseptic Sore Throat</td></tr><tr><td></td><td>Dermatologic preparations</td><td>Bactine; Dermoplast; Solarcaine</td></tr><tr><td></td><td>Hemorrhoidal products</td><td>Americaine Ointment; Tronolane</td></tr><tr><td>Toothache, cold sore, and teething products</td><td>Anbesol; Kank-A; Zilactin-B</td></tr><tr><td rowspan="4">Sodium (mg/tablet or as stated)</td><td>Analgesics/antacids</td><td>Alka-Seltzer Original Effervescent Tablet (567); Alka-Seltzer</td></tr><tr><td></td><td></td><td>Extra Strength Effervescent Tablet (588); Alka-Seltzer Gold (309)</td></tr><tr><td></td><td>Cold/cough preparations</td><td>Alka-Seltzer Plus Formulations: Day and Night Cold (416); Cold &amp; Cough (415); Severe Cold &amp; Flu (416); Night Cold (474); Cold Sparkling Original (476)</td></tr><tr><td></td><td>Laxatives</td><td>Fleets Enema (4439 mg, of which 275-400 mg/enema is absorbed)</td></tr><tr><td rowspan="3">Sympathomimetics (ephedrine, phenylephrine)</td><td>Analgesics</td><td>Sine-Off; Tylenol Sinus</td></tr><tr><td></td><td>Asthma products</td><td>Bronkaid; Primatene Tablets</td></tr><tr><td></td><td>Cold/cough/allergy preparations</td><td>Advil Cold &amp; Sinus; Alka-Seltzer Plus (many); Dimetapp (many); PediaCare (many); Robitussin (many); Sudafed (many); Theraflu (many); Tylenol Cold (many); Tylenol Allergy (many)</td></tr></table>
======================================
<table><thead><th>Scientific Name, Plant Parts</th><th>Intended Use</th><th>Toxic Agents, Effects</th><th>Comments</th></thead><tr><td>Aconite Aconitum species</td><td>Analgesic</td><td>Alkaloid, cardiac and central nervous system effects</td><td>Avoid</td></tr><tr><td>Aristolochic acid Aristolochia species</td><td>Traditional Chinese medicine; various uses</td><td>Carcinogen, nephrotoxicity</td><td>Avoid</td></tr><tr><td>Black cohosh Cimicifuga racemosa</td><td>Menopausal symptoms</td><td>Hepatotoxicity</td><td>Avoid!</td></tr><tr><td>Borage Borago officinalis Tops, leaves</td><td>Anti-inflammatory; diuretic</td><td>Pyrrolizidine alkaloids, hepatotoxicity</td><td>Avoid</td></tr><tr><td>Chaparral Larrea tridentata Twigs, leaves</td><td>Anti-infective; antioxidant; anticancer</td><td>Hepatotoxicity</td><td>Avoid</td></tr><tr><td>Coltsfoot Tussilago farfara Leaves, flower</td><td>Upper respiratory tract infections</td><td>Pyrrolizidine alkaloids, hepatotoxicity</td><td>Avoid ingestion of any parts of plant; leaves may be used topi- cally for anti-inflammatory effects for up to 4-6 weeks</td></tr><tr><td>Comfrey Symphytum species Leaves and roots</td><td>Internal digestive aid; topical for wound healing</td><td>Pyrrolizidine alkaloids, hepatotoxicity</td><td>Avoid ingestion; topical use should be limited to 4-6 weeks</td></tr><tr><td>Ephedra, Ma-huang Ephedra species</td><td>Diet aid; stimulant; bronchodilator</td><td>Central nervous system toxicity, cardiac toxicity</td><td>Avoid in patients at risk for stroke, myocardial infarction, arrhythmia, hypertension, seizures, general anxiety disorder</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>Germander Teucrium chamaedrys</td><td>Diet aid</td><td>Hepatotoxicity</td><td>Avoid</td></tr><tr><td>Leaves, tops</td><td></td><td></td><td></td></tr><tr><td>Gland-derived extracts (thymus, adrenal, thyroid)</td><td>Hormone replacement</td><td>Risk of bacterial, viral, or prion transmission; variable hormone content</td><td>Avoid</td></tr><tr><td>Human placenta derivatives</td><td>Antirheumatic; anti-inflammatory</td><td>Risk of bacterial, viral, or prion transmission</td><td>Avoid</td></tr><tr><td>Jin Bu Huan</td><td>Analgesic; sedative</td><td>Hepatotoxicity</td><td>Avoid</td></tr><tr><td>Kava-kava</td><td>Anxiety</td><td>Hepatotoxicity</td><td>Avoid</td></tr><tr><td>Pennyroyal Extract of Mentha pulegium or Hedeoma pulegioides</td><td>Digestive aid; induction of menstrual flow; abortifacient</td><td>Pulegone and pulegone metabolite, liver failure, renal failure</td><td>Avoid</td></tr><tr><td colspan="4">Poke root Phytolacca americana Antirheumatic Hemorrhagic gastritis Avoid</td></tr><tr><td>Royal jelly of Apis mellifera (honeybee)</td><td>Tonic</td><td>Bronchospasm, anaphylaxis</td><td>Avoid in patients with chronic allergies or respiratory diseases;</td></tr></table>
======================================
<table><thead><th>a</th><th>before</th><th></th><th>by mouth</th></thead><tr><td></td><td>before meals</td><td></td><td>per rectum</td></tr><tr><td></td><td>shake, stir</td><td>prn</td><td>when needed</td></tr><tr><td></td><td>water</td><td></td><td>every</td></tr><tr><td></td><td>distilled water</td><td>gam, om</td><td>every morning</td></tr><tr><td></td><td>twice a day</td><td>qd (do not use)</td><td>every day (write “daily”)</td></tr><tr><td></td><td>with</td><td>qh, qih</td><td>every hour</td></tr><tr><td></td><td>capsule</td><td>qz2h, q3h, etc</td><td>every 2 hours, every 3 hours, etc</td></tr><tr><td></td><td>dextrose 5% in water</td><td>qhs</td><td>every night at bedtime</td></tr><tr><td></td><td>dissolve dilute</td><td>qid</td><td>four times a day</td></tr><tr><td>elix</td><td>elixir</td><td>qs</td><td>every day sufficient quantity</td></tr><tr><td>ext</td><td>extract</td><td>rept, repet</td><td>may be repeated</td></tr><tr><td></td><td>gram</td><td>Rx</td><td>take</td></tr><tr><td></td><td>grain</td><td>s</td><td>without</td></tr><tr><td></td><td>drops</td><td>Sc, SQ</td><td>subcutaneous</td></tr><tr><td></td><td>hour</td><td>sid (veterinary)</td><td>once a day</td></tr><tr><td></td><td>at bedtime</td><td>Sig, S</td><td>label</td></tr><tr><td></td><td>intra-arterial</td><td>sos</td><td>if needed</td></tr><tr><td></td><td>intramuscular</td><td>5S, SS</td><td>one-half</td></tr><tr><td></td><td>intravenous</td><td>stat</td><td>at once</td></tr><tr><td></td><td>IV piggyback</td><td>sup, supp</td><td>suppository</td></tr><tr><td>kg</td><td>kilogram</td><td>susp</td><td>suspension</td></tr><tr><td>mcg, Lg (do not use)</td><td>microgram (always write out “microgram’)</td><td>tab</td><td>tablet</td></tr><tr><td>mEq, meq</td><td>milliequivalent</td><td>tbsp, T (do not use)</td><td>tablespoon (always write out “15 mL”)</td></tr><tr><td>mg</td><td>milligram</td><td>tid</td><td>three times a day</td></tr><tr><td>no</td><td>number</td><td>Tr, tinct</td><td>tincture</td></tr><tr><td>non rep</td><td>do not repeat</td><td>tsp (do not use)</td><td>teaspoon (always write out “5 mL")</td></tr><tr><td>OD</td><td>right eye</td><td>U (do not use)</td><td>units (always write out “units”)</td></tr><tr><td>Os, OL</td><td>left eye</td><td>vag</td><td>vaginal</td></tr><tr><td>OTC</td><td>over-the-counter</td><td>i, ii, iii, iv, etc</td><td>one, two, three, four, etc</td></tr><tr><td>OU</td><td>both eyes</td><td>3 (do not use)</td><td>dram (in fluid measure 3.7 mL)</td></tr><tr><td>Pp</td><td>after</td><td>4 (do not use)</td><td>ounce (in fluid measure 29.6 mL)</td></tr></table>
======================================
<table><thead><th>State</th><th>Pharmacists</th><th></th><th>Physician's Assistants</th><th>Optometrists</th></thead><tr><td>California</td><td>7 a ae a Yes, under protocol ; must be trained in clinical practice</td><td></td><td>Yes, under protocol!</td><td>Yes; limited to certain drug classes</td></tr><tr><td>Florida</td><td>Yes, according to state formulary; protocol not required</td><td></td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Michigan</td><td>Yes, under protocol; must be specially qualified by education, training, or experience</td><td></td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Mississippi</td><td>Yes, under protocol in an institutional setting</td><td>Yes,? under narrowly specified conditions</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Nevada</td><td>Yes, under protocol, within a licensed medical facility</td><td>2 Yes’</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>New Mexico</td><td>Yes, under protocol, must be “pharmacist clinician”</td><td>Yes; do not need physician supervision</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>North Dakota</td><td>Yes, under protocol in an institutional setting</td><td>Yes; do not need physician supervision</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Oregon</td><td>Yes, under guidelines set by the state board</td><td>Yes; do not need physician supervision</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Texas</td><td>Yes, under protocol set for a particular patient in an institutional setting</td><td>Yes; do not need physician supervision</td><td></td><td>Yes; limited to certain drug classes</td></tr><tr><td>Washington</td><td>Yes, under guidelines set by the state board</td><td>Yes; do not need physician supervision</td><td></td><td>Yes; limited to certain drug classes</td></tr></table>
======================================
<table><thead><th>Schedule</th><th>Potential for Abuse</th><th>Other Comments</th></thead><tr><td>I</td><td>High</td><td>No accepted medical use; lack of accepted safety as drug.</td></tr><tr><td></td><td>High</td><td>Current accepted medical use. Abuse may lead to psychological or physical dependence.</td></tr><tr><td></td><td>Less than | orll</td><td>Current accepted medical use. Moderate or low potential for physical dependence and high potential for psychological dependence.</td></tr><tr><td></td><td>Less than III</td><td>Current accepted medical use. Limited potential for dependence.</td></tr><tr><td></td><td>Less than IV</td><td>Current accepted medical use. Limited dependence possible.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="10">Acid-reducing agents</td><td rowspan="10">Antacids may adsorb drugs in gastrointestinal tract, thus reduc- ing absorption. Some antacids (eg, magnesium hydroxide with alumi- num hydroxide) alkalinize the urine somewhat, thus altering excretion of drugs sensitive to urinary pH. H,-antagonists and proton-pump inhibitors can alter the absorption of drugs requiring gastric acidity for dissolution.</td><td>Antivirals: [P] Decreased absorption of antivirals that require acid for dissolution including atazanavir, fosamprenavir, indinavir, nelfinavir, rilpivirine.</td></tr><tr><td></td><td></td><td>Azole antifungals: [P] Reduced gastrointestinal absorption of itraconazole, ketoconazole, and posaconazole due to increased gastric pH.</td></tr><tr><td></td><td></td><td>Digoxin: [NP] Decreased gastrointestinal absorption of digoxin.</td></tr><tr><td></td><td></td><td>Iron: [P] Decreased gastrointestinal absorption of iron with calcium-containing antacids.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Reduced gastrointestinal absorption of bosutinib, dabrafenib, dasatinib, erlotinib, idelalisib, and lapatinib due to increased gastric pH.</td></tr><tr><td></td><td></td><td>Quinolones: [HP] Decreased gastrointestinal absorption of ciprofloxacin, norfloxacin, and enoxacin (and probably other quinolones).</td></tr><tr><td></td><td></td><td>Rosuvastatin: [P] Decreased absorption of rosuvastatin.</td></tr><tr><td></td><td></td><td>Salicylates: [P] Increased renal clearance of salicylates due to increased urine pH; occurs only with large doses of salicylates.</td></tr><tr><td></td><td></td><td>Tetracyclines: [HP] Decreased gastrointestinal absorption of tetracyclines.</td></tr><tr><td></td><td></td><td>Thyroxine: [NP] Reduced gastrointestinal absorption of thyroxine.</td></tr><tr><td rowspan="11">Alcohol</td><td rowspan="11">Chronic alcoholism results in enzyme induction. Acute alcoholic intoxication tends to inhibit drug metabolism (whether person is alcoholic or not). Severe alcohol- induced hepatic dysfunction may inhibit ability to metabolize drugs. Disulfiram-like reaction in the presence of certain drugs. Additive central nervous system depression with other central nervous system depressants.</td><td>Acetaminophen: [NE] Increased formation of hepatotoxic acetaminophen metabolites (in chronic alcoholics).</td></tr><tr><td></td><td></td><td>Acitretin: [P] Increased conversion of acitretin to etretinate (teratogenic).</td></tr><tr><td></td><td></td><td>Anticoagulants, oral: [NE] Increased hypoprothrombinemic effect with acute alcohol intoxication.</td></tr><tr><td></td><td></td><td>Central nervous system depressants: [HP] Additive or synergistic central nervous system depression.</td></tr><tr><td></td><td></td><td>Insulin: [NE] Acute alcohol intake may increase hypoglycemic effect of insulin (especially in fasting patients).</td></tr><tr><td></td><td></td><td>Drugs that may produce a disulfiram-like reaction:</td></tr><tr><td></td><td></td><td>Cephalosporins: [NP] Disulfiram-like reactions are noted with cefamandole, cefoperazone, cefotetan, and moxalactam.</td></tr><tr><td></td><td></td><td>Chloral hydrate: [NP] Mechanism not established.</td></tr><tr><td></td><td></td><td>Disulfiram: [HP] Inhibited aldehyde dehydrogenase.</td></tr><tr><td></td><td></td><td>Metronidazole: [NP] Mechanism not established.</td></tr><tr><td></td><td></td><td>Sulfonylureas: [NE] Chlorpropamide is most likely to produce a disulfiram-like reaction; acute alcohol intake may increase hypoglycemic effect (especially in fasting patients).</td></tr><tr><td rowspan="2">Allopurinol</td><td>Inhibits hepatic drug-metabolizing</td><td>Anticoagulants, oral: [NP] Increased hypoprothrombinemic effect.</td></tr><tr><td></td><td>enzymes. Febuxostat will also inhibit the metabolism of azathioprine and mercaptopur
======================================
ine.</td><td>Azathioprine: [P] Decreased azathioprine detoxification resulting in increased azathioprine toxicity.</td></tr></table>
======================================
<table><tr><td>Anticoagulants,</td><td>Susceptible to induction and</td><td>Drugs that may increase anticoagulant effect:</td></tr><tr><td rowspan="16">oral</td><td>inhibition of CYP2C9 (warfarin), CYP3A4 (apixaban, rivaroxaban),</td><td>Acetaminophen: [NE] Impaired synthesis of clotting factors at higher doses.</td></tr><tr><td></td><td>and P-glycoprotein (apixaban, edoxaban, rivaroxaban).</td><td>Amiodarone: [P] Inhibited anticoagulant elimination.</td></tr><tr><td></td><td>dabigatran, Warfarin highly bound to plasma</td><td>Anabolic steroids: [P] Altered clotting factor disposition?</td></tr><tr><td></td><td>proteins. Anticoagulation response altered by drugs that affect clotting factor synthesis or catabolism.</td><td>Azole antifungals: [P] Ketoconazole, itraconazole, voriconazole, and posaconazole can decrease apixaban, dabigatran, edoxaban, rivaroxaban, and perhaps warfarin elimination</td></tr><tr><td></td><td></td><td>Cimetidine: [HP] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Clopidogrel: [NP] Decreased warfarin metabolism and inhibits platelet function.</td></tr><tr><td></td><td></td><td>Disulfiram: [P] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Efavirenz: [NP] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Fluconazole: [P] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Fluoxetine: [P] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Gemfibrozil: [NE] Mechanism not established.</td></tr><tr><td></td><td></td><td>Lovastatin: [NP] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [NP] Clarithromycin and erythromycin inhibit the metabolism of oral anticoagulants.</td></tr><tr><td></td><td></td><td>Metronidazole: [P] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Miconazole: [NE] Decreased warfarin metabolism.</td></tr><tr><td></td><td></td><td>Nonsteroidal anti-inflammatory drugs (NSAIDs): [HP] Inhibition of platelet function, gastric erosions; some agents increase hypoprothrombinemic response (unlikely with</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="6">Anticoagulants, oral (cont.)</td><td></td><td>Phenytoin: [NE] Increased metabolism of anticoagulant. Anticoagulant effect may increase transiently at start of phenytoin therapy due to protein-binding displacement of warfarin.</td></tr><tr><td></td><td></td><td>Primidone: [P] Increased metabolism of anticoagulant.</td></tr><tr><td></td><td></td><td>Rifabutin: [P] Increased elimination of anticoagulant.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased elimination of anticoagulant.</td></tr><tr><td></td><td></td><td>St. John’s wort: [NE] Increased elimination of anticoagulant.</td></tr><tr><td></td><td></td><td>Tipranavir: [NP] Increased elimination of apixaban, dabigatran, edoxaban, rivaroxaban.</td></tr><tr><td rowspan="15">Antidepressants, tricyclic and heterocyclic</td><td>Inhibition of transmitter uptake into 5-HT and NE neurons. Antimuscarinic</td><td>Amiodarone: [P] Decreased antidepressant metabolism. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td>effects may be additive with other antimuscarinic drugs. Susceptible to</td><td>Barbiturates: [P] Increased antidepressant metabolism.</td></tr><tr><td></td><td>induction and inhibition of metabo- lism via CYP2D6, CYP3A4, and other</td><td>Bupropion: [NE] Decreased antidepressant metabolism.</td></tr><tr><td></td><td>CYP450 enzymes.</td><td>Carbamazepine: [NP] Enhanced metabolism of antidepressants.</td></tr><tr><td></td><td></td><td>Cimetidine: [P] Decreased antidepressant metabolism.</td></tr><tr><td></td><td></td><td>Clonidine: [P] Decreased clonidine antihypertensive effect.</td></tr><tr><td></td><td></td><td>Diphenhydramine: [P] Decreased metabolism of antidepressants metabolized by CYP2D6.</td></tr><tr><td></td><td></td><td>Guanadrel: [P] Decreased uptake of guanadrel into sites of action.</td></tr><tr><td></td><td></td><td>Haloperidol: [P] Decreased metabolism of antidepressants metabolized by CYP2D6.</td></tr><tr><td></td><td></td><td>Monoamine oxidase inhibitors (MAOIs): [NP] Some cases of excitation, hyperpyrexia, mania, and convulsions, especially with serotonergic antidepressants such as clomipramine and imipramine, but many patients have received combination without ill effects.</td></tr><tr><td></td><td></td><td>Qui ine: [NP] Decreased metabolism of antidepressants metabolized by CYP2D6.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased antidepressant metabolism.</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake inhibitors (SSRIs): [P] Fluoxetine and paroxetine inhibit CYP2D6 and decrease metabolism of antidepressants metabolized by this enzyme (eg, desipramine). Citalopram, sertraline, and fluvoxamine are only weak inhibitors of CYP2D6, but fluvoxamine inhibits CYP1A2 and CYP3A4 and thus can inhibit the metabolism of antidepressants metabolized by these enzymes.</td></tr><tr><td></td><td></td><td>Sympathomimetics: [P] Increased pressor response to norepinephrine, epinephrine, and phenylephrine.</td></tr><tr><td></td><td></td><td>Terbinafine: [P] Decreased antidepressant metabolism.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="13">Azole antifungals (cont.)</td><td></td><td>Eplerenone: [P] Decreased metabolism of eplerenone.</td></tr><tr><td></td><td></td><td>Ergot alkaloids: [P] Decreased metabolism of ergot alkaloids.</td></tr><tr><td></td><td></td><td>HMG-CoA reductase inhibitors: [HP] Decreased metabolism of lovastatin, simvastatin, and, to a lesser extent, atorvastatin.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [P] Decreased elimination of alfentanil, fentanyl, methadone, oxycodone, and sufentanil.</td></tr><tr><td></td><td></td><td>Qui ine: [P] Decreased metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Decreased metabolism of phenytoin with fluconazole and probably voriconazole.</td></tr><tr><td></td><td></td><td>Phosphodiesterase inhibitors: [P] Decreased metabolism of phosphodiesterase inhibitor.</td></tr><tr><td></td><td></td><td>Pimozide: [NE] Decreased pimozide metabolism.</td></tr><tr><td></td><td></td><td>Rifabutin: [P] Decreased rifabutin metabolism. Increased metabolism of itraconazole, ketoconazole, and voriconazole.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased metabolism of itraconazole, ketoconazole, and voriconazole.</td></tr><tr><td></td><td></td><td>Sirolimus: [P] Decreased elimination of sirolimus.</td></tr><tr><td></td><td></td><td>Tacrolimus: [P] Decreased elimination of tacrolimus.</td></tr><tr><td></td><td></td><td>See also Acid-Reducing Agents; Anticoagulants, oral.</td></tr><tr><td rowspan="11">Barbiturates</td><td rowspan="11">Induction of hepatic microsomal drug metabolizing enzymes and P-glycoprotein. Additive central nervous system depression with other central nervous system depressants.</td><td>Antivirals: Increased metabolism of antivirals amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir with barbiturates.</td></tr><tr><td></td><td></td><td>Beta-adrenoceptor blockers: [P] Increased }-blocker metabolism.</td></tr><tr><td></td><td></td><td>Calcium channel blockers: [P] Increased calcium channel blocker metabolism.</td></tr><tr><td></td><td></td><td>Central nervous system depressants: [HP] Additive central nervous system depression.</td></tr><tr><td></td><td></td><td>Corticosteroids: [P] Increased corticosteroid metabolism.</td></tr><tr><td></td><td></td><td>Cyclosporine: [NE] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Doxycycline: [P] Increased doxycycline metabolism.</td></tr><tr><td></td><td></td><td>Estrogens: [P] Increased estrogen metabolism.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Increased metabolism of axitinib, bosutinib, ceritinib, cabozantinib, cobimetinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, olaparib, osimertinib, palbociclib, pazopanib, ponatinib, regorafenib, ruxolitinib, sunitinib, tofacitinib, vandetanib, vemurafenib.</td></tr><tr><td></td><td></td><td>Methadone: [NE] Increased methadone metabolism.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [P] Increased elimination of alfentanil, fentanyl, methadone,</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="16">Beta- adrenoceptor blockers</td><td rowspan="13">Beta blockade (especially with noncardioselective agents such as propranolol) alters response to sympathomimetics with B-agonist activity (eg, epinephrine, albuterol). Beta blockers that undergo extensive first-pass metabolism may be affected by drugs capable of altering this process.</td><td>Drugs that may increase B-blocker effect:</td></tr><tr><td></td><td></td><td>Amiodarone: [P] Decreased metabolism of B blockers metabolized by CYP2D6 (timolol, propranolol, nebivolol, metoprolol, carvedilol). Enhanced effects on myocar- dial conduction. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td></td><td>Cimetidine: [P] Decreased metabolism of B blockers that are cleared primarily by the liver, eg, propranolol. Less effect (if any) on those cleared by the kidneys, eg, atenolol, nadolol.</td></tr><tr><td></td><td></td><td>Diphenhydramine: [P] Decreased metabolism of 8 blockers metabolized by CYP2D6 (timolol, propranolol, nebivolol, metoprolol, carvedilol).</td></tr><tr><td></td><td></td><td>Haloperidol: [P] Decreased metabolism of B blockers metabolized by CYP2D6 (timolol, propranolol, nebivolol, metoprolol, carvedilol).</td></tr><tr><td></td><td></td><td>Quinidine: [P] Decreased metabolism of B blockers metabolized by CYP2D6 (timolol, propranolol, nebivolol, metoprolol, carvedilol).</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake inhibitors (SSRIs): [P] Fluoxetine and paroxetine inhibit CYP2D6 and increase concentrations of timolol, propranolol, metoprolol, carvedilol, and nebivolol.</td></tr><tr><td></td><td></td><td>Terbinafine: [P] Decreased metabolism of f blockers metabolized by CYP2D6 (timolol, propranolol, nebivolol, metoprolol, carvedilol).</td></tr><tr><td></td><td></td><td>Drugs that may decrease B-blocker effect:</td></tr><tr><td></td><td></td><td>Nonsteroidal anti-inflammatory drugs (NSAIDs): [P] Indomethacin reduces antihypertensive response; other prostaglandin inhibitors probably also interact.</td></tr><tr><td></td><td></td><td>Effects of blockers other</td></tr><tr><td></td><td></td><td>B on drugs: Clonidine: [NE] Hypertensive reaction if clonidine is withdrawn; this is more likely to</td></tr><tr><td></td><td></td><td>occur with non-cardioselective beta blockers. Insulin: [P] Inhibition of glucose recovery from hypoglycemia; inhibition of symptoms of hypoglycemia (except sweating); increased blood pressure during</td></tr><tr><td></td><td></td><td>hypoglycemia. Prazosin: [P] Increased hypotensive response to first dose of prazosin.</td></tr><tr><td></td><td></td><td>Sympathomimetics: [P] Increased pressor response to epinephrine (and possibly other sympathomimetics); this is more likely to occur with noncardioselective B blockers.</td></tr><tr><td></td><td></td><td>See also Barbiturates; Theophylline.</td></tr><tr><td>Bile acid-</td><td>Resins bind with orally adminis-</td><td>Acetaminophen: [NE] Decreased gastrointestinal absorption of acetaminophen.</td></tr><tr><td rowspan="5">binding resins</td><td rowspan="5">may tered drugs in gastrointestinal tract. Resins may bind in gastrointestinal tract with drugs that undergo enterohepatic circulation, even if the latter are given parenterally.</td><td>Digitalis glycosides: [NE] Decreased gastrointestinal absorption of digitoxin (possibly also digoxin).</td></tr><tr><td></td><td></td><td>Furosemide: [P] Decreased gastrointestinal absorption of furosemide.</td></tr><tr><td></td><td></td><td>Methotrexate: [NE] Reduced gastrointestinal absorption of methotrexate.</td></tr><tr><td></td><td></td><td>Mycophenolate: [P] Reduced gastrointestinal absorption of mycophenolate.</td></tr><tr><td></td><td></td><td>Thiazide diuretics: [P] Reduced gastrointestinal absorption of thiazides.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="18">Calcium channel blockers</td><td rowspan="14">Verapamil, diltiazem, and perhaps nicardipine inhibit hepatic drug- metabolizing enzymes (CYP3A4) and P-glycoprotein. Metabolism (via CYP3A4) of diltiazem, felodipine, nicardipine, nifedipine, verapamil, and other calcium channel blockers subject to induction and inhibition.</td><td>Amiodarone: [P] Decreased metabolism of calcium channel blockers. Enhanced effects on myocardial conduction with bepridil, diltiazem, and verapamil. Expect similar inter- actions with dronedarone.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabo- lism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Boceprevir: [P] Decreased metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Carbamazepine: [P] Decreased carbamazepine metabolism with diltiazem and verapamil; possible increase in calcium channel blocker metabolism.</td></tr><tr><td></td><td></td><td>Cimetidine: [NP] Decreased metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Colchicine: [P] Decreased colchicine elimination with diltiazem, nicardipine, and verapamil.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Cyclosporine: [P] Decreased cyclosporine elimination with diltiazem, nicardipine, verapamil.</td></tr><tr><td></td><td></td><td>Digitalis glycosides: [P] Decreased elimination of digitalis glycoside with bepridil, diltiazem and verapamil.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of calcium channel blockers with ceritinib, dasatinib, imatinib, idelalisib, and lapatinib. Decreased metabolism of kinase inhibitors by diltiazem, nicardipine, and verapamil.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Increased metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased metabolism of calcium channel blockers.</td></tr><tr><td></td><td></td><td>Sirolimus: [P] Decreased sirolimus elimination with diltiazem, nicardipine, verapamil.</td></tr><tr><td></td><td></td><td>Statins: [P] Decreased atorvastatin, lovastatin, and simvastatin elimination with diltiazem, nicardipine, verapamil.</td></tr><tr><td></td><td></td><td>Tacrolimus: [P] Decreased tacrolimus elimination with diltiazem, nicardipine, verapamil.</td></tr><tr><td></td><td></td><td>Theophylline: [P] Decreased theophylline metabolism with diltiazem, nicardipine, and verapamil.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Barbiturates.</td></tr><tr><td rowspan="2">Carbamazepine</td><td>Induction of hepatic microsomal drug-metabolizing enzymes and Susceptible</td><td>Amiodarone: [P] Decreased metabolism of carbamazepine; increased metabolism of amiodarone. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td>P-glycoprotein. to induction and inhibition of metabolism, primarily by CYP3A4.</td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of carbamazepine. Increased metabolism of antivirals by carbamazepine.</td></tr></table>
======================================
<table><thead><th>TABLE 66-1</th><th colspan="2">Important drug interactions.</th></thead><tr><td rowspan="14">Drug or Drug Group Carbamazepine cont. ( )</td><td>Properties Promoting Drug Interaction</td><td>Clinically Documented Interactions</td></tr><tr><td></td><td></td><td>Haloperidol: [P] Increased haloperidol metabolism.</td></tr><tr><td></td><td></td><td>Isoniazid: [P] Decreased carbamazepine metabolism.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of carbamazepine with cerit dasatinib, imatinib, idelalisib, and lapatinib. Increased metabolism of kinase inhibitors.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of carbamazepine.</td></tr><tr><td></td><td></td><td>Nefazodone: [NE] Decreased carbamazepine metabolism.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [P] Increased elimination of alfentanil, fentanyl, methadone, oxycodone, and sufentanil.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased carbamazepine metabolism.</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake in itors (SSRIs): [NE] Fluoxetine and fluvoxamine decrease carbamazepine metabolism.</td></tr><tr><td></td><td></td><td>Sirolimus: [P] Increased sirolimus metabolism.</td></tr><tr><td></td><td></td><td>St. John’s wort: [P] Increased carbamazepine metabolism.</td></tr><tr><td></td><td></td><td>Tacrolimus: [P] Increased tacrolimus metabolism.</td></tr><tr><td></td><td></td><td>Theophylline: [NE] Increased theophylline metabolism.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; Antidepressants, tricyclic; Azole antifungals; Calcium channel blockers.</td></tr><tr><td rowspan="11">Cimetidine</td><td rowspan="11">Inhibits hepatic microsomal drug- metabolizing enzymes. (Ranitidine, famotidine, and nizatidine do not.) May inhibit the renal tubular aaarctitenciiueel: beaaa,</td><td>Antivirals: [P] Decreased metabolism of amprenavir, atazanavir, boceprevir, daclatasvir, darunavir, delavirdine, etravirine, fosamprenavir, indinavir, lopinavir, maraviroc, nelfinavir, rilpivirine, ritonavir, saquinavir, and tipranavir.</td></tr><tr><td></td><td></td><td>Benzodiazepines: [P] Decreased metabolism of alprazolam, chlordiazepoxide, diazepam, halazepam, prazepam, and clorazepate but not oxazepam, lorazepam, or temazepam.</td></tr><tr><td></td><td></td><td>Carmustine: [NE] Increased bone marrow suppression.</td></tr><tr><td></td><td></td><td>Dofetilide: [NP] Decreased renal excretion of dofetilide.</td></tr><tr><td></td><td></td><td>Lidocaine: [P] Decreased metabolism of lidocaine.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [P] Decreased elimination of alfentanil, fentanyl, methadone, oxycodone, and sufentanil.</td></tr><tr><td></td><td></td><td>Phenytoin: [NE] Decreased phenytoin metabolism.</td></tr><tr><td></td><td></td><td>Procainamide: [P] Decreased renal excretion of procainamide.</td></tr><tr><td></td><td></td><td>Quinidine: [P] Decreased metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Theophylline: [P] Decreased theophylline metabolism.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; Antidepressants, tricyclic; Azole antifungals; B-Adrenoceptor blockers; Calcium channel blockers; Carbamazepine.</td></tr></table>
======================================
<table><tr><td rowspan="5">Cisapride (cont.)</td><td></td><td>Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of cisapride.</td></tr><tr><td></td><td></td><td>Nefazodone: [NP] Decreased metabolism of cisapride by CYP3A4.</td></tr><tr><td></td><td></td><td>Ritonavir: [P] Decreased metabolism of cisapride.</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake inhibitors (SSRIs): [NP] Fluvoxamine reduces cisapride metabolism.</td></tr><tr><td></td><td></td><td>See also Azole antifungals.</td></tr><tr><td rowspan="12">Colchicine</td><td rowspan="13">Susceptible to changes in CYP3A4 metabolism and P-glycoprotein transport. Susceptible to induction and</td><td>Amiodarone: [NP] Decreased colchicine metabolism and transport. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of colchicine.</td></tr><tr><td></td><td></td><td>Carbamazepine: [P] Increased metabolism of colchicine.</td></tr><tr><td></td><td></td><td>Cobicistat: [P] Decreased metabolism of colchicine.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased metabolism of colchicine.</td></tr><tr><td></td><td></td><td>Cyclosporine: [P] Decreased colchicine elimination.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of colchicine with ceritinib, dasatinib, imatinib, idelalisib, and lapatinib.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of colchicine.</td></tr><tr><td></td><td></td><td>Nefazodone: [NE] Decreased colchicine metabolism.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased colchicine metabolism.</td></tr><tr><td></td><td></td><td>St. John’s wort: [NP] Increased colchicine metabolism.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Calcium channel blockers.</td></tr><tr><td rowspan="9">Cyclosporine</td><td rowspan="9">inhibition of elimination by CYP3A4 and P-glycoprotein. (Tacrolimus and sirolimus appear to have similar interactions.)</td><td></td><td>Aminoglycosides: [NE] Possible additive nephrotoxicity.</td></tr><tr><td></td><td></td><td>Amphotericin B: [NE] Possible additive nephrotoxicity.</td></tr><tr><td></td><td></td><td>Cidofovir: [NE] Possible additive nephrotoxicity.</td></tr><tr><td></td><td></td><td>Drugs that may increase cyclosporine effect:</td></tr><tr><td></td><td></td><td>Amiodarone: [P] Decreased cyclosporine elimination. Expect similar interaction with dronedarone.</td></tr><tr><td></td><td></td><td>Androgens: [NE] Increased serum cyclosporine concentration.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the elimination of cyclosporine.</td></tr><tr><td></td><td></td><td>Cobicistat: [P] Decreased cyclosporine elimination.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased cyclosporine elimination.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="13">Cyclosporine (cont.)</td><td></td><td>Statins: [NP] Decreased metabolism of atorvastatin, lovastatin, and simvastatin. Myopathy and rhabdomyolysis noted in patients taking statins and cyclosporine.</td></tr><tr><td></td><td></td><td>Drugs that may decrease cyclosporine effect:</td></tr><tr><td></td><td></td><td>Bosentan: [P] Increased cyclosporine elimination.</td></tr><tr><td></td><td></td><td>Dexamethasone: [NP] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Efavirenz: [P] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Etravirine: [NP] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Nevirapine: [NP] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Rifabutin: [NP] Increased cyclosporine metabolism.</td></tr><tr><td></td><td></td><td>Increased elimination.</td></tr><tr><td></td><td></td><td>Rifampin: [P] cyclosporine</td></tr><tr><td></td><td></td><td>St. John’s wort: [NP] Increased cyclosporine elimination.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Barbiturates; Calcium channel blockers; Carbamazepine.</td></tr><tr><td rowspan="15">Digitalis glycosides</td><td>Digoxin susceptible to alteration of</td><td>Drugs that may increase digitalis effect:</td></tr><tr><td></td><td rowspan="14">gastrointestinal absorption. Renal and nonrenal excretion of digoxin susceptible to inhibition. Digitalis toxicity may be increased by drug- induced electrolyte imbalance (eg, hypokalemia).</td><td>Amiodarone: [P] Increased digoxin plasma concentrations. Expect similar interaction with dronedarone.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Daclatasvir, indinavir, nelfinavir, paritaprevir, ritonavir, saquinavir, and telaprevir reduce the elimination of digoxin.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Increased digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>Cyclosporine: [P] Increased digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [P] Azithromycin, clarithromycin, and erythromycin inhibit the elimination of digoxin.</td></tr><tr><td></td><td></td><td>Potassium-depleting drugs: [P] Increases likelihood of digitalis toxicity.</td></tr><tr><td></td><td></td><td>Propafenone: [P] Increases digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>] Increased digoxin plasma concentrations; displaces digoxin from tissue binding sites.</td></tr><tr><td></td><td></td><td>Spironolactone: [NE] Increased digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>Tacrolimus: [P] Increased digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>Ticagrelor: [P] Increased digoxin plasma concentrations.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Calcium channel blockers.</td></tr><tr><td></td><td></td><td>Drugs that may decrease digitalis effect:</td></tr><tr><td></td><td></td><td>Kaolin-pectin: [P] Decreased gastrointestinal digoxin absorption.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Cli ically Documented Interactions</th></thead><tr><td rowspan="4">Disulfiram</td><td rowspan="4">Inhibits CYP2C9. Inhibits aldehyde dehydrogenase.</td><td>Benzodiazepines: [P] Decreased metabolism of chlordiazepoxide and diazepam but not lorazepam and oxazepam.</td></tr><tr><td></td><td></td><td>Metronidazole: [NE] Confusion and psychoses reported in patients receiving this combination; mechanisms unknown.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Decreased phenytoin metabolism.</td></tr><tr><td rowspan="15">Estrogens</td><td></td><td rowspan="16">Estrogen metabolism (CYP3A4) susceptible to induction and inhibition. Enterohepatic circulation of estrogen may be interrupted by alteration in bowel flora (eg, due to antibiotics). Lovastatin, simvastatin, and, to a lesser extent, atorvastatin are</td><td></td><td>See also Alcohol; Anticoagulants, oral.</td></tr><tr><td></td><td></td><td>Ampicillin: [NP] Interruption of enterohepatic circulation of estrogen; possible reduction in oral contraceptive efficacy. Some other oral antibiotics may have a similar effect.</td></tr><tr><td></td><td></td><td>Bexarotene: [P] Increased estrogen metabolism, possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Bosentan: [NP] Enzyme induction leading to reduced estrogen effect.</td></tr><tr><td></td><td></td><td>Corticosteroids: [P] Decreased metabolism of corticosteroids leading to increased corticosteroid effect. Dexamethasone may increase estrogen metabolism.</td></tr><tr><td></td><td></td><td>Efavirenz: [P] Increased estrogen metabolism, possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Griseofulvin: [NP] Increased estrogen metabolism, possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Nelfinavir: [P] Increased estrogen metabolism, possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Nevirapine: [NP] Increased estrogen metabolism, possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Increased estrogen metabolism; possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Primidone: [P] Increased estrogen metabolism; possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>Rifabutin: efficacy. P] Increased estrogen metabolism; possible reduction in oral contraceptive</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased estrogen metabolism; possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>St. John’s wort: [P] Increased estrogen metabolism; possible reduction in oral contraceptive efficacy.</td></tr><tr><td></td><td></td><td>See also Barbiturates; Carbamazepine.</td></tr><tr><td rowspan="5">HMG-CoA reductase inhibitors (statins)</td><td rowspan="5">susceptible to CYP3A4 inhibitors and inducers; additive risk with other drugs that can cause myopathy.</td><td></td><td>Amiodarone: [NP] Decreased atorvastatin, lovastatin, and simvastatin metabolism. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of atorvastatin, lovastatin, and simvastatin.</td></tr><tr><td></td><td></td><td>Bosentan: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>Carbamazepine: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>Clofibrate: [NP] Increased risk of myopathy.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="8">HMG-CoA reductase inhibitors (statins) (cont.)</td><td></td><td>Gemfibrozil: [NP] Increased plasma lovastatin and simvastatin and increased risk of myopathy.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of atorvastatin, lovastatin, and simvastatin by ceritinib, dasatinib, imatinib, idelalisib, and lapatinib.</td></tr><tr><td></td><td></td><td>Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the elimination of statins.</td></tr><tr><td></td><td></td><td>Nefazodone: [NP] Decreased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>St. John’s wort: [NP] Increased atorvastatin, lovastatin, and simvastatin metabolism.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Calcium channel blockers; Cyclosporine.</td></tr><tr><td rowspan="5">Iron</td><td>Binds with drugs in gastrointestinal</td><td>Methyldopa: [NE] Decreased methyldopa absorption.</td></tr><tr><td></td><td>tract, reducing absorption.</td><td>Mycophenolate: [P] Decreased mycophenolate absorption.</td></tr><tr><td></td><td></td><td>Tetracyclines: [P] Decreased absorption of tetracyclines; decreased efficacy of iron.</td></tr><tr><td></td><td></td><td>Thyroid hormones: [P] Decreased thyroxine absorption.</td></tr><tr><td></td><td></td><td>See also Antacids.</td></tr><tr><td rowspan="8">Levodopa</td><td></td><td rowspan="8">Levodopa degraded in gut prior to reaching sites of absorption. Agents that alter gastrointestinal motility may alter degree of intraluminal degradation. Antiparkinsonism effect of levodopa susceptible to inhibition by other drugs.</td><td></td><td>Clonidine: [NE] Inhibited antiparkinsonism effect.</td></tr><tr><td></td><td></td><td>Haloperidol: [NP] Inhibited antiparkinsonism effect.</td></tr><tr><td>Metoclopramide: [NP] Inhibited antiparkinsonism effect.</td></tr><tr><td></td><td></td><td>Monoamine oxidase inhibitors (MAOIs): [P] Hypertensive reaction (carbidopa prevents the interaction).</td></tr><tr><td></td><td></td><td>Papaverine: [NE] Inhibited antiparkinsonism effect.</td></tr><tr><td></td><td></td><td>Phenothiazines: [P] Inhibited antiparkinsonism effect.</td></tr><tr><td></td><td></td><td>Phenytoin: [NE] Inhibited antiparkinsonism effect.</td></tr><tr><td></td><td></td><td>Pyridoxine: [P] Inhibited antiparkinsonism effect (carbidopa prevents the interaction).</td></tr><tr><td rowspan="3">Lithium</td><td></td><td>Renal lithium excretion sensitive to changes in sodium balance.</td><td>ACE inhibitors (ACEIs): [NE] Reduce renal clearance of lithium; increase lithium effect.</td></tr><tr><td></td><td>(Sodium depletion tends to cause lithium retention.) Susceptible to drugs enhancing central nervous</td><td>Angiotensin II receptor blockers (ARBs): [NE] Reduce renal clearance of lithium; increase lithium effect.</td></tr><tr><td>system lithium toxicity.</td><td>Diuretics (especially thiazides): [P] Decreased excretion of lithium; furosemide</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>‘ally Documented Interactions</th></thead><tr><td rowspan="10">Macrolides</td><td rowspan="10">The macrolides clarithromycin and erythromycin are known to inhibit CYP3A4 and P-glycoprotein. Azithromycin does not appear to inhibit CYP3A4 but is a modest inhibitor of P-glycoprotein.</td><td>Benzodiazepines: [P] Decreased metabolism of alprazolam, midazolam, triazolam.</td></tr><tr><td></td><td></td><td>Eplerenone: [P] Decreased metabolism of eplerenone.</td></tr><tr><td></td><td></td><td>Ergot alkaloids: [P] Decreased elimination of ergot alkaloids.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of axitinib, bosutinib, ceritinib, cabozantinib, cobimetinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, olaparib, osimertinib, palbociclib, pazopanib, ponatinib, regorafenib, ruxolitinib, sunitinib, tofacitinib, vandetanib, and vemurafenib by clarithromycin and erythromycin.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [P] Decreased elimination of alfentanil, fentanyl, methadone, oxycodone, and sufentanil.</td></tr><tr><td></td><td></td><td>Phosphodiesterase inhibitors: [P] Decreased metabolism of phosphodiesterase inhibitor.</td></tr><tr><td></td><td></td><td>Pimozide: [P] Increased pimozide concentrations.</td></tr><tr><td></td><td></td><td>Quinidine: [P] Increased serum quinidine concentrations.</td></tr><tr><td></td><td></td><td>Theophylline: [P] Decreased metabolism of theophylline.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; Calcium channel blockers; Carbamazepine; Cisapride; Colchicine; Cyclosporine; Digitalis glycosides; HMG-CoA reductase inhibitors.</td></tr><tr><td rowspan="14">Monoamine oxidase inhibitors (MAOIs)</td><td rowspan="14">Increased norepinephrine stored in adrenergic neuron. Displacement of these stores by other drugs may produce acute hypertensive response. MAOIs have intrinsic hypoglycemic activity.</td><td>Anorexiants: [P] Hypertensive episodes due to release of stored norepinephrine (benzphetamine, diethylpropion, mazindol, phendimetrazine, phentermine).</td></tr><tr><td></td><td></td><td>Antidiabetic agents: [P] Additive hypoglycemic effect.</td></tr><tr><td></td><td></td><td>Buspirone: [NE] Possible serotonin syndrome; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Dextromethorphan: [NP] Severe reactions (hyperpyrexia, coma, death) have been reported.</td></tr><tr><td></td><td></td><td>Guanethidine: [P] Reversal of the hypotensive action of guanethidine.</td></tr><tr><td></td><td></td><td>Mirtazapine: [NE] Possible serotonin syndrome; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Nefazodone: [NP] Possible serotonin syndrome; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Opioid analgesics: [NP] Some patients develop hypertension, rigidity, excitation; meperidine more likely to interact than morphine; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Phenylephrine: [P] Hypertensive episode, since phenylephrine is metabolized by monoamine oxidase.</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake inhibitors (SSRIs): [P] Fatalities have occurred due to serotonin syndrome; contraindicated in patients taking MAOIs; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Sibutramine: [NE] Possible serotonin syndrome; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Sympathomimetics (indirect-acting): [HP] Hypertensive episode due to release of stored norepinephrine (amphetamines, ephedrine, isometheptene, phenylpropanol- amine, pseudoephedrine).</td></tr><tr><td></td><td></td><td>Tramadol: [NP] Possible serotonin syndrome; avoid concurrent use.</td></tr><tr><td></td><td></td><td>Venlafaxine: [NP] Possible serotonin syndrome; avoid concurrent use.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="8">Nonsteroidal anti- inflammatory drugs (NSAIDs)</td><td rowspan="9">Prostaglandin inhibition may result in reduced renal sodium excretion, impaired resistance to hypertensive stimuli, and reduced renal lithium excretion. Most NSAIDs inhibit platelet function; may increase likelihood of bleeding due to other drugs that impair hemostasis.</td><td>ACE inhibitors (ACEIs): [P] Decreased antihypertensive response.</td></tr><tr><td></td><td></td><td>Angiotensin II receptor blockers (ARBs): [P] Decreased antihypertensive response.</td></tr><tr><td></td><td></td><td>Furosemide: [P] Decreased diuretic, natriuretic, and antihypertensive response to furosemide.</td></tr><tr><td></td><td></td><td>Hydralazine: [NE] Decreased antihypertensive response to hydralazine.</td></tr><tr><td></td><td></td><td>Methotrexate: [NP] Possibly increased methotrexate toxicity (especially with anticancer doses of methotrexate).</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake in! platelet inhibition. itors (SSRIs): [P] Increased risk of bleeding due to</td></tr><tr><td></td><td></td><td>Thiazide diuretics: [P] Decreased diuretic, natriuretic, and antihypertensive response.</td></tr><tr><td></td><td></td><td>Triamterene: [NE] Decreased renal function noted with triamterene plus indomethacin in both healthy subjects and patients.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; B-Adrenoceptor blockers; Lithium.</td></tr><tr><td>Opioid analgesics</td><td rowspan="17">Opioid analgesics that are substrates of CYP3A4 (alfentanil, fentanyl, oxycodone, sufentanil, and to a lesser extent methadone) are susceptible to inhibitors and inducers. Methadone is primarily metabolized by CYP2B6. Additive central nervous system depression with other central nervous system depressants. Induces hepatic microsomal</td><td>Amiodarone: [NP] Decreased CYP3A4-dependent opioid metabolism. Expect similar interactions with dronedarone.</td></tr><tr><td></td><td></td><td>Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir</td></tr><tr><td></td><td></td><td>inhibit the metabolism of CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td>Boceprevir: [P] Decreased metabolism of CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Bosentan: [P] Increased CYP3A4-dependent opioid metabolism.</td></tr><tr><td></td><td></td><td>Cobicistat: [P] Decreased metabolism of CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased metabolism of CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td>Efavirenz: [P] Increased metabolism of CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of CYP3A4-dependent opioid by ceritinib, dasatinib, imatinib, idelalisib, and lapatinib. Nefazodone: Decreased metabolism.</td></tr><tr><td></td><td></td><td>[NP] CYP3A4-dependent opioid Increased metabolism of</td></tr><tr><td></td><td></td><td>Nevirapine: [P] CYP3A4-dependent opioids.</td></tr><tr><td></td><td></td><td>Phenytoin: [P] Increased CYP3A4-dependent opioid metabolism.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased CYP3A4-dependent opioid metabolism.</td></tr><tr><td></td><td></td><td>St. John’s wort: [NP] Increased CYP3A4-dependent opioid metabolism.</td></tr><tr><td></td><td></td><td>See also Azole antifungal agents; Barbiturates; Carbamazepine; Cimetidine; Macrolides; Monoamine oxidase inhibitors.</td></tr><tr><td>Phenytoin</td><td></td><td>Drugs whose metabolism is stimulated by phenytoin:</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Cli ically Documented Interactions</th></thead><tr><td rowspan="18">Phenytoin (cont.)</td><td></td><td>Drugs that inhibit phenytoin metabolism:</td></tr><tr><td></td><td></td><td>Amiodarone: [P] Increased serum phenytoin concentration; possible reduction in serum amiodarone concentration.</td></tr><tr><td></td><td></td><td>Capecitabine: [NE] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Chloramphenicol: [P] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Felbamate: [P] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Fluorouracil: [NE] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Fluvoxamine: [NP] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Isoniazid: [NP] Increased serum phenytoin; problem primarily with slow acetylators of isoniazid.</td></tr><tr><td></td><td></td><td>Metronidazole: [NP] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Sulfamethoxazole: [P] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Ticlopidine: [NP] Increased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Cimetidine; Disulfiram.</td></tr><tr><td></td><td></td><td>Drugs that enhance phenytoin metabolism:</td></tr><tr><td></td><td></td><td>Bosentan: [P] Decreased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Carbamazepine: [P] Decreased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Decreased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>St. John’s wort: [P] Decreased phenytoin plasma concentrations.</td></tr><tr><td></td><td></td><td>See also Barbiturates.</td></tr><tr><td rowspan="7">Pimozide</td><td rowspan="7">Susceptible to CYP3A4 inhibitors; may exhibit additive effects with other agents that prolong QT. interval.</td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of pimozide.</td></tr><tr><td></td><td></td><td>Boceprevir: [P] Decreased metabolism of pimozide.</td></tr><tr><td></td><td></td><td>Cobicistat: [P] Decreased metabolism of pimozide.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased metabolism of pimozide.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of pimozide with ceritinib, dasatinib, imatinib, idelalisib, and lapatinib.</td></tr><tr><td></td><td></td><td>Nefazodone: [NP] Decreased pimozide metabolism.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Cyclosporine; Macrolides.</td></tr><tr><td rowspan="3">Potassium- sparing diuret- ics (amiloride, eplerenone, Spironolactone, triamterene)</td><td rowspan="3">Additive effects with other agents increasing serum potassium con- centration. Eplerenone is a substrate for CYP3A4 and is susceptible to inhibition and induction. May alter renal excretion of substances other than potassium (eg, digoxin, hydrogen ions).</td><td>ACE inhibitors (ACEIs): [NP] Additive hyperkalemic effect.</td></tr><tr><td></td><td></td><td>Angiotensin II receptor blockers (ARBs): [NP] Additive hyperkalemic effect.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of eplerenone. Boceprevir: [P] Decreased metabolism of eplerenone.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>cli ically Documented Interactions</th></thead><tr><td rowspan="5">Potassium- sparing diuret- ics (amiloride, eplerenone, Spironolactone, triamterene) (cont.)</td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of eplerenone with ceritinib, dasatinib, imatinib, idelalisib, and lapatinib.</td></tr><tr><td></td><td></td><td>Potassium-sparing diuretics: [P] Additive hyperkalemic effect.</td></tr><tr><td></td><td></td><td>Potassium supplements: [P] Additive hyperkalemic effect; especially a problem in presence of renal impairment.</td></tr><tr><td></td><td></td><td>See also Azole antifungals; Digitalis glycosides; Macrolides; Nonsteroidal anti-</td></tr><tr><td></td><td></td><td>inflammatory drugs.</td></tr><tr><td rowspan="5">Probenecid</td><td rowspan="5">Interference with renal excretion of drugs that undergo active tubular secretion, especially weak acids. Inhibition of glucuronide conjugation of other drugs.</td><td>Clofibrate: [P] Reduced glucuronide conjugation of clofibric acid.</td></tr><tr><td></td><td></td><td>Methotrexate: [P] Decreased renal methotrexate excretion; possible methotrexate toxicity.</td></tr><tr><td></td><td></td><td>Pralatrexate: [P] Decreased renal pralatrexate excretion; possible pralatrexate toxicity.</td></tr><tr><td></td><td></td><td>Peni : [P] Decreased renal penicillin excretion.</td></tr><tr><td></td><td></td><td>Salicylates: [P] Decreased uricosuric effect of probenecid (interaction unlikely with less than 1.5 of</td></tr><tr><td rowspan="12">Quinidine</td><td rowspan="12">Substrate of CYP3A4. Inhibits CYP2D6. Renal excretion susceptible to changes in urine pH. Additive effects with other agents that prolong the QT- interval.</td><td>g salicylate daily). Acetazolamide: [P] Decreased renal quinidine excretion due to increased urinary pH;</td></tr><tr><td></td><td></td><td>elevated serum quinidine.</td></tr><tr><td></td><td></td><td>Amiodarone: [NP] Increased serum quinidine levels; additive prolongation of QT. interval.</td></tr><tr><td></td><td></td><td>Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Boceprevir: [P] Decreased metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Cobicistat: [P] Decreased metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Conivaptan: [P] Decreased metabolism of quinidine.</td></tr><tr><td></td><td></td><td>Kaolin-pectin: [NE] Decreased gastrointestinal absorption of quinidine.</td></tr><tr><td></td><td></td><td>Kinase inhibitors: [P] Decreased metabolism of quinidine with ceritinib, dasatinib, imatinib, idelalisib, and lapatinib.</td></tr><tr><td></td><td></td><td>Rifampin: [P] Increased quinidine metabolism.</td></tr><tr><td></td><td></td><td>Thioridazine: [NE] Decreased thioridazine metabolism; additive prolongation of QT. interval.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; Antidepressants, tricyclic; Azole antifungals; Barbiturates; Cimetidine; Digitalis glycosides; Macrolides; Phenytoin.</td></tr><tr><td rowspan="2">Quinolone</td><td></td><td>Susceptible to inhibition of gastrointestinal absorption. Some</td><td>Caffeine: [P] Ciprofloxacin, enoxacin, and, to a lesser extent, norfloxacin inhibit caffeine metabolism.</td></tr><tr><td>quinolones (ciprofloxacin, enoxacin) inhibit CYP1A2, while ciprofloxacin also inhibits CYP3A4.</td><td>Frovatriptan: [P] Ciprofloxacin, enoxacin, and, to a lesser extent, norfloxacin inhibit frovatriptan metabolism.</td></tr></table>
======================================
<table><thead><th>Drug or Drug Group</th><th>Properties Promoting Drug Interaction</th><th>Clinically Documented Interactions</th></thead><tr><td rowspan="3">Quinolone antibiotics (cont.)</td><td></td><td>Tizanidine: [P] Ciprofloxacin, enoxacin, and, to a lesser extent, norfloxacin inhibit tizanidine metabolism.</td></tr><tr><td></td><td></td><td>Zolmitriptan: [P] Ciprofloxacin, enoxacin, and, to a lesser extent, norfloxacin inhibit zolmitriptan metabolism.</td></tr><tr><td></td><td></td><td>See also Acid-reducing agents; Anticoagulants, oral; Iron.</td></tr><tr><td rowspan="5">Rifampin</td><td rowspan="5">Inducer (strong) of hepatic microsomal drug-metabolizing enzymes and P-glycoprotein.</td><td>Corticosteroids: [P] Increased corticosteroid hepatic metabolism; reduced corticosteroid effect.</td></tr><tr><td></td><td></td><td>Mexiletine: [NE] Increased mexiletine metabolism; reduced mexiletine effect.</td></tr><tr><td></td><td></td><td>Sulfonylurea hypoglycemics: [P] Increased hepatic metabolism of tolbutamide and probably other sulfonylureas metabolized by the liver (including chlorpropamide).</td></tr><tr><td></td><td></td><td>Theophylline: [P] Increased theophylline metabolism.</td></tr><tr><td></td><td></td><td>See also Anticoagulants, oral; Antidepressants, tricyclic and heterocyclic; Azole antifungals; Beta-adrenoceptor blockers; Calcium channel blockers; Cyclosporine; Digitalis glycosides; Estrogens; HMG-CoA reductase inhibitors; Opioid analgesics; Phenytoin; Quinidine.</td></tr><tr><td rowspan="7">Salicylates</td><td rowspan="7">Interference with renal excretion of drugs that undergo active tubular secretion. Salicylate renal excretion dependent on urinary pH when large doses of salicylate used. Aspirin (but not other salicylates) interferes with platelet function. Large doses of salicylates have intrinsic hypoglycemic activity.</td><td>Carbonic anhydrase inhibitors: [NE] Increased acetazolamide serum concentrations; increase salicylate toxicity due to decreased blood pH.</td></tr><tr><td></td><td></td><td>Corticosteroids: [P] Increased salicylate elimination; possible additive toxic effect on gastric mucosa.</td></tr><tr><td></td><td></td><td>Heparin: [NP] Increased bleeding tendency with aspirin, but probably not with other salicylates.</td></tr><tr><td></td><td></td><td>Methotrexate: [P] Decreased renal methotrexate clearance; increases methotrexate toxicity (primarily at anticancer doses).</td></tr><tr><td></td><td></td><td>Selective serotonin reuptake inhibitors (SSRIs): [P] Increased risk of bleeding due to platelet inhibition.</td></tr><tr><td></td><td></td><td>Sulfinpyrazone: [HP] Decreased uricosuric effect of sulfinpyrazone (interaction unlikely with less than 1.5 g of salicylate daily).</td></tr><tr><td></td><td></td><td>See also Acid-reducing agents; Anticoagulants, oral; Probenecid.</td></tr><tr><td rowspan="3">Selective serotonin reuptake inhibitors (SSRIs)</td><td rowspan="3">SSRIs can lead to excessive serotonin response when administered with other serotonergic drugs (eg, MAOIs). Some SSRIs inhibit various cytochrome P450s including CYP2D6, CYP1A2, CYP3A4, and CYP2C19. to induction and</td><td>Codeine: [HP] Reduced analgesic effect due to inhibition of codeine metabolism to morphine by fluoxetine and paroxetine.</td></tr><tr><td></td><td></td><td>Theophylline: [P] Decreased metabolism of theophylline by fluvoxamine-induced inhibition of CYP1A2. See also Anticoagulants, oral; Antidepressants, tricyclic and heterocyclic;</td></tr><tr><td></td><td></td><td>B-Adrenoceptor blockers; Carbamazepine; Cisapride; Colchicine; Cyclosporine; HMG-CoA reductase inhibitors; Monoamine oxidase inhibitors; Nonsteroidal anti-inflammatory drugs; Phenytoin; Pimozide; Salicylates. blockers: Decreased bronchodilation</td></tr><tr><td rowspan="4">Theophylline</td><td rowspan="4">Susceptible inhibition of hepatic metabolism by CYP1A2 and CYP3A4.</td><td>with noncardioselective B blockers.</td></tr><tr><td></td><td></td><td>Bet
======================================
a-adrenoceptor [NP] theophylline especially Smoking: [HP] Increased theophylline metabolism. Tacrine: [NP] Decreased theophylline metabolism. Ticlopidine: [NP] Decreased theophylline metabolism.</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th>SUOHIPUOD</th><th>seaue</th><th>suasn Bnup YD1\|! (WSW)</th><th>SJAPJOSIP 10}32}</th><th>UO!}&gt;aJU! 10} ¥s1U</th><th>sease 31Wapua ‘0}</th><th>(sjuajed ydajas ul ¥ sieday aynde yim sjenpiaipul jo</th><th>VSN ay} U! JeALe Jaye skep 09 IsAy AY) ue YUM JDeJUOD JeUOsJad asoj&gt; ajediaUe</th><th>AyOlwWapua ayelpawuayu! 40</th><th>sqjnpe Buno{ pue</th><th>SU Je}UBWUUOAIAUA JO ‘a[AYsayI]</th><th></th><th>abe Jo</th><th>BSPASIP JBAI] IUOAYD JO ‘AIH ‘BSeasip</th><th></th><th>PAdH Jo 97 pue 6 UdaMjaq DIUOAYD puke ayNde YUM sjeNpIAIpu! Jo</th><th>sueak ‘abe sueak</th><th>sieak 97 abe yBnosy)</th><th></th><th>sueak g| 0}</th></thead><tr><td>UaJp|yp [Je 104</td><td>Ualpyiyp [Je 404 *L</td><td>ysl1-32 JaYI0 pue elUa|dsy °Z</td><td>YM aneYy OYM JIWapua y siyeday 0} suajaned| “1</td><td>UoDafUlUOU JO UONIAfU| “¢ Yau xas Ud °Z</td><td>Guly10|9 JO aseasip JdAl] NUOIYD “y</td><td>|2UOIedNDI0 YIM sUOSIad “S</td><td>Huljedo/aJ Jo ‘Ul BulAl] suosiadg “9</td><td>uljnqo/6 ewiweb jeuoN!ppe yyM) s}2e]U0D jenxas pue pjoyasnoy *Z</td><td>HuLNp aaydope jeuoneusayU! OYM suOsiad payeUIDIeAUN, *6</td><td>yy ym Aujyunod e Woy,</td><td>‘sjuarsajope ‘sjuarsajopeaig “7</td><td>/EUOI}EdND30 YIM SUOSIag “€</td><td></td><td>sieak 99&gt; synpe 2naqeiq *y</td><td>[eas a6e}s-puUa YIIM SUOSIag *S</td><td>sixe|Aydoid ainsodxaysog 9</td><td>sa|eWay 10} 6/\dH ‘L g@sanedey s}9eyUOD jeNxas pue pjoyasnoy *Z</td><td>97 WSW ‘7 17-6 pabe sajew 10) 6AdH 40 JO ‘~AdH ‘ZAdH</td><td>suosiad pasituosdwosounwWiW| *¢ seat abe yBnolyy</td><td>sueak BL&lt; synpe jy “L</td><td>syjuolW 9 pabe uaipyiyp [IV “7</td></tr><tr><td>aUON _da}s00g</td><td>papuawwosas JON</td><td></td><td>W4a}-Huo| 10} syjuow 71-9 IV</td><td>Ayunwun</td><td></td><td></td><td></td><td></td><td></td><td></td><td>papuawworas</td><td></td><td></td><td></td><td></td><td></td><td>auON</td><td></td><td></td><td>ym Ajiea,</td><td>auIDDeA JUaLIND</td></tr><tr><td>7Z-¥ algel vas</td><td>(a]npayps pooypyiy&gt; 40} Z-V 2/ge as) asop BUD</td><td></td><td>Jaysiulwupe) (a;npayas pooypy!y&gt; 40} Z-V 8/ge 8as) asop BUD</td><td>0} jane aiojaq syaam p-Z Isea| Ie</td><td>(sease JIWapua</td><td></td><td></td><td></td><td></td><td></td><td>Ppooypy!y&gt; 40} Z-y a|qe] as)</td><td>(aInpayas</td><td></td><td></td><td></td><td></td><td>pue sasop aly</td><td>SyaaM HZ ’g-p ‘0 32</td><td></td><td>OM seat 6&gt; UaJp|I4) Bsop aU</td><td>BAI9DA1 P|NOYs Aw} 1S1y BY} 10} duIDDeA eZUaNYU! BulAladad ae</td></tr><tr><td>JejnosnweyUuy</td><td>Jejnosnweyuy</td><td></td><td>Jejndsnweyuy</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>snoaueynoqns)</td><td></td><td>a eeetin</td><td>pee eae</td><td>Bulpaeiq yum</td><td>(sdapsosip</td><td>JejnosnwesUy</td><td></td><td></td><td>uejndsnwiedjuy</td><td>-[HeAe S| BUIDIeA Jeuuapenui ue</td></tr></table>
======================================
<table><tr><td>Jeak ysed ay} ul Buizaaym yum sueak pa6be asou) (Z) pue ‘saewyyse (|) }dadxa sueat g1-Z Ayyeay us aulddeA payeanseul 10} paynyysqns aq Ae “ezuanyul ysuyeBe uo!}Da} 01d aalsap OYM s4eak G/-6 | Pabe suosiad</td><td>uaupliup jle</td><td>9S6| Joye Uog siinpy</td><td>sueak s¢-| | pabe suosiad ul aulazeA apUeYyresAjOd J9AO Pauajasg syuarsajope</td><td>sunidad Keyl SOLJOUWUOP Ul BAI] OYM suea{ 77&gt; pabe uewYsar abajo</td><td>DUassiaN JO Sayejos! 0} pasodxa Ajauljnos ase OYM s}sIHOjO!qQOIDIW (savas asop-om}) ADualayap juatua|dwod Jo ejuajdse YIM sjenplAIpU|</td><td>eseasip DIwapida Jo d!WapuaradAy YIM seare 0} sueak Sg&lt; suajaAes} YNPY ual YUM xas aAeY OYM UAW aAIYSOd-AIH sipij6ujuau</td><td>jeoD0206uluaw</td><td>sjue|duu! 128/490 JO ‘syea| Jeuidsoiqaiad ‘eluajdse ‘suoljpuod BHuls!wos;dwodounWU! YIM s}Npy asp [Je</td><td>Ajsnoiaaid payeulddeA uaaq Jou aaey OM seat Sgz S\INpY</td><td>SUO!}e9!|dWUOD Si! 10 aseasip |e9D030WNAU 404 ¥sLU paseaIDU! Je SUOSIag sueak S9z syINpY</td><td>4o JeUoledNd30 4OJ ¥sSI1 paseasdu! ye s}Npe payeulsdeaun AjsnolAaid uasp|lyp [2</td><td>SasNsJAOI}Od 0} ainsodxa jaAes)</td><td>Ul Ul]Ngoj6 aun! saiqes YIM JaysiulUpe) sixe|Aydoid aansodxa3sog SNAIA SAIqed Y}IM 1DL}UOD JOJ ysSI1 Je SUOSJad UI sIxe|Aydoid aAnsodxaaig</td><td>(sjenpiaipu! payeulsdeaun Ajsnoinaid</td><td>syuejul</td><td>SOP JSP] adUIS passed sey sueak G&lt; 4! sIxe|Aydosd ainsodxalsog synpe</td></tr><tr><td>$asOp OM} aAla2al pjnoys SWI} ISI} BY} JO} BUIDIEA eZUD Bulalazas ave OyM g-s abe uasp|iy&gt; ‘|uJsou Yea ul asop yds</td><td>c-V a1geL 22S yede syaam 01-9 pasaysiulwupe</td><td></td><td>asop auQ</td><td></td><td></td><td>asop auQ</td><td></td><td>alqeL eas</td><td></td><td>asop auQ Jo</td><td>sasop OML:s}|npy ‘@jNpayrs pooypy!y&gt; 40) 7-y a|geL eas</td><td>puodas ay} Jaye syjuOW 71-9 pily} e pue ‘ede syaam g-py</td><td>87 40 LZ pue ‘Z ‘0 sasop aaiy| saansodxaaig</td><td>gz Aep ye UIs e aAladaJ Pjnoys sjualed passaiddnsounwwt ‘y| pue ‘Z ‘¢ ‘0 sasop ino :aansodxaysod</td><td>Z-¥ 21921 885</td><td>Jaye syjUuoWw 71-9 asop p4lyy ‘yede syaam g—p Sasop OML</td></tr><tr><td>yeseuesu|</td><td>snoaueynaqns</td><td></td><td>Se dejndsnwuesjU]</td><td>pio</td><td></td><td>Se snoaueynsqns</td><td></td><td>snoouejnsqns Se JejNIsNwedU]</td><td></td><td>snosuejnsqns JO Se sejnosnwesU|</td><td>dal snoaueynoqns</td><td></td><td>deyndsnwuedj}uy sn</td><td></td><td>1240</td><td>JejndsnwesjU]</td></tr></table>
======================================
<table><tr><td>Jeak ysed ay} ul Buizaaym yum sueak pa6be asou) (Z) pue ‘saewyyse (|) }dadxa sueat g1-Z Ayyeay us aulddeA payeanseul 10} paynyysqns aq Ae “ezuanyul ysuyeBe uo!}Da} 01d aalsap OYM s4eak G/-6 | Pabe suosiad</td><td>uaupliup jle</td><td>9S6| Joye Uog siinpy</td><td>sueak s¢-| | pabe suosiad ul aulazeA apUeYyresAjOd J9AO Pauajasg syuarsajope</td><td>sunidad Keyl SOLJOUWUOP Ul BAI] OYM suea{ 77&gt; pabe uewYsar abajo</td><td>DUassiaN JO Sayejos! 0} pasodxa Ajauljnos ase OYM s}sIHOjO!qQOIDIW (savas asop-om}) ADualayap juatua|dwod Jo ejuajdse YIM sjenplAIpU|</td><td>eseasip DIwapida Jo d!WapuaradAy YIM seare 0} sueak Sg&lt; suajaAes} YNPY ual YUM xas aAeY OYM UAW aAIYSOd-AIH sipij6ujuau</td><td>jeoD0206uluaw</td><td>sjue|duu! 128/490 JO ‘syea| Jeuidsoiqaiad ‘eluajdse ‘suoljpuod BHuls!wos;dwodounWU! YIM s}Npy asp [Je</td><td>Ajsnoiaaid payeulddeA uaaq Jou aaey OM seat Sgz S\INpY</td><td>SUO!}e9!|dWUOD Si! 10 aseasip |e9D030WNAU 404 ¥sLU paseaIDU! Je SUOSIag sueak S9z syINpY</td><td>4o JeUoledNd30 4OJ ¥sSI1 paseasdu! ye s}Npe payeulsdeaun AjsnolAaid uasp|lyp [2</td><td>SasNsJAOI}Od 0} ainsodxa jaAes)</td><td>Ul Ul]Ngoj6 aun! saiqes YIM JaysiulUpe) sixe|Aydoid aansodxa3sog SNAIA SAIqed Y}IM 1DL}UOD JOJ ysSI1 Je SUOSJad UI sIxe|Aydoid aAnsodxaaig</td><td>(sjenpiaipu! payeulsdeaun Ajsnoinaid</td><td>syuejul</td><td>SOP JSP] adUIS passed sey sueak G&lt; 4! sIxe|Aydosd ainsodxalsog synpe</td></tr><tr><td>$asOp OM} aAla2al pjnoys SWI} ISI} BY} JO} BUIDIEA eZUD Bulalazas ave OyM g-s abe uasp|iy&gt; ‘|uJsou Yea ul asop yds</td><td>c-V a1geL 22S yede syaam 01-9 pasaysiulwupe</td><td></td><td>asop auQ</td><td></td><td></td><td>asop auQ</td><td></td><td>alqeL eas</td><td></td><td>asop auQ Jo</td><td>sasop OML:s}|npy ‘@jNpayrs pooypy!y&gt; 40) 7-y a|geL eas</td><td>puodas ay} Jaye syjuOW 71-9 pily} e pue ‘ede syaam g-py</td><td>87 40 LZ pue ‘Z ‘0 sasop aaiy| saansodxaaig</td><td>gz Aep ye UIs e aAladaJ Pjnoys sjualed passaiddnsounwwt ‘y| pue ‘Z ‘¢ ‘0 sasop ino :aansodxaysod</td><td>Z-¥ 21921 885</td><td>Jaye syjUuoWw 71-9 asop p4lyy ‘yede syaam g—p Sasop OML</td></tr><tr><td>yeseuesu|</td><td>snoaueynaqns</td><td></td><td>Se dejndsnwuesjU]</td><td>pio</td><td></td><td>Se snoaueynsqns</td><td></td><td>snoouejnsqns Se JejNIsNwedU]</td><td></td><td>snosuejnsqns JO Se sejnosnwesU|</td><td>dal snoaueynoqns</td><td></td><td>deyndsnwuedj}uy sn</td><td></td><td>1240</td><td>JejndsnwesjU]</td></tr></table>
======================================
<table><tr><td>suone&gt;ipul</td><td>(uoneysab Jo syaam 9¢-Z7 Buinp pauayaid) AdueuBbaid yea YIM asop e adladaJ pjnoys uawom jUeUBbad ‘syjnpe</td><td>JAB} ploydd} 0} ainsodxa</td><td>Janay ploydAy 0} ainsodxa</td><td>asp|lyD [12</td><td>UO!JEZIUNWWWI! UONDaJU! eI/aDUeA Jo ANOsiy e INoYyWM Aepyyg YAE| say} sed suosiag</td><td>suosiad ajqijdadsns ul sixejAydoid ainsodxaysog</td><td>SMAIA JaAa} Mo||ah 0} pasodxa ag Kew oym jauuosiad Aioyes0ge7</td><td>$1N220 Jaa} MO|JaK B1BYM Seale O} S1BJBAL1|</td><td>abe jo sieak gz synpe</td><td>auldzeA ayebnfuod q adfy avzuanyur snjiydowany (¢) pue “(J-d¥d) a¥e6nfuor</td><td>quayeniq (¢) pue (sajewiay pue sajew ul) sjiem jeyUab pue (sajeway ul) s1adUeD</td><td>eLayiydip Jo JuNOWe ales ay} SUle}UOD) abe Jo sueaf / &gt; SUOSJad Ul ASN JO} S|</td></tr><tr><td>7ie3s00g uoneziunuiwy Avewid</td><td>aUuON synpe |je ut PL 40} dep) Jo asop auo aynysqns</td><td>sieak ¢ sasop sno4 Aep 49430 Ajaad paia|siuluupe sasop 1no4</td><td>7 AlaAq asop 8uO</td><td>umouxun, ul pede syaam g—-p sasop OM,</td><td>Pooypl!y&gt; 40} Z—V 8]qe] 82s) Aepyyig yi¢ 414} sed suosiad</td><td>(@]Npayos</td><td>QL Alaa sKep 0| 0} sueak Q| aSOp aUQ</td><td>Jane. a1ojyaq</td><td>“Hasu! abeyDed ssaunyoejynueww ay} Wo pauleygo auON asop auQ</td><td>snueja}-ayeydsoyd jou \AsoquAjod (Z) ‘(9OQH) au!D2eA qIH aeHn[uoD</td><td>‘e&gt;!A499 JO UO!JUAAaIC AY JO} (6dH) BU!DIEA JUA|eA-G (Z) PUL</td><td>snueja} ‘(1d pue Ldg vey, XO} PLAYYCIp ssaj sujeyUo&gt;)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>suo}eueA Bulp!</td><td>:asn Joy a/qe| “(dWO-d</td><td>[eI JUAa|eAIpeNb (|) :as</td><td>suosiad ul asn S4BDURD</td></tr></table>
======================================
<table><thead><th>Age</th><th>Immunization</th><th>Comments</th></thead><tr><td>Birth to 2 months</td><td>Hepatitis B vaccine (HBV)</td><td>Infants born to seronegative mothers: Administration should begin prior to hospital discharge, with the second dose administered at least 4 weeks after the first dose.</td></tr><tr><td></td><td></td><td>Infants born to seropositive mothers: Should receive the first dose within 12 hours of birth (with hepatitis B immune globulin), the second dose at 1-2 months of age, and the third dose at 6-18 months of age.</td></tr><tr><td>2 months</td><td>Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), inactivated poliovirus vaccine (IPV), Haemophilus influenzae type b conjugate vaccine (Hib),' pneumococcal conjugate vaccine (PCV), rotavirus vaccine (Rv)</td><td></td></tr><tr><td>1-2 months</td><td>HBV</td><td>The second dose should be given at least 4 weeks after the first dose.</td></tr><tr><td>4 months</td><td>DTaP, Hib," IPV, PCV, RV?</td><td></td></tr><tr><td>6 months</td><td>DTaP, Hib,’ PCV, RV”</td><td>The third dose of RV is only necessary if RV-5 is used for one or two of the first two doses.</td></tr><tr><td>6-18 months</td><td>HBY, IPV, influenza</td><td>The third dose of HBV should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose, but not before age 24 weeks. Influenza vaccine should be administered annually to children aged 6 months to 18 years. Live attenuated influenza vaccine cannot be administered until age 2 years.</td></tr><tr><td>12-15 months</td><td>Measles-mumps-rubella vaccine (MMR), Hib,' PCV, varicella vaccine</td><td>The first dose of MMR may be administered at 6-11 months before depar- ture from the USA for international travel. These infants should receive two additional doses at the usual interval. Children &gt;12 months of age should receive a second dose at least 4 weeks after the first dose before departure from the USA for international travel.</td></tr><tr><td>15-18 months</td><td>DTaP</td><td>DTaP may be given as early as age 12 months if there has been at least 6 months since the third dose.</td></tr><tr><td>12-23 months</td><td>Hepatitis A vaccine</td><td>Two doses &gt;6 months apart.</td></tr><tr><td>4-6 years</td><td>DTaP IPV, MMR, varicella vaccine</td><td>The second dose of MMR should be routinely administered at age 4-6 years but may be given during any visit if at least 4 weeks have elapsed since administration of the first dose.</td></tr><tr><td>11-12 years</td><td>Tetanus, diphtheria, pertussis (Tdap) vaccine, human papillomavirus vaccine (HPV)? meningococcal conjugate vaccine (MCV)</td><td>Three doses of HPV should be administered to females at 0, 1-2, and 6 months (may be started as early as age 9 years). HPV4 or HPV9 may be administered to males aged 9-18 years to reduce the likelihood of devel- oping genital warts. Administer one dose of Tdap to pregnant adolescents during each pregnancy at 27-36 weeks of gestation. A booster dose of MCV should be given at age 16 years.</td></tr><tr><td>Three Hib conjugate 3) Haemophilus influenzae dose at 6 months of age.</td><td>vaccines are available for use: (1) oligosaccharide conjugate type b conjugate vaccine (meningococcal protein conjugate) PRP-T should only be used for the booster dose in children</td><td>Hib vaccine (HbOC), (2) polyribosylribitol phosphate-tetanus toxoid conjugate (PRP-T), and (PRP-OMP). Children immunized with PRP-OMP at 2 and 4 months of age do not require aged 12-15 months.</td></tr></table>
======================================
<table><thead><th></th><th>Product</th><th>Dosage</th><th>Comments</th></thead><tr><td>Black widow spider bite</td><td>Antivenin (Latrodectus mactans), equine</td><td>One vial (6000 units) IV or IM. Some patients may require a repeat dose.</td><td>For persons with hypertensive cardiovascular disease or aged &lt;16 or &gt;60 years.</td></tr><tr><td>Bone marrow transplantation</td><td>Immune globulin (intra- venous {Iv})?</td><td>500 mg/kg IV on days 7 and 2 prior to transplantation and then once weekly through day 90 after transplantation.</td><td>Prophylaxis to decrease the risk of infection, intersti- tial pneumonia, and acute graft-versus-host disease in adults undergoing bone marrow transplantation.</td></tr><tr><td rowspan="2">Botulism</td><td>Botulism antitoxin hep- tavalent equine, Types A-G</td><td>Consult the CDC.’</td><td>Treatment of symptomatic botulism. Available from the CDC.’ Incidence of serum reactions is &lt;1%.</td></tr><tr><td></td><td>Botulism immune globulin (IV)</td><td>75 mg/kg IV.</td><td>For the treatment of patients &lt;1 year of age with infant botulism caused by toxin type A or B.</td></tr><tr><td>Chronic lymphocytic leukemia (CLL)</td><td>Immune globulin (lv)?</td><td>400 mg/kg IV every 3-4 weeks. Dosage should be adjusted upward if bacterial infections occur.</td><td>CLL patients with hypogammaglobulinemia and a history of at least one serious bacterial infection.</td></tr><tr><td>Cytomegalovi- rus (CMV)</td><td>Cytomegalovirus immune globulin (IV)</td><td>Consult the manufacturer's dosing recommendations.</td><td>Prophylaxis of CMV infection in bone marrow, kidney, liver, lung, pancreas, and heart transplant recipients.</td></tr><tr><td>Diphtheria</td><td>Diphtheria antitoxin, equine</td><td>20,000-100,000 units IV or IM depending on the severity and duration of illness.</td><td>Early treatment of respiratory diphtheria. Available from the CDC.’ Anaphylactic reactions in &gt;7% of adults and serum reactions in &gt;5-10% of adults.</td></tr><tr><td></td><td></td><td>&gt;3 months, repeated every 4-6 months for continued exposure. Postexposure: 0.02 mL/kg IM as soon as possible after exposure up to 2 weeks.</td><td>prophylaxis. Patients &gt;40 years should receive hepatitis A vaccine in addition to immune globulin for postexposure prophylaxis</td></tr><tr><td>Hepatitis B</td><td>Hepatitis B immune globulin (HBIG)</td><td>0.06 mL/kg IM as soon as possible after exposure up to 1 week for percutaneous exposure or 2 weeks for sexual expo- sure. 0.5 mL IM within 12 hours after birth for perinatal exposure.</td><td>Postexposure prophylaxis in nonimmune persons following percutaneous, mucosal, sexual, or perinatal exposure. Hepatitis B vaccine should also be administered.</td></tr><tr><td>HIV-infected children</td><td>Immune globulin (lv)?</td><td>400 mg/kg IV every 28 days.</td><td>HIV-infected children with recurrent serious bacterial infections or hypogammaglobulinemia.</td></tr><tr><td>Idiopathic thrombocyto- penic purpura (ITP)</td><td>Immune globulin (lv)?</td><td>Consult the manufacturer's dosing recommendations for the specific product being used.</td><td>Response in children with ITP is greater than in adults. Corticosteroids are the treatment of choice in adults, except for severe pregnancy-associated ITP.</td></tr><tr><td>Kawasaki disease</td><td>Immune globulin (lv)?</td><td>400 mg/kg IV daily for 4 consecutive days within 4 days after the onset of illness. A single dose of 2 g/kg IV over 10 hours is also effective.</td><td>Effective in the prevention of coronary aneurysms. For use in patients who meet strict criteria for Kawasaki disease.</td></tr><tr><td>Measles</td><td>Immune globulin (IM)</td><td>Normal hosts: 0.25 mL/kg IM. Immunocompromised hosts: 0.5 mL/kg IM (maximum 15 mL for all patients).</td><td>Postexposure prophylaxis (within 6 days after exposure) in nonimmune contacts of acute cases.</td></tr><tr><td>Primary immu- nodeficiency</td><td>Immune globulin (lv)?</td><td>Consult the ma
======================================
nufacturer's dosing recommendations for the specific</td><td>Primary immunodeficiency disorders include specific antibody deficiencies (eg, X-linked agammaglobulin-</td></tr></table>
======================================
<table><thead><th>Indication</th><th>Product</th><th colspan="2">Dosage</th><th>Comments</th></thead><tr><td>Respiratory syn- cytial virus (RSV)</td><td>Palivizumab</td><td colspan="2">15 mg/kg IM once prior to the beginning of the RSV season and once monthly until the end of the season.</td><td>For use in infants and children &lt;24 months with chronic lung disease, hemodynamically significant congenital heart disease, or a history of premature birth (235 weeks of gestation).</td></tr><tr><td>Rubella</td><td>Immune globulin (IM)</td><td colspan="2">0.55 mL/kg IM.</td><td>Nonimmune pregnant women exposed to rubella who will not consider therapeutic abortion. Admin- istration does not prevent rubella in the fetus of an exposed mother.</td></tr><tr><td>Scorpion sting (Centruroides)</td><td>Scorpion Immune F(ab)2</td><td colspan="2">3 vials IV over 10 minutes</td><td>Use as soon as possible after scorpion sting</td></tr><tr><td>Snake bite (coral snake)</td><td>Antivenin (Micrurus fulvius), equine</td><td colspan="2">At least 3-5 vials (30-50 mL) IV initially within 4 hours after the bite. Additional doses may be required.</td><td>Neutralizes venom of eastern coral snake and Texas coral snake. Serum sickness occurs in almost all patients who receive &gt;7 vials.</td></tr><tr><td>Snake bite (pit vipers)</td><td>Antivenin (Crotalidae) polyvalent immune Fab, ovine</td><td colspan="2">An initial dose of 4-6 vials should be infused intravenously over 1 hour. The dose should be repeated if initial control is not achieved. After initial control, 2 vials should be given every 6 hours for up to three doses.</td><td>For the management of minimal to moderate North American crotalid envenomation.</td></tr><tr><td></td><td></td><td colspan="2">has been a delay in administration, 500 units is recommended. Treatment: 3000-6000 units IM.</td><td>immunized persons (less than two doses of tetanus toxoid or less than three doses if wound is &gt;24 hours old).</td></tr><tr><td>Vaccinia</td><td>Vaccinia immune globulin</td><td colspan="2">Consult the CDC.’</td><td>Treatment of severe reactions to vaccinia vaccination, including eczema vaccinatum, vaccinia necrosum, and ocular vaccinia. Available from the CDC.’</td></tr><tr><td rowspan="6">Varicella</td><td rowspan="6">Varicella-zoster immune globulin</td><td>Weight (kg)</td><td>Dose (units)</td><td rowspan="6">Postexposure prophylaxis (preferably within 48 hours but no later than within 96 hours after exposure) in susceptible immunocompromised hosts, selected pregnant women, and perinatally exposed newborns.</td></tr><tr><td></td><td></td><td>22</td><td>62.5 IM</td><td></td></tr><tr><td></td><td></td><td>2.1-10</td><td>125 1M</td><td></td></tr><tr><td></td><td></td><td>10.1-20</td><td>250 1M</td><td></td></tr><tr><td></td><td></td><td>20.1-30</td><td>375 IM</td><td></td></tr><tr><td></td><td></td><td>30.1-40</td><td>500 IM</td><td></td></tr></table>